<SEC-DOCUMENT>0001654954-21-012154.txt : 20211115
<SEC-HEADER>0001654954-21-012154.hdr.sgml : 20211115
<ACCEPTANCE-DATETIME>20211115114126
ACCESSION NUMBER:		0001654954-21-012154
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		46
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211115
DATE AS OF CHANGE:		20211115

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ainos, Inc.
		CENTRAL INDEX KEY:			0001014763
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				751974352
		STATE OF INCORPORATION:			TX
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-20791
		FILM NUMBER:		211407751

	BUSINESS ADDRESS:	
		STREET 1:		AINOS, INC.
		STREET 2:		8880 RIO SAN DIEGO DRIVE SUITE 800
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92108
		BUSINESS PHONE:		858-869-2986

	MAIL ADDRESS:	
		STREET 1:		AINOS, INC.
		STREET 2:		8880 RIO SAN DIEGO DRIVE SUITE 800
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92108

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARILLO BIOSCIENCES INC
		DATE OF NAME CHANGE:	19960516
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>aimd_10q.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:aimd="http://aimd.com/20210930"><head><title>aimd_10q.htm</title><!--Document Created by XBRLMaster--><meta http-equiv="Content-Type" content="text/html" /></head><body style="text-align:justify;font:10pt times new roman"><div style='display:none;text-align:justify;font:10pt times new roman;' id='XBRLDIV'><ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="From2021-01-01to2021-09-30">0001014763</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="From2021-01-01to2021-09-30" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="From2021-01-01to2021-09-30">--12-31</ix:nonNumeric><ix:nonNumeric name="dei:EntityShellCompany" contextRef="From2021-01-01to2021-09-30" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="From2021-01-01to2021-09-30" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="From2021-01-01to2021-09-30">Q3</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="From2021-01-01to2021-09-30">2021</ix:nonNumeric><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31" unitRef="USDPShares" decimals="INF">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2020-12-31" unitRef="Shares" decimals="0">10000000</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2020-12-31" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-09-30" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2020-12-31" unitRef="Shares" decimals="0">0</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31" unitRef="USDPShares" decimals="INF">0.01</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2020-12-31" unitRef="Shares" decimals="0">300000000</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2020-12-31" unitRef="Shares" decimals="0">42066172</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-09-30" unitRef="Shares" decimals="0">142442215</ix:nonFraction><ix:nonFraction name="aimd:OptionExpense" contextRef="From2020-01-01to2020-09-30" unitRef="USD" decimals="0">272604</ix:nonFraction><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="Shares" decimals="0">1</ix:nonFraction><ix:nonFraction name="us-gaap:Revenues" contextRef="From2020-01-01to2020-09-30_aimd_SecuritiesPurchaseAgreementsMember" unitRef="USD" decimals="0">15786</ix:nonFraction><ix:nonNumeric name="aimd:DueDate" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember">2021/04/01</ix:nonNumeric><ix:nonFraction name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember" unitRef="Pure" decimals="INF">0.0185</ix:nonFraction><ix:nonNumeric name="aimd:EffectiveDate" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember">2021/01/01</ix:nonNumeric><ix:nonFraction name="aimd:AnnualInterestRateFollowingMaturity" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember" unitRef="Pure" decimals="INF">0.1</ix:nonFraction><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_ElevenTwoOneMember" unitRef="Pure" decimals="INF">0.0065</ix:nonFraction><ix:nonNumeric name="aimd:Date" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember">3/18/2016</ix:nonNumeric><ix:nonNumeric name="aimd:Date" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_ElevenOneTwoOneMember">3/18/2016</ix:nonNumeric><ix:nonNumeric name="aimd:Date" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_TotalMember">3/18/2016</ix:nonNumeric><ix:nonFraction name="aimd:ParValue" contextRef="AsOf2021-06-30_aimd_BernardCohenMember" unitRef="USD" decimals="0">534</ix:nonFraction><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2021-01-01to2021-09-30" unitRef="USD" decimals="0">122680</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type='simple' xlink:href='aimd-20210930.xsd'></link:schemaRef></ix:references><ix:resources><xbrli:context id="From2021-01-01to2021-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-10-23to2021-11-01_us-gaap_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-23</xbrli:startDate><xbrli:endDate>2021-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-06-30_aimd_BernardCohenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">aimd:BernardCohenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-06-30_aimd_DrStephenTChenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-09-30_aimd_I2ChinaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:I2ChinaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_aimd_I2ChinaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:I2ChinaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_aimd_RelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-09-30_aimd_RelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:AinosKYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-09-30_aimd_AinosKYMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:AinosKYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_OneOneSixMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:OneOneSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_ElevenOneTwoOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:ITwoChinaManagementGroupLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:ElevenOneTwoOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:ITwoChinaManagementGroupLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:EightBTwoZeroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightATwozeroMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:ITwoChinaManagementGroupLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:EightATwozeroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_FiveOneNineMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:ITwoChinaManagementGroupLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:FiveOneNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_aimd_DrStephenTChenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_ElevenTwoOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:ElevenTwoOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_TenTwoOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:TenTwoOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_NineTwoZeroMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:NineTwoZeroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_SevenTwoZeroMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:SevenTwoZeroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_SixTwoZeroMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:SixTwoZeroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_FourOneNineMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:FourOneNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_ThreeOneNineMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:ThreeOneNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_TwoOneSixMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:TwoOneSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-12-31_aimd_DrStephenTChenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-12-31_aimd_DrStephenTChenMember_aimd_NineTwoZeroMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:NineTwoZeroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TenTwoOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:TenTwoOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ElevenTwoOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:ElevenTwoOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-12-31_aimd_DrStephenTChenMember_aimd_SixTwoZeroMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:SixTwoZeroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_NineTwoZeroMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:NineTwoZeroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-12-31_aimd_DrStephenTChenMember_aimd_SevenTwoZeroMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:SevenTwoZeroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SevenTwoZeroMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:SevenTwoZeroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SixTwoZeroMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:SixTwoZeroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-12-31_aimd_DrStephenTChenMember_aimd_FourOneNineMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:FourOneNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-12-31_aimd_DrStephenTChenMember_aimd_TwoOneSixMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:TwoOneSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_FourOneNineMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:FourOneNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-12-31_aimd_DrStephenTChenMember_aimd_ThreeOneNineMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:ThreeOneNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-12-31_aimd_DrStephenTChenMember_aimd_OneOneSixMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:OneOneSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ThreeOneNineMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:ThreeOneNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_OneOneSixMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:OneOneSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-12-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:ITwoChinaManagementGroupLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:EightBTwoZeroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-12-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightATwozeroMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:ITwoChinaManagementGroupLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:EightATwozeroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightATwozeroMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:ITwoChinaManagementGroupLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:EightATwozeroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-12-31_aimd_AinosKYMember_aimd_TotalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:AinosKYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:TotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_TotalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:AinosKYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:TotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_TwentyTwoOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:AinosKYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:TwentyTwoOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_NinteenTwoOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:AinosKYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:NinteenTwoOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_EighteenTwoOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:AinosKYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:EighteenTwoOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_SeventeenTwoOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:AinosKYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:SeventeenTwoOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_SixteenTwoOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:AinosKYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:SixteenTwoOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_FifteenTwoOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:AinosKYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:FifteenTwoOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_FourteenTwoOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:AinosKYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:FourteenTwoOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:ITwoChinaManagementGroupLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:EightBTwoZeroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-12-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_TotalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:ITwoChinaManagementGroupLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:TotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_TotalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:ITwoChinaManagementGroupLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:TotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_ThirteenTwoOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:AinosKYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:ThirteenTwoOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-12-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_FiveOneNineMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:ITwoChinaManagementGroupLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:FiveOneNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_FiveOneNineMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:ITwoChinaManagementGroupLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:FiveOneNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_ElevenOneTwoOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:ITwoChinaManagementGroupLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:ElevenOneTwoOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_TwelveTwoOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:AinosKYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:TwelveTwoOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TwoOneSixMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">aimd:TwoOneSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-09-30_aimd_SecuritiesPurchaseAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">aimd:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-09-30_aimd_SecuritiesPurchaseAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">aimd:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_aimd_SecuritiesPurchaseAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">aimd:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_aimd_SecuritiesPurchaseAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">aimd:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-07-01to2021-09-30_aimd_TranslationAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aimd:TranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-07-01to2021-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-07-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-07-01to2021-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-07-01to2021-09-30_us-gaap_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-06-30_aimd_TranslationAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aimd:TranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-06-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-06-30_us-gaap_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_aimd_TranslationAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aimd:TranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30_us-gaap_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-09-30_aimd_TranslationAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aimd:TranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-01-01to2021-09-30_us-gaap_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_aimd_TranslationAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aimd:TranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31_us-gaap_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-07-01to2020-09-30_aimd_TranslationAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aimd:TranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-07-01to2020-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-07-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-07-01to2020-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-07-01to2020-09-30_us-gaap_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-06-30_aimd_TranslationAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aimd:TranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-06-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-06-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-06-30_us-gaap_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_aimd_TranslationAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aimd:TranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-09-30_us-gaap_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-09-30_aimd_TranslationAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aimd:TranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-09-30_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-09-30_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-09-30_us-gaap_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-12-31_aimd_TranslationAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aimd:TranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2019-12-31_us-gaap_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="From2020-01-01to2020-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2020-07-01to2020-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="From2021-07-01to2021-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="AsOf2020-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="AsOf2021-11-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001014763</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="USDPShares"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 5px solid;"></td></tr><tr><td style="BORDER-BOTTOM: 2px solid;"></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.45pt; text-align:center;"><strong>UNITED STATES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.65pt; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.65pt; text-align:center;"><strong>Washington, D.C. 20549</strong>&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 1.45pt; text-align:center;"><br /><strong><span style="font-size:18pt">FORM <ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:DocumentType">10-Q</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>(Mark One)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric>&#160;&#160;&#160;&#160; QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">For the quarterly period ended <strong><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen">September 30, 2021</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">or</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160; TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">For the transition period from ____ to____ </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Commission File No. <strong><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:EntityFileNumber">0-20791</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:left;margin-left:auto;margin-right:auto;width:60%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span style="font-size:18pt"><strong><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:EntityRegistrantName">AINOS, INC.</ix:nonNumeric></strong></span></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Exact name of registrant as specified in its charter)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:45%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen">Texas</ix:nonNumeric></strong></p></td><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:45%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:EntityTaxIdentificationNumber">75-1974352</ix:nonNumeric></strong></p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(State or other jurisdiction of incorporation or organization)</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(IRS Employer Identification No.)</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px"><td colspan="3" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:EntityAddressAddressLine1">8880 Rio San Diego Drive</ix:nonNumeric>, <ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:EntityAddressAddressLine2">Ste. 800</ix:nonNumeric>, <ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:EntityAddressCityOrTown">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric> <ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:EntityAddressPostalZipCode">92108</ix:nonNumeric> </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="text-decoration:underline">(<ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:CityAreaCode">858</ix:nonNumeric>) <ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:LocalPhoneNumber">869-2986</ix:nonNumeric></span></strong></p></td></tr><tr style="height:15px"><td colspan="3" style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Address and telephone number, including area code, of registrant's principal executive offices)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#9746; <ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160; &#9744;&#160;No</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#9746; <ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160; &#9744;&#160;No </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:30%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Large accelerated filer</p></td><td style="width:20%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#9744;</p></td><td style="width:30%;vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Accelerated filer</p></td><td style="width:20%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#9746;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Smaller reporting company </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2021-01-01to2021-09-30" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Emerging growth company</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#9744;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act)&#160;&#9744; Yes&#160;&#160;&#160;&#160; &#9746; No</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><ix:nonFraction contextRef="AsOf2021-11-15" name="dei:EntityCommonStockSharesOutstanding" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">142,442,215</ix:nonFraction> shares of common stock, par value $0.01 per share, outstanding as of November 15, 2021 </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 2px solid;"></td></tr><tr><td style="BORDER-BOTTOM: 5px solid;"></td></tr></tbody></table><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="TEXT-INDENT: 0px;"></td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>AINOS, INC.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><span class="atag" style="display: inline" id="Toc">INDEX </span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:10%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PAGE NO.</strong></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#P1">PART I:</a></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#P1">FINANCIAL INFORMATION</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i1">ITEM 1.</a></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i1">Financial Statements</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#BS">Balance Sheets&#8211; September 30, 2021 and December 31, 2020 (unaudited)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#SO">Statements of Operations &#8211; Three and Nine Months Ended September 30, 2021 and 2020 (unaudited)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#SSE">Statements of Stockholders&#8217; Equity (Deficit) &#8211; Three Months Ended September 30, 2021 and 2020</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">5</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#SSE2">Statements of Stockholders&#8217; Equity (Deficit) &#8211; Nine Months Ended September 30, 2021 and 2020</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">6</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#CF">Condensed Statements of Cash Flows &#8211; Nine Months Ended September 30, 2021 and 2020 (unaudited)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">7</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#Notes">Notes to Financial Statements (unaudited)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#item2">ITEM 2.</a></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#item2">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">14</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#item3">ITEM 3.</a></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#item3">Quantitative and Qualitative Disclosures About Market Risk</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">32</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#item4">ITEM 4.</a></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#item4">Controls and Procedures</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">32</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#P2">PART II:</a></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#P2">OTHER INFORMATION</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#item1">ITEM 1.</a></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#item1">Legal Proceedings</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">33</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i2">ITEM 2.</a></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i2">Unregistered Sales of Equity Securities and Use of Proceeds</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">36</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i3">ITEM 3.</a></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i3">Defaults Upon Senior Securities</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">36</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i4">ITEM 4.</a></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i4">Mine Safety Disclosures</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">36</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i5">ITEM 5.</a></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i5">Other Information</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">36</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i6">ITEM 6.</a></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#i6">Exhibits</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">38</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="#sig">Signatures</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">39</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="P1">PART I - FINANCIAL INFORMATION</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="i1">ITEM 1. Financial Statements</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Ainos, Inc.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="BS">Balance Sheets</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(Unaudited)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September 30,</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Assets</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_907" contextRef="AsOf2021-09-30" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">706,931</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_908" contextRef="AsOf2020-12-31" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,245</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accounts receivable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_909" contextRef="AsOf2021-09-30" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,643</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_910" contextRef="AsOf2020-12-31" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Inventory</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_911" contextRef="AsOf2021-09-30" name="us-gaap:InventoryGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_912" contextRef="AsOf2020-12-31" name="us-gaap:InventoryGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,024</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Prepaid expense and other current assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_913" contextRef="AsOf2021-09-30" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">133,065</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_914" contextRef="AsOf2020-12-31" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,144</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total current assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_915" contextRef="AsOf2021-09-30" name="us-gaap:AssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">884,814</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_916" contextRef="AsOf2020-12-31" name="us-gaap:AssetsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,413</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Patents, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_917" contextRef="AsOf2021-09-30" name="us-gaap:FiniteLivedPatentsGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,011,337</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_918" contextRef="AsOf2020-12-31" name="us-gaap:FiniteLivedPatentsGross" format="ixt:numdotdecimal" decimals="0" unitRef="USD">180,628</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Property and equipment, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_919" contextRef="AsOf2021-09-30" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,956</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_920" contextRef="AsOf2020-12-31" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,249</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Right of Use Asset </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_921" contextRef="AsOf2021-09-30" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,724</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_922" contextRef="AsOf2020-12-31" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Other Assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_923" contextRef="AsOf2021-09-30" name="us-gaap:OtherAssetsNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,795</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_924" contextRef="AsOf2020-12-31" name="us-gaap:OtherAssetsNoncurrent" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_925" contextRef="AsOf2021-09-30" name="us-gaap:Assets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,993,626</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_926" contextRef="AsOf2020-12-31" name="us-gaap:Assets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">260,290</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Liabilities and Stockholders' Equity (Deficit)</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Current liabilities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accounts payable and accrued expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_929" contextRef="AsOf2021-09-30" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">578,549</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_930" contextRef="AsOf2020-12-31" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145,567</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Contract liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_931" contextRef="AsOf2021-09-30" name="us-gaap:DepositContractsLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,616</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_932" contextRef="AsOf2020-12-31" name="us-gaap:DepositContractsLiabilities" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Convertible notes payable &#8211; related party</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_933" contextRef="AsOf2021-09-30" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,193</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_934" contextRef="AsOf2020-12-31" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">805,001</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Convertible notes payable</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_935" contextRef="AsOf2021-09-30" name="us-gaap:ConvertibleNotesPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">185,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_936" contextRef="AsOf2020-12-31" name="us-gaap:ConvertibleNotesPayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Lease Obligation-Current</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_937" contextRef="AsOf2021-09-30" name="us-gaap:CapitalLeaseObligationsCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,619</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_938" contextRef="AsOf2020-12-31" name="us-gaap:CapitalLeaseObligationsCurrent" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total current liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_939" contextRef="AsOf2021-09-30" name="us-gaap:LiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,821,977</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_940" contextRef="AsOf2020-12-31" name="us-gaap:LiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,098,568</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-current liabilities:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Lease Obligation-Non current</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_942" contextRef="AsOf2021-09-30" name="aimd:LeaseObligationNonCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,289</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_943" contextRef="AsOf2020-12-31" name="aimd:LeaseObligationNonCurrent" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_944" contextRef="AsOf2021-09-30" name="us-gaap:Liabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,857,266</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_945" contextRef="AsOf2020-12-31" name="us-gaap:Liabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,098,568</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Stockholders' equity (deficit)</strong></p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Preferred stock, $<ix:nonFraction id="fid_256" contextRef="AsOf2021-09-30" name="us-gaap:PreferredStockParOrStatedValuePerShare" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction> par value, <ix:nonFraction id="fid_258" contextRef="AsOf2021-09-30" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:numdotdecimal" decimals="-6" unitRef="Shares" scale="6">10</ix:nonFraction> million shares authorized, <ix:nonFraction id="fid_260" contextRef="AsOf2021-09-30" name="us-gaap:PreferredStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">0</ix:nonFraction> shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_947" contextRef="AsOf2021-09-30" name="us-gaap:PreferredStockValue" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_948" contextRef="AsOf2020-12-31" name="us-gaap:PreferredStockValue" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Common Stock, $<ix:nonFraction id="fid_264" contextRef="AsOf2021-09-30" name="us-gaap:CommonStockParOrStatedValuePerShare" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction> par value, <ix:nonFraction id="fid_266" contextRef="AsOf2021-09-30" name="us-gaap:CommonStockSharesAuthorized" format="ixt:numdotdecimal" decimals="-6" unitRef="Shares" scale="6">300</ix:nonFraction> million shares authorized, <ix:nonFraction id="fid_268" contextRef="AsOf2021-09-30" name="us-gaap:CommonStockSharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">142,442,215</ix:nonFraction> and<ix:nonFraction id="fid_271" contextRef="AsOf2020-12-31" name="us-gaap:CommonStockSharesOutstanding" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">42,066,172</ix:nonFraction> shares outstanding at September 30, 2021 and December 31, 2020, respectively</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_949" contextRef="AsOf2021-09-30" name="us-gaap:CommonStockValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,424,422</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_950" contextRef="AsOf2020-12-31" name="us-gaap:CommonStockValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">420,662</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Additional paid-in capital</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_951" contextRef="AsOf2021-09-30" name="us-gaap:AdditionalPaidInCapital" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,369,245</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_952" contextRef="AsOf2020-12-31" name="us-gaap:AdditionalPaidInCapital" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,961,315</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Accumulated deficit</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_953" contextRef="AsOf2021-09-30" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">8,664,145</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_954" contextRef="AsOf2020-12-31" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">6,220,255</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Translation adjustment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_955" contextRef="AsOf2021-09-30" name="aimd:TranslationAdjustmentLiability" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,838</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_956" contextRef="AsOf2020-12-31" name="aimd:TranslationAdjustmentLiability" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total stockholders&#8217; equity (deficit)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_957" contextRef="AsOf2021-09-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,136,360</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_958" contextRef="AsOf2020-12-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">838,278</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total liabilities and stockholders&#8217; equity (deficit)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_959" contextRef="AsOf2021-09-30" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,993,626</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_960" contextRef="AsOf2020-12-31" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">260,290</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>See accompanying notes to financial statements.</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Ainos, Inc.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="SO">Statements of Operations </span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(Unaudited)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three months ended September 30</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine months ended September 30</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Revenues</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_961" contextRef="From2021-07-01to2021-09-30" name="us-gaap:Revenues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">363,052</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_962" contextRef="From2020-07-01to2020-09-30" name="us-gaap:Revenues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">192</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_963" contextRef="From2021-01-01to2021-09-30" name="us-gaap:Revenues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">568,164</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_964" contextRef="From2020-01-01to2020-09-30" name="us-gaap:Revenues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,876</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cost of revenues</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_965" contextRef="From2021-07-01to2021-09-30" name="us-gaap:CostOfRevenue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">103,638</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_966" contextRef="From2020-07-01to2020-09-30" name="us-gaap:CostOfRevenue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">123</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_967" contextRef="From2021-01-01to2021-09-30" name="us-gaap:CostOfRevenue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">174,395</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_968" contextRef="From2020-01-01to2020-09-30" name="us-gaap:CostOfRevenue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,221</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Gross margin </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_969" contextRef="From2021-07-01to2021-09-30" name="us-gaap:GrossProfit" format="ixt:numdotdecimal" decimals="0" unitRef="USD">259,414</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_970" contextRef="From2020-07-01to2020-09-30" name="us-gaap:GrossProfit" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_971" contextRef="From2021-01-01to2021-09-30" name="us-gaap:GrossProfit" format="ixt:numdotdecimal" decimals="0" unitRef="USD">393,769</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_972" contextRef="From2020-01-01to2020-09-30" name="us-gaap:GrossProfit" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,655</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating expenses:</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Research and development expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_974" contextRef="From2021-07-01to2021-09-30" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">646,798</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_975" contextRef="From2020-07-01to2020-09-30" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_976" contextRef="From2021-01-01to2021-09-30" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">646,798</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_977" contextRef="From2020-01-01to2020-09-30" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">389</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Selling, general and administrative expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_978" contextRef="From2021-07-01to2021-09-30" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">795,958</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_979" contextRef="From2020-07-01to2020-09-30" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">321,153</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_980" contextRef="From2021-01-01to2021-09-30" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,178,969</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_981" contextRef="From2020-01-01to2020-09-30" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,001,893</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;Total operating expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_982" contextRef="From2021-07-01to2021-09-30" name="us-gaap:NonoperatingIncomeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,442,756</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_983" contextRef="From2020-07-01to2020-09-30" name="us-gaap:NonoperatingIncomeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">321,153</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_984" contextRef="From2021-01-01to2021-09-30" name="us-gaap:NonoperatingIncomeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,825,767</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_985" contextRef="From2020-01-01to2020-09-30" name="us-gaap:NonoperatingIncomeExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,002,282</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_986" contextRef="From2021-07-01to2021-09-30" name="us-gaap:OperatingIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">1,183,342</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_987" contextRef="From2020-07-01to2020-09-30" name="us-gaap:OperatingIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">321,084</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_988" contextRef="From2021-01-01to2021-09-30" name="us-gaap:OperatingIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,431,998</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_989" contextRef="From2020-01-01to2020-09-30" name="us-gaap:OperatingIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">997,627</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-operating income and expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Interest Income, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_991" contextRef="From2021-07-01to2021-09-30" name="us-gaap:InvestmentIncomeInterest" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,517</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_992" contextRef="From2020-07-01to2020-09-30" name="us-gaap:InvestmentIncomeInterest" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,201</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_993" contextRef="From2021-01-01to2021-09-30" name="us-gaap:InvestmentIncomeInterest" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,361</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_994" contextRef="From2020-01-01to2020-09-30" name="us-gaap:InvestmentIncomeInterest" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,503</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Other Losses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_995" contextRef="From2021-07-01to2021-09-30" name="aimd:OtherLosses" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">285</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_996" contextRef="From2020-07-01to2020-09-30" name="aimd:OtherLosses" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_997" contextRef="From2021-01-01to2021-09-30" name="aimd:OtherLosses" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,532</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_998" contextRef="From2020-01-01to2020-09-30" name="aimd:OtherLosses" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;Total Non-operating income and expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_999" contextRef="From2021-07-01to2021-09-30" name="aimd:TotalNonOperatingIncomeAndExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,232</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1000" contextRef="From2020-07-01to2020-09-30" name="aimd:TotalNonOperatingIncomeAndExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,201</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1001" contextRef="From2021-01-01to2021-09-30" name="aimd:TotalNonOperatingIncomeAndExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">11,893</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1002" contextRef="From2020-01-01to2020-09-30" name="aimd:TotalNonOperatingIncomeAndExpenses" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">4,503</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Profit before income tax</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1003" contextRef="From2021-07-01to2021-09-30" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">1,160,110</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1004" contextRef="From2020-07-01to2020-09-30" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">323,285</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1005" contextRef="From2021-01-01to2021-09-30" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,443,891</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1006" contextRef="From2020-01-01to2020-09-30" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">1,002,130</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Less: Income tax</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1009" contextRef="From2021-01-01to2021-09-30" name="aimd:LessIncomeTax" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1007" contextRef="From2021-07-01to2021-09-30" name="aimd:LessIncomeTax" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1010" contextRef="From2020-01-01to2020-09-30" name="aimd:LessIncomeTax" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1008" contextRef="From2020-07-01to2020-09-30" name="aimd:LessIncomeTax" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1011" contextRef="From2021-07-01to2021-09-30" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">1,160,110</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1012" contextRef="From2020-07-01to2020-09-30" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">323,285</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1013" contextRef="From2021-01-01to2021-09-30" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,443,891</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1014" contextRef="From2020-01-01to2020-09-30" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">1,002,130</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Basic and diluted net loss per average share available to common shareholders</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1015" contextRef="From2021-07-01to2021-09-30" name="us-gaap:EarningsPerShareBasicAndDiluted" decimals="INF" unitRef="USDPShares" sign="-">0.10</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1016" contextRef="From2020-07-01to2020-09-30" name="us-gaap:EarningsPerShareBasicAndDiluted" decimals="INF" unitRef="USDPShares" sign="-">0.01</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1017" contextRef="From2021-01-01to2021-09-30" name="us-gaap:EarningsPerShareBasicAndDiluted" decimals="INF" unitRef="USDPShares" sign="-">0.03</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1018" contextRef="From2020-01-01to2020-09-30" name="us-gaap:EarningsPerShareBasicAndDiluted" decimals="INF" unitRef="USDPShares" sign="-">0.02</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Weighted average common shares outstanding &#8211; basic and diluted</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1019" contextRef="From2021-07-01to2021-09-30" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">142,419,337</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1020" contextRef="From2020-07-01to2020-09-30" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">40,516,351</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1021" contextRef="From2021-01-01to2021-09-30" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">75,919,713</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1022" contextRef="From2020-01-01to2020-09-30" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">40,620,055</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>See accompanying notes to financial statements.</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Ainos, Inc.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="SSE">Statements of Stockholders&#8217; Equity (Deficit)</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>For the three months ended September 30, 2021 and 2020</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(Unaudited)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Preferred Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Common Stock</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Additional Paid in&#160;&#160;</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Accumulated&#160;&#160;</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Translation&#160;&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total Stockholders&#8217; Equity </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Par Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Par Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Capital</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Deficit</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Adjustment</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;(Deficit)</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance June 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1025" contextRef="AsOf2021-06-30_us-gaap_PreferredStockMember" name="us-gaap:StockholdersEquity" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1024" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">142,271,815</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1026" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,422,718</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1027" contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,286,875</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1028" contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">7,504,035</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1029" contextRef="AsOf2021-06-30_aimd_TranslationAdjustmentMember" name="us-gaap:StockholdersEquity" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1030" contextRef="AsOf2021-06-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,205,557</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Issuance of stock for compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1031" contextRef="From2021-07-01to2021-09-30_us-gaap_PreferredStockMember" name="aimd:IssuanceOfStockForCompensationAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1032" contextRef="From2021-07-01to2021-09-30_us-gaap_CommonStockMember" name="aimd:IssuanceOfStockForCompensationAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1033" contextRef="From2021-07-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember" name="aimd:IssuanceOfStockForCompensationAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1034" contextRef="From2021-07-01to2021-09-30_us-gaap_RetainedEarningsMember" name="aimd:IssuanceOfStockForCompensationAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1035" contextRef="From2021-07-01to2021-09-30_aimd_TranslationAdjustmentMember" name="aimd:IssuanceOfStockForCompensationAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1036" contextRef="From2021-07-01to2021-09-30" name="aimd:IssuanceOfStockForCompensationAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Issuance of stock for Patent assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1037" contextRef="From2021-07-01to2021-09-30_us-gaap_PreferredStockMember" name="aimd:IssuanceOfStockForPatentAssetsAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1038" contextRef="From2021-07-01to2021-09-30_us-gaap_CommonStockMember" name="aimd:IssuanceOfStockForPatentAssetsAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1039" contextRef="From2021-07-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember" name="aimd:IssuanceOfStockForPatentAssetsAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1040" contextRef="From2021-07-01to2021-09-30_us-gaap_RetainedEarningsMember" name="aimd:IssuanceOfStockForPatentAssetsAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1041" contextRef="From2021-07-01to2021-09-30_aimd_TranslationAdjustmentMember" name="aimd:IssuanceOfStockForPatentAssetsAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1042" contextRef="From2021-07-01to2021-09-30" name="aimd:IssuanceOfStockForPatentAssetsAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Issuance of stock for Option</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1045" contextRef="From2021-07-01to2021-09-30_us-gaap_PreferredStockMember" name="aimd:IssuanceOfStockForOptionAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1044" contextRef="From2021-07-01to2021-09-30_us-gaap_CommonStockMember" name="aimd:IssuanceOfStockForOptionShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">170,400</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1046" contextRef="From2021-07-01to2021-09-30_us-gaap_CommonStockMember" name="aimd:IssuanceOfStockForOptionAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,704</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1047" contextRef="From2021-07-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember" name="aimd:IssuanceOfStockForOptionAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">63,048</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1048" contextRef="From2021-07-01to2021-09-30_us-gaap_RetainedEarningsMember" name="aimd:IssuanceOfStockForOptionAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1049" contextRef="From2021-07-01to2021-09-30_aimd_TranslationAdjustmentMember" name="aimd:IssuanceOfStockForOptionAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1050" contextRef="From2021-07-01to2021-09-30" name="aimd:IssuanceOfStockForOptionAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,752</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrant expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1051" contextRef="From2021-07-01to2021-09-30_us-gaap_PreferredStockMember" name="aimd:WarrantExpense" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1052" contextRef="From2021-07-01to2021-09-30_us-gaap_CommonStockMember" name="aimd:WarrantExpense" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1053" contextRef="From2021-07-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember" name="aimd:WarrantExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,417</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1054" contextRef="From2021-07-01to2021-09-30_us-gaap_RetainedEarningsMember" name="aimd:WarrantExpense" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1055" contextRef="From2021-07-01to2021-09-30_aimd_TranslationAdjustmentMember" name="aimd:WarrantExpense" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1056" contextRef="From2021-07-01to2021-09-30" name="aimd:WarrantExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,417</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Option expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1057" contextRef="From2021-07-01to2021-09-30_us-gaap_PreferredStockMember" name="aimd:OptionExpense" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1058" contextRef="From2021-07-01to2021-09-30_us-gaap_CommonStockMember" name="aimd:OptionExpense" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1059" contextRef="From2021-07-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember" name="aimd:OptionExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,905</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1060" contextRef="From2021-07-01to2021-09-30_us-gaap_RetainedEarningsMember" name="aimd:OptionExpense" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1061" contextRef="From2021-07-01to2021-09-30_aimd_TranslationAdjustmentMember" name="aimd:OptionExpense" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1062" contextRef="From2021-07-01to2021-09-30" name="aimd:OptionExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,905</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1063" contextRef="From2021-07-01to2021-09-30_us-gaap_PreferredStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1064" contextRef="From2021-07-01to2021-09-30_us-gaap_CommonStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1065" contextRef="From2021-07-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1066" contextRef="From2021-07-01to2021-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">1,160,110</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1067" contextRef="From2021-07-01to2021-09-30_aimd_TranslationAdjustmentMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(1,160,109</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Translation adjustment </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1069" contextRef="From2021-07-01to2021-09-30_us-gaap_PreferredStockMember" name="aimd:TranslationAdjustment" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1070" contextRef="From2021-07-01to2021-09-30_us-gaap_CommonStockMember" name="aimd:TranslationAdjustment" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1071" contextRef="From2021-07-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember" name="aimd:TranslationAdjustment" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1072" contextRef="From2021-07-01to2021-09-30_us-gaap_RetainedEarningsMember" name="aimd:TranslationAdjustment" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1073" contextRef="From2021-07-01to2021-09-30_aimd_TranslationAdjustmentMember" name="aimd:TranslationAdjustment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,838</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1074" contextRef="From2021-07-01to2021-09-30" name="aimd:TranslationAdjustment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,838</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance September 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1077" contextRef="AsOf2021-09-30_us-gaap_PreferredStockMember" name="us-gaap:StockholdersEquity" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1076" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">142,442,215</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1078" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,424,422</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1079" contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,369,245</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1080" contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">8,664,145</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1081" contextRef="AsOf2021-09-30_aimd_TranslationAdjustmentMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,838</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1082" contextRef="AsOf2021-09-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,136,360</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance June 30, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1085" contextRef="AsOf2020-06-30_us-gaap_PreferredStockMember" name="us-gaap:StockholdersEquity" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1084" contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">40,516,351</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1086" contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">405,164</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1087" contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,299,196</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1088" contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">5,448,477</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1089" contextRef="AsOf2020-06-30_aimd_TranslationAdjustmentMember" name="us-gaap:StockholdersEquity" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1090" contextRef="AsOf2020-06-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">744,117</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Issuance of stock for compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1091" contextRef="From2020-07-01to2020-09-30_us-gaap_PreferredStockMember" name="aimd:IssuanceOfStockForCompensationAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1092" contextRef="From2020-07-01to2020-09-30_us-gaap_CommonStockMember" name="aimd:IssuanceOfStockForCompensationAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1093" contextRef="From2020-07-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember" name="aimd:IssuanceOfStockForCompensationAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1094" contextRef="From2020-07-01to2020-09-30_us-gaap_RetainedEarningsMember" name="aimd:IssuanceOfStockForCompensationAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1095" contextRef="From2020-07-01to2020-09-30_aimd_TranslationAdjustmentMember" name="aimd:IssuanceOfStockForCompensationAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1096" contextRef="From2020-07-01to2020-09-30" name="aimd:IssuanceOfStockForCompensationAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Issuance of stock for cash</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1099" contextRef="From2020-07-01to2020-09-30_us-gaap_PreferredStockMember" name="aimd:IssuanceOfStockForCashAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1098" contextRef="From2020-07-01to2020-09-30_us-gaap_CommonStockMember" name="aimd:IssuanceOfStockForCashShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">400,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1100" contextRef="From2020-07-01to2020-09-30_us-gaap_CommonStockMember" name="aimd:IssuanceOfStockForCashAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1101" contextRef="From2020-07-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember" name="aimd:IssuanceOfStockForCashAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1102" contextRef="From2020-07-01to2020-09-30_us-gaap_RetainedEarningsMember" name="aimd:IssuanceOfStockForCashAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1103" contextRef="From2020-07-01to2020-09-30_aimd_TranslationAdjustmentMember" name="aimd:IssuanceOfStockForCashAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1104" contextRef="From2020-07-01to2020-09-30" name="aimd:IssuanceOfStockForCashAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrant expense </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1105" contextRef="From2020-07-01to2020-09-30_us-gaap_PreferredStockMember" name="aimd:WarrantExpense" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1106" contextRef="From2020-07-01to2020-09-30_us-gaap_CommonStockMember" name="aimd:WarrantExpense" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1107" contextRef="From2020-07-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember" name="aimd:WarrantExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,496</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1108" contextRef="From2020-07-01to2020-09-30_us-gaap_RetainedEarningsMember" name="aimd:WarrantExpense" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1109" contextRef="From2020-07-01to2020-09-30_aimd_TranslationAdjustmentMember" name="aimd:WarrantExpense" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1110" contextRef="From2020-07-01to2020-09-30" name="aimd:WarrantExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,496</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Option expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1111" contextRef="From2020-07-01to2020-09-30_us-gaap_PreferredStockMember" name="aimd:OptionExpense" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1112" contextRef="From2020-07-01to2020-09-30_us-gaap_CommonStockMember" name="aimd:OptionExpense" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1113" contextRef="From2020-07-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember" name="aimd:OptionExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181,376</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1114" contextRef="From2020-07-01to2020-09-30_us-gaap_RetainedEarningsMember" name="aimd:OptionExpense" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1115" contextRef="From2020-07-01to2020-09-30_aimd_TranslationAdjustmentMember" name="aimd:OptionExpense" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1116" contextRef="From2020-07-01to2020-09-30" name="aimd:OptionExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181,376</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss for the period ended June 30, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1117" contextRef="From2020-07-01to2020-09-30_us-gaap_PreferredStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1118" contextRef="From2020-07-01to2020-09-30_us-gaap_CommonStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1119" contextRef="From2020-07-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1120" contextRef="From2020-07-01to2020-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">323,285</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1121" contextRef="From2020-07-01to2020-09-30_aimd_TranslationAdjustmentMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1122" contextRef="From2020-07-01to2020-09-30" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">323,285</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Translation adjustment </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1123" contextRef="From2020-07-01to2020-09-30_us-gaap_PreferredStockMember" name="aimd:TranslationAdjustment" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1124" contextRef="From2020-07-01to2020-09-30_us-gaap_CommonStockMember" name="aimd:TranslationAdjustment" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1125" contextRef="From2020-07-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember" name="aimd:TranslationAdjustment" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1126" contextRef="From2020-07-01to2020-09-30_us-gaap_RetainedEarningsMember" name="aimd:TranslationAdjustment" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1127" contextRef="From2020-07-01to2020-09-30_aimd_TranslationAdjustmentMember" name="aimd:TranslationAdjustment" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1128" contextRef="From2020-07-01to2020-09-30" name="aimd:TranslationAdjustment" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance September 30, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1131" contextRef="AsOf2020-09-30_us-gaap_PreferredStockMember" name="us-gaap:StockholdersEquity" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1130" contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">40,916,351</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1132" contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">409,164</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1133" contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,586,068</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1134" contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">5,771,762</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1135" contextRef="AsOf2020-09-30_aimd_TranslationAdjustmentMember" name="us-gaap:StockholdersEquity" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1136" contextRef="AsOf2020-09-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">776,530</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>See accompanying notes to financial statements.</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Ainos, Inc.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="SSE2">Statements of Stockholders&#8217; Equity (Deficit)</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>For the nine months ended September 30, 2021 and 2020</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(Unaudited)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Preferred Stock</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Common Stock</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Additional Paid in </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Accumulated </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Translation </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="width:6%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total Stockholders&#8217; Equity </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Par Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Par Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;Capital</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Deficit&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Adjustment&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:bottom;text-align:center;" colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>(Deficit)</strong>&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance December 31, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1139" contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember" name="us-gaap:StockholdersEquity" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1138" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">42,066,172</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1140" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">420,661</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1141" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,961,315</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1142" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">6,220,254</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1143" contextRef="AsOf2020-12-31_aimd_TranslationAdjustmentMember" name="us-gaap:StockholdersEquity" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1144" contextRef="AsOf2020-12-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">838,278</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Issuance of stock for compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1147" contextRef="From2021-01-01to2021-09-30_us-gaap_PreferredStockMember" name="aimd:IssuanceOfStockForCompensationAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1146" contextRef="From2021-01-01to2021-09-30_us-gaap_CommonStockMember" name="aimd:IssuanceOfStockForCompensationShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">205,643</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1148" contextRef="From2021-01-01to2021-09-30_us-gaap_CommonStockMember" name="aimd:IssuanceOfStockForCompensationAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,056</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1149" contextRef="From2021-01-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember" name="aimd:IssuanceOfStockForCompensationAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">137,349</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1150" contextRef="From2021-01-01to2021-09-30_us-gaap_RetainedEarningsMember" name="aimd:IssuanceOfStockForCompensationAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1151" contextRef="From2021-01-01to2021-09-30_aimd_TranslationAdjustmentMember" name="aimd:IssuanceOfStockForCompensationAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1152" contextRef="From2021-01-01to2021-09-30" name="aimd:IssuanceOfStockForCompensationAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">139,405</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Issuance of stock for Patent assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1155" contextRef="From2021-01-01to2021-09-30_us-gaap_PreferredStockMember" name="aimd:IssuanceOfStockForPatentAssetsAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1154" contextRef="From2021-01-01to2021-09-30_us-gaap_CommonStockMember" name="aimd:IssuanceOfStockForPatentAssetsShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">100,000,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1156" contextRef="From2021-01-01to2021-09-30_us-gaap_CommonStockMember" name="aimd:IssuanceOfStockForPatentAssetsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1157" contextRef="From2021-01-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember" name="aimd:IssuanceOfStockForPatentAssetsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,000,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1158" contextRef="From2021-01-01to2021-09-30_us-gaap_RetainedEarningsMember" name="aimd:IssuanceOfStockForPatentAssetsAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1159" contextRef="From2021-01-01to2021-09-30_aimd_TranslationAdjustmentMember" name="aimd:IssuanceOfStockForPatentAssetsAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1160" contextRef="From2021-01-01to2021-09-30" name="aimd:IssuanceOfStockForPatentAssetsAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Issuance of stock for Option</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1163" contextRef="From2021-01-01to2021-09-30_us-gaap_PreferredStockMember" name="aimd:IssuanceOfStockForOptionAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1162" contextRef="From2021-01-01to2021-09-30_us-gaap_CommonStockMember" name="aimd:IssuanceOfStockForOptionShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">170,400</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1164" contextRef="From2021-01-01to2021-09-30_us-gaap_CommonStockMember" name="aimd:IssuanceOfStockForOptionAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,704</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1165" contextRef="From2021-01-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember" name="aimd:IssuanceOfStockForOptionAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">63,048</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1166" contextRef="From2021-01-01to2021-09-30_us-gaap_RetainedEarningsMember" name="aimd:IssuanceOfStockForOptionAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1167" contextRef="From2021-01-01to2021-09-30_aimd_TranslationAdjustmentMember" name="aimd:IssuanceOfStockForOptionAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1168" contextRef="From2021-01-01to2021-09-30" name="aimd:IssuanceOfStockForOptionAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,752</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrant expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1169" contextRef="From2021-01-01to2021-09-30_us-gaap_PreferredStockMember" name="aimd:WarrantExpense" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1170" contextRef="From2021-01-01to2021-09-30_us-gaap_CommonStockMember" name="aimd:WarrantExpense" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1171" contextRef="From2021-01-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember" name="aimd:WarrantExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,252</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1172" contextRef="From2021-01-01to2021-09-30_us-gaap_RetainedEarningsMember" name="aimd:WarrantExpense" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1173" contextRef="From2021-01-01to2021-09-30_aimd_TranslationAdjustmentMember" name="aimd:WarrantExpense" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1174" contextRef="From2021-01-01to2021-09-30" name="aimd:WarrantExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,252</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Option expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1175" contextRef="From2021-01-01to2021-09-30_us-gaap_PreferredStockMember" name="aimd:OptionExpense" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1176" contextRef="From2021-01-01to2021-09-30_us-gaap_CommonStockMember" name="aimd:OptionExpense" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1177" contextRef="From2021-01-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember" name="aimd:OptionExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">197,281</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1178" contextRef="From2021-01-01to2021-09-30_us-gaap_RetainedEarningsMember" name="aimd:OptionExpense" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1179" contextRef="From2021-01-01to2021-09-30_aimd_TranslationAdjustmentMember" name="aimd:OptionExpense" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1180" contextRef="From2021-01-01to2021-09-30" name="aimd:OptionExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">197,281</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1181" contextRef="From2021-01-01to2021-09-30_us-gaap_PreferredStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1182" contextRef="From2021-01-01to2021-09-30_us-gaap_CommonStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1183" contextRef="From2021-01-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1184" contextRef="From2021-01-01to2021-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,443,891</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1185" contextRef="From2021-01-01to2021-09-30_aimd_TranslationAdjustmentMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1186" contextRef="From2021-01-01to2021-09-30" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">2,443,891</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Translation adjustment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1187" contextRef="From2021-01-01to2021-09-30_us-gaap_PreferredStockMember" name="aimd:TranslationAdjustment" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1188" contextRef="From2021-01-01to2021-09-30_us-gaap_CommonStockMember" name="aimd:TranslationAdjustment" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1189" contextRef="From2021-01-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember" name="aimd:TranslationAdjustment" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1190" contextRef="From2021-01-01to2021-09-30_us-gaap_RetainedEarningsMember" name="aimd:TranslationAdjustment" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1191" contextRef="From2021-01-01to2021-09-30_aimd_TranslationAdjustmentMember" name="aimd:TranslationAdjustment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,838</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1192" contextRef="From2021-01-01to2021-09-30" name="aimd:TranslationAdjustment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,838</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance September 30, 2021</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1195" contextRef="AsOf2021-09-30_us-gaap_PreferredStockMember" name="us-gaap:StockholdersEquity" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1194" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">142,442,215</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1196" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,424,422</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1197" contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,369,245</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1198" contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">8,664,145</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1199" contextRef="AsOf2021-09-30_aimd_TranslationAdjustmentMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,838</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1200" contextRef="AsOf2021-09-30" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,136,360</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance December 31, 2019</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1203" contextRef="AsOf2019-12-31_us-gaap_PreferredStockMember" name="us-gaap:StockholdersEquity" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1202" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">40,516,351</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1204" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">405,164</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1205" contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,207,786</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1206" contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">4,769,632</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1207" contextRef="AsOf2019-12-31_aimd_TranslationAdjustmentMember" name="us-gaap:StockholdersEquity" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1208" contextRef="AsOf2019-12-31" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">156,682</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Issuance of stock for compensation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1209" contextRef="From2020-01-01to2020-09-30_us-gaap_PreferredStockMember" name="aimd:IssuanceOfStockForCompensationAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1210" contextRef="From2020-01-01to2020-09-30_us-gaap_CommonStockMember" name="aimd:IssuanceOfStockForCompensationAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1211" contextRef="From2020-01-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember" name="aimd:IssuanceOfStockForCompensationAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1212" contextRef="From2020-01-01to2020-09-30_us-gaap_RetainedEarningsMember" name="aimd:IssuanceOfStockForCompensationAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1213" contextRef="From2020-01-01to2020-09-30_aimd_TranslationAdjustmentMember" name="aimd:IssuanceOfStockForCompensationAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1214" contextRef="From2020-01-01to2020-09-30" name="aimd:IssuanceOfStockForCompensationAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Issuance of stock for cash</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1216" contextRef="From2020-01-01to2020-09-30_us-gaap_CommonStockMember" name="aimd:IssuanceOfStockForCashShares" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">400,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1218" contextRef="From2020-01-01to2020-09-30_us-gaap_CommonStockMember" name="aimd:IssuanceOfStockForCashAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1219" contextRef="From2020-01-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember" name="aimd:IssuanceOfStockForCashAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1220" contextRef="From2020-01-01to2020-09-30_us-gaap_RetainedEarningsMember" name="aimd:IssuanceOfStockForCashAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1221" contextRef="From2020-01-01to2020-09-30_aimd_TranslationAdjustmentMember" name="aimd:IssuanceOfStockForCashAmount" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1222" contextRef="From2020-01-01to2020-09-30" name="aimd:IssuanceOfStockForCashAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Issuance of stock for debt</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrant expense </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1229" contextRef="From2020-01-01to2020-09-30_us-gaap_PreferredStockMember" name="aimd:WarrantExpense" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1230" contextRef="From2020-01-01to2020-09-30_us-gaap_CommonStockMember" name="aimd:WarrantExpense" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1231" contextRef="From2020-01-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember" name="aimd:WarrantExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,218</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1232" contextRef="From2020-01-01to2020-09-30_us-gaap_RetainedEarningsMember" name="aimd:WarrantExpense" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1233" contextRef="From2020-01-01to2020-09-30_aimd_TranslationAdjustmentMember" name="aimd:WarrantExpense" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1234" contextRef="From2020-01-01to2020-09-30" name="aimd:WarrantExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,218</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Option expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1235" contextRef="From2020-01-01to2020-09-30_us-gaap_PreferredStockMember" name="aimd:OptionExpense" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1236" contextRef="From2020-01-01to2020-09-30_us-gaap_CommonStockMember" name="aimd:OptionExpense" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1237" contextRef="From2020-01-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember" name="aimd:OptionExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">272,064</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1238" contextRef="From2020-01-01to2020-09-30_us-gaap_RetainedEarningsMember" name="aimd:OptionExpense" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1239" contextRef="From2020-01-01to2020-09-30_aimd_TranslationAdjustmentMember" name="aimd:OptionExpense" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">272,064</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1241" contextRef="From2020-01-01to2020-09-30_us-gaap_PreferredStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1242" contextRef="From2020-01-01to2020-09-30_us-gaap_CommonStockMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1243" contextRef="From2020-01-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1244" contextRef="From2020-01-01to2020-09-30_us-gaap_RetainedEarningsMember" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">1,002,130</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1245" contextRef="From2020-01-01to2020-09-30_aimd_TranslationAdjustmentMember" name="us-gaap:NetIncomeLoss" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:6%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1246" contextRef="From2020-01-01to2020-09-30" name="us-gaap:NetIncomeLoss" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">1,002,130</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Translation adjustment </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1247" contextRef="From2020-01-01to2020-09-30_us-gaap_PreferredStockMember" name="aimd:TranslationAdjustment" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1248" contextRef="From2020-01-01to2020-09-30_us-gaap_CommonStockMember" name="aimd:TranslationAdjustment" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1249" contextRef="From2020-01-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember" name="aimd:TranslationAdjustment" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1250" contextRef="From2020-01-01to2020-09-30_us-gaap_RetainedEarningsMember" name="aimd:TranslationAdjustment" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1251" contextRef="From2020-01-01to2020-09-30_aimd_TranslationAdjustmentMember" name="aimd:TranslationAdjustment" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1252" contextRef="From2020-01-01to2020-09-30" name="aimd:TranslationAdjustment" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Balance September 30, 2020</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1254" contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" name="us-gaap:SharesIssued" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">40,916,351</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">409,164</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">4,586,068</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">(5,771,762</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:6%;vertical-align:bottom;text-align:right;">(776,530</td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>See accompanying notes to financial statements.</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Ainos, Inc.<br /><span class="atag" style="display: inline" id="CF">Condensed Statements of Cash Flow</span><br />(Unaudited)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine months ended </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September 30, 2021</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net cash used in operating activities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1256" contextRef="From2021-01-01to2021-09-30" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">569,150</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1257" contextRef="From2020-01-01to2020-09-30" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">244,967</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cash flows from investing activities </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Investment in patents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1259" contextRef="From2021-01-01to2021-09-30" name="aimd:InvestmentInPatents" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1260" contextRef="From2020-01-01to2020-09-30" name="aimd:InvestmentInPatents" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">1,891</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Purchase of fixed assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1261" contextRef="From2021-01-01to2021-09-30" name="us-gaap:PaymentsToAcquireAssetsInvestingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,581</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1262" contextRef="From2020-01-01to2020-09-30" name="us-gaap:PaymentsToAcquireAssetsInvestingActivities" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Proceeds from disposal of property, plant and equipment</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1263" contextRef="From2021-01-01to2021-09-30" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1264" contextRef="From2020-01-01to2020-09-30" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Increase in refundable deposits</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1265" contextRef="From2021-01-01to2021-09-30" name="aimd:IncreaseInRefundableDeposits" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,795</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1266" contextRef="From2020-01-01to2020-09-30" name="aimd:IncreaseInRefundableDeposits" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Net cash flows used in investing activities </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1267" contextRef="From2021-01-01to2021-09-30" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">43,340</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1268" contextRef="From2020-01-01to2020-09-30" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">1,891</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cash flows from financing activities </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Advances from shareholder</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1270" contextRef="From2021-01-01to2021-09-30" name="aimd:AdvancesFromShareholder" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1271" contextRef="From2020-01-01to2020-09-30" name="aimd:AdvancesFromShareholder" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Proceeds from private placement offering, net</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1272" contextRef="From2021-01-01to2021-09-30" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1273" contextRef="From2020-01-01to2020-09-30" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Proceeds from exercise of share options</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1274" contextRef="From2021-01-01to2021-09-30" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,752</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1275" contextRef="From2020-01-01to2020-09-30" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Payments of lease liabilities</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1276" contextRef="From2021-01-01to2021-09-30" name="aimd:PaymentsOfLeaseLiabilities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,815</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1277" contextRef="From2020-01-01to2020-09-30" name="aimd:PaymentsOfLeaseLiabilities" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Proceeds from convertible note payable &#8211;related party</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1278" contextRef="From2021-01-01to2021-09-30" name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,232,192</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1279" contextRef="From2020-01-01to2020-09-30" name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 30px">Net cash&#160;provided by&#160;financing activities </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1280" contextRef="From2021-01-01to2021-09-30" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,290,129</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1281" contextRef="From2020-01-01to2020-09-30" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Effect of changes in exchange rates</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1282" contextRef="From2021-01-01to2021-09-30" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,046</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1283" contextRef="From2020-01-01to2020-09-30" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">Net&#160;change in cash and cash equivalents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1284" contextRef="From2021-01-01to2021-09-30" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" format="ixt:numdotdecimal" decimals="0" unitRef="USD">677,639</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(<ix:nonFraction id="fid_1285" contextRef="From2020-01-01to2020-09-30" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" format="ixt:numdotdecimal" decimals="0" unitRef="USD" sign="-">325,272</ix:nonFraction></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cash and cash equivalents at beginning of period </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1286" contextRef="AsOf2020-12-31" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,245</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1287" contextRef="AsOf2019-12-31" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">409,039</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cash and cash equivalents at end of period </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1288" contextRef="AsOf2021-09-30" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">706,931</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1289" contextRef="AsOf2020-09-30" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">83,767</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Supplemental Cash Flow Information </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 15px">Interest paid</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1291" contextRef="From2021-01-01to2021-09-30" name="us-gaap:InterestPaid" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,363</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1292" contextRef="From2020-01-01to2020-09-30" name="us-gaap:InterestPaid" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,895</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Non-Cash Transactions </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Stock issued for acquisition of patents</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1294" contextRef="From2021-01-01to2021-09-30" name="aimd:StockIssuedForAcquisitionOfPatents" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1295" contextRef="From2020-01-01to2020-09-30" name="aimd:StockIssuedForAcquisitionOfPatents" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Stock issued for compensation, warrant and option expense</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1296" contextRef="From2021-01-01to2021-09-30" name="aimd:StockIssuedForCompensationWarrantAndOptionExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">346,938</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1297" contextRef="From2020-01-01to2020-09-30" name="aimd:StockIssuedForCompensationWarrantAndOptionExpense" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Stock issued for advances from investors</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1298" contextRef="From2021-01-01to2021-09-30" name="aimd:StockIssuedForAdvancesFromInvestors" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1299" contextRef="From2020-01-01to2020-09-30" name="aimd:StockIssuedForAdvancesFromInvestors" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">ROU Leased assets</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1300" contextRef="From2021-01-01to2021-09-30" name="aimd:RouLeasedAssets" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,723</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1301" contextRef="From2020-01-01to2020-09-30" name="aimd:RouLeasedAssets" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:15px">Lease obligation</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1302" contextRef="From2021-01-01to2021-09-30" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,723</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_1303" contextRef="From2020-01-01to2020-09-30" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><em>See accompanying notes to financial statements.</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Ainos, Inc.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="Notes">Notes to Financial Statements </span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(Unaudited)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1304" contextRef="From2021-01-01to2021-09-30" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>1.</strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Organization and Business.</strong> Ainos, Inc., formerly known as Amarillo Biosciences, Inc. (the &#8220;Company&#8221;) is a diversified healthcare company engaged in the research and development and sales and marketing of pharmaceutical and biotech products. The Company is a Texas corporation incorporated in 1984. The Company currently has offices in the United States and Taiwan. The Company operates a branch office in Taiwan registered as AINOS, INC. TAIWAN BRANCH.</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><ix:nonNumeric id="fid_1305" contextRef="From2021-01-01to2021-09-30" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true"><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>2.</strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is engaged in developing biologics for the treatment of human and animal diseases. Our current focus is research aimed at the treatment of human disease indications, including Sj&#246;gren&#8217;s syndrome, thrombocytopenia, and other indications using interferon (IFN) alpha that is administered in a proprietary low-dose non-injectable form. In addition to our core technology, we are working to expand our current focus into a diversified healthcare business portfolio in order to generate new revenue streams. We own patents with claims that encompass method of use or treatment, and/or composition of matter and manufacturing as well as design utility and/or invention. Of twelve issued patents, four patents are related to the low-dose oral delivery of interferon, three patents are associated with treatment of metabolic disorders, and five patents related to the development and manufacturing of point-of-care testing rapid test kit products that include diagnostics for COVID-19 (SARS CoV2 Antigen Rapid Test), pneumonia, vaginal infection and helicobacter pylori (H. pylori) bacterial infection.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We primarily operate three business units: the Pharmaceutical, Medical Devices and Preventive Medicine Divisions. Our Pharmaceutical Division is focused on low-dose, orally administered lozenges containing the natural immune system activator interferon-alpha as a treatment for a variety of disease indications. We own a proprietary library of over thirty years of scientific and clinical data on the human and animal applications of low-dose oral interferon. Our Medical Device Division is dedicated to developing a novel insulin pump and further development of point-of-care rapid test kits for the detection and diagnosis of human infections. Our Preventative Medicine Division, which has been restructured from our former Consumer Product Division, is focused on SRNA-based therapeutics.</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160; </p><ix:nonNumeric id="fid_1306" contextRef="From2021-01-01to2021-09-30" name="us-gaap:BasisOfAccounting" escape="true"><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>3. </strong></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Basis of presentation.</strong> The accompanying consolidated financial statements, which should be read in conjunction with the audited financial statements and footnotes included in the Company's Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission on March 30, 2021 attached hereto as Exhibit 13 and which is incorporated by this reference, have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months and nine months ended September 30, 2021, are not necessarily indicative of the results that may be expected for the full year ending December 31, 2021.</p></td></tr></tbody></table></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><ix:nonNumeric id="fid_1307" contextRef="From2021-01-01to2021-09-30" name="aimd:FinancialConditionTextBlock" escape="true" continuedAt="cont_d2c383"><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>4.</strong></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Financial Condition. </strong>These financial statements have been prepared in accordance with United States generally accepted accounting principles, assuming that the Company will continue as a going concern. The accompanying financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</p></td></tr></tbody></table></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><ix:continuation id="cont_d2c383"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">While the Company has recurring losses and generated negative cash flows from operations, the Company has taken initiatives to improve its management capacity and business operations. Such initiatives include the procurement of innovative diagnostic technologies and securing a strategic investor, as a result of the closing of a securities purchase agreement with Ainos, Inc. a Cayman Island corporation (&#8220;Ainos KY&#8221;) on April 15, 2021 (the &#8220;Ainos KY Transaction&#8221;). Details of the Ainos Transaction were disclosed in the Company&#8217;s Form 10-Q filing for the second quarter of 2021.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">After closing the Ainos KY Transaction, the Company engaged additional management resources including Mr. Chun-Hsien Tsai as Chairman and CEO, Ms. Hui-Lan (Celia) Wu as CFO and Mr. Chih-Heng (Jack Lu) as Head of Corporate Development, retained key management and legal staff, and implemented new business initiatives. On June 14, 2021, the Company became the master sales and marketing agent for the Ainos SARS-Cov-2 Antigen Rapid Test Kit (&#8220;Ainos Covid-19 Test Kit&#8221;) which has generated $568,164 in sales thus far in 2021.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As of September 30, 2021, the Company&#8217;s financial improvement includes the following:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Total stockholder&#8217;s equity increased to $<ix:nonFraction id="fid_21" contextRef="AsOf2021-09-30_aimd_SecuritiesPurchaseAgreementsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,136,360</ix:nonFraction> as of September 30, 2021 compared to a negative total shareholder&#8217;s equity of $<ix:nonFraction id="fid_22" contextRef="AsOf2020-12-31_aimd_SecuritiesPurchaseAgreementsMember" name="us-gaap:StockholdersEquity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">838,278</ix:nonFraction> as of December 2021.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Cash and cash equivalents increased to $<ix:nonFraction id="fid_12" contextRef="AsOf2021-09-30_aimd_SecuritiesPurchaseAgreementsMember" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">706,931</ix:nonFraction> as of September 30, 2021 compared to $<ix:nonFraction id="fid_13" contextRef="AsOf2020-12-31_aimd_SecuritiesPurchaseAgreementsMember" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,245</ix:nonFraction> at December 31, 2020. This is attributable to increased revenues from sales of our Ainos Covid-19 Test Kit in Taiwan and operational loans made to the Company by Ainos KY. The Company&#8217;s revenues increased to $<ix:nonFraction id="fid_9" contextRef="From2021-01-01to2021-09-30_aimd_SecuritiesPurchaseAgreementsMember" name="us-gaap:Revenues" format="ixt:numdotdecimal" decimals="0" unitRef="USD">568,164</ix:nonFraction> during this reporting period compared to $15,876 as of third quarter of 2020.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company anticipates business revenues and potential additional financial support from Ainos KY and other entities to fund the Company&#8217;s operations over the next twelve months. The Company may raise additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available when needed and at adequate levels, the Company will need to reevaluate its operating plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">There can be no assurance that capital will be available as necessary to meet the Company's working capital requirements or, if the capital is available, that it will be on terms acceptable to the Company. Any issuances of additional equity securities by the Company may result in dilution in the equity interests of its current stockholders. Obtaining commercial loans will increase the Company's liabilities and future cash commitments to the extent such loans would be available. While management believes in its strategic plans, management cannot be certain that projected financial results can be achieved.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1308" contextRef="From2021-01-01to2021-09-30" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>5.</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Common Stock. </strong>As of September 30, 2021 there was an increase of $<ix:nonFraction id="fid_554" contextRef="AsOf2021-09-30" name="aimd:SharesIncreaseValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,003,760</ix:nonFraction> in par value common stock primarily as a result of the Ainos KY Transaction.</p></td></tr></tbody></table></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><ix:nonNumeric id="fid_1309" contextRef="From2021-01-01to2021-09-30" name="us-gaap:DebtDisclosureTextBlock" escape="true" continuedAt="cont_5e6f44"><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>6.</strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Convertible Notes Payable and Other Related Party Notes Payable.</strong> As of September 30, 2021 and December 31, 2020, the amount of convertible and non-convertible debt principal was $<ix:nonFraction id="fid_887" contextRef="From2021-01-01to2021-09-30" name="us-gaap:DebtConversionOriginalDebtAmount1" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,185,953</ix:nonFraction> and $<ix:nonFraction id="fid_888" contextRef="From2020-01-01to2020-12-31" name="us-gaap:DebtConversionOriginalDebtAmount1" format="ixt:numdotdecimal" decimals="0" unitRef="USD">953,001</ix:nonFraction>, respectively. The details of the convertible and other non-convertible promissory notes payable are shown in the table below.</p></td></tr></tbody></table></ix:nonNumeric><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160; </p><ix:continuation id="cont_5e6f44" continuedAt="cont_ebc702"><ix:nonNumeric id="fid_1312" contextRef="From2021-01-01to2021-09-30" name="us-gaap:ConvertibleDebtTableTextBlock" escape="true" continuedAt="cont_b8761c"><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;" colspan="4"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Annual Interest Rate</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;" colspan="7"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Unpaid Principal Balance</strong>&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>No#</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Effective Date</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Due Date</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>From</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Effective</strong></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Following</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Maturity</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Payee</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Issuing</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Purpose</strong></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Sep 30,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td colspan="3"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Dec 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td></tr><tr style="height:15px"><td colspan="24"><p style="font-size:10pt;font-family:times new roman;margin:0px">Payee: Dr. Stephen T. Chen, resigned as Chairman of the Board, President, and Board director April 15, 2021</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#1.16</p></td><td style="width:1%;"></td><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_569" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_OneOneSixMember" name="aimd:EffectiveDate">2016/01/30</ix:nonNumeric></p></td><td style="width:1%;"></td><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_556" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_OneOneSixMember" name="aimd:DueDate">Payable on demand</ix:nonNumeric></p></td><td style="width:1%;"></td><td style="width:7%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_557" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_OneOneSixMember" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" decimals="INF" unitRef="Pure" scale="-2">0.75</ix:nonFraction>%</p></td><td colspan="2" style="width:1%;"></td><td style="width:8%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td style="width:1%;"></td><td style="width:8%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen Chen</p></td><td style="width:1%;"></td><td colspan="2" style="width:12%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2" style="width:1%;"></td><td colspan="2" style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_559" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_OneOneSixMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">114,026</ix:nonFraction></p></td><td colspan="3" style="width:1%;"></td><td colspan="2" style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_561" contextRef="From2020-01-01to2020-12-31_aimd_DrStephenTChenMember_aimd_OneOneSixMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">114,026</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#2.16</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_555" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TwoOneSixMember" name="aimd:EffectiveDate">2016/03/18</ix:nonNumeric></p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_619" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TwoOneSixMember" name="aimd:DueDate">Payable on demand</ix:nonNumeric></p></td><td></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_565" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TwoOneSixMember" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" decimals="INF" unitRef="Pure" scale="-2">0.65</ix:nonFraction>%</p></td><td colspan="2"></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen Chen</p></td><td></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_699" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TwoOneSixMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">262,500</ix:nonFraction></p></td><td colspan="3"></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_700" contextRef="From2020-01-01to2020-12-31_aimd_DrStephenTChenMember_aimd_TwoOneSixMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">262,500</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#3.19</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_562" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ThreeOneNineMember" name="aimd:EffectiveDate">2019/09/01</ix:nonNumeric></p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_582" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ThreeOneNineMember" name="aimd:DueDate">2020/09/01</ix:nonNumeric></p></td><td></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_574" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ThreeOneNineMember" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" decimals="INF" unitRef="Pure" scale="-2">1.85</ix:nonFraction>%</p></td><td colspan="2"></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_573" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ThreeOneNineMember" name="aimd:AnnualInterestRateFollowingMaturity" decimals="INF" unitRef="Pure" scale="-2">10</ix:nonFraction>%</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen Chen</p></td><td></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">salary</p></td><td colspan="2"></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_571" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ThreeOneNineMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,392</ix:nonFraction></p></td><td colspan="3"></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_572" contextRef="From2020-01-01to2020-12-31_aimd_DrStephenTChenMember_aimd_ThreeOneNineMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,620</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#4.19</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_588" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_FourOneNineMember" name="aimd:EffectiveDate">2019/12/01</ix:nonNumeric></p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_575" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_FourOneNineMember" name="aimd:DueDate">2020/12/31</ix:nonNumeric></p></td><td></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_576" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_FourOneNineMember" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" decimals="INF" unitRef="Pure" scale="-2">1.61</ix:nonFraction>%</p></td><td colspan="2"></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_577" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_FourOneNineMember" name="aimd:AnnualInterestRateFollowingMaturity" decimals="INF" unitRef="Pure" scale="-2">10</ix:nonFraction>%</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen Chen</p></td><td></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_578" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_FourOneNineMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,879</ix:nonFraction></p></td><td colspan="3"></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_579" contextRef="From2020-01-01to2020-12-31_aimd_DrStephenTChenMember_aimd_FourOneNineMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,879</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#6.20</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_580" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SixTwoZeroMember" name="aimd:EffectiveDate">2020/01/01</ix:nonNumeric></p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_583" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SixTwoZeroMember" name="aimd:DueDate">2021/01/</ix:nonNumeric>01</p></td><td></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_584" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SixTwoZeroMember" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" decimals="INF" unitRef="Pure" scale="-2">1.85</ix:nonFraction>%</p></td><td colspan="2"></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_585" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SixTwoZeroMember" name="aimd:AnnualInterestRateFollowingMaturity" decimals="INF" unitRef="Pure" scale="-2">10</ix:nonFraction>%</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen Chen</p></td><td></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">salary</p></td><td colspan="2"></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_595" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SixTwoZeroMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">216,600</ix:nonFraction></p></td><td colspan="3"></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_596" contextRef="From2020-01-01to2020-12-31_aimd_DrStephenTChenMember_aimd_SixTwoZeroMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">216,600</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#7.20</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_602" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SevenTwoZeroMember" name="aimd:EffectiveDate">2020/01/01</ix:nonNumeric></p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_592" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SevenTwoZeroMember" name="aimd:DueDate">2021/01/02</ix:nonNumeric></p></td><td></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_591" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SevenTwoZeroMember" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" decimals="INF" unitRef="Pure" scale="-2">1.60</ix:nonFraction>%</p></td><td colspan="2"></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_590" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SevenTwoZeroMember" name="aimd:AnnualInterestRateFollowingMaturity" decimals="INF" unitRef="Pure" scale="-2">10</ix:nonFraction>%</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen Chen</p></td><td></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_586" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SevenTwoZeroMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,366</ix:nonFraction></p></td><td colspan="3"></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_587" contextRef="From2020-01-01to2020-12-31_aimd_DrStephenTChenMember_aimd_SevenTwoZeroMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,366</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#9.20</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_593" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_NineTwoZeroMember" name="aimd:EffectiveDate">2020/01/01</ix:nonNumeric></p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_597" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_NineTwoZeroMember" name="aimd:DueDate">2021/04/14</ix:nonNumeric></p></td><td></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_598" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_NineTwoZeroMember" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" decimals="INF" unitRef="Pure" scale="-2">0.13</ix:nonFraction>%</p></td><td colspan="2"></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_599" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_NineTwoZeroMember" name="aimd:AnnualInterestRateFollowingMaturity" decimals="INF" unitRef="Pure" scale="-2">10</ix:nonFraction>%</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen Chen</p></td><td></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_609" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_NineTwoZeroMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">279,405</ix:nonFraction></p></td><td colspan="3"></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_610" contextRef="From2020-01-01to2020-12-31_aimd_DrStephenTChenMember_aimd_NineTwoZeroMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">134,010</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#10.21</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_607" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TenTwoOneMember" name="aimd:EffectiveDate">2021/01/01</ix:nonNumeric></p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_606" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TenTwoOneMember" name="aimd:DueDate">2021/04/01</ix:nonNumeric></p></td><td></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_605" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TenTwoOneMember" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" decimals="INF" unitRef="Pure" scale="-2">1.85</ix:nonFraction>%</p></td><td colspan="2"></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_604" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TenTwoOneMember" name="aimd:AnnualInterestRateFollowingMaturity" decimals="INF" unitRef="Pure" scale="-2">10</ix:nonFraction>%</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen Chen</p></td><td></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">salary</p></td><td colspan="2"></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_618" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TenTwoOneMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59,025</ix:nonFraction></p></td><td colspan="3"></td><td colspan="2"></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#11.21</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_614" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ElevenTwoOneMember" name="aimd:EffectiveDate">2021/04/01</ix:nonNumeric></p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_613" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ElevenTwoOneMember" name="aimd:DueDate">2021/05/01</ix:nonNumeric></p></td><td></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_612" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ElevenTwoOneMember" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" decimals="INF" unitRef="Pure" scale="-2">1.85</ix:nonFraction>%</p></td><td colspan="2"></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_611" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ElevenTwoOneMember" name="aimd:AnnualInterestRateFollowingMaturity" decimals="INF" unitRef="Pure" scale="-2">10</ix:nonFraction>%</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen Chen</p></td><td></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">salary</p></td><td colspan="2"></td><td style="BORDER-BOTTOM: 1px solid;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_600" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ElevenTwoOneMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></p></td><td colspan="3"></td><td style="BORDER-BOTTOM: 1px solid;" colspan="2"></td></tr><tr style="height:15px;background-color:#ffffff"><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2"></td><td></td><td></td><td></td><td></td><td colspan="2"></td><td colspan="2"></td><td style="BORDER-BOTTOM: 1px solid;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_616" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,019,193</ix:nonFraction></p></td><td colspan="3"></td><td style="BORDER-BOTTOM: 1px solid;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_617" contextRef="From2020-01-01to2020-12-31_aimd_DrStephenTChenMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">805,001</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2"></td><td></td><td></td><td></td><td></td><td colspan="2"></td><td colspan="2"></td><td colspan="2"></td><td colspan="3"></td><td colspan="2"></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="5"><p style="font-size:10pt;font-family:times new roman;margin:0px">Payee: Ainos KY, an affiliated company </p></td><td></td><td></td><td></td><td colspan="2"></td><td></td><td></td><td></td><td colspan="2"></td><td colspan="2"></td><td colspan="2"></td><td colspan="2"></td><td colspan="3"></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#12.21</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_626" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_TwelveTwoOneMember" name="aimd:EffectiveDate">2021/04/27</ix:nonNumeric></p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_624" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_TwelveTwoOneMember" name="aimd:DueDate">2021/10/27</ix:nonNumeric></p></td><td></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_625" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_TwelveTwoOneMember" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" decimals="INF" unitRef="Pure" scale="-2">1.85</ix:nonFraction>%</p></td><td colspan="2"></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_674" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_TwelveTwoOneMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,000</ix:nonFraction></p></td><td colspan="3"></td><td colspan="2"></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#13.21</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_632" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_ThirteenTwoOneMember" name="aimd:EffectiveDate">2021/05/05</ix:nonNumeric></p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_634" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_ThirteenTwoOneMember" name="aimd:DueDate">2021/11/05</ix:nonNumeric></p></td><td></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_633" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_ThirteenTwoOneMember" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" decimals="INF" unitRef="Pure" scale="-2">1.85</ix:nonFraction>%</p></td><td colspan="2"></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_630" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_ThirteenTwoOneMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000</ix:nonFraction></p></td><td colspan="3"></td><td colspan="2"></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#14.21</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_637" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_FourteenTwoOneMember" name="aimd:EffectiveDate">2021/05/25</ix:nonNumeric></p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_639" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_FourteenTwoOneMember" name="aimd:DueDate">2021/11/25</ix:nonNumeric></p></td><td></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_638" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_FourteenTwoOneMember" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" decimals="INF" unitRef="Pure" scale="-2">1.85</ix:nonFraction>%</p></td><td colspan="2"></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_635" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_FourteenTwoOneMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,000</ix:nonFraction></p></td><td colspan="3"></td><td colspan="2"></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#15.21</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_642" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_FifteenTwoOneMember" name="aimd:EffectiveDate">2021/05/28</ix:nonNumeric></p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_640" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_FifteenTwoOneMember" name="aimd:DueDate">2021/11/28</ix:nonNumeric></p></td><td></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_641" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_FifteenTwoOneMember" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" decimals="INF" unitRef="Pure" scale="-2">1.85</ix:nonFraction>%</p></td><td colspan="2"></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_643" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_FifteenTwoOneMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,000</ix:nonFraction></p></td><td colspan="3"></td><td colspan="2"></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#16.21</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_647" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_SixteenTwoOneMember" name="aimd:EffectiveDate">2021/06/09</ix:nonNumeric></p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_645" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_SixteenTwoOneMember" name="aimd:DueDate">2021/12/09</ix:nonNumeric></p></td><td></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_646" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_SixteenTwoOneMember" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" decimals="INF" unitRef="Pure" scale="-2">1.85</ix:nonFraction>%</p></td><td colspan="2"></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_648" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_SixteenTwoOneMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></p></td><td colspan="3"></td><td colspan="2"></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#17.21</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_652" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_SeventeenTwoOneMember" name="aimd:EffectiveDate">2021/06/21</ix:nonNumeric></p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_650" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_SeventeenTwoOneMember" name="aimd:DueDate">2021/12/21</ix:nonNumeric></p></td><td></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_651" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_SeventeenTwoOneMember" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" decimals="INF" unitRef="Pure" scale="-2">1.85</ix:nonFraction>%</p></td><td colspan="2"></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_653" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_SeventeenTwoOneMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,000</ix:nonFraction></p></td><td colspan="3"></td><td colspan="2"></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#18.21</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_657" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_EighteenTwoOneMember" name="aimd:EffectiveDate">2021/07/02</ix:nonNumeric></p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_655" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_EighteenTwoOneMember" name="aimd:DueDate">2022/01/02</ix:nonNumeric></p></td><td></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_656" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_EighteenTwoOneMember" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" decimals="INF" unitRef="Pure" scale="-2">1.85</ix:nonFraction>%</p></td><td colspan="2"></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_658" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_EighteenTwoOneMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">54,000</ix:nonFraction></p></td><td colspan="3"></td><td colspan="2"></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#19.21</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_662" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_NinteenTwoOneMember" name="aimd:EffectiveDate">2021/09/01</ix:nonNumeric></p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_664" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_NinteenTwoOneMember" name="aimd:DueDate">2021/03/01</ix:nonNumeric></p></td><td></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_663" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_NinteenTwoOneMember" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" decimals="INF" unitRef="Pure" scale="-2">1.85</ix:nonFraction>%</p></td><td colspan="2"></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_660" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_NinteenTwoOneMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,000</ix:nonFraction></p></td><td colspan="3"></td><td colspan="2"></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#20.21</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_667" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_TwentyTwoOneMember" name="aimd:EffectiveDate">2021/09/28</ix:nonNumeric></p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_669" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_TwentyTwoOneMember" name="aimd:DueDate">2021/03/28</ix:nonNumeric></p></td><td></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_668" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_TwentyTwoOneMember" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" decimals="INF" unitRef="Pure" scale="-2">1.85</ix:nonFraction>%</p></td><td colspan="2"></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"></td><td style="BORDER-BOTTOM: 1px solid;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_665" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_TwentyTwoOneMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></p></td><td colspan="3"></td><td style="BORDER-BOTTOM: 1px solid;" colspan="2"></td></tr><tr style="height:15px;background-color:#ffffff"><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2"></td><td></td><td></td><td></td><td></td><td colspan="2"></td><td colspan="2"></td><td style="BORDER-BOTTOM: 1px solid;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_670" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_TotalMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">981,000</ix:nonFraction></p></td><td colspan="3"></td><td style="BORDER-BOTTOM: 1px solid;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0 </p></td></tr><tr style="height:15px;background-color:#cceeff"><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="9"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">Convertible and other notes payable- related parties</p></td><td colspan="2"></td><td style="BORDER-BOTTOM: 1px solid;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_672" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_TotalMember" name="aimd:ConvertibleAndOtherNotesPayableRelatedParties" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,193</ix:nonFraction></p></td><td colspan="3"></td><td style="BORDER-BOTTOM: 1px solid;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_673" contextRef="From2020-01-01to2020-12-31_aimd_AinosKYMember_aimd_TotalMember" name="aimd:ConvertibleAndOtherNotesPayableRelatedParties" format="ixt:numdotdecimal" decimals="0" unitRef="USD">805,001</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2"></td><td></td><td></td><td></td><td></td><td colspan="2"></td><td colspan="2"></td><td colspan="2"></td><td colspan="3"></td><td colspan="2"></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="10"><p style="font-size:10pt;font-family:times new roman;margin:0px">Payee: i2China Management Group LLC, a management consultant</p></td><td></td><td></td><td></td><td colspan="2"></td><td colspan="2"></td><td colspan="2"></td><td colspan="2"></td><td colspan="3"></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#5.19</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_678" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_FiveOneNineMember" name="aimd:EffectiveDate">2019/09/01</ix:nonNumeric></p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_680" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_FiveOneNineMember" name="aimd:DueDate">2020/09/01</ix:nonNumeric></p></td><td></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_679" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_FiveOneNineMember" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" decimals="INF" unitRef="Pure" scale="-2">1.85</ix:nonFraction>%</p></td><td colspan="2"></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_681" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_FiveOneNineMember" name="aimd:AnnualInterestRateFollowingMaturity" decimals="INF" unitRef="Pure" scale="-2">10</ix:nonFraction>%</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">i2China</p></td><td></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">consulting fee</p></td><td colspan="2"></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_628" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_FiveOneNineMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,000</ix:nonFraction></p></td><td colspan="3"></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_629" contextRef="From2020-01-01to2020-12-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_FiveOneNineMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,000</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#8a.20</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_684" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightATwozeroMember" name="aimd:EffectiveDate">2020/01/01</ix:nonNumeric></p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_686" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightATwozeroMember" name="aimd:DueDate">2021/01/01</ix:nonNumeric></p></td><td></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_685" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightATwozeroMember" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" decimals="INF" unitRef="Pure" scale="-2">1.85</ix:nonFraction>%</p></td><td colspan="2"></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_687" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightATwozeroMember" name="aimd:AnnualInterestRateFollowingMaturity" decimals="INF" unitRef="Pure" scale="-2">10</ix:nonFraction>%</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">i2China</p></td><td></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">consulting fee</p></td><td colspan="2"></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_682" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightATwozeroMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,000</ix:nonFraction></p></td><td colspan="3"></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_683" contextRef="From2020-01-01to2020-12-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightATwozeroMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,000</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#8b.20</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_690" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember" name="aimd:EffectiveDate">Retroactive from 2020/01/01</ix:nonNumeric></p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_688" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember" name="aimd:DueDate">2021/01/01</ix:nonNumeric></p></td><td></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_689" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" decimals="INF" unitRef="Pure" scale="-2">1.85</ix:nonFraction>%</p></td><td colspan="2"></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_698" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember" name="aimd:AnnualInterestRateFollowingMaturity" decimals="INF" unitRef="Pure" scale="-2">10</ix:nonFraction>%</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">i2China</p></td><td></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">consulting fee</p></td><td colspan="2"></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_691" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,000</ix:nonFraction></p></td><td colspan="3"></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_692" contextRef="From2020-01-01to2020-12-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,000</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#11.21</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_695" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_ElevenOneTwoOneMember" name="aimd:EffectiveDate">2021/01/01</ix:nonNumeric></p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_697" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_ElevenOneTwoOneMember" name="aimd:DueDate">2021/04/01</ix:nonNumeric></p></td><td></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_696" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_ElevenOneTwoOneMember" name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" decimals="INF" unitRef="Pure" scale="-2">1.85</ix:nonFraction>%</p></td><td colspan="2"></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_627" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_ElevenOneTwoOneMember" name="aimd:AnnualInterestRateFollowingMaturity" decimals="INF" unitRef="Pure" scale="-2">10</ix:nonFraction>%</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">i2China</p></td><td></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">consulting fee</p></td><td colspan="2"></td><td style="BORDER-BOTTOM: #000000 1px solid;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_693" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_ElevenOneTwoOneMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,000</ix:nonFraction></p></td><td colspan="3"></td><td style="BORDER-BOTTOM: #000000 1px solid;" colspan="2"></td></tr><tr style="height:15px;background-color:#ffffff"><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="9"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">Convertible and other notes payable</p></td><td colspan="2"></td><td style="BORDER-BOTTOM: 1px solid;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_567" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_TotalMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">185,000</ix:nonFraction></p></td><td colspan="3"></td><td style="BORDER-BOTTOM: 1px solid;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_568" contextRef="From2020-01-01to2020-12-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_TotalMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,000</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="9"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">Total Convertible and other notes payable</p></td><td colspan="2"></td><td style="BORDER-BOTTOM: 3px double;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_701" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_TotalMember" name="aimd:ConvertibleAndOtherNotesPayableRelatedParties" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,185,193</ix:nonFraction></p></td><td colspan="3"></td><td style="BORDER-BOTTOM: 3px double;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_702" contextRef="From2020-01-01to2020-12-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_TotalMember" name="aimd:ConvertibleAndOtherNotesPayableRelatedParties" format="ixt:numdotdecimal" decimals="0" unitRef="USD">953,001</ix:nonFraction></p></td></tr></tbody></table></ix:nonNumeric></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_ebc702"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">All of the aforementioned convertible and non-convertible promissory notes are unsecured and due on demand. All shares issued upon conversion are restricted and subject to Rule 144 promulgated under the U.S. Securities Act of 1933 (the &#8220;Securities Act&#8221;); subject to any exemptions or exclusions under the Act. The Company may prepay the notes in whole or in part at any time without penalty.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The promissory notes due to Dr. Stephen T. Chen and Ainos KY are related party notes.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">i2China Management Group, LLC (&#8220;i2China&#8221;) and Dr. Stephen T. Chen (together the &#8220;Payees&#8221;), have both agreed to waive any and all rights pertaining to the conditional term &#8220;Annual Interest Rate on Matured, Unpaid Amounts: 10% per annum, compounded annually of Convertible Notes&#8221; in regards to interest charged on any unpaid amounts following maturity for all of their respective notes. The Company and the Payees agree that the originally agreed annual interest rate will continue to be valid for any unpaid amounts after maturity. The amended terms of the above convertible notes were made during 2021 Q3 on September 1, 2021. The waived interest amount was $45,875.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_b8761c"><table style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Unpaid </strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;" colspan="3"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Interest Rate</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;" colspan="5"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Interest amount</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;Interest </strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>No#</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Date</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Payee</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Description</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong><strong>Principal </strong><strong>Amount</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Original</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>after</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Maturity</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;Original&#160;rate</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>10%</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total </strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>after</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Maturity</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong><strong>Interest</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Waived</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#1.16</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:10%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_735" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_OneOneSixMember" name="aimd:Date">1/30/2016</ix:nonNumeric></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:10%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:10%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_743" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_OneOneSixMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">114,026</ix:nonFraction></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_736" contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_OneOneSixMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" decimals="INF" unitRef="Pure" scale="-2">0.75</ix:nonFraction>%</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_738" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_OneOneSixMember" name="aimd:InterestAmountOriginalRate" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,624</ix:nonFraction></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_739" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_OneOneSixMember" name="aimd:InterestAmount10" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction> </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_740" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_OneOneSixMember" name="us-gaap:InterestPaid" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,624</ix:nonFraction></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_741" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_OneOneSixMember" name="aimd:InterestAfterMaturity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,624</ix:nonFraction></p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_742" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_OneOneSixMember" name="aimd:InterestWaived" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#2.16</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_746" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TwoOneSixMember" name="aimd:Date">3/18/2016</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_744" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TwoOneSixMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">262,500</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_747" contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_TwoOneSixMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" decimals="INF" unitRef="Pure" scale="-2">0.65</ix:nonFraction>%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_749" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TwoOneSixMember" name="aimd:InterestAmountOriginalRate" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,447</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_750" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TwoOneSixMember" name="aimd:InterestAmount10" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_751" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TwoOneSixMember" name="us-gaap:InterestPaid" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,447</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_752" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TwoOneSixMember" name="aimd:InterestAfterMaturity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,447</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_753" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TwoOneSixMember" name="aimd:InterestWaived" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#3.19</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_756" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ThreeOneNineMember" name="aimd:Date">9/1/2019(DS</ix:nonNumeric>)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">salary</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_754" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ThreeOneNineMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,392</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_758" contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_ThreeOneNineMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" decimals="INF" unitRef="Pure" scale="-2">1.85</ix:nonFraction>%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_757" contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_ThreeOneNineMember" name="aimd:InterestRateAfterMaturity" decimals="INF" unitRef="Pure" scale="-2">10</ix:nonFraction>%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_759" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ThreeOneNineMember" name="aimd:InterestAmountOriginalRate" format="ixt:numdotdecimal" decimals="0" unitRef="USD">714</ix:nonFraction> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_760" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ThreeOneNineMember" name="aimd:InterestAmount10" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,340</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_761" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ThreeOneNineMember" name="us-gaap:InterestPaid" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,054</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_762" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ThreeOneNineMember" name="aimd:InterestAfterMaturity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,518</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_763" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ThreeOneNineMember" name="aimd:InterestWaived" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,536</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#4.19</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_766" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_FourOneNineMember" name="aimd:Date">12/1/2019(DE)</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_764" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_FourOneNineMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,879</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_767" contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_FourOneNineMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" decimals="INF" unitRef="Pure" scale="-2">1.61</ix:nonFraction>%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_768" contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_FourOneNineMember" name="aimd:InterestRateAfterMaturity" decimals="INF" unitRef="Pure" scale="-2">10</ix:nonFraction>%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_769" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_FourOneNineMember" name="aimd:InterestAmountOriginalRate" format="ixt:numdotdecimal" decimals="0" unitRef="USD">257</ix:nonFraction> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_770" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_FourOneNineMember" name="aimd:InterestAmount10" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,132</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_771" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_FourOneNineMember" name="us-gaap:InterestPaid" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,389</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_772" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_FourOneNineMember" name="aimd:InterestAfterMaturity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">439</ix:nonFraction> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_773" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_FourOneNineMember" name="aimd:InterestWaived" format="ixt:numdotdecimal" decimals="0" unitRef="USD">950</ix:nonFraction> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#6.20</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_776" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SixTwoZeroMember" name="aimd:Date">1/1/2020(DS)</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">salary</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_774" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SixTwoZeroMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">216,600</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_777" contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_SixTwoZeroMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" decimals="INF" unitRef="Pure" scale="-2">1.85</ix:nonFraction>%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_778" contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_SixTwoZeroMember" name="aimd:InterestRateAfterMaturity" decimals="INF" unitRef="Pure" scale="-2">10</ix:nonFraction>%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_779" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SixTwoZeroMember" name="aimd:InterestAmountOriginalRate" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,179</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_780" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SixTwoZeroMember" name="aimd:InterestAmount10" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,363</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_781" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SixTwoZeroMember" name="us-gaap:InterestPaid" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,543</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_782" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SixTwoZeroMember" name="aimd:InterestAfterMaturity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,206</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_783" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SixTwoZeroMember" name="aimd:InterestWaived" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,336</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#7.20</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_786" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SevenTwoZeroMember" name="aimd:Date">1/1/2020(DE)</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_784" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SevenTwoZeroMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,366</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_787" contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_SevenTwoZeroMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" decimals="INF" unitRef="Pure" scale="-2">1.60</ix:nonFraction>%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_788" contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_SevenTwoZeroMember" name="aimd:InterestRateAfterMaturity" decimals="INF" unitRef="Pure" scale="-2">10</ix:nonFraction>%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_789" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SevenTwoZeroMember" name="aimd:InterestAmount10" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72</ix:nonFraction> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_790" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SevenTwoZeroMember" name="aimd:InterestAmountOriginalRate" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,753</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_791" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SevenTwoZeroMember" name="us-gaap:InterestPaid" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,825</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_792" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SevenTwoZeroMember" name="aimd:InterestAfterMaturity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">352</ix:nonFraction> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_793" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SevenTwoZeroMember" name="aimd:InterestWaived" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,473</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#9.20</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_796" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_NineTwoZeroMember" name="aimd:Date">11/2020 (Open)</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_794" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_NineTwoZeroMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">279,405</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_797" contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_NineTwoZeroMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" decimals="INF" unitRef="Pure" scale="-2">0.13</ix:nonFraction>%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_798" contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_NineTwoZeroMember" name="aimd:InterestRateAfterMaturity" decimals="INF" unitRef="Pure" scale="-2">10</ix:nonFraction>%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_799" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_NineTwoZeroMember" name="aimd:InterestAmountOriginalRate" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81</ix:nonFraction> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_800" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_NineTwoZeroMember" name="aimd:InterestAmount10" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,864</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_801" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_NineTwoZeroMember" name="us-gaap:InterestPaid" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,945</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_802" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_NineTwoZeroMember" name="aimd:InterestAfterMaturity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">248</ix:nonFraction> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_803" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_NineTwoZeroMember" name="aimd:InterestWaived" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,697</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#10.21</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_806" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TenTwoOneMember" name="aimd:Date">1/1/2021(DS)</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">salary</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_804" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TenTwoOneMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59,025</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_807" contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_TenTwoOneMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" decimals="INF" unitRef="Pure" scale="-2">1.85</ix:nonFraction>%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_808" contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_TenTwoOneMember" name="aimd:InterestRateAfterMaturity" decimals="INF" unitRef="Pure" scale="-2">10</ix:nonFraction>%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_809" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TenTwoOneMember" name="aimd:InterestAmountOriginalRate" format="ixt:numdotdecimal" decimals="0" unitRef="USD">178</ix:nonFraction> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_810" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TenTwoOneMember" name="aimd:InterestAmount10" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,968</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_811" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TenTwoOneMember" name="us-gaap:InterestPaid" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,146</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_812" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TenTwoOneMember" name="aimd:InterestAfterMaturity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">725</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_813" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TenTwoOneMember" name="aimd:InterestWaived" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,421</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#11.21</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_816" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ElevenTwoOneMember" name="aimd:Date">4/1/2021(DS)</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">salary</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_814" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ElevenTwoOneMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_818" contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_ElevenTwoOneMember" name="aimd:InterestRateAfterMaturity" decimals="INF" unitRef="Pure" scale="-2">10</ix:nonFraction>%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_819" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ElevenTwoOneMember" name="aimd:InterestAmountOriginalRate" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15</ix:nonFraction> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_820" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ElevenTwoOneMember" name="aimd:InterestAmount10" format="ixt:numdotdecimal" decimals="0" unitRef="USD">420</ix:nonFraction> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_821" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ElevenTwoOneMember" name="us-gaap:InterestPaid" format="ixt:numdotdecimal" decimals="0" unitRef="USD">435</ix:nonFraction> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_822" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ElevenTwoOneMember" name="aimd:InterestAfterMaturity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93</ix:nonFraction> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_823" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ElevenTwoOneMember" name="aimd:InterestWaived" format="ixt:numdotdecimal" decimals="0" unitRef="USD">342</ix:nonFraction> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_824" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,019,193</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_827" contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" decimals="INF" unitRef="Pure" scale="-2">1.85</ix:nonFraction>%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_828" contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember" name="aimd:InterestRateAfterMaturity" decimals="INF" unitRef="Pure" scale="-2">10</ix:nonFraction>%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_829" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember" name="aimd:InterestAmountOriginalRate" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,566</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_830" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember" name="aimd:InterestAmount10" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,841</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_831" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember" name="us-gaap:InterestPaid" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,407</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_832" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember" name="aimd:InterestAfterMaturity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,653</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_833" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember" name="aimd:InterestWaived" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,754</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#5.19</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_836" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_FiveOneNineMember" name="aimd:Date">9/1/2019</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">i2China</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">consulting fee</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_834" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_FiveOneNineMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,000</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_837" contextRef="AsOf2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_FiveOneNineMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" decimals="INF" unitRef="Pure" scale="-2">1.85</ix:nonFraction>%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_838" contextRef="AsOf2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_FiveOneNineMember" name="aimd:InterestRateAfterMaturity" decimals="INF" unitRef="Pure" scale="-2">10</ix:nonFraction>%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_839" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_FiveOneNineMember" name="aimd:InterestAmountOriginalRate" format="ixt:numdotdecimal" decimals="0" unitRef="USD">253</ix:nonFraction> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_840" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_FiveOneNineMember" name="aimd:InterestAmount10" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,759</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_841" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_FiveOneNineMember" name="us-gaap:InterestPaid" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,012</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_842" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_FiveOneNineMember" name="aimd:InterestAfterMaturity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">579</ix:nonFraction> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_843" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_FiveOneNineMember" name="aimd:InterestWaived" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,433</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#8a.20</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_847" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightATwozeroMember" name="aimd:Date">1/1/2020</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">i2China</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">consulting fee</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_844" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightATwozeroMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,000</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_846" contextRef="AsOf2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightATwozeroMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" decimals="INF" unitRef="Pure" scale="-2">1.85</ix:nonFraction>%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_848" contextRef="AsOf2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightATwozeroMember" name="aimd:InterestRateAfterMaturity" decimals="INF" unitRef="Pure" scale="-2">10</ix:nonFraction>%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_849" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightATwozeroMember" name="aimd:InterestAmountOriginalRate" format="ixt:numdotdecimal" decimals="0" unitRef="USD">483</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_850" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightATwozeroMember" name="aimd:InterestAmount10" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,626</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_851" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightATwozeroMember" name="us-gaap:InterestPaid" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,109</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_852" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightATwozeroMember" name="aimd:InterestAfterMaturity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,154</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_853" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightATwozeroMember" name="aimd:InterestWaived" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,955</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#8b.20</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric id="fid_856" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember" name="aimd:Date">1/1/2020</ix:nonNumeric></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">i2China</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">retroactive increase</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_854" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,000</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_857" contextRef="AsOf2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" decimals="INF" unitRef="Pure" scale="-2">1.85</ix:nonFraction>%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_858" contextRef="AsOf2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember" name="aimd:InterestRateAfterMaturity" decimals="INF" unitRef="Pure" scale="-2">10</ix:nonFraction>%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_859" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember" name="aimd:InterestAmountOriginalRate" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,554</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_860" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember" name="aimd:InterestAmount10" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,399</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_861" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember" name="us-gaap:InterestPaid" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,953</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_862" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember" name="aimd:InterestAfterMaturity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,738</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_863" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember" name="aimd:InterestWaived" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,215</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#11.21</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">1/1/2021(DS)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">i2China</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">consulting fee</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_864" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_ElevenOneTwoOneMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,000</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_867" contextRef="AsOf2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_ElevenOneTwoOneMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" decimals="INF" unitRef="Pure" scale="-2">1.85</ix:nonFraction>%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><ix:nonFraction id="fid_868" contextRef="AsOf2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_ElevenOneTwoOneMember" name="aimd:InterestRateAfterMaturity" decimals="INF" unitRef="Pure" scale="-2">10</ix:nonFraction>%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_869" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_ElevenOneTwoOneMember" name="aimd:InterestAmountOriginalRate" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107</ix:nonFraction> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_870" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_ElevenOneTwoOneMember" name="aimd:InterestAmount10" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,860</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_871" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_ElevenOneTwoOneMember" name="us-gaap:InterestPaid" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,967</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_872" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_ElevenOneTwoOneMember" name="aimd:InterestAfterMaturity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">450</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_873" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_ElevenOneTwoOneMember" name="aimd:InterestWaived" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,517</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#ffffff"><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_874" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_TotalMember" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" format="ixt:numdotdecimal" decimals="0" unitRef="USD">185,000</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_879" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_TotalMember" name="aimd:InterestAmountOriginalRate" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,397</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_880" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_TotalMember" name="aimd:InterestAmount10" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,645</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_881" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_TotalMember" name="us-gaap:InterestPaid" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,041</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_882" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_TotalMember" name="aimd:InterestAfterMaturity" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,920</ix:nonFraction></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><ix:nonFraction id="fid_883" contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_TotalMember" name="aimd:InterestWaived" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,121</ix:nonFraction></p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">TOTAL ACCRUED</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td></td><td></td><td style="BORDER-BOTTOM: black 3px double;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,204,193 </p></td><td style="PADDING-BOTTOM: 3px;"></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">20,963&#160;</p></td><td style="BORDER-BOTTOM: black 3px double; PADDING-BOTTOM: 3px;"></td><td style="BORDER-BOTTOM: black 3px double;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;53,485</p></td><td style="PADDING-BOTTOM: 3px;"></td><td style="BORDER-BOTTOM: black 3px double;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">74,448 </p></td><td style="PADDING-BOTTOM: 3px;"></td><td style="BORDER-BOTTOM: black 3px double;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">28,573 </p></td><td style="PADDING-BOTTOM: 3px;"></td><td style="BORDER-BOTTOM: black 3px double;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">45,875 </p></td></tr></tbody></table></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The accrued interest amount was $<ix:nonFraction id="fid_889" contextRef="AsOf2021-09-30" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,983</ix:nonFraction> and $<ix:nonFraction id="fid_891" contextRef="AsOf2020-12-31" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,691</ix:nonFraction> as of September 30, 2021 and December 31, 2020, respectively.</p></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1310" contextRef="From2021-01-01to2021-09-30" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true" continuedAt="cont_65a63d"><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>7.</strong></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Related Party Transactions</strong></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following is a list of related parties who have undertaken transactions with the Company during this reporting period:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1313" contextRef="From2021-01-01to2021-09-30" name="us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock" escape="true"><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:26%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Name of the related party</strong></p></td><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Relationship</strong></p></td><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Description</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Taiwan Carbon Nano Technology Corporation (TCNT)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Affiliated company</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos, Inc. (Cayman Island) ( Ainos KY)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Affiliated company</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">ASE Technology Holding</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Affiliated company</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Parent company of ASE Test Inc. which is Ainos KY's board member and with more than 10% of the voting rights </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">i2 China Management Group LLC (i2 China)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Affiliated company</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Sole member owner is Lawrence Lin, EVP Operations effective August 1, 2021</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Dr. Stephen T. Chen</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Principal owner</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Shareholder with more than 5% of Company voting rights, Ainos' former Chairman, President, CEO and CFO</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Chun-Hsien Tsai</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Board of Director, Executive Officer and Immediate Family</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Chairman of BOD, President, CEO and spouse of Ting-Chuan Lee</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ting-Chuan Lee</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Board of Director and Immediate Family</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Spouse of Chun Hsien Tsai</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Hui-Lan Wu</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Executive Officer</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CFO</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Lawrence Lin</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Key management</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">EVP Operations effective August 1, 2021</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Chih-Heng Lu</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Key management</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Director of Corporate Development and Corporate Secretary</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">John Junyong Lee</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Key management</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Chief Legal Counsel and Corporate Secretary rewarded by fixed monthly fee and performance bonus effective September 1,2021 Chief Legal Counsel and Corporate Secretary</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Chien-Hsuan Huang </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Immediate Family of Director</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Spouse of Wen-Han Chang</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Bernard Cohen</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Former CFO</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Resigned on April 5, 2021</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Below is a summary of the significant related party transactions entered into by the Company over the first nine months of 2021:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Financial support</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1314" contextRef="From2021-01-01to2021-09-30" name="aimd:ScheduleOfFinancialSupportListtabletextblock" escape="true" continuedAt="cont_7a0a38"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Convertible Note</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Related Interest Expense</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine months ended </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September 30, 2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>As of</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September 30, 2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine months ended September 30, 2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>As of </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September 30, 2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_703" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember" name="us-gaap:ProceedsFromRelatedPartyDebt" format="ixt:numdotdecimal" decimals="0" unitRef="USD">981,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_705" contextRef="AsOf2021-09-30_aimd_AinosKYMember" name="us-gaap:ConvertibleDebtCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">981,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_704" contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember" name="us-gaap:InterestExpenseRelatedParty" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,410</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_706" contextRef="AsOf2021-09-30_aimd_AinosKYMember" name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,410</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">i2China</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_712" contextRef="From2021-01-01to2021-09-30_aimd_I2ChinaMember" name="us-gaap:ProceedsFromRelatedPartyDebt" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_713" contextRef="AsOf2021-09-30_aimd_I2ChinaMember" name="us-gaap:ConvertibleDebtCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">185,000</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_714" contextRef="From2021-01-01to2021-09-30_aimd_I2ChinaMember" name="us-gaap:InterestExpenseRelatedParty" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,087</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_711" contextRef="AsOf2021-09-30_aimd_I2ChinaMember" name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,920</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Dr. Stephen T. Chen</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_715" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember" name="us-gaap:ProceedsFromRelatedPartyDebt" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,272</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_716" contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember" name="us-gaap:ConvertibleDebtCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,019,193</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_717" contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember" name="us-gaap:InterestExpenseRelatedParty" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,936</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_718" contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember" name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,653</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_707" contextRef="From2021-01-01to2021-09-30_aimd_RelatedPartyMember" name="us-gaap:ProceedsFromRelatedPartyDebt" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,033,272</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_709" contextRef="AsOf2021-09-30_aimd_RelatedPartyMember" name="us-gaap:ConvertibleDebtCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,185,193</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_708" contextRef="From2021-01-01to2021-09-30_aimd_RelatedPartyMember" name="us-gaap:InterestExpenseRelatedParty" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,433</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_710" contextRef="AsOf2021-09-30_aimd_RelatedPartyMember" name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,983</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">i2China became an affiliate of the Company as of August 1, 2021. From August 1, 2021 to September 30, 2021, interest payable to i2China amounted to $<ix:nonFraction id="fid_893" contextRef="AsOf2021-09-30" name="us-gaap:InterestPayableCurrentAndNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">496</ix:nonFraction>.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Other transactions</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">-</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Inventory purchases from TCNT totaling $<ix:nonFraction id="fid_894" contextRef="AsOf2021-09-30" name="us-gaap:InventoryNet" format="ixt:numdotdecimal" decimals="0" unitRef="USD">173,657</ix:nonFraction>.</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">-</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Product co-development agreement with TCNT resulting in $<ix:nonFraction id="fid_901" contextRef="From2021-01-01to2021-09-30" name="us-gaap:DevelopmentCosts" format="ixt:numdotdecimal" decimals="0" unitRef="USD">117,386</ix:nonFraction> in costs and $<ix:nonFraction id="fid_895" contextRef="AsOf2021-09-30" name="us-gaap:AccountsPayableTradeCurrentAndNoncurrent" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,680</ix:nonFraction> in accounts payable.</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">-</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Sale of products to ASE Technology Holding totaling $185,376.</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">-</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Three-year office space was leased from a related party resulting in ROU Asset totaling $<ix:nonFraction id="fid_896" contextRef="AsOf2021-09-30" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,728</ix:nonFraction> and Lease Obligations totaling $<ix:nonFraction id="fid_897" contextRef="AsOf2021-09-30" name="us-gaap:CapitalLeaseObligations" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,908</ix:nonFraction>. The Company makes monthly lease payments of $<ix:nonFraction id="fid_898" contextRef="From2021-01-01to2021-09-30" name="us-gaap:LeaseAndRentalExpense" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,785</ix:nonFraction>.</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">-</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Product development consulting fee of $<ix:nonFraction id="fid_899" contextRef="From2021-01-01to2021-09-30" name="aimd:ConsultingFee" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,215</ix:nonFraction> payable to Huang Chien-Hsuan, of which $<ix:nonFraction id="fid_900" contextRef="AsOf2021-09-30" name="aimd:ConsultingFeePayable" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,671</ix:nonFraction> remains outstanding and payable.</p></td></tr></tbody></table></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:continuation id="cont_65a63d"><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">-</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Product development consulting fee of $7,215 payable to Huang Chien-Hsuan, of which $6,671 remains outstanding and payable.</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">-&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On August 1, 2021, the Company entered into a five-year product development agreement with TCNT. Pursuant to the agreement both parties will endeavor to develop pharmaceutical, medical and preventive medicine related products.&#160; Under the agreement the Company is designated as the exclusive sales agent of the resulting products.&#160; The agreement also provides for the Company to bear the expenses of product development and for TCNT to contribute personnel and facilities. Both parties shall each jointly own an equal proportion of the intellectual property rights arising from the product co-development cooperation. As a result, the Company incurred $117,386 in product co-development expenses and $122,680 in accounts payable during the reporting period.</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">-</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">The Company issued common stock as partial compensation to Dr. Stephen T. Chen and Bernard Cohen as follows:</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; &#160;</p><ix:continuation id="cont_7a0a38"><table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Par Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Paid in </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Excess of Par</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Price per share</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;06/30/2021</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Bernard Cohen</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_723" contextRef="AsOf2021-06-30_aimd_DrStephenTChenMember" name="aimd:Shares" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,876</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_727" contextRef="AsOf2021-06-30_aimd_DrStephenTChenMember" name="aimd:ParValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58</ix:nonFraction>.76</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_726" contextRef="AsOf2021-06-30_aimd_DrStephenTChenMember" name="aimd:PaidInExcessOfPar" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,107</ix:nonFraction>.89</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_725" contextRef="AsOf2021-06-30_aimd_DrStephenTChenMember" name="aimd:TotalAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,166</ix:nonFraction>.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_724" contextRef="AsOf2021-06-30_aimd_DrStephenTChenMember" name="us-gaap:SharePrice" decimals="INF" unitRef="USDPShares">0.5389</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;06/30/2021</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Dr. Stephen T. Chen</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_728" contextRef="AsOf2021-06-30_aimd_BernardCohenMember" name="aimd:Shares" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,419</ix:nonFraction></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">534.19</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_730" contextRef="AsOf2021-06-30_aimd_BernardCohenMember" name="aimd:PaidInExcessOfPar" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,799</ix:nonFraction>.14</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_731" contextRef="AsOf2021-06-30_aimd_BernardCohenMember" name="aimd:TotalAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,333</ix:nonFraction>.33</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_732" contextRef="AsOf2021-06-30_aimd_BernardCohenMember" name="us-gaap:SharePrice" decimals="INF" unitRef="USDPShares">0.6240</ix:nonFraction></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_719" contextRef="AsOf2021-06-30" name="aimd:Shares" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59,295</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_720" contextRef="AsOf2021-06-30" name="aimd:ParValue" format="ixt:numdotdecimal" decimals="0" unitRef="USD">593</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_721" contextRef="AsOf2021-06-30" name="aimd:PaidInExcessOfPar" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,907</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><ix:nonFraction id="fid_722" contextRef="AsOf2021-06-30" name="aimd:TotalAmount" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,500</ix:nonFraction></td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table></ix:continuation></ix:continuation><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><ix:nonNumeric id="fid_1311" contextRef="From2021-01-01to2021-09-30" name="us-gaap:SubsequentEventsTextBlock" escape="true"><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>8.</strong></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Subsequent Events.</strong></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company engaged PricewaterhouseCoopers, Taiwan (&#8220;PWC&#8221;) as independent accountants of Ainos Inc. Taiwan Branch under an engagement agreement dated October 4, 2021 (&#8220;Audit Engagement&#8221;). The Audit Engagement covers audit services for the years ending December 31, 2021 and 2022 and PWC will issue interfirm audit reports for group reporting purposes to the Company&#8217;s group audit firm, PWR CPA, LLP. Additionally, the Company engaged PWC under separate agreements dated October 4, 2021 for PWC to render advisory services in connection to the Company&#8217;s internal controls over financial reporting as required under section 404 of the Sarbanes-Oxley Act (&#8220;SOX Engagement&#8221;) and in respect to compliance with Taiwan corporate income tax requirements for the tax years ending December 31, 2021 and 2022 (&#8220;Taiwan Tax Engagement&#8221;).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On October 6, 2021, the Company board of directors approved and adopted the following resolutions:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Effective August 30, 2021, the Board appointed Hsiu-Chen Chiu and Wen-Han Chang to serve on the Compensation Committee;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Effective August 30, 2021, the Board appointed Yao-Chung Chiang, Wen-Han Chang and Hsiu-Chen Chiu to serve on the Audit Committee;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Board approval of the Company&#8217;s 2021 Employee Stock Purchase Plan, 2021 Stock Incentive Plan, and 2021 Director Compensation Policy and, if required, shall submit the same for formal adoption by a vote of the Company&#8217;s shareholders</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Board approval of the Company&#8217;s Related Transaction Policy, Hedging Policy, and the Diversity Policy of the Board; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Board approval of the Company&#8217;s engagement agreements dated October 4, 2021 with PricewaterhouseCoopers, Taiwan (&#8220;PWC&#8221;)</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On November 1, 2021, the Company engaged its former President and CEO, Dr. Stephen T. Chen, as a consultant to assist with its pharmaceutical division. <ix:nonNumeric id="fid_905" contextRef="From2021-10-23to2021-11-01_us-gaap_SubsequentEventMember" name="aimd:DescriptionOfConsultant">The Company agrees to pay Dr. Chen 50,000 New Taiwan Dollars (NTD) per month for a period of one year for his services. With over 30 years of pharmaceutical professional experience</ix:nonNumeric>, we expect Dr. Chen to provide technical assistance on our pharmaceutical development initiatives, analyze results from second phase interferon studies for Thrombocytopenia, and contribute to the protocol design of the third phase of interferon development focused on Sj&#246;gren&#8217;s syndrome. Lastly, we expect that Dr. Chen will provide assistance for our mass commercial production of low-dose interferon products.</p></ix:nonNumeric><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="item2">ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>The following discussion should be read in conjunction with our financial statements and the notes thereto which appear elsewhere in this report. The results shown herein are not necessarily indicative of the results to be expected in any future periods. </em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>OVERVIEW</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em><span style="text-decoration:underline">The Company</span></em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Ainos, Inc. (the &#8220;Company&#8221;) is a Texas corporation incorporated in 1984 engaged in the discovery and development of pharmaceuticals, medical devices and preventative medicine. The Company currently has offices in the United States and Taiwan. The Company operates a branch office in Taiwan registered as AINOS, INC. TAIWAN BRANCH.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em><span style="text-decoration:underline">Our Business Divisions</span></em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We operate through three business divisions: Pharmaceutical, Medical Devices and Preventive Medicine. Our Preventive Medicine Division was formerly the Consumer Product Division. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Pharmaceutical</strong>: Low-dose lozenge interferon alpha (IFN-&#945;) Research. Our core pharmaceutical drug development platform, VELDONA (Very Low-Dose Oral Interferon Alpha), is the result of more than thirty years of clinical research on low-dose non-injectable interferon alpha (IFN-&#945;), which has been shown to be effective in trials against a variety of diseases, including thrombocytopenia, Sj&#246;gren&#8217;s syndrome, hepatitis C, influenza, HIV, SARS, and other conditions ranging from genital warts to canker sores. Shifting to a more focused approach, we plan to conduct further clinical trials of VELDONA on thrombocytopenia and Sj&#246;gren&#8217;s syndrome. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Medical Devices</strong>: Our previous focus on insulin infusion therapy under our SMART (Simultaneous Metabolic Activation &amp; Restoration Therapy) treatment resulted in the development of a prototype novel insulin pulsatile pump. Our pump prototype delivers insulin intravenously in pulses, as opposed to the typical subcutaneous route of administration, in order to more closely imitate how the pancreas secretes insulin in healthy non-diabetics. The pump requires additional stages of development and is subject to further studies. Meanwhile, we have expanded our product lines to include COVID-19 diagnostics and VOC diagnostics. Going forward we plan to accelerate commercialization of these new products following receipt of the applicable regulatory approval. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Preventive Medicine</strong>: We have restructured our former Consumer Product Division into a Preventive Medicine Division to expand our focus on treatments to prevent disease. Our previous efforts in the sale and marketing of liposomal nutraceutical and food supplements lacked synergies with our focus on specific disease indications and pharmaceutical treatment potentials. While we continue to believe in the efficacy of nutrition as a primary contributor to human health, we restructured this division in the third quarter of 2021 in order to incorporate a broader perspective centered on preventative interventions and to pivot towards more cutting-edge, revolutionary technologies. Going forward we are seeking new efforts on SRNA-based therapeutics development, to truly effect medical approaches that prevent the advancement of diseases. Our focus will be on fundamental research and development of vaccines with the intent to seek out-licensing opportunities and strategic partnerships when appropriate.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em><span style="text-decoration:underline">Our Medtech Transformation</span></em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The COVID-19 pandemic has fundamentally changed the healthcare and medical industries. Digital transformation of healthcare is underway to provide access to quality healthcare with reduced physical contact. As a result, telehealth adoption has substantially accelerated. We believe that better telehealth service requires enhanced telehealth-enabled diagnostics, and therefore we anticipate the need for rapid, convenient, low-cost, cloud-connected digital diagnostics. In addition, the recent commercialization of mRNA COVID-19 vaccines suggests SRNA's has established SRNA&#8217;s promising potential in expediting pharmaceutical innovation. In order to meet these structural changes, we are transforming to a diversified medtech company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We envision playing a major role in the digital healthcare revolution through an evolution in artificial intelligence, enabled by our AI Nose platform. We believe our AI Nose technology platform can potentially enable the eventual utilization of smell digitization for a plethora of applications, beginning with healthcare volatile organic compound (VOC) diagnostics. In our view, VOCs within the human body can be digitally profiled to facilitate personalized medicine. We refer to the digital identification of VOCs as &#8220;Smell ID.&#8221; As we train our AI algorithm with more Smell ID data, we believe we can provide more value-added service to our customers.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em><span style="text-decoration:underline">Our Strategic Partner</span></em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Ainos, Inc., a Cayman Islands incorporated company (&#8220;Ainos KY&#8221;), acquired majority ownership and management of the Company earlier this year. Under a Securities Purchase Agreement that closed on April 15, 2021 (the &#8220;Ainos KY Transaction&#8221;), we acquired intellectual properties valued at approximately $20 million that included VOC AI algorithms, digital nose technology, and a pipeline of innovative point-of-care testing (POCT) diagnostic technologies for a myriad of diseases including COVID-19, vaginitis and certain sexual transmitted diseases (STD), pneumonia and helicobacter pylori (h. pylori). </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We expect that our newly-acquired in vitro POCTs can generate organic cash flows to support our business while we invest in our Pharmaceutical and Preventive Medicine Divisions. We have successfully commercialized our Ainos Covid-19 Test Kit this year in Taiwan and plan to commercialize other new in-vitro POCT diagnostics over the next several years if our products receive regulatory approval. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Ainos KY has also provided financial and management resources to supplement our business management capacity and operations. The current Board of Directors represents a broad spectrum of scientific, management, legal, and financial expertise that will be necessary to implement our business plans. After closing the Ainos KY Transaction, the Company engaged additional management resources including Mr. Chun-Hsien Tsai as Chairman and CEO, Ms. Hui-Lan (Celia) Wu as CFO and Mr. Chih-Heng (Jack) Lu as Head of Corporate Development, retained key management and legal staff. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em><span style="text-decoration:underline">Ainos Transformational Technologies</span></em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The intellectual property and other assets acquired from Ainos KY address key gaps in our former business model and provide a foundation for a more holistic drug and medical device development program.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>First, by infusing the Company with VOC + AI algorithms and digital nose technology, we are now positioned to transition from our treatment-driven model for medical interventions to a more proactive diagnostic-driven pharmaceutical, medical device, and preventative medicine business plan. Ainos&#8217; VOC AI assets are central to our telehealth friendly, point-of-care diagnostic-driven approaches throughout our Company&#8217;s product development program.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>VOC Diagnostics</strong>. Volatile organic compounds (VOCs) profiles measured in exhaled breath as well as from headspaces of feces or urine samples are a source of information with respect to disease detection. Emerging advances in analytical technologies in the detection and measurement of VOCs in clinical matrices have generated increasing interest for their use in evaluating the diagnostic potential of VOCs for different diseases. VOCs represent a wide range of stable chemicals, are volatile at ambient temperature (may emit odors), and are detectable in exhaled breath, urine, feces, and sweat. Testing clinical samples for VOCs offers an option for developing rapid and potentially inexpensive disease screening tools. Most of the studies on volatile biomarkers have been carried out on exhaled-breath samples, although other clinical matrices, such as urine and feces, have also been investigated. Analysis of breath samples for testing of volatiles can be performed frequently in follow-up studies and may reflect disease progression and be helpful in monitoring therapeutic intervention. Moreover, breath tests are noninvasive and thus suitable for critically ill patients in intensive care units and small children.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>AI Nose Technology Platform</strong>. Our AI Nose technology platform comprises the key building block of our VOC-based approaches. AI Nose&#8217;s main technology pillars include the digital nose sensor array, our proprietary VOC AI analytics, Smell ID, and our Company&#8217;s extensive knowhow of VOC-based medical device engineering. Our technology digitally profiles each VOC as a Smell ID and as more Smell IDs are collected for individuals, we may be able to build personalized medical treatment based on this data. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Our early efforts to develop a diabetes-focused insulin pump have significantly expanded into a more comprehensive development of a wide range of innovative point-of-care testing (POCT) diagnostic technologies, starting with our recent launch of the Ainos COVID-19 Antigen Test Kit in Taiwan.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>COVID-19 Antigen Test Kit</strong>. On June 14, 2021 we entered into an exclusive agreement to serve as the master sales and marketing agent for the Ainos SARS-CoV-2 Antigen Rapid Test Kit (&#8220;Ainos Covid-19 Test Kit&#8221;) for Taiwan Carbon Nano Corporation (&#8220;TCNT&#8221;), the majority shareholder of Ainos KY. The Ainos COVID-19 Test Kit has been granted the CE mark, enabling us to market the product in Europe. On June 7, 2021, the Taiwan Food and Drug Administration (&#8220;TFDA&#8221;) granted emergency use authorization for the Ainos COVID-19 Test Kit for use by healthcare professionals in Taiwan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Ainos Covid-19 Test Kit uses an antigen rapid test technology jointly developed by Taiwan&#8217;s National Health Research Institutes (&#8220;NHRI&#8221;), National Defense Medical Center (&#8220;NDMC&#8221;), and TCNT. Our test kit features a smartphone-based test management function, which can be accessed through a data matrix code. The data matrix code stores each test kit&#8217;s unique ID. Each user will be able to store the results directly to the individual&#8217;s mobile phone. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Continuous personalized testing and community-wide tracing capabilities are fully integrated in our rapid test kit designs by leveraging smart phone applications and cloud-based technologies.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We developed a comprehensive, end-to-end, cloud-based COVID-19 management platform that allows individuals and organizations to manage tests and trace infection effectively. Our platform is comprised of our test kits, a consumer app and an enterprise app. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>We aim to empower our customers and telehealth practitioners with rapid, accurate and non-invasive tools to monitor health with our Ainos Flora, Ainos Pen and CHS340 VAP rapid test devices. </em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Ainos Flora</strong>. We designed our iF-award winning Ainos Flora to empower patients to effortlessly, non-invasively and quickly test their vaginal health at home. Through specialized digital nose sensor arrays and A.I. algorithms, Ainos Flora is designed to detect vaginal infection and common STDs (including bacterial vaginosis, fungus infection, gonorrhea and trichomoniasis) in minutes. Ainos Flora is portable, handheld, and enables remote monitoring by designated medical professionals. Patients can store test results in a mobile app. Ainos Flora is designed to give women back control of monitoring their personal health.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">16</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Ainos Pen</strong>. Conventional breathalyzers are typically single-purpose and primarily designed to test for alcohol and drug use. Ainos Pen is a multi-purpose, cloud-connected breathalyzer intended for routine health monitoring. By enabling self-care at home, we anticipate Ainos Pen will create new applications for the telehealth ecosystem by allowing its users to non-invasively monitor their health. Ainos Pen securely stores test data in a complimentary mobile app with the ability to upload test data to a cloud server for access by designated healthcare providers. Through telehealth and A.I. analytics, patients can provide comprehensive and long-term health data to their healthcare providers.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>CHS430 VAP Rapid Test</strong>. Ventilator-associated pneumonia (VAP) is one of the most frequent ICU-acquired infections. Reported prevalence varies widely from 5% to 40%. Causes of VAP include prolonged duration of mechanical ventilation or endotracheal intubation. The estimated mortality of VAP is around 10%, with higher mortality rates in surgical ICU patients and in patients with mid-range severity scores at admission. CHS430 is a patented portable breathalyzer that connects into a respirator&#8217;s y-connector and detects VAP within 10 minutes. It is designed to screen VAP infections and the likely causation pathogen. A specialized sensor array and algorithms quickly identify infections and the most common bacterial species related to VAP. The device is easy to operate with the press of a button. The sensor array inside the device is designed to be periodically replaced. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em><span style="text-decoration:underline">Our Divisions and Product Lines</span></em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As part of our medtech transformation strategy, we reclassified our divisions into the Pharmaceutical Division, Medical Device Division and Preventive Medicine Division. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Our Pharmaceutical Division researches and develops drug therapeutics that support the human immune system and address persistent diseases.</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>VELDONA Pharmaceutical Drug Development Program </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Since our inception we have engaged in the research of low-dose non-injectable interferon delivered through nasal, oral mucosal, topical and transdermal pathways and in liquid, ointment or lozenge forms. Our core pharmaceutical drug development platform, VELDONA (Very Low-Dose Oral Interferon Alpha), is predicated on a comprehensive library of scientific clinical data for low-dose non-injectable interferon, including more than 100 clinical and pre-clinical animal and human studies conducted over several decades that we believe substantiates its safety and efficacy. We have an accomplished track record of completing numerous late-stage clinical trials for a variety of disease indications and also own several active patents associated with the treatment of thrombocytopenia, related to the prevention of viral recurrence of hepatitis C.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Ainos differentiates itself from other interferon drug developers through the distinct advantage of owning a proprietary library of over sixty late-stage clinical studies and trials aggregated over decades of research experience. The VELDONA platform leverages our research of numerous disease indications where we have established safety data for the use of low-dose non-injectable interferon from over thirty years of clinical studies and trials without any adverse side effects from low-dose interferon. We believe we have a higher likelihood to potentially accelerate clinical trials without the need to substantiate safety data through preliminary trials normally required for new drug applications. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We believe that low-dose non-injectable interferon therapeutics have broad potential applications for new drugs and nutraceuticals that address infectious diseases, autoimmune diseases and cancer. It has anti-proliferative effects which can be targeted at rapidly spreading viruses or rapidly dividing cancer cells. We believe VELDONA is a safe, universal and multi-functional product that is a well-suited for the prevention and treatment of viral infections. We have developed a proprietary formulation for the production of an IFN-&#945; lozenge that can be administered sublingually as a small tablet in doses ten-thousand times less than FDA-approved high-dose injectable interferon therapies, which we believe may dramatically reduce side effects. The VELDONA lozenge is also stable at room temperature, which makes them easy and inexpensive to transport, store and administer.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">17</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Interferon-alpha (IFN-&#945;)</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Ainos currently focuses primarily on therapeutic applications of interferon-alpha (IFN-&#945;). Interferons are a family of natural occurring proteins that can be used to potentially treat many diseases that involve the immune system &#8211; for example, cancers, hepatitis, AIDS, multiple sclerosis (MS), genital and perianal warts, and granulomatous disease. IFN-&#945; is a key modulator in our innate immune response to viral infection. Almost every cell in the body can produce interferon when under attack, but research indicates that interferon seems especially important in the cells that form the frontline defense with the external environment, such as the oral and nasal mucosa. Its anti-viral effects include inhibition of viral replication, destruction of virus-infected cells, and activation of other, important immune cells. IFN-&#945; also has anti-proliferative effects which can be targeted at rapidly spreading viruses or rapidly dividing cancer cells. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">High-dose systemically administered IFN-&#945; has been used alone or in combination to treat a variety of diseases, including hepatitis C, polycythemia vera, and adult T-cell leukemia/lymphoma (ATLL). While IFN-&#945; has powerful anti-viral and anti-proliferative actions, its therapeutic success has been limited by a host of adverse effects some of which are life-threatening, such as neutropenia and thrombocytopenia. Our research with low-dose oral IFN-&#945; in animal and human clinical trials has shown promise to deliver equal or superior efficacy to that of high-dose systemic IFN-&#945; without the associated adverse effects. A significantly lower dose of IFN-&#945; and its absorbance across the mucous membrane of the oral cavity, more closely mimics our innate immune response. Our oral IFN-&#945; lozenges, VELDONA, exert both local and systemic effects, but at such low doses that the adverse events which plague high dose injectable IFN are not an issue. In fact, low-dose oral IFN-&#945; has even been shown to reverse some of the adverse effects of thrombocytopenia directly caused by high-dose IFN. The Company is in prime position to meet this need having secured several patents for the treatment of thrombocytopenia using orally administered IFN-&#945;. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have aggregated many years of testing in the use of low-dose oral IFN-&#945; for applications ranging from the common cold and warts to cancers and HIV. The therapeutic diversity of IFN-&#945; stems from its ability to induce the transcription of hundreds of genes that stimulate the immune system. These genes effect numerous parts of the innate and adaptive immune system, including antigen processing and presentation, leukocyte migration, lymphocyte activation, immune effector and modulation functions, apoptosis, hematopoiesis, enzymatic destruction of viral RNA. In the past, we typically used natural human cell interferon in clinical trials as this was the specific form manufactured by our previous investment partner, Hayashibara Co., Ltd. We are now considering a substitute form of recombinant interferon product to replace natural human cell interferon and plan on conducting pilot studies to establish efficacy prior to advancing further clinical trials for our target disease indications. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Much clinical trial research has already evidenced recombinant interferon to be effective in adjuvant cancer therapies and FDA-approved high-dose injectable recombinant interferon alfa-2b treatments have been used globally to treat a multitude of disease indications such as AIDS-related Kaposi sarcoma, lymphoma, hairy cell leukemia and melanoma. In fact, interferon alpha (IFN-&#945;), a cytokine that is responsible for regulating and activating the immune response, was the first cancer immunotherapy approved by the FDA in 1986. This helps support a higher level of certainty that recombinant interferon should demonstrate a desired level of efficacy, especially given that low-dose IFN-&#945; is delivered as a miniscule dose compared to high-dose injectable IFN-&#945; treatments. We plan to conduct pilot clinical trials starting in the first half of 2022 to validate newly-sourced interferon material and pursue several disease indications including thrombocytopenia, and Sj&#246;gren&#8217;s syndrome. We intend to continue exploring the modernization of interferon technology by researching new sources and types of interferon and are looking into methods of new interferon production, preparation, and purification methods.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">18</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Clinical Trials for Key Disease Indications</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We plan to orchestrate a concerted effort with research and medical expert supporters of the VELDONA drug program to facilitate the advancement of various low-dose IFN-&#945; formulations and delivery modalities. We own proprietary clinical data on previously studied indications that can potentially be delivered to market at minimal clinical trial cost. The Company plans to resume clinical studies for key disease indications. In the near term, we will seek to advance our drug program with a particular focus on conducting clinical trials for two disease indications &#8211; thrombocytopenia and Sj&#246;gren&#8217;s syndrome. We believe these two indications can reach late-stage trials with the highest probability of successful approval in the shortest time. At any time during the drug development stage, the Company aims to out-license the intellectual property, ultimately acquiring global approvals for various disease indications. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Thrombocytopenia</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In a 2014 data study, &#8220;Efficacy of Low Dose Oral Interferon-alpha in Preventing Hepatitis C Relapse,&#8221; was published based on a phase 2 clinical trial of 169 hepatitis C patients conducted at Chang Gung Hospital in Taiwan that found VELDONA to reduce the relapse rate of hepatitis C and improve the function of platelets. In connection with this study, Ainos received four thrombocytopenia related patents. Low-dose oral IFN-&#945; can contribute to reversing the immunosuppressive tumor microenvironment and prevent some of the dangerous side-effects of chemotherapy such as thrombocytopenia. We will leverage our previous clinical trial experience to prepare a well-designed protocol to test whether VELDONA is effective in treating thrombocytopenia and determine whether it can continue the next-stage trials. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Sj&#246;gren&#8217;s Syndrome</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company intends to resume late-stage clinical trials in late 2022 for Sj&#246;gren&#8217;s syndrome, an immune system disorder characterized by dry eyes and dry mouth. We previously reached two phase 3 trials in 2003 but were unable to conduct the final FDA-mandated studies for drug approval due to capital constraints (&#8220;Treatment of primary Sj&#246;gren&#8217;s syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results&#8221;). Ainos will reference its previous research to design an efficient phase 3 study based on previous FDA guidance.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In respect to its VELDONA program, the Company owns three (3) patents issued in the U.S. and one (1) issued in Taiwan as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">&#8220;TREATMENT OF THROMBOCYTOPENIA USING ORALLY ADMINISTERED INTERFERON&#8221; as described and claimed in U.S. Patent No. 9,526,694 B2 issued December 27, 2016, Owned. Expiration: April 2033.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">&#8220;TREATMENT OF THROMBOCYTOPENIA USING ORALLY ADMINISTERED INTERFERON&#8221; as described and claimed in U.S. Patent No. 9,750,786 B2 issued September 5, 2017, Owned. Expiration: April 2033.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">&#8220;TREATMENT OF THROMBOCYTOPENIA USING ORALLY ADMINISTERED INTERFERON&#8221; as described and claimed in U.S. Patent No. 9,839,672 B2 issued December 12, 2017, Owned. Expiration: April 2033.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">&#8220;TREATMENT OF THROMBOCYTOPENIA USING ORALLY ADMINISTERED INTERFERON&#8221; as described and claimed in TAIWAN Patent No. I592165 issued July 21, 2017, Owned. Expiration: May 2033.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">19</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company continues to seek to expand its patent licensing and commercialization opportunities for VELDONA with global partners. The Company&#8217;s licensing, development and commercialization of its VELDONA patents and research library are subject to approval by the FDA and other regulatory agencies in the U.S., and other regulatory agencies for use and marketing in other countries.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Our Medical Device Division focuses on research and development of novel medical devices.</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Innovations in point-of-care testing </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We develop, market, and sell various easy-to-use, cloud-connected POCT diagnostics for infectious disease indications. Our product pipeline target indications include COVID-19, vaginitis, certain sexually transmitted diseases (STD), ventilator-associated pneumonia (VAP), and helicobacter pylori (H. pylori). We categorize our POCT portfolio into the following: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>COVID-19 POCT</strong>. This category currently includes an antigen rapid test kit based on lateral flow immunoassay technology, a molecular test kit based on reverse transcription loop-mediated isothermal amplification (&#8220;RT-LAMP&#8221;) technology, and test management apps for personal and enterprise users. The COVID-19 antigen test kit includes professional-use and at-home SKUs. The professional SKU targets the professional healthcare segment, while at-home SKUs aims the at-home self-testing segment. We also offer a cloud-based test management platform with a personal app as well as an enterprise app. Our molecular tests comprised of test kit assay and a low-cost portable tester.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>VOC-based POCT</strong>. This category employs digital nose sensors and AI algorithms to detect and analyze VOC biomarkers for rapid detection of infectious disease and everyday self-care. We further implement wireless and secured cloud technologies to enable seamless, easy-to-use test data transmission to the telehealth community. Our target disease indications include vaginitis, STD, VAP, and H. pylori. We anticipate that our near-term revenue stream for VOC-based POCTs will mainly come from hardware sales. Longer-term, we plan to introduce a subscription-based analytics service to our customers, and when sales of medical devices reach scale, we anticipate subscription revenue to create substantial operating cash flow.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>The opportunities of digital nose innovation</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The digital nose, also known as the electric nose (e-nose) or, more generally, gas sensor, is a more scalable technology to analyze VOCs in a clinical setting, in our view. Comprised of gas sensors, the digital nose electronically mimics the human nose and the advancement in semiconductor manufacturing technologies allow digital noses to be made small, and at low cost. When combined with a pattern recognition algorithm, the digital nose directly detects components of different VOCs present in a gas mixture, which eliminates the need for complex preprocessing steps. A digital nose can be customized for specific applications using an array of sensors, which can detect volatile components included in a predetermined VOC profile. With the help of algorithms and other electronic components such as microprocessors, and wireless technologies, the digital nose can convert a VOC profile into unique digital signals that can be understood by many electric devices, which may enable a digital nose to be quickly developed into many easy-to-use, affordable, portable, cloud-connected POCTs for a wide range of diseases. We believe these potential new tools could facilitate new telehealth services previously unavailable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Our AI Nose technology platform</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our AI Nose technology platform comprises the key building block of our VOC-based POCT. AI Nose&#8217;s main technology pillars include the digital nose sensor array, our proprietary VOC AI analytics, Smell ID, and the Company&#8217;s extensive knowhow of VOC-based medical device engineering. Our technology digitally profiles each VOC as a Smell ID and as more Smell IDs are collected for individuals, we may be able to build personalized medical treatment based on this data. We believe Smell ID&#8217;s long-term potential goes beyond healthcare. As we populate AI with more Smell ID, we believe we may eventually enable the AI Nose to detect smell in the broader, non-healthcare settings.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">20</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>COVID-19 Antigen Test Kit </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Antigen test kits have been vital in testing COVID-19 at high frequency, large scale, and at low cost. Most EUA-approved test kits claim nearly identical value propositions and these essential functions are already commoditized. In our opinion, helping communities to better store and report the test results, and assisting organizations to better trace infection are critical attributes as countries try to reopen their economies. Unfortunately, few COVID-19 antigen test kits in the market provide these services. While testing labs are required to report their findings, many at-home tests are not required to report results to the health authorities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have developed a comprehensive, end-to-end, cloud-based platform that allows individuals and organizations to manage tests and trace infection effectively. Our platform is comprised of our test kit, a consumer app and an enterprise app. Consumers can visually see the test result on our test kit without using the app. We launched a free, consumer-friendly app called the Ainos Antigen Rapid Test App, available on iOS and Android. The app is currently available in Taiwan and we plan to roll out to additional countries in which we receive authorization to market, if approved. The app provides a simple and comprehensive interface platform to manage test results with the following vital services:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><span style="text-decoration:underline">Secure log-in</span>: User logs in with email and mobile phone number, receives a PIN number to authenticate.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><span style="text-decoration:underline">Double authentication</span>: Each test kit carries a data matrix code storing a unique serial number. User takes a selfie, and then scans the data matrix code before and after testing. This establishes a double authentication protocol for a reliable at-home testing experience.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><span style="text-decoration:underline">Digital test report</span>: Our app stores and displays vital information from the user&#8217;s latest test. The report includes the result, the unique I.D. number of the test kit associated with the test result, the date of the test and the user&#8217;s picture. Another Ainos user can scan the test report&#8217;s QR code. With this function, the user can display and share results with businesses, organizations, and healthcare authorities, allowing informed and safe gathering of data as well as improved test management.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><span style="text-decoration:underline">Manage test results</span>. The app stores all past tests results performed by the test kit and uploads these results to our secure cloud server. If the test kit is purchased by an organization that uses our enterprise app, the organization can access the user&#8217;s testing history in the enterprise app to facilitate remote tracing of COVID-19.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><span style="text-decoration:underline">Filter visitors at entry</span>. The app can scan another person&#8217;s digital test report. Organizations and business owners can use this function at any point of entry, creating a safe environment for gathering.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><span style="text-decoration:underline">Proximity alert</span>. The app notifies the user if someone tested positive has been in proximity with the user.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our Ainos Enterprise App is a centralized, cloud-based COVID-19 test management platform designed for public and private institutions. With this app, institutions can centrally manage and trace COVID-19 testing. The key features are:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Manage test result centrally</span>. The app tracks inventory and sends testing reminders, daily reports to a designated person. An app administrator can download the test results as a spreadsheet.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><span style="text-decoration:underline">Trace footprint of positive cases</span>. The app administrator can trace a positive case&#8217;s footprint over the past seven days.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">21</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>COVID-19 Nucleic Acid Test Kit</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">COVID-19 testing methods generally fall into three categories: molecular tests, antigen tests and antibody tests. The molecular test features the best accuracy. Current molecular tests rely on centralized laboratory testing, and face complex sample transportation, logistics, and throughput challenges. As a result, molecular test results can take from two to 14 days, require highly trained technicians to operate complex instruments and are generally expensive. These attributes present challenges to the rollout of testing capacity at the scale needed to meet current global demand. Lastly, effectively tracking molecular test results is difficult, as reporting is often conducted manually.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Based on our proprietary reverse transcription loop-mediated isothermal amplification (RT-LAMP) technology, Ainos has developed a fast and affordable molecular test. It consists of a color-changing assay that is compatible with standard PCR machines and portable, low-cost equipment. We offer the following functionality to our customers and when combined, we believe that they enable accurate, fast, cost-effective COVID-19 management.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Intuitive test results</span>. Our assay displays test results by change of color. Yellow indicates positive results while red indicates negative results, permitting the naked eye or a smartphone camera to easily interpret the test result.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Quick result</span>: Our assay delivers test results in 30-40 minutes, faster than a traditional test that may take from one hour to a two-day cycle.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><span style="text-decoration:underline">Compatible with standard PCR machines</span>. We have designed our assay to be compatible with most standard PCR machines. As a result, healthcare stakeholders can quickly deploy our assay without investing in new equipment.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Portable, low-cost equipment</span>. Our RT-LAMP assay tests COVID-19 at a constant temperature. This allows us to develop a portable test device. As the result, we can deliver PCR-comparable performance with portability and low-cost. In contrast, standard PCR tests operate at multiple temperature changes, which require complex and large machines.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Ainos Flora &#8211; discreet, telehealth-enabled STD tests in your hands</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Invasive sampling is essential in the diagnosis of certain sexually transmitted diseases (STDs), such as vaginitis, gonorrhea, chlamydia and trichomoniasis. Pelvic exams are conducted primarily in an outpatient setting as they require the trained operation of specialized instruments.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Conventional testing methods, including pelvic exams, have several disadvantages. First, while the pelvic test/whiff test is quick, the wait time at the outpatient clinic is often long. Second, patients commonly feel anxiety before and during the pelvic exam. Third, the pelvic test and pH test cannot by themselves provide a definitive diagnosis. Fourth, the laboratory culture test takes a few hours to a few days to complete. Fifth, the pelvic exam is vulnerable to healthcare disputes. Lastly, the overall inconvenience may discourage follow-up visits and treatments. These shortcomings have two critical implications. First, crowded hospitals and clinics and long wait times may amplify patients&#8217; anxiety levels. This may discourage patients with STD-suspected infections from getting tested or cause delays in seeking medical help. This may increase the risk of patients with mild symptoms unknowingly contributing to the spread of STDs. Second, it implies that the STD testing market size could be larger than reported by market research data.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have designed our iF-award winning Ainos Flora to empower patients to effortlessly, non-invasively and quickly test their vaginal health at home. Through specialized digital nose sensor arrays and A.I. pattern recognition, Ainos Flora is designed to detect vaginal infection and common STDs (including bacterial vaginosis, fungus infection, gonorrhea and trichomoniasis) in minutes. Ainos Flora is portable, handheld, and enables remote monitoring by designated medical professionals. Patients can store test results in a mobile app. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">22</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Flora is designed to give women back control of monitoring their personal health with the following clinical and commercial benefits:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><span style="text-decoration:underline">Convenience</span>. Ainos Flora&#8217;s form factor is designed to allow easy self-testing or clinical testing.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><span style="text-decoration:underline">Non-invasive and no skin contact</span>. The digital nose sensors enable Flora to gather and analyze a pathogen&#8217;s metabolic VOC a few centimeters away from the private area, without skin contact.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><span style="text-decoration:underline">Results within minutes</span>. The complex digital nose sensor and A.I. algorithm work together to deliver test results in about one minute. In contrast, a culture test can take days.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><span style="text-decoration:underline">Remote monitor</span>. A complementary mobile app wirelessly receives test results from Ainos Flora and uploads results to our secure cloud server. A patient&#8217;s designated physicians can then download the test results and remotely prescribe treatment. The process is designed to avoid potentially long wait times and remain discreet.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Ainos Pen &#8211; a multipurpose breathalyzer for everyday telehealth</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Conventional breathalyzers are typically single-purpose and primarily designed to test for alcohol and drug use. Ainos Pen is a multi-purpose, cloud-connected breathalyzer intended for routine health monitoring. By enabling self-care at home, we anticipate Ainos Pen will create new applications for the telehealth ecosystem by allowing users to non-invasively monitor their health. Ainos Pen securely stores test data in a complimentary mobile app with the ability to upload test data to a cloud server for access by designated healthcare providers. Through telehealth and A.I. analytics, patients can provide comprehensive and long-term health information for their healthcare providers.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Ainos Pen brings easy-to-use testing in a sleek pocket-sized form factor. This portable breath analyzer identifies VOCs from human breath in minutes and our A.I. algorithms. We designed the Ainos Pen to detect total VOC, eCO2, carbon monoxide, ethanol, hydrogen sulfide, and ammonia. Inside the Ainos Pen, the digital nose sensor technology can be built to specifications for monitoring various health conditions, such as halitosis (bad breath), gastrointestinal, liver, renal health, and smoking habits. Additional functions can potentially be created as we identify more new VOC biomarkers.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>CHS430: ventilator-associated pneumonia (VAP) detection within 10 minutes </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Ventilator-associated pneumonia (VAP) is one of the most frequent ICU-acquired infections. Reported prevalence varies widely from 5% to 40%. Causes of VAP include prolonged duration of mechanical ventilation or endotracheal intubation. The estimated mortality of VAP is around 10%, with higher mortality rates in surgical ICU patients and in patients with mid-range severity scores at admission. VAP also imposes a significant economic burden.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In our opinion, the current diagnosis of VAP is inefficient in method and speed, which complicates treatment, prevention and affects patient outcomes. The first step of diagnosis relies on clinical evaluation (e.g. evaluation of symptoms, use of a Clinical Pulmonary Infection Score (&#8220;CPIS&#8221;) and chest x-rays) and culture analysis. However, no single clinical criterion is sufficient to provide a definitive diagnosis. The second step of diagnosis is to perform microbiological sampling for culture analysis. However, sampling techniques for VAPs can be confusing. Culture analysis is a complex and slow process that increases the risk of antibiotics overuse. Performing culture analysis requires trained clinicians while sampling is often invasive and poses a threat to intensive care unit (ICU) patients who are already physically and emotionally vulnerable. Culture test results are often delayed, and during the wait time, healthcare providers may prescribe broad-spectrum antibiotics empirically, which may lead to poor patient outcome. The prescription of broad-spectrum antibiotics prior to a diagnosis raises the risk of antibiotic resistance, as studies suggest that VAP accounts for nearly 50% of all antibiotic consumption in ICUs in the United States.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CHS430 is a patented portable breathalyzer that connects into to the y-connector of a respirator and detects VAP within 10 minutes. It is designed to screen VAP infections and the likely causation pathogen, subject to further clinical validation. The device quickly screens a patient&#8217;s breath VOC using an AI-powered digital nose. A specialized sensor array and algorithms quickly identify infections and the most common bacterial species related to VAP. The sensor array inside the device is designed to be periodically replaced. The device also requires regular maintenance.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">23</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CHS430 is intended for use by medical professionals, particularly in critical care centers and ICUs. We believe the device serves as a rapid screening tool and enables faster, better decision making by critical care providers. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Key benefits include:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><span style="text-decoration:underline">Quick result</span>. CHS430 completes self-cleaning and testing within 10 minutes, faster than a culture test.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><span style="text-decoration:underline">Non-invasive testing</span>. The device non-invasively analyzes a patient&#8217;s breath VOC, improving quality of care and avoiding the cross-contamination risk associated with invasive sampling.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><span style="text-decoration:underline">Easy-to-use</span>. Connecting CHS430 to the y-tube requires minimal training. CHS430 self-cleans and begins testing with a simple press of button. The device can monitor the patient in real-time at customizable intervals.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><span style="text-decoration:underline">Better treatment options</span>. Faster bacteria identification allows doctors to select the right treatment path earlier than culture analysis.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><span style="text-decoration:underline">Improves outcome</span>. Early identification leads to better patient outcomes. Treating VAP requires the right antibiotic for the right strain at the right time and mistakes can result in harm to patients. Early detection reduces the risk of mortality or disease metastasis.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>AI Nose &#8211; healthcare digital nose for consumer electrics</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are developing a highly integrated multi-element digital nose sensor module, called the AI Nose. AI Nose is comprised of four sensor chips and an integrated digital processing chip. The sensor chip&#8217;s structure utilizes a complex semiconductor manufacturing process called microelectromechanical systems (MEMS).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are developing AI Nose to introduce powerful VOC detection to the healthcare market. Each module can work alone or in arrays. We also designed the module&#8217;s form factor to be small enough so that it can be adopted into mobile devices such as smartphones. We believe that the AI Noise offers a great companion technology for medtech innovators to launch the next generation of healthcare devices. AI Nose can detect breath VOCs or environmental VOCs at the parts-per billion (ppb) level. Because exhaled VOCs are produced at the ppb level, we believe AI Nose is an ideal solution to monitor health. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our digital nose technology learns to recognize scent in much the same way human learn to smell. In the presence of a VOC, AI Nose generates a digital signal corresponding to the incoming VOC&#8217;s unique profile (&#8220;the Smell ID&#8221;). As we collect and populate our database with more Smell IDs, we can train AI Nose to be smarter and more accurate. Combined with a subscription-based service, we plan to provide analytic and monitoring services to our customers.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em><strong>Our Preventive Medicine Division is dedicated to developing innovative technologies that prevent disease, disability, and death while promoting health and well-being. </strong></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>sRNA research initiative </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Ainos is in the process of establishing a synthetic RNA (SRNA) technology platform capable of producing messenger RNAs (mRNAs) and/or short inhibitory RNAs (siRNAs) for potential vaccine development and disease treatment. Based on this platform, our short-term goal is to research and develop 2nd generation COVID-19 mRNA vaccines. Our long-term goal is to develop therapeutic RNA drugs featuring the use of mRNA and siRNA as genetic modulators for effective control of aberrant immune or genetic disorders.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">24</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We believe effective production of RNA based vaccines or therapeutics through SRNA platform represents promising potential for numerous biomedical applications and disease prevention. Although clinical implementation of SRNAs as drugs to treat human diseases is still rare, we believe this is changing as clinical application of mRNAs are proving to be successful in expressing functional protein antigens and inducing protective neutralizing antibodies against the SARS-CoV-2 virus. As RNA&#8217;s fabrication, purification, and cellular delivery technologies continue to advance, we anticipate increased interest in the use of RNA-based vaccines or therapeutics to treat various human diseases for two reasons. First, SRNAs are cost-effective and simple to manufacture. Second, SRNAs can be rapidly developed as personalized drugs for most clinical and inherited diseases.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Due to the continuous outbreaks and the emergent SARS-CoV-2 variants, our short-term goal focuses on developing 2nd generation SARS-CoV-2 vaccines using a synthetic mRNA-based platform. We plan to use the full-length spike gene sequence of the British alpha variant (lineage B1.1.7) and the Indian delta variant (lineage B.1.617.2) as reference sequences to generate mRNA vaccines with 6 proline mutations. We also plan to adopt sequence modifications and codon optimization of the mRNA vaccines. We will test vaccine delivery with a liposome of known formulation and evaluate the immunization through intramuscular (systemic) and nasal (mucosal) routs in mice. We anticipate the research will generate a T helper 1 (Th1) biased immune response with potent neutralization antibody and effector CD8 T cell response. In addition, relevant recombinant spike proteins will be produced in Baculovirus expression systems. These proteins can be used as alternative immunogens, immunostimulatory adjuvants, or antigens to develop therapeutic monoclonal antibodies.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our long-term vision is to enable treatment of inflammatory diseases and cancers. We will generate mRNAs and/or siRNAs critical for immune modulations or tumor suppression. These mRNAs may express tumor suppressors, cancer-associated antigens, or immune agonists, while siRNAs may be used to degrade disease associated genes of aberrant expression. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We plan to focus on the research and development of the technology. In addition, we intend to explore strategic partnership opportunities upon completion of phase 1 clinical trial(s). </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Our asset-light manufacturing model</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We operate an asset light business model that allows us to fully dedicate resources towards technological innovation and business development. We believe this strategy allows us to optimize capital and stay cost competitive by working with suppliers in Asia. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Taiwan Carbon Nano Technology Corporation (TCNT) is our primary manufacturing partner. On August 1, 2021, we entered into a Product Co-development Agreement with TCNT. Pursuant to the agreement, TCNT will manufacture our POCT products. TCNT operates its facilities in conformance with a variety of International Organization for Standardization (ISO) and Good Manufacturing Practice (GMP) certifications, with most of our healthcare facilities&#8217; quality management systems meeting ISO 13485. Based on our design of the AI Nose module and our co-developed manufacturing process, TCNT subcontracts to other semiconductor manufacturers including a specialized contract manufacturer that produces our sensors and an outsourced semiconductor assembly and testing company, or &#8220;OSAT&#8221; company, that assembles our sensors into a highly miniaturized module and tests the functionality.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We expect that the following five (5) Patent Assets assigned to the Company as a result of the Ainos transaction will form the basis for the next generation of the Company&#8217;s rapid test kit products:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">A GAS SENSOR AND MANUFACTURE METHOD THEREOF as described and claimed in TAIWAN invention patent number I565944.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">MEDICAL VENTILATOR CAPABLE OF ANALYZING INFECTION AND BACTERIA OF PNEUMONIA VIA GAS IDENTIFICATION as described and claimed in TAIWAN invention patent number I565945.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">25</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">GAS DETECTOR as described and claimed in TAIWAN invention patent number D183554.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">MEDICAL VENTILATOR CAPABLE OF ANALYZING INFECTION AND BACTERIA OF PNEUMONIA VIA GAS IDENTIFICATION as described and claimed in Japan Patent No.: JP 6392811 B2. The Company is granted exclusive license rights in Japan from January 1, 2021 to December 31, 2028.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">GAS DETECTOR as described and claimed in CHINA invention patent number CN 304042244 S. The Company is granted exclusive license rights in China from January 1, 2021 to December 31, 2028.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s development and commercialization of its rapid test kit products are subject to approval by the FDA and other regulatory agencies in the U.S., and other regulatory agencies for use and marketing in other countries.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Patents and Proprietary Rights</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Since inception, the Company has worked to build an extensive patent portfolio for the medical diagnosis and treatment of persistent diseases. This portfolio consists of patents with claims that encompass method of use or treatment, and/or composition of matter and manufacturing. As listed in this Overview section, the Company presently owns eleven (11) issued patents with two patents pending and license rights in Japan and China for two (2) patents under patent licensing agreements. There are no current patent litigation proceedings involving the Company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Cost of Compliance with Environmental Regulations</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company incurred no costs to comply with environment regulations during the timeframe of this report.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>United States Regulation</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Before products with health claims can be marketed in the United States, they must receive approval from the U.S. Food and Drug Administration (&#8220;FDA&#8221;). To receive this approval, any drug must undergo rigorous preclinical testing and clinical trials that demonstrate the product candidate&#8217;s safety and effectiveness for each indicated use. This extensive regulatory process controls, among other things, the development, testing, manufacture, safety, efficacy, record keeping, labeling, storage, approval, advertising, promotion, sale, and distribution of pharmaceutical products.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In general, before any ethical pharmaceutical product can be marketed in the United States, the FDA will require the following process:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-size:14pt">&#8226;</span></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Preclinical laboratory and animal tests;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-size:14pt">&#8226;</span></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Submission of an investigational new drug application, or IND, which must become effective before human clinical trials may begin;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><span style="font-size:14pt">&#8226;</span></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed drug for its intended use;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><span style="font-size:14pt">&#8226;</span></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pre-approval inspection of manufacturing facilities and selected clinical investigators;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-size:14pt">&#8226;</span></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Submission of a New Drug Application (NDA) to the FDA; and</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="font-size:14pt">&#8226;</span></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">FDA approval of an NDA, or of an NDA supplement (for subsequent indications or other modifications, including a change in location of the manufacturing facility).</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Substantial financial resources are necessary to fund the research, clinical trials, and related activities necessary to satisfy FDA requirements or similar requirements of state, local, and foreign regulatory agencies. At such time as the Company undertakes to commercialize any of its products, all necessary preclinical testing, clinical trials, data review, and approval steps will be judiciously executed to insure that the product satisfies all regulatory requirements at all levels. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">26</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><span style="text-decoration:underline">505(b)(2)</span></em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has historically followed and will continue to follow the traditional approval process for New Drugs as set out in Section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act. If an alternative path to FDA approval for new or improved formulations of previously approved products is scientifically and economically feasible and beneficial to the Company and the public, the Company may choose to follow this alternative path as established by section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act. This section of the Act permits the applicant to rely on certain preclinical or clinical studies conducted for an approved product as some of the information required for approval and for which the applicant has not obtained a right of reference. The process of approval under 505(b)(2) will be followed as judiciously as 505(b)(1) or any regulation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Orphan Drug Designation</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States. The Company may choose to seek approval for a product satisfying the definition of an Orphan Drug if that product can be used to treat such an indication. Orphan drug designation does not convey any advantage in or shorten the duration or rigidity of the regulatory review and approval process. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Similarly, substantial financial resources are necessary to fund the research, design, testing, fabrication and related activities necessary to satisfy FDA requirements or similar requirements of state, local, and foreign regulatory agencies for medical devices. The Company may seek to obtain FDA clearance for the sales, marketing, and use of its novel pulsatile insulin pump for the U.S. market after obtaining FDA approvals under one of the following regulatory approvals:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Premarket Notification 510(k) </em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Each person who intends to market in the U.S., a Class I, II, and III device intended for human use, for which a Premarket Approval application (&#8220;PMA&#8221;) is not required, must submit a 510(k) to FDA unless the device is exempt from 510(k) requirements of the Federal Food, Drug, and Cosmetic Act (the &#8220;FD&amp;C Act&#8221;) and does not exceed the limitations of exemptions in .9 of the device classification regulation chapters (e.g., 21 CFR 862.9, 21 CFR 864.9).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If the Company&#8217;s novel pulsatile insulin pump is determined to be similar to one already cleared for the U.S. market, the Company will seek FDA clearance under 510(k) at least 90 days before the device is marketed. A 510(k) application requires demonstration of substantial equivalence to another legally U.S. marketed device. Substantial equivalence means that the new device is as safe and effective as the predicate. Documented laboratory testing among other submissions will be required and if the Company&#8217;s device features significant alterations from predecessor devices the Company may be required to present results from clinical trials. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Premarket Approval (PMA) </em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Alternatively, if the Company&#8217;s device is deemed to be completely new to the U.S. market or classified as a Class III device, the Company will be required to apply for PMA approval. The Medical Device Amendments of 1976 to the FD&amp;C Act established three regulatory classes for medical devices. The three classes are based on the degree of control necessary to assure that the various types of devices are safe and effective. The most regulated devices are in Class III. The amendments define a Class III device as one that supports or sustains human life or is of substantial importance in preventing impairment of human health or presents a potential, unreasonable risk of illness or injury. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">27</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Under Section 515 of the FD&amp;C Act, all devices placed into Class III are subject to premarket approval requirements. Premarket approval by FDA is the required process of scientific review to ensure the safety and effectiveness of Class III devices.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Foreign Regulation</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In addition to regulations in the United States, a variety of foreign regulations govern clinical trials and commercial sales and distribution of products in foreign countries. Whether or not the Company obtains FDA approval for a product, the Company must obtain approval of a product by the comparable regulatory authorities of foreign countries before the Company can commence clinical trials or market the product in those countries. The approval process varies from country to country, and the time may be longer or shorter than that required for FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The policies of the FDA and foreign regulatory authorities may change and additional government regulations may be enacted which could prevent or delay regulatory approval of investigational drugs or approval of new diseases for existing products and could also increase the cost of regulatory compliance. It is not possible to predict the likelihood, nature or extent of adverse governmental regulation that might arise from future legislative or administrative action, either in the United States or abroad.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Employees and Consultants</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of September 30, 2021, the Company had a total of twenty-seven employees, compared to four in the same period 2020. Research and development employees currently represent approximately 33% of our total employees. In the future, we plan to increase research and development human resources to support our various technology development efforts.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Following the consummation of the Ainos Transaction, the Company retained key personnel in its U.S. office to ensure continuity in its operations and as a foundation for future growth:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Lawrence Lin, who previously worked as Executive Advisor to the Company through his firm, i2China Management Group, LLC, is now an employee serving as Executive Vice-President of Operations.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">John Junyong Lee, Esq. continues to serve as Chief Legal Counsel and Corporate Secretary.</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Chrystal Shelton continues to serves as Administration Manager.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is actively interviewing additional research and development, management, manufacturing, and sales and marketing personnel to broaden its product and service lines and market reach. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Results of Operation for Quarter Ended September 30, 2021 and 2020</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Revenues, Costs and Gross Margins</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three months ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Revenues</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">363,052</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">192</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cost of revenues</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(103,638</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(123</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Gross margin</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">259,414</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">69</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">28</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Revenues for the quarter ended September 30, 2021 was $363,052, compared to $192 in the same period of 2020. Cost of revenues was $103,638, compared to $123 in the same period of 2020. Gross margin was $259,414, compared to $69 in the same period of 2020. The Company began sales of its Ainos Covid-19 Test Kits in June this year, of which 64% were sold through distribution channels and the remaining 36% mainly sold to enterprises, schools and medical institutions. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Research and Development Expenses</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three months ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Research and development expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">646,798</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the quarter ended September 30, 2021, the Company&#8217;s research and development expenses increased to $646,798 primarily due to spending on testing and development of the Ainos Covid-19 Test Kit and a mold to be used for manufacturing of our AI Nose pen product.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Since August 2021, in support of our medtech transformation we have begun expanding our research and development staffing and committed additional resources into technology and product developments across our Pharmaceutical, Medical Device and Preventive Medicine divisions. As a result, we incurred increased R&amp;D expenses that reflect increased salary for R&amp;D personnel, amortization of acquired intellectual properties, as well as expenses for technology development and technology license fees. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For the Pharmaceutical Division, we have established a focused approach to our core pharmaceutical drug development platform, VELDONA (Very Low-Dose Oral Interferon Alpha). We plan to analyze and explore new applications for VELDONA to optimize business opportunities. To execute this new approach, we plan to conduct further clinical trials of VELDONA for thrombocytopenia and Sj&#246;gren&#8217;s syndrome, for which we are deploying key resources that include staffing, capital and securing strategic business relationships with various partners, including biotech companies and medical research centers. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For the Medical Device Division, we have implemented a product roadmap for our diagnostics business. We are focused on establishing partnerships for technology development, clinical trials and business development in order to facilitate our product launch schedule. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For the Preventive Medicine Division, we have set up a research initiative for SRNA technologies to truly effect medical approaches that prevent the advancement of diseases. Our focus is on fundamental research and development of vaccines with the intent to seek out-licensing opportunities and strategic partnerships when appropriate. We have invested in additional staffing, and initiated product development partnerships with medical centers and universities for our mRNA vaccine research initiative.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Selling, General and Administration Expenses</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three months ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Selling, general and administrative expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">795,958</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">321,153</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our selling, general and administration expense was $795,958, compared to $321,153 in the same period of 2020. The increase was associated with increased marketing expenses of our Ainos Covid-19 Test Kit, expenses related to the Ainos KY Transaction, an increase of employee salaries and professional service fees for corporate governance and legal compliance matters.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">29</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Operating Loss</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three months ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,183,343</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(321,084</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our operating loss was $1,183,343 during the third quarter of 2021, compared to an operating loss of $321,084 in the same period of 2020 as a result of expenses associated with the Ainos KY Transaction and newly-initiated operational activities. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Net Loss</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Three months ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,161,110</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(323,285</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Net loss was $1,161,110 for the three months ended September 30, 2021, compared to $323,285 in the same period of 2020. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Results of Operation for the Nine months Ended September 30, 2021 and 2020</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Revenues, Costs and Gross Margins</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine months ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Revenues</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">568,164</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,876</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cost of revenues</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(174,395</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(11,221</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Gross margin</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">393,769</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,655</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Revenues for the first nine months of 2021 were $568,164, compared to $15,876 in the same period of 2020. Cost of revenue was $174,395 compared to $11,221 in the same period of 2020. Gross margin was $393,769 compared to $4,655 in the same period 2020. The Company began sales of its Ainos Covid-19 Test Kits in June 2021, of which 62% are sold through distribution channels and the remaining 38% mainly sold to enterprises, schools and medical institutions. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Research and Development Expenses</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine months ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Research and development expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">646,798</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">389</td><td style="width:1%;white-space: nowrap;"></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Research and development cost for the nine months of 2021 was $646,798, compared to $389 in the same period of 2020. The increase was due to the purchase of patents under the Ainos KY Transaction and associated new product development and research expenses.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Selling, General and Administrative Expenses </span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine months ended September 30</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Selling, general and administrative expenses</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,178,969</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,001,893</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">30</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Selling, general and administrative expenses were $2,178,969 for the nine months ended September 30, 2021, compared to $1,001,893 in the same period of 2020. The increase was associated with increased marketing expenses for the Ainos Covid-19 Test Kit, expenses related to the Ainos KY Transaction, an increase of employee salaries, and professional service fees for corporate governance and legal compliance matters.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Operating Loss</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine months ended September 30 </strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Operating loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,431,998</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(997,627</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Company operating loss was $2,431,998 for the nine months ended September 30, 2021, compared with $997,927 in the same period of 2020. This was the result of an increase of sales, research and development, and newly-initiated operational expenses.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Net Loss</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine months ended September 30,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Net loss</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,443,891</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,002,130</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Net loss was $2,443,891 for the nine months ended September 30, 2021, compared to $1,002,130 in the same period of 2020. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Liquidity and Capital Resources</strong><strong> </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of September 30, 2021, the Company had available cash of $706,931 whereas it had a cash position of $83,767 for the same period in 2020 and $22,245 as of December 31, 2020. The Company had a working capital deficit of $1,937,163 at the end of September 30, 2021, and a working capital deficit of $919,880 for the same period in 2020, an increase of 111%. As of December 31, 2020, working capital was a deficit of $1,022,155. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company anticipates business revenues and potential financial support to fund the Company&#8217;s operations over the next twelve months. There can be no assurance that we will be successful in our efforts to make the Company profitable. If those efforts are not successful, the Company may raise additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available when needed and at adequate levels, the Company will need to reevaluate its operating plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">31</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="item3">ITEM 3. Quantitative and Qualitative Disclosures About Market Risk.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As a &#8220;smaller reporting company,&#8221; we are not required to provide the information under this Item 3.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="item4">ITEM 4. Controls and Procedures</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Disclosure Controls and Procedures</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">At the end of the period covered by this report, our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2021. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September 30, 2021, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Management's Report on Internal Control Over Financial Reporting</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in <em>Internal Control - Integrated Framework (2013)</em> issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under the framework in <em>Internal Control - Integrated Framework (2013),</em> our management concluded that our internal control over financial reporting was effective at the reasonable assurance level as of September 30, 2021. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Changes in Internal Control Over Financial Reporting</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have not experienced any material impact to our internal controls over financial reporting even though our workforce continues to primarily work-from-home due to COVID-19. We are continually monitoring and assessing the COVID-19 situation and its impact on our internal controls.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This quarter report does not include an attestation report of the Company&#8217;s independent registered public accounting firm regarding internal control over financial reporting. Management&#8217;s report was not subject to attestation by our independent registered public accounting firm pursuant to temporary rules of the SEC that permit the company to provide only management's report in this quarter report.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">32</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="P2">PART II - OTHER INFORMATION</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="item1">ITEM 1. Legal Proceedings.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. As of the date of this report, we were not aware of any such legal proceedings or claims against us.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="i1A">ITEM 1A. Risk Factors.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Please carefully consider the following discussion of significant factors, events, and uncertainties that make an investment in our securities risky. The events and consequences discussed in these risk factors could, in circumstances we may or may not be able to accurately predict, recognize, or control, have a material adverse effect on our business, growth, reputation, prospects, financial condition, operating results (including components of our financial results), cash flows, liquidity, and stock price. These risk factors do not identify all risks that we face; our operations could also be affected by factors, events, or uncertainties that are not presently known to us or that we currently do not consider to present significant risks to our operations. In addition, the global economic climate amplifies many of these risks.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>We Face Intense Competition</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The pharmaceutical industry is an expanding and rapidly changing industry characterized by intense competition. The Company believes that our ability to compete will be dependent in large part upon our ability to successfully operate business lines, continue recapitalization, and steadily enhance and improve our core technology products. In order to do so, we must effectively utilize and expand our research and development capabilities and, once developed, quickly convert new technology into products and processes, which can then be commercialized. Competition is based primarily on scientific and technological superiority, technical support, availability of patent protection, access to adequate capital, the ability to develop, acquire and market products and processes successfully, the ability to obtain governmental approvals and the ability to serve the particular needs of commercial customers. Corporations and institutions with greater resources therefore, have a significant competitive advantage.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our potential competitors include entities that develop and produce therapeutic agents and/or medical devices for treatment of human and animal disease. These include numerous public and private academic and research organizations and pharmaceutical and biotechnology companies pursuing production of, among other things, biologics from cell cultures, genetically engineered drugs and natural and chemically synthesized drugs. Many of these potential competitors have substantially greater capital resources, research and development capabilities, manufacturing and marketing resources. Competitors may succeed in developing products or processes that are more effective or less costly or that gain regulatory approval prior to our products. The Company expects that the number of competitors and potential competitors will increase as more anti-viral and cytotoxic products receive commercial marketing approvals from the FDA or analogous foreign regulatory agencies. Any of these competitors may be more successful in manufacturing, marketing and distributing its products. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Our Expansion Places a Significant Strain on our Management, Operational, Financial, and Other Resources</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Increasing our product and service offerings will require scaling our management, financial and research and development resources. The complexity of the current focus of our business on innovative biotechnologies and treatments, digital health, and diagnostic point-of-care testing can place significant strain on our management, personnel, operations, systems, technical performance, financial resources, and internal financial control and reporting functions, and our expansion increases these factors. Failure to manage growth effectively could damage our reputation, limit our growth, and negatively affect our operating results.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">33</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Our Expansion into New Products, Services, Technologies, and Geographic Regions Subjects Us to Additional Risks</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We may have limited or no experience in our newer market segments, and our customers may not adopt our product or service offerings. These offerings, which can present new and difficult technology challenges, may subject us to claims if customers of these offerings experience service disruptions or failures or other quality issues. In addition, profitability, if any, in our newer activities may not meet our expectations, and we may not be successful enough in these newer activities to recoup our investments in them. Failure to realize the benefits of amounts we invest in new technologies, products, or services could result in the value of those investments being written down or written off.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Our International Operations Expose Us to a Number of Risks</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have relatively little operating experience and may not benefit from any first-to-market advantages or otherwise succeed. It is costly to establish, develop, and maintain international operations, sales and marketing channels, and research and development and licensing capacity. Our international operations may not become profitable on a sustained basis.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In addition to risks described elsewhere in this section, our international sales and operations are subject to a number of risks, including:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">local economic and political conditions;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">government regulation (such as regulation of our product and service offerings and of competition); restrictive governmental actions (such as trade protection measures, including export duties and quotas and custom duties and tariffs); nationalization; and restrictions on foreign ownership restrictions on sales or distribution of certain products or services and uncertainty regarding liability for products, services, and content, including uncertainty as a result of less Internet-friendly legal systems, local laws, lack of legal precedent, and varying rules, regulations, and practices regarding the physical and digital distribution of media products and enforcement of intellectual property rights;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">business licensing or certification requirements, such as for imports, exports, medical devices and medical treatments;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">limitations on the repatriation and investment of funds and foreign currency exchange restrictions;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">difficulty in staffing, developing, and managing foreign operations as a result of distance, language, and cultural differences;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">compliance with the U.S. Foreign Corrupt Practices Act and other applicable U.S. and foreign laws prohibiting corrupt payments to government officials and other third parties;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">laws and policies of the U.S. and other jurisdictions affecting trade, foreign investment, loans, and taxes; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">geopolitical events, including war and terrorism.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Our Commercial Agreements, Strategic Alliances, and Other Business Relationships Expose Us to Risks</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our business growth depends on commercial agreements, strategic alliances, and business relationships. Under these agreements, we provide access to our research library and clinical data as part of licensing and sales and marketing agreements. These arrangements are complex and require substantial infrastructure capacity, personnel, and other resource commitments, which may limit the amount of business we can service. We may not be able to implement, maintain, and develop the components of these commercial relationships, which may include research and development, clinical trials, diagnostic software and hardware design, and engaging third parties to perform services. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our licensing agreements may be dependent on the volume of another company&#8217;s sales. Therefore, when the other company&#8217;s offerings are not successful, the compensation we receive may be lower than expected or the agreement may be terminated. Moreover, we may not be able to enter into additional or alternative commercial relationships and strategic alliances on favorable terms. We also may be subject to claims from businesses to which we provide these services if we are unsuccessful in implementing, maintaining, or developing these services.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">34</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>We Face Supply Risk</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are vulnerable to supply risks. The Company&#8217;s long-time human interferon producer is no longer manufacturing interferon. Plans for further clinical trials and commercialization of a low-dose interferon product are dependent upon identifying a new source of interferon. The Company has secured a supply partner for current needs but will continue to actively seek new alternative suppliers and explore additional sourcing options. Procuring a new source of interferon may require additional studies to compare results to the Company&#8217;s research and further clinical trials may have to be performed. The Company&#8217;s inability to secure interferon supplies may adversely affect our operating results.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is the master sales and marketing agent for the Ainos Covid-19 Test Kit developed by Taiwan Carbon Nano Corporation (&#8220;TCNT&#8221;), a related party. The Company sources the Ainos Covid-19 Test Kit exclusively from TCNT. TCNT currently manufactures the Covid-19 Test Kit in Taiwan. Any unexpected supply disruption by TCNT may adversely affect our business results.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We plan to develop, sell, and/or market other rapid test kit products with a focus on point-of-care diagnostic medical devices. We may continue to rely on TCNT to manufacture these devices. Any unplanned supply risk at TCNT may negatively affect our future business plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Government Regulation Is Evolving and Unfavorable Changes Could Harm Our Business</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are subject to general business regulations and laws, as well as regulations and laws specifically governing biologics, pharmaceuticals, and medical devices and treatments. A large number of jurisdictions regulate our operations, and the extent, nature, and scope of such regulations is evolving and expanding as the scope of our businesses expands. We are regularly subject to formal and informal reviews and investigations by governments and regulatory authorities under existing laws, regulations, or interpretations or pursuing new and novel approaches to regulate our operations. Unfavorable regulations, laws, decisions, or interpretations by government or regulatory authorities applying those laws and regulations, or inquiries, investigations, or enforcement actions threatened or initiated by them, could cause us to incur substantial costs, expose us to unanticipated civil and criminal liability or penalties (including substantial monetary fines), diminish the demand for, or availability of, our products and services, increase our cost of doing business, require us to change our business practices in a manner materially adverse to our business, damage our reputation, impede our growth, or otherwise have a material effect on our operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Claims, Litigation, Government Investigations, and Other Proceedings May Adversely Affect Our Business and Results of Operations</em></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As a company focusing on diagnostics and treatments for a wide range of human health care needs, we may be subject to actual and threatened claims, litigation, reviews, investigations, and other proceedings, including proceedings by governments and regulatory authorities, involving a wide range of issues, including patent and other intellectual property matters, taxes, labor and employment, competition and antitrust, privacy and data protection, product liability, consumer protection, commercial disputes, goods and services offered by us and by third parties, and other matters. Any of these types of proceedings can have an adverse effect on us because of legal costs, disruption of our operations, diversion of management resources, negative publicity, and other factors. The outcomes of these matters are inherently unpredictable and subject to significant uncertainties. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Our results of operations may be negatively impacted by the COVID-19 outbreak</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">To date the outbreak has not had a material adverse impact on our operations. The future impact of the outbreak is highly uncertain and cannot be predicted, and there is no assurance that the outbreak will not have a material adverse impact on the future results of the Company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">35</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="i2">ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">None</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="i3">ITEM 3. Defaults Upon Senior Securities.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">None</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="i4">ITEM 4. Mine Safety Disclosures.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Not applicable </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="i5">ITEM 5. Other Information.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Employment Offer Letters to CEO and CFO</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On August 11, 2021, the Company and the CEO of the Company executed an Offer Letter, subject to mutual agreement of employment terms and conditions and approval of the Board, under which Mr. Tsai was offered a monthly salary of 250,000 New Taiwan Dollars (equivalent to approximately $8,929), a year-end bonus of 2 months&#8217; salary, and a variable compensation based on Company profit targets decided by the Company&#8217;s Compensation Committee, and payable as 10-30% of total annual compensation in the form of cash, securities and/or other discretionary remuneration. An initial equity grant to Mr. Tsai will be determined by the Compensation Committee at a later date. Other benefits, including labor insurance, health insurance and other benefits, will be based on local regulations and the Company&#8217;s policies.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On August 11, 2021, the Company and the CFO of the Company executed an Offer Letter, subject to mutual agreement of employment terms and approval of the Board, under which Ms. Wu was offered a monthly salary of 230,000 New Taiwan Dollars (equivalent to approximately $8,214), a year-end bonus of 2 months&#8217; salary, and a variable compensation based on Company profit targets decided by the Company&#8217;s Compensation Committee, and payable as 10-30% of total annual compensation in the form of cash, securities and/or other discretionary remuneration. An initial equity grant to Ms. Wu will be determined by the Compensation Committee at a later date. Other benefits, including labor insurance, health insurance and other benefits, will be based on local regulations and the Company&#8217;s policies. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">36</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As part of our Board&#8217;s commitment to corporate governance, our Company&#8217;s Board adopted the following policies governing the Board, the Company, and its Committees: </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Board Policies</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Rules and Procedures of Board of Directors Meetings, adopted August 20, 2021, incorporated herein by this reference, and attached hereto as Exhibit 99.1; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Corporate Governance Policies of the Board of Directors, adopted August 20, 2021, incorporated herein by this reference, and attached hereto as Exhibit 99.2; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Charter of the Audit Committee of the Board of Directors, adopted August 20, 2021, incorporated herein by this reference, and attached hereto as Exhibit 99.3; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Charter of the Compensation Committee of the Board of Directors, adopted August 20, 2021, incorporated herein by this reference, and attached hereto as Exhibit 99.4; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Insider Trading Policy of the Board of Directors, as amended and adopted August 20, 2021, incorporated herein by this reference, and attached hereto as Exhibit 99.5; and </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Code of Business Conduct and Ethics, adopted August 20, 2021, as reported in our Form 8-K, incorporated herein by this reference, filed on August 26, 2021 and attached hereto as Exhibit 99.6</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">Amendments to Bylaws</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Board of Directors of the Company approved the following amendment to Article II, Section 10 of the Company&#8217;s Bylaws effective August 20, 2021, as reported in our Form 8-K, incorporated herein by this reference, filed on August 26, 2021:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">&#8220;Section 10. Compensation.</span> <em><span style="text-decoration:underline">The Board of Directors</span> <span style="text-decoration:underline">may provide for the compensation to members of the Board of Directors upon the recommendation of its Compensation Committee and in accordance with its Compensation Policies; </span></em>provided, that nothing contained herein shall be construed to preclude any director from serving the Corporation in any other capacity or receiving compensation therefor.&#8221; (emphasis added)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Prior to the amendment, Article II, Section 10 of the Company&#8217;s Bylaws provided as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><span style="text-decoration:underline">&#8220;Section 10. Compensation.</span> Directors as such shall not receive any stated salary for their services, but by resolution of the Board a fixed sum and expense of attendance, if any, may be allowed for attendance at such regular or special meetings of the Board; provided, that nothing contained herein shall be construed to preclude any director from serving the Corporation in any other capacity or receiving compensation therefor.&#8221;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Additionally, the Board of Directors of the Company approved an administrative amendment to the Company&#8217;s Bylaws replacing the Company&#8217;s former corporate name, &#8220;AMARILLO CELL CULTURE COMPANY, INCORPORATED&#8221; to the Company&#8217;s current corporate name &#8220;Ainos, Inc.&#8221;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr"></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">37</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><span class="atag" style="display: inline" id="i6">ITEM 6. Exhibits.</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>EXHIBIT INDEX</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;" colspan="7"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>INCORPORATED BY REFERENCE</strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>EXHIBIT NUMBER</strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:54%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>DESCRIPTION</strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:5%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>FILED WITH THIS FORM 10-K</strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:5%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>FILING DATE WITH SEC</strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:5%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>FORM</strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:5%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>EXH #</strong></p></td><td style="width:1%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;width:12%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>HYPERLINK TO FILINGS</strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/0001014763/000165495421004461/amar_ex31.htm">3.1(a)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/0001014763/000165495421004461/amar_ex31.htm">Restated Certificate of Formation of the Company, dated April 15, 2021 and filed April 21, 2021 </a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4/21/2021</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">3.</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Restated Certificate of Formation of the Company, dated and filed July 27, 2015.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="aimd_ex32.htm">3.2</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="aimd_ex32.htm">Bylaws of the Company, as amended August 20, 2021</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">X</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">4.1</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Specimen Common Stock Certificate</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8/8/1996</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">SB-2</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">4.1</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Specimen Common Stock Certificate.</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="aimd_ex311a.htm">31.1(a)</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="aimd_ex311a.htm">Certification of Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">X</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="aimd_ex321.htm">32.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="aimd_ex321.htm">Certification of CEO and CFO pursuant to 18 U.S.C. Section 1350</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">X</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="aimd_ex991.htm">99.1</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="aimd_ex991.htm">Rules and Procedures of Board of Directors Meetings, adopted August 20, 2021</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">X</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="aimd_ex992.htm">99.2</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="aimd_ex992.htm">Corporate Governance Policies of the Board of Directors, adopted August 20, 2021</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">X</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="aimd_ex993.htm">99.3</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="aimd_ex993.htm">Charter of the Audit Committee of the Board of Directors, adopted August 20, 2021</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">X</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="aimd_ex994.htm">99.4</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="aimd_ex994.htm">Charter of the Compensation Committee of the Board of Directors, adopted August 20, 2021</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">X</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="aimd_ex995.htm">99.5</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><a href="aimd_ex995.htm">Insider Trading Policy of the Board of Directors, as amended and adopted August 20, 2021</a></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">X</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">99.6</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Code of Business Conduct and Ethics, adopted August 20, 2021</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8/26/21</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">8-K</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">5.05</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">https://www.sec.gov/ix?doc=/Archives/edgar/data/1014763/000165495421009457/amar_8k.htm</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">101.INS</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the XBRL document.</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">X</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">101.SCH</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">XBRL Taxonomy Extension Schema Document</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">X</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">101.CAL</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">XBRL Taxonomy Extension Calculation Linkbase</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">X</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">101.DEF</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">XBRL Taxonomy Extension Definition Linkbase</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">X</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">101.LAB</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">XBRL Taxonomy Extension Label Linkbase</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">X</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">101.PRE</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">XBRL Taxonomy Extension Presentation Linkbase</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">X</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">104.1</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Cover Page Interactive Data File</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">X</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The exhibits listed in the Exhibit Index are filed or incorporated by reference as part of this filing.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">+ Schedules (as similar attachments) have been omitted from this filing pursuant to Item 601(a)(5) of Regulation S-K. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">* Indicates a management contract or compensatory plan or arrangement.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">38</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td><em><a href="#Toc">Table of Contents</a></em></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span class="atag" style="display: inline" id="sig">SIGNATURES</span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Pursuant to the requirements of Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="width:50%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:3%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:35%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:12%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Date: November 15, 2021</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">By:</p></td><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><em>/s/ Chun-Hsien Tsai</em></p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Chun-Hsien Tsai, Chairman of the Board, and</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Chief Executive Officer</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Date: November 15, 2021</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">By: </p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"><em>/s/ Hui-Lan Wu</em></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Hui-Lan Wu, Chief Financial Officer </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 2in; text-align:right;">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">39</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1A
<SEQUENCE>2
<FILENAME>aimd_ex311a.htm
<DESCRIPTION>CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF THE SARBANES-OXLY ACT OF 2002
<TEXT>
<html><head><title>aimd_ex311a.htm</title><!--Document created using EDGARMaster--></head><body style="COLOR: #000000; TEXT-ALIGN: justify; FONT: 10pt Times New Roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 31.1(a)</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong></strong>&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>FORM OF CERTIFICATION</strong><strong></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PURSUANT TO RULE 13a-14(a) AND 15d-14(a)</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CERTIFICATION</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 0.5in; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I, Chun-Hsien Tsai and Hui-Lan Wu, certify that:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;line-height:normal;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">1.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">I have reviewed this report on Form 10-Q of Ainos, Inc.;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px">2.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Based on my knowledge, this report does not contain any untrue statement of material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the periods covered by this report;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px">3.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px">4.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;line-height:normal;margin-left:auto;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">(a)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">(b)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">(c)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">(d)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">5.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">(a)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize, and report financial information; and</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">(b)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;vertical-align:bottom;"> <p style="margin:0px">Date: November 15, 2021</p></td> <td style="width:3%;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:35%;vertical-align:bottom;"> <p style="margin:0px"><em>/s/ </em><em>Chun-Hsien Tsai</em><em></em></p></td> <td style="width:12%;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="margin:0px">Chun-Hsien Tsai, Chairman of the Board, and</p> <p style="margin:0px">Chief Executive Officer</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;vertical-align:bottom;"> <p style="margin:0px">Date: November 15, 2021</p></td> <td style="width:3%;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:35%;vertical-align:bottom;"> <p style="margin:0px"><em>/s/ </em><em>Hui-Lan Wu</em><em></em></p></td> <td style="width:12%;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:bottom;"> <p style="margin:0px">Hui-Lan Wu, Chief Financial Officer</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>3
<FILENAME>aimd_ex32.htm
<DESCRIPTION>CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
<TEXT>
<html><head><title>aimd_ex32.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 3.2</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>AINOS, INC.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>BYLAWS</strong> <strong>&#8211; EFFECTIVE AUGUST 20 2021 </strong></p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>ARTICLE I: </strong><strong>SHAREHOLDERS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section</u></strong><strong><u> 1</u></strong><strong><u>.</u></strong><strong><u> </u></strong><strong><u>Annual</u></strong><strong><u> Meeting.</u></strong> The annual meeting of shareholders shall be held on the 2nd Tuesday in May of each year at 10:00 A.M<strong>. </strong>if not a legal holiday, and if a legal holiday, then on the next succeeding business day, or at such other time or on such other date as may be fixed by resolution of the Board of Directors, for the purpose of electing directors. Any business may be transacted at an annual meeting, except as otherwise provided by law or by these Bylaws.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section</u></strong><strong><u> </u></strong><strong><u>2.</u></strong><strong><u> </u></strong><strong><u>Special</u></strong><strong><u> Meeting.</u></strong> A special meeting of shareholders may be called at any time by the holders of at least ten percent (10%) of the outstanding stock entitled to be voted at such meeting, by the Board of Directors, by the Chairman of the Board, if any, or by the President. Only such business shall be transacted at a special meeting as may be stated or indicated in the notice of such meeting.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section</u></strong><strong><u> </u></strong><strong><u>3.</u></strong><strong><u> Place</u></strong><strong><u>.</u></strong> The annual meeting of shareholders may be held at any place within or without the State of Texas designated by the Board of Directors. Special meetings of shareholders may be held at any place within or without the State of Texas designated by the Board of Directors or, in the absence of such designation, by the chief executive officer. Any meeting may be held at any place within or without the State of Texas designated in a waiver of notice of such meeting signed by shareholders. Meetings of shareholders shall be held at the principal office of the Corporation unless another place is designated for meetings in the manner provided herein.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section</u></strong><strong><u> 4. </u></strong><strong><u>Notice.</u></strong> Written or printed notice stating the place, day and hour of each meeting of shareholders and, in case of a special meeting, the purpose or purposes for which the meeting is called, shall be delivered not less than ten (10) nor more than fifty (50) days before the date of the meeting, either personally or by mail or electronic transmission, to each shareholder entitled to vote at such meeting. Such notice, if given by electronic transmission, shall be effective only if the shareholder receiving such notice shall have previously consented to receive notices by electronic transmission, and shall be sent using a form of electronic transmission specified by the shareholder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section</u></strong><strong><u> </u></strong><strong><u>5</u></strong><strong><u>. Quorum.</u></strong> The holders of at least a majority of the outstanding stock entitled to vote thereat and present in person or by proxy, shall constitute a quorum. Except as otherwise required by law, the Articles of Incorporation or these Bylaws, the act of a majority of the stock at any meeting at which a quorum is present shall be the act of the shareholders&#8217; meeting. The shareholders present at any meeting, though less than a quorum, may adjourn the meeting, and any business may be transacted at the adjournment that could be transacted at the original meeting. No notice of adjournment, other than the announcement at the meeting, need be given.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. BYLAWS &#8211; EFFECTIVE AUGUST 20 2021 </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page 1 of 11</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section</u></strong><strong><u> 6. Proxies.</u></strong> At all meetings of shareholders, a shareholder may vote either in person or by proxy executed in writing by the shareholder or by his duly authorized attorney-in-fact. Such proxies shall be filed with the Secretary of the Corporation before or at the time of the meeting. No proxy shall be valid after eleven (11) months from the date of its execution unless otherwise provided in the proxy. Each proxy shall be revocable unless expressly provided therein to be irrevocable or unless otherwise made irrevocable by law.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section</u></strong><strong><u> 7. Voting of Shares.</u></strong> Each outstanding share of a class entitled to vote upon a matter submitted to a vote at a meeting of shareholders shall be entitled to one vote on such matter.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section</u></strong><strong><u> 8. List of Shareholders.</u></strong> A complete list of shareholders entitled to vote at each shareholders&#8217; meeting, arranged in alphabetical order, with the address of and number of shares held by each, shall be prepared by the Secretary and filed at the registered office of the Corporation and shall be subject to inspection by any shareholder during usual business hours for a period of ten (10) days prior to such meeting and shall be produced at such meeting and at all times during such meeting be subject to inspection by any shareholder.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section</u></strong><strong><u> 9. Action </u></strong><strong><u>Without</u></strong><strong><u> </u></strong><strong><u>Meeting.</u></strong><strong> </strong>Any action permitted or required by law, by these Bylaws or by the Articles of Incorporation of the Corporation to be taken at a meeting of shareholders of the Corporation may be taken without a meeting or by means of conference telephone as provided in Article VI, Section 6 of the Bylaws.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>ARTICLE II: BOARD OF DIRECTORS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section</u></strong><strong><u> 1. </u></strong><strong><u>Number</u></strong><strong><u> </u></strong><strong><u>and</u></strong><strong><u> Term of Office.</u></strong> The business and property of the Corporation shall be managed by the Board of Directors, and subject to the restrictions imposed by law, the Articles of Incorporation or by these Bylaws, they may exercise all the powers of the Corporation.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Board of Directors shall consist of not less than one nor more than thirty directors, as so determined from time to time by resolution of the Board of Directors. Within the above limits, the number of directors may be increased or decreased (provided such decrease does not shorten the term of any incumbent director) from time to time by resolution of the Board of Directors.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Each director shall hold office for the term for which he is elected and until his successor shall have been elected and qualified. Directors need not be shareholders nor residents of Texas. Any director may be removed from office, with or without cause, by a majority vote of the shareholders at any meeting at which a forum of shareholders is present; provided that, if the Articles of Incorporation do not expressly deny to shareholders the right of cumulative voting for the election of directors and if less than the entire Board is to be removed, no one of the directors may be removed if the votes cast against his removal would be sufficient to elect him if then cumulatively voted at an election of the entire Board of Directors.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. BYLAWS &#8211; EFFECTIVE AUGUST 20 2021 </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;2 of 11</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Any vacancy occurring in the Board of Directors may be filled by the affirmative vote of a majority of the remaining directors though less than a quorum of the Board of Directors. A director elected to fill a vacancy shall be elected for the unexpired term of his predecessor in office. In case of any increase in the number of directors, the additional directors shall be elected at an annual or special meeting of shareholders called for that purpose or by the Board of Directors for a term of office continuing only until the next election of one or more directors by the shareholders; provided, however, that during a period between two successive annual meetings of shareholders, the Board of Directors may not fill more than two vacancies created by an increase in the number of directors.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section 2. Meetings of Directors.</u></strong> The directors may hold their meetings and may have an office and keep the books of the Corporation, except as otherwise provided by statute, in such place or places in the State of Texas, or outside the State of Texas, as the Board of Directors may from time to time determine.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section</u></strong><strong><u> 3. First Meeting.</u></strong> Each newly elected Board of Directors may hold its first meeting for the purpose of organization and the transaction of business, if a quorum is present, immediately after and at the same place as the annual meeting of the shareholders, and no notice of such meeting shall be necessary.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section</u></strong><strong><u> 4. Election of Officers.</u></strong> At<strong> </strong>the first meeting of the Board of Directors in each year at which a quorum shall be present, held next after the annual meeting of shareholders, the Board of Directors shall proceed to the election of the officers of the Corporation.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section</u></strong><strong><u> 5. </u></strong><strong><u>Regular</u></strong><strong><u> </u></strong><strong><u>Meetings.</u></strong> Regular meetings of the Board of Directors shall be held at such times and places as shall be designated from time to time by resolution of the Board of Directors. Notice of such regular meetings shall not be required.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section 6.</u></strong><strong><u> Special Meetings.</u></strong> Special meetings of the Board of Directors shall be held whenever called by the Chairman of the Board, if any, the President, or by a majority of the directors for the time being in office. Each such special meeting shall be held at such time and place as shall be designated by the officer or directors calling such meeting.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section 7. Notice</u></strong><strong>.</strong> The Secretary shall give notice of each special meeting in person, or by mail or electronic transmission, to each director at least four (4) hours before the time of such meeting. Such notice, if given by electronic transmission, shall be effective only if the director receiving such notice shall have previously consented to receive notices by electronic transmission, and shall be sent using a form of electronic transmission specified by the director. The attendance of a director at any meeting shall constitute a waiver of notice of such meeting, except where a director attends a meeting for the express purpose of objecting to the transactions any business on the grounds that the meeting is not lawfully called or convened. Notice may also be waived in writing as provided in Article VI, Section 4 of these Bylaws. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the Board of Directors need be specified in the notice or written waiver of notice of such meeting.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. BYLAWS &#8211; EFFECTIVE AUGUST 20 2021 </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;3 of 11</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section 8</u></strong><strong><u>.</u></strong><strong><u> </u></strong><strong><u>Quorum</u></strong><strong><u>.</u></strong> A majority of the directors fixed in the manner provided in these Bylaws shall constitute a quorum for the transaction of business, but if at any meeting of the Board of Directors there be less than a quorum present, a majority of those present or any director solely present may adjourn the meeting from time to time without further notice. The act of a majority of the directors present at a meeting at which a quorum is in attendance shall be the act of the Board of Directors, unless the act of a greater number is required by the Articles of Incorporation or by these Bylaws.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section</u></strong><strong><u> 9. </u></strong><strong><u>Order</u></strong><strong><u> </u></strong><strong><u>of</u></strong><strong><u> Business.</u></strong> At meetings of the Board of Directors, business shall be transacted in such order as from time to time the Board may determine.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">At meetings of the Board of Directors, the Chairman of the Board, if any, shall preside. In the absence of the Chairman of the Board, the President shall preside, and in the absence of the President, a chairman shall be chosen by the Board from among the directors present.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Secretary of the Corporation shall act as secretary of the meetings of the Board of Directors, but in the absence of the Secretary, the presiding officer may appoint any person to act as secretary of the meeting.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Se</u></strong><strong><u>c</u></strong><strong><u>tion 10.</u></strong><strong><u> </u></strong><strong><u>Compensation.</u></strong> The Board of Directors may provide for the compensation to members of the Board of Directors upon the recommendation of its Compensation Committee and in accordance with its Compensation Policies; provided, that nothing contained herein shall be construed to preclude any director from serving the Corporation in any other capacity or receiving compensation therefor.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section</u></strong><strong><u> 11. Presumption </u></strong><strong><u>of</u></strong><strong><u> Assent.</u></strong> A director of the Corporation who is present at a meeting of the Board of Directors at which action on any corporate matter is taken shall be presumed to have assented to the action unless his dissent shall be entered in the minutes of the meeting or unless he shall file his written dissent to such action with the person acting as secretary of the meeting before the adjournment thereof or shall forward such dissent by registered mail to the Secretary of the Corporation immediately after adjournment of the meeting. Such right to dissent shall not apply to a director who voted in favor of such action.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section</u></strong><strong><u> 12. </u></strong><strong><u>Action</u></strong><strong><u> Without </u></strong><strong><u>Meeting.</u></strong> Any action permitted or required by law, by these Bylaws or by the Articles of Incorporation of the Corporation, to be taken at a meeting of the Board of Directors or any committee thereof may be taken without a meeting or by means of conference telephone as provided in Article VI, Section 6 of these Bylaws.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. BYLAWS &#8211; EFFECTIVE AUGUST 20 2021 </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;4 of 11</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Sect</u></strong><strong><u>ion 13. Committees </u></strong><strong><u>of </u></strong><strong><u>Directors</u></strong><u>.</u> The Board of Directors, by resolution adopted by a majority of the full Board of Directors, may designate from among its members an executive committee and one or more other committees, each of which, to the extent provided in such resolution, shall have and may exercise all of the authority of the Board of Directors, except that no such committee shall have the authority of the Board of Directors in reference to amending the Articles of Incorporation, approving a merger or consolidation, recommending to the shareholders the sale, lease or exchange of all or substantially all of the property and assets of the Corporation otherwise than in the usual and regular course of business, recommending to the shareholders a voluntary dissolution of the Corporation or a revocation thereof, amending, altering or repealing the Bylaws of the Corporation or adopting new Bylaws for the Corporation, filling vacancies in or removing members of the Board of Directors or any such committee, fixing the compensation of any member of such committee or altering or repealing any resolution of the Board of Directors which by its term provides that it shall not be so amendable or repealable, and, unless such resolution expressly so provides, no such committee shall have the power or authority to declare a dividend or to authorize the issuance of shares of the Corporation.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>ARTICLE III: OFFICERS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section 1. Number, Titles </u></strong><strong><u>and </u></strong><strong><u>Term</u></strong><strong><u> of </u></strong><strong><u>Office</u></strong><strong><u>.</u></strong> The officers of the Corporation shall be a President, one or more Vice-Presidents, a Secretary, a Treasurer and, if the Board of Directors so elects, a Chairman of the Board and such other officers as the Board of Directors may from time to time elect or appoint. Each officer shall hold office until his successor shall have been duly elected and qualified or until his death or until he shall resign or shall have been removed in the manner hereinafter provided. One person may hold more than one office, except that the President shall not hold the office of Secretary. No officer, except the Chairman of the Board, must be a director.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section</u></strong><strong><u> </u></strong><strong><u>2.</u></strong><strong><u> </u></strong><strong><u>Removal.</u></strong> Any officer or agent elected or appointed by the Board of Directors may be removed by the Board of Directors whenever in its judgment the best interests of the Corporation will be served thereby, but such removal shall be without prejudice to the contract rights, if any, of the person so removed. Election or appointment of an officer or agent shall not of itself create contract rights.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section</u></strong><strong><u> 3. </u></strong><strong><u>Vacancies.</u></strong> A vacancy in the office of any officer may be filled by a vote of a majority of the directors.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section 4. Powers and Duties of the Chief Executive </u></strong><strong><u>Officer.</u></strong> The President shall be the chief executive officer of the Corporation unless the Board of Directors designates the Chairman of the Board as chief executive officer. Subject to the control of the Board of Directors, the chief executive officer shall have general executive charge, management and control of the properties, business and operations of the Corporation with all such powers as may be reasonably incident to such responsibilities; he may agree upon and execute all leases, contracts, evidences of indebtedness and other obligations in the name of the Corporation and may sign all certificates for shares of capital stock of the Corporation; and shall have such other powers and duties as designated in accordance with these Bylaws and as from time to time may be assigned to him by the Board of Directors.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. BYLAWS &#8211; EFFECTIVE AUGUST 20 2021 </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;5 of 11</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section </u></strong><strong><u>5. </u></strong><strong><u>Powers </u></strong><strong><u>and </u></strong><strong><u>Duties </u></strong><strong><u>of </u></strong><strong><u>the </u></strong><strong><u>Chairman of </u></strong><strong><u>th</u></strong><strong><u>e </u></strong><strong><u>Board.</u></strong> If elected, the Chairman of the Board shall preside at all meetings of the shareholders and of the Board of Directors; and he shall have such other powers and duties as designated in these Bylaws and as from time to time may be assigned to him by the Board of Directors.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section</u></strong><strong><u> </u></strong><strong><u>6.</u></strong><strong><u> Powers and </u></strong><strong><u>Duti</u></strong><strong><u>es</u></strong><strong><u> </u></strong><strong><u>o</u></strong><strong><u>f</u></strong><strong><u> </u></strong><strong><u>the</u></strong><strong><u> President</u></strong><u>.</u> The President, if any, shall have the authority to agree upon and execute all leases, contracts, evidences of indebtedness, and other obligations in the name of the Corporation; unless the Board of Directors otherwise determines, he shall, in the absence of the Chairman of the Board of if there be no Chairman of the Board, preside at all meetings of the stockholders and (should he be a director) of the Board of Directors; and he shall have such other powers and duties as designated in accordance with these Bylaws and as from time to time may be assigned to him by the Board of Directors.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section</u></strong><strong><u> 7. </u></strong><strong><u>Vi</u></strong><strong><u>ce-Presidents.</u></strong> In the absence of the Chairman of the Board, if any, or President, or in the event of their inability or refusal to act, a Vice-President designated by the Board of Directors shall perform the duties of the Chairman of the Board, if any, or the President, as the case may be, and when so acting shall have all the powers of and be subject to all the restrictions upon the Chairman of the Board, if any, or the President. In the absence of a designation by the Board of Directors of a Vice-President to perform the duties of the Chairman of the Board, if any, or President, the Vice-President who is senior in terms of time as a Vice-President of the Corporation shall so act. The Vice-Presidents shall perform such other duties and have such other powers as the Board of Directors may from time to time prescribe.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section</u></strong><strong><u> 8. </u></strong><strong><u>Treasurer.</u></strong> The Treasurer shall have custody of all the funds and securities of the Corporation which come into his hands. When necessary or proper, he may endorse, on behalf of the Corporation, for collection checks, notes and other obligations and shall deposit the same to the credit of the Corporation in such bank or banks or depositories as shall be designated in the manner prescribed by the Board of Directors, and he may sign all receipts and vouchers for payments made to the Corporation, either alone or jointly with such other officer as is designated by the Board of Directors. Whenever required by the Board of Directors, he shall render a statement of his cash account, he shall enter or cause to be entered regularly in the books of the Corporation to be kept by him for that purpose full and accurate accounts of all moneys received and paid out on account of the Corporation; he shall perform all acts incident to the position of Treasurer subject to the control of the Board of Directors; and he shall, if required by the Board of Directors, give such bond for the faithful discharge of his duties in such form as the Board of Directors may require.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section</u></strong><strong><u> </u></strong><strong><u>9. </u></strong><strong><u>Assistant</u></strong><strong><u> </u></strong><strong><u>Treasurer.</u></strong> Each Assistant Treasurer shall have the usual powers and duties pertaining to his office, together with such other powers and duties as may be assigned to him by the Board of Directors. The Assistant Treasurers shall exercise the powers of the Treasurer during that officer&#8217;s absence or inability to act.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. BYLAWS &#8211; EFFECTIVE AUGUST 20 2021 </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;6 of 11</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section</u></strong><strong><u> 10. Secretary.</u></strong> The Secretary shall keep the minutes of all meetings of the Board of Directors and the minutes of all meetings of the shareholders, in books provided for that purpose; he shall attend to the giving and serving of all notices; he may in the name of the Corporation attest to all contracts of the Corporation and affix the seal of the Corporation thereto; he may sign with the President all certificates for shares of the capital stock of the Corporation; he shall have charge of the certificate books, transfer books and stock ledgers, and such other books and papers as the Board of Directors may direct, all of which shall at all reasonable times be open to inspection of any director upon application at the office of the Corporation during business hours, and he shall in general perform all duties incident to the office of Secretary, subject to the control of the Board of Directors.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section</u></strong><strong><u> 11. Assistant Secretaries.</u></strong> Each Assistant Secretary shall have the usual powers and duties pertaining to his office, together with such other powers and duties as may be assigned to him by the Board of Directors or the Secretary. The Assistant Secretaries shall exercise the powers of the Secretary during that officer&#8217;s absence or inability to act.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>ARTICLE IV: </strong><strong>INDEMNIFICATION AND </strong><strong>INSURANCE OF</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>DIRECTORS AND OFFICERS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Each director and each officer or former director or officer of this Corporation or each person who may have served at request as a director or officer of another corporation in which it owned shares of capital stock or of which it is a creditor, shall be indemnified by the Corporation against liabilities imposed upon him and expenses reasonably incurred by him in connection with any claim made against him, or any action, suit or proceeding to which he may be a party by reason of his being, or having been such director or officer, and against such sums as independent counsel selected by the Board of Directors shall deem reasonable payment made in settlement of any such claim, action, suit or proceeding primarily with a view of avoiding expenses of litigation; provided, however, that no director or officer shall be indemnified with respect to matters as to which he shall be adjudged in such action, suit or proceeding to be liable for negligence or misconduct in performance of duty, or with respect to any matters which shall be settled by the payment of sums which counsel selected by the Board of Directors shall not deem reasonable payment made primarily with a view to avoiding expenses of litigation, or with respect to matters for which such indemnification would be against public policy. Such right of indemnification shall be in addition to any other rights to which directors or officers maybe entitled.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">This Corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee, or agent of the Corporation, or is or was serving at the request of the Corporation as a director, officer, employee, or agent of another corporation, partnership, joint venture, trust, or other enterprise against any liability asserted against him and incurred by him in any such capacity or arising out of his status as such, whether or not the Corporation would have the power to indemnify him against such liability.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">AINOS, INC. BYLAWS &#8211; EFFECTIVE AUGUST 20 2021 </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Page&nbsp;7 of 11</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>ARTICLE </strong><strong>V: </strong><strong>CAPITAL STOCK</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section</u></strong><strong><u> 1. Certificates of Shares.</u></strong> The certificates for shares of the capital stock of the Corporation shall be in such form as shall be approved by the Board of Directors. The certificates shall be signed by the Chairman of the Board, if any, or the President, and also by the Secretary or an Assistant Secretary or by the Treasurer or an Assistant Treasurer and may be sealed with the seal of this Corporation or a facsimile thereof. Where any such certificate is countersigned by a transfer agent, or registered by a registrar, either of which is other than the Corporation itself or an employee of the Corporation, the signatures of any such Chairman of the Board, if any, or President and Secretary or Assistant Secretary or Treasurer or Assistant Treasurer may be facsimiles. They shall be consecutively numbered and shall be entered in the books of the Corporation as they are issued and shall exhibit the holder&#8217;s name and number of shares.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section</u></strong><strong><u> 2. Transfer of Shares.</u></strong> The shares of stock of the Corporation shall be transferable only on the books of the Corporation by the holders thereof in person or by their duly authorized attorneys or legal representatives, upon surrender and cancellation of certificates for a like number of shares.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section</u></strong><strong><u> </u></strong><strong><u>3.</u></strong><strong><u> </u></strong><strong><u>Closing</u></strong><strong><u> </u></strong><strong><u>of</u></strong><strong><u> Transfer </u></strong><strong><u>Books.</u></strong> For the purpose of determining shareholders entitled to notice of or to vote at any meeting of shareholders, or any adjournment thereof, or entitled to receive payment of any dividend, or in order to make a determination of shareholders for any other proper purpose, the Board of Directors of the Corporation may provide that the stock transfer books shall be closed for a stated period but not to exceed in any case one hundred ten (110) days. If the stock transfer books shall be closed for the purpose of determining shareholders entitled to notice of or to vote at a meeting of shareholders, such books shall be closed for at least ten (10) days immediately preceding such meeting. In lieu of closing the stock transfer books, the Board of Directors may fix in advance a date as the record date for any such determination of shareholders, such date in any case to be not more than one hundred ten (110) days and, in case of a meeting of shareholders, not less than ten (10) days prior to the date on which the particular action requiring such determination of shareholders is to be taken. If the stock transfer books are not closed and no record date is fixed for the determination of shareholders entitled to notice of or to vote at a meeting of shareholders or shareholders entitled to receive payment of a dividend, the date on which the notice of the meeting is mailed or date on which the resolution of the Board of Directors declaring such dividend is adopted, as the case may be, shall be the record date for such determination of shareholders.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section 4. </u></strong><strong><u>Regulations.</u></strong> The Board of Directors shall have power and authority to make all such rules and regulations as they may deem expedient concerning the issue, transfer and registration or the replacement of certificates for shares of capital stock of the Corporation.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. BYLAWS &#8211; EFFECTIVE AUGUST 20 2021 </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;8 of 11</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>ARTICLE VI: MISCELLANEOUS PROVISIONS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section</u></strong><strong><u> 1. Offices.</u></strong> Until the Board of Directors otherwise determines, the registered office of the Corporation required by the Texas Business Corporation Act to be maintained in the State of Texas, shall be the registered office named in the original Articles of Incorporation of the Corporation, or such other office as may be designated from time to time by the Board of Directors in the manner provided by law. Such registered office need not be identical to the principal place of business of the Corporation.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section</u></strong><strong><u> </u></strong><strong><u>2.</u></strong><strong><u> </u></strong><strong><u>Fiscal</u></strong><strong><u> Year.</u></strong> The fiscal year of the Corporation shall be such as the Board of Directors shall by resolution establish.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section</u></strong><strong><u> </u></strong><strong><u>3.</u></strong><strong> </strong><strong>Seal.</strong> The seal of the Corporation shall be such as from time to time may be approved by the Board of Directors.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section</u></strong><strong><u> 4. </u></strong><strong><u>Notice</u></strong><strong><u> </u></strong><strong><u>and</u></strong><strong><u> Waiver of Notice.</u></strong> Whenever any notice whatever is required to be given under the provisions of these Bylaws, said notice shall be deemed to be sufficient if given by depositing the same in a post office box in a sealed postpaid wrapper addressed to the person entitled thereto at his post office address, as it appears on the books of the Corporation, and such notice shall be deemed to have been given on the day of such mailing. A waiver of notice, signed by the person or persons entitled to said notice, whether before or after the time stated therein, shall be deemed equivalent thereto.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section</u></strong><strong><u> 5. Resignations.</u></strong> Any director or officer may resign at any time. Such resignation shall be made in writing and shall take effect at the time specified therein, or if no time is specified, at the time of its receipt by the Chairman of the Board, if any, the President or Secretary. The acceptance of a resignation shall not be necessary to make it effective, unless expressly so provided in the resignation.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. BYLAWS &#8211; EFFECTIVE AUGUST 20 2021 </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;9 of 11</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section </u></strong><strong><u>6.</u></strong><strong><u> </u></strong><strong><u>Action Without Meeting or by Conference Telephone.</u></strong> Any action permitted or required by law, these Bylaws or by the Articles of Incorporation of the Corporation, to be taken at a meeting of the shareholders, the Board of Directors or any committee designated by the Board of Directors may be taken without a meeting if a consent in writing, setting forth the action so taken, is signed by all the shareholders or members of the Board of Directors or committee, as the case may be. Such consent shall have the same force and effect as a unanimous vote at a meeting, and may be stated as such in any document or instrument filed with the Secretary of State. In addition, the shareholders of the Corporation are authorized to take any action required or authorized to be taken under the Texas Business Organizations Code (the &#8220;Code&#8221;) or the governing documents of this Corporation at an annual or special meeting of the shareholders of the Corporation, without holding a meeting, providing notice, or taking a vote if shareholders of the Corporation having at least the minimum number of votes that would be necessary to take the action that is the subject of the consent at a meeting, in which each owner or member entitled to vote on the action is present and votes, sign a written consent or consents stating the action taken. Any action taken by less-than-unanimous consent of shareholders shall be subject to the notification requirements contained in Section 6.202 of the Texas Business Organizations Code, or successor provisions. Subject to the requirement for notice of meetings, shareholders, members of the Board of Directors, or members of any committee designated by the Board of Directors, may participate in and hold a meeting of such shareholders, Board of Directors or committee, as the case may be, by means of conference telephone or similar communications equipment, or another suitable electronic communications system, including videoconferencing technology or the Internet, or any combination, if the equipment or system permits each person participating in the meeting to communicate with all other persons participating in the meeting; all subject to any identification and/or record keeping requirements of the Texas Business Organizations Code, or successor statutes.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u>Section</u></strong><strong><u> 7. </u></strong><strong><u>Securities</u></strong><strong><u> </u></strong><strong><u>of</u></strong><strong><u> Other </u></strong><strong><u>Corporations</u></strong><strong><u>.</u></strong> The chief executive officer (or any other officers designated by the Board of Directors) of the Corporation shall have power and authority to transfer, endorse for transfer, vote, consent or take any other action with respect to any securities of another issuer which may be held or owned by the Corporation and to make, execute and deliver any waiver, proxy or consent with respect to any such securities.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>ARTICLE VII: AMENDMENTS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">These Bylaws may be altered, amended, or repealed by the affirmative vote of the holders of a majority of the outstanding stock at any annual meeting, or at any special meeting if notice of the proposed amendment be contained in the notice of said special meeting, or by the affirmative vote of a majority of the full Board of Directors at any regular or special meeting, provided notice of said proposed amendment be contained in the notice of the meeting.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. BYLAWS &#8211; EFFECTIVE AUGUST 20 2021 </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;10 of 11</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><u>Prior Version:</u> Adopted July 10, 2015</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><u>Amendments:</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><u>Article II, Section 10 of the Company&#8217;s Bylaws shall be amended as follows: <em>Section 10. Compensation.</em></u><em> The Board of Directors <u>may provide for the compensation to members of the Board of Directors upon the recommendation of its Compensation Committee and in accordance with its Compensation Policies</u> as such shall not receive any stated salary for their services, but by resolution of the Board a fixed sum and expense of attendance, if any, may be allowed for attendance at such regular or special meetings of the Board; provided, that nothing contained herein shall be construed to preclude any director from serving the Corporation in any other capacity or receiving compensation therefor.&#8221;</em> (emphasis added, modified provisions underlined). Amended by the Board on August 20, 2021; No. Ainos-2021-04</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The corporate name identified in the Company&#8217;s Bylaws shall be amended to be &#8220;Ainos, Inc.&#8221; Amended by the Board on August 20, 2021; No. Ainos-2021-04</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">AINOS, INC. BYLAWS &#8211; EFFECTIVE AUGUST 20 2021&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Page&nbsp;11 of 11</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>aimd_ex321.htm
<DESCRIPTION>CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
<TEXT>
<html><head><title>aimd_ex321.htm</title><!--Document created using EDGARMaster--></head><body style="COLOR: #000000; TEXT-ALIGN: justify; FONT: 10pt Times New Roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 32.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CERTIFICATION PURSUANT TO</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>18 U.S.C. SECTION 1350</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>AS ADOPTED PURSUANT TO</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In connection with the Quarterly Report of Ainos, Inc. on Form 10-Q for the period ended September 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned, in the capacities and on the dates indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">1.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px">2.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="margin:0px">AINOS, INC. </p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:50%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:3%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:35%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:12%;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px">Date: November 15, 2021</p></td> <td> <p style="margin:0px">&nbsp;By:</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"> <p style="margin:0px"><em>/s/ Chun-Hsien Tsai</em></p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">Chun-Hsien Tsai, Chairman of the Board, </p> <p style="margin:0px">and Chief Executive Officer </p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px">Date: November 15, 2021</p></td> <td> <p style="margin:0px">By:</p></td> <td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"> <p style="margin:0px"><em>/s/ Hui-Lan Wu</em></p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">Hui-Lan Wu, Chief Financial Officer</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>aimd_ex991.htm
<DESCRIPTION>RULES AND PROCEDURES OF BOARD OF DIRECTORS MEETINGS, ADOPTED AUGUST 20, 2021
<TEXT>
<html><head><title>aimd_ex991.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: left; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 99.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>AINOS, INC.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="MARGIN: 0px; text-align:left;"><strong>RULES AND PROCEDURES OF BOARD OF DIRECTORS MEETINGS &#8211; </strong><strong>ADOPTED</strong></p> <p style="MARGIN: 0px; text-align:left;"><strong>AUGUST 20 2021</strong></p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>1.0 SCOPE OF RULES AND PROCEDURES</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Unless relevant laws and regulations or the Company&#8217;s Certificate of Formation or Bylaws provide otherwise, the Company&#8217;s Board of Directors meetings (&#8220;Board Meetings&#8221;) shall be conducted in accordance with the Rules and Procedures of Board of Directors Meetings (the &#8220;Rules and Procedures&#8221;).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>2.0 CONVENING OF MEETINGS AND CHAIRMAN ROLE </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>2.1 Minimum Quarterly Meetings.</em></strong> Board Meetings shall be held at least once every quarter but may be held at any time in case of urgent circumstances.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>2.2 Chairman of the Board Role.</em></strong> Board Meetings shall be convened and presided over by the Chairman of the Board of Directors. However, the first meeting of every term of the newly elected Board of Directors shall be convened and presided over by the Director who has received the largest number of votes after such election; if there are two or more persons with such convening rights, they shall elect from amongst themselves one person to convene and preside over the meeting.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>2.3 Absence of Chairman of the Board.</em></strong> In case the Chairman of the Board of Directors is on leave or unable to exercise his powers for any cause, the Vice Chairman of the Board of Directors shall act on his behalf. If the Vice Chairman is also on leave or unable to exercise his powers for any cause, the Chairman shall appoint a Director to act on his behalf. In the absence of such an appointee, the Directors shall elect from amongst themselves one person to act on the behalf of the Chairman.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>2.4 Place of Meetings.</em></strong> Board Meetings at any appropriate place, time, and manner convenient for the Directors to attend in accordance with the Bylaws.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>3.0</strong> <strong>DESIGNATED SECRETARIAT, MEETING NOTICES, AND </strong><strong>MEETING MATERIALS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>3.1 Meeting Agenda.</em></strong> The subject matter of Board Meetings shall be decided by the Chairman of the Board of Directors. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>3.2 Role of Corporate Secretary.</em></strong> The Board Corporate Secretary shall conduct the drafting of meeting agendas and minutes, and handle other administrative matters related to Board Meetings, and reports to the Chairman of the Board of Directors. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>3.3 Regular Meetings.</em></strong> Regular meetings of the Board of Directors shall be held at such times and places as shall be designated from time to time by resolution of the Board of Directors. Notice of such regular meetings shall not be required.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. RULES AND PROCEDURES OF BOARD OF DIRECTORS MEETINGS &#8211; ADOPTED</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AUGUST 20 2021</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page 1 of 6</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>3.4 Special Meetings.</em></strong> Special meetings of the Board of Directors shall be held whenever called by the Chairman of the Board, if any, the President, or by a majority of the directors for the time being in office. Each such special meeting shall be held at such time and place as shall be designated by the officer or directors calling such meeting.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>3.5 Notice of Meetings.</em></strong> The Secretary shall give notice of each special meeting in person, or by mail or electronic transmission, to each director at least four (4) hours before the time of such meeting. Such notice, if given by electronic transmission, shall be effective only if the director receiving such notice shall have previously consented to receive notices by electronic transmission, and shall be sent using a form of electronic transmission specified by the director. The attendance of a director at any meeting shall constitute a waiver of notice of such meeting, except where a director attends a meeting for the express purpose of objecting to the transactions any business on the grounds that the meeting is not lawfully called or convened. Notice may also be waived in writing as provided in Article VI, Section 4 of the Bylaws. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the Board of Directors need be specified in the notice or written waiver of notice of such meeting.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>4.0</strong> <strong>SUBJECT MATTER OF BOARD MEETINGS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">The agenda of regular Board Meetings shall include at least the following items:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">(1)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">The meeting minutes of the preceding meeting;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">(2)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Material business and financial reports;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">(3)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Internal audit matters reports; and</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">(4)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Other important matters report, including the report on implementation status of previous resolutions.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">2.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Discussion items:</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">(1)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Discussion items reserved by the preceding meeting; and</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">(2)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Discussion items of the current meeting.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">3.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Special motions</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. RULES AND PROCEDURES OF BOARD OF DIRECTORS MEETINGS &#8211; ADOPTED</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AUGUST 20 2021</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;2 of 6</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>5.0 ATTENDANCE SIGNING BOOKLET AND PROXIES</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>5.1 Attendance Record.</em></strong> A signing booklet shall be provided at every Board Meeting for the attending Directors to sign in. The Directors shall attend Board Meetings in accordance with the Bylaws. If unable to attend, a Director may appoint another </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>5.2 Proxies.</em></strong> Director to attend on his behalf by proxy which specifies the scope of authorization; any appointee shall not act as proxy for more than one Director. Any Director attending the meeting via telephone or video conference shall be deemed to have attended the meeting in person but shall sign an attendance confirmation and transmit his/her attendance confirmation to the Corporate Secretary.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>5.3 Special Rules for Independent Directors.</em></strong> Independent Directors shall attend the Board Meetings in person; if an Independent Director is unable to attend a Board Meeting in person and wishes to delegate his/her rights, he/she can only delegate another Independent Director to attend on his/her behalf. Any dissenting opinion or abstention by Independent Directors shall be recorded in the Board Meetings minutes. If Independent Directors are unable to attend Board Meetings in person to express their dissenting opinion or abstention, except for legitimate reasons, they shall submit a written statement in advance to be recorded in the Board Meetings minutes.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>5.4 Attendance by Non-Directors.</em></strong> Depending on the subject matter of proposed resolutions, relevant managerial personnel may be invited to present at Board Meetings to assist the Directors in understanding the Company&#8217;s current conditions so that they can make appropriate resolutions. In addition, accountants, legal counsel, or other professional personnel may be invited to the meetings to provide professional opinions for the Board of Directors&#8217; reference, but shall excuse themselves and vacate the meeting when the proposed resolution will be discussed and resolved.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>6.0 QUORUM </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">A majority of the directors fixed in the manner provided in these Bylaws shall constitute a quorum for the transaction of business, but if at any meeting of the Board of Directors there be less than a quorum present, a majority of those present or any director solely present may adjourn the meeting from time to time without further notice. The act of a majority of the directors present at a meeting at which a quorum is in attendance shall be the act of the Board of Directors, unless the act of a greater number is required by the Certificate of Formation or by the Bylaws.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>7.0 DISCUSSION OF PROPOSED RESOLUTIONS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>7.1 Order of Discussion.</em></strong> In principle, the discussion of proposed resolutions at a Board Meeting shall proceed in accordance with the agenda attached to the meeting notice. However, if no objection is voiced by any Director present at the meeting or with more than half of the attending Directors&#8217; consent, the Chairman may make changes. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. RULES AND PROCEDURES OF BOARD OF DIRECTORS MEETINGS &#8211; ADOPTED</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AUGUST 20 2021</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;3 of 6</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>7.2 Intermission of Meeting.</em></strong> During a meeting, the Chairman may, at his discretion, set time for intermission or negotiation.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>8.0 VOTING</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>8.1 Call for a Vote.</em></strong> The Chairman may announce an end of the discussion of any resolution and call for a vote.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>8.2 Assent.</em></strong> A director of the Corporation who is present at a meeting of the Board of Directors at which action on any corporate matter is taken shall be presumed to have assented to the action unless his dissent shall be entered in the minutes of the meeting or unless he shall file his written dissent to such action with the person acting as secretary of the meeting before the adjournment thereof or shall forward such dissent by registered mail to the Secretary of the Corporation immediately after adjournment of the meeting. Such right to dissent shall not apply to a director who voted in favor of such action.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>8.3 Amendments or Modifications to Resolutions or Motions</em></strong>. If there is an amendment to or substitute for a proposed resolution or motion, the Chairman shall decide the sequence of voting and the amendment or substitute. If any one of them has been adopted, the others shall be deemed vetoed and no further voting is required. The result of voting shall be announced at the meeting and placed on record.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>8.4 Methods for Voting.</em></strong> The method of voting shall be one of the following as determined by the Chairman:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">1.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">By showing of hands;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">2.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">By voicing votes; or</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">3.</p></td> <td style="vertical-align:top;"> <p style="margin:0px">By casting ballots. The Chairman shall appoint person(s) to monitor the voting process and person(s) to count the ballots; and the person(s) appointed to monitor the voting process should be a Director.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>9.0 THE RECUSAL OF CONFLICT-INTERESTED DIRECTORS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">If a Director or a proxy the Director represents has a personal interest in the matter under discussion at the meeting, the relevant Director shall disclose the nature of such personal interest. If such interest may impair the interest of the Company, the relevant Director shall not join the discussion and voting of such matter, and shall recuse himself/herself when the matter is being discussed and resolved; nor shall the relevant Director exercise voting right on behalf of another Director.</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. RULES AND PROCEDURES OF BOARD OF DIRECTORS MEETINGS &#8211; ADOPTED</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AUGUST 20 2021</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;4 of 6</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>10.0 MEETING ITEMS TO BE RECORDED AND SIGNED</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>10.1 Meeting Minutes.</em></strong> The resolutions of every Board Meeting shall be recorded in the meeting minutes. The meeting minutes shall accurately record the following items:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">The term (or year), place, and time of the meeting;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">The name of the chairman;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">The attendance situation of the Directors, including the names and numbers of those who are present, on leave, and absent;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">The names and titles of the other attendants;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">The name of the recorder</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Report items;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Discussion items: the voting method and the result of each proposed resolution; the summary of opinion by the Directors, experts, and other personnel; the names of the Directors that disclosed a conflict of interest under Article 11 of the Rules and Procedures, summary of the nature of the conflict of interest, the reasons for recusal or non-recusal, and the circumstances of recusal; any dissenting opinion or abstention with a written statement; any written statement provided by the Independent Directors pursuant to Paragraph 2 of Articles 6 of the Rules and Procedures;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Special motions: the names of the persons proposing the special motions; the voting method and the result of each proposed resolution; the summary of opinion by the Directors, experts, and other personnel; any dissenting opinion or abstention with a written statement; and</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Other items that shall be recorded.</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>10.2 Signing and Distribution of Minutes.</em></strong> Meeting minutes shall be signed by the Chairman of the meeting and the Corporate Secretary (or recording secretary appointed at the meeting) , distributed to each Director within twenty (20) days after the meeting, and carefully kept as the Company&#8217;s important file throughout the life of the Company. The attendance record of a Board Meeting shall be part of the meeting minutes and be permanently retained throughout the life of the Company. The recording and distribution of meeting minutes may be performed by means of electronic transmission.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>11.0 CANCELLATION OF BOARD MEETINGS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">In the case of special circumstances where a scheduled Board Meeting of the Company must be cancelled after meeting notices have been sent to the Directors, the meeting may be cancelled if the person with convening right notifies the Directors in writing at least three days prior to the scheduled meeting date. In the case of urgent circumstances where the scheduled Board Meeting must be cancelled and it is impossible to notify the Directors prior to the time specified above, the meeting may be cancelled if the person with convening right notifies the Directors by telephone or other means at least three hours prior to the scheduled meeting time and confirms that each Director has received such notice.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. RULES AND PROCEDURES OF BOARD OF DIRECTORS MEETINGS &#8211; ADOPTED</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AUGUST 20 2021</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;5 of 6</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>12.0 EFFECTIVE DATE AND AMENDMENT</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">These Rules and Procedures shall be effective from August 20, 2021. Any amendment to these Rules and Procedures shall be approved by the Board of Directors.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. RULES AND PROCEDURES OF BOARD OF DIRECTORS MEETINGS &#8211; ADOPTED </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AUGUST 20 2021</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;6 of 6</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>6
<FILENAME>aimd_ex992.htm
<DESCRIPTION>CORPORATE GOVERNANCE POLICIES OF THE BOARD OF DIRECTORS, ADOPTED AUGUST 20, 2021
<TEXT>
<html><head><title>aimd_ex992.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 99.2</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>AINOS, INC.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;"><strong>CORPORATE GOVERNANCE</strong><strong> </strong><strong>POLICIES</strong><strong> </strong><strong>OF</strong><strong> </strong><strong>THE</strong><strong> </strong><strong>BOARD</strong><strong> </strong><strong>OF</strong><strong> </strong><strong>DIRECTORS &#8211; </strong></p> <p style="MARGIN: 0px; text-align:justify;"><strong>ADOPTED AUGUST 20 2021</strong></p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>1.0 </strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>PURPOSE OF THE POLICIES</strong></p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">These Corporate Governance Policies (the &#8220;<a name="_9kR3WTr24446EdSvqijmx"><strong><em>Policies</em></strong></a>&#8221;) have been adopted by the Board of Directors (the &#8220;<a name="_9kR3WTr244468JEkos"><strong><em>Board</em></strong></a>&#8221;) of AINOS, INC., a Texas corporation (the &#8220;<a name="_9kR3WTr244467JFwynmB"><strong><em>Company</em></strong></a>&#8221;) to assist the Board in carrying out its responsibilities and in following corporate best practices. These Policies are to be interpreted in the context of all applicable laws and regulations, the Company&#8217;s charter documents and other governing legal documents.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s management is responsible for: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">development of strategic, financial and management <a name="_9kMHG5YVt46668GfUxskloz">policies</a> of the Company for consideration by the Board;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the operations of the Company in accordance with such <a name="_9kMIH5YVt46668GfUxskloz">policies</a>;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">timely preparation of financial statements and other reports about the Company, and informing the Board about the Company&#8217;s operations; and</td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">identification and management of the Company&#8217;s risks and development of risk mitigation strategies.</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Board is responsible for protecting and enhancing the assets of the Company and serving the best interests of the Company&#8217;s stockholders. These duties include: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">monitoring the effectiveness of management and Company <a name="_9kMJI5YVt46668GfUxskloz">policies</a> and decisions; and</td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">oversight of the Company&#8217;s risk management process, which shall include periodic review of management&#8217;s risk analysis.</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>2.0 </strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>AUTHORITY OF THE BOARD</strong></p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pursuant to Article II, Section 1 of the Company&#8217;s <a name="_9kR3WTr266478IO5iuD">Bylaws</a> adopted on July 10, 2015: <em>&#8220;</em><em>The business and property of the <a name="_9kR3WTr266479KF1314ru3z5">Corporation</a> shall be managed by the Board of Directors, and subject to the restrictions imposed by law, the Articles of Incorporation or by these <a name="_9kMHG5YVt48869AKQ7kwF">Bylaws</a>, they may exercise all the powers of the <a name="_9kMHG5YVt48869BMH3536tw517">Corporation</a>.&#8221;</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. CORPORATE COVERNANCE POLICIES OF THE BOARD OF DIRECTORS &#8211; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AUGUST 20 2021 &#8211; ADOPTED</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;1 of 10</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>3.0 </strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>COMPOSITION OF BOARD</strong></p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>3.1</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Selection of Directors</em></strong>. The Board shall select members to fill Board vacancies and nominate candidates for election at the annual meeting of stockholders (the &#8220;<strong><em>Annual Meeting</em></strong>&#8221;) or other similar meeting. All directors are appointed or elected for a three (3) year term.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">3.1.1</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><u>Board Membership Criteria</u>. The Board encourages selection of directors, including nominees by stockholders, who will contribute to the Company&#8217;s overall corporate goals. The Board and the Executive Committee will periodically review the characteristics appropriate for directors to possess in light of the Board&#8217;s composition and skills and expertise needed at the Board and committee levels. In determining whether to recommend a nominee for election, the Executive Committee shall consider all of his or her relationships with any of the Company&#8217;s stockholders, competitors, customers, suppliers or other persons related to the Company, and for determining whether to recommend a director for re-election, the Executive Committee shall also consider the director&#8217;s past meeting attendance and participation in and contributions to the activities of the Board. The Executive Committee is committed to Board diversity and shall consider a nominee&#8217;s background and experience to ensure that a broad range of perspectives is represented on the Board. In particular, the Executive Committee will consider a nominee&#8217;s membership in an underrepresented community, such as race, ethnicity, sexuality, gender or veteran status.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">3.1.2</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><u>Management Director</u>. The Board anticipates that the Company&#8217;s Chief Executive Officer (&#8220;<strong><em>CEO</em></strong>&#8221;) will be nominated to serve on the Board.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">3.1.3</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><u>Nomination Process</u>. The Company&#8217;s Secretary shall be notified of all potential candidates for nomination to the Board. Nominations made other than by the Board must be made in full compliance with the Company&#8217;s Bylaws. Each potential candidate must provide a list of references and agree (i) to be interviewed by the Board and (ii) to a background check or other review of qualifications by the Company. Prior to nomination of any candidate by the Board, each director shall be provided the opportunity to meet with the candidate. Any candidate nominated shall upon request agree in writing to comply with these Policies and all other Company policies and procedures applicable to members of the Board.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. CORPORATE COVERNANCE POLICIES OF THE BOARD OF DIRECTORS &#8211; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AUGUST 20 2021 &#8211; ADOPTED</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;2 of 10</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">3.1.4</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><u>Vacancies</u>. Pursuant to Article II, Section 1 of the Bylaws, any vacancy occurring in the Board may be filled by the affirmative vote of a majority of the remaining directors though less than a quorum of the Board. A director elected to fill a vacancy shall be elected for the unexpired term of his predecessor in office. In case of any increase in the number of directors, the additional directors shall be elected at an annual or special meeting of shareholders called for that purpose or by the Board for a term of office continuing only until the next election of one or more directors by the shareholders; provided, however, that during a period between two successive annual meetings of shareholders, the Board may not fill more than two vacancies created by an increase in the number of directors.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong><em>3.2</em></strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Size of the Board</em></strong>. The number of directors shall be established by the Board in accordance with the Company&#8217;s Certificate of Formation and Bylaws. The Board will review the appropriate size of the Board from time to time and may approve a change in the authorized number of directors. The Bylaws of the Company states: &#8220;<em>The Board of Directors shall consist of not less than one nor more than thirty directors, as so determined from time to time by resolution of the Board of Directors. Within the above limits, the number of directors may be increased or decreased (provided such decrease does not shorten the term of any incumbent director) from time to time by resolution of the Board of Directors</em>.&#8221;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>3.3</em></strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Independent Directors</em></strong>.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">3.3.1</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><u>Independent Directors</u>. The Company has elected to be covered by the Controlled Company exemption from the independent director requirement of Nasdaq 5065(b)(1). According to the Nasdaq Listing Rule 5615(c) and IM-5615-5, a &#8220;Controlled Company&#8221; is a company of which more than 50% of the voting power for the election of directors is held by an individual, a group or another company. The calculation of voting power held by a group can include shares covered under voting agreements between or among shareholders relating to the election of directors. For a group to exist, the shareholders must have filed a notice that they are acting as a group (e.g., a Schedule 13D). A majority of the Directors of the Company are not &#8220;Independent Directors&#8221; as defined by Nasdaq rule 5605(a)(2) and IM-5605 due to their affiliation with Ainos, Inc., a Cayman Island corporation (&#8220;<strong><em>Ainos KY</em></strong>&#8221;), the majority shareholder of the Company, and their status as an executive officer, employee, or an individual having a relationship with the foregoing including as a family member.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. CORPORATE COVERNANCE POLICIES OF THE BOARD OF DIRECTORS &#8211; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AUGUST 20 2021 &#8211; ADOPTED</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;3 of 10</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">3.3.2</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><u>Affirmative Determination of Independence</u>. Based on information provided by Board members and advice of counsel, the Board, or a designated committee of the Board shall affirmatively determine at times required by the Nasdaq listing standards (the &#8220;<strong><em>Listing Standards</em></strong>&#8221;) that the directors designated as independent have no material relationships to the Company (either directly or indirectly) that may interfere with the exercise of their independence from management and the Company.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">3.3.3</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><u>Proposed Transactions</u>. Directors may be asked from time to time to leave a Board meeting when the Board is considering a transaction in which the director (or another organization in which a director is a director or officer) has a financial or other interest. The Board shall review and approve any proposed related party transactions in compliance with the Company&#8217;s policies and Listing Standards.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">3.3.4</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><u>Annual Determination</u>. The Board will make an affirmative determination, at least annually, that other commitments of non-employee directors, including services on additional public boards, continue to allow sufficient time to perform their Board and committee duties.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong><em>3.4</em></strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Board Leadership</em></strong>. The Board may elect a chairperson of the Board pursuant to Article III, Section 5 of the Bylaws. If elected, the Chairman of the Board shall preside at all meetings of the shareholders and of the Board of Directors; and he shall have such other powers and duties as designated in the Bylaws and as from time to time may be assigned to him by the Board of Directors.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>3.5</em></strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Fixed Terms</em></strong>. Longer-serving directors have valuable insight about the Company&#8217;s business, operations, history, policies and objectives. The Board believes that term limits and mandatory retirement ages for directors are not in the best interests of the Company, and the Board shall instead review annually the current effectiveness of each director in nominating candidates for election or re-election.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>3.6</em></strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Executive Committee</em></strong>. The Board shall include an Executive Committee composed of Independent Directors. In addition to duties delegated to it by the Board, the Executive Committee shall periodically assess the performance of the Board and its committees and report the results of such assessment to the Board.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. CORPORATE COVERNANCE POLICIES OF THE BOARD OF DIRECTORS &#8211; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AUGUST 20 2021 &#8211; ADOPTED</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page 4 of 10</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:1%;vertical-align:top;"> <p style="margin:0px"><strong><em>3.7</em></strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Director Time Commitment</em></strong>. Directors should be able to devote sufficient time to Board and committee duties and to understanding the Company&#8217;s business. The Executive Committee will review the other commitments of potential Board candidates, and do so annually for existing Board members, to make this determination. Board members must notify the Executive Committee and the General Counse1l, and obtain the Executive Committee&#8217;s approval, before accepting an invitation to serve on the board of another company. Factors the Executive Committee may consider include the following: (i) resulting actual or potential conflicts of interest; (ii) actual or potential competition between the Company and the other company; (iii) significant or potentially significant relationships between the Company and the other company, such as vendor, customer, supplier, contractor or consultant; and (iv) whether acceptance of the offer may reflect unfavorably on the Company. Unless otherwise approved by the Board, no Board member shall serve on the board of any significant Company competitor, supplier or customer (as determined by the Executive Committee).</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:1%;vertical-align:top;"> <p style="margin:0px"><strong><em>3.8</em></strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Change in Circumstances</em></strong>. Directors who change their principal occupation or business association should not necessarily leave the Board. However, if any director has a Change in Circumstances (as defined below), then the director shall promptly disclose it to the General Counsel (or if none, the CFO), who will notify the Executive Committee of any material Change in Circumstances (as determined by the General Counsel or if none, the CFO). The Board, excluding the applicable director, will determine whether to request that director to resign if the Board receives such a recommendation from the Executive Committee (excluding the applicable director, if an Executive Committee member). For these purposes, &#8220;Change in Circumstances&#8221; will mean any change in a director&#8217;s personal or professional circumstances, since such director&#8217;s most recent election to the Board, that would require disclosure in such director&#8217;s D&amp;O Questionnaire or the proxy statement of the Company if such director were to be nominated for re-election at the next Annual Meeting, including, but not limited to, a change of employer or primary occupation (including retirement) or a material change in occupational responsibilities.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:1%;vertical-align:top;"> <p style="margin:0px"><strong><em>3.9</em></strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Ownership Guidelines</em></strong>. The Board expects all directors and executive officers to display confidence in the Company by owning shares of the Company&#8217;s common stock. For purposes of these guidelines, stock ownership includes shares of the Company&#8217;s common stock held in trust for the director or executive officer, as applicable, and his or her immediate family, plus vested deferred stock, but not unvested or unexercised equity. If the Board adopts a minimum ownership requirement, the number of shares is calculated annually as of the last day of the Company&#8217;s fiscal year. The value of a share shall be the greater of the then current market price or the closing price on the acquisition date.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. CORPORATE COVERNANCE POLICIES OF THE BOARD OF DIRECTORS &#8211; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AUGUST 20 2021 &#8211; ADOPTED</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;5 of 10</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:1%;vertical-align:top;"> <p style="margin:0px"><strong><em>3.10</em></strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Director Education</em></strong>. Each director is expected to participate in continuing education to maintain the necessary level of expertise to perform his or her responsibilities. The Executive Committee and the General Counsel are responsible for administering or approving eligible continuing education programs, which may include a mix of in-house and third-party programs. The Company will pay the out-of-pocket costs of attendance for any director.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:1%;vertical-align:top;"> <p style="margin:0px"><strong><em>3.11</em></strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Board Assessment</em></strong>. The Executive Committee and the Board shall conduct, at least annually, an assessment of its overall effectiveness and performance.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:1%;vertical-align:top;"> <p style="margin:0px"><strong><em>3.12</em></strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Executive Officer Review</em></strong>. The Compensation Committee of the Board shall conduct, and review with the Board, an annual evaluation of the performance of all executive officers.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:1%;vertical-align:top;"> <p style="margin:0px"><strong><em>3.13</em></strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><em><strong>Management Development</strong></em>. Annually, the Board shall review management development and discuss candidates to fulfill the CEO&#8217;s responsibilities on an interim basis in the event that the CEO is disabled or otherwise incapacitated.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:1%;vertical-align:top;"> <p style="margin:0px"><strong>4.0</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>MEETINGS AND MINUTES</strong></p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:1%;vertical-align:top;"> <p style="margin:0px"><strong>4.1</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Meetings of Executive Committee</em></strong>. Each fiscal year, the Executive Committee will hold at least two (2) meetings without management present, and may invite the Company&#8217;s independent auditors, legal counsel, finance staff and other employees to attend.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:1%;vertical-align:top;"> <p style="margin:0px"><strong>4.2</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Session with CEO</em></strong>. Each regular Board meeting is intended to include a session between the CEO and the independent directors, to permit discussion of personnel and management issues, management development and other topics.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="width:1%;vertical-align:top;"> <p style="margin:0px"><strong>4.3</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Agenda.</em></strong> The chairperson of the Board, if designated, or the CEO will have primary responsibility for preparing any Board meeting agenda and distributing it to the directors with appropriate written information and background materials. Agendas should address items suggested by Board members.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. CORPORATE COVERNANCE POLICIES OF THE BOARD OF DIRECTORS &#8211; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AUGUST 20 2021 &#8211; ADOPTED</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;6 of 10</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>4.4</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Board Materials Distributed In Advance</em></strong>. Information concerning the Company, and its finances, operations and strategy, is important to the Board&#8217;s understanding and decision-making process. When feasible, appropriate information relating to agenda items should be distributed in writing to the Board in advance of the Board meeting. For sensitive or late-breaking topics, discussion will be held at the meeting and no materials need be distributed.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>4.5</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Board Access to Management</em></strong>. Management will afford each Board member access to Company employees, and outside auditors, legal counsel and other professional advisors for any purpose reasonably related to the Board&#8217;s responsibilities, with the Executive Committee authorized to establish reasonable processes related to such matters. The Board encourages management to include in Board meetings Company personnel who can provide additional insight into the items being discussed, and/or to present key employees who should be given exposure to the Board. Management is responsible for arranging presentations at Board meetings and providing information to the Board about the operations of the Company. Each director is entitled to inspect the Company&#8217;s books and records and obtain such other data and information as the director may reasonably request; inspect facilities as reasonably appropriate for the performance of director duties; and to receive notice of all meetings in which a director is entitled to participate and copies of all Board meeting minutes, with the Executive Committee authorized to establish reasonable processes related to such matters.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>4.6</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Outside Advisors</em></strong>. The Board and its committees are authorized to obtain legal or other advisors of their choice, at the Company&#8217;s expense, who shall report directly to the Board or the committee.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>5.0</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>BOARD COMMITTEES</strong></p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>5.1</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><em><strong>Committees</strong></em>. The current committees of the Board are the Audit Committee, the Compensation Committee and the Executive Committee. The Board may form, merge or dissolve committees as it deems appropriate from time to time. The Audit Committee, the Compensation Committee and the Executive Committee shall be comprised entirely of Independent Directors. Exceptions shall only be made under unusual circumstances and only with unanimous approval of the Independent Directors. Committee composition shall conform to applicable laws and regulations.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>5.2</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Committee Member Selection</em></strong>. Upon recommendation by the Executive Committee, the Board will designate the members and the chairperson of each committee, endeavoring to match the committee&#8217;s function and needs for expertise with individual skills and experience of the appointees.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. CORPORATE COVERNANCE POLICIES OF THE BOARD OF DIRECTORS &#8211; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AUGUST 20 2021 &#8211; ADOPTED</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;7 of 10</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>5.3</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Committee Functions</em></strong>. Each committee will have a written charter approved by the Board. The charters shall be at a minimum in compliance with all legal requirements and Listing Standards. The number of, and content and processes for, such committee meetings (including attendees at such meetings) and means of carrying out committee responsibilities will be determined by each committee in light of the committee&#8217;s charter, the committee&#8217;s authority delegated by the Board, and the legal, regulatory, accounting and governance principles applicable to the committee&#8217;s function. The minutes of the committees will be available to the full Board. The Company will afford access to the Company&#8217;s employees, professional advisors and other resources to enable committee members to carry out their responsibilities.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>6.0</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>BOARD MEMBER RESPONSIBILITIES</strong></p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>6.1</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Generally</em></strong>. A director is expected to discharge his or her duties, including duties as a committee member, in good faith and in a manner the director reasonably believes to be in the best interests of the Company and its stockholders and to abide by the highest ethical and fiduciary standards.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>6.2</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Disclose Relationships and Other Information</em></strong>. Each director is expected to disclose promptly to the Board and to respond promptly and accurately to periodic inquiries from the Company regarding any existing or proposed relationships with the Company, including compensation and stock ownership, which could affect the independence of the director under applicable Listing Standards or any additional standards as may be established by the Board. Each director shall also promptly inform the Company of any material change in such information.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>6.3</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Attendance</em></strong>. Board members are expected to devote sufficient time and attention to prepare for, attend and participate in Board meetings and meetings of committees on which they serve, including advance review of meeting materials that may be circulated prior to each meeting.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>6.4</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Reporting and compliance systems</em></strong>. Based on information available, each director should be satisfied that the Company&#8217;s management maintains an effective system for timely reporting to the Board or appropriate Board committees on the following, without limitation: (1) the Company&#8217;s financial and business plans, strategies and objectives; (2) the recent financial results and condition of the Company and its business segments; (3) significant accounting, regulatory, competitive, litigation and other external issues affecting the Company; and (4) systems of control which promote accurate and timely reporting of financial information to stockholders and compliance with laws and corporate policies. Each director is expected to have a basic understanding of the foregoing matters to the extent information is furnished by management or otherwise available to the Board.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. CORPORATE COVERNANCE POLICIES OF THE BOARD OF DIRECTORS &#8211; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AUGUST 20 2021 &#8211; ADOPTED</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;8 of 10</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>6.5</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Continuing education</em></strong>. The Board is expected periodically to review the Company&#8217;s policies and procedures for providing orientation sessions for newly elected or appointed directors and to recommend, on an as-needed basis, continuing director education programs for Board or committee members.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>6.6</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Annual evaluation</em></strong>. The Board will evaluate these corporate governance guidelines and whether the Board and its committees are functioning effectively at least annually.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>6.7</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Risk Oversight.</em></strong> The Board should understand the principal risks associated with the Company&#8217;s business on an on-going basis and it is the responsibility of management to assure that the Board and its committees are kept well informed of these changing risks on a timely basis. It is important that the Board oversee the key risk decisions of management, which includes comprehending the appropriate balance between risks and rewards. The Board reserves oversight of the major risks facing the Company and has delegated risk oversight responsibility to the appropriate committees in the following areas: the audit committee oversees risks relating to financial matters, financial reporting and auditing and the compensation committee oversees risks relating to the design and implementation of the Company&#8217;s compensation policies and procedures.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>6.8</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Reliance on Information</em></strong>. A director is entitled to rely on reports or other information provided by Company management, independent auditors, legal counsel and other persons, in the discharge of his or her duties.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>6.9</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Confidentiality.</em></strong> Directors have an obligation to protect and keep confidential all non-public information related to the Company (&#8220;<strong><em>Confidential Information</em></strong>&#8221;) unless and until the Company has authorized public disclosure (or unless otherwise required by law or regulation). Confidential Information includes all non-public information entrusted to or obtained by a director by reason of his or her position on the Board, such as information regarding the strategy, business, finances and operations of the Company and third parties, minutes, reports and materials of the Board and its committees, other documents identified as confidential by the Company and all other non-public information provided by the Company, including but not limited to non-public information concerning: (i) the Company&#8217;s financial condition, prospects or plans, its marketing and sales programs and research and development information, as well as information relating to acquisitions, divestitures and actions relating to the Company&#8217;s stock; (ii) possible transactions with other companies or information about the Company&#8217;s suppliers, customers or partners that the Company is under an obligation to maintain as confidential; and (iii) the proceedings and deliberations of the Board and its committees, and the discussions and decisions between and among employees, officers and directors and their advisors. Directors may not use Confidential Information for personal benefit or to benefit other persons or entities other than the Company. Directors shall refrain from disclosing Confidential Information to anyone outside the Company, specifically including any principal or employee of any entity or person that employs the director or has sponsored the director&#8217;s election to the Board, except with Company authorization or as otherwise may be required by applicable law. The obligations described above continue even after service on the Board has ended. Any questions or concerns about potential disclosures should be directed to the General Counsel.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. CORPORATE COVERNANCE POLICIES OF THE BOARD OF DIRECTORS &#8211; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AUGUST 20 2021 &#8211; ADOPTED</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;9 of 10</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>6.10</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><em><strong>Management Succession Planning</strong></em>. At least annually, the Compensation Committee will consider and assist the Board in developing succession plans for the CEO and other key executive officers and appropriate management personnel. The Board may from time to time ask the Compensation Committee to undertake other specific reviews concerning management succession planning.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>6.11</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Applicable Laws and Policies</em></strong>. Board members will comply with all applicable laws and requirements of applicable regulatory agencies, including the Listing Standards, and with all policies and guidelines of the Company, including, without limitation, the Company&#8217;s Code of Conduct and Financial Team Code of Conduct.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>7.0</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>REVIEW OF GOVERNANCE GUIDELINES</strong></p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td colspan="2" style="vertical-align:top;"> <p style="margin:0px">The Executive Committee will periodically review and assess the adequacy of these guidelines and recommend any proposed changes to the Board for approval.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>8.0</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>ADOPTIONS, REVIEWS AND REVISIONS</strong></p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of July 30, 2021 &#8211; No prior <a name="_9kMH0H6ZWu57779HgVytlmp0">policy</a></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Adopted &#8211; August 20, 2021</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. CORPORATE COVERNANCE POLICIES OF THE BOARD OF DIRECTORS &#8211; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AUGUST 20 2021 &#8211; ADOPTED</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;10 of 10</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>7
<FILENAME>aimd_ex993.htm
<DESCRIPTION>CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS, ADOPTED AUGUST 20, 2021
<TEXT>
<html><head><title>aimd_ex993.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 99.3</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>AINOS, INC.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px"><strong>CHARTER</strong><strong> </strong><strong>OF</strong><strong> </strong><strong>THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS &#8211; </strong></p> <p style="margin:0px"><strong>ADOPTED AUGUST 20 2021 </strong></p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>1.0 </strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>PURPOSE OF THE COMMITTEE</strong></p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Audit Committee (the &#8220;<a name="_9kR3WTr24447CLJtizUK10x5H3p"></a><a name="_9kR3WTr24447HQJtizUK10x5H3p"><strong><em>Audit</em></strong></a><strong><em> Committee</em></strong>&#8221;) is appointed by the Board of Directors (the &#8220;<strong><em>Board</em></strong>&#8221;) of AINOS, INC., a Texas corporation (the &#8220;<strong><em>Company</em></strong>&#8221;), to act on behalf of the Board in fulfilling the Board&#8217;s oversight responsibilities with respect to the Company&#8217;s:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">corporate accounting and reporting practices and the quality and integrity of the Company&#8217;s consolidated financial statements;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">reports and systems of internal control over financial reporting (the &#8220;<a name="_9kR3WTr24446EWK2ut3nmPN5BGC7C"></a><a name="_9kR3WTr244489PK2ut3nmPN5BGC7C"><strong>Internal Controls</strong></a>&#8221;); and</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">qualifications, independence and performance of the Company&#8217;s independent registered public accounting firm engaged for the purposes of preparing or issuing an audit report or performing audit services (the &#8220;<a name="_9kR3WTr24446GQJtiz65A"></a><a name="_9kR3WTr24448BJJtiz65A"><strong><em>Auditors</em></strong></a>&#8221;).</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The policy of the Audit Committee in discharging these obligations shall be to maintain and foster an open avenue of communication between the Audit Committee, the <a name="_9kMHG5YVt3DE68FXM4wv5poPT3s9gfCs9RGJG">Internal Audit Executive</a> (as defined below) appointed by Audit Committee or other members of the Company&#8217;s internal audit department (the &#8220;<strong><em>Internal</em></strong><strong><em> Auditors</em></strong>&#8221;), the Auditors and the Company&#8217;s financial management. The Audit Committee shall also provide oversight in connection with legal, regulatory and ethical compliance programs as established by management and help the Board oversee the Company&#8217;s legal and regulatory compliance. The operation of the Audit Committee shall be subject to the <a name="_9kR3WTr26645DPO5iuD">Bylaws</a> of the Company as in effect from time to time and the <a name="_9kR3WTr26645EiMxuqSPD2yv1Gnh6qy7KD8HDJO">Texas Business Organizations</a> Law.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>2.0 </strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>AUTHORITY OF THE COMMITTEE</strong></p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In discharging its oversight role, the Audit Committee is empowered to investigate any matter brought to its attention as necessary and appropriate. The Audit Committee shall have authority to:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">appoint, determine compensation for, at the expense of the Company, and retain and oversee the Auditors as set forth in Section 10A(m)(2) of the Securities Exchange Act of 1934 and the rules thereunder and otherwise to fulfill its responsibilities under this <a name="_9kR3WTr26645FS8do8wv">Charter</a>;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS &#8211; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AUGUST 20 2021 &#8211; ADOPTED</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;1 of 9</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">retain and determine compensation for, at the Company&#8217;s expense, special legal, accounting or other advisors or consultants as it deems necessary or appropriate in the performance of its duties;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">pay, at the expense of the Company, ordinary administrative expenses that, as determined by the Audit Committee, are necessary or appropriate in carrying out its duties; and</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">without limitation, comply with Rule 10A-3(b)(2), (3), (4) and (5) under the Securities Exchange Act (the &#8220;<a name="_9kR3WTr24446FP1r"></a><a name="_9kR3WTr24448AI1r"><strong><em>Act</em></strong></a>&#8221;) (subject to the exemptions provided in Rule 10A-3(c) under the Act), concerning responsibilities relating to registered public accounting firms; complaints relating to accounting; internal accounting controls or auditing matters; authority to engage advisers; and funding.</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Audit Committee shall have full access to all books, records, facilities and personnel of the Company as deemed necessary or appropriate by any member of the Audit Committee to discharge his or her responsibilities hereunder. The Audit Committee shall have authority to require that any of the Company&#8217;s personnel, counsel, Auditors or Internal Auditors or investment bankers, or any other consultant or advisor to the Company, attend any meeting of the Audit Committee or meet with any of its special legal, accounting or other advisors and consultants for any matter within the Audit Committee purview. The Audit Committee may form and delegate authority to subcommittees when appropriate, or to one or more members of the Audit Committee.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The approval of this <a name="_9kMHG5YVt48867HUAfqAyx">Charter</a> by the Board shall be construed as a delegation of authority to the Audit Committee with respect to the responsibilities set forth herein.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>3.0 </strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>COMPOSITION OF COMMITTEE </strong></p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Audit Committee members shall meet the independence and experience requirements of The Nasdaq Stock Market LLC (&#8220;<strong><em>Nasdaq</em></strong>&#8221;) applicable to <a name="_9kMHG5YVt46669ENLvk1WM32z7J5r"></a><a name="_9kMHG5YVt46669JSLvk1WM32z7J5r">Audit Committee</a> members as in effect from time to time, when and as required by Nasdaq, as well as the rules and regulations of the Securities and Exchange Commission (the &#8220;<strong><em>SEC</em></strong>&#8221;) and applicable provisions of the Sarbanes-Oxley Act of 2002. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Audit Committee shall be comprised of at least three (3) <a name="_9kR3WTr266467PKmersrrjuAbL63p5IHM">&#8220;<strong><em>Independent Directors</em></strong></a>&#8221; (as defined under Nasdaq Rule 5605(a)(2)), one of whom shall serve as <a name="_9kR3WTr266468K8dfx5twB95">Chairperson</a>, and none of whom shall be an employee and each of whom shall be free from any relationship that would interfere with the exercise of his or her independent judgment, as determined by the Board, in accordance with Nasdaq requirements. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS &#8211; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AUGUST 20 2021 &#8211; ADOPTED</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;2 of 9</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">All members of the Audit Committee must (i) be an <a name="_9kMHG5YVt488689RMogtuttlwCdN85r7KJO">Independent Director</a>; (ii) meet the criteria for independence set forth in Rule 10A-3(b)(1) under the Act (subject to the exemptions provided in Rule 10A-3(c) under the Act); (iii) not have participated in the preparation of the financial statements of the Company or any current subsidiary of the Company at any time during the past three years; and (iv) be financially literate, meaning able to read and understand fundamental financial statements, including the Company&#8217;s balance sheet, income statement, and cash flow statement in accordance with listing standards. At least one member of the Audit Committee shall qualify as an &#8220;<a name="_9kMIH5YVt46669ENLvk1WM32z7J5r"></a><a name="_9kMIH5YVt46669JSLvk1WM32z7J5r">audit</a> committee financial expert&#8221; (as defined by the SEC from time to time).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The members of the Audit Committee and the <a name="_9kMIH5YVt48868AMAfhz7vyDB7">Chairperson</a> shall be appointed by the Board, on the recommendation of the <a name="_9kR3WTr266469NQxduC141JO5419L7t">Executive Committee</a>, and serve at the discretion of the Board in accordance with the Company&#8217;s <a name="_9kMHG5YVt48867FRQ7kwF">Bylaws</a>. Audit Committee members will serve such terms as the Board may fix. Vacancies occurring on the Audit Committee shall be filled by the Board.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>4.0</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>MEETINGS AND MINUTES</strong></p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>4.1</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>MEETINGS</em></strong>. The Audit Committee shall hold such regular or special meetings as its members shall deem necessary or appropriate, including by written consent. In addition, the Audit Committee should communicate with management and the Auditors quarterly to review the Company&#8217;s financial statements and significant findings based upon the Auditors&#8217; limited review procedures.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>4.2</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>MINUTES</em></strong>. Minutes of each meeting of the Audit Committee shall be kept and distributed to each member of the Audit Committee, CFO and the Secretary of the Company.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>5.0</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>RESPONSIBILITIES AND DUTIES</strong></p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Audit Committee shall oversee the Company&#8217;s financial reporting process (including direct oversight of the Auditors) on behalf of the Board, and shall have direct responsibility for the appointment, compensation, retention and oversight of the work of the Auditors and any other registered public accounting firm engaged for the purpose of performing other review or attest services for the Company. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Auditors and each such other registered public accounting firm shall report directly and be accountable to the Audit Committee. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Audit Committee&#8217;s functions and procedures should remain flexible to address changing circumstances most effectively. To implement the Audit Committee&#8217;s purpose and policy, the Audit Committee shall be charged with the functions and processes described below, with the understanding, however, that the Audit Committee may supplement or (except as otherwise required by law or the applicable rules) deviate from these activities as appropriate under the circumstances.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS &#8211; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AUGUST 20 2021 &#8211; ADOPTED</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;3 of 9</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>5.1 </strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>REVIEW PROCEDURES</strong></p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">5.1.1</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Review and assess the adequacy of this Charter, annually in accordance with Nasdaq rules and regulations. Submit the Charter or any recommendations of proposed changes to the Board for approval.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">5.1.2</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Review and recommend to the Board, upon completion of the annual audit, the financial statements, any internal controls report, and as appropriate, &#8220;Risk Factors&#8221; to be included in the Company&#8217;s Annual Report on Form 10-K and any internal controls report. Review should include oversight of the Auditors&#8217; assessment of the quality, not just acceptability, of accounting principles, the reasonableness of significant judgments and estimates (including material changes in estimates), the nature of significant risks and exposures, any audit adjustments noted or proposed by the Auditors (whether &#8220;passed&#8221; or implemented in the financial statements), the adequacy of the disclosures in the financial statements and any other matters required to be communicated to the Audit Committee by the Auditors.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">5.1.3</p></td> <td style="vertical-align:top;"> <p style="margin:0px">In consultation with the management, the Internal Auditors and the Auditors, review the Company&#8217;s guidelines and policies with respect to risk assessment, risk management and internal financial and disclosure controls.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">5.1.4</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Discuss with management and the Auditors the results of the Auditors&#8217; review of the Company&#8217;s quarterly financial statements, prior to public disclosure of quarterly financial information, if practicable, or filing with the SEC of the Company&#8217;s Quarterly Report on Form 10-Q, and any other matters required to be communicated to the Audit Committee by the Auditors under applicable standards.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">5.1.5</p></td> <td style="vertical-align:top;"> <p style="margin:0px">To review generally with management and the Auditors, as appropriate, earnings press releases, as well as the substance of financial information and earnings outlook provided to analysts and ratings agencies. The Chairperson of the Audit Committee may represent the entire Audit Committee for purposes of this discussion.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">5.1.6</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Review periodically, either individually or as a committee and discuss with management and the Auditors, as appropriate, the Company&#8217;s disclosures contained under the caption &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in its periodic reports to be filed with the SEC.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS &#8211; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AUGUST 20 2021 &#8211; ADOPTED</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;4 of 9</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">5.1.7</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Review with management, the Internal Auditors and the Auditors significant issues that arise regarding accounting principles and financial statement presentation, including the adoption of new, or material changes to existing, critical accounting policies or to the application of those policies, the potential effect of alternative accounting policies available under GAAP, the potential impact of regulatory and accounting initiatives, any off-balance sheet structures and any other significant reporting issues and judgments.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>5.2</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>INDEPENDENT AND INTERNAL AUDITORS</em></strong></p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">5.2.1</p></td> <td style="vertical-align:top;"> <p style="margin:0px">The Auditors are ultimately accountable to the Audit Committee and Board as representatives of the Company&#8217;s stockholders. The Audit Committee shall review the independence and performance of the Auditors (including the Auditor&#8217;s lead partner) and annually select the Auditors or approve any discharge of Auditors when circumstances warrant.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">5.2.2</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Review and determine the engagement of the Auditors, including the scope of and plans for the audit, the adequacy of staffing and the compensation to be paid to the Auditors.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">5.2.3</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Review and approve the retention of Auditors to perform any proposed permissible non-audit services, including the compensation to be paid therefor, authority for which may be delegated to one or more Audit Committee members, provided that to the extent provided by law all approvals of non-audit services pursuant to this delegated authority be presented to the full Audit Committee at its next meeting.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">5.2.4</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Monitor the rotation of the partners of the Auditors on the Company&#8217;s audit engagement team as required by applicable law and to consider periodically, if deemed appropriate, adopting a policy regarding rotation of auditing firms.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">5.2.5</p></td> <td style="vertical-align:top;"> <p style="margin:0px">On an annual basis, consistent with applicable rules and requirements of the Public Company Accounting Oversight Board (United States) (the &#8220;<strong><em>PCAOB</em></strong>&#8221;), receive and review written disclosures from the Auditors delineating all relationships between the Auditors, or their affiliates, and the Company, or persons in financial oversight roles at the Company, that may reasonably be thought to bear on independence and a letter from the Auditors affirming their independence, to consider and discuss with the Auditors any potential effects of any such relationships on the independence of the Auditors as well as any compensation or services that could affect the Auditors&#8217; objectivity and independence, and to assess and otherwise take appropriate action to oversee the independence of the Auditors.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS &#8211; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AUGUST 20 2021 &#8211; ADOPTED</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;5 of 9</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">5.2.6 </p></td> <td style="vertical-align:top;"> <p style="margin:0px">At least annually, to discuss with the Auditors the matters required to be discussed by Auditing Standard No. 1301 and 2410, <em>Communications with Audit Committees and Related Parties</em>, adopted by the PCAOB and any other matters required to be discussed by any other applicable rules or requirements of the PCAOB (including any successor rule adopted by the PCAOB), including any fraud or illegal acts.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">5.2.7 </p></td> <td style="vertical-align:top;"> <p style="margin:0px">Review the audit plans of the Company&#8217;s Internal Auditors, discuss scope, staffing, compensation, locations, reliance upon management and general audit approach and any significant reports prepared by the Internal Auditors as well as management&#8217;s responses, approve the hiring and dismissal of an executive officer responsible for coordinating the internal audit (the &#8220;<strong><em>Internal Audit Executive</em></strong>&#8221;), to review periodically the Internal Auditors&#8217; function to ensure that the function has guidelines that allow it to operate effectively, and ensure that the Internal Audit Executive (and those reporting to the Internal Audit Executive on internal audit matters) has access to the Company&#8217;s records as necessary to permit the function to operate effectively.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">5.2.8</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Consider the Auditors&#8217; judgments about the quality and appropriateness of the Company&#8217;s staffing and accounting principles as applied in its financial reporting.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">5.2.9</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Review with the Auditors any management or internal control letter issued or, to the extent practicable, proposed to be issued by the Auditors and management&#8217;s response, if any, to such letter, as well as any additional material written communications between the Auditors and management, and to confer with the senior management of the Company and the Auditors, as appropriate, regarding any deficiencies, the scope, adequacy and effectiveness of internal control over financial reporting.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">5.2.10</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Consider and review with management, the Internal Auditors and Auditors, outside counsel, as appropriate, and, in the judgment of the Audit Committee, such special counsel, separate accounting firm and other consultants and advisors as the Audit Committee deems appropriate, any correspondence with regulators or governmental agencies, litigation or legal matters that could have a significant impact on the Company&#8217;s financial results and any published reports that raise material issues regarding the Company&#8217;s financial statements or accounting policies.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS &#8211; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AUGUST 20 2021 &#8211; ADOPTED</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;6 of 9</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">5.2.11</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Review with the Auditors and management, and ultimately resolve, any conflicts or disagreements between management and the Auditors regarding financial reporting, accounting practices or policies and review with the Auditors any difficulties the Auditors encountered in the course of the audit work, including restrictions on the scope of work or access to requested information.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">5.2.12</p></td> <td style="vertical-align:top;"> <p style="margin:0px">To review with the Auditors, as appropriate, material communications between the audit team and the Auditors&#8217; national office with respect to accounting or auditing issues presented by the engagement.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">5.2.13</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Meet periodically in separate sessions as an Audit Committee and meet periodically with the Auditors, senior management and the Internal Audit Executive to discuss any matters that the Audit Committee, the Auditors, senior management or the Internal Audit Executive believe should be privately discussed.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">5.2.14</p></td> <td style="vertical-align:top;"> <p style="margin:0px">To ensure receipt from the Auditors of a formal written statement delineating all relationships between the Auditor and the Company, actively engaging in a dialogue with the Auditor with respect to any disclosed relationships or services that may impact the objectivity and independence of the Auditor and for taking, or recommending that the full Board take, appropriate action to oversee the independence of the Auditor.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>5.3</strong> </p></td> <td style="vertical-align:top;"> <p style="margin:0px"><em><strong>LEGAL COMPLIANCE AND RISK MANAGEMENT</strong></em></p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">5.3.1</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Establish procedures for the receipt, retention and treatment of complaints received by the Company regarding accounting, internal accounting controls or auditing matters, including the confidential and anonymous submission by employees of concerns regarding questionable accounting or auditing matters as required by applicable law and as deemed appropriate.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">5.3.2</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Investigate any matter brought to the attention of the Audit Committee within the scope of its duties if, in the judgment of the Audit Committee, such investigation is necessary or appropriate. The Chairperson of the Audit Committee may represent the entire Audit Committee in making such determination.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">5.3.3</p></td> <td style="vertical-align:top;"> <p style="margin:0px">In conjunction with the Executive Committee, review on a periodic basis with senior management any proposed revisions to, and compliance with, the Company&#8217;s Code of Conduct and Code of Ethics for Senior Financial Officers (as defined by the US Securities and Exchange Commission).</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS &#8211; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AUGUST 20 2021 &#8211; ADOPTED</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;7 of 9</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">5.3.4 </p></td> <td style="vertical-align:top;"> <p style="margin:0px">Review and discuss with management the Auditors. the Company&#8217;s processes and policies on risk identification, management and assessment in all areas of the Company&#8217;s business, including financial and accounting. Areas of focus shall include but not be limited to the Company&#8217;s policies and other matters relating to the Company&#8217;s investments, cash management and foreign exchange management, major financial risk exposures, the adequacy and effectiveness of the Company&#8217;s information security policies and practices and the internal controls regarding information security, and the steps taken by management to monitor and mitigate or otherwise control these exposures and to identify future risks. </p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>5.4<em> </em></strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><em><strong>OTHER RESPONSIBILITIES</strong></em></p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">5.4.1</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Annually prepare a report to stockholders as required by the SEC and to be included in the Company&#8217;s proxy statement.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">5.4.2</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Report to the Board with respect to material issues that arise regarding the quality or integrity of the Company&#8217;s financial statements, the Company&#8217;s compliance with legal or regulatory requirements, the performance or independence of the Auditors, the performance of the Company&#8217;s internal audit functions or such other matters as the Audit Committee deems appropriate from time to time or whenever it shall be called upon to do so.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">5.4.3</p></td> <td style="vertical-align:top;"> <p style="margin:0px">The Audit Committee shall review, discuss and assess its own performance as well as the Audit Committee&#8217;s role and responsibilities as outlined in this Charter annually.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">5.4.4</p></td> <td style="vertical-align:top;"> <p style="margin:0px">The Audit Committee shall review this Charter annually and file an annual certification by the Company with respect to its annual review with applicable regulatory authorities.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">5.4.5</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Perform any other activities consistent with this Charter, the Company&#8217;s Bylaws, and governing law, as the Audit Committee or the Board deems necessary or appropriate. Perform such other functions and to have such powers as may be necessary or appropriate in the efficient and lawful discharge of the foregoing.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS &#8211; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AUGUST 20 2021 &#8211; ADOPTED</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;8 of 9</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>6.0 </strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>MANAGEMENT RESPONSIBILITIES</strong></p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">It shall be the responsibility of management to (1) make and keep books, records and accounts, which, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company, (2) devise and maintain an effective system of internal accounting controls, (3) devise and maintain effective disclosure controls and procedures and <a name="_9kMML5YVt46668GYM4wv5poRP7DIE9E"></a><a name="_9kMML5YVt4666ABRM4wv5poRP7DIE9E">internal controls</a> over financial reporting and (4) prepare financial statements that are accurate and complete and fairly present the financial condition, results of operations and cash flows of the Company, and further does not relieve the independent <a name="_9kMHG5YVt46668ISLvk187C"></a><a name="_9kMHG5YVt4666ADLLvk187C">auditors</a> of their responsibilities relating to the audit or review of financial statements. These functions shall neither be the responsibility of the Audit Committee, nor shall it be the Audit Committee&#8217;s responsibility to ensure that the financial statements or periodic reports are complete and accurate, conform to generally accepted accounting principles or otherwise comply with applicable laws.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>7.0 </strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>ADOPTIONS, REVIEWS AND REVISIONS </strong></p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of July 30, 2021 &#8211; No prior policy</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Adopted &#8211; August 20, 2021</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS &#8211; </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AUGUST 20 2021 &#8211; ADOPTED</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page 9 of 9</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>8
<FILENAME>aimd_ex994.htm
<DESCRIPTION>CHARTER OF THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS, ADOPTED AUGUST 20, 2021
<TEXT>
<html><head><title>aimd_ex994.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 99.4</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>AINOS, INC.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;"><strong>CHARTER</strong><strong> </strong><strong>OF</strong><strong> </strong><strong>THE COMPENSATION COMMITTEE OF THE BOARD OF </strong></p> <p style="MARGIN: 0px; text-align:justify;"><strong>DIRECTORS &#8211; ADOPTED AUGUST 20 2021 </strong></p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>1.0 </strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>PURPOSE OF THE COMMITTEE</strong></p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The purpose of the Compensation Committee (the &#8220;<a name="_9kR3WTr24445FSFwvs0Cyk"></a><a name="_9kR3WTr24446BNFwvs0Cyk"><strong><em>Committee</em></strong></a>&#8221;) of the Board of Directors (the &#8220;<strong><em>Board</em></strong>&#8221;) of AINOS, INC., a Texas corporation (the &#8220;<a name="_9kR3WTr244467JFwynmB"><strong><em>Company</em></strong></a>&#8221;), shall be to act on behalf of the Board in:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">determining and approving the compensation of the Company&#8217;s Chief Executive Officer;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">reviewing and approving compensation for the Company&#8217;s other executive officers and senior management, including those classified by the Company as officers for purposes of Securities and Exchange Commission (the &#8220;<strong><em>SEC</em></strong>&#8221;) rules under Section 16 of the Securities Exchange Act (the &#8220;<strong><em>Act</em></strong>&#8221;);</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">reviewing and recommending to the Board compensation for the Company&#8217;s directors;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">reviewing and discussing with management the Company&#8217;s <a name="_9kR3WTr266458LFwyrq5tv406WM836NMDAG348W">C</a>ompensation Discussion and Analysis (&#8220;<strong><em>CD&amp;A</em></strong>&#8221;) to be included in the Company&#8217;s proxy statements and annual reports on Form 10-K;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">preparing the annual <a name="_9kR3WTr26646COFwyrq5tv406VR874COAw">Compensation </a><a name="_9kMHG5YVt46668DPHyxu2E0m">Committee</a> report for inclusion into the Company&#8217;s proxy statements and annual reports on Form 10-K;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">fulfilling the Board&#8217;s oversight responsibilities with respect to the Company&#8217;s overall compensation policies, plans and programs; and</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">performing other activities related to the Company&#8217;s compensation plans and structure<a name="_9kR3WTr5DA468"></a><a name="_9kR3WTr5DA469">.</a> The term &#8220;compensation&#8221; shall include salary, long-term incentives, variable compensation, perquisites, equity incentives, severance arrangements and employee benefit plans, including but not limited to retirement/401(k), health, welfare, disability, deferred compensation plans and any other rights or compensation received under the Company&#8217;s compensation and employee benefit plans.</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. CHARTER OF THE COMPENSATION COMMITTEE OF THE BOARD OF </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">DIRECTORS &#8211; ADOPTED AUGUST 20 2021 </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;1 of 8</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>2.0</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>AUTHORITY OF THE COMMITTEE</strong></p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>2.1</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Full Access</em></strong>. The Committee shall have full access to all books, records, facilities and personnel of the Company as deemed necessary or appropriate by any member of the Committee to discharge his or her responsibilities hereunder, including human resources personnel preparing the CD&amp;A for use in the Company&#8217;s annual reports on Form 10-K, registration statements, proxy statements or information statements for the Company reports to be filed with the SEC.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>2.2</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Authority to Obtain Advice and Retain Advisors</em></strong>. The Committee shall have the authority to obtain advice and assistance from internal or external legal, accounting or other advisors. In addition, the Committee shall have authority to retain and terminate any compensation consultant to assist in the evaluation of director, executive officer or senior management compensation, including authority to approve such reasonable consultant&#8217;s fees and other retention terms, all at the Company&#8217;s expense. Such compensation consultants, independent legal counsel or other advisors and consultants shall report directly, and be accountable, to the Committee. The Committee shall recommend to the Board for its approval expenditures for external resources that are expected to be material and outside the ordinary course of the Committee&#8217;s practices.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>2.3</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Delegation of Authority</em></strong>. The Committee may form and delegate authority to subcommittees as appropriate, including, but not limited to, a subcommittee composed of one or more members of the Committee to grant stock awards under the Company&#8217;s equity incentive plans to persons who are not then subject to the Act.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>2.4</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Specific Responsibilities and Authority</em></strong>. Without limiting the generality of this section, pursuant to Rule 10C-1(b)(2), (3) and (4)(i)-(vi) under the Act, the Committee shall have the following specific responsibilities and authority:</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">2.4.1</p></td> <td style="vertical-align:top;"> <p style="margin:0px">In its sole discretion, retain or obtain the advice of a compensation consultant, legal counsel or other advisers.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">2.4.2</p></td> <td style="vertical-align:top;"> <p style="margin:0px">The Committee shall be directly responsible for the appointment, compensation and oversight of the work of any compensation consultant, legal counsel and other adviser retained by the Committee.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">2.4.3</p></td> <td style="vertical-align:top;"> <p style="margin:0px">The Company must provide for appropriate funding, as determined by the Committee, for payment of reasonable compensation to a compensation consultant, legal counsel or any other adviser retained by the Committee.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. CHARTER OF THE COMPENSATION COMMITTEE OF THE BOARD OF </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">DIRECTORS &#8211; ADOPTED AUGUST 20 2021 </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;2 of 8</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">2.4.4</p></td> <td colspan="2" style="vertical-align:top;"> <p style="margin:0px">The Committee may select, or receive advice from, a compensation consultant, legal counsel or other adviser to the Committee, other than in-house legal counsel, only after taking into consideration the following factors:</p></td></tr> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:5%;"> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">2.4.4.1</p></td> <td style="vertical-align:top;"> <p style="margin:0px">the provision of other services to the Company by the person that employs the compensation consultant, legal counsel or other adviser;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">2.4.4.2</p></td> <td style="vertical-align:top;"> <p style="margin:0px">the amount of fees received from the Company by the person that employs the compensation consultant, legal counsel or other adviser, as a percentage of the total revenue of the person that employs the compensation consultant, legal counsel or other adviser;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">2.4.4.3</p></td> <td style="vertical-align:top;"> <p style="margin:0px">the policies and procedures of the person that employs the compensation consultant, legal counsel or other adviser that are designed to prevent conflicts of interest;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">2.4.4.4</p></td> <td style="vertical-align:top;"> <p style="margin:0px">any business or personal relationship of the compensation consultant, legal counsel or other adviser with a member of the Committee;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">2.4.4.5</p></td> <td style="vertical-align:top;"> <p style="margin:0px">any stock of the Company owned by the compensation consultant, legal counsel or other adviser; and</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">2.4.4.6</p></td> <td style="vertical-align:top;"> <p style="margin:0px">any business or personal relationship of the compensation consultant, legal counsel, other adviser or the person employing the adviser with an executive officer of the Company.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>2.5</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Determination of Independence of Advisors</em></strong>. Before engaging, or receiving advice from, a compensation consultant, external legal counsel or any other advisor, the Committee shall consider the independence of each such advisor by taking into account the following factors and any other factors required by The Nasdaq Stock Market LLC (&#8220;<strong><em>Nasdaq</em></strong>&#8221;) or the SEC and corresponding rules that may be amended from time to time, including any exceptions permitted by such rules:</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:5%;vertical-align:top;"> <p style="margin:0px">2.5.1</p></td> <td style="vertical-align:top;"> <p style="margin:0px">the provision of other services to the Company by the employer of the compensation consultant, counsel or other advisor (the &#8220;<strong><em>Advisory Firm</em></strong>&#8221;);</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. CHARTER OF THE COMPENSATION COMMITTEE OF THE BOARD OF </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">DIRECTORS &#8211; ADOPTED AUGUST 20 2021 </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;3 of 8</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:5%;vertical-align:top;"> <p style="margin:0px">2.5.2</p></td> <td style="vertical-align:top;"> <p style="margin:0px">the amount of fees received from the Company by the Advisory Firm, as a percentage of the Advisory Firm&#8217;s total revenue;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">2.5.3</p></td> <td style="vertical-align:top;"> <p style="margin:0px">the Advisory Firm&#8217;s policies and procedures that are designed to prevent conflicts of interest;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">2.5.4</p></td> <td style="vertical-align:top;"> <p style="margin:0px">any business or personal relationship of the compensation consultant, counsel or other advisor with a member of the Committee;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">2.5.5</p></td> <td style="vertical-align:top;"> <p style="margin:0px">any stock of the Company owned by the compensation consultant, counsel or other advisor;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">2.5.6</p></td> <td style="vertical-align:top;"> <p style="margin:0px">any business or personal relationship between an executive officer of the Company and the compensation consultant, counsel, other advisor or the Advisory Firm; and</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">2.5.7</p></td> <td style="vertical-align:top;"> <p style="margin:0px">The Committee shall review and discuss with management any conflicts of interest raised by the work of a compensation consultant or advisor retained by the Committee or management and how such conflict is being addressed, and prepare any necessary disclosure in the Company&#8217;s annual proxy statement in accordance with applicable SEC rules and regulations.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>3.0</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>COMPOSITION OF COMMITTEE</strong></p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>3.1</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Membership</em></strong>. The Committee shall be comprised of at least two (2) members of the Board.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>3.2</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong><em>Independence of Members</em></strong>. Each member of the Committee shall satisfy:</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">3.2.1</p></td> <td style="vertical-align:top;"> <p style="margin:0px">the independence requirements of Nasdaq applicable to compensation committees and members, as in effect from time to time, when and as required by Nasdaq and be free from any relationship that would interfere with the exercise of his or her independent judgment, as determined by the Board;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">3.2.2</p></td> <td style="vertical-align:top;"> <p style="margin:0px">the &#8220;non-employee director&#8221; standard within the meaning of Rule 16b-3 promulgated under the Act; and</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. CHARTER OF THE COMPENSATION COMMITTEE OF THE BOARD OF </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">DIRECTORS &#8211; ADOPTED AUGUST 20 2021 </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;4 of 8</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">3.2.3</p></td> <td style="vertical-align:top;"> <p style="margin:0px">any other requirements imposed by other applicable laws.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>3.3</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>Affirmative Determination of Independence</strong>. The Board shall affirmatively determine the independence of any director who will serve on the Compensation Committee considering all factors specifically relevant to determining whether a director has a relationship to the Company which is material to that director&#8217;s ability to be independent from management in connection with the duties of a compensation committee member, including, but not limited to:</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">3.3.1</p></td> <td style="vertical-align:top;"> <p style="margin:0px">the source of compensation of such director, including any consulting, advisory or other compensatory fee paid by the Company to such director; and</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">3.3.2</p></td> <td style="vertical-align:top;"> <p style="margin:0px">whether such director is affiliated with the Company, a subsidiary of the Company or an affiliate of a subsidiary of the Company.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>3.4</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>Appointment and Removal</strong>. The members of the Committee and the Committee&#8217;s Chairperson shall be appointed by the Board, on the recommendation of the Executive Committee of the Board of Directors as defined in the Company&#8217;s Corporate Governance Policies, and serve at the discretion of the Board in accordance with the Company&#8217;s Bylaws. Committee members will serve such terms as the Board may fix. Vacancies occurring on the Committee shall be filled by the Board.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>3.5</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>Succession Planning</strong>. At least annually, the Committee will consider and assist the Board in developing succession plans for the CEO and other key executive officers and appropriate management personnel.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>4.0</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>MEETINGS AND MINUTES</strong></p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>4.1</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>Meetings</strong>. The Committee will hold such regular and special meetings as its members deem necessary or appropriate. Each independent director may attend any meeting of the Committee, except for portions of the meetings where his or her presence would be inappropriate, as determined by the Committee. The Chief Executive Officer may attend at the invitation of the Committee.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>4.2</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>Minutes and Reports</strong>. Minutes of each meeting of the Committee shall be kept and distributed to each member of the Committee and members of the Board who are not members of the Committee. The Chairperson of the Committee shall report to the Board from time to time, or whenever so requested by the Board.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. CHARTER OF THE COMPENSATION COMMITTEE OF THE BOARD OF </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">DIRECTORS &#8211; ADOPTED AUGUST 20 2021 </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;5 of 8</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>5.0 </strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>COMMITTEE DUTIES</strong></p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Committee&#8217;s procedures should remain flexible to address changing circumstances most effectively<a name="_9kMHzG6ZWu8GD79B"></a><a name="_9kMHzG6ZWu8GD79C">.</a> Accordingly, the Committee may supplement and, except as otherwise required by applicable law or the requirements of Nasdaq, deviate from these activities as appropriate under the circumstances:<a name="1._CEO_Compensation.__The_Committee_shal"></a></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>5.1 </strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>CEO Compensation</strong>. The Committee shall review, modify (as needed) and approve, in its sole discretion, the salary, variable compensation, equity compensation and any other compensation and terms of employment of the Company&#8217;s Chief Executive Officer, at least annually based on performance. In determining the compensation of the Chief Executive Officer, the Committee shall consider the Company&#8217;s short-term and long-term performance goals and metrics to measure achievement of such goals, in light of the Committee&#8217;s determination of the appropriate means of retaining and motivating the Chief Executive Officer. The Committee should also consider the Company&#8217;s results and relative stockholder return, the value of similar incentive awards given to chief executive officers of comparable companies and awards given to the Company&#8217;s Chief Executive Officer in past years. The Chief Executive Officer may not be present during the voting or deliberations regarding his compensation.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>5.2 </strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>Compensation of Other Executive Officers and Other Senior Management</strong>. The Committee shall review, modify (as needed) and approve the salary levels, variable compensation plans, and structures and payments thereunder and other forms of compensation policies, plans and programs for other executive officers and other senior management of the Company, at least annually based on performance, including:</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">5.2.1</p></td> <td style="vertical-align:top;"> <p style="margin:0px">reviewing and approving corporate performance goals, the structure and method for determining the terms of overall executive variable compensation or other compensatory plans, method of determination of individual goals for executives and other senior management thereunder, and payment of individual executive variable compensation to the extent such variable compensation contains a discretionary component; and</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">5.2.2</p></td> <td style="vertical-align:top;"> <p style="margin:0px">reviewing national and industry-wide executive compensation practices and trends to assess the adequacy and competitiveness of the Company&#8217;s executive compensation programs among comparable peer group companies, as well as the appropriateness of such programs.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. CHARTER OF THE COMPENSATION COMMITTEE OF THE BOARD OF </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">DIRECTORS &#8211; ADOPTED AUGUST 20 2021 </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;6 of 8</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>5.3</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>Risk Management</strong>. The Committee shall review the Company&#8217;s practices and policies of employee compensation as they relate to risk management and risk-taking incentives, to determine whether such compensation policies and practices are reasonably likely to have a material adverse effect on the Company.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>5.4</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>Advisory Votes</strong>. The Committee shall review and consider the results of any advisory vote on executive compensation.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>5.5</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>Overall Company Compensation</strong>. The Committee shall review, modify (as needed) and approve the Company&#8217;s overall compensation plans and structure, including reviewing the Company&#8217;s overall compensation philosophy, evaluating and approving the compensation plans and programs for the Company, modifying or terminating existing plans and programs, and reviewing and establishing equity and variable compensation programs.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>5.6</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>Independent Director Compensation</strong>. The Committee shall review and recommend to the Board the compensation for independent Board members, including any retainer, committee and committee chair fees and/or equity compensation. Such recommendation shall take into account national and industry-wide compensation practices and trends and a comparison of the Company&#8217;s compensation programs among comparable companies as well as the appropriateness of such programs in light of corporate governance standards and the Committee&#8217;s determination of the appropriate method of motivating independent Board members.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>5.7</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>Administration of Benefit Plans</strong>. The Committee shall have full power and authority to administer the Company&#8217;s stock option plans, stock appreciation rights plans, stock purchase plans, variable compensation plans, including the adoption, amendment and termination of such plans and any sub-plans thereof, putting forth such plans or amendments before the Company&#8217;s stockholders for approval, approving any SEC filings needed in order to register the shares under any such plans, establishing guidelines, interpreting plan documents, selecting participants, approving grants and awards, and exercising such other power and authority as may be permitted or required under such plans. The Committee shall have full power and authority to provide oversight of any employee benefit plans subject to ERISA, including but not limited to retirement/401(k), deferred compensation plans, health, welfare, and disability plans and to delegate its legal obligations with respect to the employee benefit plans subject to ERISA to subcommittees, officers or employees of the Company as permitted by the terms as such plans and applicable law. Notwithstanding the foregoing, the Board shall retain the right to act on all such matters without limiting the Committee&#8217;s authority.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. CHARTER OF THE COMPENSATION COMMITTEE OF THE BOARD OF </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">DIRECTORS &#8211; ADOPTED AUGUST 20 2021 </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;7 of 8</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><strong>5.8</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>Compensation Discussion and Analysis</strong>. The Committee shall review and discuss with management the Company&#8217;s disclosures contained under the caption &#8220;Compensation Discussion and Analysis&#8221; and make recommendations to the Board that the CD&amp;A be approved for inclusion in the Company&#8217;s annual reports on Form 10-K, registration statements, proxy statements or information statements, as may be required under applicable SEC rules.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>5.9</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>Committee Report</strong>. The Committee shall prepare and review the Committee report on executive compensation to be included in the Company&#8217;s annual proxy statement in accordance with applicable SEC rules and regulations.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>5.10</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>Committee Self-Assessment and Charter</strong>. The Committee shall review, discuss and assess at least annually its own performance, as well as the Committee&#8217;s role and responsibilities as outlined in this Charter. The Committee shall also review and reassess annually the adequacy of this Charter and shall submit any suggested changes to the Charter to the Board for its consideration.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>6.0</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>COMPENSATION PROPOSALS</strong>. The Committee shall provide recommendations to the Board on compensation-related proposals to be considered at the Company&#8217;s annual meeting, including the frequency of advisory votes on executive compensation.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>7.0</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>OTHER DUTIES</strong>. The Committee shall perform such other functions and have such other powers as may be necessary or convenient in the efficient discharge of the foregoing.</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>8.0</strong></p></td> <td style="vertical-align:top;"> <p style="margin:0px"><strong>ADOPTIONS, REVIEWS AND REVISIONS</strong></p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">As of July 30, 2021 &#8211; No prior policy</p> <p style="MARGIN: 0px; text-align:justify;">Adopted &#8211; August 20, 2021</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px">AINOS, INC. CHARTER OF THE COMPENSATION COMMITTEE OF THE BOARD OF </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">DIRECTORS &#8211; ADOPTED AUGUST 20 2021 </p> <p style="font-size:10pt;font-family:times new roman;margin:0px">Page&nbsp;8 of 8</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.5
<SEQUENCE>9
<FILENAME>aimd_ex995.htm
<DESCRIPTION>INSIDER TRADING POLICY OF THE BOARD OF DIRECTORS, AS AMENDED AND ADOPTED AUGUST 20, 2021
<TEXT>
<html><head><title>aimd_ex995.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: left; FONT: 10pt times new roman"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 99.5</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>AINOS, INC.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="MARGIN: 0px; text-align:left;"><strong>INSIDER TRADING POLICY OF THE BOARD OF DIRECTORS &#8211; ADOPTED </strong><strong>AUGUST 20 2021 </strong></p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>1.0 PURPOSES OF THE POLICY</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Anyone who has knowledge of material nonpublic information may be considered an &#8220;Insider&#8221; for purposes of the federal securities laws prohibiting insider trading. As a result, it is a violation of the policy of AINOS, INC., a Texas corporation (the <strong><em>&#8220;Company</em></strong>&#8221;) and the federal securities laws for any Covered Person, as defined in this Policy to (a) trade in securities of the Company while aware of &#8220;material nonpublic information&#8221; concerning the Company or (b) communicate, &#8220;tip&#8221; or disclose material nonpublic information to outsiders so that they may trade in securities of the Company based on that information. To prevent even the appearance of improper insider trading or tipping, the Company has adopted this Insider Trading Policy <em>(</em>the <strong><em>&#8220;Policy&#8221;</em></strong><em>)</em> for applicable Covered Persons including, but not limited to, all of its directors, officers and employees and their family members, as well as for others who have access to information through business relationships with the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">The consequences of prohibited insider trading or tipping can be severe. Violation of this Policy by any officer or employee may result in disciplinary action by the Company up to and including immediate termination for cause. Moreover, persons violating insider trading or tipping rules may be required to:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">disgorge the profit made or the loss avoided by the trading, whether received by the insider or someone receiving a tip;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">pay significant civil penalties; and</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">pay a criminal penalty and serve time in jail.</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">In addition to individual sanctions, the Company may also be required to pay civil or criminal penalties.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>2.0 SCOPE OF THE POLICY</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>2.1 Covered Persons</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">This Policy covers all directors, officers and employees of the Company and their respective family members and any outsiders whom the Insider Trading Compliance Officer (defined below) may designate as Insiders because they have access to material nonpublic information concerning the Company (Insiders).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:left;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">AINOS, INC.</p> <p style="margin:0px">INSIDER TRADING POLICY &#8211; ADOPTED AUGUST 20 2021 </p> <p style="margin:0px">Page 1 of 11</p></td></tr></table> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>2.2 Covered Transactions</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">The Policy applies to any and all transactions in the Company&#8217;s securities. For purposes of the Policy, the Company&#8217;s securities include its common stock, options to purchase or sell common stock and any other type of securities that the Company may issue, such as preferred stock, convertible debentures, warrants and exchange-traded options or other derivative securities and short sales (collectively, &#8220;Company Securities&#8221;). Transactions in Company Securities include not only market transactions, but also private sales of Company Securities, pledges of Company Securities to secure a loan or margin account, as well as charitable donations of Company Securities.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>2.3 Policy Delivery</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">The Policy will be delivered to all directors, officers and employees and other designated persons. Upon first receiving a copy of the Policy or any revised versions, each recipient must sign an acknowledgment that he or she has received a copy of the Policy and agrees to comply with the Policy&#8217;s terms.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>3.0 SECTION 16 PERSONS AND DESIGNATED EMPLOYEES</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>3.1 Section 16 Persons</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Each member of the Company&#8217;s Board of Directors (&#8220;Board&#8221;) and those officers of the Company designated by the Board to be Section 16 officers of the Company are subject to the reporting provisions and trading restrictions of Section 16 of the Securities Exchange Act of 1934 and the underlying rules and regulations promulgated by the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) (&#8220;Section 16 Persons&#8221;). Section 16 Persons must obtain prior approval of all trades in Company Securities from the Company&#8217;s Compliance Officer in accordance with the procedures set below.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a name="A0Q5F4Y1Z1"></a>Note that the Exchange Act Section 16(a) requires directors, officers and any beneficial owners of more than 10 percent of a class of the issuer&#8217;s registered equity securities to file ownership reports with the SEC, and Section 16(b) imposes liability for short-swing trading on these persons.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>3.2 Designated Employees</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">In addition to Section 16 Persons, the Compliance Officer may designate additional officers and employees as &#8220;Designated Employees.&#8221; Designated Employees are those officers or employees or outside consultants or contractors that the Company considers, because of their duties, to have regular access to material nonpublic information. In addition to the Policy&#8217;s general proscription against insider trading or tipping, Designated Employees must comply with additional trading restrictions detailed below.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px 0px 0px 0in">AINOS, INC.</p> <p style="margin:0px 0px 0px 0in">INSIDER TRADING POLICY &#8211; ADOPTED AUGUST 20 2021 </p> <p style="margin:0px 0px 0px 0in">Page&nbsp;2 of 11</p></td></tr></table> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a name="IV._Definition_of_''Material_Nonpublic_I"></a><strong>4.0 DEFINITION OF &#8220;MATERIAL NONPUBLIC INFORMATION&#8221;</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>4.1 &#8220;Material&#8221; Information</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#8220;Material Information&#8221; is any information about the Company that a reasonable investor would consider important in making an investment decision to buy or sell the Company&#8217;s Securities. If an investor would want to buy or sell securities based in part on the information, the information should be considered material. In simple terms, material information is any type of information that could reasonably be expected to affect the price of Company Securities. While it is not possible to identify all information that would be deemed &#8220;material,&#8221; the following types of information ordinarily would be considered material:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">financial performance, especially quarterly and year-end earnings;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">significant changes in financial performance outlook or liquidity of the Company as a whole or of a reporting segment of the Company&#8217;s business;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">company projections that significantly differ from external expectations;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">potential mergers and acquisitions or the sale of significant Company assets or subsidiaries;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">new major contracts, orders, suppliers, customers or finance sources, or the loss thereof;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">major discoveries or significant changes or developments in products or product lines, research or technologies;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">approvals or denials of requests for regulatory approval by government agencies of products, patents or trademarks;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">significant changes or developments in supplies or inventory, including significant product defects, recalls or product returns;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">significant pricing changes;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">stock splits, public or private securities/debt offerings or changes in Company dividend policies or amounts;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">significant changes in management;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">significant labor disputes or negotiations, including possible strikes;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">actual or potential exposure to major litigation, or the resolution of such litigation;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">possible proxy contests;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">imminent or potential changes in the Company&#8217;s credit rating by a rating agency;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">voluntary calls of debt or preferred stock of the Company;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the contents of forthcoming publications that may affect the market price of Company Securities;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">statements by stock market analysts regarding the Company and/or its securities;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">significant changes in sales volumes, market share, production scheduling, product pricing or mix of sales;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">analyst upgrades or downgrades of a Company Security;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px 0px 0px 0in">AINOS, INC.</p> <p style="margin:0px 0px 0px 0in">INSIDER TRADING POLICY &#8211; ADOPTED AUGUST 20 2021 </p> <p style="margin:0px 0px 0px 0in">Page&nbsp;3 of 11</p></td></tr></table> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">significant changes in accounting treatment, write-offs or effective tax rate;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">impending bankruptcy or financial liquidity problems of the company or one of its subsidiaries or significant business partners;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">gain or loss of a substantial customer or supplier; or</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">a significant cybersecurity incident experienced by the company that has not yet been made public.</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>4.2 &#8220;Nonpublic&#8221; Information</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Information is considered &#8220;nonpublic&#8221; until it has not been widely disseminated to the public through SEC filings, major newswire services, national news services and financial news services and there has been sufficient time for the market to digest that information. For the purposes of this Policy, information will be considered public after the close of trading on the third full business day after the Company&#8217;s widespread public release of the information. Thus, no transaction should take place until the third business day after the disclosure of the material information.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>5.0 STATEMENT OF COMPANY POLICY AND PROCEDURES</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>5.1 Prohibited Activities</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">5.1.1 No Insider may trade in Company Securities while aware of material nonpublic information concerning the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">5.1.2 No Insider may trade in Company Securities during any special trading blackout periods as designated by the Compliance Officer. The deviation of any blackout period as well as those Insiders subject to the blackout shall be determined by the Compliance Officer. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">5.1.3 Moreover, the Insider will not disclose to any person the applicability of a special blackout period without prior permission of the Compliance Officer.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">5.1.4 No Section 16 Person or Designated Employee may trade in Company Securities without prior written approval of the Compliance Officer under the procedures set forth below. To the extent possible, Section 16 Persons and Designated Employees should retain all records and documents that support their reasons for making each trade.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">5.1.5 No Section 16 Person or Designated Employee may trade in Company Securities outside of the applicable &#8220;trading windows&#8221; described below.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">5.1.6 The Compliance Officer may not trade in Company Securities unless the trade(s) have been approved by the Chief Financial Officer or Chief Executive Officer in accordance with the procedures set forth below.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px 0px 0px 0in">AINOS, INC.</p> <p style="margin:0px 0px 0px 0in">INSIDER TRADING POLICY &#8211; ADOPTED AUGUST 20 2021 </p> <p style="margin:0px 0px 0px 0in">Page&nbsp;4 of 11</p></td></tr></table> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">5.1.7 No Insider may &#8220;tip&#8221; or disclose material nonpublic information concerning the Company to any outside person, including family members, even if that person is expected to hold such &#8220;tip&#8221; in confidence, unless required as part of that Insider&#8217;s regular duties for the Company or authorized by the Compliance Officer. In the case of inadvertent disclosure to an outside person, the Insider must advise the Compliance Officer as soon as the inadvertent disclosure has been discovered. To protect against inadvertent disclosures, all inquiries from outsiders regarding material nonpublic information about the Company must be forwarded to the Compliance Officer or Investor Relations.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">5.1.8 No Insider may give trading advice of any kind about the Company to anyone, whether or not such Insider is aware of material nonpublic information about the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">5.1.9 No Insider may trade in any interest or position relating to the future price of Company Securities, such as a put, call or short sale.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">5.1.10 Without the specific prior approval of the Compliance Officer and the Chief Executive Officer or the Audit Committee, no Insider shall accept outside employment, as a consultant, independent contractor or employee, where the Insider is being compensated for the Insider&#8217;s knowledge of the Company or the industry or potential products of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">5.1.11 Without the specific prior approval of the Compliance Officer and the Chief Executive Officer, no Insider shall respond to market rumors or otherwise make any public statements regarding the Company or its prospects. This includes responding to or commenting on Internet-based bulletin boards or social media platforms. If you become aware of any rumors or false statements, you should report them to the Compliance Officer.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>5.2 Trading Windows and Blackout Periods</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Provided that no other restrictions on trading in Company Securities apply, Section 16 Persons and Designated Employees may trade in Company Securities during and only during the period beginning at the close of trading third full trading day[s] following the Company&#8217;s widespread public release of quarterly or year-end earnings and ending on the last trading day of the second month following the end of the preceding quarter.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Notwithstanding the above provisions, any Section 16 Person or Designated Employee who is aware of material nonpublic information concerning the Company may not trade in Company Securities even during a trading window until three (3) business day[s] after such material nonpublic information has been subject to the Company&#8217;s widespread public release of the information.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px 0px 0px 0in">AINOS, INC.</p> <p style="margin:0px 0px 0px 0in">INSIDER TRADING POLICY &#8211; ADOPTED AUGUST 20 2021 </p> <p style="margin:0px 0px 0px 0in">Page&nbsp;5 of 11</p></td></tr></table> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a name="A0Q5F4Y2A0"></a>&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">No Insiders identified by the Compliance Officer as being subject to a special blackout period may trade in Company Securities during such special blackout period. The Compliance Officer may, following consultation with the Chief Financial Officer or Chief Executive Officer, declare such special blackout periods from time-to-time as conditions warrant. No Insider, whether or not subject to a special black out period, may disclose to any outside third party that a special blackout period has been designated.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>5.3 Procedures for Approving Trades by Section 16 Individuals</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">No Section 16 Person or Designated Employee may trade in Company Securities until:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the Section 16 Person or Designated Employee seeking to trade has notified the Compliance Officer in writing before at least three (3) business day[s] prior to the proposed trade(s) and the amount and nature of the proposed trade(s); and</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">the Section 16 Person or Designated Employee seeking to trade has certified in writing to the Compliance Officer before [no more than three business days prior to] the proposed trade(s) that he or she is not aware of material nonpublic information concerning the Company.</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">If the Compliance Officer desires to complete any trades involving Company Securities, he or she must first obtain the approval of the Chief Executive Officer or the Chief Financial Officer of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">The existence of the foregoing approval procedures does not in any way obligate the Compliance Officer (or, in the case of any trade by the Compliance Officer, the Chief Executive Officer or the Chief Financial Officer of the Company) to approve any trades requested by Section 16 Persons or the Compliance Officer.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">All trades approved under this section must be exercised within 24 hours of the approval (the &#8220;Approval Period&#8221;). Provided, however, if the Insider comes into possession of material nonpublic information before trading, the Insider may not trade. Trades not exercised within the Approval Period require new approval from the Compliance Officer.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px 0px 0px 0in">AINOS, INC.</p> <p style="margin:0px 0px 0px 0in">INSIDER TRADING POLICY &#8211; ADOPTED AUGUST 20 2021 </p> <p style="margin:0px 0px 0px 0in">Page&nbsp;6 of 11</p></td></tr></table> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table>&nbsp; <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a name="A0Q5F4Y2A3"></a><a name="VI._Exceptions_to_Application_of_Policy"></a><strong>6.0 EXCEPTIONS TO APPLICATION OF POLICY</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>6.1 Employee Benefit Plans</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">The trading prohibitions and restrictions set forth in this Policy do not apply to periodic contributions by the Company or employees to the Company&#8217;s stock option, employee stock purchase, and/or equity incentive plans subject to the terms and conditions of those plans. However, no officer or employee may alter his or her instructions regarding the purchase or sale of Company Securities in such plans:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">while aware of material nonpublic information;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">in the case of Section 16 Persons or Designated Employees, prior to receiving approval of the purchase or sale as described above; and</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">in the case of Section 16 Persons and Designated Employees, while any applicable trading window is closed or applicable special blackout period is in effect.</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Stock Option Plans. Insiders may exercise company stock options where no company stock is sold in the market. Cashless sales&#8212;e.g., &#8220;cashless sales&#8221; where company stock is sold to pay for exercising the options&#8212;are considered under this Policy to be transactions in Company Securities and must comply with the provisions of this Policy, including the applicability of any prior approval, trading window or blackout period requirements as they may apply to an Insider. No cashless sale is permitted when the insider is in possession of material, nonpublic information, except as provided below.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong><em>6.2 Rule 10b5-1 Plans</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Exchange Act Rule 10b5- l was adopted by the SEC to protect persons from insider trading liability for transactions under a written trading plan previously established at a time when the insider did not possess material nonpublic information. Under a properly established 10b5-1 plan with respect to securities (a &#8220;10b5-1 Plan&#8221;), Insiders may complete transactions in Company Securities at any time, including during blackout periods and outside trading windows or even when the Insider possesses material nonpublic information. Thus a 10b5-1 Plan offers an opportunity for Insiders to establish a systematic program of transactions in Company Securities over periods of time that might include periods in which such transactions would otherwise be prohibited under the federal securities laws or this policy. A variety of arrangements can be structured to meet the requirements of Rule 10b5-1. In particular, a 10b5-1 Plan can take the form of a blind trust, other trust, pre-scheduled stock option exercises and sales, pre-arranged trading instructions and other brokerage and third-party arrangements over which the Insider has no control once the plan takes effect.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Insiders who desire to implement a 10b5-1 Plan must first obtain approval of the plan by the Compliance Officer. To be eligible for approval, the 10b5-1 Plan:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">must be established during a trading window (and not during any black out period);</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">must be in writing;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px 0px 0px 0in">AINOS, INC.</p> <p style="margin:0px 0px 0px 0in">INSIDER TRADING POLICY &#8211; ADOPTED AUGUST 20 2021 </p> <p style="margin:0px 0px 0px 0in">Page&nbsp;7 of 11</p></td></tr></table> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">must either irrevocably set forth the future date or dates on which purchase or sale of securities are to be made, the prices at which the securities are to be purchased or sold, the broker who will be responsible for effecting the transactions (or method of transaction if not through a broker), or provide a formula for determining the price of the securities to be purchased or sold and the date or dates on which the transactions are to be completed;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">may not permit the direct or indirect exercise of any influence over the timing or terms of the purchase or sale by the Insider; and</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">may not take effect until thirty (30) days after the plan is approved by the Compliance Officer.</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a name="A0Q5F4Y2A6"></a>The Compliance Officer will maintain a copy of all 10b5-1 Plans.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">The Insider must provide the Compliance Officer written notice of any termination or modification (in which case, the modification must be approved in writing by the Compliance Officer prior to effectiveness and may not take effect until thirty (30) days after the plan is approved by the Compliance Officer.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a name="VII._Reporting_of_Violations"></a><strong>7.0 REPORTING OF VIOLATIONS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Any Insider who violates this Policy or any federal, state or SRO rule or law governing insider trading or tipping, or knows of any such violation by any other Insider, must report the violation immediately to the Compliance Officer. Upon receipt of notice of a potential violation of this Policy, the Compliance Officer:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">shall make inquiry either through the office of the General Counsel or with assistance of outside counsel, to determine whether a violation may have occurred;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">shall report the potential violation of this Policy to the Audit Committee if the Compliance Officer concludes a violation occurred or if the Compliance Officer is unable to conclude that no violation occurred; and</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px;text-indent:30px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">upon determining that any such violation has occurred, in consultation with the Company&#8217;s Disclosure Committee and, where appropriate, the Chair of the Audit Committee of the Board, will determine whether the Company should release any material nonpublic information.</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">If the Compliance Officer or Board of Directors determines that a violation of the Policy occurred, they may discipline the Insider, including immediate termination. The Board of Directors may also report the violation to federal or state law enforcement agencies and/or applicable SRO.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px 0px 0px 0in">AINOS, INC.</p> <p style="margin:0px 0px 0px 0in">INSIDER TRADING POLICY &#8211; ADOPTED AUGUST 20 2021 </p> <p style="margin:0px 0px 0px 0in">Page&nbsp;8 of 11</p></td></tr></table> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a name="VIII._Inquiries"></a><strong></strong>&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>8.0 INQUIRIES</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Please direct all inquiries regarding any of the provisions or procedures of this Policy to the Compliance Officer.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a name="IX._Insider_Trading_Compliance_Officer"></a><strong>9.0 INSIDER TRADING COMPLIANCE OFFICER</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">The Company has designated the Company&#8217;s Chief Legal Counsel as its Insider Trading Compliance Officer. The Insider Trading Compliance Officer, in consultation with the Company&#8217;s Chief Financial Officer and/or Chief Executive Officer, will review and either approve or prohibit all proposed trades by Section 16 Persons in accordance with the procedures set forth above.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><a name="A0Q5F4Y2A9"></a>In addition to the trading approval duties described above, the duties of the Insider Trading Compliance Officer shall include the following:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">administering this Policy and monitoring and enforcing compliance with all Policy provisions and procedures;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">with the assistance of the Human Resources Department, overseeing the training of new and existing officers, directors, employees and others on the requirements of this Policy;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">responding to all inquiries relating to this Policy and its procedures;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">designating and announcing special trading blackout periods during which Insiders, that the Insider Trading Compliance Officer determines, may not trade in Company Securities;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">providing copies of this Policy and other appropriate materials to all current and new directors, officers, employees and such other persons whom the Insider Trading Compliance Officer determines may regularly have access to material nonpublic information concerning the Company, and assuring that human resources has collected and maintained the required certification of employee receipt of the Policy;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">administering, monitoring and enforcing compliance with all federal, state and SRO insider trading statutes, regulations and rules;</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">proposing recommendations for revisions to the Policy to the board of directors as necessary to reflect changes in insider trading laws, regulations or rules of any federal or state governmental body or SRO; and</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px 0px 0px 0in">AINOS, INC.</p> <p style="margin:0px 0px 0px 0in">INSIDER TRADING POLICY &#8211; ADOPTED AUGUST 20 2021 </p> <p style="margin:0px 0px 0px 0in">Page&nbsp;9 of 11</p></td></tr></table> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">maintaining as Company records originals or copies of all documents required by the provisions of this Policy or the procedures set forth herein, and copies of all required SEC reports relating to insider trading.</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">The Insider Trading Compliance Officer may designate one or more individuals who may perform the Compliance Officer&#8217;s duties in the event that the Insider Trading Compliance Officer is unable or unavailable to perform such duties.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"><strong>10.0 ADOPTIONS, REVIEWS AND REVISIONS </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Adopted &#8211; March 15, 2021</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Revised &#8211; July 31, 2021 with non-material modifications: Changed enumeration, replaced &#8220;John Junyong Lee,Esq.&#8221; as Insider Trading Compliance Officer to &#8220;the Company&#8217;s Chief Legal Counsel.&#8221;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Revised &#8211; August 20 2021: Modification of preamble to Section 6.1 to read:<strong> &#8220;</strong>The trading prohibitions and restrictions set forth in this Policy do not apply to periodic contributions by the Company or employees to <u>the Company&#8217;s stock option, employee stock purchase, and/or equity incentive plans subject to the terms and conditions of those plans</u>. However, no officer or employee may alter his or her instructions regarding the purchase or sale of Company Securities in such plans:&#8230;&#8221; (emphasis added)</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px 0px 0px 0in">AINOS, INC.</p> <p style="margin:0px 0px 0px 0in">INSIDER TRADING POLICY &#8211; ADOPTED AUGUST 20 2021 </p> <p style="margin:0px 0px 0px 0in">Page 10 of 11</p></td></tr></table> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><u>CONFIRMATION</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">I HEREBY ACKNOWLEDGE THAT I HAVE RECEIVED, HAVE READ, UNDERSTAND, AND SHALL COMPLY WITH THE AINOS, INC. INSIDER TRADING POLICY (Adopted August 20, 2021).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">By:_____________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Name:__________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">Date:__________________</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: #000000 1px solid;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px 0px 0px 0in">AINOS, INC.</p> <p style="margin:0px 0px 0px 0in">INSIDER TRADING POLICY &#8211; ADOPTED AUGUST 20 2021 </p> <p style="margin:0px 0px 0px 0in">Page 11 of 11</p></td></tr></table> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>aimd-20210930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 11/15/2021-->
<!--Software architectural design and coding: Dipendra K. Singh-->
<!--Copyright (c) 2021 I-NET Business Solutions, Inc. All Rights Reserved.-->
<schema xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:aimd="http://aimd.com/20210930" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://aimd.com/20210930">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://aimd.com/role/Cover" id="Cover">
        <link:definition>000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aimd.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
        <link:definition>000002 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aimd.com/role/BalanceSheets" id="BalanceSheets">
        <link:definition>000003 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aimd.com/role/StatementsOfOperationsUnaudited" id="StatementsOfOperationsUnaudited">
        <link:definition>000004 - Statement - Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aimd.com/role/StatementsOfStockholdersEquityDeficitUnaudited" id="StatementsOfStockholdersEquityDeficitUnaudited">
        <link:definition>000005 - Statement - Statements of Stockholders' Equity (Deficit) (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" id="CondensedStatementsOfCashFlowsUnaudited">
        <link:definition>000006 - Statement - Condensed Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aimd.com/role/OrganizationAndBusiness" id="OrganizationAndBusiness">
        <link:definition>000007 - Disclosure - Organization and Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aimd.com/role/General" id="General">
        <link:definition>000008 - Disclosure - General</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aimd.com/role/BasisOfPresentation" id="BasisOfPresentation">
        <link:definition>000009 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aimd.com/role/FinancialCondition" id="FinancialCondition">
        <link:definition>000010 - Disclosure - Financial Condition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aimd.com/role/CommonStock" id="CommonStock">
        <link:definition>000011 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aimd.com/role/ConvertibleNotesPayableAndOtherRelatedPartyNotesPayable" id="ConvertibleNotesPayableAndOtherRelatedPartyNotesPayable">
        <link:definition>000012 - Disclosure - Convertible Notes Payable and Other Related Party Notes Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aimd.com/role/OtherRelatedPartyTransactions" id="OtherRelatedPartyTransactions">
        <link:definition>000013 - Disclosure - Other Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aimd.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>000014 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aimd.com/role/ConvertibleNotesPayableAndOtherRelatedPartyNotesPayableTables" id="ConvertibleNotesPayableAndOtherRelatedPartyNotesPayableTables">
        <link:definition>000015 - Disclosure - Convertible Notes Payable and Other Related Party Notes Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aimd.com/role/RelatedPartyTransactionsTables" id="RelatedPartyTransactionsTables">
        <link:definition>000016 - Disclosure - Related Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aimd.com/role/FinancialConditionDetailsNarrative" id="FinancialConditionDetailsNarrative">
        <link:definition>000017 - Disclosure - Financial Condition (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aimd.com/role/CommonStockDetailsNarrative" id="CommonStockDetailsNarrative">
        <link:definition>000018 - Disclosure - Common Stock (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails" id="ConvertibleNotesPayableAndOayableDetails">
        <link:definition>000019 - Disclosure - Convertible Notes Payable and Oayable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1" id="ConvertibleNotesPayableAndOayableDetails1">
        <link:definition>000020 - Disclosure - Convertible Notes Payable and Oayable (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aimd.com/role/ConvertibleNotesPayableAndOayableDetailsNarrative" id="ConvertibleNotesPayableAndOayableDetailsNarrative">
        <link:definition>000021 - Disclosure - Convertible Notes Payable and Oayable (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aimd.com/role/RelatedPartyTransactionsDetails" id="RelatedPartyTransactionsDetails">
        <link:definition>000022 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aimd.com/role/RelatedPartyTransactionsDetails1" id="RelatedPartyTransactionsDetails1">
        <link:definition>000023 - Disclosure - Related Party Transactions (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
        <link:definition>000024 - Disclosure - Related Party Transactions (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://aimd.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
        <link:definition>000025 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="aimd-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="aimd-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="aimd-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="aimd-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" />
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" />
  <import namespace="http://fasb.org/srt-roles/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" />
  <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <import namespace="http://fasb.org/us-roles/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" />
  <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
  <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
  <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
  <element id="aimd_LeaseObligationNonCurrent" name="LeaseObligationNonCurrent" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_TranslationAdjustmentLiability" name="TranslationAdjustmentLiability" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_OtherLosses" name="OtherLosses" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_TotalNonOperatingIncomeAndExpenses" name="TotalNonOperatingIncomeAndExpenses" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_LessIncomeTax" name="LessIncomeTax" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_IssuanceOfStockForCompensationAmount" name="IssuanceOfStockForCompensationAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_IssuanceOfStockForCashShares" name="IssuanceOfStockForCashShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_IssuanceOfStockForCashAmount" name="IssuanceOfStockForCashAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_WarrantExpense" name="WarrantExpense" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_OptionExpense" name="OptionExpense" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_TranslationAdjustment" name="TranslationAdjustment" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_IssuanceOfStockForCompensationShares" name="IssuanceOfStockForCompensationShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_IssuanceOfStockForPatentAssetsShares" name="IssuanceOfStockForPatentAssetsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_IssuanceOfStockForPatentAssetsAmount" name="IssuanceOfStockForPatentAssetsAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_IssuanceOfStockForOptionShares" name="IssuanceOfStockForOptionShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_IssuanceOfStockForOptionAmount" name="IssuanceOfStockForOptionAmount" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_InvestmentInPatents" name="InvestmentInPatents" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_IncreaseInRefundableDeposits" name="IncreaseInRefundableDeposits" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_AdvancesFromShareholder" name="AdvancesFromShareholder" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_PaymentsOfLeaseLiabilities" name="PaymentsOfLeaseLiabilities" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_StockIssuedForAcquisitionOfPatents" name="StockIssuedForAcquisitionOfPatents" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_StockIssuedForCompensationWarrantAndOptionExpense" name="StockIssuedForCompensationWarrantAndOptionExpense" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_StockIssuedForAdvancesFromInvestors" name="StockIssuedForAdvancesFromInvestors" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_RouLeasedAssets" name="RouLeasedAssets" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_FinancialConditionTextBlock" name="FinancialConditionTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_ScheduleOfFinancialSupportListtabletextblock" name="ScheduleOfFinancialSupportListtabletextblock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_SharesIncreaseValue" name="SharesIncreaseValue" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_DueDate" name="DueDate" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_EffectiveDate" name="EffectiveDate" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_AnnualInterestRateFollowingMaturity" name="AnnualInterestRateFollowingMaturity" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_ConvertibleAndOtherNotesPayableRelatedParties" name="ConvertibleAndOtherNotesPayableRelatedParties" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_Date" name="Date" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_InterestAmountOriginalRate" name="InterestAmountOriginalRate" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_InterestAmount10" name="InterestAmount10" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_InterestAfterMaturity" name="InterestAfterMaturity" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_InterestWaived" name="InterestWaived" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_InterestRateAfterMaturity" name="InterestRateAfterMaturity" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_Shares" name="Shares" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_ParValue" name="ParValue" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_PaidInExcessOfPar" name="PaidInExcessOfPar" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_TotalAmount" name="TotalAmount" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_ConsultingFee" name="ConsultingFee" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_ConsultingFeePayable" name="ConsultingFeePayable" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
  <element id="aimd_DescriptionOfConsultant" name="DescriptionOfConsultant" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
  <element name="SecuritiesPurchaseAgreementsMember" id="aimd_SecuritiesPurchaseAgreementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="DrStephenTChenMember" id="aimd_DrStephenTChenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="OneOneSixMember" id="aimd_OneOneSixMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="AinosKYMember" id="aimd_AinosKYMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TwelveTwoOneMember" id="aimd_TwelveTwoOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="FourOneNineMember" id="aimd_FourOneNineMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SixTwoZeroMember" id="aimd_SixTwoZeroMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SevenTwoZeroMember" id="aimd_SevenTwoZeroMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="NineTwoZeroMember" id="aimd_NineTwoZeroMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TenTwoOneMember" id="aimd_TenTwoOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ElevenTwoOneMember" id="aimd_ElevenTwoOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ThirteenTwoOneMember" id="aimd_ThirteenTwoOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="FourteenTwoOneMember" id="aimd_FourteenTwoOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="FifteenTwoOneMember" id="aimd_FifteenTwoOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SixteenTwoOneMember" id="aimd_SixteenTwoOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ITwoChinaManagementGroupLLCMember" id="aimd_ITwoChinaManagementGroupLLCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ElevenOneTwoOneMember" id="aimd_ElevenOneTwoOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TotalMember" id="aimd_TotalMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="RelatedPartyMember" id="aimd_RelatedPartyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="I2ChinaMember" id="aimd_I2ChinaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="BernardCohenMember" id="aimd_BernardCohenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TranslationAdjustmentMember" id="aimd_TranslationAdjustmentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="SeventeenTwoOneMember" id="aimd_SeventeenTwoOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="EighteenTwoOneMember" id="aimd_EighteenTwoOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="NinteenTwoOneMember" id="aimd_NinteenTwoOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TwentyTwoOneMember" id="aimd_TwentyTwoOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="FiveOneNineMember" id="aimd_FiveOneNineMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="EightATwozeroMember" id="aimd_EightATwozeroMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="EightBTwoZeroMember" id="aimd_EightBTwoZeroMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="TwoOneSixMember" id="aimd_TwoOneSixMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
  <element name="ThreeOneNineMember" id="aimd_ThreeOneNineMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>aimd-20210930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 11/15/2021-->
<!--Software architectural design and coding: Dipendra K. Singh-->
<!--Copyright (c) 2021 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://aimd.com/role/Cover" xlink:href="aimd-20210930.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/BalanceSheetsParenthetical" xlink:href="aimd-20210930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/BalanceSheets" xlink:href="aimd-20210930.xsd#BalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/StatementsOfOperationsUnaudited" xlink:href="aimd-20210930.xsd#StatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/StatementsOfStockholdersEquityDeficitUnaudited" xlink:href="aimd-20210930.xsd#StatementsOfStockholdersEquityDeficitUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:href="aimd-20210930.xsd#CondensedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/OrganizationAndBusiness" xlink:href="aimd-20210930.xsd#OrganizationAndBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/General" xlink:href="aimd-20210930.xsd#General" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/BasisOfPresentation" xlink:href="aimd-20210930.xsd#BasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/FinancialCondition" xlink:href="aimd-20210930.xsd#FinancialCondition" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/CommonStock" xlink:href="aimd-20210930.xsd#CommonStock" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/ConvertibleNotesPayableAndOtherRelatedPartyNotesPayable" xlink:href="aimd-20210930.xsd#ConvertibleNotesPayableAndOtherRelatedPartyNotesPayable" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/OtherRelatedPartyTransactions" xlink:href="aimd-20210930.xsd#OtherRelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/SubsequentEvents" xlink:href="aimd-20210930.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/ConvertibleNotesPayableAndOtherRelatedPartyNotesPayableTables" xlink:href="aimd-20210930.xsd#ConvertibleNotesPayableAndOtherRelatedPartyNotesPayableTables" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/RelatedPartyTransactionsTables" xlink:href="aimd-20210930.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/FinancialConditionDetailsNarrative" xlink:href="aimd-20210930.xsd#FinancialConditionDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/CommonStockDetailsNarrative" xlink:href="aimd-20210930.xsd#CommonStockDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails" xlink:href="aimd-20210930.xsd#ConvertibleNotesPayableAndOayableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1" xlink:href="aimd-20210930.xsd#ConvertibleNotesPayableAndOayableDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/ConvertibleNotesPayableAndOayableDetailsNarrative" xlink:href="aimd-20210930.xsd#ConvertibleNotesPayableAndOayableDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/RelatedPartyTransactionsDetails" xlink:href="aimd-20210930.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/RelatedPartyTransactionsDetails1" xlink:href="aimd-20210930.xsd#RelatedPartyTransactionsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="aimd-20210930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/SubsequentEventsDetailsNarrative" xlink:href="aimd-20210930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://aimd.com/role/Cover" xlink:title="00000001 - Document - Document and Entity Information" />
  <link:calculationLink xlink:type="extended" xlink:role="http://aimd.com/role/BalanceSheetsParenthetical" xlink:title="000002 - Statement - Balance Sheets (Parenthetical)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://aimd.com/role/BalanceSheets" xlink:title="000003 - Statement - Balance Sheets">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaapInventoryGross" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryGross" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="loc_us-gaapFiniteLivedPatentsGross" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFiniteLivedPatentsGross" xlink:type="arc" weight="1" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaapCapitalLeaseObligationsCurrent" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapCapitalLeaseObligationsCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
    <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
    <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositContractsLiabilities" xlink:label="loc_us-gaapDepositContractsLiabilities" />
    <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDepositContractsLiabilities" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_LeaseObligationNonCurrent" xlink:label="loc_aimdLeaseObligationNonCurrent" />
    <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_aimdLeaseObligationNonCurrent" xlink:type="arc" weight="1" />
    <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_TranslationAdjustmentLiability" xlink:label="loc_aimdTranslationAdjustmentLiability" />
    <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_aimdTranslationAdjustmentLiability" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
    <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
    <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
    <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
    <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
    <link:calculationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    <link:calculationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://aimd.com/role/StatementsOfOperationsUnaudited" xlink:title="000004 - Statement - Statements of Operations (Unaudited)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_TotalNonOperatingIncomeAndExpenses" xlink:label="loc_aimdTotalNonOperatingIncomeAndExpenses" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_OtherLosses" xlink:label="loc_aimdOtherLosses" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_aimdTotalNonOperatingIncomeAndExpenses" xlink:to="loc_aimdOtherLosses" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_aimdTotalNonOperatingIncomeAndExpenses" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_aimdTotalNonOperatingIncomeAndExpenses" xlink:type="arc" weight="1" />
    <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://aimd.com/role/StatementsOfStockholdersEquityDeficitUnaudited" xlink:title="000005 - Statement - Statements of Stockholders' Equity (Deficit) (Unaudited)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:title="000006 - Statement - Condensed Statements of Cash Flows (Unaudited)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_IncreaseInRefundableDeposits" xlink:label="loc_aimdIncreaseInRefundableDeposits" />
    <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_aimdIncreaseInRefundableDeposits" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAssetsInvestingActivities" xlink:label="loc_us-gaapPaymentsToAcquireAssetsInvestingActivities" />
    <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireAssetsInvestingActivities" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_InvestmentInPatents" xlink:label="loc_aimdInvestmentInPatents" />
    <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_aimdInvestmentInPatents" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt" />
    <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_PaymentsOfLeaseLiabilities" xlink:label="loc_aimdPaymentsOfLeaseLiabilities" />
    <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_aimdPaymentsOfLeaseLiabilities" xlink:type="arc" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
    <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
    <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" weight="1" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_AdvancesFromShareholder" xlink:label="loc_aimdAdvancesFromShareholder" />
    <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_aimdAdvancesFromShareholder" xlink:type="arc" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://aimd.com/role/OrganizationAndBusiness" xlink:title="000007 - Disclosure - Organization and Business" />
  <link:calculationLink xlink:type="extended" xlink:role="http://aimd.com/role/General" xlink:title="000008 - Disclosure - General" />
  <link:calculationLink xlink:type="extended" xlink:role="http://aimd.com/role/BasisOfPresentation" xlink:title="000009 - Disclosure - Basis of Presentation" />
  <link:calculationLink xlink:type="extended" xlink:role="http://aimd.com/role/FinancialCondition" xlink:title="000010 - Disclosure - Financial Condition" />
  <link:calculationLink xlink:type="extended" xlink:role="http://aimd.com/role/CommonStock" xlink:title="000011 - Disclosure - Common Stock" />
  <link:calculationLink xlink:type="extended" xlink:role="http://aimd.com/role/ConvertibleNotesPayableAndOtherRelatedPartyNotesPayable" xlink:title="000012 - Disclosure - Convertible Notes Payable and Other Related Party Notes Payable" />
  <link:calculationLink xlink:type="extended" xlink:role="http://aimd.com/role/OtherRelatedPartyTransactions" xlink:title="000013 - Disclosure - Other Related Party Transactions" />
  <link:calculationLink xlink:type="extended" xlink:role="http://aimd.com/role/SubsequentEvents" xlink:title="000014 - Disclosure - Subsequent Events" />
  <link:calculationLink xlink:type="extended" xlink:role="http://aimd.com/role/ConvertibleNotesPayableAndOtherRelatedPartyNotesPayableTables" xlink:title="000015 - Disclosure - Convertible Notes Payable and Other Related Party Notes Payable (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://aimd.com/role/RelatedPartyTransactionsTables" xlink:title="000016 - Disclosure - Related Party Transactions (Tables)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://aimd.com/role/FinancialConditionDetailsNarrative" xlink:title="000017 - Disclosure - Financial Condition (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://aimd.com/role/CommonStockDetailsNarrative" xlink:title="000018 - Disclosure - Common Stock (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails" xlink:title="000019 - Disclosure - Convertible Notes Payable and Oayable (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1" xlink:title="000020 - Disclosure - Convertible Notes Payable and Oayable (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://aimd.com/role/ConvertibleNotesPayableAndOayableDetailsNarrative" xlink:title="000021 - Disclosure - Convertible Notes Payable and Oayable (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://aimd.com/role/RelatedPartyTransactionsDetails" xlink:title="000022 - Disclosure - Related Party Transactions (Details)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://aimd.com/role/RelatedPartyTransactionsDetails1" xlink:title="000023 - Disclosure - Related Party Transactions (Details 1)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="000024 - Disclosure - Related Party Transactions (Details Narrative)" />
  <link:calculationLink xlink:type="extended" xlink:role="http://aimd.com/role/SubsequentEventsDetailsNarrative" xlink:title="000025 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>aimd-20210930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 11/15/2021-->
<!--Software architectural design and coding: Dipendra K. Singh-->
<!--Copyright (c) 2021 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://aimd.com/role/Cover" xlink:href="aimd-20210930.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/BalanceSheetsParenthetical" xlink:href="aimd-20210930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/BalanceSheets" xlink:href="aimd-20210930.xsd#BalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/StatementsOfOperationsUnaudited" xlink:href="aimd-20210930.xsd#StatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/StatementsOfStockholdersEquityDeficitUnaudited" xlink:href="aimd-20210930.xsd#StatementsOfStockholdersEquityDeficitUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:href="aimd-20210930.xsd#CondensedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/OrganizationAndBusiness" xlink:href="aimd-20210930.xsd#OrganizationAndBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/General" xlink:href="aimd-20210930.xsd#General" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/BasisOfPresentation" xlink:href="aimd-20210930.xsd#BasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/FinancialCondition" xlink:href="aimd-20210930.xsd#FinancialCondition" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/CommonStock" xlink:href="aimd-20210930.xsd#CommonStock" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/ConvertibleNotesPayableAndOtherRelatedPartyNotesPayable" xlink:href="aimd-20210930.xsd#ConvertibleNotesPayableAndOtherRelatedPartyNotesPayable" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/OtherRelatedPartyTransactions" xlink:href="aimd-20210930.xsd#OtherRelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/SubsequentEvents" xlink:href="aimd-20210930.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/ConvertibleNotesPayableAndOtherRelatedPartyNotesPayableTables" xlink:href="aimd-20210930.xsd#ConvertibleNotesPayableAndOtherRelatedPartyNotesPayableTables" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/RelatedPartyTransactionsTables" xlink:href="aimd-20210930.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/FinancialConditionDetailsNarrative" xlink:href="aimd-20210930.xsd#FinancialConditionDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/CommonStockDetailsNarrative" xlink:href="aimd-20210930.xsd#CommonStockDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails" xlink:href="aimd-20210930.xsd#ConvertibleNotesPayableAndOayableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1" xlink:href="aimd-20210930.xsd#ConvertibleNotesPayableAndOayableDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/ConvertibleNotesPayableAndOayableDetailsNarrative" xlink:href="aimd-20210930.xsd#ConvertibleNotesPayableAndOayableDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/RelatedPartyTransactionsDetails" xlink:href="aimd-20210930.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/RelatedPartyTransactionsDetails1" xlink:href="aimd-20210930.xsd#RelatedPartyTransactionsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="aimd-20210930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/SubsequentEventsDetailsNarrative" xlink:href="aimd-20210930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://aimd.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCover" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://aimd.com/role/BalanceSheetsParenthetical" xlink:title="000002 - Statement - Balance Sheets (Parenthetical)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://aimd.com/role/BalanceSheets" xlink:title="000003 - Statement - Balance Sheets" />
  <link:definitionLink xlink:type="extended" xlink:role="http://aimd.com/role/StatementsOfOperationsUnaudited" xlink:title="000004 - Statement - Statements of Operations (Unaudited)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://aimd.com/role/StatementsOfStockholdersEquityDeficitUnaudited" xlink:title="000005 - Statement - Statements of Stockholders' Equity (Deficit) (Unaudited)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember" order="24" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_TranslationAdjustmentMember" xlink:label="loc_aimdTranslationAdjustmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_aimdTranslationAdjustmentMember" order="25" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" order="2" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_IssuanceOfStockForCompensationAmount" xlink:label="loc_aimdIssuanceOfStockForCompensationAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aimdIssuanceOfStockForCompensationAmount" order="3" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_IssuanceOfStockForCashShares" xlink:label="loc_aimdIssuanceOfStockForCashShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aimdIssuanceOfStockForCashShares" order="4" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_IssuanceOfStockForCashAmount" xlink:label="loc_aimdIssuanceOfStockForCashAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aimdIssuanceOfStockForCashAmount" order="5" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_WarrantExpense" xlink:label="loc_aimdWarrantExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aimdWarrantExpense" order="6" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_OptionExpense" xlink:label="loc_aimdOptionExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aimdOptionExpense" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" order="8" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_TranslationAdjustment" xlink:label="loc_aimdTranslationAdjustment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aimdTranslationAdjustment" order="9" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_IssuanceOfStockForCompensationShares" xlink:label="loc_aimdIssuanceOfStockForCompensationShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aimdIssuanceOfStockForCompensationShares" order="10" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_IssuanceOfStockForPatentAssetsShares" xlink:label="loc_aimdIssuanceOfStockForPatentAssetsShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aimdIssuanceOfStockForPatentAssetsShares" order="11" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_IssuanceOfStockForPatentAssetsAmount" xlink:label="loc_aimdIssuanceOfStockForPatentAssetsAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aimdIssuanceOfStockForPatentAssetsAmount" order="12" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_IssuanceOfStockForOptionShares" xlink:label="loc_aimdIssuanceOfStockForOptionShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aimdIssuanceOfStockForOptionShares" order="13" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_IssuanceOfStockForOptionAmount" xlink:label="loc_aimdIssuanceOfStockForOptionAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aimdIssuanceOfStockForOptionAmount" order="14" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:title="000006 - Statement - Condensed Statements of Cash Flows (Unaudited)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://aimd.com/role/OrganizationAndBusiness" xlink:title="000007 - Disclosure - Organization and Business" />
  <link:definitionLink xlink:type="extended" xlink:role="http://aimd.com/role/General" xlink:title="000008 - Disclosure - General" />
  <link:definitionLink xlink:type="extended" xlink:role="http://aimd.com/role/BasisOfPresentation" xlink:title="000009 - Disclosure - Basis of Presentation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://aimd.com/role/FinancialCondition" xlink:title="000010 - Disclosure - Financial Condition" />
  <link:definitionLink xlink:type="extended" xlink:role="http://aimd.com/role/CommonStock" xlink:title="000011 - Disclosure - Common Stock" />
  <link:definitionLink xlink:type="extended" xlink:role="http://aimd.com/role/ConvertibleNotesPayableAndOtherRelatedPartyNotesPayable" xlink:title="000012 - Disclosure - Convertible Notes Payable and Other Related Party Notes Payable" />
  <link:definitionLink xlink:type="extended" xlink:role="http://aimd.com/role/OtherRelatedPartyTransactions" xlink:title="000013 - Disclosure - Other Related Party Transactions" />
  <link:definitionLink xlink:type="extended" xlink:role="http://aimd.com/role/SubsequentEvents" xlink:title="000014 - Disclosure - Subsequent Events" />
  <link:definitionLink xlink:type="extended" xlink:role="http://aimd.com/role/ConvertibleNotesPayableAndOtherRelatedPartyNotesPayableTables" xlink:title="000015 - Disclosure - Convertible Notes Payable and Other Related Party Notes Payable (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://aimd.com/role/RelatedPartyTransactionsTables" xlink:title="000016 - Disclosure - Related Party Transactions (Tables)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://aimd.com/role/FinancialConditionDetailsNarrative" xlink:title="000017 - Disclosure - Financial Condition (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_SecuritiesPurchaseAgreementsMember" xlink:label="loc_aimdSecuritiesPurchaseAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_aimdSecuritiesPurchaseAgreementsMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues" order="3" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://aimd.com/role/CommonStockDetailsNarrative" xlink:title="000018 - Disclosure - Common Stock (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails" xlink:title="000019 - Disclosure - Convertible Notes Payable and Oayable (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="40" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="50" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" order="60" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_DrStephenTChenMember" xlink:label="loc_aimdDrStephenTChenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_aimdDrStephenTChenMember" order="41" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_TwoOneSixMember" xlink:label="loc_aimdTwoOneSixMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdTwoOneSixMember" order="42" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_AinosKYMember" xlink:label="loc_aimdAinosKYMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_aimdAinosKYMember" order="43" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_TwelveTwoOneMember" xlink:label="loc_aimdTwelveTwoOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdTwelveTwoOneMember" order="44" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_ITwoChinaManagementGroupLLCMember" xlink:label="loc_aimdITwoChinaManagementGroupLLCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_aimdITwoChinaManagementGroupLLCMember" order="45" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_ElevenOneTwoOneMember" xlink:label="loc_aimdElevenOneTwoOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdElevenOneTwoOneMember" order="46" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_FiveOneNineMember" xlink:label="loc_aimdFiveOneNineMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdFiveOneNineMember" order="47" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_ThirteenTwoOneMember" xlink:label="loc_aimdThirteenTwoOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdThirteenTwoOneMember" order="48" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_TotalMember" xlink:label="loc_aimdTotalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdTotalMember" order="49" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_EightBTwoZeroMember" xlink:label="loc_aimdEightBTwoZeroMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdEightBTwoZeroMember" order="50" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_FourteenTwoOneMember" xlink:label="loc_aimdFourteenTwoOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdFourteenTwoOneMember" order="51" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_FifteenTwoOneMember" xlink:label="loc_aimdFifteenTwoOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdFifteenTwoOneMember" order="52" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_SixteenTwoOneMember" xlink:label="loc_aimdSixteenTwoOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdSixteenTwoOneMember" order="53" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_SeventeenTwoOneMember" xlink:label="loc_aimdSeventeenTwoOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdSeventeenTwoOneMember" order="54" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_EighteenTwoOneMember" xlink:label="loc_aimdEighteenTwoOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdEighteenTwoOneMember" order="55" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_NinteenTwoOneMember" xlink:label="loc_aimdNinteenTwoOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdNinteenTwoOneMember" order="56" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_TwentyTwoOneMember" xlink:label="loc_aimdTwentyTwoOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdTwentyTwoOneMember" order="57" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_EightATwozeroMember" xlink:label="loc_aimdEightATwozeroMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdEightATwozeroMember" order="58" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_OneOneSixMember" xlink:label="loc_aimdOneOneSixMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdOneOneSixMember" order="59" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_ThreeOneNineMember" xlink:label="loc_aimdThreeOneNineMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdThreeOneNineMember" order="60" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_FourOneNineMember" xlink:label="loc_aimdFourOneNineMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdFourOneNineMember" order="61" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_SixTwoZeroMember" xlink:label="loc_aimdSixTwoZeroMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdSixTwoZeroMember" order="62" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_SevenTwoZeroMember" xlink:label="loc_aimdSevenTwoZeroMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdSevenTwoZeroMember" order="63" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_NineTwoZeroMember" xlink:label="loc_aimdNineTwoZeroMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdNineTwoZeroMember" order="64" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_ElevenTwoOneMember" xlink:label="loc_aimdElevenTwoOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdElevenTwoOneMember" order="65" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_TenTwoOneMember" xlink:label="loc_aimdTenTwoOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdTenTwoOneMember" order="66" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_DueDate" xlink:label="loc_aimdDueDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aimdDueDate" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionOriginalDebtInterestRateOfDebt" xlink:label="loc_us-gaapDebtConversionOriginalDebtInterestRateOfDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtConversionOriginalDebtInterestRateOfDebt" order="2" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_EffectiveDate" xlink:label="loc_aimdEffectiveDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aimdEffectiveDate" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal" order="4" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_AnnualInterestRateFollowingMaturity" xlink:label="loc_aimdAnnualInterestRateFollowingMaturity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aimdAnnualInterestRateFollowingMaturity" order="5" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_ConvertibleAndOtherNotesPayableRelatedParties" xlink:label="loc_aimdConvertibleAndOtherNotesPayableRelatedParties" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aimdConvertibleAndOtherNotesPayableRelatedParties" order="6" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1" xlink:title="000020 - Disclosure - Convertible Notes Payable and Oayable (Details 1)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_DrStephenTChenMember" xlink:label="loc_aimdDrStephenTChenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_aimdDrStephenTChenMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_TwoOneSixMember" xlink:label="loc_aimdTwoOneSixMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdTwoOneSixMember" order="22" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_ITwoChinaManagementGroupLLCMember" xlink:label="loc_aimdITwoChinaManagementGroupLLCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_aimdITwoChinaManagementGroupLLCMember" order="23" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_ElevenOneTwoOneMember" xlink:label="loc_aimdElevenOneTwoOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdElevenOneTwoOneMember" order="24" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_FiveOneNineMember" xlink:label="loc_aimdFiveOneNineMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdFiveOneNineMember" order="25" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_TotalMember" xlink:label="loc_aimdTotalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdTotalMember" order="26" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_EightBTwoZeroMember" xlink:label="loc_aimdEightBTwoZeroMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdEightBTwoZeroMember" order="27" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_EightATwozeroMember" xlink:label="loc_aimdEightATwozeroMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdEightATwozeroMember" order="28" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_OneOneSixMember" xlink:label="loc_aimdOneOneSixMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdOneOneSixMember" order="29" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_ThreeOneNineMember" xlink:label="loc_aimdThreeOneNineMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdThreeOneNineMember" order="30" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_FourOneNineMember" xlink:label="loc_aimdFourOneNineMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdFourOneNineMember" order="31" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_SixTwoZeroMember" xlink:label="loc_aimdSixTwoZeroMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdSixTwoZeroMember" order="32" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_SevenTwoZeroMember" xlink:label="loc_aimdSevenTwoZeroMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdSevenTwoZeroMember" order="33" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_NineTwoZeroMember" xlink:label="loc_aimdNineTwoZeroMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdNineTwoZeroMember" order="34" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_ElevenTwoOneMember" xlink:label="loc_aimdElevenTwoOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdElevenTwoOneMember" order="35" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_TenTwoOneMember" xlink:label="loc_aimdTenTwoOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_aimdTenTwoOneMember" order="36" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal" order="1" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_Date" xlink:label="loc_aimdDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aimdDate" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" order="3" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_InterestAmountOriginalRate" xlink:label="loc_aimdInterestAmountOriginalRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aimdInterestAmountOriginalRate" order="4" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_InterestAmount10" xlink:label="loc_aimdInterestAmount10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aimdInterestAmount10" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestPaid" order="6" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_InterestAfterMaturity" xlink:label="loc_aimdInterestAfterMaturity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aimdInterestAfterMaturity" order="7" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_InterestWaived" xlink:label="loc_aimdInterestWaived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aimdInterestWaived" order="8" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_InterestRateAfterMaturity" xlink:label="loc_aimdInterestRateAfterMaturity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aimdInterestRateAfterMaturity" order="9" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://aimd.com/role/ConvertibleNotesPayableAndOayableDetailsNarrative" xlink:title="000021 - Disclosure - Convertible Notes Payable and Oayable (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://aimd.com/role/RelatedPartyTransactionsDetails" xlink:title="000022 - Disclosure - Related Party Transactions (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_AinosKYMember" xlink:label="loc_aimdAinosKYMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_aimdAinosKYMember" order="31" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_RelatedPartyMember" xlink:label="loc_aimdRelatedPartyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_aimdRelatedPartyMember" order="32" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_I2ChinaMember" xlink:label="loc_aimdI2ChinaMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_aimdI2ChinaMember" order="33" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_DrStephenTChenMember" xlink:label="loc_aimdDrStephenTChenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_aimdDrStephenTChenMember" order="34" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="loc_us-gaapInterestExpenseRelatedParty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestExpenseRelatedParty" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaapConvertibleDebtCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertibleDebtCurrent" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="loc_us-gaapNotesPayableRelatedPartiesClassifiedCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNotesPayableRelatedPartiesClassifiedCurrent" order="4" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://aimd.com/role/RelatedPartyTransactionsDetails1" xlink:title="000023 - Disclosure - Related Party Transactions (Details 1)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" order="30" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="40" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" order="50" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_DrStephenTChenMember" xlink:label="loc_aimdDrStephenTChenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_aimdDrStephenTChenMember" order="31" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_BernardCohenMember" xlink:label="loc_aimdBernardCohenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_aimdBernardCohenMember" order="32" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_Shares" xlink:label="loc_aimdShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aimdShares" order="1" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_ParValue" xlink:label="loc_aimdParValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aimdParValue" order="2" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_PaidInExcessOfPar" xlink:label="loc_aimdPaidInExcessOfPar" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aimdPaidInExcessOfPar" order="3" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_TotalAmount" xlink:label="loc_aimdTotalAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aimdTotalAmount" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice" order="5" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="000024 - Disclosure - Related Party Transactions (Details Narrative)" />
  <link:definitionLink xlink:type="extended" xlink:role="http://aimd.com/role/SubsequentEventsDetailsNarrative" xlink:title="000025 - Disclosure - Subsequent Events (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" order="2000" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" order="40" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" order="21" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_DescriptionOfConsultant" xlink:label="loc_aimdDescriptionOfConsultant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aimdDescriptionOfConsultant" order="1" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>aimd-20210930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 11/15/2021-->
<!--Software architectural design and coding: Dipendra K. Singh-->
<!--Copyright (c) 2021 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:roleRef xlink:type="simple" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address Address Line 1</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address Address Line 2</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address City Or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address State Or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_4acd2d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl_4acd2d" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl_726320" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl_726320" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl_ebf968" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl_ebf968" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl_63df01" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl_63df01" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl_2c3522" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl_2c3522" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl_478304" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl_478304" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl_53ab24" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl_53ab24" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl_4649f1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl_4649f1" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl_1b8dfb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl_1b8dfb" xml:lang="en-US">Balance Sheets</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl_4208ca" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl_4208ca" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_ce648d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_ce648d" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl_161d95" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl_161d95" xml:lang="en-US">Accounts receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross" xlink:label="us-gaap_InventoryGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_lbl_bb4335" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryGross_lbl_bb4335" xml:lang="en-US">Inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl_e2a729" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl_e2a729" xml:lang="en-US">Prepaid expense and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_4d91ea" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl_4d91ea" xml:lang="en-US">Total current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl_7" xml:lang="en-US">[Assets, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="us-gaap_FiniteLivedPatentsGross" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedPatentsGross" xlink:to="us-gaap_FiniteLivedPatentsGross_lbl_d9e8e8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedPatentsGross_lbl_d9e8e8" xml:lang="en-US">Patents, net</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl_027c90" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl_027c90" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl_970938" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl_970938" xml:lang="en-US">Right of Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl_25f602" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl_25f602" xml:lang="en-US">Other Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_b76d3e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl_b76d3e" xml:lang="en-US">Total assets</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl_12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl_12" xml:lang="en-US">[Assets]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_8cd00a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl_8cd00a" xml:lang="en-US">Liabilities and Stockholders' Equity (Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl_72d3d7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl_72d3d7" xml:lang="en-US">Current liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl_c7edc2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl_c7edc2" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositContractsLiabilities" xlink:label="us-gaap_DepositContractsLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositContractsLiabilities" xlink:to="us-gaap_DepositContractsLiabilities_lbl_5b286d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositContractsLiabilities_lbl_5b286d" xml:lang="en-US">Contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl_66ea9d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl_66ea9d" xml:lang="en-US">Convertible notes payable - related party</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl_800ce2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl_800ce2" xml:lang="en-US">Convertible notes payable</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent_lbl_fc0e12" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl_fc0e12" xml:lang="en-US">Lease Obligation-Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_00bfde" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl_00bfde" xml:lang="en-US">Total current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl_20" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl_20" xml:lang="en-US">[Liabilities, Current]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl_2a1e8c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl_2a1e8c" xml:lang="en-US">Non-current liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_LeaseObligationNonCurrent" xlink:label="aimd_LeaseObligationNonCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_LeaseObligationNonCurrent" xlink:to="aimd_LeaseObligationNonCurrent_lbl_9bfc2b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_LeaseObligationNonCurrent_lbl_9bfc2b" xml:lang="en-US">Lease Obligation-Non current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_008cd6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl_008cd6" xml:lang="en-US">Total liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl_23" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl_23" xml:lang="en-US">[Liabilities]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl_c7ee89" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl_c7ee89" xml:lang="en-US">Stockholders' equity (deficit)</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl_0ddd3a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl_0ddd3a" xml:lang="en-US">Preferred stock, $0.01 par value, 10 million shares authorized, 0 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl_2f1dae" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl_2f1dae" xml:lang="en-US">Common Stock, $0.01 par value, 300 million shares authorized, 142,442,215 and 42,066,172 shares outstanding at September 30, 2021 and December 31, 2020, respectively</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl_891f53" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl_891f53" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_6d023f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl_6d023f" xml:lang="en-US">Accumulated deficit</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_TranslationAdjustmentLiability" xlink:label="aimd_TranslationAdjustmentLiability" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_TranslationAdjustmentLiability" xlink:to="aimd_TranslationAdjustmentLiability_lbl_19a451" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_TranslationAdjustmentLiability_lbl_19a451" xml:lang="en-US">Translation adjustment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_5d786f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl_5d786f" xml:lang="en-US">Total stockholders' equity (deficit)</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_30" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl_30" xml:lang="en-US">[Stockholders' Equity Attributable to Parent]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_b44af8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_b44af8" xml:lang="en-US">Total liabilities and stockholders' equity (deficit)</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl_31" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl_31" xml:lang="en-US">[Liabilities and Equity]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl_7b41eb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl_7b41eb" xml:lang="en-US">Statements of Operations (Unaudited)</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl_819756" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl_819756" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl_72ee50" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl_72ee50" xml:lang="en-US">Cost of revenues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl_8b57f6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl_8b57f6" xml:lang="en-US">Gross margin</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl_4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl_4" xml:lang="en-US">[Gross Profit]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl_67200f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl_67200f" xml:lang="en-US">Operating expenses:</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl_250016" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl_250016" xml:lang="en-US">Research and development expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl_579b5d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl_579b5d" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl_4193f4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl_4193f4" xml:lang="en-US">Total operating expense</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl_8" xml:lang="en-US">[Nonoperating Income (Expense)]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_3e4008" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl_3e4008" xml:lang="en-US">Operating loss</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl_9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl_9" xml:lang="en-US">[Operating Income (Loss)]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl_ddb15a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl_ddb15a" xml:lang="en-US">Non-operating income and expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl_c3a640" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl_c3a640" xml:lang="en-US">Interest Income, net</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl_11" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl_11" xml:lang="en-US">[Investment Income, Interest]</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_OtherLosses" xlink:label="aimd_OtherLosses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_OtherLosses" xlink:to="aimd_OtherLosses_lbl_8addae" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_OtherLosses_lbl_8addae" xml:lang="en-US">Other Losses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_TotalNonOperatingIncomeAndExpenses" xlink:to="aimd_TotalNonOperatingIncomeAndExpenses_lbl_077b1c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="aimd_TotalNonOperatingIncomeAndExpenses_lbl_077b1c" xml:lang="en-US">Total Non-operating income and expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_TotalNonOperatingIncomeAndExpenses" xlink:label="aimd_TotalNonOperatingIncomeAndExpenses" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_TotalNonOperatingIncomeAndExpenses" xlink:to="aimd_TotalNonOperatingIncomeAndExpenses_lbl_13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_TotalNonOperatingIncomeAndExpenses_lbl_13" xml:lang="en-US">[Total Non-operating income and expenses]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl_4a54b0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl_4a54b0" xml:lang="en-US">Profit before income tax</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl_14" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl_14" xml:lang="en-US">[Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest]</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_LessIncomeTax" xlink:label="aimd_LessIncomeTax" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_LessIncomeTax" xlink:to="aimd_LessIncomeTax_lbl_0e148e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_LessIncomeTax_lbl_0e148e" xml:lang="en-US">Less: Income tax</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_b9182a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl_b9182a" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl_95f621" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl_95f621" xml:lang="en-US">Basic and diluted net loss per average share available to common shareholders</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl_129f8a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl_129f8a" xml:lang="en-US">Weighted average common shares outstanding - basic and diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl_dc7d73" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl_dc7d73" xml:lang="en-US">Statements of Stockholders' Equity (Deficit) (Unaudited)</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl_90a36f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl_90a36f" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl_819d4c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl_819d4c" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl_951d33" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl_951d33" xml:lang="en-US">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl_62ec4c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl_62ec4c" xml:lang="en-US">Preferred Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl_f98124" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl_f98124" xml:lang="en-US">Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl_23" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl_23" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl_0c3e2f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl_0c3e2f" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl_5e2621" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl_5e2621" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_TranslationAdjustmentMember" xlink:label="aimd_TranslationAdjustmentMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_TranslationAdjustmentMember" xlink:to="aimd_TranslationAdjustmentMember_lbl_790d1e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_TranslationAdjustmentMember_lbl_790d1e" xml:lang="en-US">Translation Adjustment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_1b43b9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl_1b43b9" xml:lang="en-US">Balance, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl_2" xml:lang="en-US">[Shares, Issued]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_bb46d6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl_bb46d6" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_IssuanceOfStockForCompensationAmount" xlink:label="aimd_IssuanceOfStockForCompensationAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_IssuanceOfStockForCompensationAmount" xlink:to="aimd_IssuanceOfStockForCompensationAmount_lbl_c30456" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_IssuanceOfStockForCompensationAmount_lbl_c30456" xml:lang="en-US">Issuance of stock for compensation, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_IssuanceOfStockForCashShares" xlink:label="aimd_IssuanceOfStockForCashShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_IssuanceOfStockForCashShares" xlink:to="aimd_IssuanceOfStockForCashShares_lbl_02f0d2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_IssuanceOfStockForCashShares_lbl_02f0d2" xml:lang="en-US">Issuance of stock for cash, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_IssuanceOfStockForCashAmount" xlink:label="aimd_IssuanceOfStockForCashAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_IssuanceOfStockForCashAmount" xlink:to="aimd_IssuanceOfStockForCashAmount_lbl_a695f2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_IssuanceOfStockForCashAmount_lbl_a695f2" xml:lang="en-US">Issuance of stock for cash, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_WarrantExpense" xlink:label="aimd_WarrantExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_WarrantExpense" xlink:to="aimd_WarrantExpense_lbl_252deb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_WarrantExpense_lbl_252deb" xml:lang="en-US">Warrant expense</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_OptionExpense" xlink:label="aimd_OptionExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_OptionExpense" xlink:to="aimd_OptionExpense_lbl_1ffa2e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_OptionExpense_lbl_1ffa2e" xml:lang="en-US">Option expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl_34f161" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl_34f161" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_TranslationAdjustment" xlink:to="aimd_TranslationAdjustment_lbl_52d602" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aimd_TranslationAdjustment_lbl_52d602" xml:lang="en-US">Translation adjustment</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_TranslationAdjustment" xlink:label="aimd_TranslationAdjustment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_TranslationAdjustment" xlink:to="aimd_TranslationAdjustment_lbl_10" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_TranslationAdjustment_lbl_10" xml:lang="en-US">[Translation adjustment]</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_IssuanceOfStockForCompensationShares" xlink:label="aimd_IssuanceOfStockForCompensationShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_IssuanceOfStockForCompensationShares" xlink:to="aimd_IssuanceOfStockForCompensationShares_lbl_7b65c9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_IssuanceOfStockForCompensationShares_lbl_7b65c9" xml:lang="en-US">Issuance of stock for compensation, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_IssuanceOfStockForPatentAssetsShares" xlink:label="aimd_IssuanceOfStockForPatentAssetsShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_IssuanceOfStockForPatentAssetsShares" xlink:to="aimd_IssuanceOfStockForPatentAssetsShares_lbl_e8f0ec" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_IssuanceOfStockForPatentAssetsShares_lbl_e8f0ec" xml:lang="en-US">Issuance of stock for Patent assets, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_IssuanceOfStockForPatentAssetsAmount" xlink:label="aimd_IssuanceOfStockForPatentAssetsAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_IssuanceOfStockForPatentAssetsAmount" xlink:to="aimd_IssuanceOfStockForPatentAssetsAmount_lbl_97fa64" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_IssuanceOfStockForPatentAssetsAmount_lbl_97fa64" xml:lang="en-US">Issuance of stock for Patent assets, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_IssuanceOfStockForOptionShares" xlink:label="aimd_IssuanceOfStockForOptionShares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_IssuanceOfStockForOptionShares" xlink:to="aimd_IssuanceOfStockForOptionShares_lbl_f9114e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_IssuanceOfStockForOptionShares_lbl_f9114e" xml:lang="en-US">Issuance of stock for Option, shares</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_IssuanceOfStockForOptionAmount" xlink:label="aimd_IssuanceOfStockForOptionAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_IssuanceOfStockForOptionAmount" xlink:to="aimd_IssuanceOfStockForOptionAmount_lbl_4e32c3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_IssuanceOfStockForOptionAmount_lbl_4e32c3" xml:lang="en-US">Issuance of stock for Option, amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl_83e5bb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl_83e5bb" xml:lang="en-US">Balance, shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_e528f1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl_e528f1" xml:lang="en-US">Balance, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl_ef7e8f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl_ef7e8f" xml:lang="en-US">Condensed Statements of Cash Flows (Unaudited)</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_db366c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl_db366c" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_776608" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl_776608" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_InvestmentInPatents" xlink:label="aimd_InvestmentInPatents" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_InvestmentInPatents" xlink:to="aimd_InvestmentInPatents_lbl_b72445" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_InvestmentInPatents_lbl_b72445" xml:lang="en-US">Investment in patents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAssetsInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAssetsInvestingActivities_lbl_ef6986" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireAssetsInvestingActivities_lbl_ef6986" xml:lang="en-US">Purchase of fixed assets</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAssetsInvestingActivities" xlink:label="us-gaap_PaymentsToAcquireAssetsInvestingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAssetsInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAssetsInvestingActivities_lbl_5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireAssetsInvestingActivities_lbl_5" xml:lang="en-US">[Payments to Acquire Assets, Investing Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl_679cb0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl_679cb0" xml:lang="en-US">Proceeds from disposal of property, plant and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_IncreaseInRefundableDeposits" xlink:to="aimd_IncreaseInRefundableDeposits_lbl_eb2fc5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="aimd_IncreaseInRefundableDeposits_lbl_eb2fc5" xml:lang="en-US">Increase in refundable deposits</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_IncreaseInRefundableDeposits" xlink:label="aimd_IncreaseInRefundableDeposits" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_IncreaseInRefundableDeposits" xlink:to="aimd_IncreaseInRefundableDeposits_lbl_7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_IncreaseInRefundableDeposits_lbl_7" xml:lang="en-US">[Increase in refundable deposits]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_2506de" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_2506de" xml:lang="en-US">Net cash flows used in investing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_8" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl_8" xml:lang="en-US">[Net Cash Provided by (Used in) Investing Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_96d7fd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl_96d7fd" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_AdvancesFromShareholder" xlink:label="aimd_AdvancesFromShareholder" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_AdvancesFromShareholder" xlink:to="aimd_AdvancesFromShareholder_lbl_53be1e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_AdvancesFromShareholder_lbl_53be1e" xml:lang="en-US">Advances from shareholder</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl_240011" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl_240011" xml:lang="en-US">Proceeds from private placement offering, net</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl_747992" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl_747992" xml:lang="en-US">Proceeds from exercise of share options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_PaymentsOfLeaseLiabilities" xlink:to="aimd_PaymentsOfLeaseLiabilities_lbl_60fd29" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="aimd_PaymentsOfLeaseLiabilities_lbl_60fd29" xml:lang="en-US">Payments of lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_PaymentsOfLeaseLiabilities" xlink:label="aimd_PaymentsOfLeaseLiabilities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_PaymentsOfLeaseLiabilities" xlink:to="aimd_PaymentsOfLeaseLiabilities_lbl_13" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_PaymentsOfLeaseLiabilities_lbl_13" xml:lang="en-US">[Payments of lease liabilities]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl_7f1d5c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl_7f1d5c" xml:lang="en-US">Proceeds from convertible note payable -related party</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_b92b33" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_b92b33" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_15" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl_15" xml:lang="en-US">[Net Cash Provided by (Used in) Financing Activities]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl_001020" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl_001020" xml:lang="en-US">Effect of changes in exchange rates</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl_5b7a49" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl_5b7a49" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_2ab07d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_2ab07d" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_3aba4c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl_3aba4c" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl_873082" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl_873082" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl_d31cef" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl_d31cef" xml:lang="en-US">Interest paid</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl_ed9ce9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl_ed9ce9" xml:lang="en-US">Non-Cash Transactions</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_StockIssuedForAcquisitionOfPatents" xlink:label="aimd_StockIssuedForAcquisitionOfPatents" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_StockIssuedForAcquisitionOfPatents" xlink:to="aimd_StockIssuedForAcquisitionOfPatents_lbl_4bd039" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_StockIssuedForAcquisitionOfPatents_lbl_4bd039" xml:lang="en-US">Stock issued for acquisition of patents</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_StockIssuedForCompensationWarrantAndOptionExpense" xlink:label="aimd_StockIssuedForCompensationWarrantAndOptionExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_StockIssuedForCompensationWarrantAndOptionExpense" xlink:to="aimd_StockIssuedForCompensationWarrantAndOptionExpense_lbl_97e010" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_StockIssuedForCompensationWarrantAndOptionExpense_lbl_97e010" xml:lang="en-US">Stock issued for compensation, warrant and option expense</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_StockIssuedForAdvancesFromInvestors" xlink:label="aimd_StockIssuedForAdvancesFromInvestors" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_StockIssuedForAdvancesFromInvestors" xlink:to="aimd_StockIssuedForAdvancesFromInvestors_lbl_793dbb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_StockIssuedForAdvancesFromInvestors_lbl_793dbb" xml:lang="en-US">Stock issued for advances from investors</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_RouLeasedAssets" xlink:label="aimd_RouLeasedAssets" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_RouLeasedAssets" xlink:to="aimd_RouLeasedAssets_lbl_5c78c0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_RouLeasedAssets_lbl_5c78c0" xml:lang="en-US">ROU Leased assets</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl_9132d2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl_9132d2" xml:lang="en-US">Lease obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl_f08559" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl_f08559" xml:lang="en-US">Organization and Business</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl_1d6068" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl_1d6068" xml:lang="en-US">1. Organization and Business</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl_b08bff" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl_b08bff" xml:lang="en-US">General</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl_866c68" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl_866c68" xml:lang="en-US">2. General</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting_lbl_e9720b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccounting_lbl_e9720b" xml:lang="en-US">3. Basis of Presentation</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl_9e6211" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl_9e6211" xml:lang="en-US">Financial Condition</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_FinancialConditionTextBlock" xlink:label="aimd_FinancialConditionTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_FinancialConditionTextBlock" xlink:to="aimd_FinancialConditionTextBlock_lbl_37b54b" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_FinancialConditionTextBlock_lbl_37b54b" xml:lang="en-US">4. Financial Condition</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl_31d7d0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl_31d7d0" xml:lang="en-US">Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_b1bc4a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl_b1bc4a" xml:lang="en-US">5. Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl_3f37c7" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl_3f37c7" xml:lang="en-US">Convertible Notes Payable and Other Related Party Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl_490733" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl_490733" xml:lang="en-US">6. Convertible Notes Payable and Other Related Party Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl_282b8a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl_282b8a" xml:lang="en-US">Other Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_aa5036" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl_aa5036" xml:lang="en-US">7. Other Related Party Transactions</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl_49d274" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl_49d274" xml:lang="en-US">Subsequent Events</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl_75c8a5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl_75c8a5" xml:lang="en-US">8. Subsequent Events</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:label="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract_lbl_567869" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract_lbl_567869" xml:lang="en-US">Convertible Notes Payable and Other Related Party Notes Payable (Tables)</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock_lbl_c11448" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl_c11448" xml:lang="en-US">Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock" xlink:label="us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock" xlink:to="us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock_lbl_73d3c2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock_lbl_73d3c2" xml:lang="en-US">Schedule of list of related parties</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_ScheduleOfFinancialSupportListtabletextblock" xlink:label="aimd_ScheduleOfFinancialSupportListtabletextblock" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_ScheduleOfFinancialSupportListtabletextblock" xlink:to="aimd_ScheduleOfFinancialSupportListtabletextblock_lbl_5a1c57" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_ScheduleOfFinancialSupportListtabletextblock_lbl_5a1c57" xml:lang="en-US">schedule of financial support list</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl_2dbb9c" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesAxis_lbl_2dbb9c" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_SecuritiesPurchaseAgreementsMember" xlink:label="aimd_SecuritiesPurchaseAgreementsMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_SecuritiesPurchaseAgreementsMember" xlink:to="aimd_SecuritiesPurchaseAgreementsMember_lbl_6152cd" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_SecuritiesPurchaseAgreementsMember_lbl_6152cd" xml:lang="en-US">Securities Purchase Agreements [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl_06c252" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl_06c252" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl_2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl_2" xml:lang="en-US">[Cash Equivalents, at Carrying Value]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl_c70bb5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquity_lbl_c70bb5" xml:lang="en-US">Total stockholders' equity (deficit)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl_25e55d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl_25e55d" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_SharesIncreaseValue" xlink:label="aimd_SharesIncreaseValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_SharesIncreaseValue" xlink:to="aimd_SharesIncreaseValue_lbl_8ab8d9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_SharesIncreaseValue_lbl_8ab8d9" xml:lang="en-US">Shares increase value</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl_010e94" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl_010e94" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl_35de03" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl_35de03" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_DrStephenTChenMember" xlink:label="aimd_DrStephenTChenMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_DrStephenTChenMember" xlink:to="aimd_DrStephenTChenMember_lbl_7be18d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_DrStephenTChenMember_lbl_7be18d" xml:lang="en-US">Dr. Stephen T. Chen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_TwoOneSixMember" xlink:label="aimd_TwoOneSixMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_TwoOneSixMember" xlink:to="aimd_TwoOneSixMember_lbl_5cd40e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_TwoOneSixMember_lbl_5cd40e" xml:lang="en-US">2.16 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_AinosKYMember" xlink:label="aimd_AinosKYMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_AinosKYMember" xlink:to="aimd_AinosKYMember_lbl_993988" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_AinosKYMember_lbl_993988" xml:lang="en-US">Ainos KY [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_TwelveTwoOneMember" xlink:label="aimd_TwelveTwoOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_TwelveTwoOneMember" xlink:to="aimd_TwelveTwoOneMember_lbl_68d25a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_TwelveTwoOneMember_lbl_68d25a" xml:lang="en-US">12.21 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_ITwoChinaManagementGroupLLCMember" xlink:label="aimd_ITwoChinaManagementGroupLLCMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_ITwoChinaManagementGroupLLCMember" xlink:to="aimd_ITwoChinaManagementGroupLLCMember_lbl_4c6867" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_ITwoChinaManagementGroupLLCMember_lbl_4c6867" xml:lang="en-US">i2China Management Group LLC [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_ElevenOneTwoOneMember" xlink:to="aimd_ElevenOneTwoOneMember_lbl_0d0af4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aimd_ElevenOneTwoOneMember_lbl_0d0af4" xml:lang="en-US">11.21 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_ElevenOneTwoOneMember" xlink:label="aimd_ElevenOneTwoOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_ElevenOneTwoOneMember" xlink:to="aimd_ElevenOneTwoOneMember_lbl_47" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_ElevenOneTwoOneMember_lbl_47" xml:lang="en-US">[11.21 [Member]]</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_FiveOneNineMember" xlink:label="aimd_FiveOneNineMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_FiveOneNineMember" xlink:to="aimd_FiveOneNineMember_lbl_3207e4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_FiveOneNineMember_lbl_3207e4" xml:lang="en-US">5.19 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_ThirteenTwoOneMember" xlink:label="aimd_ThirteenTwoOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_ThirteenTwoOneMember" xlink:to="aimd_ThirteenTwoOneMember_lbl_cddce0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_ThirteenTwoOneMember_lbl_cddce0" xml:lang="en-US">13.21 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_TotalMember" xlink:label="aimd_TotalMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_TotalMember" xlink:to="aimd_TotalMember_lbl_1a3404" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_TotalMember_lbl_1a3404" xml:lang="en-US">Total [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_EightBTwoZeroMember" xlink:label="aimd_EightBTwoZeroMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_EightBTwoZeroMember" xlink:to="aimd_EightBTwoZeroMember_lbl_ba37e0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_EightBTwoZeroMember_lbl_ba37e0" xml:lang="en-US">8b.20 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_FourteenTwoOneMember" xlink:label="aimd_FourteenTwoOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_FourteenTwoOneMember" xlink:to="aimd_FourteenTwoOneMember_lbl_2cd012" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_FourteenTwoOneMember_lbl_2cd012" xml:lang="en-US">14.21 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_FifteenTwoOneMember" xlink:label="aimd_FifteenTwoOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_FifteenTwoOneMember" xlink:to="aimd_FifteenTwoOneMember_lbl_04e0e5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_FifteenTwoOneMember_lbl_04e0e5" xml:lang="en-US">15.21 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_SixteenTwoOneMember" xlink:label="aimd_SixteenTwoOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_SixteenTwoOneMember" xlink:to="aimd_SixteenTwoOneMember_lbl_2b3060" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_SixteenTwoOneMember_lbl_2b3060" xml:lang="en-US">16.21 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_SeventeenTwoOneMember" xlink:label="aimd_SeventeenTwoOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_SeventeenTwoOneMember" xlink:to="aimd_SeventeenTwoOneMember_lbl_d14870" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_SeventeenTwoOneMember_lbl_d14870" xml:lang="en-US">17.21 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_EighteenTwoOneMember" xlink:label="aimd_EighteenTwoOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_EighteenTwoOneMember" xlink:to="aimd_EighteenTwoOneMember_lbl_3d224a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_EighteenTwoOneMember_lbl_3d224a" xml:lang="en-US">18.21 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_NinteenTwoOneMember" xlink:label="aimd_NinteenTwoOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_NinteenTwoOneMember" xlink:to="aimd_NinteenTwoOneMember_lbl_5d2fcf" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_NinteenTwoOneMember_lbl_5d2fcf" xml:lang="en-US">19.21 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_TwentyTwoOneMember" xlink:label="aimd_TwentyTwoOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_TwentyTwoOneMember" xlink:to="aimd_TwentyTwoOneMember_lbl_4d8798" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_TwentyTwoOneMember_lbl_4d8798" xml:lang="en-US">20.21 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_EightATwozeroMember" xlink:label="aimd_EightATwozeroMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_EightATwozeroMember" xlink:to="aimd_EightATwozeroMember_lbl_6391a0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_EightATwozeroMember_lbl_6391a0" xml:lang="en-US">8a.20 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_OneOneSixMember" xlink:label="aimd_OneOneSixMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_OneOneSixMember" xlink:to="aimd_OneOneSixMember_lbl_f38c5d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_OneOneSixMember_lbl_f38c5d" xml:lang="en-US">1.16 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_ThreeOneNineMember" xlink:label="aimd_ThreeOneNineMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_ThreeOneNineMember" xlink:to="aimd_ThreeOneNineMember_lbl_d6a4de" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_ThreeOneNineMember_lbl_d6a4de" xml:lang="en-US">3.19 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_FourOneNineMember" xlink:label="aimd_FourOneNineMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_FourOneNineMember" xlink:to="aimd_FourOneNineMember_lbl_27b4ff" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_FourOneNineMember_lbl_27b4ff" xml:lang="en-US">4.19 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_SixTwoZeroMember" xlink:label="aimd_SixTwoZeroMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_SixTwoZeroMember" xlink:to="aimd_SixTwoZeroMember_lbl_610ff2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_SixTwoZeroMember_lbl_610ff2" xml:lang="en-US">6.20 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_SevenTwoZeroMember" xlink:label="aimd_SevenTwoZeroMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_SevenTwoZeroMember" xlink:to="aimd_SevenTwoZeroMember_lbl_809135" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_SevenTwoZeroMember_lbl_809135" xml:lang="en-US">7.20 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_NineTwoZeroMember" xlink:label="aimd_NineTwoZeroMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_NineTwoZeroMember" xlink:to="aimd_NineTwoZeroMember_lbl_38f40e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_NineTwoZeroMember_lbl_38f40e" xml:lang="en-US">9.20 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_ElevenTwoOneMember" xlink:label="aimd_ElevenTwoOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_ElevenTwoOneMember" xlink:to="aimd_ElevenTwoOneMember_lbl_b2e76e" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_ElevenTwoOneMember_lbl_b2e76e" xml:lang="en-US">11.21 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_TenTwoOneMember" xlink:label="aimd_TenTwoOneMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_TenTwoOneMember" xlink:to="aimd_TenTwoOneMember_lbl_94dfec" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_TenTwoOneMember_lbl_94dfec" xml:lang="en-US">10.21 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_DueDate" xlink:label="aimd_DueDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_DueDate" xlink:to="aimd_DueDate_lbl_c5601f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_DueDate_lbl_c5601f" xml:lang="en-US">Due Date</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionOriginalDebtInterestRateOfDebt" xlink:label="us-gaap_DebtConversionOriginalDebtInterestRateOfDebt" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtInterestRateOfDebt" xlink:to="us-gaap_DebtConversionOriginalDebtInterestRateOfDebt_lbl_09038f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionOriginalDebtInterestRateOfDebt_lbl_09038f" xml:lang="en-US">Annual interest rate, From effective</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_EffectiveDate" xlink:label="aimd_EffectiveDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_EffectiveDate" xlink:to="aimd_EffectiveDate_lbl_db37b1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_EffectiveDate_lbl_db37b1" xml:lang="en-US">Effective Date</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl_54c718" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl_54c718" xml:lang="en-US">Unpaid principal balance</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_AnnualInterestRateFollowingMaturity" xlink:label="aimd_AnnualInterestRateFollowingMaturity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_AnnualInterestRateFollowingMaturity" xlink:to="aimd_AnnualInterestRateFollowingMaturity_lbl_5f45ee" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_AnnualInterestRateFollowingMaturity_lbl_5f45ee" xml:lang="en-US">Annual interest rate, Following maturity</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_ConvertibleAndOtherNotesPayableRelatedParties" xlink:label="aimd_ConvertibleAndOtherNotesPayableRelatedParties" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_ConvertibleAndOtherNotesPayableRelatedParties" xlink:to="aimd_ConvertibleAndOtherNotesPayableRelatedParties_lbl_6274a6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_ConvertibleAndOtherNotesPayableRelatedParties_lbl_6274a6" xml:lang="en-US">Convertible and other notes payable- related parties</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_TotalMember" xlink:to="aimd_TotalMember_lbl_7bc5f5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aimd_TotalMember_lbl_7bc5f5" xml:lang="en-US">Total [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl_ab6580" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl_ab6580" xml:lang="en-US">Unpaid principal balance</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_Date" xlink:label="aimd_Date" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_Date" xlink:to="aimd_Date_lbl_b63e45" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_Date_lbl_b63e45" xml:lang="en-US">Date</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl_3e556f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl_3e556f" xml:lang="en-US">Interest rate original</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_InterestAmountOriginalRate" xlink:label="aimd_InterestAmountOriginalRate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_InterestAmountOriginalRate" xlink:to="aimd_InterestAmountOriginalRate_lbl_95c24a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_InterestAmountOriginalRate_lbl_95c24a" xml:lang="en-US">Interest amount original rate</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_InterestAmount10" xlink:label="aimd_InterestAmount10" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_InterestAmount10" xlink:to="aimd_InterestAmount10_lbl_64caba" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_InterestAmount10_lbl_64caba" xml:lang="en-US">Interest amount 10%</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl_94c8ec" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestPaid_lbl_94c8ec" xml:lang="en-US">Interest amount total</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_InterestAfterMaturity" xlink:label="aimd_InterestAfterMaturity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_InterestAfterMaturity" xlink:to="aimd_InterestAfterMaturity_lbl_2caba5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_InterestAfterMaturity_lbl_2caba5" xml:lang="en-US">Interest after Maturity</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_InterestWaived" xlink:label="aimd_InterestWaived" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_InterestWaived" xlink:to="aimd_InterestWaived_lbl_01ca05" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_InterestWaived_lbl_01ca05" xml:lang="en-US">Interest waived</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_InterestRateAfterMaturity" xlink:label="aimd_InterestRateAfterMaturity" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_InterestRateAfterMaturity" xlink:to="aimd_InterestRateAfterMaturity_lbl_80a4a4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_InterestRateAfterMaturity_lbl_80a4a4" xml:lang="en-US">Interest rate after maturity</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl_3ab683" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl_3ab683" xml:lang="en-US">Accrued interest</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_lbl_e1f169" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl_e1f169" xml:lang="en-US">Total Convertible and other notes payable</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl_02009a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl_02009a" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_AinosKYMember" xlink:to="aimd_AinosKYMember_lbl_b1012f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aimd_AinosKYMember_lbl_b1012f" xml:lang="en-US">Ainos KY [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_RelatedPartyMember" xlink:label="aimd_RelatedPartyMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_RelatedPartyMember" xlink:to="aimd_RelatedPartyMember_lbl_78abc2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_RelatedPartyMember_lbl_78abc2" xml:lang="en-US">Related Party</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_I2ChinaMember" xlink:label="aimd_I2ChinaMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_I2ChinaMember" xlink:to="aimd_I2ChinaMember_lbl_958cd4" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_I2ChinaMember_lbl_958cd4" xml:lang="en-US">I2China [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_DrStephenTChenMember" xlink:to="aimd_DrStephenTChenMember_lbl_0382e0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aimd_DrStephenTChenMember_lbl_0382e0" xml:lang="en-US">Dr. Stephen T. Chen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl_822c93" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl_822c93" xml:lang="en-US">Related party debt</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="us-gaap_InterestExpenseRelatedParty" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseRelatedParty" xlink:to="us-gaap_InterestExpenseRelatedParty_lbl_48680a" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseRelatedParty_lbl_48680a" xml:lang="en-US">Related Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent_lbl_d23bc0" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl_d23bc0" xml:lang="en-US">Convertible Note</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_lbl_19bdda" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_lbl_19bdda" xml:lang="en-US">Related parties</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl_cd32bc" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl_cd32bc" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_BernardCohenMember" xlink:label="aimd_BernardCohenMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_BernardCohenMember" xlink:to="aimd_BernardCohenMember_lbl_1d4ef6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_BernardCohenMember_lbl_1d4ef6" xml:lang="en-US">Bernard Cohen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_Shares" xlink:label="aimd_Shares" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_Shares" xlink:to="aimd_Shares_lbl_c149f5" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_Shares_lbl_c149f5" xml:lang="en-US">Shares</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_ParValue" xlink:label="aimd_ParValue" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_ParValue" xlink:to="aimd_ParValue_lbl_5f8548" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_ParValue_lbl_5f8548" xml:lang="en-US">Par Value</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_PaidInExcessOfPar" xlink:label="aimd_PaidInExcessOfPar" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_PaidInExcessOfPar" xlink:to="aimd_PaidInExcessOfPar_lbl_1ff250" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_PaidInExcessOfPar_lbl_1ff250" xml:lang="en-US">Paid in Excess of Par</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_TotalAmount" xlink:label="aimd_TotalAmount" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_TotalAmount" xlink:to="aimd_TotalAmount_lbl_811cce" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_TotalAmount_lbl_811cce" xml:lang="en-US">Total amount</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl_724443" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl_724443" xml:lang="en-US">Price per share</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl_71e8fb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl_71e8fb" xml:lang="en-US">Interest payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl_8ab9d2" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryNet_lbl_8ab9d2" xml:lang="en-US">Inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl_3" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl_3" xml:lang="en-US">[Inventory, Net]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableTradeCurrentAndNoncurrent" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableTradeCurrentAndNoncurrent_lbl_65b1cb" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrentAndNoncurrent_lbl_65b1cb" xml:lang="en-US">Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl_29556f" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl_29556f" xml:lang="en-US">Right of usee asset</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="us-gaap_CapitalLeaseObligations" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligations" xlink:to="us-gaap_CapitalLeaseObligations_lbl_3f01d6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligations_lbl_3f01d6" xml:lang="en-US">lease obligations</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl_937b53" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl_937b53" xml:lang="en-US">Lease payment monthly</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_ConsultingFee" xlink:label="aimd_ConsultingFee" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_ConsultingFee" xlink:to="aimd_ConsultingFee_lbl_0a62b9" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_ConsultingFee_lbl_0a62b9" xml:lang="en-US">Consulting fee</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_ConsultingFeePayable" xlink:label="aimd_ConsultingFeePayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_ConsultingFeePayable" xlink:to="aimd_ConsultingFeePayable_lbl_dad5b6" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_ConsultingFeePayable_lbl_dad5b6" xml:lang="en-US">Consulting fee payable</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopmentCosts" xlink:label="us-gaap_DevelopmentCosts" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopmentCosts" xlink:to="us-gaap_DevelopmentCosts_lbl_f73d08" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DevelopmentCosts_lbl_f73d08" xml:lang="en-US">Development expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_bd7f98" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl_bd7f98" xml:lang="en-US">Account payable</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl_a823c1" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl_a823c1" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl_c45f7d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl_c45f7d" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_DescriptionOfConsultant" xlink:label="aimd_DescriptionOfConsultant" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aimd_DescriptionOfConsultant" xlink:to="aimd_DescriptionOfConsultant_lbl_346a8d" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aimd_DescriptionOfConsultant_lbl_346a8d" xml:lang="en-US">Description of Consultant</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="aimd_StockIssuedForAdvancesFromInvestors" xlink:to="aimd_StockIssuedForAdvancesFromInvestors_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="aimd_StockIssuedForAdvancesFromInvestors_d">The fair value of stock issued for advances from investors in noncash financing activities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="aimd_AdvancesFromShareholder" xlink:to="aimd_AdvancesFromShareholder_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="aimd_AdvancesFromShareholder_d">Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" xlink:from="aimd_FinancialConditionTextBlock" xlink:to="aimd_FinancialConditionTextBlock_d" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US" xlink:label="aimd_FinancialConditionTextBlock_d">Disclosure on the Financial Condition of the company.</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>aimd-20210930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 11/15/2021-->
<!--Software architectural design and coding: Dipendra K. Singh-->
<!--Copyright (c) 2021 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://aimd.com/role/Cover" xlink:href="aimd-20210930.xsd#Cover" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/BalanceSheetsParenthetical" xlink:href="aimd-20210930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/BalanceSheets" xlink:href="aimd-20210930.xsd#BalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/StatementsOfOperationsUnaudited" xlink:href="aimd-20210930.xsd#StatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/StatementsOfStockholdersEquityDeficitUnaudited" xlink:href="aimd-20210930.xsd#StatementsOfStockholdersEquityDeficitUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:href="aimd-20210930.xsd#CondensedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/OrganizationAndBusiness" xlink:href="aimd-20210930.xsd#OrganizationAndBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/General" xlink:href="aimd-20210930.xsd#General" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/BasisOfPresentation" xlink:href="aimd-20210930.xsd#BasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/FinancialCondition" xlink:href="aimd-20210930.xsd#FinancialCondition" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/CommonStock" xlink:href="aimd-20210930.xsd#CommonStock" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/ConvertibleNotesPayableAndOtherRelatedPartyNotesPayable" xlink:href="aimd-20210930.xsd#ConvertibleNotesPayableAndOtherRelatedPartyNotesPayable" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/OtherRelatedPartyTransactions" xlink:href="aimd-20210930.xsd#OtherRelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/SubsequentEvents" xlink:href="aimd-20210930.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/ConvertibleNotesPayableAndOtherRelatedPartyNotesPayableTables" xlink:href="aimd-20210930.xsd#ConvertibleNotesPayableAndOtherRelatedPartyNotesPayableTables" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/RelatedPartyTransactionsTables" xlink:href="aimd-20210930.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/FinancialConditionDetailsNarrative" xlink:href="aimd-20210930.xsd#FinancialConditionDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/CommonStockDetailsNarrative" xlink:href="aimd-20210930.xsd#CommonStockDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails" xlink:href="aimd-20210930.xsd#ConvertibleNotesPayableAndOayableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1" xlink:href="aimd-20210930.xsd#ConvertibleNotesPayableAndOayableDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/ConvertibleNotesPayableAndOayableDetailsNarrative" xlink:href="aimd-20210930.xsd#ConvertibleNotesPayableAndOayableDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/RelatedPartyTransactionsDetails" xlink:href="aimd-20210930.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/RelatedPartyTransactionsDetails1" xlink:href="aimd-20210930.xsd#RelatedPartyTransactionsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="aimd-20210930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
  <link:roleRef roleURI="http://aimd.com/role/SubsequentEventsDetailsNarrative" xlink:href="aimd-20210930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://aimd.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
    <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://aimd.com/role/BalanceSheetsParenthetical" xlink:title="000002 - Statement - Balance Sheets (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_5670d5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_941a1b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_5670d5" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_941a1b" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_0446f0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_5670d5" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_0446f0" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_2fcdb3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_5670d5" xlink:to="loc_us-gaapPreferredStockSharesIssued_2fcdb3" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_95f886" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_5670d5" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_95f886" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_fe60f5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_5670d5" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_fe60f5" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_6753d0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_5670d5" xlink:to="loc_us-gaapCommonStockSharesAuthorized_6753d0" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_ce3504" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_5670d5" xlink:to="loc_us-gaapCommonStockSharesIssued_ce3504" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_c929c7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_5670d5" xlink:to="loc_us-gaapCommonStockSharesOutstanding_c929c7" order="8" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://aimd.com/role/BalanceSheets" xlink:title="000003 - Statement - Balance Sheets">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract_032378" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_cc1738" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract_032378" xlink:to="loc_us-gaapAssetsAbstract_cc1738" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_c0d38b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract_cc1738" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_c0d38b" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent_411cfc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract_cc1738" xlink:to="loc_us-gaapAccountsReceivableNetCurrent_411cfc" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaapInventoryGross_cf2125" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract_cc1738" xlink:to="loc_us-gaapInventoryGross_cf2125" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_f75565" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract_cc1738" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_f75565" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_9da20d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract_cc1738" xlink:to="loc_us-gaapAssetsCurrent_9da20d" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="loc_us-gaapFiniteLivedPatentsGross_ccce6c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract_cc1738" xlink:to="loc_us-gaapFiniteLivedPatentsGross_ccce6c" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_666193" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract_cc1738" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_666193" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaapFinanceLeaseRightOfUseAsset_81f595" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract_cc1738" xlink:to="loc_us-gaapFinanceLeaseRightOfUseAsset_81f595" order="9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent_490f9f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract_cc1738" xlink:to="loc_us-gaapOtherAssetsNoncurrent_490f9f" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_872819" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract_cc1738" xlink:to="loc_us-gaapAssets_872819" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_949229" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract_cc1738" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_949229" order="12" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_8490f4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_949229" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_8490f4" order="13" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent_0f72ab" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_8490f4" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent_0f72ab" order="14" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositContractsLiabilities" xlink:label="loc_us-gaapDepositContractsLiabilities_1c8203" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_8490f4" xlink:to="loc_us-gaapDepositContractsLiabilities_1c8203" order="15" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent_a9d8f0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_8490f4" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent_a9d8f0" order="16" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable_e74ee5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_8490f4" xlink:to="loc_us-gaapConvertibleNotesPayable_e74ee5" order="17" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaapCapitalLeaseObligationsCurrent_287eda" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_8490f4" xlink:to="loc_us-gaapCapitalLeaseObligationsCurrent_287eda" order="18" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_c9c43c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_8490f4" xlink:to="loc_us-gaapLiabilitiesCurrent_c9c43c" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract_e5dba7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_8490f4" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract_e5dba7" order="20" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_LeaseObligationNonCurrent" xlink:label="loc_aimdLeaseObligationNonCurrent_fb92e6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_e5dba7" xlink:to="loc_aimdLeaseObligationNonCurrent_fb92e6" order="21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_3a7a64" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_e5dba7" xlink:to="loc_us-gaapLiabilities_3a7a64" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_5c3031" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_e5dba7" xlink:to="loc_us-gaapStockholdersEquityAbstract_5c3031" order="23" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_66c139" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_5c3031" xlink:to="loc_us-gaapPreferredStockValue_66c139" order="24" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_e194a8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_5c3031" xlink:to="loc_us-gaapCommonStockValue_e194a8" order="25" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_495ab5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_5c3031" xlink:to="loc_us-gaapAdditionalPaidInCapital_495ab5" order="26" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_c7ab2d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_5c3031" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_c7ab2d" order="27" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_TranslationAdjustmentLiability" xlink:label="loc_aimdTranslationAdjustmentLiability_a0cc31" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_5c3031" xlink:to="loc_aimdTranslationAdjustmentLiability_a0cc31" order="28" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_9addc6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_5c3031" xlink:to="loc_us-gaapStockholdersEquity_9addc6" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_8fbdf4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_5c3031" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_8fbdf4" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://aimd.com/role/StatementsOfOperationsUnaudited" xlink:title="000004 - Statement - Statements of Operations (Unaudited)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract_601eb1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_d8a013" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_601eb1" xlink:to="loc_us-gaapRevenues_d8a013" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue_ad9421" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_601eb1" xlink:to="loc_us-gaapCostOfRevenue_ad9421" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit_444d29" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_601eb1" xlink:to="loc_us-gaapGrossProfit_444d29" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_13699e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract_601eb1" xlink:to="loc_us-gaapOperatingExpensesAbstract_13699e" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_1600aa" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_13699e" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_1600aa" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense_8a67a6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_13699e" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense_8a67a6" order="6" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense_af801c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_13699e" xlink:to="loc_us-gaapNonoperatingIncomeExpense_af801c" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_785b33" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_13699e" xlink:to="loc_us-gaapOperatingIncomeLoss_785b33" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_31fc39" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract_13699e" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_31fc39" order="9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest_7f2e96" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_31fc39" xlink:to="loc_us-gaapInvestmentIncomeInterest_7f2e96" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_OtherLosses" xlink:label="loc_aimdOtherLosses_59eff4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_31fc39" xlink:to="loc_aimdOtherLosses_59eff4" order="11" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_TotalNonOperatingIncomeAndExpenses" xlink:label="loc_aimdTotalNonOperatingIncomeAndExpenses_b7573b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_31fc39" xlink:to="loc_aimdTotalNonOperatingIncomeAndExpenses_b7573b" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3ad063" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_31fc39" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3ad063" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_LessIncomeTax" xlink:label="loc_aimdLessIncomeTax_c38128" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_31fc39" xlink:to="loc_aimdLessIncomeTax_c38128" order="14" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_c84ed3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_31fc39" xlink:to="loc_us-gaapNetIncomeLoss_c84ed3" order="15" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted_d05254" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_31fc39" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted_d05254" order="16" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted_e61396" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_31fc39" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted_e61396" order="17" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://aimd.com/role/StatementsOfStockholdersEquityDeficitUnaudited" xlink:title="000005 - Statement - Statements of Stockholders' Equity (Deficit) (Unaudited)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract_d45858" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_c005fc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract_d45858" xlink:to="loc_us-gaapStatementTable_c005fc" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_d89fc2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_c005fc" xlink:to="loc_us-gaapStatementLineItems_d89fc2" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis_e17f20" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_c005fc" xlink:to="loc_us-gaapStatementEquityComponentsAxis_e17f20" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_3b8864" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis_e17f20" xlink:to="loc_us-gaapEquityComponentDomain_3b8864" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0ad3f4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_3b8864" xlink:to="loc_us-gaapPreferredStockMember_0ad3f4" order="21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_7c10e1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_3b8864" xlink:to="loc_us-gaapCommonStockMember_7c10e1" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_2b7e06" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_3b8864" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_2b7e06" order="23" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_aa57d0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_3b8864" xlink:to="loc_us-gaapRetainedEarningsMember_aa57d0" order="24" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_TranslationAdjustmentMember" xlink:label="loc_aimdTranslationAdjustmentMember_f5bc22" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain_3b8864" xlink:to="loc_aimdTranslationAdjustmentMember_f5bc22" order="25" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_857215" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d89fc2" xlink:to="loc_us-gaapSharesIssued_857215" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_3ee2b4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d89fc2" xlink:to="loc_us-gaapStockholdersEquity_3ee2b4" order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_IssuanceOfStockForCompensationAmount" xlink:label="loc_aimdIssuanceOfStockForCompensationAmount_4c4879" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d89fc2" xlink:to="loc_aimdIssuanceOfStockForCompensationAmount_4c4879" order="3" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_IssuanceOfStockForCashShares" xlink:label="loc_aimdIssuanceOfStockForCashShares_43ccb7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d89fc2" xlink:to="loc_aimdIssuanceOfStockForCashShares_43ccb7" order="4" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_IssuanceOfStockForCashAmount" xlink:label="loc_aimdIssuanceOfStockForCashAmount_98e408" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d89fc2" xlink:to="loc_aimdIssuanceOfStockForCashAmount_98e408" order="5" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_WarrantExpense" xlink:label="loc_aimdWarrantExpense_6b6064" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d89fc2" xlink:to="loc_aimdWarrantExpense_6b6064" order="6" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_OptionExpense" xlink:label="loc_aimdOptionExpense_661610" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d89fc2" xlink:to="loc_aimdOptionExpense_661610" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_cbf5b6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d89fc2" xlink:to="loc_us-gaapNetIncomeLoss_cbf5b6" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_TranslationAdjustment" xlink:label="loc_aimdTranslationAdjustment_cea71e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d89fc2" xlink:to="loc_aimdTranslationAdjustment_cea71e" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_IssuanceOfStockForCompensationShares" xlink:label="loc_aimdIssuanceOfStockForCompensationShares_fa235f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d89fc2" xlink:to="loc_aimdIssuanceOfStockForCompensationShares_fa235f" order="10" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_IssuanceOfStockForPatentAssetsShares" xlink:label="loc_aimdIssuanceOfStockForPatentAssetsShares_5f06bd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d89fc2" xlink:to="loc_aimdIssuanceOfStockForPatentAssetsShares_5f06bd" order="11" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_IssuanceOfStockForPatentAssetsAmount" xlink:label="loc_aimdIssuanceOfStockForPatentAssetsAmount_11b25f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d89fc2" xlink:to="loc_aimdIssuanceOfStockForPatentAssetsAmount_11b25f" order="12" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_IssuanceOfStockForOptionShares" xlink:label="loc_aimdIssuanceOfStockForOptionShares_7949a3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d89fc2" xlink:to="loc_aimdIssuanceOfStockForOptionShares_7949a3" order="13" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_IssuanceOfStockForOptionAmount" xlink:label="loc_aimdIssuanceOfStockForOptionAmount_415354" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d89fc2" xlink:to="loc_aimdIssuanceOfStockForOptionAmount_415354" order="14" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_b9a211" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d89fc2" xlink:to="loc_us-gaapSharesIssued_b9a211" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_63ee2d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_d89fc2" xlink:to="loc_us-gaapStockholdersEquity_63ee2d" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited" xlink:title="000006 - Statement - Condensed Statements of Cash Flows (Unaudited)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract_0db96f" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_a4cf9a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_0db96f" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_a4cf9a" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_27cf2b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract_0db96f" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_27cf2b" order="2" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_InvestmentInPatents" xlink:label="loc_aimdInvestmentInPatents_0828d0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_27cf2b" xlink:to="loc_aimdInvestmentInPatents_0828d0" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAssetsInvestingActivities" xlink:label="loc_us-gaapPaymentsToAcquireAssetsInvestingActivities_66a01b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_27cf2b" xlink:to="loc_us-gaapPaymentsToAcquireAssetsInvestingActivities_66a01b" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment_f48003" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_27cf2b" xlink:to="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment_f48003" order="5" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_IncreaseInRefundableDeposits" xlink:label="loc_aimdIncreaseInRefundableDeposits_2d09d9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_27cf2b" xlink:to="loc_aimdIncreaseInRefundableDeposits_2d09d9" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_248716" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_27cf2b" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_248716" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_11e21d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_27cf2b" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_11e21d" order="8" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_AdvancesFromShareholder" xlink:label="loc_aimdAdvancesFromShareholder_5165a2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_11e21d" xlink:to="loc_aimdAdvancesFromShareholder_5165a2" order="9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_92e0dc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_11e21d" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_92e0dc" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised_f6866a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_11e21d" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised_f6866a" order="11" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_PaymentsOfLeaseLiabilities" xlink:label="loc_aimdPaymentsOfLeaseLiabilities_443cf3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_11e21d" xlink:to="loc_aimdPaymentsOfLeaseLiabilities_443cf3" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt_f0b669" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_11e21d" xlink:to="loc_us-gaapProceedsFromRepaymentsOfRelatedPartyDebt_f0b669" order="13" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_9897c5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_11e21d" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_9897c5" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashAndCashEquivalents_024bb2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_11e21d" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashAndCashEquivalents_024bb2" order="15" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease_0ebe60" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_11e21d" xlink:to="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease_0ebe60" order="16" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_9dd84f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_11e21d" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_9dd84f" order="17" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_82e494" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_11e21d" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_82e494" order="18" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract_2084d9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_11e21d" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract_2084d9" order="19" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid_e1801c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract_2084d9" xlink:to="loc_us-gaapInterestPaid_e1801c" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_49e890" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract_2084d9" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_49e890" order="21" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_StockIssuedForAcquisitionOfPatents" xlink:label="loc_aimdStockIssuedForAcquisitionOfPatents_b02989" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_49e890" xlink:to="loc_aimdStockIssuedForAcquisitionOfPatents_b02989" order="22" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_StockIssuedForCompensationWarrantAndOptionExpense" xlink:label="loc_aimdStockIssuedForCompensationWarrantAndOptionExpense_f1e79e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_49e890" xlink:to="loc_aimdStockIssuedForCompensationWarrantAndOptionExpense_f1e79e" order="23" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_StockIssuedForAdvancesFromInvestors" xlink:label="loc_aimdStockIssuedForAdvancesFromInvestors_98e7d3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_49e890" xlink:to="loc_aimdStockIssuedForAdvancesFromInvestors_98e7d3" order="24" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_RouLeasedAssets" xlink:label="loc_aimdRouLeasedAssets_b2cb27" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_49e890" xlink:to="loc_aimdRouLeasedAssets_b2cb27" order="25" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations_97af3a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract_49e890" xlink:to="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations_97af3a" order="26" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://aimd.com/role/OrganizationAndBusiness" xlink:title="000007 - Disclosure - Organization and Business">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b1eb05" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_ec64ce" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b1eb05" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_ec64ce" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://aimd.com/role/General" xlink:title="000008 - Disclosure - General">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract_457c28" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock_3cee94" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract_457c28" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock_3cee94" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://aimd.com/role/BasisOfPresentation" xlink:title="000009 - Disclosure - Basis of Presentation">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8c9795" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="loc_us-gaapBasisOfAccounting_eedfce" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8c9795" xlink:to="loc_us-gaapBasisOfAccounting_eedfce" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://aimd.com/role/FinancialCondition" xlink:title="000010 - Disclosure - Financial Condition">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract_c41c14" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_FinancialConditionTextBlock" xlink:label="loc_aimdFinancialConditionTextBlock_be4216" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract_c41c14" xlink:to="loc_aimdFinancialConditionTextBlock_be4216" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://aimd.com/role/CommonStock" xlink:title="000011 - Disclosure - Common Stock">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract_6d8cc8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_92fa76" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract_6d8cc8" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock_92fa76" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://aimd.com/role/ConvertibleNotesPayableAndOtherRelatedPartyNotesPayable" xlink:title="000012 - Disclosure - Convertible Notes Payable and Other Related Party Notes Payable">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract_f858e1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock_81093a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract_f858e1" xlink:to="loc_us-gaapDebtDisclosureTextBlock_81093a" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://aimd.com/role/OtherRelatedPartyTransactions" xlink:title="000013 - Disclosure - Other Related Party Transactions">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract_36a995" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock_9e1c8d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_36a995" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock_9e1c8d" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://aimd.com/role/SubsequentEvents" xlink:title="000014 - Disclosure - Subsequent Events">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract_274104" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock_27cafb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract_274104" xlink:to="loc_us-gaapSubsequentEventsTextBlock_27cafb" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://aimd.com/role/ConvertibleNotesPayableAndOtherRelatedPartyNotesPayableTables" xlink:title="000015 - Disclosure - Convertible Notes Payable and Other Related Party Notes Payable (Tables)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:label="loc_us-gaapConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract_61633c" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaapConvertibleDebtTableTextBlock_745779" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract_61633c" xlink:to="loc_us-gaapConvertibleDebtTableTextBlock_745779" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://aimd.com/role/RelatedPartyTransactionsTables" xlink:title="000016 - Disclosure - Related Party Transactions (Tables)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract_411b13" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfRealEstatePropertiesTableTextBlock_af9f04" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_411b13" xlink:to="loc_us-gaapScheduleOfRealEstatePropertiesTableTextBlock_af9f04" order="1" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_ScheduleOfFinancialSupportListtabletextblock" xlink:label="loc_aimdScheduleOfFinancialSupportListtabletextblock_f384e2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_411b13" xlink:to="loc_aimdScheduleOfFinancialSupportListtabletextblock_f384e2" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://aimd.com/role/FinancialConditionDetailsNarrative" xlink:title="000017 - Disclosure - Financial Condition (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract_af4ec2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_e9642f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract_af4ec2" xlink:to="loc_us-gaapStatementTable_e9642f" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_f0b8a8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_e9642f" xlink:to="loc_us-gaapStatementLineItems_f0b8a8" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis_338dd6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_e9642f" xlink:to="loc_srtConsolidatedEntitiesAxis_338dd6" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_dda08f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis_338dd6" xlink:to="loc_srtConsolidatedEntitiesDomain_dda08f" order="20" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_SecuritiesPurchaseAgreementsMember" xlink:label="loc_aimdSecuritiesPurchaseAgreementsMember_4f5134" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain_dda08f" xlink:to="loc_aimdSecuritiesPurchaseAgreementsMember_4f5134" order="21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue_ae2da1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f0b8a8" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue_ae2da1" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_76f575" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f0b8a8" xlink:to="loc_us-gaapStockholdersEquity_76f575" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_edefc2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_f0b8a8" xlink:to="loc_us-gaapRevenues_edefc2" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://aimd.com/role/CommonStockDetailsNarrative" xlink:title="000018 - Disclosure - Common Stock (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_9460b7" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_SharesIncreaseValue" xlink:label="loc_aimdSharesIncreaseValue_b55669" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract_9460b7" xlink:to="loc_aimdSharesIncreaseValue_b55669" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails" xlink:title="000019 - Disclosure - Convertible Notes Payable and Oayable (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:label="loc_us-gaapConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract_fa6ddf" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_ba6758" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract_fa6ddf" xlink:to="loc_us-gaapStatementTable_ba6758" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_eecdcb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_ba6758" xlink:to="loc_us-gaapStatementLineItems_eecdcb" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis_691dc2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_ba6758" xlink:to="loc_srtTitleOfIndividualAxis_691dc2" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_b35b6a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis_691dc2" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_b35b6a" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis_7369d6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_ba6758" xlink:to="loc_srtRangeAxis_7369d6" order="40" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_6745a5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis_7369d6" xlink:to="loc_srtRangeMember_6745a5" order="40" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_DrStephenTChenMember" xlink:label="loc_aimdDrStephenTChenMember_df5ff0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_b35b6a" xlink:to="loc_aimdDrStephenTChenMember_df5ff0" order="41" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_TwoOneSixMember" xlink:label="loc_aimdTwoOneSixMember_221525" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_6745a5" xlink:to="loc_aimdTwoOneSixMember_221525" order="42" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_AinosKYMember" xlink:label="loc_aimdAinosKYMember_722693" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_b35b6a" xlink:to="loc_aimdAinosKYMember_722693" order="43" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_TwelveTwoOneMember" xlink:label="loc_aimdTwelveTwoOneMember_17fb9e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_6745a5" xlink:to="loc_aimdTwelveTwoOneMember_17fb9e" order="44" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_ITwoChinaManagementGroupLLCMember" xlink:label="loc_aimdITwoChinaManagementGroupLLCMember_292250" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_b35b6a" xlink:to="loc_aimdITwoChinaManagementGroupLLCMember_292250" order="45" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_ElevenOneTwoOneMember" xlink:label="loc_aimdElevenOneTwoOneMember_c86d18" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_6745a5" xlink:to="loc_aimdElevenOneTwoOneMember_c86d18" order="46" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_FiveOneNineMember" xlink:label="loc_aimdFiveOneNineMember_3d5efc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_6745a5" xlink:to="loc_aimdFiveOneNineMember_3d5efc" order="47" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_ThirteenTwoOneMember" xlink:label="loc_aimdThirteenTwoOneMember_eecc13" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_6745a5" xlink:to="loc_aimdThirteenTwoOneMember_eecc13" order="48" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_TotalMember" xlink:label="loc_aimdTotalMember_39b7fe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_6745a5" xlink:to="loc_aimdTotalMember_39b7fe" order="49" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_EightBTwoZeroMember" xlink:label="loc_aimdEightBTwoZeroMember_8622bc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_6745a5" xlink:to="loc_aimdEightBTwoZeroMember_8622bc" order="50" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_FourteenTwoOneMember" xlink:label="loc_aimdFourteenTwoOneMember_3cff12" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_6745a5" xlink:to="loc_aimdFourteenTwoOneMember_3cff12" order="51" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_FifteenTwoOneMember" xlink:label="loc_aimdFifteenTwoOneMember_3e3264" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_6745a5" xlink:to="loc_aimdFifteenTwoOneMember_3e3264" order="52" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_SixteenTwoOneMember" xlink:label="loc_aimdSixteenTwoOneMember_30062c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_6745a5" xlink:to="loc_aimdSixteenTwoOneMember_30062c" order="53" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_SeventeenTwoOneMember" xlink:label="loc_aimdSeventeenTwoOneMember_942ed4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_6745a5" xlink:to="loc_aimdSeventeenTwoOneMember_942ed4" order="54" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_EighteenTwoOneMember" xlink:label="loc_aimdEighteenTwoOneMember_99857e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_6745a5" xlink:to="loc_aimdEighteenTwoOneMember_99857e" order="55" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_NinteenTwoOneMember" xlink:label="loc_aimdNinteenTwoOneMember_c22891" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_6745a5" xlink:to="loc_aimdNinteenTwoOneMember_c22891" order="56" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_TwentyTwoOneMember" xlink:label="loc_aimdTwentyTwoOneMember_38adee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_6745a5" xlink:to="loc_aimdTwentyTwoOneMember_38adee" order="57" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_EightATwozeroMember" xlink:label="loc_aimdEightATwozeroMember_2d84b7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_6745a5" xlink:to="loc_aimdEightATwozeroMember_2d84b7" order="58" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_OneOneSixMember" xlink:label="loc_aimdOneOneSixMember_15f6f0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_6745a5" xlink:to="loc_aimdOneOneSixMember_15f6f0" order="59" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_ThreeOneNineMember" xlink:label="loc_aimdThreeOneNineMember_0002a7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_6745a5" xlink:to="loc_aimdThreeOneNineMember_0002a7" order="60" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_FourOneNineMember" xlink:label="loc_aimdFourOneNineMember_a9018b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_6745a5" xlink:to="loc_aimdFourOneNineMember_a9018b" order="61" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_SixTwoZeroMember" xlink:label="loc_aimdSixTwoZeroMember_b84c90" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_6745a5" xlink:to="loc_aimdSixTwoZeroMember_b84c90" order="62" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_SevenTwoZeroMember" xlink:label="loc_aimdSevenTwoZeroMember_a6f530" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_6745a5" xlink:to="loc_aimdSevenTwoZeroMember_a6f530" order="63" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_NineTwoZeroMember" xlink:label="loc_aimdNineTwoZeroMember_1bc435" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_6745a5" xlink:to="loc_aimdNineTwoZeroMember_1bc435" order="64" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_ElevenTwoOneMember" xlink:label="loc_aimdElevenTwoOneMember_8970ae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_6745a5" xlink:to="loc_aimdElevenTwoOneMember_8970ae" order="65" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_TenTwoOneMember" xlink:label="loc_aimdTenTwoOneMember_b20d08" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_6745a5" xlink:to="loc_aimdTenTwoOneMember_b20d08" order="66" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_DueDate" xlink:label="loc_aimdDueDate_4be9b7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_eecdcb" xlink:to="loc_aimdDueDate_4be9b7" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionOriginalDebtInterestRateOfDebt" xlink:label="loc_us-gaapDebtConversionOriginalDebtInterestRateOfDebt_23d617" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_eecdcb" xlink:to="loc_us-gaapDebtConversionOriginalDebtInterestRateOfDebt_23d617" order="2" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_EffectiveDate" xlink:label="loc_aimdEffectiveDate_deb086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_eecdcb" xlink:to="loc_aimdEffectiveDate_deb086" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal_513f4d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_eecdcb" xlink:to="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal_513f4d" order="4" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_AnnualInterestRateFollowingMaturity" xlink:label="loc_aimdAnnualInterestRateFollowingMaturity_51f043" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_eecdcb" xlink:to="loc_aimdAnnualInterestRateFollowingMaturity_51f043" order="5" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_ConvertibleAndOtherNotesPayableRelatedParties" xlink:label="loc_aimdConvertibleAndOtherNotesPayableRelatedParties_6a62fc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_eecdcb" xlink:to="loc_aimdConvertibleAndOtherNotesPayableRelatedParties_6a62fc" order="6" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1" xlink:title="000020 - Disclosure - Convertible Notes Payable and Oayable (Details 1)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:label="loc_us-gaapConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract_01a3da" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_5d5592" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract_01a3da" xlink:to="loc_us-gaapStatementTable_5d5592" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_0f681a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_5d5592" xlink:to="loc_us-gaapStatementLineItems_0f681a" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis_1d64c6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_5d5592" xlink:to="loc_srtTitleOfIndividualAxis_1d64c6" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_c8e2d0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis_1d64c6" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_c8e2d0" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis_2e1c1a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_5d5592" xlink:to="loc_srtRangeAxis_2e1c1a" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_ed3f72" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis_2e1c1a" xlink:to="loc_srtRangeMember_ed3f72" order="20" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_DrStephenTChenMember" xlink:label="loc_aimdDrStephenTChenMember_633bfe" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_c8e2d0" xlink:to="loc_aimdDrStephenTChenMember_633bfe" order="21" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_TwoOneSixMember" xlink:label="loc_aimdTwoOneSixMember_bff132" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_ed3f72" xlink:to="loc_aimdTwoOneSixMember_bff132" order="22" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_ITwoChinaManagementGroupLLCMember" xlink:label="loc_aimdITwoChinaManagementGroupLLCMember_87e25a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_c8e2d0" xlink:to="loc_aimdITwoChinaManagementGroupLLCMember_87e25a" order="23" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_ElevenOneTwoOneMember" xlink:label="loc_aimdElevenOneTwoOneMember_8c5378" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_ed3f72" xlink:to="loc_aimdElevenOneTwoOneMember_8c5378" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_FiveOneNineMember" xlink:label="loc_aimdFiveOneNineMember_7100ce" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_ed3f72" xlink:to="loc_aimdFiveOneNineMember_7100ce" order="25" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_TotalMember" xlink:label="loc_aimdTotalMember_bcf18b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_ed3f72" xlink:to="loc_aimdTotalMember_bcf18b" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_EightBTwoZeroMember" xlink:label="loc_aimdEightBTwoZeroMember_7b16a8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_ed3f72" xlink:to="loc_aimdEightBTwoZeroMember_7b16a8" order="27" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_EightATwozeroMember" xlink:label="loc_aimdEightATwozeroMember_e216a6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_ed3f72" xlink:to="loc_aimdEightATwozeroMember_e216a6" order="28" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_OneOneSixMember" xlink:label="loc_aimdOneOneSixMember_376d1b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_ed3f72" xlink:to="loc_aimdOneOneSixMember_376d1b" order="29" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_ThreeOneNineMember" xlink:label="loc_aimdThreeOneNineMember_86bfa2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_ed3f72" xlink:to="loc_aimdThreeOneNineMember_86bfa2" order="30" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_FourOneNineMember" xlink:label="loc_aimdFourOneNineMember_625ef2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_ed3f72" xlink:to="loc_aimdFourOneNineMember_625ef2" order="31" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_SixTwoZeroMember" xlink:label="loc_aimdSixTwoZeroMember_62447d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_ed3f72" xlink:to="loc_aimdSixTwoZeroMember_62447d" order="32" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_SevenTwoZeroMember" xlink:label="loc_aimdSevenTwoZeroMember_ac8148" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_ed3f72" xlink:to="loc_aimdSevenTwoZeroMember_ac8148" order="33" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_NineTwoZeroMember" xlink:label="loc_aimdNineTwoZeroMember_b98b78" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_ed3f72" xlink:to="loc_aimdNineTwoZeroMember_b98b78" order="34" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_ElevenTwoOneMember" xlink:label="loc_aimdElevenTwoOneMember_330351" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_ed3f72" xlink:to="loc_aimdElevenTwoOneMember_330351" order="35" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_TenTwoOneMember" xlink:label="loc_aimdTenTwoOneMember_438f0c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember_ed3f72" xlink:to="loc_aimdTenTwoOneMember_438f0c" order="36" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal_72c138" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0f681a" xlink:to="loc_us-gaapDebtInstrumentPeriodicPaymentPrincipal_72c138" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_Date" xlink:label="loc_aimdDate_9602ea" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0f681a" xlink:to="loc_aimdDate_9602ea" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_f4745b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0f681a" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_f4745b" order="3" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_InterestAmountOriginalRate" xlink:label="loc_aimdInterestAmountOriginalRate_77a563" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0f681a" xlink:to="loc_aimdInterestAmountOriginalRate_77a563" order="4" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_InterestAmount10" xlink:label="loc_aimdInterestAmount10_076d9d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0f681a" xlink:to="loc_aimdInterestAmount10_076d9d" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid_2ab934" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0f681a" xlink:to="loc_us-gaapInterestPaid_2ab934" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_InterestAfterMaturity" xlink:label="loc_aimdInterestAfterMaturity_fd1483" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0f681a" xlink:to="loc_aimdInterestAfterMaturity_fd1483" order="7" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_InterestWaived" xlink:label="loc_aimdInterestWaived_352b95" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0f681a" xlink:to="loc_aimdInterestWaived_352b95" order="8" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_InterestRateAfterMaturity" xlink:label="loc_aimdInterestRateAfterMaturity_89e447" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_0f681a" xlink:to="loc_aimdInterestRateAfterMaturity_89e447" order="9" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://aimd.com/role/ConvertibleNotesPayableAndOayableDetailsNarrative" xlink:title="000021 - Disclosure - Convertible Notes Payable and Oayable (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:label="loc_us-gaapConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract_a1be56" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_ec3a03" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract_a1be56" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_ec3a03" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaapDebtConversionOriginalDebtAmount1_673776" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract_a1be56" xlink:to="loc_us-gaapDebtConversionOriginalDebtAmount1_673776" order="2" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://aimd.com/role/RelatedPartyTransactionsDetails" xlink:title="000022 - Disclosure - Related Party Transactions (Details)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract_560c56" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_dde76e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_560c56" xlink:to="loc_us-gaapStatementTable_dde76e" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_70f2ec" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_dde76e" xlink:to="loc_us-gaapStatementLineItems_70f2ec" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis_9f5ee8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_dde76e" xlink:to="loc_srtTitleOfIndividualAxis_9f5ee8" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_950dbb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis_9f5ee8" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_950dbb" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis_656998" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_dde76e" xlink:to="loc_us-gaapRelatedPartyTransactionAxis_656998" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_d4d66f" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis_656998" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_d4d66f" order="30" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_AinosKYMember" xlink:label="loc_aimdAinosKYMember_cf09eb" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_950dbb" xlink:to="loc_aimdAinosKYMember_cf09eb" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_RelatedPartyMember" xlink:label="loc_aimdRelatedPartyMember_9cd8e4" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain_d4d66f" xlink:to="loc_aimdRelatedPartyMember_9cd8e4" order="32" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_I2ChinaMember" xlink:label="loc_aimdI2ChinaMember_a7d39e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain_d4d66f" xlink:to="loc_aimdI2ChinaMember_a7d39e" order="33" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_DrStephenTChenMember" xlink:label="loc_aimdDrStephenTChenMember_8f387e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_950dbb" xlink:to="loc_aimdDrStephenTChenMember_8f387e" order="34" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt_0d54bd" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_70f2ec" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt_0d54bd" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="loc_us-gaapInterestExpenseRelatedParty_8dc4a6" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_70f2ec" xlink:to="loc_us-gaapInterestExpenseRelatedParty_8dc4a6" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaapConvertibleDebtCurrent_64070e" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_70f2ec" xlink:to="loc_us-gaapConvertibleDebtCurrent_64070e" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="loc_us-gaapNotesPayableRelatedPartiesClassifiedCurrent_10efe3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_70f2ec" xlink:to="loc_us-gaapNotesPayableRelatedPartiesClassifiedCurrent_10efe3" order="4" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://aimd.com/role/RelatedPartyTransactionsDetails1" xlink:title="000023 - Disclosure - Related Party Transactions (Details 1)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract_77673b" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_e6f6d3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_77673b" xlink:to="loc_us-gaapStatementTable_e6f6d3" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_3cd1ad" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_e6f6d3" xlink:to="loc_us-gaapStatementLineItems_3cd1ad" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis_8da066" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_e6f6d3" xlink:to="loc_srtTitleOfIndividualAxis_8da066" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_a98066" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis_8da066" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_a98066" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_864880" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_e6f6d3" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_864880" order="30" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_41a453" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_864880" xlink:to="loc_us-gaapRelatedPartyDomain_41a453" order="30" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_DrStephenTChenMember" xlink:label="loc_aimdDrStephenTChenMember_9c03a7" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_a98066" xlink:to="loc_aimdDrStephenTChenMember_9c03a7" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_BernardCohenMember" xlink:label="loc_aimdBernardCohenMember_214d35" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain_41a453" xlink:to="loc_aimdBernardCohenMember_214d35" order="32" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_Shares" xlink:label="loc_aimdShares_e0c940" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3cd1ad" xlink:to="loc_aimdShares_e0c940" order="1" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_ParValue" xlink:label="loc_aimdParValue_9aaec5" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3cd1ad" xlink:to="loc_aimdParValue_9aaec5" order="2" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_PaidInExcessOfPar" xlink:label="loc_aimdPaidInExcessOfPar_409590" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3cd1ad" xlink:to="loc_aimdPaidInExcessOfPar_409590" order="3" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_TotalAmount" xlink:label="loc_aimdTotalAmount_00a2e8" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3cd1ad" xlink:to="loc_aimdTotalAmount_00a2e8" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_2badae" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_3cd1ad" xlink:to="loc_us-gaapSharePrice_2badae" order="5" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="000024 - Disclosure - Related Party Transactions (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract_00cdfe" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapInterestPayableCurrentAndNoncurrent_dc1c39" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_00cdfe" xlink:to="loc_us-gaapInterestPayableCurrentAndNoncurrent_dc1c39" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet_991560" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_00cdfe" xlink:to="loc_us-gaapInventoryNet_991560" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableTradeCurrentAndNoncurrent_4ba797" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_00cdfe" xlink:to="loc_us-gaapAccountsPayableTradeCurrentAndNoncurrent_4ba797" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_0c7e7b" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_00cdfe" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_0c7e7b" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="loc_us-gaapCapitalLeaseObligations_f5f9bc" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_00cdfe" xlink:to="loc_us-gaapCapitalLeaseObligations_f5f9bc" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense_971a86" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_00cdfe" xlink:to="loc_us-gaapLeaseAndRentalExpense_971a86" order="6" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_ConsultingFee" xlink:label="loc_aimdConsultingFee_5a6a63" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_00cdfe" xlink:to="loc_aimdConsultingFee_5a6a63" order="7" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_ConsultingFeePayable" xlink:label="loc_aimdConsultingFeePayable_53cdc9" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_00cdfe" xlink:to="loc_aimdConsultingFeePayable_53cdc9" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopmentCosts" xlink:label="loc_us-gaapDevelopmentCosts_6306ab" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_00cdfe" xlink:to="loc_us-gaapDevelopmentCosts_6306ab" order="9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable_4219b0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract_00cdfe" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable_4219b0" order="10" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://aimd.com/role/SubsequentEventsDetailsNarrative" xlink:title="000025 - Disclosure - Subsequent Events (Details Narrative)">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract_52f614" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable_60a3a0" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract_52f614" xlink:to="loc_us-gaapStatementTable_60a3a0" order="100" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems_06c23a" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_60a3a0" xlink:to="loc_us-gaapStatementLineItems_06c23a" order="2000" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis_ddfd5c" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable_60a3a0" xlink:to="loc_us-gaapSubsequentEventTypeAxis_ddfd5c" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_995968" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis_ddfd5c" xlink:to="loc_us-gaapSubsequentEventTypeDomain_995968" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_6ac24d" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain_995968" xlink:to="loc_us-gaapSubsequentEventMember_6ac24d" order="21" />
    <link:loc xlink:type="locator" xlink:href="aimd-20210930.xsd#aimd_DescriptionOfConsultant" xlink:label="loc_aimdDescriptionOfConsultant_b26292" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems_06c23a" xlink:to="loc_aimdDescriptionOfConsultant_b26292" order="1" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>aimd_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:aimd="http://aimd.com/20210930"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="aimd-20210930.xsd" xlink:type="simple"/>
    <context id="From2021-01-01to2021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-23to2021-11-01_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-23</startDate>
            <endDate>2021-11-01</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_aimd_BernardCohenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">aimd:BernardCohenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_aimd_DrStephenTChenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2021-01-01to2021-09-30_aimd_I2ChinaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:I2ChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_aimd_I2ChinaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:I2ChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_aimd_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-01-01to2021-09-30_aimd_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">aimd:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_aimd_AinosKYMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:AinosKYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-01-01to2021-09-30_aimd_AinosKYMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:AinosKYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_OneOneSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:OneOneSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_ElevenOneTwoOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:ElevenOneTwoOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:ITwoChinaManagementGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:EightBTwoZeroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:ITwoChinaManagementGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightATwozeroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:EightATwozeroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:ITwoChinaManagementGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_FiveOneNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:FiveOneNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:ITwoChinaManagementGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_aimd_DrStephenTChenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_ElevenTwoOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:ElevenTwoOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_TenTwoOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:TenTwoOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_NineTwoZeroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:NineTwoZeroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_SevenTwoZeroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:SevenTwoZeroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_SixTwoZeroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:SixTwoZeroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_FourOneNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:FourOneNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_ThreeOneNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:ThreeOneNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_TwoOneSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:TwoOneSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2020-01-01to2020-12-31_aimd_DrStephenTChenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-12-31_aimd_DrStephenTChenMember_aimd_NineTwoZeroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:NineTwoZeroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TenTwoOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:TenTwoOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ElevenTwoOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:ElevenTwoOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-12-31_aimd_DrStephenTChenMember_aimd_SixTwoZeroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:SixTwoZeroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_NineTwoZeroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:NineTwoZeroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-12-31_aimd_DrStephenTChenMember_aimd_SevenTwoZeroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:SevenTwoZeroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SevenTwoZeroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:SevenTwoZeroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SixTwoZeroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:SixTwoZeroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-12-31_aimd_DrStephenTChenMember_aimd_FourOneNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:FourOneNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-12-31_aimd_DrStephenTChenMember_aimd_TwoOneSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:TwoOneSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_FourOneNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:FourOneNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-12-31_aimd_DrStephenTChenMember_aimd_ThreeOneNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:ThreeOneNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-12-31_aimd_DrStephenTChenMember_aimd_OneOneSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:OneOneSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ThreeOneNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:ThreeOneNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_OneOneSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:OneOneSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-12-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:EightBTwoZeroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:ITwoChinaManagementGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-12-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightATwozeroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:EightATwozeroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:ITwoChinaManagementGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightATwozeroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:EightATwozeroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:ITwoChinaManagementGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-12-31_aimd_AinosKYMember_aimd_TotalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:TotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:AinosKYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_TotalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:TotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:AinosKYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_TwentyTwoOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:TwentyTwoOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:AinosKYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_NinteenTwoOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:NinteenTwoOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:AinosKYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_EighteenTwoOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:EighteenTwoOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:AinosKYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_SeventeenTwoOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:SeventeenTwoOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:AinosKYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_SixteenTwoOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:SixteenTwoOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:AinosKYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_FifteenTwoOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:FifteenTwoOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:AinosKYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_FourteenTwoOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:FourteenTwoOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:AinosKYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:EightBTwoZeroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:ITwoChinaManagementGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-12-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_TotalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:TotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:ITwoChinaManagementGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_TotalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:TotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:ITwoChinaManagementGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_ThirteenTwoOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:ThirteenTwoOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:AinosKYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-12-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_FiveOneNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:FiveOneNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:ITwoChinaManagementGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_FiveOneNineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:FiveOneNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:ITwoChinaManagementGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_ElevenOneTwoOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:ElevenOneTwoOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:ITwoChinaManagementGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_TwelveTwoOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:TwelveTwoOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:AinosKYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TwoOneSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">aimd:TwoOneSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">aimd:DrStephenTChenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-09-30_aimd_SecuritiesPurchaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">aimd:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-09-30_aimd_SecuritiesPurchaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">aimd:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-09-30_aimd_SecuritiesPurchaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">aimd:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_aimd_SecuritiesPurchaseAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">aimd:SecuritiesPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-07-01to2021-09-30_aimd_TranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aimd:TranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-01to2021-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-01to2021-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-01to2021-09-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_aimd_TranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aimd:TranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_aimd_TranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aimd:TranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2021-01-01to2021-09-30_aimd_TranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aimd:TranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-01to2021-09-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_aimd_TranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aimd:TranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-07-01to2020-09-30_aimd_TranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aimd:TranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-01to2020-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-01to2020-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-01to2020-09-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_aimd_TranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aimd:TranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_aimd_TranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aimd:TranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-01-01to2020-09-30_aimd_TranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aimd:TranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-01-01to2020-09-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_aimd_TranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">aimd:TranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-01to2020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-01to2020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-01to2021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-11-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001014763</identifier>
        </entity>
        <period>
            <instant>2021-11-15</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-01-01to2021-09-30">0001014763</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-01-01to2021-09-30">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2021-01-01to2021-09-30">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityShellCompany contextRef="From2021-01-01to2021-09-30">false</dei:EntityShellCompany>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-01-01to2021-09-30">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentFiscalPeriodFocus contextRef="From2021-01-01to2021-09-30">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2021-01-01to2021-09-30">2021</dei:DocumentFiscalYearFocus>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-12-31" decimals="0" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2020-12-31" decimals="0" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-09-30" decimals="0" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2020-12-31" decimals="0" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-12-31" decimals="0" unitRef="Shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-12-31" decimals="0" unitRef="Shares">42066172</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-09-30" decimals="0" unitRef="Shares">142442215</us-gaap:CommonStockSharesOutstanding>
    <aimd:OptionExpense
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      unitRef="USD">272604</aimd:OptionExpense>
    <us-gaap:SharesIssued
      contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="Shares">1</us-gaap:SharesIssued>
    <us-gaap:Revenues
      contextRef="From2020-01-01to2020-09-30_aimd_SecuritiesPurchaseAgreementsMember"
      decimals="0"
      unitRef="USD">15786</us-gaap:Revenues>
    <aimd:DueDate contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember">2021/04/01</aimd:DueDate>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember"
      decimals="INF"
      unitRef="Pure">0.0185</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <aimd:EffectiveDate contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember">2021/01/01</aimd:EffectiveDate>
    <aimd:AnnualInterestRateFollowingMaturity
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember"
      decimals="INF"
      unitRef="Pure">0.1</aimd:AnnualInterestRateFollowingMaturity>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_ElevenTwoOneMember"
      decimals="INF"
      unitRef="Pure">0.0065</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <aimd:Date contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember">3/18/2016</aimd:Date>
    <aimd:Date contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_ElevenOneTwoOneMember">3/18/2016</aimd:Date>
    <aimd:Date contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_TotalMember">3/18/2016</aimd:Date>
    <aimd:ParValue
      contextRef="AsOf2021-06-30_aimd_BernardCohenMember"
      decimals="0"
      unitRef="USD">534</aimd:ParValue>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      unitRef="USD">122680</us-gaap:IncreaseDecreaseInAccountsPayable>
    <dei:DocumentType contextRef="From2021-01-01to2021-09-30">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2021-01-01to2021-09-30">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2021-01-01to2021-09-30">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2021-01-01to2021-09-30">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2021-01-01to2021-09-30">0-20791</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2021-01-01to2021-09-30">AINOS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-01-01to2021-09-30">TX</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-01-01to2021-09-30">75-1974352</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-01-01to2021-09-30">8880 Rio San Diego Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-01-01to2021-09-30">Ste. 800</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-01-01to2021-09-30">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-01-01to2021-09-30">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-01-01to2021-09-30">92108</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-01-01to2021-09-30">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-01-01to2021-09-30">869-2986</dei:LocalPhoneNumber>
    <dei:EntityCurrentReportingStatus contextRef="From2021-01-01to2021-09-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2021-01-01to2021-09-30">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2021-01-01to2021-09-30">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2021-01-01to2021-09-30">true</dei:EntitySmallBusiness>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2021-11-15" decimals="INF" unitRef="Shares">142442215</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_907"
      unitRef="USD">706931</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_908"
      unitRef="USD">22245</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_909"
      unitRef="USD">44643</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_910"
      unitRef="USD">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryGross
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_911"
      unitRef="USD">175</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_912"
      unitRef="USD">3024</us-gaap:InventoryGross>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_913"
      unitRef="USD">133065</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_914"
      unitRef="USD">51144</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_915"
      unitRef="USD">884814</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_916"
      unitRef="USD">76413</us-gaap:AssetsCurrent>
    <us-gaap:FiniteLivedPatentsGross
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_917"
      unitRef="USD">19011337</us-gaap:FiniteLivedPatentsGross>
    <us-gaap:FiniteLivedPatentsGross
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_918"
      unitRef="USD">180628</us-gaap:FiniteLivedPatentsGross>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_919"
      unitRef="USD">39956</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_920"
      unitRef="USD">3249</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_921"
      unitRef="USD">55724</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_922"
      unitRef="USD">0</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_923"
      unitRef="USD">1795</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_924"
      unitRef="USD">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_925"
      unitRef="USD">19993626</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_926"
      unitRef="USD">260290</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_929"
      unitRef="USD">578549</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_930"
      unitRef="USD">145567</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DepositContractsLiabilities
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_931"
      unitRef="USD">37616</us-gaap:DepositContractsLiabilities>
    <us-gaap:DepositContractsLiabilities
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_932"
      unitRef="USD">0</us-gaap:DepositContractsLiabilities>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_933"
      unitRef="USD">2000193</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_934"
      unitRef="USD">805001</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_935"
      unitRef="USD">185000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_936"
      unitRef="USD">148000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:CapitalLeaseObligationsCurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_937"
      unitRef="USD">20619</us-gaap:CapitalLeaseObligationsCurrent>
    <us-gaap:CapitalLeaseObligationsCurrent
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_938"
      unitRef="USD">0</us-gaap:CapitalLeaseObligationsCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_939"
      unitRef="USD">2821977</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_940"
      unitRef="USD">1098568</us-gaap:LiabilitiesCurrent>
    <aimd:LeaseObligationNonCurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_942"
      unitRef="USD">35289</aimd:LeaseObligationNonCurrent>
    <aimd:LeaseObligationNonCurrent
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_943"
      unitRef="USD">0</aimd:LeaseObligationNonCurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_944"
      unitRef="USD">2857266</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_945"
      unitRef="USD">1098568</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-09-30"
      decimals="INF"
      id="fid_256"
      unitRef="USDPShares">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2021-09-30"
      decimals="-6"
      id="fid_258"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_260"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_947"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_948"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-09-30"
      decimals="INF"
      id="fid_264"
      unitRef="USDPShares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2021-09-30"
      decimals="-6"
      id="fid_266"
      unitRef="Shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_268"
      unitRef="Shares">142442215</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_271"
      unitRef="Shares">42066172</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_949"
      unitRef="USD">1424422</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_950"
      unitRef="USD">420662</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_951"
      unitRef="USD">24369245</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_952"
      unitRef="USD">4961315</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_953"
      unitRef="USD">-8664145</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_954"
      unitRef="USD">-6220255</us-gaap:RetainedEarningsAccumulatedDeficit>
    <aimd:TranslationAdjustmentLiability
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_955"
      unitRef="USD">6838</aimd:TranslationAdjustmentLiability>
    <aimd:TranslationAdjustmentLiability
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_956"
      unitRef="USD">0</aimd:TranslationAdjustmentLiability>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_957"
      unitRef="USD">17136360</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_958"
      unitRef="USD">-838278</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_959"
      unitRef="USD">19993626</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_960"
      unitRef="USD">260290</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      id="fid_961"
      unitRef="USD">363052</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-07-01to2020-09-30"
      decimals="0"
      id="fid_962"
      unitRef="USD">192</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_963"
      unitRef="USD">568164</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_964"
      unitRef="USD">15876</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      id="fid_965"
      unitRef="USD">103638</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2020-07-01to2020-09-30"
      decimals="0"
      id="fid_966"
      unitRef="USD">123</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_967"
      unitRef="USD">174395</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_968"
      unitRef="USD">11221</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      id="fid_969"
      unitRef="USD">259414</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2020-07-01to2020-09-30"
      decimals="0"
      id="fid_970"
      unitRef="USD">69</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_971"
      unitRef="USD">393769</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_972"
      unitRef="USD">4655</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      id="fid_974"
      unitRef="USD">646798</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-07-01to2020-09-30"
      decimals="0"
      id="fid_975"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_976"
      unitRef="USD">646798</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_977"
      unitRef="USD">389</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      id="fid_978"
      unitRef="USD">795958</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2020-07-01to2020-09-30"
      decimals="0"
      id="fid_979"
      unitRef="USD">321153</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_980"
      unitRef="USD">2178969</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_981"
      unitRef="USD">1001893</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      id="fid_982"
      unitRef="USD">1442756</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2020-07-01to2020-09-30"
      decimals="0"
      id="fid_983"
      unitRef="USD">321153</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_984"
      unitRef="USD">2825767</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_985"
      unitRef="USD">1002282</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      id="fid_986"
      unitRef="USD">-1183342</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-07-01to2020-09-30"
      decimals="0"
      id="fid_987"
      unitRef="USD">-321084</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_988"
      unitRef="USD">-2431998</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_989"
      unitRef="USD">-997627</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      id="fid_991"
      unitRef="USD">23517</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2020-07-01to2020-09-30"
      decimals="0"
      id="fid_992"
      unitRef="USD">2201</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_993"
      unitRef="USD">9361</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_994"
      unitRef="USD">4503</us-gaap:InvestmentIncomeInterest>
    <aimd:OtherLosses
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      id="fid_995"
      unitRef="USD">-285</aimd:OtherLosses>
    <aimd:OtherLosses
      contextRef="From2020-07-01to2020-09-30"
      decimals="0"
      id="fid_996"
      unitRef="USD">0</aimd:OtherLosses>
    <aimd:OtherLosses
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_997"
      unitRef="USD">-2532</aimd:OtherLosses>
    <aimd:OtherLosses
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_998"
      unitRef="USD">0</aimd:OtherLosses>
    <aimd:TotalNonOperatingIncomeAndExpenses
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      id="fid_999"
      unitRef="USD">23232</aimd:TotalNonOperatingIncomeAndExpenses>
    <aimd:TotalNonOperatingIncomeAndExpenses
      contextRef="From2020-07-01to2020-09-30"
      decimals="0"
      id="fid_1000"
      unitRef="USD">-2201</aimd:TotalNonOperatingIncomeAndExpenses>
    <aimd:TotalNonOperatingIncomeAndExpenses
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_1001"
      unitRef="USD">-11893</aimd:TotalNonOperatingIncomeAndExpenses>
    <aimd:TotalNonOperatingIncomeAndExpenses
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_1002"
      unitRef="USD">-4503</aimd:TotalNonOperatingIncomeAndExpenses>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      id="fid_1003"
      unitRef="USD">-1160110</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2020-07-01to2020-09-30"
      decimals="0"
      id="fid_1004"
      unitRef="USD">-323285</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_1005"
      unitRef="USD">-2443891</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_1006"
      unitRef="USD">-1002130</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <aimd:LessIncomeTax
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_1009"
      unitRef="USD">0</aimd:LessIncomeTax>
    <aimd:LessIncomeTax
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      id="fid_1007"
      unitRef="USD">0</aimd:LessIncomeTax>
    <aimd:LessIncomeTax
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_1010"
      unitRef="USD">0</aimd:LessIncomeTax>
    <aimd:LessIncomeTax
      contextRef="From2020-07-01to2020-09-30"
      decimals="0"
      id="fid_1008"
      unitRef="USD">0</aimd:LessIncomeTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      id="fid_1011"
      unitRef="USD">-1160110</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-07-01to2020-09-30"
      decimals="0"
      id="fid_1012"
      unitRef="USD">-323285</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_1013"
      unitRef="USD">-2443891</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_1014"
      unitRef="USD">-1002130</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2021-07-01to2021-09-30"
      decimals="INF"
      id="fid_1015"
      unitRef="USDPShares">-0.10</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2020-07-01to2020-09-30"
      decimals="INF"
      id="fid_1016"
      unitRef="USDPShares">-0.01</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2021-01-01to2021-09-30"
      decimals="INF"
      id="fid_1017"
      unitRef="USDPShares">-0.03</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2020-01-01to2020-09-30"
      decimals="INF"
      id="fid_1018"
      unitRef="USDPShares">-0.02</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      id="fid_1019"
      unitRef="Shares">142419337</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2020-07-01to2020-09-30"
      decimals="0"
      id="fid_1020"
      unitRef="Shares">40516351</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_1021"
      unitRef="Shares">75919713</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_1022"
      unitRef="Shares">40620055</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="fid_1025"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1024"
      unitRef="Shares">142271815</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1026"
      unitRef="USD">1422718</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1027"
      unitRef="USD">24286875</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1028"
      unitRef="USD">-7504035</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_aimd_TranslationAdjustmentMember"
      decimals="0"
      id="fid_1029"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30"
      decimals="0"
      id="fid_1030"
      unitRef="USD">18205557</us-gaap:StockholdersEquity>
    <aimd:IssuanceOfStockForCompensationAmount
      contextRef="From2021-07-01to2021-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="fid_1031"
      unitRef="USD">0</aimd:IssuanceOfStockForCompensationAmount>
    <aimd:IssuanceOfStockForCompensationAmount
      contextRef="From2021-07-01to2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1032"
      unitRef="USD">0</aimd:IssuanceOfStockForCompensationAmount>
    <aimd:IssuanceOfStockForCompensationAmount
      contextRef="From2021-07-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1033"
      unitRef="USD">0</aimd:IssuanceOfStockForCompensationAmount>
    <aimd:IssuanceOfStockForCompensationAmount
      contextRef="From2021-07-01to2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1034"
      unitRef="USD">0</aimd:IssuanceOfStockForCompensationAmount>
    <aimd:IssuanceOfStockForCompensationAmount
      contextRef="From2021-07-01to2021-09-30_aimd_TranslationAdjustmentMember"
      decimals="0"
      id="fid_1035"
      unitRef="USD">0</aimd:IssuanceOfStockForCompensationAmount>
    <aimd:IssuanceOfStockForCompensationAmount
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      id="fid_1036"
      unitRef="USD">0</aimd:IssuanceOfStockForCompensationAmount>
    <aimd:IssuanceOfStockForPatentAssetsAmount
      contextRef="From2021-07-01to2021-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="fid_1037"
      unitRef="USD">0</aimd:IssuanceOfStockForPatentAssetsAmount>
    <aimd:IssuanceOfStockForPatentAssetsAmount
      contextRef="From2021-07-01to2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1038"
      unitRef="USD">0</aimd:IssuanceOfStockForPatentAssetsAmount>
    <aimd:IssuanceOfStockForPatentAssetsAmount
      contextRef="From2021-07-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1039"
      unitRef="USD">0</aimd:IssuanceOfStockForPatentAssetsAmount>
    <aimd:IssuanceOfStockForPatentAssetsAmount
      contextRef="From2021-07-01to2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1040"
      unitRef="USD">0</aimd:IssuanceOfStockForPatentAssetsAmount>
    <aimd:IssuanceOfStockForPatentAssetsAmount
      contextRef="From2021-07-01to2021-09-30_aimd_TranslationAdjustmentMember"
      decimals="0"
      id="fid_1041"
      unitRef="USD">0</aimd:IssuanceOfStockForPatentAssetsAmount>
    <aimd:IssuanceOfStockForPatentAssetsAmount
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      id="fid_1042"
      unitRef="USD">0</aimd:IssuanceOfStockForPatentAssetsAmount>
    <aimd:IssuanceOfStockForOptionAmount
      contextRef="From2021-07-01to2021-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="fid_1045"
      unitRef="USD">0</aimd:IssuanceOfStockForOptionAmount>
    <aimd:IssuanceOfStockForOptionShares
      contextRef="From2021-07-01to2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1044"
      unitRef="Shares">170400</aimd:IssuanceOfStockForOptionShares>
    <aimd:IssuanceOfStockForOptionAmount
      contextRef="From2021-07-01to2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1046"
      unitRef="USD">1704</aimd:IssuanceOfStockForOptionAmount>
    <aimd:IssuanceOfStockForOptionAmount
      contextRef="From2021-07-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1047"
      unitRef="USD">63048</aimd:IssuanceOfStockForOptionAmount>
    <aimd:IssuanceOfStockForOptionAmount
      contextRef="From2021-07-01to2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1048"
      unitRef="USD">0</aimd:IssuanceOfStockForOptionAmount>
    <aimd:IssuanceOfStockForOptionAmount
      contextRef="From2021-07-01to2021-09-30_aimd_TranslationAdjustmentMember"
      decimals="0"
      id="fid_1049"
      unitRef="USD">0</aimd:IssuanceOfStockForOptionAmount>
    <aimd:IssuanceOfStockForOptionAmount
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      id="fid_1050"
      unitRef="USD">64752</aimd:IssuanceOfStockForOptionAmount>
    <aimd:WarrantExpense
      contextRef="From2021-07-01to2021-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="fid_1051"
      unitRef="USD">0</aimd:WarrantExpense>
    <aimd:WarrantExpense
      contextRef="From2021-07-01to2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1052"
      unitRef="USD">0</aimd:WarrantExpense>
    <aimd:WarrantExpense
      contextRef="From2021-07-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1053"
      unitRef="USD">3417</aimd:WarrantExpense>
    <aimd:WarrantExpense
      contextRef="From2021-07-01to2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1054"
      unitRef="USD">0</aimd:WarrantExpense>
    <aimd:WarrantExpense
      contextRef="From2021-07-01to2021-09-30_aimd_TranslationAdjustmentMember"
      decimals="0"
      id="fid_1055"
      unitRef="USD">0</aimd:WarrantExpense>
    <aimd:WarrantExpense
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      id="fid_1056"
      unitRef="USD">3417</aimd:WarrantExpense>
    <aimd:OptionExpense
      contextRef="From2021-07-01to2021-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="fid_1057"
      unitRef="USD">0</aimd:OptionExpense>
    <aimd:OptionExpense
      contextRef="From2021-07-01to2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1058"
      unitRef="USD">0</aimd:OptionExpense>
    <aimd:OptionExpense
      contextRef="From2021-07-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1059"
      unitRef="USD">15905</aimd:OptionExpense>
    <aimd:OptionExpense
      contextRef="From2021-07-01to2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1060"
      unitRef="USD">0</aimd:OptionExpense>
    <aimd:OptionExpense
      contextRef="From2021-07-01to2021-09-30_aimd_TranslationAdjustmentMember"
      decimals="0"
      id="fid_1061"
      unitRef="USD">0</aimd:OptionExpense>
    <aimd:OptionExpense
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      id="fid_1062"
      unitRef="USD">15905</aimd:OptionExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-01to2021-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="fid_1063"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-01to2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1064"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1065"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-01to2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1066"
      unitRef="USD">-1160110</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-01to2021-09-30_aimd_TranslationAdjustmentMember"
      decimals="0"
      id="fid_1067"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <aimd:TranslationAdjustment
      contextRef="From2021-07-01to2021-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="fid_1069"
      unitRef="USD">0</aimd:TranslationAdjustment>
    <aimd:TranslationAdjustment
      contextRef="From2021-07-01to2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1070"
      unitRef="USD">0</aimd:TranslationAdjustment>
    <aimd:TranslationAdjustment
      contextRef="From2021-07-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1071"
      unitRef="USD">0</aimd:TranslationAdjustment>
    <aimd:TranslationAdjustment
      contextRef="From2021-07-01to2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1072"
      unitRef="USD">0</aimd:TranslationAdjustment>
    <aimd:TranslationAdjustment
      contextRef="From2021-07-01to2021-09-30_aimd_TranslationAdjustmentMember"
      decimals="0"
      id="fid_1073"
      unitRef="USD">6838</aimd:TranslationAdjustment>
    <aimd:TranslationAdjustment
      contextRef="From2021-07-01to2021-09-30"
      decimals="0"
      id="fid_1074"
      unitRef="USD">6838</aimd:TranslationAdjustment>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="fid_1077"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1076"
      unitRef="Shares">142442215</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1078"
      unitRef="USD">1424422</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1079"
      unitRef="USD">24369245</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1080"
      unitRef="USD">-8664145</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_aimd_TranslationAdjustmentMember"
      decimals="0"
      id="fid_1081"
      unitRef="USD">6838</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1082"
      unitRef="USD">17136360</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="fid_1085"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1084"
      unitRef="Shares">40516351</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1086"
      unitRef="USD">405164</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1087"
      unitRef="USD">4299196</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1088"
      unitRef="USD">-5448477</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_aimd_TranslationAdjustmentMember"
      decimals="0"
      id="fid_1089"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30"
      decimals="0"
      id="fid_1090"
      unitRef="USD">-744117</us-gaap:StockholdersEquity>
    <aimd:IssuanceOfStockForCompensationAmount
      contextRef="From2020-07-01to2020-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="fid_1091"
      unitRef="USD">0</aimd:IssuanceOfStockForCompensationAmount>
    <aimd:IssuanceOfStockForCompensationAmount
      contextRef="From2020-07-01to2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1092"
      unitRef="USD">0</aimd:IssuanceOfStockForCompensationAmount>
    <aimd:IssuanceOfStockForCompensationAmount
      contextRef="From2020-07-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1093"
      unitRef="USD">0</aimd:IssuanceOfStockForCompensationAmount>
    <aimd:IssuanceOfStockForCompensationAmount
      contextRef="From2020-07-01to2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1094"
      unitRef="USD">0</aimd:IssuanceOfStockForCompensationAmount>
    <aimd:IssuanceOfStockForCompensationAmount
      contextRef="From2020-07-01to2020-09-30_aimd_TranslationAdjustmentMember"
      decimals="0"
      id="fid_1095"
      unitRef="USD">0</aimd:IssuanceOfStockForCompensationAmount>
    <aimd:IssuanceOfStockForCompensationAmount
      contextRef="From2020-07-01to2020-09-30"
      decimals="0"
      id="fid_1096"
      unitRef="USD">0</aimd:IssuanceOfStockForCompensationAmount>
    <aimd:IssuanceOfStockForCashAmount
      contextRef="From2020-07-01to2020-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="fid_1099"
      unitRef="USD">0</aimd:IssuanceOfStockForCashAmount>
    <aimd:IssuanceOfStockForCashShares
      contextRef="From2020-07-01to2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1098"
      unitRef="Shares">400000</aimd:IssuanceOfStockForCashShares>
    <aimd:IssuanceOfStockForCashAmount
      contextRef="From2020-07-01to2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1100"
      unitRef="USD">4000</aimd:IssuanceOfStockForCashAmount>
    <aimd:IssuanceOfStockForCashAmount
      contextRef="From2020-07-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1101"
      unitRef="USD">96000</aimd:IssuanceOfStockForCashAmount>
    <aimd:IssuanceOfStockForCashAmount
      contextRef="From2020-07-01to2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1102"
      unitRef="USD">0</aimd:IssuanceOfStockForCashAmount>
    <aimd:IssuanceOfStockForCashAmount
      contextRef="From2020-07-01to2020-09-30_aimd_TranslationAdjustmentMember"
      decimals="0"
      id="fid_1103"
      unitRef="USD">0</aimd:IssuanceOfStockForCashAmount>
    <aimd:IssuanceOfStockForCashAmount
      contextRef="From2020-07-01to2020-09-30"
      decimals="0"
      id="fid_1104"
      unitRef="USD">100000</aimd:IssuanceOfStockForCashAmount>
    <aimd:WarrantExpense
      contextRef="From2020-07-01to2020-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="fid_1105"
      unitRef="USD">0</aimd:WarrantExpense>
    <aimd:WarrantExpense
      contextRef="From2020-07-01to2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1106"
      unitRef="USD">0</aimd:WarrantExpense>
    <aimd:WarrantExpense
      contextRef="From2020-07-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1107"
      unitRef="USD">9496</aimd:WarrantExpense>
    <aimd:WarrantExpense
      contextRef="From2020-07-01to2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1108"
      unitRef="USD">0</aimd:WarrantExpense>
    <aimd:WarrantExpense
      contextRef="From2020-07-01to2020-09-30_aimd_TranslationAdjustmentMember"
      decimals="0"
      id="fid_1109"
      unitRef="USD">0</aimd:WarrantExpense>
    <aimd:WarrantExpense
      contextRef="From2020-07-01to2020-09-30"
      decimals="0"
      id="fid_1110"
      unitRef="USD">9496</aimd:WarrantExpense>
    <aimd:OptionExpense
      contextRef="From2020-07-01to2020-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="fid_1111"
      unitRef="USD">0</aimd:OptionExpense>
    <aimd:OptionExpense
      contextRef="From2020-07-01to2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1112"
      unitRef="USD">0</aimd:OptionExpense>
    <aimd:OptionExpense
      contextRef="From2020-07-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1113"
      unitRef="USD">181376</aimd:OptionExpense>
    <aimd:OptionExpense
      contextRef="From2020-07-01to2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1114"
      unitRef="USD">0</aimd:OptionExpense>
    <aimd:OptionExpense
      contextRef="From2020-07-01to2020-09-30_aimd_TranslationAdjustmentMember"
      decimals="0"
      id="fid_1115"
      unitRef="USD">0</aimd:OptionExpense>
    <aimd:OptionExpense
      contextRef="From2020-07-01to2020-09-30"
      decimals="0"
      id="fid_1116"
      unitRef="USD">181376</aimd:OptionExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-07-01to2020-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="fid_1117"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-07-01to2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1118"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-07-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1119"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-07-01to2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1120"
      unitRef="USD">-323285</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-07-01to2020-09-30_aimd_TranslationAdjustmentMember"
      decimals="0"
      id="fid_1121"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-07-01to2020-09-30"
      decimals="0"
      id="fid_1122"
      unitRef="USD">-323285</us-gaap:NetIncomeLoss>
    <aimd:TranslationAdjustment
      contextRef="From2020-07-01to2020-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="fid_1123"
      unitRef="USD">0</aimd:TranslationAdjustment>
    <aimd:TranslationAdjustment
      contextRef="From2020-07-01to2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1124"
      unitRef="USD">0</aimd:TranslationAdjustment>
    <aimd:TranslationAdjustment
      contextRef="From2020-07-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1125"
      unitRef="USD">0</aimd:TranslationAdjustment>
    <aimd:TranslationAdjustment
      contextRef="From2020-07-01to2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1126"
      unitRef="USD">0</aimd:TranslationAdjustment>
    <aimd:TranslationAdjustment
      contextRef="From2020-07-01to2020-09-30_aimd_TranslationAdjustmentMember"
      decimals="0"
      id="fid_1127"
      unitRef="USD">0</aimd:TranslationAdjustment>
    <aimd:TranslationAdjustment
      contextRef="From2020-07-01to2020-09-30"
      decimals="0"
      id="fid_1128"
      unitRef="USD">0</aimd:TranslationAdjustment>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="fid_1131"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1130"
      unitRef="Shares">40916351</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1132"
      unitRef="USD">409164</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1133"
      unitRef="USD">4586068</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1134"
      unitRef="USD">-5771762</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_aimd_TranslationAdjustmentMember"
      decimals="0"
      id="fid_1135"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_1136"
      unitRef="USD">-776530</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="fid_1139"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1138"
      unitRef="Shares">42066172</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1140"
      unitRef="USD">420661</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1141"
      unitRef="USD">4961315</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1142"
      unitRef="USD">-6220254</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_aimd_TranslationAdjustmentMember"
      decimals="0"
      id="fid_1143"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_1144"
      unitRef="USD">-838278</us-gaap:StockholdersEquity>
    <aimd:IssuanceOfStockForCompensationAmount
      contextRef="From2021-01-01to2021-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="fid_1147"
      unitRef="USD">0</aimd:IssuanceOfStockForCompensationAmount>
    <aimd:IssuanceOfStockForCompensationShares
      contextRef="From2021-01-01to2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1146"
      unitRef="Shares">205643</aimd:IssuanceOfStockForCompensationShares>
    <aimd:IssuanceOfStockForCompensationAmount
      contextRef="From2021-01-01to2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1148"
      unitRef="USD">2056</aimd:IssuanceOfStockForCompensationAmount>
    <aimd:IssuanceOfStockForCompensationAmount
      contextRef="From2021-01-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1149"
      unitRef="USD">137349</aimd:IssuanceOfStockForCompensationAmount>
    <aimd:IssuanceOfStockForCompensationAmount
      contextRef="From2021-01-01to2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1150"
      unitRef="USD">0</aimd:IssuanceOfStockForCompensationAmount>
    <aimd:IssuanceOfStockForCompensationAmount
      contextRef="From2021-01-01to2021-09-30_aimd_TranslationAdjustmentMember"
      decimals="0"
      id="fid_1151"
      unitRef="USD">0</aimd:IssuanceOfStockForCompensationAmount>
    <aimd:IssuanceOfStockForCompensationAmount
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_1152"
      unitRef="USD">139405</aimd:IssuanceOfStockForCompensationAmount>
    <aimd:IssuanceOfStockForPatentAssetsAmount
      contextRef="From2021-01-01to2021-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="fid_1155"
      unitRef="USD">0</aimd:IssuanceOfStockForPatentAssetsAmount>
    <aimd:IssuanceOfStockForPatentAssetsShares
      contextRef="From2021-01-01to2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1154"
      unitRef="Shares">100000000</aimd:IssuanceOfStockForPatentAssetsShares>
    <aimd:IssuanceOfStockForPatentAssetsAmount
      contextRef="From2021-01-01to2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1156"
      unitRef="USD">1000000</aimd:IssuanceOfStockForPatentAssetsAmount>
    <aimd:IssuanceOfStockForPatentAssetsAmount
      contextRef="From2021-01-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1157"
      unitRef="USD">19000000</aimd:IssuanceOfStockForPatentAssetsAmount>
    <aimd:IssuanceOfStockForPatentAssetsAmount
      contextRef="From2021-01-01to2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1158"
      unitRef="USD">0</aimd:IssuanceOfStockForPatentAssetsAmount>
    <aimd:IssuanceOfStockForPatentAssetsAmount
      contextRef="From2021-01-01to2021-09-30_aimd_TranslationAdjustmentMember"
      decimals="0"
      id="fid_1159"
      unitRef="USD">0</aimd:IssuanceOfStockForPatentAssetsAmount>
    <aimd:IssuanceOfStockForPatentAssetsAmount
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_1160"
      unitRef="USD">20000000</aimd:IssuanceOfStockForPatentAssetsAmount>
    <aimd:IssuanceOfStockForOptionAmount
      contextRef="From2021-01-01to2021-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="fid_1163"
      unitRef="USD">0</aimd:IssuanceOfStockForOptionAmount>
    <aimd:IssuanceOfStockForOptionShares
      contextRef="From2021-01-01to2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1162"
      unitRef="Shares">170400</aimd:IssuanceOfStockForOptionShares>
    <aimd:IssuanceOfStockForOptionAmount
      contextRef="From2021-01-01to2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1164"
      unitRef="USD">1704</aimd:IssuanceOfStockForOptionAmount>
    <aimd:IssuanceOfStockForOptionAmount
      contextRef="From2021-01-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1165"
      unitRef="USD">63048</aimd:IssuanceOfStockForOptionAmount>
    <aimd:IssuanceOfStockForOptionAmount
      contextRef="From2021-01-01to2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1166"
      unitRef="USD">0</aimd:IssuanceOfStockForOptionAmount>
    <aimd:IssuanceOfStockForOptionAmount
      contextRef="From2021-01-01to2021-09-30_aimd_TranslationAdjustmentMember"
      decimals="0"
      id="fid_1167"
      unitRef="USD">0</aimd:IssuanceOfStockForOptionAmount>
    <aimd:IssuanceOfStockForOptionAmount
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_1168"
      unitRef="USD">64752</aimd:IssuanceOfStockForOptionAmount>
    <aimd:WarrantExpense
      contextRef="From2021-01-01to2021-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="fid_1169"
      unitRef="USD">0</aimd:WarrantExpense>
    <aimd:WarrantExpense
      contextRef="From2021-01-01to2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1170"
      unitRef="USD">0</aimd:WarrantExpense>
    <aimd:WarrantExpense
      contextRef="From2021-01-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1171"
      unitRef="USD">10252</aimd:WarrantExpense>
    <aimd:WarrantExpense
      contextRef="From2021-01-01to2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1172"
      unitRef="USD">0</aimd:WarrantExpense>
    <aimd:WarrantExpense
      contextRef="From2021-01-01to2021-09-30_aimd_TranslationAdjustmentMember"
      decimals="0"
      id="fid_1173"
      unitRef="USD">0</aimd:WarrantExpense>
    <aimd:WarrantExpense
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_1174"
      unitRef="USD">10252</aimd:WarrantExpense>
    <aimd:OptionExpense
      contextRef="From2021-01-01to2021-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="fid_1175"
      unitRef="USD">0</aimd:OptionExpense>
    <aimd:OptionExpense
      contextRef="From2021-01-01to2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1176"
      unitRef="USD">0</aimd:OptionExpense>
    <aimd:OptionExpense
      contextRef="From2021-01-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1177"
      unitRef="USD">197281</aimd:OptionExpense>
    <aimd:OptionExpense
      contextRef="From2021-01-01to2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1178"
      unitRef="USD">0</aimd:OptionExpense>
    <aimd:OptionExpense
      contextRef="From2021-01-01to2021-09-30_aimd_TranslationAdjustmentMember"
      decimals="0"
      id="fid_1179"
      unitRef="USD">0</aimd:OptionExpense>
    <aimd:OptionExpense
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_1180"
      unitRef="USD">197281</aimd:OptionExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="fid_1181"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1182"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1183"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1184"
      unitRef="USD">-2443891</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-09-30_aimd_TranslationAdjustmentMember"
      decimals="0"
      id="fid_1185"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_1186"
      unitRef="USD">-2443891</us-gaap:NetIncomeLoss>
    <aimd:TranslationAdjustment
      contextRef="From2021-01-01to2021-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="fid_1187"
      unitRef="USD">0</aimd:TranslationAdjustment>
    <aimd:TranslationAdjustment
      contextRef="From2021-01-01to2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1188"
      unitRef="USD">0</aimd:TranslationAdjustment>
    <aimd:TranslationAdjustment
      contextRef="From2021-01-01to2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1189"
      unitRef="USD">0</aimd:TranslationAdjustment>
    <aimd:TranslationAdjustment
      contextRef="From2021-01-01to2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1190"
      unitRef="USD">0</aimd:TranslationAdjustment>
    <aimd:TranslationAdjustment
      contextRef="From2021-01-01to2021-09-30_aimd_TranslationAdjustmentMember"
      decimals="0"
      id="fid_1191"
      unitRef="USD">6838</aimd:TranslationAdjustment>
    <aimd:TranslationAdjustment
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_1192"
      unitRef="USD">6838</aimd:TranslationAdjustment>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="fid_1195"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1194"
      unitRef="Shares">142442215</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1196"
      unitRef="USD">1424422</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1197"
      unitRef="USD">24369245</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1198"
      unitRef="USD">-8664145</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_aimd_TranslationAdjustmentMember"
      decimals="0"
      id="fid_1199"
      unitRef="USD">6838</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1200"
      unitRef="USD">17136360</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_PreferredStockMember"
      decimals="0"
      id="fid_1203"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1202"
      unitRef="Shares">40516351</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1204"
      unitRef="USD">405164</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1205"
      unitRef="USD">4207786</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1206"
      unitRef="USD">-4769632</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_aimd_TranslationAdjustmentMember"
      decimals="0"
      id="fid_1207"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_1208"
      unitRef="USD">-156682</us-gaap:StockholdersEquity>
    <aimd:IssuanceOfStockForCompensationAmount
      contextRef="From2020-01-01to2020-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="fid_1209"
      unitRef="USD">0</aimd:IssuanceOfStockForCompensationAmount>
    <aimd:IssuanceOfStockForCompensationAmount
      contextRef="From2020-01-01to2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1210"
      unitRef="USD">0</aimd:IssuanceOfStockForCompensationAmount>
    <aimd:IssuanceOfStockForCompensationAmount
      contextRef="From2020-01-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1211"
      unitRef="USD">0</aimd:IssuanceOfStockForCompensationAmount>
    <aimd:IssuanceOfStockForCompensationAmount
      contextRef="From2020-01-01to2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1212"
      unitRef="USD">0</aimd:IssuanceOfStockForCompensationAmount>
    <aimd:IssuanceOfStockForCompensationAmount
      contextRef="From2020-01-01to2020-09-30_aimd_TranslationAdjustmentMember"
      decimals="0"
      id="fid_1213"
      unitRef="USD">0</aimd:IssuanceOfStockForCompensationAmount>
    <aimd:IssuanceOfStockForCompensationAmount
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_1214"
      unitRef="USD">0</aimd:IssuanceOfStockForCompensationAmount>
    <aimd:IssuanceOfStockForCashShares
      contextRef="From2020-01-01to2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1216"
      unitRef="Shares">400000</aimd:IssuanceOfStockForCashShares>
    <aimd:IssuanceOfStockForCashAmount
      contextRef="From2020-01-01to2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1218"
      unitRef="USD">4000</aimd:IssuanceOfStockForCashAmount>
    <aimd:IssuanceOfStockForCashAmount
      contextRef="From2020-01-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1219"
      unitRef="USD">96000</aimd:IssuanceOfStockForCashAmount>
    <aimd:IssuanceOfStockForCashAmount
      contextRef="From2020-01-01to2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1220"
      unitRef="USD">0</aimd:IssuanceOfStockForCashAmount>
    <aimd:IssuanceOfStockForCashAmount
      contextRef="From2020-01-01to2020-09-30_aimd_TranslationAdjustmentMember"
      decimals="0"
      id="fid_1221"
      unitRef="USD">0</aimd:IssuanceOfStockForCashAmount>
    <aimd:IssuanceOfStockForCashAmount
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_1222"
      unitRef="USD">100000</aimd:IssuanceOfStockForCashAmount>
    <aimd:WarrantExpense
      contextRef="From2020-01-01to2020-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="fid_1229"
      unitRef="USD">0</aimd:WarrantExpense>
    <aimd:WarrantExpense
      contextRef="From2020-01-01to2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1230"
      unitRef="USD">0</aimd:WarrantExpense>
    <aimd:WarrantExpense
      contextRef="From2020-01-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1231"
      unitRef="USD">10218</aimd:WarrantExpense>
    <aimd:WarrantExpense
      contextRef="From2020-01-01to2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1232"
      unitRef="USD">0</aimd:WarrantExpense>
    <aimd:WarrantExpense
      contextRef="From2020-01-01to2020-09-30_aimd_TranslationAdjustmentMember"
      decimals="0"
      id="fid_1233"
      unitRef="USD">0</aimd:WarrantExpense>
    <aimd:WarrantExpense
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_1234"
      unitRef="USD">10218</aimd:WarrantExpense>
    <aimd:OptionExpense
      contextRef="From2020-01-01to2020-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="fid_1235"
      unitRef="USD">0</aimd:OptionExpense>
    <aimd:OptionExpense
      contextRef="From2020-01-01to2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1236"
      unitRef="USD">0</aimd:OptionExpense>
    <aimd:OptionExpense
      contextRef="From2020-01-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1237"
      unitRef="USD">272064</aimd:OptionExpense>
    <aimd:OptionExpense
      contextRef="From2020-01-01to2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1238"
      unitRef="USD">0</aimd:OptionExpense>
    <aimd:OptionExpense
      contextRef="From2020-01-01to2020-09-30_aimd_TranslationAdjustmentMember"
      decimals="0"
      id="fid_1239"
      unitRef="USD">0</aimd:OptionExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="fid_1241"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1242"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1243"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1244"
      unitRef="USD">-1002130</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-09-30_aimd_TranslationAdjustmentMember"
      decimals="0"
      id="fid_1245"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_1246"
      unitRef="USD">-1002130</us-gaap:NetIncomeLoss>
    <aimd:TranslationAdjustment
      contextRef="From2020-01-01to2020-09-30_us-gaap_PreferredStockMember"
      decimals="0"
      id="fid_1247"
      unitRef="USD">0</aimd:TranslationAdjustment>
    <aimd:TranslationAdjustment
      contextRef="From2020-01-01to2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1248"
      unitRef="USD">0</aimd:TranslationAdjustment>
    <aimd:TranslationAdjustment
      contextRef="From2020-01-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="fid_1249"
      unitRef="USD">0</aimd:TranslationAdjustment>
    <aimd:TranslationAdjustment
      contextRef="From2020-01-01to2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="fid_1250"
      unitRef="USD">0</aimd:TranslationAdjustment>
    <aimd:TranslationAdjustment
      contextRef="From2020-01-01to2020-09-30_aimd_TranslationAdjustmentMember"
      decimals="0"
      id="fid_1251"
      unitRef="USD">0</aimd:TranslationAdjustment>
    <aimd:TranslationAdjustment
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_1252"
      unitRef="USD">0</aimd:TranslationAdjustment>
    <us-gaap:SharesIssued
      contextRef="AsOf2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="fid_1254"
      unitRef="Shares">40916351</us-gaap:SharesIssued>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_1256"
      unitRef="USD">-569150</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_1257"
      unitRef="USD">-244967</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <aimd:InvestmentInPatents
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_1259"
      unitRef="USD">0</aimd:InvestmentInPatents>
    <aimd:InvestmentInPatents
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_1260"
      unitRef="USD">-1891</aimd:InvestmentInPatents>
    <us-gaap:PaymentsToAcquireAssetsInvestingActivities
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_1261"
      unitRef="USD">41581</us-gaap:PaymentsToAcquireAssetsInvestingActivities>
    <us-gaap:PaymentsToAcquireAssetsInvestingActivities
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_1262"
      unitRef="USD">0</us-gaap:PaymentsToAcquireAssetsInvestingActivities>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_1263"
      unitRef="USD">36</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_1264"
      unitRef="USD">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <aimd:IncreaseInRefundableDeposits
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_1265"
      unitRef="USD">1795</aimd:IncreaseInRefundableDeposits>
    <aimd:IncreaseInRefundableDeposits
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_1266"
      unitRef="USD">0</aimd:IncreaseInRefundableDeposits>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_1267"
      unitRef="USD">-43340</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_1268"
      unitRef="USD">-1891</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <aimd:AdvancesFromShareholder
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_1270"
      unitRef="USD">0</aimd:AdvancesFromShareholder>
    <aimd:AdvancesFromShareholder
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_1271"
      unitRef="USD">35000</aimd:AdvancesFromShareholder>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_1272"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_1273"
      unitRef="USD">50000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_1274"
      unitRef="USD">64752</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_1275"
      unitRef="USD">0</us-gaap:ProceedsFromStockOptionsExercised>
    <aimd:PaymentsOfLeaseLiabilities
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_1276"
      unitRef="USD">6815</aimd:PaymentsOfLeaseLiabilities>
    <aimd:PaymentsOfLeaseLiabilities
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_1277"
      unitRef="USD">0</aimd:PaymentsOfLeaseLiabilities>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_1278"
      unitRef="USD">1232192</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_1279"
      unitRef="USD">0</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_1280"
      unitRef="USD">1290129</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_1281"
      unitRef="USD">85000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_1282"
      unitRef="USD">7046</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_1283"
      unitRef="USD">0</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_1284"
      unitRef="USD">677639</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_1285"
      unitRef="USD">-325272</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_1286"
      unitRef="USD">22245</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2019-12-31"
      decimals="0"
      id="fid_1287"
      unitRef="USD">409039</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_1288"
      unitRef="USD">706931</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2020-09-30"
      decimals="0"
      id="fid_1289"
      unitRef="USD">83767</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InterestPaid
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_1291"
      unitRef="USD">9363</us-gaap:InterestPaid>
    <us-gaap:InterestPaid
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_1292"
      unitRef="USD">4895</us-gaap:InterestPaid>
    <aimd:StockIssuedForAcquisitionOfPatents
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_1294"
      unitRef="USD">20000000</aimd:StockIssuedForAcquisitionOfPatents>
    <aimd:StockIssuedForAcquisitionOfPatents
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_1295"
      unitRef="USD">0</aimd:StockIssuedForAcquisitionOfPatents>
    <aimd:StockIssuedForCompensationWarrantAndOptionExpense
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_1296"
      unitRef="USD">346938</aimd:StockIssuedForCompensationWarrantAndOptionExpense>
    <aimd:StockIssuedForCompensationWarrantAndOptionExpense
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_1297"
      unitRef="USD">0</aimd:StockIssuedForCompensationWarrantAndOptionExpense>
    <aimd:StockIssuedForAdvancesFromInvestors
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_1298"
      unitRef="USD">0</aimd:StockIssuedForAdvancesFromInvestors>
    <aimd:StockIssuedForAdvancesFromInvestors
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_1299"
      unitRef="USD">100000</aimd:StockIssuedForAdvancesFromInvestors>
    <aimd:RouLeasedAssets
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_1300"
      unitRef="USD">62723</aimd:RouLeasedAssets>
    <aimd:RouLeasedAssets
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_1301"
      unitRef="USD">0</aimd:RouLeasedAssets>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_1302"
      unitRef="USD">62723</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="From2020-01-01to2020-09-30"
      decimals="0"
      id="fid_1303"
      unitRef="USD">0</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2021-01-01to2021-09-30" id="fid_1304">&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;1.&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Organization and Business.&lt;/strong&gt; Ainos, Inc., formerly known as Amarillo Biosciences, Inc. (the &#x201c;Company&#x201d;) is a diversified healthcare company engaged in the research and development and sales and marketing of pharmaceutical and biotech products. The Company is a Texas corporation incorporated in 1984. The Company currently has offices in the United States and Taiwan. The Company operates a branch office in Taiwan registered as AINOS, INC. TAIWAN BRANCH.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2021-01-01to2021-09-30" id="fid_1305">&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;2.&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The Company is engaged in developing biologics for the treatment of human and animal diseases. Our current focus is research aimed at the treatment of human disease indications, including Sj&#xf6;gren&#x2019;s syndrome, thrombocytopenia, and other indications using interferon (IFN) alpha that is administered in a proprietary low-dose non-injectable form. In addition to our core technology, we are working to expand our current focus into a diversified healthcare business portfolio in order to generate new revenue streams. We own patents with claims that encompass method of use or treatment, and/or composition of matter and manufacturing as well as design utility and/or invention. Of twelve issued patents, four patents are related to the low-dose oral delivery of interferon, three patents are associated with treatment of metabolic disorders, and five patents related to the development and manufacturing of point-of-care testing rapid test kit products that include diagnostics for COVID-19 (SARS CoV2 Antigen Rapid Test), pneumonia, vaginal infection and helicobacter pylori (H. pylori) bacterial infection.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;We primarily operate three business units: the Pharmaceutical, Medical Devices and Preventive Medicine Divisions. Our Pharmaceutical Division is focused on low-dose, orally administered lozenges containing the natural immune system activator interferon-alpha as a treatment for a variety of disease indications. We own a proprietary library of over thirty years of scientific and clinical data on the human and animal applications of low-dose oral interferon. Our Medical Device Division is dedicated to developing a novel insulin pump and further development of point-of-care rapid test kits for the detection and diagnosis of human infections. Our Preventative Medicine Division, which has been restructured from our former Consumer Product Division, is focused on SRNA-based therapeutics.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:BasisOfAccounting contextRef="From2021-01-01to2021-09-30" id="fid_1306">&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;3. &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Basis of presentation.&lt;/strong&gt; The accompanying consolidated financial statements, which should be read in conjunction with the audited financial statements and footnotes included in the Company's Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission on March 30, 2021 attached hereto as Exhibit 13 and which is incorporated by this reference, have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months and nine months ended September 30, 2021, are not necessarily indicative of the results that may be expected for the full year ending December 31, 2021.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:BasisOfAccounting>
    <aimd:FinancialConditionTextBlock contextRef="From2021-01-01to2021-09-30" id="fid_1307">&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;4.&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Financial Condition. &lt;/strong&gt;These financial statements have been prepared in accordance with United States generally accepted accounting principles, assuming that the Company will continue as a going concern. The accompanying financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;While the Company has recurring losses and generated negative cash flows from operations, the Company has taken initiatives to improve its management capacity and business operations. Such initiatives include the procurement of innovative diagnostic technologies and securing a strategic investor, as a result of the closing of a securities purchase agreement with Ainos, Inc. a Cayman Island corporation (&#x201c;Ainos KY&#x201d;) on April 15, 2021 (the &#x201c;Ainos KY Transaction&#x201d;). Details of the Ainos Transaction were disclosed in the Company&#x2019;s Form 10-Q filing for the second quarter of 2021.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;After closing the Ainos KY Transaction, the Company engaged additional management resources including Mr. Chun-Hsien Tsai as Chairman and CEO, Ms. Hui-Lan (Celia) Wu as CFO and Mr. Chih-Heng (Jack Lu) as Head of Corporate Development, retained key management and legal staff, and implemented new business initiatives. On June 14, 2021, the Company became the master sales and marketing agent for the Ainos SARS-Cov-2 Antigen Rapid Test Kit (&#x201c;Ainos Covid-19 Test Kit&#x201d;) which has generated $568,164 in sales thus far in 2021.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;As of September 30, 2021, the Company&#x2019;s financial improvement includes the following:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Total stockholder&#x2019;s equity increased to $17,136,360 as of September 30, 2021 compared to a negative total shareholder&#x2019;s equity of $838,278 as of December 2021.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;Cash and cash equivalents increased to $706,931 as of September 30, 2021 compared to $22,245 at December 31, 2020. This is attributable to increased revenues from sales of our Ainos Covid-19 Test Kit in Taiwan and operational loans made to the Company by Ainos KY. The Company&#x2019;s revenues increased to $568,164 during this reporting period compared to $15,876 as of third quarter of 2020.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company anticipates business revenues and potential additional financial support from Ainos KY and other entities to fund the Company&#x2019;s operations over the next twelve months. The Company may raise additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available when needed and at adequate levels, the Company will need to reevaluate its operating plan.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;There can be no assurance that capital will be available as necessary to meet the Company's working capital requirements or, if the capital is available, that it will be on terms acceptable to the Company. Any issuances of additional equity securities by the Company may result in dilution in the equity interests of its current stockholders. Obtaining commercial loans will increase the Company's liabilities and future cash commitments to the extent such loans would be available. While management believes in its strategic plans, management cannot be certain that projected financial results can be achieved.&lt;/p&gt;</aimd:FinancialConditionTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_aimd_SecuritiesPurchaseAgreementsMember"
      decimals="0"
      id="fid_21"
      unitRef="USD">17136360</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_aimd_SecuritiesPurchaseAgreementsMember"
      decimals="0"
      id="fid_22"
      unitRef="USD">838278</us-gaap:StockholdersEquity>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2021-09-30_aimd_SecuritiesPurchaseAgreementsMember"
      decimals="0"
      id="fid_12"
      unitRef="USD">706931</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2020-12-31_aimd_SecuritiesPurchaseAgreementsMember"
      decimals="0"
      id="fid_13"
      unitRef="USD">22245</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:Revenues
      contextRef="From2021-01-01to2021-09-30_aimd_SecuritiesPurchaseAgreementsMember"
      decimals="0"
      id="fid_9"
      unitRef="USD">568164</us-gaap:Revenues>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2021-01-01to2021-09-30" id="fid_1308">&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;5.&lt;/strong&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Common Stock. &lt;/strong&gt;As of September 30, 2021 there was an increase of $1,003,760 in par value common stock primarily as a result of the Ainos KY Transaction.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <aimd:SharesIncreaseValue
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_554"
      unitRef="USD">1003760</aimd:SharesIncreaseValue>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2021-01-01to2021-09-30" id="fid_1309">&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;6.&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Convertible Notes Payable and Other Related Party Notes Payable.&lt;/strong&gt; As of September 30, 2021 and December 31, 2020, the amount of convertible and non-convertible debt principal was $2,185,953 and $953,001, respectively. The details of the convertible and other non-convertible promissory notes payable are shown in the table below.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="BORDER-BOTTOM: #000000 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Annual Interest Rate&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Unpaid Principal Balance&lt;/strong&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;No#&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Effective Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Due Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;From&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Effective&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Following&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Maturity&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Payee&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM: #000000 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Issuing&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Purpose&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM: #000000 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Sep 30,&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM: #000000 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Dec 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td colspan="24"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Payee: Dr. Stephen T. Chen, resigned as Chairman of the Board, President, and Board director April 15, 2021&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#1.16&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2016/01/30&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Payable on demand&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;0.75%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:1%;"/&gt;&lt;td style="width:8%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;NA&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stephen Chen&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"/&gt;&lt;td colspan="2" style="width:12%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:1%;"/&gt;&lt;td colspan="2" style="width:9%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;114,026&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="width:1%;"/&gt;&lt;td colspan="2" style="width:9%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;114,026&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#2.16&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2016/03/18&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Payable on demand&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;0.65%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;NA&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stephen Chen&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;262,500&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;262,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#3.19&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2019/09/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2020/09/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stephen Chen&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;salary&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;39,392&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;39,620&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#4.19&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2019/12/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2020/12/31&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.61%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stephen Chen&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;14,879&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;14,879&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#6.20&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2020/01/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/01/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stephen Chen&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;salary&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;216,600&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;216,600&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#7.20&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2020/01/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/01/02&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.60%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stephen Chen&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;23,366&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;23,366&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#9.20&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2020/01/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/04/14&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;0.13%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stephen Chen&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;279,405&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;134,010&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#10.21&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/01/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/04/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stephen Chen&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;salary&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;59,025&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#11.21&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/04/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/05/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stephen Chen&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;salary&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10,000&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;"/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td colspan="2"/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,019,193&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;805,001&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td colspan="2"/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"/&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td colspan="5"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Payee: Ainos KY, an affiliated company &lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td colspan="2"/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"/&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#12.21&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/04/27&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/10/27&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;NA&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ainos KY&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;15,000&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#13.21&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/05/05&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/11/05&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;NA&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ainos KY&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;20,000&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#14.21&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/05/25&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/11/25&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;NA&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ainos KY&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;30,000&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#15.21&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/05/28&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/11/28&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;NA&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ainos KY&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;35,000&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#16.21&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/06/09&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/12/09&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;NA&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ainos KY&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;300,000&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#17.21&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/06/21&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/12/21&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;NA&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ainos KY&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;107,000&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#18.21&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/07/02&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2022/01/02&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;NA&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ainos KY&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;54,000&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#19.21&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/09/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/03/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;NA&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ainos KY&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;120,000&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#20.21&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/09/28&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/03/28&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;NA&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ainos KY&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;300,000&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;"/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td colspan="2"/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;981,000&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;0 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td colspan="9"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;Convertible and other notes payable- related parties&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2,000,193&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;805,001&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td colspan="2"/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"/&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td colspan="10"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Payee: i2China Management Group LLC, a management consultant&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"/&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#5.19&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2019/09/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2020/09/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;i2China&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;consulting fee&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;16,000&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;16,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#8a.20&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2020/01/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/01/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;i2China&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;consulting fee&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;48,000&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;48,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#8b.20&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Retroactive from 2020/01/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/01/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;i2China&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;consulting fee&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;84,000&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;84,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#11.21&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/01/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/04/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;i2China&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;consulting fee&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2" style="BORDER-BOTTOM: #000000 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;37,000&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2" style="BORDER-BOTTOM: #000000 1px solid;"/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td colspan="9"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;Convertible and other notes payable&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;185,000&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;148,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td colspan="9"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;Total Convertible and other notes payable&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 3px double;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2,185,193&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 3px double;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;953,001&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;All of the aforementioned convertible and non-convertible promissory notes are unsecured and due on demand. All shares issued upon conversion are restricted and subject to Rule 144 promulgated under the U.S. Securities Act of 1933 (the &#x201c;Securities Act&#x201d;); subject to any exemptions or exclusions under the Act. The Company may prepay the notes in whole or in part at any time without penalty.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The promissory notes due to Dr. Stephen T. Chen and Ainos KY are related party notes.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;i2China Management Group, LLC (&#x201c;i2China&#x201d;) and Dr. Stephen T. Chen (together the &#x201c;Payees&#x201d;), have both agreed to waive any and all rights pertaining to the conditional term &#x201c;Annual Interest Rate on Matured, Unpaid Amounts: 10% per annum, compounded annually of Convertible Notes&#x201d; in regards to interest charged on any unpaid amounts following maturity for all of their respective notes. The Company and the Payees agree that the originally agreed annual interest rate will continue to be valid for any unpaid amounts after maturity. The amended terms of the above convertible notes were made during 2021 Q3 on September 1, 2021. The waived interest amount was $45,875.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Unpaid &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Interest Rate&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Interest amount&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;Interest &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;No#&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Payee&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Description&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;strong&gt;Principal &lt;/strong&gt;&lt;strong&gt;Amount&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Original&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;after&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Maturity&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;Original&#160;rate&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;10%&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Total &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;after&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Maturity&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;strong&gt;Interest&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Waived&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="width:10%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;#1.16&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;1/30/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stephen&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;114,026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;0.75%&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;NA&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;5,624&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;0 &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;5,624&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;5,624&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;0 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;#2.16&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;3/18/2016&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stephen&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;262,500&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;0.65%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;NA&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;9,447&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;0 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;9,447&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;9,447&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;0 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;#3.19&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;9/1/2019(DS)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stephen&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;salary&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;39,392&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;714 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;4,340&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;5,054&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,518&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;3,536&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;#4.19&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;12/1/2019(DE)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stephen&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;14,879&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.61%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;257 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,132&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,389&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;439 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;950 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;#6.20&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;1/1/2020(DS)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stephen&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;salary&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;216,600&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2,179&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;16,363&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;18,543&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;5,206&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;13,336&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;#7.20&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;1/1/2020(DE)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stephen&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;23,366&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.60%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;72 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,753&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,825&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;352 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,473&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;#9.20&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;11/2020 (Open)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stephen&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;279,405&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;0.13%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;81 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;12,864&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;12,945&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;248 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;12,697&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;#10.21&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;1/1/2021(DS)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stephen&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;salary&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;59,025&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;178 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2,968&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;3,146&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;725&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2,421&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;#11.21&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;4/1/2021(DS)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stephen&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;salary&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;15 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;420 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;435 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;93 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;342 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,019,193&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;18,566&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;39,841&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;58,407&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;23,653&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;34,754&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;#5.19&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;9/1/2019&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;i2China&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;consulting fee&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;16,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;253 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,759&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2,012&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;579 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,433&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;#8a.20&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;1/1/2020&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;i2China&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;consulting fee&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;48,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;483&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;3,626&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;4,109&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,154&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2,955&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;#8b.20&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;1/1/2020&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;i2China&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;retroactive increase&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;84,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,554&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6,399&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7,953&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2,738&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;5,215&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;#11.21&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;1/1/2021(DS)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;i2China&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;consulting fee&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;37,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;107 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,860&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,967&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;450&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,517&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;185,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2,397&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;13,645&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;16,041&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;4,920&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;11,121&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td colspan="3"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;TOTAL ACCRUED&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td style="BORDER-BOTTOM: black 3px double;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,204,193 &lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;"/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;20,963&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double; PADDING-BOTTOM: 3px;"/&gt;&lt;td style="BORDER-BOTTOM: black 3px double;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;53,485&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;"/&gt;&lt;td style="BORDER-BOTTOM: black 3px double;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;74,448 &lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;"/&gt;&lt;td style="BORDER-BOTTOM: black 3px double;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;28,573 &lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;"/&gt;&lt;td style="BORDER-BOTTOM: black 3px double;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;45,875 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The accrued interest amount was $31,983 and $18,691 as of September 30, 2021 and December 31, 2020, respectively.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_887"
      unitRef="USD">2185953</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="From2020-01-01to2020-12-31"
      decimals="0"
      id="fid_888"
      unitRef="USD">953001</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:ConvertibleDebtTableTextBlock contextRef="From2021-01-01to2021-09-30" id="fid_1312">&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="BORDER-BOTTOM: #000000 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Annual Interest Rate&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Unpaid Principal Balance&lt;/strong&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;No#&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Effective Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Due Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;From&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Effective&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Following&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Maturity&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Payee&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM: #000000 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Issuing&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Purpose&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM: #000000 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Sep 30,&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM: #000000 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Dec 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td colspan="24"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Payee: Dr. Stephen T. Chen, resigned as Chairman of the Board, President, and Board director April 15, 2021&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#1.16&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2016/01/30&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Payable on demand&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;0.75%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:1%;"/&gt;&lt;td style="width:8%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;NA&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stephen Chen&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"/&gt;&lt;td colspan="2" style="width:12%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:1%;"/&gt;&lt;td colspan="2" style="width:9%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;114,026&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="width:1%;"/&gt;&lt;td colspan="2" style="width:9%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;114,026&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#2.16&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2016/03/18&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Payable on demand&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;0.65%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;NA&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stephen Chen&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;262,500&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;262,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#3.19&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2019/09/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2020/09/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stephen Chen&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;salary&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;39,392&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;39,620&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#4.19&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2019/12/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2020/12/31&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.61%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stephen Chen&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;14,879&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;14,879&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#6.20&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2020/01/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/01/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stephen Chen&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;salary&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;216,600&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;216,600&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#7.20&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2020/01/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/01/02&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.60%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stephen Chen&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;23,366&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;23,366&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#9.20&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2020/01/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/04/14&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;0.13%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stephen Chen&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;279,405&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;134,010&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#10.21&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/01/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/04/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stephen Chen&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;salary&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;59,025&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#11.21&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/04/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/05/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stephen Chen&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;salary&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10,000&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;"/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td colspan="2"/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,019,193&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;805,001&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td colspan="2"/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"/&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td colspan="5"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Payee: Ainos KY, an affiliated company &lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td colspan="2"/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"/&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#12.21&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/04/27&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/10/27&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;NA&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ainos KY&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;15,000&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#13.21&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/05/05&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/11/05&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;NA&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ainos KY&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;20,000&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#14.21&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/05/25&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/11/25&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;NA&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ainos KY&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;30,000&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#15.21&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/05/28&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/11/28&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;NA&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ainos KY&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;35,000&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#16.21&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/06/09&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/12/09&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;NA&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ainos KY&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;300,000&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#17.21&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/06/21&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/12/21&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;NA&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ainos KY&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;107,000&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#18.21&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/07/02&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2022/01/02&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;NA&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ainos KY&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;54,000&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#19.21&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/09/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/03/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;NA&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ainos KY&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;120,000&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#20.21&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/09/28&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/03/28&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;NA&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ainos KY&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;300,000&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;"/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td colspan="2"/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;981,000&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;0 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td colspan="9"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;Convertible and other notes payable- related parties&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2,000,193&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;805,001&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td colspan="2"/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"/&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td colspan="10"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Payee: i2China Management Group LLC, a management consultant&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"/&gt;&lt;td colspan="3"/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#5.19&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2019/09/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2020/09/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;i2China&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;consulting fee&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;16,000&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;16,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#8a.20&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2020/01/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/01/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;i2China&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;consulting fee&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;48,000&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;48,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#8b.20&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Retroactive from 2020/01/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/01/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;i2China&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;consulting fee&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;84,000&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;84,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;#11.21&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/01/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;2021/04/01&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;i2China&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td colspan="2"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;consulting fee&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2" style="BORDER-BOTTOM: #000000 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;37,000&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2" style="BORDER-BOTTOM: #000000 1px solid;"/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td colspan="9"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;Convertible and other notes payable&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;185,000&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;148,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td colspan="9"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;Total Convertible and other notes payable&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"/&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 3px double;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2,185,193&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3"/&gt;&lt;td colspan="2" style="BORDER-BOTTOM: 3px double;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;953,001&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Unpaid &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Interest Rate&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Interest amount&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;Interest &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;No#&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Date&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Payee&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Description&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;strong&gt;Principal &lt;/strong&gt;&lt;strong&gt;Amount&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Original&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;after&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Maturity&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;Original&#160;rate&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;10%&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Total &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;after&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Maturity&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;strong&gt;Interest&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Waived&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="width:10%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;#1.16&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;1/30/2016&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stephen&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;114,026&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;0.75%&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;NA&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;5,624&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;0 &lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;5,624&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;5,624&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6%;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;0 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;#2.16&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;3/18/2016&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stephen&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;262,500&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;0.65%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;NA&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;9,447&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;0 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;9,447&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;9,447&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;0 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;#3.19&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;9/1/2019(DS)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stephen&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;salary&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;39,392&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;714 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;4,340&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;5,054&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,518&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;3,536&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;#4.19&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;12/1/2019(DE)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stephen&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;14,879&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.61%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;257 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,132&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,389&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;439 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;950 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;#6.20&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;1/1/2020(DS)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stephen&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;salary&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;216,600&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2,179&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;16,363&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;18,543&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;5,206&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;13,336&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;#7.20&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;1/1/2020(DE)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stephen&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;23,366&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.60%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;72 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,753&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,825&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;352 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,473&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;#9.20&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;11/2020 (Open)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stephen&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;working capital&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;279,405&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;0.13%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;81 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;12,864&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;12,945&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;248 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;12,697&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;#10.21&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;1/1/2021(DS)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stephen&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;salary&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;59,025&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;178 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2,968&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;3,146&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;725&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2,421&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;#11.21&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;4/1/2021(DS)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Stephen&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;salary&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;10,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;15 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;420 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;435 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;93 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;342 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,019,193&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;18,566&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;39,841&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;58,407&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;23,653&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;34,754&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;#5.19&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;9/1/2019&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;i2China&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;consulting fee&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;16,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;253 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,759&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2,012&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;579 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,433&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;#8a.20&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;1/1/2020&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;i2China&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;consulting fee&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;48,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;483&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;3,626&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;4,109&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,154&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2,955&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;#8b.20&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;1/1/2020&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;i2China&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;retroactive increase&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;84,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,554&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;6,399&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;7,953&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2,738&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;5,215&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;#11.21&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;1/1/2021(DS)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;i2China&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;consulting fee&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;37,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;1.85%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;10%&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;107 &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,860&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,967&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;450&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,517&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;185,000&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;2,397&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;13,645&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;16,041&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;4,920&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;11,121&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td colspan="3"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;TOTAL ACCRUED&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td style="BORDER-BOTTOM: black 3px double;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;1,204,193 &lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;"/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;20,963&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: black 3px double; PADDING-BOTTOM: 3px;"/&gt;&lt;td style="BORDER-BOTTOM: black 3px double;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;&#160;53,485&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;"/&gt;&lt;td style="BORDER-BOTTOM: black 3px double;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;74,448 &lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;"/&gt;&lt;td style="BORDER-BOTTOM: black 3px double;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;28,573 &lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;"/&gt;&lt;td style="BORDER-BOTTOM: black 3px double;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"&gt;45,875 &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <aimd:EffectiveDate
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_OneOneSixMember"
      id="fid_569">2016/01/30</aimd:EffectiveDate>
    <aimd:DueDate
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_OneOneSixMember"
      id="fid_556">Payable on demand</aimd:DueDate>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_OneOneSixMember"
      decimals="INF"
      id="fid_557"
      unitRef="Pure">0.0075</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_OneOneSixMember"
      decimals="0"
      id="fid_559"
      unitRef="USD">114026</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2020-01-01to2020-12-31_aimd_DrStephenTChenMember_aimd_OneOneSixMember"
      decimals="0"
      id="fid_561"
      unitRef="USD">114026</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <aimd:EffectiveDate
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TwoOneSixMember"
      id="fid_555">2016/03/18</aimd:EffectiveDate>
    <aimd:DueDate
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TwoOneSixMember"
      id="fid_619">Payable on demand</aimd:DueDate>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TwoOneSixMember"
      decimals="INF"
      id="fid_565"
      unitRef="Pure">0.0065</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TwoOneSixMember"
      decimals="0"
      id="fid_699"
      unitRef="USD">262500</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2020-01-01to2020-12-31_aimd_DrStephenTChenMember_aimd_TwoOneSixMember"
      decimals="0"
      id="fid_700"
      unitRef="USD">262500</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <aimd:EffectiveDate
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ThreeOneNineMember"
      id="fid_562">2019/09/01</aimd:EffectiveDate>
    <aimd:DueDate
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ThreeOneNineMember"
      id="fid_582">2020/09/01</aimd:DueDate>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ThreeOneNineMember"
      decimals="INF"
      id="fid_574"
      unitRef="Pure">0.0185</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <aimd:AnnualInterestRateFollowingMaturity
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ThreeOneNineMember"
      decimals="INF"
      id="fid_573"
      unitRef="Pure">0.10</aimd:AnnualInterestRateFollowingMaturity>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ThreeOneNineMember"
      decimals="0"
      id="fid_571"
      unitRef="USD">39392</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2020-01-01to2020-12-31_aimd_DrStephenTChenMember_aimd_ThreeOneNineMember"
      decimals="0"
      id="fid_572"
      unitRef="USD">39620</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <aimd:EffectiveDate
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_FourOneNineMember"
      id="fid_588">2019/12/01</aimd:EffectiveDate>
    <aimd:DueDate
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_FourOneNineMember"
      id="fid_575">2020/12/31</aimd:DueDate>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_FourOneNineMember"
      decimals="INF"
      id="fid_576"
      unitRef="Pure">0.0161</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <aimd:AnnualInterestRateFollowingMaturity
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_FourOneNineMember"
      decimals="INF"
      id="fid_577"
      unitRef="Pure">0.10</aimd:AnnualInterestRateFollowingMaturity>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_FourOneNineMember"
      decimals="0"
      id="fid_578"
      unitRef="USD">14879</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2020-01-01to2020-12-31_aimd_DrStephenTChenMember_aimd_FourOneNineMember"
      decimals="0"
      id="fid_579"
      unitRef="USD">14879</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <aimd:EffectiveDate
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SixTwoZeroMember"
      id="fid_580">2020/01/01</aimd:EffectiveDate>
    <aimd:DueDate
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SixTwoZeroMember"
      id="fid_583">2021/01/</aimd:DueDate>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SixTwoZeroMember"
      decimals="INF"
      id="fid_584"
      unitRef="Pure">0.0185</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <aimd:AnnualInterestRateFollowingMaturity
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SixTwoZeroMember"
      decimals="INF"
      id="fid_585"
      unitRef="Pure">0.10</aimd:AnnualInterestRateFollowingMaturity>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SixTwoZeroMember"
      decimals="0"
      id="fid_595"
      unitRef="USD">216600</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2020-01-01to2020-12-31_aimd_DrStephenTChenMember_aimd_SixTwoZeroMember"
      decimals="0"
      id="fid_596"
      unitRef="USD">216600</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <aimd:EffectiveDate
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SevenTwoZeroMember"
      id="fid_602">2020/01/01</aimd:EffectiveDate>
    <aimd:DueDate
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SevenTwoZeroMember"
      id="fid_592">2021/01/02</aimd:DueDate>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SevenTwoZeroMember"
      decimals="INF"
      id="fid_591"
      unitRef="Pure">0.0160</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <aimd:AnnualInterestRateFollowingMaturity
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SevenTwoZeroMember"
      decimals="INF"
      id="fid_590"
      unitRef="Pure">0.10</aimd:AnnualInterestRateFollowingMaturity>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SevenTwoZeroMember"
      decimals="0"
      id="fid_586"
      unitRef="USD">23366</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2020-01-01to2020-12-31_aimd_DrStephenTChenMember_aimd_SevenTwoZeroMember"
      decimals="0"
      id="fid_587"
      unitRef="USD">23366</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <aimd:EffectiveDate
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_NineTwoZeroMember"
      id="fid_593">2020/01/01</aimd:EffectiveDate>
    <aimd:DueDate
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_NineTwoZeroMember"
      id="fid_597">2021/04/14</aimd:DueDate>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_NineTwoZeroMember"
      decimals="INF"
      id="fid_598"
      unitRef="Pure">0.0013</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <aimd:AnnualInterestRateFollowingMaturity
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_NineTwoZeroMember"
      decimals="INF"
      id="fid_599"
      unitRef="Pure">0.10</aimd:AnnualInterestRateFollowingMaturity>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_NineTwoZeroMember"
      decimals="0"
      id="fid_609"
      unitRef="USD">279405</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2020-01-01to2020-12-31_aimd_DrStephenTChenMember_aimd_NineTwoZeroMember"
      decimals="0"
      id="fid_610"
      unitRef="USD">134010</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <aimd:EffectiveDate
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TenTwoOneMember"
      id="fid_607">2021/01/01</aimd:EffectiveDate>
    <aimd:DueDate
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TenTwoOneMember"
      id="fid_606">2021/04/01</aimd:DueDate>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TenTwoOneMember"
      decimals="INF"
      id="fid_605"
      unitRef="Pure">0.0185</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <aimd:AnnualInterestRateFollowingMaturity
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TenTwoOneMember"
      decimals="INF"
      id="fid_604"
      unitRef="Pure">0.10</aimd:AnnualInterestRateFollowingMaturity>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TenTwoOneMember"
      decimals="0"
      id="fid_618"
      unitRef="USD">59025</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <aimd:EffectiveDate
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ElevenTwoOneMember"
      id="fid_614">2021/04/01</aimd:EffectiveDate>
    <aimd:DueDate
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ElevenTwoOneMember"
      id="fid_613">2021/05/01</aimd:DueDate>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ElevenTwoOneMember"
      decimals="INF"
      id="fid_612"
      unitRef="Pure">0.0185</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <aimd:AnnualInterestRateFollowingMaturity
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ElevenTwoOneMember"
      decimals="INF"
      id="fid_611"
      unitRef="Pure">0.10</aimd:AnnualInterestRateFollowingMaturity>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ElevenTwoOneMember"
      decimals="0"
      id="fid_600"
      unitRef="USD">10000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember"
      decimals="0"
      id="fid_616"
      unitRef="USD">1019193</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2020-01-01to2020-12-31_aimd_DrStephenTChenMember"
      decimals="0"
      id="fid_617"
      unitRef="USD">805001</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <aimd:EffectiveDate
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_TwelveTwoOneMember"
      id="fid_626">2021/04/27</aimd:EffectiveDate>
    <aimd:DueDate
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_TwelveTwoOneMember"
      id="fid_624">2021/10/27</aimd:DueDate>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_TwelveTwoOneMember"
      decimals="INF"
      id="fid_625"
      unitRef="Pure">0.0185</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_TwelveTwoOneMember"
      decimals="0"
      id="fid_674"
      unitRef="USD">15000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <aimd:EffectiveDate
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_ThirteenTwoOneMember"
      id="fid_632">2021/05/05</aimd:EffectiveDate>
    <aimd:DueDate
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_ThirteenTwoOneMember"
      id="fid_634">2021/11/05</aimd:DueDate>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_ThirteenTwoOneMember"
      decimals="INF"
      id="fid_633"
      unitRef="Pure">0.0185</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_ThirteenTwoOneMember"
      decimals="0"
      id="fid_630"
      unitRef="USD">20000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <aimd:EffectiveDate
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_FourteenTwoOneMember"
      id="fid_637">2021/05/25</aimd:EffectiveDate>
    <aimd:DueDate
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_FourteenTwoOneMember"
      id="fid_639">2021/11/25</aimd:DueDate>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_FourteenTwoOneMember"
      decimals="INF"
      id="fid_638"
      unitRef="Pure">0.0185</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_FourteenTwoOneMember"
      decimals="0"
      id="fid_635"
      unitRef="USD">30000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <aimd:EffectiveDate
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_FifteenTwoOneMember"
      id="fid_642">2021/05/28</aimd:EffectiveDate>
    <aimd:DueDate
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_FifteenTwoOneMember"
      id="fid_640">2021/11/28</aimd:DueDate>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_FifteenTwoOneMember"
      decimals="INF"
      id="fid_641"
      unitRef="Pure">0.0185</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_FifteenTwoOneMember"
      decimals="0"
      id="fid_643"
      unitRef="USD">35000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <aimd:EffectiveDate
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_SixteenTwoOneMember"
      id="fid_647">2021/06/09</aimd:EffectiveDate>
    <aimd:DueDate
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_SixteenTwoOneMember"
      id="fid_645">2021/12/09</aimd:DueDate>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_SixteenTwoOneMember"
      decimals="INF"
      id="fid_646"
      unitRef="Pure">0.0185</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_SixteenTwoOneMember"
      decimals="0"
      id="fid_648"
      unitRef="USD">300000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <aimd:EffectiveDate
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_SeventeenTwoOneMember"
      id="fid_652">2021/06/21</aimd:EffectiveDate>
    <aimd:DueDate
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_SeventeenTwoOneMember"
      id="fid_650">2021/12/21</aimd:DueDate>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_SeventeenTwoOneMember"
      decimals="INF"
      id="fid_651"
      unitRef="Pure">0.0185</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_SeventeenTwoOneMember"
      decimals="0"
      id="fid_653"
      unitRef="USD">107000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <aimd:EffectiveDate
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_EighteenTwoOneMember"
      id="fid_657">2021/07/02</aimd:EffectiveDate>
    <aimd:DueDate
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_EighteenTwoOneMember"
      id="fid_655">2022/01/02</aimd:DueDate>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_EighteenTwoOneMember"
      decimals="INF"
      id="fid_656"
      unitRef="Pure">0.0185</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_EighteenTwoOneMember"
      decimals="0"
      id="fid_658"
      unitRef="USD">54000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <aimd:EffectiveDate
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_NinteenTwoOneMember"
      id="fid_662">2021/09/01</aimd:EffectiveDate>
    <aimd:DueDate
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_NinteenTwoOneMember"
      id="fid_664">2021/03/01</aimd:DueDate>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_NinteenTwoOneMember"
      decimals="INF"
      id="fid_663"
      unitRef="Pure">0.0185</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_NinteenTwoOneMember"
      decimals="0"
      id="fid_660"
      unitRef="USD">120000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <aimd:EffectiveDate
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_TwentyTwoOneMember"
      id="fid_667">2021/09/28</aimd:EffectiveDate>
    <aimd:DueDate
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_TwentyTwoOneMember"
      id="fid_669">2021/03/28</aimd:DueDate>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_TwentyTwoOneMember"
      decimals="INF"
      id="fid_668"
      unitRef="Pure">0.0185</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_TwentyTwoOneMember"
      decimals="0"
      id="fid_665"
      unitRef="USD">300000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_TotalMember"
      decimals="0"
      id="fid_670"
      unitRef="USD">981000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <aimd:ConvertibleAndOtherNotesPayableRelatedParties
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember_aimd_TotalMember"
      decimals="0"
      id="fid_672"
      unitRef="USD">2000193</aimd:ConvertibleAndOtherNotesPayableRelatedParties>
    <aimd:ConvertibleAndOtherNotesPayableRelatedParties
      contextRef="From2020-01-01to2020-12-31_aimd_AinosKYMember_aimd_TotalMember"
      decimals="0"
      id="fid_673"
      unitRef="USD">805001</aimd:ConvertibleAndOtherNotesPayableRelatedParties>
    <aimd:EffectiveDate
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_FiveOneNineMember"
      id="fid_678">2019/09/01</aimd:EffectiveDate>
    <aimd:DueDate
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_FiveOneNineMember"
      id="fid_680">2020/09/01</aimd:DueDate>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_FiveOneNineMember"
      decimals="INF"
      id="fid_679"
      unitRef="Pure">0.0185</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <aimd:AnnualInterestRateFollowingMaturity
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_FiveOneNineMember"
      decimals="INF"
      id="fid_681"
      unitRef="Pure">0.10</aimd:AnnualInterestRateFollowingMaturity>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_FiveOneNineMember"
      decimals="0"
      id="fid_628"
      unitRef="USD">16000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2020-01-01to2020-12-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_FiveOneNineMember"
      decimals="0"
      id="fid_629"
      unitRef="USD">16000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <aimd:EffectiveDate
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightATwozeroMember"
      id="fid_684">2020/01/01</aimd:EffectiveDate>
    <aimd:DueDate
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightATwozeroMember"
      id="fid_686">2021/01/01</aimd:DueDate>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightATwozeroMember"
      decimals="INF"
      id="fid_685"
      unitRef="Pure">0.0185</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <aimd:AnnualInterestRateFollowingMaturity
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightATwozeroMember"
      decimals="INF"
      id="fid_687"
      unitRef="Pure">0.10</aimd:AnnualInterestRateFollowingMaturity>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightATwozeroMember"
      decimals="0"
      id="fid_682"
      unitRef="USD">48000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2020-01-01to2020-12-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightATwozeroMember"
      decimals="0"
      id="fid_683"
      unitRef="USD">48000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <aimd:EffectiveDate
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember"
      id="fid_690">Retroactive from 2020/01/01</aimd:EffectiveDate>
    <aimd:DueDate
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember"
      id="fid_688">2021/01/01</aimd:DueDate>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember"
      decimals="INF"
      id="fid_689"
      unitRef="Pure">0.0185</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <aimd:AnnualInterestRateFollowingMaturity
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember"
      decimals="INF"
      id="fid_698"
      unitRef="Pure">0.10</aimd:AnnualInterestRateFollowingMaturity>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember"
      decimals="0"
      id="fid_691"
      unitRef="USD">84000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2020-01-01to2020-12-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember"
      decimals="0"
      id="fid_692"
      unitRef="USD">84000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <aimd:EffectiveDate
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_ElevenOneTwoOneMember"
      id="fid_695">2021/01/01</aimd:EffectiveDate>
    <aimd:DueDate
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_ElevenOneTwoOneMember"
      id="fid_697">2021/04/01</aimd:DueDate>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_ElevenOneTwoOneMember"
      decimals="INF"
      id="fid_696"
      unitRef="Pure">0.0185</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <aimd:AnnualInterestRateFollowingMaturity
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_ElevenOneTwoOneMember"
      decimals="INF"
      id="fid_627"
      unitRef="Pure">0.10</aimd:AnnualInterestRateFollowingMaturity>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_ElevenOneTwoOneMember"
      decimals="0"
      id="fid_693"
      unitRef="USD">37000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_TotalMember"
      decimals="0"
      id="fid_567"
      unitRef="USD">185000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2020-01-01to2020-12-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_TotalMember"
      decimals="0"
      id="fid_568"
      unitRef="USD">148000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <aimd:ConvertibleAndOtherNotesPayableRelatedParties
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_TotalMember"
      decimals="0"
      id="fid_701"
      unitRef="USD">2185193</aimd:ConvertibleAndOtherNotesPayableRelatedParties>
    <aimd:ConvertibleAndOtherNotesPayableRelatedParties
      contextRef="From2020-01-01to2020-12-31_aimd_ITwoChinaManagementGroupLLCMember_aimd_TotalMember"
      decimals="0"
      id="fid_702"
      unitRef="USD">953001</aimd:ConvertibleAndOtherNotesPayableRelatedParties>
    <aimd:Date
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_OneOneSixMember"
      id="fid_735">1/30/2016</aimd:Date>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_OneOneSixMember"
      decimals="0"
      id="fid_743"
      unitRef="USD">114026</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_OneOneSixMember"
      decimals="INF"
      id="fid_736"
      unitRef="Pure">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <aimd:InterestAmountOriginalRate
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_OneOneSixMember"
      decimals="0"
      id="fid_738"
      unitRef="USD">5624</aimd:InterestAmountOriginalRate>
    <aimd:InterestAmount10
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_OneOneSixMember"
      decimals="0"
      id="fid_739"
      unitRef="USD">0</aimd:InterestAmount10>
    <us-gaap:InterestPaid
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_OneOneSixMember"
      decimals="0"
      id="fid_740"
      unitRef="USD">5624</us-gaap:InterestPaid>
    <aimd:InterestAfterMaturity
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_OneOneSixMember"
      decimals="0"
      id="fid_741"
      unitRef="USD">5624</aimd:InterestAfterMaturity>
    <aimd:InterestWaived
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_OneOneSixMember"
      decimals="0"
      id="fid_742"
      unitRef="USD">0</aimd:InterestWaived>
    <aimd:Date
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TwoOneSixMember"
      id="fid_746">3/18/2016</aimd:Date>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TwoOneSixMember"
      decimals="0"
      id="fid_744"
      unitRef="USD">262500</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_TwoOneSixMember"
      decimals="INF"
      id="fid_747"
      unitRef="Pure">0.0065</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <aimd:InterestAmountOriginalRate
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TwoOneSixMember"
      decimals="0"
      id="fid_749"
      unitRef="USD">9447</aimd:InterestAmountOriginalRate>
    <aimd:InterestAmount10
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TwoOneSixMember"
      decimals="0"
      id="fid_750"
      unitRef="USD">0</aimd:InterestAmount10>
    <us-gaap:InterestPaid
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TwoOneSixMember"
      decimals="0"
      id="fid_751"
      unitRef="USD">9447</us-gaap:InterestPaid>
    <aimd:InterestAfterMaturity
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TwoOneSixMember"
      decimals="0"
      id="fid_752"
      unitRef="USD">9447</aimd:InterestAfterMaturity>
    <aimd:InterestWaived
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TwoOneSixMember"
      decimals="0"
      id="fid_753"
      unitRef="USD">0</aimd:InterestWaived>
    <aimd:Date
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ThreeOneNineMember"
      id="fid_756">9/1/2019(DS</aimd:Date>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ThreeOneNineMember"
      decimals="0"
      id="fid_754"
      unitRef="USD">39392</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_ThreeOneNineMember"
      decimals="INF"
      id="fid_758"
      unitRef="Pure">0.0185</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <aimd:InterestRateAfterMaturity
      contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_ThreeOneNineMember"
      decimals="INF"
      id="fid_757"
      unitRef="Pure">0.10</aimd:InterestRateAfterMaturity>
    <aimd:InterestAmountOriginalRate
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ThreeOneNineMember"
      decimals="0"
      id="fid_759"
      unitRef="USD">714</aimd:InterestAmountOriginalRate>
    <aimd:InterestAmount10
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ThreeOneNineMember"
      decimals="0"
      id="fid_760"
      unitRef="USD">4340</aimd:InterestAmount10>
    <us-gaap:InterestPaid
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ThreeOneNineMember"
      decimals="0"
      id="fid_761"
      unitRef="USD">5054</us-gaap:InterestPaid>
    <aimd:InterestAfterMaturity
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ThreeOneNineMember"
      decimals="0"
      id="fid_762"
      unitRef="USD">1518</aimd:InterestAfterMaturity>
    <aimd:InterestWaived
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ThreeOneNineMember"
      decimals="0"
      id="fid_763"
      unitRef="USD">3536</aimd:InterestWaived>
    <aimd:Date
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_FourOneNineMember"
      id="fid_766">12/1/2019(DE)</aimd:Date>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_FourOneNineMember"
      decimals="0"
      id="fid_764"
      unitRef="USD">14879</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_FourOneNineMember"
      decimals="INF"
      id="fid_767"
      unitRef="Pure">0.0161</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <aimd:InterestRateAfterMaturity
      contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_FourOneNineMember"
      decimals="INF"
      id="fid_768"
      unitRef="Pure">0.10</aimd:InterestRateAfterMaturity>
    <aimd:InterestAmountOriginalRate
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_FourOneNineMember"
      decimals="0"
      id="fid_769"
      unitRef="USD">257</aimd:InterestAmountOriginalRate>
    <aimd:InterestAmount10
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_FourOneNineMember"
      decimals="0"
      id="fid_770"
      unitRef="USD">1132</aimd:InterestAmount10>
    <us-gaap:InterestPaid
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_FourOneNineMember"
      decimals="0"
      id="fid_771"
      unitRef="USD">1389</us-gaap:InterestPaid>
    <aimd:InterestAfterMaturity
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_FourOneNineMember"
      decimals="0"
      id="fid_772"
      unitRef="USD">439</aimd:InterestAfterMaturity>
    <aimd:InterestWaived
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_FourOneNineMember"
      decimals="0"
      id="fid_773"
      unitRef="USD">950</aimd:InterestWaived>
    <aimd:Date
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SixTwoZeroMember"
      id="fid_776">1/1/2020(DS)</aimd:Date>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SixTwoZeroMember"
      decimals="0"
      id="fid_774"
      unitRef="USD">216600</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_SixTwoZeroMember"
      decimals="INF"
      id="fid_777"
      unitRef="Pure">0.0185</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <aimd:InterestRateAfterMaturity
      contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_SixTwoZeroMember"
      decimals="INF"
      id="fid_778"
      unitRef="Pure">0.10</aimd:InterestRateAfterMaturity>
    <aimd:InterestAmountOriginalRate
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SixTwoZeroMember"
      decimals="0"
      id="fid_779"
      unitRef="USD">2179</aimd:InterestAmountOriginalRate>
    <aimd:InterestAmount10
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SixTwoZeroMember"
      decimals="0"
      id="fid_780"
      unitRef="USD">16363</aimd:InterestAmount10>
    <us-gaap:InterestPaid
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SixTwoZeroMember"
      decimals="0"
      id="fid_781"
      unitRef="USD">18543</us-gaap:InterestPaid>
    <aimd:InterestAfterMaturity
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SixTwoZeroMember"
      decimals="0"
      id="fid_782"
      unitRef="USD">5206</aimd:InterestAfterMaturity>
    <aimd:InterestWaived
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SixTwoZeroMember"
      decimals="0"
      id="fid_783"
      unitRef="USD">13336</aimd:InterestWaived>
    <aimd:Date
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SevenTwoZeroMember"
      id="fid_786">1/1/2020(DE)</aimd:Date>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SevenTwoZeroMember"
      decimals="0"
      id="fid_784"
      unitRef="USD">23366</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_SevenTwoZeroMember"
      decimals="INF"
      id="fid_787"
      unitRef="Pure">0.0160</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <aimd:InterestRateAfterMaturity
      contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_SevenTwoZeroMember"
      decimals="INF"
      id="fid_788"
      unitRef="Pure">0.10</aimd:InterestRateAfterMaturity>
    <aimd:InterestAmount10
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SevenTwoZeroMember"
      decimals="0"
      id="fid_789"
      unitRef="USD">72</aimd:InterestAmount10>
    <aimd:InterestAmountOriginalRate
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SevenTwoZeroMember"
      decimals="0"
      id="fid_790"
      unitRef="USD">1753</aimd:InterestAmountOriginalRate>
    <us-gaap:InterestPaid
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SevenTwoZeroMember"
      decimals="0"
      id="fid_791"
      unitRef="USD">1825</us-gaap:InterestPaid>
    <aimd:InterestAfterMaturity
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SevenTwoZeroMember"
      decimals="0"
      id="fid_792"
      unitRef="USD">352</aimd:InterestAfterMaturity>
    <aimd:InterestWaived
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_SevenTwoZeroMember"
      decimals="0"
      id="fid_793"
      unitRef="USD">1473</aimd:InterestWaived>
    <aimd:Date
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_NineTwoZeroMember"
      id="fid_796">11/2020 (Open)</aimd:Date>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_NineTwoZeroMember"
      decimals="0"
      id="fid_794"
      unitRef="USD">279405</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_NineTwoZeroMember"
      decimals="INF"
      id="fid_797"
      unitRef="Pure">0.0013</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <aimd:InterestRateAfterMaturity
      contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_NineTwoZeroMember"
      decimals="INF"
      id="fid_798"
      unitRef="Pure">0.10</aimd:InterestRateAfterMaturity>
    <aimd:InterestAmountOriginalRate
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_NineTwoZeroMember"
      decimals="0"
      id="fid_799"
      unitRef="USD">81</aimd:InterestAmountOriginalRate>
    <aimd:InterestAmount10
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_NineTwoZeroMember"
      decimals="0"
      id="fid_800"
      unitRef="USD">12864</aimd:InterestAmount10>
    <us-gaap:InterestPaid
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_NineTwoZeroMember"
      decimals="0"
      id="fid_801"
      unitRef="USD">12945</us-gaap:InterestPaid>
    <aimd:InterestAfterMaturity
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_NineTwoZeroMember"
      decimals="0"
      id="fid_802"
      unitRef="USD">248</aimd:InterestAfterMaturity>
    <aimd:InterestWaived
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_NineTwoZeroMember"
      decimals="0"
      id="fid_803"
      unitRef="USD">12697</aimd:InterestWaived>
    <aimd:Date
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TenTwoOneMember"
      id="fid_806">1/1/2021(DS)</aimd:Date>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TenTwoOneMember"
      decimals="0"
      id="fid_804"
      unitRef="USD">59025</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_TenTwoOneMember"
      decimals="INF"
      id="fid_807"
      unitRef="Pure">0.0185</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <aimd:InterestRateAfterMaturity
      contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_TenTwoOneMember"
      decimals="INF"
      id="fid_808"
      unitRef="Pure">0.10</aimd:InterestRateAfterMaturity>
    <aimd:InterestAmountOriginalRate
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TenTwoOneMember"
      decimals="0"
      id="fid_809"
      unitRef="USD">178</aimd:InterestAmountOriginalRate>
    <aimd:InterestAmount10
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TenTwoOneMember"
      decimals="0"
      id="fid_810"
      unitRef="USD">2968</aimd:InterestAmount10>
    <us-gaap:InterestPaid
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TenTwoOneMember"
      decimals="0"
      id="fid_811"
      unitRef="USD">3146</us-gaap:InterestPaid>
    <aimd:InterestAfterMaturity
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TenTwoOneMember"
      decimals="0"
      id="fid_812"
      unitRef="USD">725</aimd:InterestAfterMaturity>
    <aimd:InterestWaived
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TenTwoOneMember"
      decimals="0"
      id="fid_813"
      unitRef="USD">2421</aimd:InterestWaived>
    <aimd:Date
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ElevenTwoOneMember"
      id="fid_816">4/1/2021(DS)</aimd:Date>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ElevenTwoOneMember"
      decimals="0"
      id="fid_814"
      unitRef="USD">10000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <aimd:InterestRateAfterMaturity
      contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember_aimd_ElevenTwoOneMember"
      decimals="INF"
      id="fid_818"
      unitRef="Pure">0.10</aimd:InterestRateAfterMaturity>
    <aimd:InterestAmountOriginalRate
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ElevenTwoOneMember"
      decimals="0"
      id="fid_819"
      unitRef="USD">15</aimd:InterestAmountOriginalRate>
    <aimd:InterestAmount10
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ElevenTwoOneMember"
      decimals="0"
      id="fid_820"
      unitRef="USD">420</aimd:InterestAmount10>
    <us-gaap:InterestPaid
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ElevenTwoOneMember"
      decimals="0"
      id="fid_821"
      unitRef="USD">435</us-gaap:InterestPaid>
    <aimd:InterestAfterMaturity
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ElevenTwoOneMember"
      decimals="0"
      id="fid_822"
      unitRef="USD">93</aimd:InterestAfterMaturity>
    <aimd:InterestWaived
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_ElevenTwoOneMember"
      decimals="0"
      id="fid_823"
      unitRef="USD">342</aimd:InterestWaived>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember"
      decimals="0"
      id="fid_824"
      unitRef="USD">1019193</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember"
      decimals="INF"
      id="fid_827"
      unitRef="Pure">0.0185</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <aimd:InterestRateAfterMaturity
      contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember"
      decimals="INF"
      id="fid_828"
      unitRef="Pure">0.10</aimd:InterestRateAfterMaturity>
    <aimd:InterestAmountOriginalRate
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember"
      decimals="0"
      id="fid_829"
      unitRef="USD">18566</aimd:InterestAmountOriginalRate>
    <aimd:InterestAmount10
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember"
      decimals="0"
      id="fid_830"
      unitRef="USD">39841</aimd:InterestAmount10>
    <us-gaap:InterestPaid
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember"
      decimals="0"
      id="fid_831"
      unitRef="USD">58407</us-gaap:InterestPaid>
    <aimd:InterestAfterMaturity
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember"
      decimals="0"
      id="fid_832"
      unitRef="USD">23653</aimd:InterestAfterMaturity>
    <aimd:InterestWaived
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember"
      decimals="0"
      id="fid_833"
      unitRef="USD">34754</aimd:InterestWaived>
    <aimd:Date
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_FiveOneNineMember"
      id="fid_836">9/1/2019</aimd:Date>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_FiveOneNineMember"
      decimals="0"
      id="fid_834"
      unitRef="USD">16000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_FiveOneNineMember"
      decimals="INF"
      id="fid_837"
      unitRef="Pure">0.0185</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <aimd:InterestRateAfterMaturity
      contextRef="AsOf2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_FiveOneNineMember"
      decimals="INF"
      id="fid_838"
      unitRef="Pure">0.10</aimd:InterestRateAfterMaturity>
    <aimd:InterestAmountOriginalRate
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_FiveOneNineMember"
      decimals="0"
      id="fid_839"
      unitRef="USD">253</aimd:InterestAmountOriginalRate>
    <aimd:InterestAmount10
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_FiveOneNineMember"
      decimals="0"
      id="fid_840"
      unitRef="USD">1759</aimd:InterestAmount10>
    <us-gaap:InterestPaid
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_FiveOneNineMember"
      decimals="0"
      id="fid_841"
      unitRef="USD">2012</us-gaap:InterestPaid>
    <aimd:InterestAfterMaturity
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_FiveOneNineMember"
      decimals="0"
      id="fid_842"
      unitRef="USD">579</aimd:InterestAfterMaturity>
    <aimd:InterestWaived
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_FiveOneNineMember"
      decimals="0"
      id="fid_843"
      unitRef="USD">1433</aimd:InterestWaived>
    <aimd:Date
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightATwozeroMember"
      id="fid_847">1/1/2020</aimd:Date>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightATwozeroMember"
      decimals="0"
      id="fid_844"
      unitRef="USD">48000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightATwozeroMember"
      decimals="INF"
      id="fid_846"
      unitRef="Pure">0.0185</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <aimd:InterestRateAfterMaturity
      contextRef="AsOf2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightATwozeroMember"
      decimals="INF"
      id="fid_848"
      unitRef="Pure">0.10</aimd:InterestRateAfterMaturity>
    <aimd:InterestAmountOriginalRate
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightATwozeroMember"
      decimals="0"
      id="fid_849"
      unitRef="USD">483</aimd:InterestAmountOriginalRate>
    <aimd:InterestAmount10
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightATwozeroMember"
      decimals="0"
      id="fid_850"
      unitRef="USD">3626</aimd:InterestAmount10>
    <us-gaap:InterestPaid
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightATwozeroMember"
      decimals="0"
      id="fid_851"
      unitRef="USD">4109</us-gaap:InterestPaid>
    <aimd:InterestAfterMaturity
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightATwozeroMember"
      decimals="0"
      id="fid_852"
      unitRef="USD">1154</aimd:InterestAfterMaturity>
    <aimd:InterestWaived
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightATwozeroMember"
      decimals="0"
      id="fid_853"
      unitRef="USD">2955</aimd:InterestWaived>
    <aimd:Date
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember"
      id="fid_856">1/1/2020</aimd:Date>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember"
      decimals="0"
      id="fid_854"
      unitRef="USD">84000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember"
      decimals="INF"
      id="fid_857"
      unitRef="Pure">0.0185</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <aimd:InterestRateAfterMaturity
      contextRef="AsOf2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember"
      decimals="INF"
      id="fid_858"
      unitRef="Pure">0.10</aimd:InterestRateAfterMaturity>
    <aimd:InterestAmountOriginalRate
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember"
      decimals="0"
      id="fid_859"
      unitRef="USD">1554</aimd:InterestAmountOriginalRate>
    <aimd:InterestAmount10
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember"
      decimals="0"
      id="fid_860"
      unitRef="USD">6399</aimd:InterestAmount10>
    <us-gaap:InterestPaid
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember"
      decimals="0"
      id="fid_861"
      unitRef="USD">7953</us-gaap:InterestPaid>
    <aimd:InterestAfterMaturity
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember"
      decimals="0"
      id="fid_862"
      unitRef="USD">2738</aimd:InterestAfterMaturity>
    <aimd:InterestWaived
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_EightBTwoZeroMember"
      decimals="0"
      id="fid_863"
      unitRef="USD">5215</aimd:InterestWaived>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_ElevenOneTwoOneMember"
      decimals="0"
      id="fid_864"
      unitRef="USD">37000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_ElevenOneTwoOneMember"
      decimals="INF"
      id="fid_867"
      unitRef="Pure">0.0185</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <aimd:InterestRateAfterMaturity
      contextRef="AsOf2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_ElevenOneTwoOneMember"
      decimals="INF"
      id="fid_868"
      unitRef="Pure">0.10</aimd:InterestRateAfterMaturity>
    <aimd:InterestAmountOriginalRate
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_ElevenOneTwoOneMember"
      decimals="0"
      id="fid_869"
      unitRef="USD">107</aimd:InterestAmountOriginalRate>
    <aimd:InterestAmount10
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_ElevenOneTwoOneMember"
      decimals="0"
      id="fid_870"
      unitRef="USD">1860</aimd:InterestAmount10>
    <us-gaap:InterestPaid
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_ElevenOneTwoOneMember"
      decimals="0"
      id="fid_871"
      unitRef="USD">1967</us-gaap:InterestPaid>
    <aimd:InterestAfterMaturity
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_ElevenOneTwoOneMember"
      decimals="0"
      id="fid_872"
      unitRef="USD">450</aimd:InterestAfterMaturity>
    <aimd:InterestWaived
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_ElevenOneTwoOneMember"
      decimals="0"
      id="fid_873"
      unitRef="USD">1517</aimd:InterestWaived>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_TotalMember"
      decimals="0"
      id="fid_874"
      unitRef="USD">185000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <aimd:InterestAmountOriginalRate
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_TotalMember"
      decimals="0"
      id="fid_879"
      unitRef="USD">2397</aimd:InterestAmountOriginalRate>
    <aimd:InterestAmount10
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_TotalMember"
      decimals="0"
      id="fid_880"
      unitRef="USD">13645</aimd:InterestAmount10>
    <us-gaap:InterestPaid
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_TotalMember"
      decimals="0"
      id="fid_881"
      unitRef="USD">16041</us-gaap:InterestPaid>
    <aimd:InterestAfterMaturity
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_TotalMember"
      decimals="0"
      id="fid_882"
      unitRef="USD">4920</aimd:InterestAfterMaturity>
    <aimd:InterestWaived
      contextRef="From2021-01-01to2021-09-30_aimd_ITwoChinaManagementGroupLLCMember_aimd_TotalMember"
      decimals="0"
      id="fid_883"
      unitRef="USD">11121</aimd:InterestWaived>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_889"
      unitRef="USD">31983</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2020-12-31"
      decimals="0"
      id="fid_891"
      unitRef="USD">18691</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2021-01-01to2021-09-30" id="fid_1310">&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;7.&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Related Party Transactions&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;The following is a list of related parties who have undertaken transactions with the Company during this reporting period:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:26%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Name of the related party&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:2%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Relationship&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:2%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Description&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Taiwan Carbon Nano Technology Corporation (TCNT)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Affiliated company&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ainos, Inc. (Cayman Island) ( Ainos KY)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Affiliated company&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;ASE Technology Holding&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Affiliated company&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Parent company of ASE Test Inc. which is Ainos KY's board member and with more than 10% of the voting rights &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;i2 China Management Group LLC (i2 China)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Affiliated company&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Sole member owner is Lawrence Lin, EVP Operations effective August 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Dr. Stephen T. Chen&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Principal owner&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Shareholder with more than 5% of Company voting rights, Ainos' former Chairman, President, CEO and CFO&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Chun-Hsien Tsai&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Board of Director, Executive Officer and Immediate Family&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Chairman of BOD, President, CEO and spouse of Ting-Chuan Lee&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ting-Chuan Lee&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Board of Director and Immediate Family&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Spouse of Chun Hsien Tsai&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Hui-Lan Wu&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Executive Officer&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;CFO&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Lawrence Lin&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Key management&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;EVP Operations effective August 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Chih-Heng Lu&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Key management&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Director of Corporate Development and Corporate Secretary&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;John Junyong Lee&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Key management&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Chief Legal Counsel and Corporate Secretary rewarded by fixed monthly fee and performance bonus effective September 1,2021 Chief Legal Counsel and Corporate Secretary&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Chien-Hsuan Huang &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Immediate Family of Director&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Spouse of Wen-Han Chang&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Bernard Cohen&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Former CFO&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Resigned on April 5, 2021&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Below is a summary of the significant related party transactions entered into by the Company over the first nine months of 2021:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Financial support&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Convertible Note&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Related Interest Expense&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Nine months ended &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;September 30, 2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;As of&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;September 30, 2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Nine months ended September 30, 2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;As of &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;September 30, 2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ainos KY&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;981,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;981,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,410&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,410&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;i2China&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;37,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;185,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,087&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,920&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Dr. Stephen T. Chen&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;15,272&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,019,193&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;5,936&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;23,653&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,033,272&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2,185,193&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;11,433&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;31,983&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;i2China became an affiliate of the Company as of August 1, 2021. From August 1, 2021 to September 30, 2021, interest payable to i2China amounted to $496.&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&lt;strong&gt;Other transactions&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Inventory purchases from TCNT totaling $173,657.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Product co-development agreement with TCNT resulting in $117,386 in costs and $122,680 in accounts payable.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Sale of products to ASE Technology Holding totaling $185,376.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Three-year office space was leased from a related party resulting in ROU Asset totaling $55,728 and Lease Obligations totaling $55,908. The Company makes monthly lease payments of $1,785.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Product development consulting fee of $7,215 payable to Huang Chien-Hsuan, of which $6,671 remains outstanding and payable.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Product development consulting fee of $7,215 payable to Huang Chien-Hsuan, of which $6,671 remains outstanding and payable.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;-&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;On August 1, 2021, the Company entered into a five-year product development agreement with TCNT. Pursuant to the agreement both parties will endeavor to develop pharmaceutical, medical and preventive medicine related products.&#160; Under the agreement the Company is designated as the exclusive sales agent of the resulting products.&#160; The agreement also provides for the Company to bear the expenses of product development and for TCNT to contribute personnel and facilities. Both parties shall each jointly own an equal proportion of the intellectual property rights arising from the product co-development cooperation. As a result, the Company incurred $117,386 in product co-development expenses and $122,680 in accounts payable during the reporting period.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;The Company issued common stock as partial compensation to Dr. Stephen T. Chen and Bernard Cohen as follows:&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160; &#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Par Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Paid in &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Excess of Par&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Total amount&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Price per share&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;06/30/2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Bernard Cohen&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5,876&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;58.76&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,107.89&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,166.65&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.5389&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;06/30/2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Dr. Stephen T. Chen&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;53,419&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;534.19&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;32,799.14&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;33,333.33&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.6240&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;59,295&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;593&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;35,907&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;36,500&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock contextRef="From2021-01-01to2021-09-30" id="fid_1313">&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:26%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Name of the related party&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:2%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Relationship&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:2%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Description&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Taiwan Carbon Nano Technology Corporation (TCNT)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Affiliated company&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ainos, Inc. (Cayman Island) ( Ainos KY)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Affiliated company&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;ASE Technology Holding&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Affiliated company&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Parent company of ASE Test Inc. which is Ainos KY's board member and with more than 10% of the voting rights &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;i2 China Management Group LLC (i2 China)&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Affiliated company&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Sole member owner is Lawrence Lin, EVP Operations effective August 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Dr. Stephen T. Chen&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Principal owner&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Shareholder with more than 5% of Company voting rights, Ainos' former Chairman, President, CEO and CFO&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Chun-Hsien Tsai&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Board of Director, Executive Officer and Immediate Family&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Chairman of BOD, President, CEO and spouse of Ting-Chuan Lee&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ting-Chuan Lee&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Board of Director and Immediate Family&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Spouse of Chun Hsien Tsai&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Hui-Lan Wu&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Executive Officer&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;CFO&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Lawrence Lin&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Key management&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;EVP Operations effective August 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Chih-Heng Lu&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Key management&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Director of Corporate Development and Corporate Secretary&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;John Junyong Lee&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Key management&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Chief Legal Counsel and Corporate Secretary rewarded by fixed monthly fee and performance bonus effective September 1,2021 Chief Legal Counsel and Corporate Secretary&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Chien-Hsuan Huang &lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Immediate Family of Director&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Spouse of Wen-Han Chang&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Bernard Cohen&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Former CFO&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Resigned on April 5, 2021&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock>
    <aimd:ScheduleOfFinancialSupportListtabletextblock contextRef="From2021-01-01to2021-09-30" id="fid_1314">&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Convertible Note&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Related Interest Expense&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Nine months ended &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;September 30, 2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;As of&lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;September 30, 2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Nine months ended September 30, 2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;As of &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;September 30, 2021&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Ainos KY&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;981,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;981,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,410&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,410&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;i2China&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;37,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;185,000&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;2,087&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;4,920&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Dr. Stephen T. Chen&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;15,272&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;1,019,193&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;5,936&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;23,653&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;1,033,272&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;2,185,193&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;11,433&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;31,983&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Par Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Paid in &lt;/strong&gt;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Excess of Par&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Total amount&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;&#160;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"&gt;&lt;strong&gt;Price per share&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;06/30/2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Bernard Cohen&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;5,876&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;58.76&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,107.89&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;3,166.65&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.5389&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;06/30/2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;Dr. Stephen T. Chen&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;53,419&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;534.19&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;32,799.14&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"&gt;33,333.33&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"&gt;0.6240&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;59,295&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;593&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;35,907&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"&gt;36,500&lt;/td&gt;&lt;td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td class="ffcell" style="width:9%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space: nowrap;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</aimd:ScheduleOfFinancialSupportListtabletextblock>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember"
      decimals="0"
      id="fid_703"
      unitRef="USD">981000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="AsOf2021-09-30_aimd_AinosKYMember"
      decimals="0"
      id="fid_705"
      unitRef="USD">981000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:InterestExpenseRelatedParty
      contextRef="From2021-01-01to2021-09-30_aimd_AinosKYMember"
      decimals="0"
      id="fid_704"
      unitRef="USD">3410</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent
      contextRef="AsOf2021-09-30_aimd_AinosKYMember"
      decimals="0"
      id="fid_706"
      unitRef="USD">3410</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2021-01-01to2021-09-30_aimd_I2ChinaMember"
      decimals="0"
      id="fid_712"
      unitRef="USD">37000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="AsOf2021-09-30_aimd_I2ChinaMember"
      decimals="0"
      id="fid_713"
      unitRef="USD">185000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:InterestExpenseRelatedParty
      contextRef="From2021-01-01to2021-09-30_aimd_I2ChinaMember"
      decimals="0"
      id="fid_714"
      unitRef="USD">2087</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent
      contextRef="AsOf2021-09-30_aimd_I2ChinaMember"
      decimals="0"
      id="fid_711"
      unitRef="USD">4920</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember"
      decimals="0"
      id="fid_715"
      unitRef="USD">15272</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember"
      decimals="0"
      id="fid_716"
      unitRef="USD">1019193</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:InterestExpenseRelatedParty
      contextRef="From2021-01-01to2021-09-30_aimd_DrStephenTChenMember"
      decimals="0"
      id="fid_717"
      unitRef="USD">5936</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent
      contextRef="AsOf2021-09-30_aimd_DrStephenTChenMember"
      decimals="0"
      id="fid_718"
      unitRef="USD">23653</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2021-01-01to2021-09-30_aimd_RelatedPartyMember"
      decimals="0"
      id="fid_707"
      unitRef="USD">1033272</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="AsOf2021-09-30_aimd_RelatedPartyMember"
      decimals="0"
      id="fid_709"
      unitRef="USD">2185193</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:InterestExpenseRelatedParty
      contextRef="From2021-01-01to2021-09-30_aimd_RelatedPartyMember"
      decimals="0"
      id="fid_708"
      unitRef="USD">11433</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent
      contextRef="AsOf2021-09-30_aimd_RelatedPartyMember"
      decimals="0"
      id="fid_710"
      unitRef="USD">31983</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_893"
      unitRef="USD">496</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InventoryNet
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_894"
      unitRef="USD">173657</us-gaap:InventoryNet>
    <us-gaap:DevelopmentCosts
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_901"
      unitRef="USD">117386</us-gaap:DevelopmentCosts>
    <us-gaap:AccountsPayableTradeCurrentAndNoncurrent
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_895"
      unitRef="USD">122680</us-gaap:AccountsPayableTradeCurrentAndNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_896"
      unitRef="USD">55728</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:CapitalLeaseObligations
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_897"
      unitRef="USD">55908</us-gaap:CapitalLeaseObligations>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_898"
      unitRef="USD">1785</us-gaap:LeaseAndRentalExpense>
    <aimd:ConsultingFee
      contextRef="From2021-01-01to2021-09-30"
      decimals="0"
      id="fid_899"
      unitRef="USD">7215</aimd:ConsultingFee>
    <aimd:ConsultingFeePayable
      contextRef="AsOf2021-09-30"
      decimals="0"
      id="fid_900"
      unitRef="USD">6671</aimd:ConsultingFeePayable>
    <aimd:Shares
      contextRef="AsOf2021-06-30_aimd_DrStephenTChenMember"
      decimals="0"
      id="fid_723"
      unitRef="USD">5876</aimd:Shares>
    <aimd:ParValue
      contextRef="AsOf2021-06-30_aimd_DrStephenTChenMember"
      decimals="0"
      id="fid_727"
      unitRef="USD">58</aimd:ParValue>
    <aimd:PaidInExcessOfPar
      contextRef="AsOf2021-06-30_aimd_DrStephenTChenMember"
      decimals="0"
      id="fid_726"
      unitRef="USD">3107</aimd:PaidInExcessOfPar>
    <aimd:TotalAmount
      contextRef="AsOf2021-06-30_aimd_DrStephenTChenMember"
      decimals="0"
      id="fid_725"
      unitRef="USD">3166</aimd:TotalAmount>
    <us-gaap:SharePrice
      contextRef="AsOf2021-06-30_aimd_DrStephenTChenMember"
      decimals="INF"
      id="fid_724"
      unitRef="USDPShares">0.5389</us-gaap:SharePrice>
    <aimd:Shares
      contextRef="AsOf2021-06-30_aimd_BernardCohenMember"
      decimals="0"
      id="fid_728"
      unitRef="USD">53419</aimd:Shares>
    <aimd:PaidInExcessOfPar
      contextRef="AsOf2021-06-30_aimd_BernardCohenMember"
      decimals="0"
      id="fid_730"
      unitRef="USD">32799</aimd:PaidInExcessOfPar>
    <aimd:TotalAmount
      contextRef="AsOf2021-06-30_aimd_BernardCohenMember"
      decimals="0"
      id="fid_731"
      unitRef="USD">33333</aimd:TotalAmount>
    <us-gaap:SharePrice
      contextRef="AsOf2021-06-30_aimd_BernardCohenMember"
      decimals="INF"
      id="fid_732"
      unitRef="USDPShares">0.6240</us-gaap:SharePrice>
    <aimd:Shares
      contextRef="AsOf2021-06-30"
      decimals="0"
      id="fid_719"
      unitRef="USD">59295</aimd:Shares>
    <aimd:ParValue
      contextRef="AsOf2021-06-30"
      decimals="0"
      id="fid_720"
      unitRef="USD">593</aimd:ParValue>
    <aimd:PaidInExcessOfPar
      contextRef="AsOf2021-06-30"
      decimals="0"
      id="fid_721"
      unitRef="USD">35907</aimd:PaidInExcessOfPar>
    <aimd:TotalAmount
      contextRef="AsOf2021-06-30"
      decimals="0"
      id="fid_722"
      unitRef="USD">36500</aimd:TotalAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2021-01-01to2021-09-30" id="fid_1311">&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;8.&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;strong&gt;Subsequent Events.&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;The Company engaged PricewaterhouseCoopers, Taiwan (&#x201c;PWC&#x201d;) as independent accountants of Ainos Inc. Taiwan Branch under an engagement agreement dated October 4, 2021 (&#x201c;Audit Engagement&#x201d;). The Audit Engagement covers audit services for the years ending December 31, 2021 and 2022 and PWC will issue interfirm audit reports for group reporting purposes to the Company&#x2019;s group audit firm, PWR CPA, LLP. Additionally, the Company engaged PWC under separate agreements dated October 4, 2021 for PWC to render advisory services in connection to the Company&#x2019;s internal controls over financial reporting as required under section 404 of the Sarbanes-Oxley Act (&#x201c;SOX Engagement&#x201d;) and in respect to compliance with Taiwan corporate income tax requirements for the tax years ending December 31, 2021 and 2022 (&#x201c;Taiwan Tax Engagement&#x201d;).&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;On October 6, 2021, the Company board of directors approved and adopted the following resolutions:&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:6%;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:4%;vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;Effective August 30, 2021, the Board appointed Hsiu-Chen Chiu and Wen-Han Chang to serve on the Compensation Committee;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;Effective August 30, 2021, the Board appointed Yao-Chung Chiang, Wen-Han Chang and Hsiu-Chen Chiu to serve on the Audit Committee;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;Board approval of the Company&#x2019;s 2021 Employee Stock Purchase Plan, 2021 Stock Incentive Plan, and 2021 Director Compensation Policy and, if required, shall submit the same for formal adoption by a vote of the Company&#x2019;s shareholders&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;Board approval of the Company&#x2019;s Related Transaction Policy, Hedging Policy, and the Diversity Policy of the Board; and&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;font-family:times new roman;margin:0px"&gt;&lt;span style="font-family:symbol"&gt;&#xb7;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;Board approval of the Company&#x2019;s engagement agreements dated October 4, 2021 with PricewaterhouseCoopers, Taiwan (&#x201c;PWC&#x201d;)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"&gt;On November 1, 2021, the Company engaged its former President and CEO, Dr. Stephen T. Chen, as a consultant to assist with its pharmaceutical division. The Company agrees to pay Dr. Chen 50,000 New Taiwan Dollars (NTD) per month for a period of one year for his services. With over 30 years of pharmaceutical professional experience, we expect Dr. Chen to provide technical assistance on our pharmaceutical development initiatives, analyze results from second phase interferon studies for Thrombocytopenia, and contribute to the protocol design of the third phase of interferon development focused on Sj&#xf6;gren&#x2019;s syndrome. Lastly, we expect that Dr. Chen will provide assistance for our mass commercial production of low-dose interferon products.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <aimd:DescriptionOfConsultant
      contextRef="From2021-10-23to2021-11-01_us-gaap_SubsequentEventMember"
      id="fid_905">The Company agrees to pay Dr. Chen 50,000 New Taiwan Dollars (NTD) per month for a period of one year for his services. With over 30 years of pharmaceutical professional experience</aimd:DescriptionOfConsultant>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139654440051496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Nov. 15, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AINOS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001014763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,442,215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-20791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">75-1974352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line 1</a></td>
<td class="text">8880 Rio San Diego Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address Address Line 2</a></td>
<td class="text">Ste. 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">92108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">869-2986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139654440778872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">142,442,215<span></span>
</td>
<td class="nump">42,066,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">142,442,215<span></span>
</td>
<td class="nump">42,066,172<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139654440367768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 706,931<span></span>
</td>
<td class="nump">$ 22,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">44,643<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">3,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expense and other current assets</a></td>
<td class="nump">133,065<span></span>
</td>
<td class="nump">51,144<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">884,814<span></span>
</td>
<td class="nump">76,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedPatentsGross', window );">Patents, net</a></td>
<td class="nump">19,011,337<span></span>
</td>
<td class="nump">180,628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">39,956<span></span>
</td>
<td class="nump">3,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Right of Use Asset</a></td>
<td class="nump">55,724<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other Assets</a></td>
<td class="nump">1,795<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">19,993,626<span></span>
</td>
<td class="nump">260,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">578,549<span></span>
</td>
<td class="nump">145,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositContractsLiabilities', window );">Contract liabilities</a></td>
<td class="nump">37,616<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Convertible notes payable - related party</a></td>
<td class="nump">2,000,193<span></span>
</td>
<td class="nump">805,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable</a></td>
<td class="nump">185,000<span></span>
</td>
<td class="nump">148,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Lease Obligation-Current</a></td>
<td class="nump">20,619<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,821,977<span></span>
</td>
<td class="nump">1,098,568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_LeaseObligationNonCurrent', window );">Lease Obligation-Non current</a></td>
<td class="nump">35,289<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,857,266<span></span>
</td>
<td class="nump">1,098,568<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value, 10 million shares authorized, 0 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.01 par value, 300 million shares authorized, 142,442,215 and 42,066,172 shares outstanding at September 30, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">1,424,422<span></span>
</td>
<td class="nump">420,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">24,369,245<span></span>
</td>
<td class="nump">4,961,315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(8,664,145)<span></span>
</td>
<td class="num">(6,220,255)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_TranslationAdjustmentLiability', window );">Translation adjustment</a></td>
<td class="nump">6,838<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="nump">17,136,360<span></span>
</td>
<td class="num">(838,278)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity (deficit)</a></td>
<td class="nump">$ 19,993,626<span></span>
</td>
<td class="nump">$ 260,290<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_LeaseObligationNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_LeaseObligationNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_TranslationAdjustmentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_TranslationAdjustmentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of capital lease obligation due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121569800&amp;loc=d3e45023-112735<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121616839&amp;loc=d3e45280-112737<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositContractsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of liabilities as of the balance sheet date pertaining to amounts received by the insurer or reinsurer from the insured (including a ceding company) under insurance or reinsurance contracts for which insurance risk is not transferred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99383045&amp;loc=d3e9351-108337<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99397363&amp;loc=d3e9420-108338<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositContractsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedPatentsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedPatentsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139654440289800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Statements of Operations (Unaudited)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 363,052<span></span>
</td>
<td class="nump">$ 192<span></span>
</td>
<td class="nump">$ 568,164<span></span>
</td>
<td class="nump">$ 15,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="nump">103,638<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="nump">174,395<span></span>
</td>
<td class="nump">11,221<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">259,414<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="nump">393,769<span></span>
</td>
<td class="nump">4,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">646,798<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">646,798<span></span>
</td>
<td class="nump">389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">795,958<span></span>
</td>
<td class="nump">321,153<span></span>
</td>
<td class="nump">2,178,969<span></span>
</td>
<td class="nump">1,001,893<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total operating expense</a></td>
<td class="nump">1,442,756<span></span>
</td>
<td class="nump">321,153<span></span>
</td>
<td class="nump">2,825,767<span></span>
</td>
<td class="nump">1,002,282<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(1,183,342)<span></span>
</td>
<td class="num">(321,084)<span></span>
</td>
<td class="num">(2,431,998)<span></span>
</td>
<td class="num">(997,627)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Non-operating income and expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest Income, net</a></td>
<td class="num">(23,517)<span></span>
</td>
<td class="num">(2,201)<span></span>
</td>
<td class="num">(9,361)<span></span>
</td>
<td class="num">(4,503)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_OtherLosses', window );">Other Losses</a></td>
<td class="num">(285)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,532)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_TotalNonOperatingIncomeAndExpenses', window );">Total Non-operating income and expenses</a></td>
<td class="nump">23,232<span></span>
</td>
<td class="num">(2,201)<span></span>
</td>
<td class="num">(11,893)<span></span>
</td>
<td class="num">(4,503)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Profit before income tax</a></td>
<td class="num">(1,160,110)<span></span>
</td>
<td class="num">(323,285)<span></span>
</td>
<td class="num">(2,443,891)<span></span>
</td>
<td class="num">(1,002,130)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_LessIncomeTax', window );">Less: Income tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (1,160,110)<span></span>
</td>
<td class="num">$ (323,285)<span></span>
</td>
<td class="num">$ (2,443,891)<span></span>
</td>
<td class="num">$ (1,002,130)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per average share available to common shareholders</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding - basic and diluted</a></td>
<td class="nump">142,419,337<span></span>
</td>
<td class="nump">40,516,351<span></span>
</td>
<td class="nump">75,919,713<span></span>
</td>
<td class="nump">40,620,055<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_LessIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_LessIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_OtherLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_OtherLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_TotalNonOperatingIncomeAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_TotalNonOperatingIncomeAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139654520445912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Retained Earnings (Accumulated Deficit)</div></th>
<th class="th"><div>Translation Adjustment</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,516,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2019</a></td>
<td class="num">$ (156,682)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 405,164<span></span>
</td>
<td class="nump">$ 4,207,786<span></span>
</td>
<td class="num">$ (4,769,632)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_IssuanceOfStockForCompensationAmount', window );">Issuance of stock for compensation, amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_IssuanceOfStockForCashShares', window );">Issuance of stock for cash, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_IssuanceOfStockForCashAmount', window );">Issuance of stock for cash, amount</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">96,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_WarrantExpense', window );">Warrant expense</a></td>
<td class="nump">10,218<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,218<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_OptionExpense', window );">Option expense</a></td>
<td class="nump">272,604<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">272,064<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(1,002,130)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,002,130)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_TranslationAdjustment', window );">Translation adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,916,351<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2020</a></td>
<td class="num">(776,530)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 409,164<span></span>
</td>
<td class="nump">$ 4,586,068<span></span>
</td>
<td class="num">(5,771,762)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,516,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Jun. 30, 2020</a></td>
<td class="num">(744,117)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 405,164<span></span>
</td>
<td class="nump">4,299,196<span></span>
</td>
<td class="num">(5,448,477)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_IssuanceOfStockForCompensationAmount', window );">Issuance of stock for compensation, amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_IssuanceOfStockForCashShares', window );">Issuance of stock for cash, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_IssuanceOfStockForCashAmount', window );">Issuance of stock for cash, amount</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">96,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_WarrantExpense', window );">Warrant expense</a></td>
<td class="nump">9,496<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,496<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_OptionExpense', window );">Option expense</a></td>
<td class="nump">181,376<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">181,376<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(323,285)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(323,285)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_TranslationAdjustment', window );">Translation adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,916,351<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2020</a></td>
<td class="num">(776,530)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 409,164<span></span>
</td>
<td class="nump">$ 4,586,068<span></span>
</td>
<td class="num">(5,771,762)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,066,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Dec. 31, 2020</a></td>
<td class="num">(838,278)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 420,661<span></span>
</td>
<td class="nump">4,961,315<span></span>
</td>
<td class="num">(6,220,254)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_IssuanceOfStockForCompensationAmount', window );">Issuance of stock for compensation, amount</a></td>
<td class="nump">139,405<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,056<span></span>
</td>
<td class="nump">137,349<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_WarrantExpense', window );">Warrant expense</a></td>
<td class="nump">10,252<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,252<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_OptionExpense', window );">Option expense</a></td>
<td class="nump">197,281<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">197,281<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,443,891)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,443,891)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_TranslationAdjustment', window );">Translation adjustment</a></td>
<td class="nump">6,838<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_IssuanceOfStockForCompensationShares', window );">Issuance of stock for compensation, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_IssuanceOfStockForPatentAssetsShares', window );">Issuance of stock for Patent assets, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_IssuanceOfStockForPatentAssetsAmount', window );">Issuance of stock for Patent assets, amount</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">19,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_IssuanceOfStockForOptionShares', window );">Issuance of stock for Option, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_IssuanceOfStockForOptionAmount', window );">Issuance of stock for Option, amount</a></td>
<td class="nump">64,752<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1,704<span></span>
</td>
<td class="nump">63,048<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,442,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2021</a></td>
<td class="nump">17,136,360<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1,424,422<span></span>
</td>
<td class="nump">24,369,245<span></span>
</td>
<td class="num">(8,664,145)<span></span>
</td>
<td class="nump">6,838<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,271,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Jun. 30, 2021</a></td>
<td class="nump">18,205,557<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1,422,718<span></span>
</td>
<td class="nump">24,286,875<span></span>
</td>
<td class="num">(7,504,035)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_IssuanceOfStockForCompensationAmount', window );">Issuance of stock for compensation, amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_WarrantExpense', window );">Warrant expense</a></td>
<td class="nump">3,417<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,417<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_OptionExpense', window );">Option expense</a></td>
<td class="nump">15,905<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,905<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(1,160,110)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,160,110)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_TranslationAdjustment', window );">Translation adjustment</a></td>
<td class="nump">6,838<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_IssuanceOfStockForPatentAssetsAmount', window );">Issuance of stock for Patent assets, amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_IssuanceOfStockForOptionShares', window );">Issuance of stock for Option, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_IssuanceOfStockForOptionAmount', window );">Issuance of stock for Option, amount</a></td>
<td class="nump">64,752<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1,704<span></span>
</td>
<td class="nump">63,048<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,442,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, amount at Sep. 30, 2021</a></td>
<td class="nump">$ 17,136,360<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,424,422<span></span>
</td>
<td class="nump">$ 24,369,245<span></span>
</td>
<td class="num">$ (8,664,145)<span></span>
</td>
<td class="nump">$ 6,838<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_IssuanceOfStockForCashAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_IssuanceOfStockForCashAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_IssuanceOfStockForCashShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_IssuanceOfStockForCashShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_IssuanceOfStockForCompensationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_IssuanceOfStockForCompensationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_IssuanceOfStockForCompensationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_IssuanceOfStockForCompensationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_IssuanceOfStockForOptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_IssuanceOfStockForOptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_IssuanceOfStockForOptionShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_IssuanceOfStockForOptionShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_IssuanceOfStockForPatentAssetsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_IssuanceOfStockForPatentAssetsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_IssuanceOfStockForPatentAssetsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_IssuanceOfStockForPatentAssetsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_OptionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_OptionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_TranslationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_TranslationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_WarrantExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_WarrantExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139654440485192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Condensed Statements of Cash Flows (Unaudited)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">$ (569,150)<span></span>
</td>
<td class="num">$ (244,967)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InvestmentInPatents', window );">Investment in patents</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,891)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAssetsInvestingActivities', window );">Purchase of fixed assets</a></td>
<td class="num">(41,581)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from disposal of property, plant and equipment</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_IncreaseInRefundableDeposits', window );">Increase in refundable deposits</a></td>
<td class="num">(1,795)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows used in investing activities</a></td>
<td class="num">(43,340)<span></span>
</td>
<td class="num">(1,891)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_AdvancesFromShareholder', window );">Advances from shareholder</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement offering, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of share options</a></td>
<td class="nump">64,752<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_PaymentsOfLeaseLiabilities', window );">Payments of lease liabilities</a></td>
<td class="num">(6,815)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt', window );">Proceeds from convertible note payable -related party</a></td>
<td class="nump">1,232,192<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="nump">1,290,129<span></span>
</td>
<td class="nump">85,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of changes in exchange rates</a></td>
<td class="nump">7,046<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">677,639<span></span>
</td>
<td class="num">(325,272)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">22,245<span></span>
</td>
<td class="nump">409,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">706,931<span></span>
</td>
<td class="nump">83,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid</a></td>
<td class="nump">9,363<span></span>
</td>
<td class="nump">4,895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-Cash Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_StockIssuedForAcquisitionOfPatents', window );">Stock issued for acquisition of patents</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_StockIssuedForCompensationWarrantAndOptionExpense', window );">Stock issued for compensation, warrant and option expense</a></td>
<td class="nump">346,938<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_StockIssuedForAdvancesFromInvestors', window );">Stock issued for advances from investors</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_RouLeasedAssets', window );">ROU Leased assets</a></td>
<td class="nump">62,723<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations', window );">Lease obligation</a></td>
<td class="nump">$ 62,723<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_AdvancesFromShareholder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_AdvancesFromShareholder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_IncreaseInRefundableDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_IncreaseInRefundableDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_InvestmentInPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_InvestmentInPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_PaymentsOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_PaymentsOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_RouLeasedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_RouLeasedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_StockIssuedForAcquisitionOfPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_StockIssuedForAcquisitionOfPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_StockIssuedForAdvancesFromInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued for advances from investors in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_StockIssuedForAdvancesFromInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_StockIssuedForCompensationWarrantAndOptionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_StockIssuedForCompensationWarrantAndOptionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAssetsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash payments for a combination of transactions that are classified as investing activities in which assets, which may include securities, other types of investments, or productive assets, are purchased from third-party sellers. This element can be used by entities to aggregate payments for all asset purchases that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAssetsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt and lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139654435837128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">1. Organization and Business</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>1.</strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Organization and Business.</strong> Ainos, Inc., formerly known as Amarillo Biosciences, Inc. (the &#8220;Company&#8221;) is a diversified healthcare company engaged in the research and development and sales and marketing of pharmaceutical and biotech products. The Company is a Texas corporation incorporated in 1984. The Company currently has offices in the United States and Taiwan. The Company operates a branch office in Taiwan registered as AINOS, INC. TAIWAN BRANCH.</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139654435770712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>General</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">2. General</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>2.</strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is engaged in developing biologics for the treatment of human and animal diseases. Our current focus is research aimed at the treatment of human disease indications, including Sj&#246;gren&#8217;s syndrome, thrombocytopenia, and other indications using interferon (IFN) alpha that is administered in a proprietary low-dose non-injectable form. In addition to our core technology, we are working to expand our current focus into a diversified healthcare business portfolio in order to generate new revenue streams. We own patents with claims that encompass method of use or treatment, and/or composition of matter and manufacturing as well as design utility and/or invention. Of twelve issued patents, four patents are related to the low-dose oral delivery of interferon, three patents are associated with treatment of metabolic disorders, and five patents related to the development and manufacturing of point-of-care testing rapid test kit products that include diagnostics for COVID-19 (SARS CoV2 Antigen Rapid Test), pneumonia, vaginal infection and helicobacter pylori (H. pylori) bacterial infection.</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We primarily operate three business units: the Pharmaceutical, Medical Devices and Preventive Medicine Divisions. Our Pharmaceutical Division is focused on low-dose, orally administered lozenges containing the natural immune system activator interferon-alpha as a treatment for a variety of disease indications. We own a proprietary library of over thirty years of scientific and clinical data on the human and animal applications of low-dose oral interferon. Our Medical Device Division is dedicated to developing a novel insulin pump and further development of point-of-care rapid test kits for the detection and diagnosis of human infections. Our Preventative Medicine Division, which has been restructured from our former Consumer Product Division, is focused on SRNA-based therapeutics.</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139654439221544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">3. Basis of Presentation</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>3. </strong></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Basis of presentation.</strong> The accompanying consolidated financial statements, which should be read in conjunction with the audited financial statements and footnotes included in the Company's Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission on March 30, 2021 attached hereto as Exhibit 13 and which is incorporated by this reference, have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months and nine months ended September 30, 2021, are not necessarily indicative of the results that may be expected for the full year ending December 31, 2021.</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139654437441336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Condition<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Financial Condition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_FinancialConditionTextBlock', window );">4. Financial Condition</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>4.</strong></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Financial Condition. </strong>These financial statements have been prepared in accordance with United States generally accepted accounting principles, assuming that the Company will continue as a going concern. The accompanying financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">While the Company has recurring losses and generated negative cash flows from operations, the Company has taken initiatives to improve its management capacity and business operations. Such initiatives include the procurement of innovative diagnostic technologies and securing a strategic investor, as a result of the closing of a securities purchase agreement with Ainos, Inc. a Cayman Island corporation (&#8220;Ainos KY&#8221;) on April 15, 2021 (the &#8220;Ainos KY Transaction&#8221;). Details of the Ainos Transaction were disclosed in the Company&#8217;s Form 10-Q filing for the second quarter of 2021.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">After closing the Ainos KY Transaction, the Company engaged additional management resources including Mr. Chun-Hsien Tsai as Chairman and CEO, Ms. Hui-Lan (Celia) Wu as CFO and Mr. Chih-Heng (Jack Lu) as Head of Corporate Development, retained key management and legal staff, and implemented new business initiatives. On June 14, 2021, the Company became the master sales and marketing agent for the Ainos SARS-Cov-2 Antigen Rapid Test Kit (&#8220;Ainos Covid-19 Test Kit&#8221;) which has generated $568,164 in sales thus far in 2021.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">As of September 30, 2021, the Company&#8217;s financial improvement includes the following:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Total stockholder&#8217;s equity increased to $17,136,360 as of September 30, 2021 compared to a negative total shareholder&#8217;s equity of $838,278 as of December 2021.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Cash and cash equivalents increased to $706,931 as of September 30, 2021 compared to $22,245 at December 31, 2020. This is attributable to increased revenues from sales of our Ainos Covid-19 Test Kit in Taiwan and operational loans made to the Company by Ainos KY. The Company&#8217;s revenues increased to $568,164 during this reporting period compared to $15,876 as of third quarter of 2020.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company anticipates business revenues and potential additional financial support from Ainos KY and other entities to fund the Company&#8217;s operations over the next twelve months. The Company may raise additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available when needed and at adequate levels, the Company will need to reevaluate its operating plan.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">There can be no assurance that capital will be available as necessary to meet the Company's working capital requirements or, if the capital is available, that it will be on terms acceptable to the Company. Any issuances of additional equity securities by the Company may result in dilution in the equity interests of its current stockholders. Obtaining commercial loans will increase the Company's liabilities and future cash commitments to the extent such loans would be available. While management believes in its strategic plans, management cannot be certain that projected financial results can be achieved.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_FinancialConditionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure on the Financial Condition of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_FinancialConditionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139654435973768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">5. Common Stock</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>5.</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Common Stock. </strong>As of September 30, 2021 there was an increase of $1,003,760 in par value common stock primarily as a result of the Ainos KY Transaction.</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139654437255720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable and Other Related Party Notes Payable<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Convertible Notes Payable and Other Related Party Notes Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">6. Convertible Notes Payable and Other Related Party Notes Payable</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>6.</strong></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Convertible Notes Payable and Other Related Party Notes Payable.</strong> As of September 30, 2021 and December 31, 2020, the amount of convertible and non-convertible debt principal was $2,185,953 and $953,001, respectively. The details of the convertible and other non-convertible promissory notes payable are shown in the table below.</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="4" style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Annual Interest Rate</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td colspan="7" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Unpaid Principal Balance</strong>&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>No#</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Effective Date</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Due Date</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>From</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Effective</strong></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Following</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Maturity</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Payee</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Issuing</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Purpose</strong></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Sep 30,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td colspan="3"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Dec 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td></tr><tr style="height:15px"><td colspan="24"><p style="font-size:10pt;font-family:times new roman;margin:0px">Payee: Dr. Stephen T. Chen, resigned as Chairman of the Board, President, and Board director April 15, 2021</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#1.16</p></td><td style="width:1%;"/><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2016/01/30</p></td><td style="width:1%;"/><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Payable on demand</p></td><td style="width:1%;"/><td style="width:7%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">0.75%</p></td><td colspan="2" style="width:1%;"/><td style="width:8%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td style="width:1%;"/><td style="width:8%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen Chen</p></td><td style="width:1%;"/><td colspan="2" style="width:12%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2" style="width:1%;"/><td colspan="2" style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">114,026</p></td><td colspan="3" style="width:1%;"/><td colspan="2" style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">114,026</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#2.16</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2016/03/18</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Payable on demand</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">0.65%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen Chen</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">262,500</p></td><td colspan="3"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">262,500</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#3.19</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2019/09/01</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2020/09/01</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen Chen</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">salary</p></td><td colspan="2"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">39,392</p></td><td colspan="3"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">39,620</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#4.19</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2019/12/01</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2020/12/31</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.61%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen Chen</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">14,879</p></td><td colspan="3"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">14,879</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#6.20</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2020/01/01</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/01/01</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen Chen</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">salary</p></td><td colspan="2"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">216,600</p></td><td colspan="3"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">216,600</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#7.20</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2020/01/01</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/01/02</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.60%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen Chen</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">23,366</p></td><td colspan="3"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">23,366</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#9.20</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2020/01/01</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/04/14</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">0.13%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen Chen</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">279,405</p></td><td colspan="3"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">134,010</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#10.21</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/01/01</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/04/01</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen Chen</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">salary</p></td><td colspan="2"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">59,025</p></td><td colspan="3"/><td colspan="2"/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#11.21</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/04/01</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/05/01</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen Chen</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">salary</p></td><td colspan="2"/><td colspan="2" style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10,000</p></td><td colspan="3"/><td colspan="2" style="BORDER-BOTTOM: 1px solid;"/></tr><tr style="height:15px;background-color:#ffffff"><td/><td/><td/><td/><td/><td/><td/><td colspan="2"/><td/><td/><td/><td/><td colspan="2"/><td colspan="2"/><td colspan="2" style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,019,193</p></td><td colspan="3"/><td colspan="2" style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">805,001</p></td></tr><tr style="height:15px;background-color:#cceeff"><td/><td/><td/><td/><td/><td/><td/><td colspan="2"/><td/><td/><td/><td/><td colspan="2"/><td colspan="2"/><td colspan="2"/><td colspan="3"/><td colspan="2"/></tr><tr style="height:15px;background-color:#ffffff"><td colspan="5"><p style="font-size:10pt;font-family:times new roman;margin:0px">Payee: Ainos KY, an affiliated company </p></td><td/><td/><td/><td colspan="2"/><td/><td/><td/><td colspan="2"/><td colspan="2"/><td colspan="2"/><td colspan="2"/><td colspan="3"/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#12.21</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/04/27</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/10/27</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">15,000</p></td><td colspan="3"/><td colspan="2"/></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#13.21</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/05/05</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/11/05</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">20,000</p></td><td colspan="3"/><td colspan="2"/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#14.21</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/05/25</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/11/25</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">30,000</p></td><td colspan="3"/><td colspan="2"/></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#15.21</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/05/28</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/11/28</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">35,000</p></td><td colspan="3"/><td colspan="2"/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#16.21</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/06/09</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/12/09</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">300,000</p></td><td colspan="3"/><td colspan="2"/></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#17.21</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/06/21</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/12/21</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">107,000</p></td><td colspan="3"/><td colspan="2"/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#18.21</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/07/02</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2022/01/02</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">54,000</p></td><td colspan="3"/><td colspan="2"/></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#19.21</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/09/01</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/03/01</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">120,000</p></td><td colspan="3"/><td colspan="2"/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#20.21</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/09/28</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/03/28</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"/><td colspan="2" style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">300,000</p></td><td colspan="3"/><td colspan="2" style="BORDER-BOTTOM: 1px solid;"/></tr><tr style="height:15px;background-color:#ffffff"><td/><td/><td/><td/><td/><td/><td/><td colspan="2"/><td/><td/><td/><td/><td colspan="2"/><td colspan="2"/><td colspan="2" style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">981,000</p></td><td colspan="3"/><td colspan="2" style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0 </p></td></tr><tr style="height:15px;background-color:#cceeff"><td/><td/><td/><td/><td/><td/><td colspan="9"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">Convertible and other notes payable- related parties</p></td><td colspan="2"/><td colspan="2" style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2,000,193</p></td><td colspan="3"/><td colspan="2" style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">805,001</p></td></tr><tr style="height:15px;background-color:#ffffff"><td/><td/><td/><td/><td/><td/><td/><td colspan="2"/><td/><td/><td/><td/><td colspan="2"/><td colspan="2"/><td colspan="2"/><td colspan="3"/><td colspan="2"/></tr><tr style="height:15px;background-color:#cceeff"><td colspan="10"><p style="font-size:10pt;font-family:times new roman;margin:0px">Payee: i2China Management Group LLC, a management consultant</p></td><td/><td/><td/><td colspan="2"/><td colspan="2"/><td colspan="2"/><td colspan="2"/><td colspan="3"/></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#5.19</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2019/09/01</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2020/09/01</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">i2China</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">consulting fee</p></td><td colspan="2"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">16,000</p></td><td colspan="3"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">16,000</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#8a.20</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2020/01/01</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/01/01</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">i2China</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">consulting fee</p></td><td colspan="2"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">48,000</p></td><td colspan="3"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">48,000</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#8b.20</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Retroactive from 2020/01/01</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/01/01</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">i2China</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">consulting fee</p></td><td colspan="2"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">84,000</p></td><td colspan="3"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">84,000</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#11.21</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/01/01</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/04/01</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">i2China</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">consulting fee</p></td><td colspan="2"/><td colspan="2" style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">37,000</p></td><td colspan="3"/><td colspan="2" style="BORDER-BOTTOM: #000000 1px solid;"/></tr><tr style="height:15px;background-color:#ffffff"><td/><td/><td/><td/><td/><td/><td colspan="9"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">Convertible and other notes payable</p></td><td colspan="2"/><td colspan="2" style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">185,000</p></td><td colspan="3"/><td colspan="2" style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">148,000</p></td></tr><tr style="height:15px;background-color:#cceeff"><td/><td/><td/><td/><td/><td/><td colspan="9"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">Total Convertible and other notes payable</p></td><td colspan="2"/><td colspan="2" style="BORDER-BOTTOM: 3px double;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2,185,193</p></td><td colspan="3"/><td colspan="2" style="BORDER-BOTTOM: 3px double;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">953,001</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">All of the aforementioned convertible and non-convertible promissory notes are unsecured and due on demand. All shares issued upon conversion are restricted and subject to Rule 144 promulgated under the U.S. Securities Act of 1933 (the &#8220;Securities Act&#8221;); subject to any exemptions or exclusions under the Act. The Company may prepay the notes in whole or in part at any time without penalty.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The promissory notes due to Dr. Stephen T. Chen and Ainos KY are related party notes.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">i2China Management Group, LLC (&#8220;i2China&#8221;) and Dr. Stephen T. Chen (together the &#8220;Payees&#8221;), have both agreed to waive any and all rights pertaining to the conditional term &#8220;Annual Interest Rate on Matured, Unpaid Amounts: 10% per annum, compounded annually of Convertible Notes&#8221; in regards to interest charged on any unpaid amounts following maturity for all of their respective notes. The Company and the Payees agree that the originally agreed annual interest rate will continue to be valid for any unpaid amounts after maturity. The amended terms of the above convertible notes were made during 2021 Q3 on September 1, 2021. The waived interest amount was $45,875.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Unpaid </strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td colspan="3" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Interest Rate</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td colspan="5" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Interest amount</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;Interest </strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>No#</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Date</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Payee</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Description</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong><strong>Principal </strong><strong>Amount</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Original</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>after</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Maturity</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;Original&#160;rate</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>10%</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total </strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>after</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Maturity</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong><strong>Interest</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Waived</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#1.16</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:10%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">1/30/2016</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:10%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:10%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">114,026</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">0.75%</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5,624</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0 </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5,624</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5,624</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0 </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#2.16</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">3/18/2016</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">262,500</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">0.65%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">9,447</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">9,447</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">9,447</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0 </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#3.19</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">9/1/2019(DS)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">salary</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">39,392</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">714 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">4,340</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5,054</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,518</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">3,536</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#4.19</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">12/1/2019(DE)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">14,879</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.61%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">257 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,132</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,389</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">439 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">950 </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#6.20</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">1/1/2020(DS)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">salary</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">216,600</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2,179</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">16,363</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">18,543</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5,206</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">13,336</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#7.20</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">1/1/2020(DE)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">23,366</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.60%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">72 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,753</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,825</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">352 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,473</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#9.20</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">11/2020 (Open)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">279,405</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">0.13%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">81 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12,864</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12,945</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">248 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12,697</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#10.21</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">1/1/2021(DS)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">salary</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">59,025</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">178 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2,968</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">3,146</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">725</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2,421</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#11.21</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">4/1/2021(DS)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">salary</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">15 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">420 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">435 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">93 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">342 </p></td></tr><tr style="height:15px;background-color:#ffffff"><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,019,193</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">18,566</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">39,841</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">58,407</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">23,653</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">34,754</p></td></tr><tr style="height:15px;background-color:#cceeff"><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#5.19</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">9/1/2019</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">i2China</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">consulting fee</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">16,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">253 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,759</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2,012</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">579 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,433</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#8a.20</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">1/1/2020</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">i2China</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">consulting fee</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">48,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">483</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">3,626</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">4,109</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,154</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2,955</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#8b.20</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">1/1/2020</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">i2China</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">retroactive increase</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">84,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,554</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6,399</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7,953</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2,738</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5,215</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#11.21</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">1/1/2021(DS)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">i2China</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">consulting fee</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">37,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">107 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,860</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,967</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">450</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,517</p></td></tr><tr style="height:15px;background-color:#ffffff"><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">185,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2,397</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">13,645</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">16,041</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">4,920</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">11,121</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">TOTAL ACCRUED</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td/><td/><td style="BORDER-BOTTOM: black 3px double;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,204,193 </p></td><td style="PADDING-BOTTOM: 3px;"/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">20,963&#160;</p></td><td style="BORDER-BOTTOM: black 3px double; PADDING-BOTTOM: 3px;"/><td style="BORDER-BOTTOM: black 3px double;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;53,485</p></td><td style="PADDING-BOTTOM: 3px;"/><td style="BORDER-BOTTOM: black 3px double;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">74,448 </p></td><td style="PADDING-BOTTOM: 3px;"/><td style="BORDER-BOTTOM: black 3px double;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">28,573 </p></td><td style="PADDING-BOTTOM: 3px;"/><td style="BORDER-BOTTOM: black 3px double;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">45,875 </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The accrued interest amount was $31,983 and $18,691 as of September 30, 2021 and December 31, 2020, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139654437357544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Other Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">7. Other Related Party Transactions</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>7.</strong></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Related Party Transactions</strong></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following is a list of related parties who have undertaken transactions with the Company during this reporting period:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:26%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Name of the related party</strong></p></td><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Relationship</strong></p></td><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Description</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Taiwan Carbon Nano Technology Corporation (TCNT)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Affiliated company</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos, Inc. (Cayman Island) ( Ainos KY)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Affiliated company</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">ASE Technology Holding</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Affiliated company</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Parent company of ASE Test Inc. which is Ainos KY's board member and with more than 10% of the voting rights </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">i2 China Management Group LLC (i2 China)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Affiliated company</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Sole member owner is Lawrence Lin, EVP Operations effective August 1, 2021</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Dr. Stephen T. Chen</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Principal owner</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Shareholder with more than 5% of Company voting rights, Ainos' former Chairman, President, CEO and CFO</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Chun-Hsien Tsai</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Board of Director, Executive Officer and Immediate Family</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Chairman of BOD, President, CEO and spouse of Ting-Chuan Lee</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ting-Chuan Lee</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Board of Director and Immediate Family</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Spouse of Chun Hsien Tsai</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Hui-Lan Wu</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Executive Officer</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CFO</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Lawrence Lin</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Key management</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">EVP Operations effective August 1, 2021</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Chih-Heng Lu</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Key management</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Director of Corporate Development and Corporate Secretary</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">John Junyong Lee</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Key management</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Chief Legal Counsel and Corporate Secretary rewarded by fixed monthly fee and performance bonus effective September 1,2021 Chief Legal Counsel and Corporate Secretary</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Chien-Hsuan Huang </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Immediate Family of Director</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Spouse of Wen-Han Chang</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Bernard Cohen</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Former CFO</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Resigned on April 5, 2021</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Below is a summary of the significant related party transactions entered into by the Company over the first nine months of 2021:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Financial support</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Convertible Note</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Related Interest Expense</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine months ended </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September 30, 2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>As of</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September 30, 2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine months ended September 30, 2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>As of </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September 30, 2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">981,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">981,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,410</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,410</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">i2China</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">37,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">185,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,087</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,920</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Dr. Stephen T. Chen</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">15,272</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,019,193</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">5,936</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">23,653</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,033,272</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,185,193</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">11,433</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">31,983</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">i2China became an affiliate of the Company as of August 1, 2021. From August 1, 2021 to September 30, 2021, interest payable to i2China amounted to $496.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Other transactions</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">-</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Inventory purchases from TCNT totaling $173,657.</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">-</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Product co-development agreement with TCNT resulting in $117,386 in costs and $122,680 in accounts payable.</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">-</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Sale of products to ASE Technology Holding totaling $185,376.</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">-</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Three-year office space was leased from a related party resulting in ROU Asset totaling $55,728 and Lease Obligations totaling $55,908. The Company makes monthly lease payments of $1,785.</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">-</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Product development consulting fee of $7,215 payable to Huang Chien-Hsuan, of which $6,671 remains outstanding and payable.</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">-</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Product development consulting fee of $7,215 payable to Huang Chien-Hsuan, of which $6,671 remains outstanding and payable.</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">-&#160;</p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On August 1, 2021, the Company entered into a five-year product development agreement with TCNT. Pursuant to the agreement both parties will endeavor to develop pharmaceutical, medical and preventive medicine related products.&#160; Under the agreement the Company is designated as the exclusive sales agent of the resulting products.&#160; The agreement also provides for the Company to bear the expenses of product development and for TCNT to contribute personnel and facilities. Both parties shall each jointly own an equal proportion of the intellectual property rights arising from the product co-development cooperation. As a result, the Company incurred $117,386 in product co-development expenses and $122,680 in accounts payable during the reporting period.</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">-</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">The Company issued common stock as partial compensation to Dr. Stephen T. Chen and Bernard Cohen as follows:</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160; &#160;</p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Par Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Paid in </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Excess of Par</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Price per share</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;06/30/2021</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Bernard Cohen</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,876</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">58.76</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,107.89</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,166.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.5389</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;06/30/2021</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Dr. Stephen T. Chen</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">53,419</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">534.19</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">32,799.14</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">33,333.33</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.6240</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">59,295</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">593</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">35,907</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">36,500</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139654437416552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">8. Subsequent Events</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>8.</strong></p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Subsequent Events.</strong></p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company engaged PricewaterhouseCoopers, Taiwan (&#8220;PWC&#8221;) as independent accountants of Ainos Inc. Taiwan Branch under an engagement agreement dated October 4, 2021 (&#8220;Audit Engagement&#8221;). The Audit Engagement covers audit services for the years ending December 31, 2021 and 2022 and PWC will issue interfirm audit reports for group reporting purposes to the Company&#8217;s group audit firm, PWR CPA, LLP. Additionally, the Company engaged PWC under separate agreements dated October 4, 2021 for PWC to render advisory services in connection to the Company&#8217;s internal controls over financial reporting as required under section 404 of the Sarbanes-Oxley Act (&#8220;SOX Engagement&#8221;) and in respect to compliance with Taiwan corporate income tax requirements for the tax years ending December 31, 2021 and 2022 (&#8220;Taiwan Tax Engagement&#8221;).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On October 6, 2021, the Company board of directors approved and adopted the following resolutions:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Effective August 30, 2021, the Board appointed Hsiu-Chen Chiu and Wen-Han Chang to serve on the Compensation Committee;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Effective August 30, 2021, the Board appointed Yao-Chung Chiang, Wen-Han Chang and Hsiu-Chen Chiu to serve on the Audit Committee;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Board approval of the Company&#8217;s 2021 Employee Stock Purchase Plan, 2021 Stock Incentive Plan, and 2021 Director Compensation Policy and, if required, shall submit the same for formal adoption by a vote of the Company&#8217;s shareholders</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Board approval of the Company&#8217;s Related Transaction Policy, Hedging Policy, and the Diversity Policy of the Board; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">&#183;</span></p></td><td style="vertical-align:top;">Board approval of the Company&#8217;s engagement agreements dated October 4, 2021 with PricewaterhouseCoopers, Taiwan (&#8220;PWC&#8221;)</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">On November 1, 2021, the Company engaged its former President and CEO, Dr. Stephen T. Chen, as a consultant to assist with its pharmaceutical division. The Company agrees to pay Dr. Chen 50,000 New Taiwan Dollars (NTD) per month for a period of one year for his services. With over 30 years of pharmaceutical professional experience, we expect Dr. Chen to provide technical assistance on our pharmaceutical development initiatives, analyze results from second phase interferon studies for Thrombocytopenia, and contribute to the protocol design of the third phase of interferon development focused on Sj&#246;gren&#8217;s syndrome. Lastly, we expect that Dr. Chen will provide assistance for our mass commercial production of low-dose interferon products.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139654437188936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable and Other Related Party Notes Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract', window );"><strong>Convertible Notes Payable and Other Related Party Notes Payable (Tables)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Convertible Debt</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td colspan="4" style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Annual Interest Rate</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td colspan="7" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Unpaid Principal Balance</strong>&#160;</p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>No#</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Effective Date</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Due Date</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>From</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Effective</strong></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Following</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Maturity</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Payee</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Issuing</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Purpose</strong></p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Sep 30,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2021</strong></p></td><td colspan="3"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Dec 31,</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td></tr><tr style="height:15px"><td colspan="24"><p style="font-size:10pt;font-family:times new roman;margin:0px">Payee: Dr. Stephen T. Chen, resigned as Chairman of the Board, President, and Board director April 15, 2021</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:6%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">#1.16</p></td><td style="width:1%;"/><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">2016/01/30</p></td><td style="width:1%;"/><td style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Payable on demand</p></td><td style="width:1%;"/><td style="width:7%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">0.75%</p></td><td colspan="2" style="width:1%;"/><td style="width:8%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td style="width:1%;"/><td style="width:8%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen Chen</p></td><td style="width:1%;"/><td colspan="2" style="width:12%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2" style="width:1%;"/><td colspan="2" style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">114,026</p></td><td colspan="3" style="width:1%;"/><td colspan="2" style="width:9%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">114,026</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#2.16</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2016/03/18</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Payable on demand</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">0.65%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen Chen</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">262,500</p></td><td colspan="3"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">262,500</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#3.19</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2019/09/01</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2020/09/01</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen Chen</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">salary</p></td><td colspan="2"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">39,392</p></td><td colspan="3"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">39,620</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#4.19</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2019/12/01</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2020/12/31</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.61%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen Chen</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">14,879</p></td><td colspan="3"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">14,879</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#6.20</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2020/01/01</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/01/01</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen Chen</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">salary</p></td><td colspan="2"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">216,600</p></td><td colspan="3"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">216,600</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#7.20</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2020/01/01</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/01/02</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.60%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen Chen</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">23,366</p></td><td colspan="3"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">23,366</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#9.20</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2020/01/01</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/04/14</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">0.13%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen Chen</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">279,405</p></td><td colspan="3"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">134,010</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#10.21</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/01/01</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/04/01</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen Chen</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">salary</p></td><td colspan="2"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">59,025</p></td><td colspan="3"/><td colspan="2"/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#11.21</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/04/01</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/05/01</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen Chen</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">salary</p></td><td colspan="2"/><td colspan="2" style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10,000</p></td><td colspan="3"/><td colspan="2" style="BORDER-BOTTOM: 1px solid;"/></tr><tr style="height:15px;background-color:#ffffff"><td/><td/><td/><td/><td/><td/><td/><td colspan="2"/><td/><td/><td/><td/><td colspan="2"/><td colspan="2"/><td colspan="2" style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,019,193</p></td><td colspan="3"/><td colspan="2" style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">805,001</p></td></tr><tr style="height:15px;background-color:#cceeff"><td/><td/><td/><td/><td/><td/><td/><td colspan="2"/><td/><td/><td/><td/><td colspan="2"/><td colspan="2"/><td colspan="2"/><td colspan="3"/><td colspan="2"/></tr><tr style="height:15px;background-color:#ffffff"><td colspan="5"><p style="font-size:10pt;font-family:times new roman;margin:0px">Payee: Ainos KY, an affiliated company </p></td><td/><td/><td/><td colspan="2"/><td/><td/><td/><td colspan="2"/><td colspan="2"/><td colspan="2"/><td colspan="2"/><td colspan="3"/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#12.21</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/04/27</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/10/27</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">15,000</p></td><td colspan="3"/><td colspan="2"/></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#13.21</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/05/05</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/11/05</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">20,000</p></td><td colspan="3"/><td colspan="2"/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#14.21</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/05/25</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/11/25</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">30,000</p></td><td colspan="3"/><td colspan="2"/></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#15.21</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/05/28</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/11/28</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">35,000</p></td><td colspan="3"/><td colspan="2"/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#16.21</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/06/09</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/12/09</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">300,000</p></td><td colspan="3"/><td colspan="2"/></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#17.21</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/06/21</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/12/21</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">107,000</p></td><td colspan="3"/><td colspan="2"/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#18.21</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/07/02</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2022/01/02</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">54,000</p></td><td colspan="3"/><td colspan="2"/></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#19.21</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/09/01</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/03/01</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">120,000</p></td><td colspan="3"/><td colspan="2"/></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#20.21</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/09/28</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/03/28</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td colspan="2"/><td colspan="2" style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">300,000</p></td><td colspan="3"/><td colspan="2" style="BORDER-BOTTOM: 1px solid;"/></tr><tr style="height:15px;background-color:#ffffff"><td/><td/><td/><td/><td/><td/><td/><td colspan="2"/><td/><td/><td/><td/><td colspan="2"/><td colspan="2"/><td colspan="2" style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">981,000</p></td><td colspan="3"/><td colspan="2" style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0 </p></td></tr><tr style="height:15px;background-color:#cceeff"><td/><td/><td/><td/><td/><td/><td colspan="9"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">Convertible and other notes payable- related parties</p></td><td colspan="2"/><td colspan="2" style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2,000,193</p></td><td colspan="3"/><td colspan="2" style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">805,001</p></td></tr><tr style="height:15px;background-color:#ffffff"><td/><td/><td/><td/><td/><td/><td/><td colspan="2"/><td/><td/><td/><td/><td colspan="2"/><td colspan="2"/><td colspan="2"/><td colspan="3"/><td colspan="2"/></tr><tr style="height:15px;background-color:#cceeff"><td colspan="10"><p style="font-size:10pt;font-family:times new roman;margin:0px">Payee: i2China Management Group LLC, a management consultant</p></td><td/><td/><td/><td colspan="2"/><td colspan="2"/><td colspan="2"/><td colspan="2"/><td colspan="3"/></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#5.19</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2019/09/01</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2020/09/01</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">i2China</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">consulting fee</p></td><td colspan="2"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">16,000</p></td><td colspan="3"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">16,000</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#8a.20</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2020/01/01</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/01/01</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">i2China</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">consulting fee</p></td><td colspan="2"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">48,000</p></td><td colspan="3"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">48,000</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#8b.20</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Retroactive from 2020/01/01</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/01/01</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">i2China</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">consulting fee</p></td><td colspan="2"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">84,000</p></td><td colspan="3"/><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">84,000</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">#11.21</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/01/01</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">2021/04/01</p></td><td/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td colspan="2"/><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">i2China</p></td><td/><td colspan="2"><p style="font-size:10pt;font-family:times new roman;margin:0px">consulting fee</p></td><td colspan="2"/><td colspan="2" style="BORDER-BOTTOM: #000000 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">37,000</p></td><td colspan="3"/><td colspan="2" style="BORDER-BOTTOM: #000000 1px solid;"/></tr><tr style="height:15px;background-color:#ffffff"><td/><td/><td/><td/><td/><td/><td colspan="9"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">Convertible and other notes payable</p></td><td colspan="2"/><td colspan="2" style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">185,000</p></td><td colspan="3"/><td colspan="2" style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">148,000</p></td></tr><tr style="height:15px;background-color:#cceeff"><td/><td/><td/><td/><td/><td/><td colspan="9"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">Total Convertible and other notes payable</p></td><td colspan="2"/><td colspan="2" style="BORDER-BOTTOM: 3px double;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2,185,193</p></td><td colspan="3"/><td colspan="2" style="BORDER-BOTTOM: 3px double;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">953,001</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:justify;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Unpaid </strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td colspan="3" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Interest Rate</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td colspan="5" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Interest amount</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;Interest </strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>No#</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Date</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Payee</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Description</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong><strong>Principal </strong><strong>Amount</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Original</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>after</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Maturity</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;Original&#160;rate</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>10%</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total </strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>after</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Maturity</strong></p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong><strong>Interest</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Waived</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:10%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#1.16</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:10%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">1/30/2016</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:10%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:10%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">114,026</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">0.75%</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5,624</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0 </p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5,624</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5,624</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:6%;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0 </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#2.16</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">3/18/2016</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">262,500</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">0.65%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">NA</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">9,447</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">9,447</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">9,447</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0 </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#3.19</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">9/1/2019(DS)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">salary</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">39,392</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">714 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">4,340</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5,054</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,518</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">3,536</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#4.19</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">12/1/2019(DE)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">14,879</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.61%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">257 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,132</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,389</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">439 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">950 </p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#6.20</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">1/1/2020(DS)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">salary</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">216,600</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2,179</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">16,363</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">18,543</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5,206</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">13,336</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#7.20</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">1/1/2020(DE)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">23,366</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.60%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">72 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,753</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,825</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">352 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,473</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#9.20</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">11/2020 (Open)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">working capital</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">279,405</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">0.13%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">81 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12,864</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12,945</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">248 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">12,697</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#10.21</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">1/1/2021(DS)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">salary</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">59,025</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">178 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2,968</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">3,146</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">725</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2,421</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#11.21</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">4/1/2021(DS)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">Stephen</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">salary</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">10,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">15 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">420 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">435 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">93 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">342 </p></td></tr><tr style="height:15px;background-color:#ffffff"><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,019,193</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">18,566</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">39,841</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">58,407</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">23,653</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">34,754</p></td></tr><tr style="height:15px;background-color:#cceeff"><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#5.19</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">9/1/2019</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">i2China</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">consulting fee</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">16,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">253 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,759</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2,012</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">579 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,433</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#8a.20</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">1/1/2020</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">i2China</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">consulting fee</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">48,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">483</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">3,626</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">4,109</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,154</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2,955</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#8b.20</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">1/1/2020</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">i2China</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">retroactive increase</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">84,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,554</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">6,399</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">7,953</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2,738</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5,215</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">#11.21</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">1/1/2021(DS)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">i2China</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">consulting fee</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">37,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">1.85%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">10%</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">107 </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,860</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,967</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">450</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,517</p></td></tr><tr style="height:15px;background-color:#ffffff"><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">185,000</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2,397</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">13,645</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">16,041</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">4,920</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">11,121</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="3"><p style="font-size:10pt;font-family:times new roman;margin:0px">TOTAL ACCRUED</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td/><td/><td style="BORDER-BOTTOM: black 3px double;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">1,204,193 </p></td><td style="PADDING-BOTTOM: 3px;"/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: black 3px double;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">20,963&#160;</p></td><td style="BORDER-BOTTOM: black 3px double; PADDING-BOTTOM: 3px;"/><td style="BORDER-BOTTOM: black 3px double;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">&#160;53,485</p></td><td style="PADDING-BOTTOM: 3px;"/><td style="BORDER-BOTTOM: black 3px double;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">74,448 </p></td><td style="PADDING-BOTTOM: 3px;"/><td style="BORDER-BOTTOM: black 3px double;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">28,573 </p></td><td style="PADDING-BOTTOM: 3px;"/><td style="BORDER-BOTTOM: black 3px double;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">45,875 </p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139654435955208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Other Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock', window );">Schedule of list of related parties</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:26%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Name of the related party</strong></p></td><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Relationship</strong></p></td><td style="width:2%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Description</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Taiwan Carbon Nano Technology Corporation (TCNT)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Affiliated company</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos, Inc. (Cayman Island) ( Ainos KY)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Affiliated company</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">ASE Technology Holding</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Affiliated company</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Parent company of ASE Test Inc. which is Ainos KY's board member and with more than 10% of the voting rights </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">i2 China Management Group LLC (i2 China)</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Affiliated company</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Sole member owner is Lawrence Lin, EVP Operations effective August 1, 2021</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Dr. Stephen T. Chen</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Principal owner</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Shareholder with more than 5% of Company voting rights, Ainos' former Chairman, President, CEO and CFO</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Chun-Hsien Tsai</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Board of Director, Executive Officer and Immediate Family</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Chairman of BOD, President, CEO and spouse of Ting-Chuan Lee</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ting-Chuan Lee</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Board of Director and Immediate Family</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Spouse of Chun Hsien Tsai</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Hui-Lan Wu</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Executive Officer</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">CFO</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Lawrence Lin</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Key management</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">EVP Operations effective August 1, 2021</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Chih-Heng Lu</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Key management</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Director of Corporate Development and Corporate Secretary</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">John Junyong Lee</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Key management</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Chief Legal Counsel and Corporate Secretary rewarded by fixed monthly fee and performance bonus effective September 1,2021 Chief Legal Counsel and Corporate Secretary</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Chien-Hsuan Huang </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Immediate Family of Director</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Spouse of Wen-Han Chang</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Bernard Cohen</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Former CFO</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Resigned on April 5, 2021</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_ScheduleOfFinancialSupportListtabletextblock', window );">schedule of financial support list</a></td>
<td class="text"><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Convertible Note</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Related Interest Expense</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td></tr><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine months ended </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September 30, 2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>As of</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September 30, 2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Nine months ended September 30, 2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>As of </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>September 30, 2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Ainos KY</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">981,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">981,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,410</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,410</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">i2China</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">37,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">185,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,087</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,920</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Dr. Stephen T. Chen</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">15,272</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,019,193</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">5,936</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">23,653</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,033,272</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2,185,193</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">11,433</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">31,983</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Par Value</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Paid in </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Excess of Par</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Total amount</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>&#160;</strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Price per share</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;06/30/2021</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Bernard Cohen</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,876</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">58.76</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,107.89</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,166.65</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.5389</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;06/30/2021</p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Dr. Stephen T. Chen</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">53,419</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">534.19</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">32,799.14</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">33,333.33</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.6240</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">59,295</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">593</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">35,907</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">36,500</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td class="ffcell" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_ScheduleOfFinancialSupportListtabletextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_ScheduleOfFinancialSupportListtabletextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of real estate properties and units in those properties that are included in the discussion of the nature of an entity's operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139654439798664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Condition (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="nump">$ 17,136,360<span></span>
</td>
<td class="num">$ (776,530)<span></span>
</td>
<td class="nump">$ 17,136,360<span></span>
</td>
<td class="num">$ (776,530)<span></span>
</td>
<td class="nump">$ 18,205,557<span></span>
</td>
<td class="num">$ (838,278)<span></span>
</td>
<td class="num">$ (744,117)<span></span>
</td>
<td class="num">$ (156,682)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">363,052<span></span>
</td>
<td class="nump">$ 192<span></span>
</td>
<td class="nump">568,164<span></span>
</td>
<td class="nump">15,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=aimd_SecuritiesPurchaseAgreementsMember', window );">Securities Purchase Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">706,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">706,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="nump">$ 17,136,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,136,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 838,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 568,164<span></span>
</td>
<td class="nump">$ 15,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=aimd_SecuritiesPurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=aimd_SecuritiesPurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139654523858696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_SharesIncreaseValue', window );">Shares increase value</a></td>
<td class="nump">$ 1,003,760<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_SharesIncreaseValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_SharesIncreaseValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139654440857832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable and Oayable (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_DrStephenTChenMember', window );">Dr. Stephen T. Chen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_DueDate', window );">Due Date</a></td>
<td class="text">2021/04/01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt', window );">Annual interest rate, From effective</a></td>
<td class="nump">1.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_EffectiveDate', window );">Effective Date</a></td>
<td class="text">2021/01/01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 1,019,193<span></span>
</td>
<td class="nump">$ 805,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_AnnualInterestRateFollowingMaturity', window );">Annual interest rate, Following maturity</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_DrStephenTChenMember', window );">Dr. Stephen T. Chen [Member] | 2.16 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_DueDate', window );">Due Date</a></td>
<td class="text">Payable on demand<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt', window );">Annual interest rate, From effective</a></td>
<td class="nump">0.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_EffectiveDate', window );">Effective Date</a></td>
<td class="text">2016/03/18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 262,500<span></span>
</td>
<td class="nump">262,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_DrStephenTChenMember', window );">Dr. Stephen T. Chen [Member] | 1.16 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_DueDate', window );">Due Date</a></td>
<td class="text">Payable on demand<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt', window );">Annual interest rate, From effective</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_EffectiveDate', window );">Effective Date</a></td>
<td class="text">2016/01/30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 114,026<span></span>
</td>
<td class="nump">114,026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_DrStephenTChenMember', window );">Dr. Stephen T. Chen [Member] | 3.19 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_DueDate', window );">Due Date</a></td>
<td class="text">2020/09/01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt', window );">Annual interest rate, From effective</a></td>
<td class="nump">1.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_EffectiveDate', window );">Effective Date</a></td>
<td class="text">2019/09/01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 39,392<span></span>
</td>
<td class="nump">39,620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_AnnualInterestRateFollowingMaturity', window );">Annual interest rate, Following maturity</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_DrStephenTChenMember', window );">Dr. Stephen T. Chen [Member] | 4.19 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_DueDate', window );">Due Date</a></td>
<td class="text">2020/12/31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt', window );">Annual interest rate, From effective</a></td>
<td class="nump">1.61%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_EffectiveDate', window );">Effective Date</a></td>
<td class="text">2019/12/01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 14,879<span></span>
</td>
<td class="nump">14,879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_AnnualInterestRateFollowingMaturity', window );">Annual interest rate, Following maturity</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_DrStephenTChenMember', window );">Dr. Stephen T. Chen [Member] | 6.20 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_DueDate', window );">Due Date</a></td>
<td class="text">2021/01/<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt', window );">Annual interest rate, From effective</a></td>
<td class="nump">1.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_EffectiveDate', window );">Effective Date</a></td>
<td class="text">2020/01/01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 216,600<span></span>
</td>
<td class="nump">216,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_AnnualInterestRateFollowingMaturity', window );">Annual interest rate, Following maturity</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_DrStephenTChenMember', window );">Dr. Stephen T. Chen [Member] | 7.20 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_DueDate', window );">Due Date</a></td>
<td class="text">2021/01/02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt', window );">Annual interest rate, From effective</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_EffectiveDate', window );">Effective Date</a></td>
<td class="text">2020/01/01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 23,366<span></span>
</td>
<td class="nump">23,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_AnnualInterestRateFollowingMaturity', window );">Annual interest rate, Following maturity</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_DrStephenTChenMember', window );">Dr. Stephen T. Chen [Member] | 9.20 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_DueDate', window );">Due Date</a></td>
<td class="text">2021/04/14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt', window );">Annual interest rate, From effective</a></td>
<td class="nump">0.13%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_EffectiveDate', window );">Effective Date</a></td>
<td class="text">2020/01/01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 279,405<span></span>
</td>
<td class="nump">134,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_AnnualInterestRateFollowingMaturity', window );">Annual interest rate, Following maturity</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_DrStephenTChenMember', window );">Dr. Stephen T. Chen [Member] | 11.21 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_DueDate', window );">Due Date</a></td>
<td class="text">2021/05/01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt', window );">Annual interest rate, From effective</a></td>
<td class="nump">1.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_EffectiveDate', window );">Effective Date</a></td>
<td class="text">2021/04/01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_AnnualInterestRateFollowingMaturity', window );">Annual interest rate, Following maturity</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_DrStephenTChenMember', window );">Dr. Stephen T. Chen [Member] | 10.21 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_DueDate', window );">Due Date</a></td>
<td class="text">2021/04/01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt', window );">Annual interest rate, From effective</a></td>
<td class="nump">1.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_EffectiveDate', window );">Effective Date</a></td>
<td class="text">2021/01/01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 59,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_AnnualInterestRateFollowingMaturity', window );">Annual interest rate, Following maturity</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_AinosKYMember', window );">Ainos KY [Member] | 12.21 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_DueDate', window );">Due Date</a></td>
<td class="text">2021/10/27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt', window );">Annual interest rate, From effective</a></td>
<td class="nump">1.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_EffectiveDate', window );">Effective Date</a></td>
<td class="text">2021/04/27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_AinosKYMember', window );">Ainos KY [Member] | 13.21 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_DueDate', window );">Due Date</a></td>
<td class="text">2021/11/05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt', window );">Annual interest rate, From effective</a></td>
<td class="nump">1.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_EffectiveDate', window );">Effective Date</a></td>
<td class="text">2021/05/05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_AinosKYMember', window );">Ainos KY [Member] | Total [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">981,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_ConvertibleAndOtherNotesPayableRelatedParties', window );">Convertible and other notes payable- related parties</a></td>
<td class="nump">$ 2,000,193<span></span>
</td>
<td class="nump">805,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_AinosKYMember', window );">Ainos KY [Member] | 14.21 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_DueDate', window );">Due Date</a></td>
<td class="text">2021/11/25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt', window );">Annual interest rate, From effective</a></td>
<td class="nump">1.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_EffectiveDate', window );">Effective Date</a></td>
<td class="text">2021/05/25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_AinosKYMember', window );">Ainos KY [Member] | 15.21 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_DueDate', window );">Due Date</a></td>
<td class="text">2021/11/28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt', window );">Annual interest rate, From effective</a></td>
<td class="nump">1.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_EffectiveDate', window );">Effective Date</a></td>
<td class="text">2021/05/28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_AinosKYMember', window );">Ainos KY [Member] | 16.21 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_DueDate', window );">Due Date</a></td>
<td class="text">2021/12/09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt', window );">Annual interest rate, From effective</a></td>
<td class="nump">1.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_EffectiveDate', window );">Effective Date</a></td>
<td class="text">2021/06/09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_AinosKYMember', window );">Ainos KY [Member] | 17.21 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_DueDate', window );">Due Date</a></td>
<td class="text">2021/12/21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt', window );">Annual interest rate, From effective</a></td>
<td class="nump">1.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_EffectiveDate', window );">Effective Date</a></td>
<td class="text">2021/06/21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 107,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_AinosKYMember', window );">Ainos KY [Member] | 18.21 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_DueDate', window );">Due Date</a></td>
<td class="text">2022/01/02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt', window );">Annual interest rate, From effective</a></td>
<td class="nump">1.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_EffectiveDate', window );">Effective Date</a></td>
<td class="text">2021/07/02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_AinosKYMember', window );">Ainos KY [Member] | 19.21 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_DueDate', window );">Due Date</a></td>
<td class="text">2021/03/01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt', window );">Annual interest rate, From effective</a></td>
<td class="nump">1.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_EffectiveDate', window );">Effective Date</a></td>
<td class="text">2021/09/01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_AinosKYMember', window );">Ainos KY [Member] | 20.21 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_DueDate', window );">Due Date</a></td>
<td class="text">2021/03/28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt', window );">Annual interest rate, From effective</a></td>
<td class="nump">1.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_EffectiveDate', window );">Effective Date</a></td>
<td class="text">2021/09/28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_ITwoChinaManagementGroupLLCMember', window );">i2China Management Group LLC [Member] | 11.21 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_DueDate', window );">Due Date</a></td>
<td class="text">2021/04/01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt', window );">Annual interest rate, From effective</a></td>
<td class="nump">1.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_EffectiveDate', window );">Effective Date</a></td>
<td class="text">2021/01/01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_AnnualInterestRateFollowingMaturity', window );">Annual interest rate, Following maturity</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_ITwoChinaManagementGroupLLCMember', window );">i2China Management Group LLC [Member] | 5.19 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_DueDate', window );">Due Date</a></td>
<td class="text">2020/09/01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt', window );">Annual interest rate, From effective</a></td>
<td class="nump">1.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_EffectiveDate', window );">Effective Date</a></td>
<td class="text">2019/09/01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_AnnualInterestRateFollowingMaturity', window );">Annual interest rate, Following maturity</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_ITwoChinaManagementGroupLLCMember', window );">i2China Management Group LLC [Member] | Total [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 185,000<span></span>
</td>
<td class="nump">148,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_ConvertibleAndOtherNotesPayableRelatedParties', window );">Convertible and other notes payable- related parties</a></td>
<td class="nump">$ 2,185,193<span></span>
</td>
<td class="nump">953,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_ITwoChinaManagementGroupLLCMember', window );">i2China Management Group LLC [Member] | 8b.20 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_DueDate', window );">Due Date</a></td>
<td class="text">2021/01/01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt', window );">Annual interest rate, From effective</a></td>
<td class="nump">1.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_EffectiveDate', window );">Effective Date</a></td>
<td class="text">Retroactive from 2020/01/01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 84,000<span></span>
</td>
<td class="nump">84,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_AnnualInterestRateFollowingMaturity', window );">Annual interest rate, Following maturity</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_ITwoChinaManagementGroupLLCMember', window );">i2China Management Group LLC [Member] | 8a.20 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_DueDate', window );">Due Date</a></td>
<td class="text">2021/01/01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt', window );">Annual interest rate, From effective</a></td>
<td class="nump">1.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_EffectiveDate', window );">Effective Date</a></td>
<td class="text">2020/01/01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 48,000<span></span>
</td>
<td class="nump">$ 48,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_AnnualInterestRateFollowingMaturity', window );">Annual interest rate, Following maturity</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_AnnualInterestRateFollowingMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_AnnualInterestRateFollowingMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_ConvertibleAndOtherNotesPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_ConvertibleAndOtherNotesPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_DueDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_DueDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_EffectiveDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_EffectiveDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The rate of interest that was being paid on the original debt issue that is being converted in the noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtInterestRateOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=aimd_DrStephenTChenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=aimd_DrStephenTChenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_TwoOneSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_TwoOneSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_OneOneSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_OneOneSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_ThreeOneNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_ThreeOneNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_FourOneNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_FourOneNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_SixTwoZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_SixTwoZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_SevenTwoZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_SevenTwoZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_NineTwoZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_NineTwoZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_ElevenTwoOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_ElevenTwoOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_TenTwoOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_TenTwoOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=aimd_AinosKYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=aimd_AinosKYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_TwelveTwoOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_TwelveTwoOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_ThirteenTwoOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_ThirteenTwoOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_TotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_TotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_FourteenTwoOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_FourteenTwoOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_FifteenTwoOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_FifteenTwoOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_SixteenTwoOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_SixteenTwoOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_SeventeenTwoOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_SeventeenTwoOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_EighteenTwoOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_EighteenTwoOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_NinteenTwoOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_NinteenTwoOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_TwentyTwoOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_TwentyTwoOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=aimd_ITwoChinaManagementGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=aimd_ITwoChinaManagementGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_ElevenOneTwoOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_ElevenOneTwoOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_FiveOneNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_FiveOneNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_EightBTwoZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_EightBTwoZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_EightATwozeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_EightATwozeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139654429010120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable and Oayable (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest amount total</a></td>
<td class="nump">$ 9,363<span></span>
</td>
<td class="nump">$ 4,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_DrStephenTChenMember', window );">Dr. Stephen T. Chen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 1,019,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 805,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_Date', window );">Date</a></td>
<td class="text">3/18/2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate original</a></td>
<td class="nump">1.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAmountOriginalRate', window );">Interest amount original rate</a></td>
<td class="nump">$ 18,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAmount10', window );">Interest amount 10%</a></td>
<td class="nump">39,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest amount total</a></td>
<td class="nump">58,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAfterMaturity', window );">Interest after Maturity</a></td>
<td class="nump">23,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestWaived', window );">Interest waived</a></td>
<td class="nump">$ 34,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestRateAfterMaturity', window );">Interest rate after maturity</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_DrStephenTChenMember', window );">Dr. Stephen T. Chen [Member] | 2.16 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 262,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_Date', window );">Date</a></td>
<td class="text">3/18/2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate original</a></td>
<td class="nump">0.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAmountOriginalRate', window );">Interest amount original rate</a></td>
<td class="nump">$ 9,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAmount10', window );">Interest amount 10%</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest amount total</a></td>
<td class="nump">9,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAfterMaturity', window );">Interest after Maturity</a></td>
<td class="nump">9,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestWaived', window );">Interest waived</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_DrStephenTChenMember', window );">Dr. Stephen T. Chen [Member] | 1.16 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 114,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_Date', window );">Date</a></td>
<td class="text">1/30/2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate original</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAmountOriginalRate', window );">Interest amount original rate</a></td>
<td class="nump">$ 5,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAmount10', window );">Interest amount 10%</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest amount total</a></td>
<td class="nump">5,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAfterMaturity', window );">Interest after Maturity</a></td>
<td class="nump">5,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestWaived', window );">Interest waived</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_DrStephenTChenMember', window );">Dr. Stephen T. Chen [Member] | 3.19 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 39,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_Date', window );">Date</a></td>
<td class="text">9/1/2019(DS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate original</a></td>
<td class="nump">1.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAmountOriginalRate', window );">Interest amount original rate</a></td>
<td class="nump">$ 714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAmount10', window );">Interest amount 10%</a></td>
<td class="nump">4,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest amount total</a></td>
<td class="nump">5,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAfterMaturity', window );">Interest after Maturity</a></td>
<td class="nump">1,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestWaived', window );">Interest waived</a></td>
<td class="nump">$ 3,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestRateAfterMaturity', window );">Interest rate after maturity</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_DrStephenTChenMember', window );">Dr. Stephen T. Chen [Member] | 4.19 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 14,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_Date', window );">Date</a></td>
<td class="text">12/1/2019(DE)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate original</a></td>
<td class="nump">1.61%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAmountOriginalRate', window );">Interest amount original rate</a></td>
<td class="nump">$ 257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAmount10', window );">Interest amount 10%</a></td>
<td class="nump">1,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest amount total</a></td>
<td class="nump">1,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAfterMaturity', window );">Interest after Maturity</a></td>
<td class="nump">439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestWaived', window );">Interest waived</a></td>
<td class="nump">$ 950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestRateAfterMaturity', window );">Interest rate after maturity</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_DrStephenTChenMember', window );">Dr. Stephen T. Chen [Member] | 6.20 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 216,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_Date', window );">Date</a></td>
<td class="text">1/1/2020(DS)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate original</a></td>
<td class="nump">1.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAmountOriginalRate', window );">Interest amount original rate</a></td>
<td class="nump">$ 2,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAmount10', window );">Interest amount 10%</a></td>
<td class="nump">16,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest amount total</a></td>
<td class="nump">18,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAfterMaturity', window );">Interest after Maturity</a></td>
<td class="nump">5,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestWaived', window );">Interest waived</a></td>
<td class="nump">$ 13,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestRateAfterMaturity', window );">Interest rate after maturity</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_DrStephenTChenMember', window );">Dr. Stephen T. Chen [Member] | 7.20 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 23,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_Date', window );">Date</a></td>
<td class="text">1/1/2020(DE)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate original</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAmountOriginalRate', window );">Interest amount original rate</a></td>
<td class="nump">$ 1,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAmount10', window );">Interest amount 10%</a></td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest amount total</a></td>
<td class="nump">1,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAfterMaturity', window );">Interest after Maturity</a></td>
<td class="nump">352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestWaived', window );">Interest waived</a></td>
<td class="nump">$ 1,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestRateAfterMaturity', window );">Interest rate after maturity</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_DrStephenTChenMember', window );">Dr. Stephen T. Chen [Member] | 9.20 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 279,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_Date', window );">Date</a></td>
<td class="text">11/2020 (Open)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate original</a></td>
<td class="nump">0.13%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAmountOriginalRate', window );">Interest amount original rate</a></td>
<td class="nump">$ 81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAmount10', window );">Interest amount 10%</a></td>
<td class="nump">12,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest amount total</a></td>
<td class="nump">12,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAfterMaturity', window );">Interest after Maturity</a></td>
<td class="nump">248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestWaived', window );">Interest waived</a></td>
<td class="nump">$ 12,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestRateAfterMaturity', window );">Interest rate after maturity</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_DrStephenTChenMember', window );">Dr. Stephen T. Chen [Member] | 11.21 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_Date', window );">Date</a></td>
<td class="text">4/1/2021(DS)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate original</a></td>
<td class="nump">0.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAmountOriginalRate', window );">Interest amount original rate</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAmount10', window );">Interest amount 10%</a></td>
<td class="nump">420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest amount total</a></td>
<td class="nump">435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAfterMaturity', window );">Interest after Maturity</a></td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestWaived', window );">Interest waived</a></td>
<td class="nump">$ 342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestRateAfterMaturity', window );">Interest rate after maturity</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_DrStephenTChenMember', window );">Dr. Stephen T. Chen [Member] | 10.21 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 59,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_Date', window );">Date</a></td>
<td class="text">1/1/2021(DS)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate original</a></td>
<td class="nump">1.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAmountOriginalRate', window );">Interest amount original rate</a></td>
<td class="nump">$ 178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAmount10', window );">Interest amount 10%</a></td>
<td class="nump">2,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest amount total</a></td>
<td class="nump">3,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAfterMaturity', window );">Interest after Maturity</a></td>
<td class="nump">725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestWaived', window );">Interest waived</a></td>
<td class="nump">$ 2,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestRateAfterMaturity', window );">Interest rate after maturity</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_ITwoChinaManagementGroupLLCMember', window );">i2China Management Group LLC [Member] | 11.21 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_Date', window );">Date</a></td>
<td class="text">3/18/2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate original</a></td>
<td class="nump">1.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAmountOriginalRate', window );">Interest amount original rate</a></td>
<td class="nump">$ 107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAmount10', window );">Interest amount 10%</a></td>
<td class="nump">1,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest amount total</a></td>
<td class="nump">1,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAfterMaturity', window );">Interest after Maturity</a></td>
<td class="nump">450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestWaived', window );">Interest waived</a></td>
<td class="nump">$ 1,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestRateAfterMaturity', window );">Interest rate after maturity</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_ITwoChinaManagementGroupLLCMember', window );">i2China Management Group LLC [Member] | 5.19 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_Date', window );">Date</a></td>
<td class="text">9/1/2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate original</a></td>
<td class="nump">1.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAmountOriginalRate', window );">Interest amount original rate</a></td>
<td class="nump">$ 253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAmount10', window );">Interest amount 10%</a></td>
<td class="nump">1,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest amount total</a></td>
<td class="nump">2,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAfterMaturity', window );">Interest after Maturity</a></td>
<td class="nump">579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestWaived', window );">Interest waived</a></td>
<td class="nump">$ 1,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestRateAfterMaturity', window );">Interest rate after maturity</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_ITwoChinaManagementGroupLLCMember', window );">i2China Management Group LLC [Member] | Total [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_Date', window );">Date</a></td>
<td class="text">3/18/2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAmountOriginalRate', window );">Interest amount original rate</a></td>
<td class="nump">$ 2,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAmount10', window );">Interest amount 10%</a></td>
<td class="nump">13,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest amount total</a></td>
<td class="nump">16,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAfterMaturity', window );">Interest after Maturity</a></td>
<td class="nump">4,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestWaived', window );">Interest waived</a></td>
<td class="nump">11,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_ITwoChinaManagementGroupLLCMember', window );">i2China Management Group LLC [Member] | 8b.20 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 84,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_Date', window );">Date</a></td>
<td class="text">1/1/2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate original</a></td>
<td class="nump">1.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAmountOriginalRate', window );">Interest amount original rate</a></td>
<td class="nump">$ 1,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAmount10', window );">Interest amount 10%</a></td>
<td class="nump">6,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest amount total</a></td>
<td class="nump">7,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAfterMaturity', window );">Interest after Maturity</a></td>
<td class="nump">2,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestWaived', window );">Interest waived</a></td>
<td class="nump">$ 5,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestRateAfterMaturity', window );">Interest rate after maturity</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_ITwoChinaManagementGroupLLCMember', window );">i2China Management Group LLC [Member] | 8a.20 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Unpaid principal balance</a></td>
<td class="nump">$ 48,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_Date', window );">Date</a></td>
<td class="text">1/1/2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate original</a></td>
<td class="nump">1.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAmountOriginalRate', window );">Interest amount original rate</a></td>
<td class="nump">$ 483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAmount10', window );">Interest amount 10%</a></td>
<td class="nump">3,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest amount total</a></td>
<td class="nump">4,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestAfterMaturity', window );">Interest after Maturity</a></td>
<td class="nump">1,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestWaived', window );">Interest waived</a></td>
<td class="nump">$ 2,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_InterestRateAfterMaturity', window );">Interest rate after maturity</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_Date">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_Date</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_InterestAfterMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_InterestAfterMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_InterestAmount10">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_InterestAmount10</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_InterestAmountOriginalRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_InterestAmountOriginalRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_InterestRateAfterMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_InterestRateAfterMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_InterestWaived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_InterestWaived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=aimd_DrStephenTChenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=aimd_DrStephenTChenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_TwoOneSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_TwoOneSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_OneOneSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_OneOneSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_ThreeOneNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_ThreeOneNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_FourOneNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_FourOneNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_SixTwoZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_SixTwoZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_SevenTwoZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_SevenTwoZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_NineTwoZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_NineTwoZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_ElevenTwoOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_ElevenTwoOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_TenTwoOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_TenTwoOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=aimd_ITwoChinaManagementGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=aimd_ITwoChinaManagementGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_ElevenOneTwoOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_ElevenOneTwoOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_FiveOneNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_FiveOneNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_TotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_TotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_EightBTwoZeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_EightBTwoZeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=aimd_EightATwozeroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=aimd_EightATwozeroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139654437492824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable and Oayable (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract', window );"><strong>Convertible Notes Payable and Other Related Party Notes Payable (Tables)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued interest</a></td>
<td class="nump">$ 31,983<span></span>
</td>
<td class="nump">$ 18,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Total Convertible and other notes payable</a></td>
<td class="nump">$ 2,185,953<span></span>
</td>
<td class="nump">$ 953,001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139654440298712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=aimd_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Related party debt</a></td>
<td class="nump">$ 1,033,272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseRelatedParty', window );">Related Interest Expense</a></td>
<td class="nump">11,433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible Note</a></td>
<td class="nump">2,185,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent', window );">Related parties</a></td>
<td class="nump">31,983<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=aimd_I2ChinaMember', window );">I2China [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Related party debt</a></td>
<td class="nump">37,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseRelatedParty', window );">Related Interest Expense</a></td>
<td class="nump">2,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible Note</a></td>
<td class="nump">185,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent', window );">Related parties</a></td>
<td class="nump">4,920<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_AinosKYMember', window );">Ainos KY [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Related party debt</a></td>
<td class="nump">981,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseRelatedParty', window );">Related Interest Expense</a></td>
<td class="nump">3,410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible Note</a></td>
<td class="nump">981,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent', window );">Related parties</a></td>
<td class="nump">3,410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_DrStephenTChenMember', window );">Dr. Stephen T. Chen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Related party debt</a></td>
<td class="nump">15,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseRelatedParty', window );">Related Interest Expense</a></td>
<td class="nump">5,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible Note</a></td>
<td class="nump">1,019,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent', window );">Related parties</a></td>
<td class="nump">$ 23,653<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense incurred on a debt or other obligation to related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=aimd_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=aimd_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=aimd_I2ChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=aimd_I2ChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=aimd_AinosKYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=aimd_AinosKYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=aimd_DrStephenTChenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=aimd_DrStephenTChenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139654439789032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Transactions (Details 1)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_Shares', window );">Shares</a></td>
<td class="nump">$ 59,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_ParValue', window );">Par Value</a></td>
<td class="nump">593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_PaidInExcessOfPar', window );">Paid in Excess of Par</a></td>
<td class="nump">35,907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_TotalAmount', window );">Total amount</a></td>
<td class="nump">36,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=aimd_BernardCohenMember', window );">Bernard Cohen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_Shares', window );">Shares</a></td>
<td class="nump">53,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_ParValue', window );">Par Value</a></td>
<td class="nump">534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_PaidInExcessOfPar', window );">Paid in Excess of Par</a></td>
<td class="nump">32,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_TotalAmount', window );">Total amount</a></td>
<td class="nump">$ 33,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share | $ / shares</a></td>
<td class="nump">$ 0.6240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=aimd_DrStephenTChenMember', window );">Dr. Stephen T. Chen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_Shares', window );">Shares</a></td>
<td class="nump">$ 5,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_ParValue', window );">Par Value</a></td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_PaidInExcessOfPar', window );">Paid in Excess of Par</a></td>
<td class="nump">3,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_TotalAmount', window );">Total amount</a></td>
<td class="nump">$ 3,166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share | $ / shares</a></td>
<td class="nump">$ 0.5389<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_PaidInExcessOfPar">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_PaidInExcessOfPar</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_ParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_ParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_Shares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_Shares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_TotalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_TotalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=aimd_BernardCohenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=aimd_BernardCohenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=aimd_DrStephenTChenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=aimd_DrStephenTChenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139654439643256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Other Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest payable</a></td>
<td class="nump">$ 496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">173,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrentAndNoncurrent', window );">Accounts Payable</a></td>
<td class="nump">122,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of usee asset</a></td>
<td class="nump">55,728<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligations', window );">lease obligations</a></td>
<td class="nump">55,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Lease payment monthly</a></td>
<td class="nump">1,785<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_ConsultingFee', window );">Consulting fee</a></td>
<td class="nump">7,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_ConsultingFeePayable', window );">Consulting fee payable</a></td>
<td class="nump">6,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DevelopmentCosts', window );">Development expenses</a></td>
<td class="nump">117,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Account payable</a></td>
<td class="nump">$ 122,680<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_ConsultingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_ConsultingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_ConsultingFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_ConsultingFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal through the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121616839&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The capitalized costs incurred during the period (excluded from amortization) to obtain access to proved reserves and to provide facilities for extracting, treating, gathering and storing the oil and gas.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 932<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-10(c)(7)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398226&amp;loc=d3e511914-122862<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139654435910472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative)<br></strong></div></th>
<th class="th"><div>Nov. 01, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aimd_DescriptionOfConsultant', window );">Description of Consultant</a></td>
<td class="text">The Company agrees to pay Dr. Chen 50,000 New Taiwan Dollars (NTD) per month for a period of one year for his services. With over 30 years of pharmaceutical professional experience<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aimd_DescriptionOfConsultant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aimd_DescriptionOfConsultant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aimd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>41
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MUC&-(G2=*G-;U9H)+*-E"F4)NY6IN:UX=J8](%_$>YK43N0&F:9APV<NB]L
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M..F2R7@(?;)7G<!KU0D6B>F8^3Z173?2TQJW#J]!\<*2UCG;>+%+^VP_2J'
MNGN^!U->+?>\YME.CU,]GF^8?:/VRT"AB&U,J-L;F0*4^1Y4?J+%/MO&>19:
MBS@[W#$:,FD?,/<W0NC3B?T'Y4[@[']02P,$%     @ *EUO4\8N-.VO @
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M8FFVL[W9I[?5].N"0'K&0Z'\,$KLLAG"L"7G^QS-AS 6)[":2<<[<?)^-(V
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M++A-PI:):)0,E^1.B>Z@0F!^S6$KOK/A  8[=C9<,3"_YJ$^OK/A #T".QM
M9M43@&![9P/U!^QL\/YRIT1W44$O?S/THCL;#D*O:V?#%?3R-T,ONK/A *?"
M.QM :145A%Y@9P,(!W8V@')@9P,H@;O?[.)#0]VGSOY5U,_EKO$VXDDV\S]$
MLC+UZ8-<IS=MM3]^CNAKU;;5]OAR+8J5J#N!_/M35;6O;[J/)IT_3G?W/U!+
M P04    "  J76]3*?V35Y@%  !]%0  &    'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;*U8;6_;-A#^*X2Q#RV0Q!(EV5:1&&C<%@NP=D&];)]IB;:)2J1*
MT7'R[W>D%,D6*28=%B")7HYWSQWO[CGQ^BCDCWI/J4)/9<'KF\E>J>K#=%IG
M>UJ2^DI4E,.;K9 E47 K=].ZDI3D9E%93'$0S*8E87RRO#;/[N7R6AQ4P3B]
MEZ@^E"61S[>T$,>;23AY>?"=[?9*/Y@NKRNRHVNJ'JI["7?33DO.2LIK)CB2
M='LS^1A^6.%4+S 2?S-ZK$^ND79E(\0/?7.7WTP"C8@6-%-:!8%_CW1%BT)K
M AP_6Z63SJ9>>'K]HOV+<1Z<V9":KD3Q#\O5_F:RF*"<;LFA4-_%\7?:.I1H
M?9DH:O,7'1O9!(2S0ZU$V2X&!"7CS7_RU ;B9 'H<2_ [0(\7!"/+(C:!9%Q
MM$%FW/I$%%E>2W%$4DN#-GUA8F-6@S>,ZVU<*PEO&:Q3RY7@.6P*S=%:$45A
M@U2-Q!:M2+U'7V"3:_3N@9-#SA3-WZ-+]+#^A-[]]OYZJL"ZUC'-6DNWC24\
M8BE%7P57^QI]!HOY^?HIH.Z@XQ?HM]BK<$VK*Q0%%P@'.'3@6;U]>>"!$W61
MC(R^Z'^)I,=@W!F,C<%XQ. W*/),*S]HHXPCJ&U)%..[ICB88K1V[5.C=F[4
MZC)_7%XFLS1,( J/I_%SR.$X3F?S3NX,=]+A3OR!TIBW)B!;*4I _DAK+^PS
M,[/.S,P;GCNC5F^#CDT%6P(;X@I'HR8Y<7,8"%OB,ERDH3L,\P[?W(OO_B"S
M/30@G2-;]@1;2.J:NB'.;0!QF"S" 4Y;+'!C7'08%WZ,4F24YNU&Y:RN1$T*
MC;B2.MO4\P6J"@(A)CQ'].>!53K@+A<6%K9H-H!OBXS 3SOXZ2LID &U08B9
MH9P#S\FFH-#EP0WFCG3JV.IYF@R0VE(C2,.@[\/!VZJYJ8R7FGZ].-K>&SA2
M)(KB82J[Y,9S.3RAD?"7BGK+..'9FXLZQ+TA[(W3Q_P1%-/63+TGDNY%D5/I
MC I^M;8=(E$2!&/[V;-!&/U"Z522/4('TL62&6J &MI2"?&Y0)PZ"Z;5[\5N
MBVCH8]A[8@G]S'*.G3Y1F;&F49EX ]'H$<R=A[$%:1;/$SQ$;HN-H>YI)4S\
MJ,ES1[J%*?N"D0TKQFLFL6MAM@B'Q>X0&\/:<U/H)Z?S"&<"JEPJIIL3%SI-
MR+/I5)>2%I V.3R 7NOTP>:F$$<X3*V(^VCNW(N>P4(_A5D3R.M5WZ*VF2K$
M:0"_0]2VX,)3G3VOA7YB^PS5E^DB1,#!? ?M!-#3I^8&P10U@MNFJ'D0#WG,
M(34&N&>RT$]E)M0-.D!J@JXIUUQHWGTDQ=A\$]IL-9O/9Y$5:P?W13C!<^P&
MCWMNPWYN6XW!142A#=TQSG7.Z+$">J+(75Y@F[@PQO&P6!UB<9 &)\Z>^] 3
M' [_NP\4GOO1AX[$F:71<()SR"VB^=C$C7O6Q-A+S^M#516&>&!\Z[Y(T!UO
M#@*@F_L^R'K2PW[2N^.*2IA7H%\Q=QQLQDJC632,@BT5+TZ&L'-T/:WAV!N$
M;X)?&M__DH37)'.0V+GFGGJPGWK62F0_$*OK _1!""FT/T@0F#'U285.C/&O
M#VRS"PZ:GV%4WLQ#N.<A[.<A"W@FR@J^8DU*7* CD?)ENF]('YJD?D^=KM@4
M$\60Y(NA(V^F(MQ3$?93D;T#9W-B,T8+Z=X"WW=3"]E!6,'XJ(5[(L)^(OK^
MYP/Z0P\KOL\_;!/*#-JR539OYAW<\P[V\X[!AL2F8#M'FVCAI=9!@1.>+3:$
M-STYR"JIW)GSO1J2\L!5<S#4/>W.$#^:D[/!\]OPPZHY">S5- >37XD$OJEA
M0MR"RN!J#N&2S5E?<Z-$98[+-D(I49K+/27P@:$%X/U6P(36WF@#W8GK\E]0
M2P,$%     @ *EUO4S)/@]?6 0  ; 0  !@   !X;"]W;W)K<VAE971S+W-H
M965T-RYX;6REE-MNG# 0AE_%\G6%6=BT301((6W57D1=997VV@L#6/&!VJ:D
M??KZP-*-U(V4] 8\]OR?_S%CBEGI!S, 6/0HN#0E'JP=KP@QS0""FD2-(-U*
MI[2@UH6Z)V;40-L@$IQD:?J6",HDKHHPM]-5H2;+F82=1F82@NI?-7 UEWB#
MCQ-WK!^LGR!5,=(>]F#OQYUV$5DI+1,@#5,2:>A*?+VYJK<^/R1\8S";DS'R
ME1R4>O#!E[;$J3<$'!KK"=2]?L(-<.Y!SL:/A8G7+;WP='RD?PJUNUH.U,"-
MXM]9:X<2O\>HA8Y.W-ZI^3,L]5QX7J.X"4\TQ]SL$J-F,E:)1>P<"";CFSXN
MYW BR-,S@FP19,%WW"BX_$ MK0JM9J1]MJ/Y02@UJ)TY)OU'V5OM5IG3V>JK
M[JEDOVD\(MFB>C(NQ9B"6(?W2:194'5$96=0E^A623L8]%&VT#[5$V=K]98=
MO=79L\ ]C G*TS<H2[/-,[Q\K34/O/S_:GW"WJ[L;6!OS[ W"7K14;Z>EOS+
M+3GI  &Z#WUN4*,F:6,SK+/K5;J.'?0W/=[#6ZI[)@WBT#EIFKR[P$C'WHZ!
M56/HIX.RKCO#<'"_ ] ^P:UW2MECX#=8?S#5'U!+ P04    "  J76]3SX(1
M>$H%  "1"P  &    'AL+W=O<FMS:&5E=',O<VAE970X+GAM;)56VW+;. S]
M%8P[TVEG?(N3WM(D,[ELMWEHFXF[Z3,M019;BM22E!WOU^\!)2MVTW1G'Q*+
M(G%T !P /%D[_R.4S)'N*V/#Z:",L3Z>3$)6<J7"V-5LL5,X7ZF(I5].0NU9
MY<FH,I/9=/IZ4BEM!V<GZ=V-/SMQ333:\HVGT%25\IL+-FY].C@8;%_<ZF49
MY<7D[*162YYS_*N^\5A->I1<5VR#=I8\%Z>#\X/CBR,YGP[<:5Z'G6<23Q;.
M_9#%=7XZF HA-IQ%05#X6?$E&R- H/%WASGH/RF&N\];] _)=_BR4($OG?FF
M\UB>#MX.*.="-2;>NO5'[OQY)7B9,R']IW5[]N!P0%D3HJLZ8S"HM&U_U7T7
MAQV#M],G#&:=P2SQ;C^46%ZIJ,Y.O%N3E]- DX?D:K(&.6TE*?/HL:MA%\_^
M9,M>F9-)!)B\FF2=X45K.'O"\!U]<C:6@?ZP.>?[]A.0Z)G,MDPN9K\%G',]
MIL/ID&;3V<%O\ Y[SPX3WN'_\6P/Z:A'.DI(1T\@S<;TFS#]I^W7DNG25;6R
M&]*!V"ZA]IRTA7I6J(I:VR4MM#-NJ;- *#2*,(FHL0CY1W(%E4VE(&&;XT]7
MRE"N T.,84Q?&@^A>"\G"P?)R$<\8]MG)2E4$(SB4Y =#MCD.E-2*&&(16::
M7&C-OS]_-CMZ_7X)^.?/WLX.WKP/%#8V]Z[B(4#QNW#9)DJ7T&J8*#I\R^\B
M4A,$3-O(OF"/8GQQ_>'S2U*F+A5 0 ^<50Y]ZX S;704U=[57G-$MR!TCU'N
MP-0Z.]+V.ZI:+0Q+N*HQ7>-XGNM4Z-&1DY@X#X\Y*ZU$=C.D-9/"*^D2P@;'
M^+Y.?!]'T&)7(3@K]D$7&H1*5B:6F2 LQ!T.@6KG8^&,=D+7^1Q>PVZ9M!+!
M%#W)(\6V80H2^PKI^L;DUI9J'+ QH-IC29E!FD(;"+:9: 7H%<?2Y9*J!FZ+
M*K;I2V&>./&QJEUHW<8Y-"E$+^4 N6T*M+S&BZ\*'T+CD]^<@UY::J(V.FZV
M0-J"IL! 3P5%'%Y!$R$T\+RC.D1L$*@M<0F$9X-5+DZ+O/H4.2\*92/AVPBQ
MA\PGS3#OP<!9E^F$E,*Q)U-$02T0XTRDFF(<6I450.]A?F+2%5;">!P-H-8.
ME$:N&*6$1@Y1-KRJ=9Y6]$-'D5_>9+%+3%L4P-9J:1T,NEJ]_')W?34Z>$<O
MYN>W<U3ZW8S.$4O(@&X3X%< OAQ2;;FI7*J2E5IJBQAI6VRGDQ6)P4VW $\D
ML=X8YS6]^#CN'E]2NZ-W[9*>4",8J-H@U'6KO#;&O4X;JV,X3I&Y*15F6<;(
M?Z;,D#ZQ5*FA*U[IC$/B<9-$*].RW08(7>F5ED'<-9Q]F'Y7RCA5$%*!U580
MPZ0(\-LK<>/^02_$-S,,$EP?4E&"HE7(DSA950V^'#8X7[7C6\6DU:V81FT#
M@:K5CF@D*0HAELZ1U/>+'M?7X4]-1B^\:B7K5E+-I?; V*"7!GD9,BV!*:!&
M"52&;I_\SS%ZQ6&A_ZA5J[HV?2<$R'Z9/'C31G8_(7N1S=-6)_.=V:'0$[$
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M0RB"25LT605;PUB(FE1P%J50,2$+QA'M@=6$*P;[F/M1U3>ZU!@\B3(J3GG
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M>ZX+U/H1\OG%6AFD0HZ^4OO4LA"6?TK7@!#4,IQDJX*Q'-0YZ$JU!(1\TO!
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M418^62W-ME;5,XYF^T>SM.O2V'6[HQ&6/<K/?I?^^"GE(PJDE@'%C4Y 87%
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MH-&-/9BU>V=@?("[/VJ-5\?/?GJY^1]02P,$%     @ *EUO4S[_'L8="@
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M65D%Q@/02<44O2=+62&K@_'5%,;4+DN0TL%EJBF,6U962.9@:C6%<6#U!#A
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M7&#9R0%F6Q[30$?KS6:1&'?9-EOPF!:Z\7J;M@(!S+8\IB_/1F\6+1W\L!G
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M/US Q>&#7Q=/STWWP?SJ<E,\E;=E\V7SN6[?S8]1'A:K<KU=5.NL+A\_7/P
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M;"]W;W)K<VAE971S+W-H965T,C0N>&ULE99M;]HP$,>_BA7M12M-3>*0!RI
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M2683SHZ(Z]U*30],J,9:.9>7^E16DJNWN;*3LR>@1$**EH3+$_K!22F(R9=
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    "  J76]3,(2_&=T"  !3$0  #P
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M&*GLP9]U_R5FGU!+ 0(4 Q0    ( "I=;U,'04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ *EUO4\DG
M/K_N    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ *EUO4YE<G",0!@  G"<  !,              ( !S $
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  J76]3#*\?)=8$   5
M%   &               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ *EUO4\8N-.VO @  D@D  !@              ("!&0T
M 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( "I=;U,W\MT=
MK@4  &(6   8              " @?X/  !X;"]W;W)K<VAE971S+W-H965T
M,RYX;6Q02P$"% ,4    "  J76]3AWOBR#,%   @%0  &
M@('B%0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ *EUO
M4]O%]HRS"   6C<  !@              ("!2QL  'AL+W=O<FMS:&5E=',O
M<VAE970U+GAM;%!+ 0(4 Q0    ( "I=;U,I_9-7F 4  'T5   8
M      " @30D  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M"  J76]3,D^#U]8!  !L!   &               @($"*@  >&PO=V]R:W-H
M965T<R]S:&5E=#<N>&UL4$L! A0#%     @ *EUO4\^"$7A*!0  D0L  !@
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M970Q,BYX;6Q02P$"% ,4    "  J76]3/F)I:AP(  "D$P  &0
M    @('/10  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (
M "I=;U-PKDU:] 4  #$.   9              " @2).  !X;"]W;W)K<VAE
M971S+W-H965T,30N>&UL4$L! A0#%     @ *EUO4R$T1#?!!@  W!(  !D
M             ("!350  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"
M% ,4    "  J76]3_(@([&4%  !F#   &0              @(%%6P  >&PO
M=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( "I=;U-E^"O/80,
M #D,   9              " @>%@  !X;"]W;W)K<VAE971S+W-H965T,3<N
M>&UL4$L! A0#%     @ *EUO4QV5(2OB 0  Q0,  !D              ("!
M>60  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  J76]3
M/O\>QAT*  !D3P  &0              @(&29@  >&PO=V]R:W-H965T<R]S
M:&5E=#$Y+GAM;%!+ 0(4 Q0    ( "I=;U,#W /K[PH  .Q2   9
M      " @>9P  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%
M  @ *EUO4^4BL(!N @  (@8  !D              ("!#'P  'AL+W=O<FMS
M:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    "  J76]3T9=_@C8#  "H#
M&0              @(&Q?@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+
M 0(4 Q0    ( "I=;U/O1ZL7]P(  $$*   9              " @1Z"  !X
M;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ *EUO4X0@W6GF
M @  L @  !D              ("!3(4  'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6Q02P$"% ,4    "  J76]3<]1T<CH"  " !   &0
M@(%IB   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( "I=
M;U/J7P',"P,  (T0   -              "  =J*  !X;"]S='EL97,N>&UL
M4$L! A0#%     @ *EUO4Y>*NQS     $P(   L              ( !$(X
M %]R96QS+RYR96QS4$L! A0#%     @ *EUO4S"$OQG= @  4Q$   \
M         ( !^8X  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( "I=;U-^
MV5 B/ $  +(/   :              "  0.2  !X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( "I=;U,KT'*.<@$  )\0   3
M      "  7>3  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     A "$ W@@
' !J5      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>127</ContextCount>
  <ElementCount>224</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>36</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="aimd_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimd.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="aimd_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000002 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimd.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="aimd_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>000003 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimd.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="aimd_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>000004 - Statement - Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimd.com/role/StatementsOfOperationsUnaudited</Role>
      <ShortName>Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="aimd_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>000005 - Statement - Statements of Stockholders' Equity (Deficit) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimd.com/role/StatementsOfStockholdersEquityDeficitUnaudited</Role>
      <ShortName>Statements of Stockholders' Equity (Deficit) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="aimd_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>000006 - Statement - Condensed Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="aimd_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>000007 - Disclosure - Organization and Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimd.com/role/OrganizationAndBusiness</Role>
      <ShortName>Organization and Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="aimd_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>000008 - Disclosure - General</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimd.com/role/General</Role>
      <ShortName>General</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="aimd_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>000009 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimd.com/role/BasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="aimd_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>000010 - Disclosure - Financial Condition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimd.com/role/FinancialCondition</Role>
      <ShortName>Financial Condition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="aimd_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>000011 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimd.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="aimd_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>000012 - Disclosure - Convertible Notes Payable and Other Related Party Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://aimd.com/role/ConvertibleNotesPayableAndOtherRelatedPartyNotesPayable</Role>
      <ShortName>Convertible Notes Payable and Other Related Party Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="aimd_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>000013 - Disclosure - Other Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimd.com/role/OtherRelatedPartyTransactions</Role>
      <ShortName>Other Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="aimd_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>000014 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimd.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="aimd_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>000015 - Disclosure - Convertible Notes Payable and Other Related Party Notes Payable (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://aimd.com/role/ConvertibleNotesPayableAndOtherRelatedPartyNotesPayableTables</Role>
      <ShortName>Convertible Notes Payable and Other Related Party Notes Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aimd.com/role/ConvertibleNotesPayableAndOtherRelatedPartyNotesPayable</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="aimd_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>000016 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimd.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="aimd_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>000017 - Disclosure - Financial Condition (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimd.com/role/FinancialConditionDetailsNarrative</Role>
      <ShortName>Financial Condition (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aimd.com/role/FinancialCondition</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="aimd_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>000018 - Disclosure - Common Stock (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimd.com/role/CommonStockDetailsNarrative</Role>
      <ShortName>Common Stock (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aimd.com/role/CommonStock</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="aimd_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>000019 - Disclosure - Convertible Notes Payable and Oayable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails</Role>
      <ShortName>Convertible Notes Payable and Oayable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aimd.com/role/ConvertibleNotesPayableAndOtherRelatedPartyNotesPayableTables</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="aimd_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>000020 - Disclosure - Convertible Notes Payable and Oayable (Details 1)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1</Role>
      <ShortName>Convertible Notes Payable and Oayable (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aimd.com/role/ConvertibleNotesPayableAndOtherRelatedPartyNotesPayableTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="aimd_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>000021 - Disclosure - Convertible Notes Payable and Oayable (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://aimd.com/role/ConvertibleNotesPayableAndOayableDetailsNarrative</Role>
      <ShortName>Convertible Notes Payable and Oayable (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aimd.com/role/ConvertibleNotesPayableAndOtherRelatedPartyNotesPayableTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="aimd_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>000022 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimd.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aimd.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="aimd_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>000023 - Disclosure - Related Party Transactions (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimd.com/role/RelatedPartyTransactionsDetails1</Role>
      <ShortName>Related Party Transactions (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aimd.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="aimd_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>000024 - Disclosure - Related Party Transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>Related Party Transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aimd.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="aimd_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>000025 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aimd.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aimd.com/role/SubsequentEvents</ParentRole>
      <Position>25</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="aimd_10q.htm">aimd_10q.htm</File>
    <File>aimd-20210930.xsd</File>
    <File>aimd-20210930_cal.xml</File>
    <File>aimd-20210930_def.xml</File>
    <File>aimd-20210930_lab.xml</File>
    <File>aimd-20210930_pre.xml</File>
    <File>aimd_ex311a.htm</File>
    <File>aimd_ex32.htm</File>
    <File>aimd_ex321.htm</File>
    <File>aimd_ex991.htm</File>
    <File>aimd_ex992.htm</File>
    <File>aimd_ex993.htm</File>
    <File>aimd_ex994.htm</File>
    <File>aimd_ex995.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>47
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "aimd_10q.htm": {
   "axisCustom": 0,
   "axisStandard": 7,
   "contextCount": 127,
   "dts": {
    "calculationLink": {
     "local": [
      "aimd-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "aimd-20210930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "aimd_10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "aimd-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "aimd-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "aimd-20210930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 231,
   "entityCount": 1,
   "hidden": {
    "http://aimd.com/20210930": 8,
    "http://fasb.org/us-gaap/2020-01-31": 14,
    "http://xbrl.sec.gov/dei/2020-01-31": 7,
    "total": 29
   },
   "keyCustom": 44,
   "keyStandard": 180,
   "memberCustom": 31,
   "memberStandard": 5,
   "nsprefix": "aimd",
   "nsuri": "http://aimd.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "strong",
       "span",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000001 - Document - Cover",
     "role": "http://aimd.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "strong",
       "span",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "aimd:FinancialConditionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000010 - Disclosure - Financial Condition",
     "role": "http://aimd.com/role/FinancialCondition",
     "shortName": "Financial Condition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "aimd:FinancialConditionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000011 - Disclosure - Common Stock",
     "role": "http://aimd.com/role/CommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000012 - Disclosure - Convertible Notes Payable and Other Related Party Notes Payable",
     "role": "http://aimd.com/role/ConvertibleNotesPayableAndOtherRelatedPartyNotesPayable",
     "shortName": "Convertible Notes Payable and Other Related Party Notes Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000013 - Disclosure - Other Related Party Transactions",
     "role": "http://aimd.com/role/OtherRelatedPartyTransactions",
     "shortName": "Other Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000014 - Disclosure - Subsequent Events",
     "role": "http://aimd.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000015 - Disclosure - Convertible Notes Payable and Other Related Party Notes Payable (Tables)",
     "role": "http://aimd.com/role/ConvertibleNotesPayableAndOtherRelatedPartyNotesPayableTables",
     "shortName": "Convertible Notes Payable and Other Related Party Notes Payable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000016 - Disclosure - Related Party Transactions (Tables)",
     "role": "http://aimd.com/role/RelatedPartyTransactionsTables",
     "shortName": "Related Party Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000017 - Disclosure - Financial Condition (Details Narrative)",
     "role": "http://aimd.com/role/FinancialConditionDetailsNarrative",
     "shortName": "Financial Condition (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "AsOf2020-12-31_aimd_SecuritiesPurchaseAgreementsMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "aimd:SharesIncreaseValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000018 - Disclosure - Common Stock (Details Narrative)",
     "role": "http://aimd.com/role/CommonStockDetailsNarrative",
     "shortName": "Common Stock (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "aimd:SharesIncreaseValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "From2021-01-01to2021-09-30_aimd_DrStephenTChenMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentPeriodicPaymentPrincipal",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000019 - Disclosure - Convertible Notes Payable and Oayable (Details)",
     "role": "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails",
     "shortName": "Convertible Notes Payable and Oayable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "From2021-01-01to2021-09-30_aimd_DrStephenTChenMember_aimd_TwoOneSixMember",
      "decimals": null,
      "lang": "en-US",
      "name": "aimd:DueDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000002 - Statement - Balance Sheets (Parenthetical)",
     "role": "http://aimd.com/role/BalanceSheetsParenthetical",
     "shortName": "Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestPaid",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000020 - Disclosure - Convertible Notes Payable and Oayable (Details 1)",
     "role": "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1",
     "shortName": "Convertible Notes Payable and Oayable (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "AsOf2021-09-30_aimd_DrStephenTChenMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000021 - Disclosure - Convertible Notes Payable and Oayable (Details Narrative)",
     "role": "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetailsNarrative",
     "shortName": "Convertible Notes Payable and Oayable (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "aimd:ScheduleOfFinancialSupportListtabletextblock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "From2021-01-01to2021-09-30_aimd_RelatedPartyMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromRelatedPartyDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000022 - Disclosure - Related Party Transactions (Details)",
     "role": "http://aimd.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "aimd:ScheduleOfFinancialSupportListtabletextblock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "From2021-01-01to2021-09-30_aimd_RelatedPartyMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromRelatedPartyDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "aimd:Shares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000023 - Disclosure - Related Party Transactions (Details 1)",
     "role": "http://aimd.com/role/RelatedPartyTransactionsDetails1",
     "shortName": "Related Party Transactions (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "aimd:Shares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestPayableCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000024 - Disclosure - Related Party Transactions (Details Narrative)",
     "role": "http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative",
     "shortName": "Related Party Transactions (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestPayableCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "From2021-10-23to2021-11-01_us-gaap_SubsequentEventMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "aimd:DescriptionOfConsultant",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000025 - Disclosure - Subsequent Events (Details Narrative)",
     "role": "http://aimd.com/role/SubsequentEventsDetailsNarrative",
     "shortName": "Subsequent Events (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "From2021-10-23to2021-11-01_us-gaap_SubsequentEventMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "aimd:DescriptionOfConsultant",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000003 - Statement - Balance Sheets",
     "role": "http://aimd.com/role/BalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "AsOf2021-09-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000004 - Statement - Statements of Operations (Unaudited)",
     "role": "http://aimd.com/role/StatementsOfOperationsUnaudited",
     "shortName": "Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "From2021-07-01to2021-09-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000005 - Statement - Statements of Stockholders' Equity (Deficit) (Unaudited)",
     "role": "http://aimd.com/role/StatementsOfStockholdersEquityDeficitUnaudited",
     "shortName": "Statements of Stockholders' Equity (Deficit) (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "000006 - Statement - Condensed Statements of Cash Flows (Unaudited)",
     "role": "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited",
     "shortName": "Condensed Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000007 - Disclosure - Organization and Business",
     "role": "http://aimd.com/role/OrganizationAndBusiness",
     "shortName": "Organization and Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000008 - Disclosure - General",
     "role": "http://aimd.com/role/General",
     "shortName": "General",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "000009 - Disclosure - Basis of Presentation",
     "role": "http://aimd.com/role/BasisOfPresentation",
     "shortName": "Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "aimd_10q.htm",
      "contextRef": "From2021-01-01to2021-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 36,
   "tag": {
    "aimd_AdvancesFromShareholder": {
     "auth_ref": [],
     "calculation": {
      "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.",
        "label": "Advances from shareholder"
       }
      }
     },
     "localname": "AdvancesFromShareholder",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aimd_AinosKYMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ainos KY [Member]",
        "verboseLabel": "Ainos KY [Member]"
       }
      }
     },
     "localname": "AinosKYMember",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails",
      "http://aimd.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "aimd_AnnualInterestRateFollowingMaturity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual interest rate, Following maturity"
       }
      }
     },
     "localname": "AnnualInterestRateFollowingMaturity",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "aimd_BernardCohenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bernard Cohen [Member]"
       }
      }
     },
     "localname": "BernardCohenMember",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/RelatedPartyTransactionsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "aimd_ConsultingFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting fee"
       }
      }
     },
     "localname": "ConsultingFee",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aimd_ConsultingFeePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting fee payable"
       }
      }
     },
     "localname": "ConsultingFeePayable",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aimd_ConvertibleAndOtherNotesPayableRelatedParties": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible and other notes payable- related parties"
       }
      }
     },
     "localname": "ConvertibleAndOtherNotesPayableRelatedParties",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aimd_Date": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Date"
       }
      }
     },
     "localname": "Date",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "aimd_DescriptionOfConsultant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Consultant"
       }
      }
     },
     "localname": "DescriptionOfConsultant",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "aimd_DrStephenTChenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr. Stephen T. Chen [Member]",
        "verboseLabel": "Dr. Stephen T. Chen [Member]"
       }
      }
     },
     "localname": "DrStephenTChenMember",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails",
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1",
      "http://aimd.com/role/RelatedPartyTransactionsDetails",
      "http://aimd.com/role/RelatedPartyTransactionsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "aimd_DueDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due Date"
       }
      }
     },
     "localname": "DueDate",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "aimd_EffectiveDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Date"
       }
      }
     },
     "localname": "EffectiveDate",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "aimd_EightATwozeroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "8a.20 [Member]"
       }
      }
     },
     "localname": "EightATwozeroMember",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails",
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "aimd_EightBTwoZeroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "8b.20 [Member]"
       }
      }
     },
     "localname": "EightBTwoZeroMember",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails",
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "aimd_EighteenTwoOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "18.21 [Member]"
       }
      }
     },
     "localname": "EighteenTwoOneMember",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "aimd_ElevenOneTwoOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "[11.21 [Member]]",
        "verboseLabel": "11.21 [Member]"
       }
      }
     },
     "localname": "ElevenOneTwoOneMember",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails",
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "aimd_ElevenTwoOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "11.21 [Member]"
       }
      }
     },
     "localname": "ElevenTwoOneMember",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails",
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "aimd_FifteenTwoOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "15.21 [Member]"
       }
      }
     },
     "localname": "FifteenTwoOneMember",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "aimd_FinancialConditionTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure on the Financial Condition of the company.",
        "label": "4. Financial Condition"
       }
      }
     },
     "localname": "FinancialConditionTextBlock",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/FinancialCondition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "aimd_FiveOneNineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "5.19 [Member]"
       }
      }
     },
     "localname": "FiveOneNineMember",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails",
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "aimd_FourOneNineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "4.19 [Member]"
       }
      }
     },
     "localname": "FourOneNineMember",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails",
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "aimd_FourteenTwoOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "14.21 [Member]"
       }
      }
     },
     "localname": "FourteenTwoOneMember",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "aimd_I2ChinaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "I2China [member]"
       }
      }
     },
     "localname": "I2ChinaMember",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "aimd_ITwoChinaManagementGroupLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "i2China Management Group LLC [Member]"
       }
      }
     },
     "localname": "ITwoChinaManagementGroupLLCMember",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails",
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "aimd_IncreaseInRefundableDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[Increase in refundable deposits]",
        "negatedLabel": "Increase in refundable deposits"
       }
      }
     },
     "localname": "IncreaseInRefundableDeposits",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aimd_InterestAfterMaturity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest after Maturity"
       }
      }
     },
     "localname": "InterestAfterMaturity",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aimd_InterestAmount10": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest amount 10%"
       }
      }
     },
     "localname": "InterestAmount10",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aimd_InterestAmountOriginalRate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest amount original rate"
       }
      }
     },
     "localname": "InterestAmountOriginalRate",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aimd_InterestRateAfterMaturity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest rate after maturity"
       }
      }
     },
     "localname": "InterestRateAfterMaturity",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "aimd_InterestWaived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest waived"
       }
      }
     },
     "localname": "InterestWaived",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aimd_InvestmentInPatents": {
     "auth_ref": [],
     "calculation": {
      "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment in patents"
       }
      }
     },
     "localname": "InvestmentInPatents",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aimd_IssuanceOfStockForCashAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of stock for cash, amount"
       }
      }
     },
     "localname": "IssuanceOfStockForCashAmount",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/StatementsOfStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aimd_IssuanceOfStockForCashShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of stock for cash, shares"
       }
      }
     },
     "localname": "IssuanceOfStockForCashShares",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/StatementsOfStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "aimd_IssuanceOfStockForCompensationAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of stock for compensation, amount"
       }
      }
     },
     "localname": "IssuanceOfStockForCompensationAmount",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/StatementsOfStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aimd_IssuanceOfStockForCompensationShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of stock for compensation, shares"
       }
      }
     },
     "localname": "IssuanceOfStockForCompensationShares",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/StatementsOfStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "aimd_IssuanceOfStockForOptionAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of stock for Option, amount"
       }
      }
     },
     "localname": "IssuanceOfStockForOptionAmount",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/StatementsOfStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aimd_IssuanceOfStockForOptionShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of stock for Option, shares"
       }
      }
     },
     "localname": "IssuanceOfStockForOptionShares",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/StatementsOfStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "aimd_IssuanceOfStockForPatentAssetsAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of stock for Patent assets, amount"
       }
      }
     },
     "localname": "IssuanceOfStockForPatentAssetsAmount",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/StatementsOfStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aimd_IssuanceOfStockForPatentAssetsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of stock for Patent assets, shares"
       }
      }
     },
     "localname": "IssuanceOfStockForPatentAssetsShares",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/StatementsOfStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "aimd_LeaseObligationNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://aimd.com/role/BalanceSheets": {
       "order": 16.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Obligation-Non current"
       }
      }
     },
     "localname": "LeaseObligationNonCurrent",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aimd_LessIncomeTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Less: Income tax"
       }
      }
     },
     "localname": "LessIncomeTax",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/StatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aimd_NineTwoZeroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "9.20 [Member]"
       }
      }
     },
     "localname": "NineTwoZeroMember",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails",
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "aimd_NinteenTwoOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "19.21 [Member]"
       }
      }
     },
     "localname": "NinteenTwoOneMember",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "aimd_OneOneSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "1.16 [Member]"
       }
      }
     },
     "localname": "OneOneSixMember",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails",
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "aimd_OptionExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Option expense"
       }
      }
     },
     "localname": "OptionExpense",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/StatementsOfStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aimd_OtherLosses": {
     "auth_ref": [],
     "calculation": {
      "http://aimd.com/role/StatementsOfOperationsUnaudited": {
       "order": 8.0,
       "parentTag": "aimd_TotalNonOperatingIncomeAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Losses"
       }
      }
     },
     "localname": "OtherLosses",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/StatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aimd_PaidInExcessOfPar": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Paid in Excess of Par"
       }
      }
     },
     "localname": "PaidInExcessOfPar",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/RelatedPartyTransactionsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aimd_ParValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Par Value"
       }
      }
     },
     "localname": "ParValue",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/RelatedPartyTransactionsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aimd_PaymentsOfLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[Payments of lease liabilities]",
        "negatedLabel": "Payments of lease liabilities"
       }
      }
     },
     "localname": "PaymentsOfLeaseLiabilities",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aimd_RelatedPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyMember",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "aimd_RouLeasedAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ROU Leased assets"
       }
      }
     },
     "localname": "RouLeasedAssets",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aimd_ScheduleOfFinancialSupportListtabletextblock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "schedule of financial support list"
       }
      }
     },
     "localname": "ScheduleOfFinancialSupportListtabletextblock",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/RelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "aimd_SecuritiesPurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Purchase Agreements [Member]"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementsMember",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/FinancialConditionDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "aimd_SevenTwoZeroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "7.20 [Member]"
       }
      }
     },
     "localname": "SevenTwoZeroMember",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails",
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "aimd_SeventeenTwoOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "17.21 [Member]"
       }
      }
     },
     "localname": "SeventeenTwoOneMember",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "aimd_Shares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares"
       }
      }
     },
     "localname": "Shares",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/RelatedPartyTransactionsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aimd_SharesIncreaseValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares increase value"
       }
      }
     },
     "localname": "SharesIncreaseValue",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/CommonStockDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aimd_SixTwoZeroMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "6.20 [Member]"
       }
      }
     },
     "localname": "SixTwoZeroMember",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails",
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "aimd_SixteenTwoOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "16.21 [Member]"
       }
      }
     },
     "localname": "SixteenTwoOneMember",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "aimd_StockIssuedForAcquisitionOfPatents": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued for acquisition of patents"
       }
      }
     },
     "localname": "StockIssuedForAcquisitionOfPatents",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aimd_StockIssuedForAdvancesFromInvestors": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued for advances from investors in noncash financing activities.",
        "label": "Stock issued for advances from investors"
       }
      }
     },
     "localname": "StockIssuedForAdvancesFromInvestors",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aimd_StockIssuedForCompensationWarrantAndOptionExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued for compensation, warrant and option expense"
       }
      }
     },
     "localname": "StockIssuedForCompensationWarrantAndOptionExpense",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aimd_TenTwoOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "10.21 [Member]"
       }
      }
     },
     "localname": "TenTwoOneMember",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails",
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "aimd_ThirteenTwoOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "13.21 [Member]"
       }
      }
     },
     "localname": "ThirteenTwoOneMember",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "aimd_ThreeOneNineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "3.19 [Member]"
       }
      }
     },
     "localname": "ThreeOneNineMember",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails",
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "aimd_TotalAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Total amount"
       }
      }
     },
     "localname": "TotalAmount",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/RelatedPartyTransactionsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aimd_TotalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total [Member]",
        "verboseLabel": "Total [Member]"
       }
      }
     },
     "localname": "TotalMember",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails",
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "aimd_TotalNonOperatingIncomeAndExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://aimd.com/role/StatementsOfOperationsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[Total Non-operating income and expenses]",
        "totalLabel": "Total Non-operating income and expenses"
       }
      }
     },
     "localname": "TotalNonOperatingIncomeAndExpenses",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/StatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aimd_TranslationAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "[Translation adjustment]",
        "verboseLabel": "Translation adjustment"
       }
      }
     },
     "localname": "TranslationAdjustment",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/StatementsOfStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aimd_TranslationAdjustmentLiability": {
     "auth_ref": [],
     "calculation": {
      "http://aimd.com/role/BalanceSheets": {
       "order": 18.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Translation adjustment"
       }
      }
     },
     "localname": "TranslationAdjustmentLiability",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "aimd_TranslationAdjustmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Translation Adjustment"
       }
      }
     },
     "localname": "TranslationAdjustmentMember",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/StatementsOfStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "aimd_TwelveTwoOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "12.21 [Member]"
       }
      }
     },
     "localname": "TwelveTwoOneMember",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "aimd_TwentyTwoOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "20.21 [Member]"
       }
      }
     },
     "localname": "TwentyTwoOneMember",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "aimd_TwoOneSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "2.16 [Member]"
       }
      }
     },
     "localname": "TwoOneSixMember",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails",
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "aimd_WarrantExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant expense"
       }
      }
     },
     "localname": "WarrantExpense",
     "nsuri": "http://aimd.com/20210930",
     "presentation": [
      "http://aimd.com/role/StatementsOfStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aimd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aimd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aimd.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aimd.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aimd.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aimd.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aimd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aimd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aimd.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line 1"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aimd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line 2"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aimd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aimd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aimd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aimd.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aimd.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aimd.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aimd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aimd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aimd.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aimd.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aimd.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aimd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aimd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aimd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aimd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aimd.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://aimd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r130",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://aimd.com/role/FinancialConditionDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r130"
     ],
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://aimd.com/role/FinancialConditionDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r115",
      "r117",
      "r118",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r194",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails",
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r115",
      "r117",
      "r118",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r194",
      "r195"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails",
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r101",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails",
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1",
      "http://aimd.com/role/RelatedPartyTransactionsDetails",
      "http://aimd.com/role/RelatedPartyTransactionsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails",
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1",
      "http://aimd.com/role/RelatedPartyTransactionsDetails",
      "http://aimd.com/role/RelatedPartyTransactionsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://aimd.com/role/BalanceSheets": {
       "order": 15.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableTradeCurrentAndNoncurrent": {
     "auth_ref": [
      "r181",
      "r191"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Accounts Payable"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r13",
      "r102",
      "r103"
     ],
     "calculation": {
      "http://aimd.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r27"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued interest"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r14",
      "r123"
     ],
     "calculation": {
      "http://aimd.com/role/BalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r61",
      "r62",
      "r63",
      "r120",
      "r121",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/StatementsOfStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r57",
      "r82",
      "r86",
      "r92",
      "r105",
      "r127",
      "r129",
      "r132",
      "r178",
      "r185"
     ],
     "calculation": {
      "http://aimd.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "[Assets]",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r33",
      "r57",
      "r105",
      "r127",
      "r129",
      "r132"
     ],
     "calculation": {
      "http://aimd.com/role/BalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "[Assets, Current]",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BasisOfAccounting": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "3. Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccounting",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalLeaseObligations": {
     "auth_ref": [
      "r10",
      "r142",
      "r187"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal through the balance sheet date.",
        "label": "lease obligations"
       }
      }
     },
     "localname": "CapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r9",
      "r141",
      "r142"
     ],
     "calculation": {
      "http://aimd.com/role/BalanceSheets": {
       "order": 11.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of capital lease obligation due within one year or the normal operating cycle, if longer.",
        "label": "Lease Obligation-Current"
       }
      }
     },
     "localname": "CapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r21",
      "r52"
     ],
     "calculation": {
      "http://aimd.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BalanceSheets",
      "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.",
        "label": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r21"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "[Cash Equivalents, at Carrying Value]",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/FinancialConditionDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r61",
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/StatementsOfStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r12",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://aimd.com/role/BalanceSheets": {
       "order": 21.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, $0.01 par value, 300 million shares authorized, 142,442,215 and 42,066,172 shares outstanding at September 30, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtCurrent": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Convertible Note"
       }
      }
     },
     "localname": "ConvertibleDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.",
        "label": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOtherRelatedPartyNotesPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Payable and Other Related Party Notes Payable (Tables)"
       }
      }
     },
     "localname": "ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConvertibleNotesPayable": {
     "auth_ref": [
      "r10",
      "r179",
      "r186",
      "r201"
     ],
     "calculation": {
      "http://aimd.com/role/BalanceSheets": {
       "order": 12.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible notes payable"
       }
      }
     },
     "localname": "ConvertibleNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r40",
      "r57",
      "r105",
      "r132"
     ],
     "calculation": {
      "http://aimd.com/role/StatementsOfOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of revenues"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/StatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "auth_ref": [
      "r54",
      "r55"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Total Convertible and other notes payable"
       }
      }
     },
     "localname": "DebtConversionOriginalDebtAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionOriginalDebtInterestRateOfDebt": {
     "auth_ref": [
      "r54",
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The rate of interest that was being paid on the original debt issue that is being converted in the noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Annual interest rate, From effective"
       }
      }
     },
     "localname": "DebtConversionOriginalDebtInterestRateOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Payable and Other Related Party Notes Payable"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "6. Convertible Notes Payable and Other Related Party Notes Payable"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOtherRelatedPartyNotesPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Interest rate original"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "auth_ref": [
      "r30"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments applied to principal.",
        "label": "Unpaid principal balance",
        "verboseLabel": "Unpaid principal balance"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails",
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositContractsLiabilities": {
     "auth_ref": [
      "r107",
      "r108"
     ],
     "calculation": {
      "http://aimd.com/role/BalanceSheets": {
       "order": 14.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of liabilities as of the balance sheet date pertaining to amounts received by the insurer or reinsurer from the insured (including a ceding company) under insurance or reinsurance contracts for which insurance risk is not transferred.",
        "label": "Contract liabilities"
       }
      }
     },
     "localname": "DepositContractsLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DevelopmentCosts": {
     "auth_ref": [
      "r164"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The capitalized costs incurred during the period (excluded from amortization) to obtain access to proved reserves and to provide facilities for extracting, treating, gathering and storing the oil and gas.",
        "label": "Development expenses"
       }
      }
     },
     "localname": "DevelopmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r24",
      "r58",
      "r147"
     ],
     "calculation": {
      "http://aimd.com/role/BalanceSheets": {
       "order": 13.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Convertible notes payable - related party"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Basic and diluted net loss per average share available to common shareholders"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/StatementsOfOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r133"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of changes in exchange rates"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r61",
      "r62",
      "r63",
      "r65",
      "r70",
      "r72",
      "r75",
      "r106",
      "r112",
      "r113",
      "r120",
      "r121",
      "r122",
      "r125",
      "r126",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r196",
      "r197",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/StatementsOfStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r143"
     ],
     "calculation": {
      "http://aimd.com/role/BalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Right of Use Asset"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedPatentsGross": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://aimd.com/role/BalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.",
        "label": "Patents, net"
       }
      }
     },
     "localname": "FiniteLivedPatentsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r39",
      "r57",
      "r82",
      "r85",
      "r88",
      "r91",
      "r94",
      "r105",
      "r132"
     ],
     "calculation": {
      "http://aimd.com/role/StatementsOfOperationsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "[Gross Profit]",
        "totalLabel": "Gross margin"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/StatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r37",
      "r82",
      "r85",
      "r88",
      "r91",
      "r94",
      "r177",
      "r182",
      "r184",
      "r193"
     ],
     "calculation": {
      "http://aimd.com/role/StatementsOfOperationsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "[Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest]",
        "totalLabel": "Profit before income tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/StatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements of Operations (Unaudited)"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Account payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.",
        "label": "Related Interest Expense"
       }
      }
     },
     "localname": "InterestExpenseRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaid": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.",
        "label": "Interest paid",
        "verboseLabel": "Interest amount total"
       }
      }
     },
     "localname": "InterestPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited",
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r181",
      "r191"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.",
        "label": "Interest payable"
       }
      }
     },
     "localname": "InterestPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://aimd.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r32"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "[Inventory, Net]",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r42",
      "r81"
     ],
     "calculation": {
      "http://aimd.com/role/StatementsOfOperationsUnaudited": {
       "order": 9.0,
       "parentTag": "aimd_TotalNonOperatingIncomeAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "[Investment Income, Interest]",
        "negatedLabel": "Interest Income, net"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/StatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Lease payment monthly"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r26",
      "r57",
      "r87",
      "r105",
      "r128",
      "r129",
      "r130",
      "r132"
     ],
     "calculation": {
      "http://aimd.com/role/BalanceSheets": {
       "order": 24.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "[Liabilities]",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r18",
      "r57",
      "r105",
      "r132",
      "r180",
      "r189"
     ],
     "calculation": {
      "http://aimd.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "[Liabilities and Equity]",
        "totalLabel": "Total liabilities and stockholders' equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r28",
      "r57",
      "r105",
      "r128",
      "r129",
      "r130",
      "r132"
     ],
     "calculation": {
      "http://aimd.com/role/BalanceSheets": {
       "order": 17.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "[Liabilities, Current]",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "[Net Cash Provided by (Used in) Financing Activities]",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "[Net Cash Provided by (Used in) Investing Activities]",
        "totalLabel": "Net cash flows used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r48",
      "r49",
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r34",
      "r35",
      "r38",
      "r51",
      "r57",
      "r64",
      "r66",
      "r67",
      "r68",
      "r69",
      "r71",
      "r72",
      "r73",
      "r82",
      "r85",
      "r88",
      "r91",
      "r94",
      "r105",
      "r132",
      "r183",
      "r192"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/StatementsOfOperationsUnaudited",
      "http://aimd.com/role/StatementsOfStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Cash Transactions"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://aimd.com/role/StatementsOfOperationsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "[Nonoperating Income (Expense)]",
        "totalLabel": "Total operating expense"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/StatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": {
     "auth_ref": [
      "r23",
      "r58",
      "r148"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Related parties"
       }
      }
     },
     "localname": "NotesPayableRelatedPartiesClassifiedCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/StatementsOfOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r82",
      "r85",
      "r88",
      "r91",
      "r94"
     ],
     "calculation": {
      "http://aimd.com/role/StatementsOfOperationsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "[Operating Income (Loss)]",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/StatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r143"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Right of usee asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "1. Organization and Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/OrganizationAndBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://aimd.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-operating income and expenses"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/StatementsOfOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireAssetsInvestingActivities": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate cash payments for a combination of transactions that are classified as investing activities in which assets, which may include securities, other types of investments, or productive assets, are purchased from third-party sellers. This element can be used by entities to aggregate payments for all asset purchases that are classified as investing activities.",
        "label": "[Payments to Acquire Assets, Investing Activities]",
        "negatedLabel": "Purchase of fixed assets"
       }
      }
     },
     "localname": "PaymentsToAcquireAssetsInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/StatementsOfStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://aimd.com/role/BalanceSheets": {
       "order": 22.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock, $0.01 par value, 10 million shares authorized, 0 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r19",
      "r20"
     ],
     "calculation": {
      "http://aimd.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expense and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from private placement offering, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.",
        "label": "Related party debt"
       }
      }
     },
     "localname": "ProceedsFromRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.",
        "label": "Proceeds from convertible note payable -related party"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from disposal of property, plant and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r46",
      "r119"
     ],
     "calculation": {
      "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from exercise of share options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "General"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r7",
      "r8",
      "r110",
      "r190"
     ],
     "calculation": {
      "http://aimd.com/role/BalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Condition"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r116",
      "r146",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/RelatedPartyTransactionsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r116",
      "r146",
      "r147",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party."
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r116",
      "r146",
      "r150",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/RelatedPartyTransactionsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r144",
      "r145",
      "r147",
      "r151",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "7. Other Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/OtherRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for short-term and long-term debt and lease obligation.",
        "label": "Lease obligation"
       }
      }
     },
     "localname": "RepaymentsOfDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r124",
      "r203"
     ],
     "calculation": {
      "http://aimd.com/role/StatementsOfOperationsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/StatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r15",
      "r113",
      "r123",
      "r188",
      "r199",
      "r200"
     ],
     "calculation": {
      "http://aimd.com/role/BalanceSheets": {
       "order": 19.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r61",
      "r62",
      "r63",
      "r65",
      "r70",
      "r72",
      "r106",
      "r120",
      "r121",
      "r122",
      "r125",
      "r126",
      "r196",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/StatementsOfStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r36",
      "r57",
      "r79",
      "r80",
      "r84",
      "r89",
      "r90",
      "r96",
      "r97",
      "r99",
      "r105",
      "r132",
      "r184"
     ],
     "calculation": {
      "http://aimd.com/role/StatementsOfOperationsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/FinancialConditionDetailsNarrative",
      "http://aimd.com/role/StatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of real estate properties and units in those properties that are included in the discussion of the nature of an entity's operations.",
        "label": "Schedule of list of related parties"
       }
      }
     },
     "localname": "ScheduleOfRealEstatePropertiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/RelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r76",
      "r77",
      "r78",
      "r82",
      "r83",
      "r88",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r98",
      "r99",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "2. General"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/General"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://aimd.com/role/StatementsOfOperationsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/StatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Price per share"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/RelatedPartyTransactionsDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "[Shares, Issued]",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/StatementsOfStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r31",
      "r61",
      "r62",
      "r63",
      "r65",
      "r70",
      "r72",
      "r75",
      "r106",
      "r112",
      "r113",
      "r120",
      "r121",
      "r122",
      "r125",
      "r126",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r196",
      "r197",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/StatementsOfStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails",
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1",
      "http://aimd.com/role/FinancialConditionDetailsNarrative",
      "http://aimd.com/role/RelatedPartyTransactionsDetails",
      "http://aimd.com/role/RelatedPartyTransactionsDetails1",
      "http://aimd.com/role/StatementsOfStockholdersEquityDeficitUnaudited",
      "http://aimd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Statements of Cash Flows (Unaudited)"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheets"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements of Stockholders' Equity (Deficit) (Unaudited)"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r61",
      "r62",
      "r63",
      "r75",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails",
      "http://aimd.com/role/ConvertibleNotesPayableAndOayableDetails1",
      "http://aimd.com/role/FinancialConditionDetailsNarrative",
      "http://aimd.com/role/RelatedPartyTransactionsDetails",
      "http://aimd.com/role/RelatedPartyTransactionsDetails1",
      "http://aimd.com/role/StatementsOfStockholdersEquityDeficitUnaudited",
      "http://aimd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r12",
      "r16",
      "r17",
      "r57",
      "r104",
      "r105",
      "r132"
     ],
     "calculation": {
      "http://aimd.com/role/BalanceSheets": {
       "order": 23.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "[Stockholders' Equity Attributable to Parent]",
        "periodEndLabel": "Balance, amount",
        "periodStartLabel": "Balance, amount",
        "totalLabel": "Total stockholders' equity (deficit)",
        "verboseLabel": "Total stockholders' equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BalanceSheets",
      "http://aimd.com/role/FinancialConditionDetailsNarrative",
      "http://aimd.com/role/StatementsOfStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r56",
      "r113",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "5. Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/CommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r140",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r140",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r140",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r153",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "8. Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/CondensedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted average common shares outstanding - basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://aimd.com/role/StatementsOfOperationsUnaudited"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=99383045&loc=d3e9351-108337"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=99397363&loc=d3e9420-108338"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121569800&loc=d3e45023-112735"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121616839&loc=d3e45280-112737"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=120398226&loc=d3e511914-122862"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r204": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r205": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r206": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r207": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>48
<FILENAME>0001654954-21-012154-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001654954-21-012154-xbrl.zip
M4$L#!!0    ( "I=;U-'1GX'U@L  -9U   1    86EM9"TR,#(Q,#DS,"YX
M<V3M7>MSVS82_WXS_1]P^G+)S$FR[":-/78Z?G8\=>R,[;;I?>E )"3A2@$*
M -I6__HNP#<)/B0E1V:.F8PC8A_8W1^P7," <OSCR])#3T1(RMG)8#+:&R#"
M'.Y2-C\9^'*(I4/I $F%F8L]SLC)8$WDX,?WW_WC^)_#X:>S^QMTP1U_29A"
MYX)@15ST3-4":=('+!41PV'(_6O0SQ':'QV,]M[%[6=8@A1G1@:(DYAR ?H0
MGR%':S:BD\EX\F:\O[>?,#WPF7K&@B LG 55Q%&^P!YRB:1SAL!P%#ATA"[H
MBC!78/3S"#U RR+6<<Y7:T'G"X5>.:^15H^NA[>7C^C,EY01*=$#]WQM@OPW
MNF;.")UZ'KK7$A+=$TG$$W%'@3KI+,@2(X@LDT<OWLE@H=3J:#Q^?GX>O4R%
M-^)B#A[L'8P_W5#VYR#D%&16ROIV#-2(T?&% )#6,;?AE,09S?G3.*+J&.T-
M]R;#@TDD"'C.,5X-L5*Q[ S+J>DE)(Z!*.C45X!R*":I8^\*")9>R(NSL/-K
MBD6 LB<BE5TDH('0Y" KQ,A<C[72B!V.!??(.&2+I3!UI+TG0](=_5 (FEJO
MB+1&S% L+DFU$B4Q XKNY5U&(./&\T'DQ&3\Z</-@QE.@W@\P9"QL4\.#P_'
MAAJQ%CBS@T^3IS#S8LU I17\E.DLX&3XW1QL(?.;<4#,L%(KZ]N E<:#F_M,
MB;*Q'1!M0UN)BJ$ U!@9H<KPC$D6_2ZA=I. 8&%G_M)NCJO$6/<Q!@XBJ!,+
M<-9 AK-A3@[393('],/(X4N3'O<.#R"9Q[/YBHOE!9EAWP/(?/;9QQZ=43TS
MB$=T]LXPI,@*BSE1MWA)Y H[I*(SR'T('6/&N#+)VCSKEM6*LAD/'Z%!C[PC
M/3T?P2ND/_QR?UU4;";P.8>WTP!1\#+X&*N)%+ED1ADU'>[I/Q,T3%Y)0V2D
MCL=YUKP6'UY!=^R]^;P2D-!9X(3.T*%TR%(EZ6#/\;TM!!/+RN7"UBAPV\7S
M#'MZ$C\L"%'R([PUF5H01<'P(,@5]-K([T.X'R!L) Q]J L%RM"KC+K7/296
M3"PPU$?^H#+R?:2C2,<QDG>SNQ41QE;Y"\.^2TV9H&-?QU2+QO<Y-!*%NI9-
M5*)7L=)^-E@Q>E#<^7/!/1=6#I>??:K6\(JB#E45D#60J47P326"Z1[^A8(^
MT*NPE]<]JO;W.',) \5IJ,ZQ7%QY_#D_ YLRU^+X-H=CK#B'J-:-C/(>/1MZ
M=V*.&?W+F'C*W&A1'*!51JQ%YP==J5'I>%SZL'P?HK0FLW"/=/5(1$C\1!B\
M/L)B+7JHC?2[?*1#R3ZN20TF*229CRD7HTJL2*B-]V$^WD:+SC1I/7WTH^A?
M40;U*L6>3M T";ZEO2[VD[U\[&,E*-;21SYY+R^7G)F*)GKW)@VUL9[D8QU(
M!Q52'^14\?-$A*)3C]QR16!=O<;P&5Z6=[ <%O?$TYN4L#Q6ZS0]+H:V$JX%
M;[\(7MP3,JI0J,N\BTUO*.P.F?ZR7#W><;F4!^918":Q8U9]8=%4R5*+W4&A
M=+*@DU;9@Q.O+_VI))]]<._R2=?_X0HRWUH+P?=Y"!(5*-#1QWS'!/BH?\B=
MTF"HHA;--U\X&:)70<_](C(>!&79+HUR#4\MC&_S,)9GQ!ZA!F7X!5&8>O(6
M"[UG^43*RO("7RU2A<6_I4S7FVI&+XH5]VC92G<[3%4,M?@4M@S2I7T/S)9O
MN^!3&+S:%UN6NQ:RPJY#S3LL>E.%'?0(;HS@9#,()[48[A=V+S;#$$UZ%#=&
ML9 V-Q6K1=6R3[(1JGV6;5Y.9I)K'5,M<H5-DJJ"LD^D&X(T:812@[19V ]I
M %.?*YL#E4N1C;EK@2OLHC0!KD^']=M:=N!JN6H!*VR4%+:]_D]QTC_T>=I[
M,D/F'.Z1/K1Y,I!TN=)[^4';PASSUM -HX.3?X"[HY>E%[%H_17G< W:^0B%
M'4<JL' *6@KGA$$)7^DBA,AQ9/P C;^86QZ>;NH6B!"OJ_[ V-K4G]QP[*)7
M,/ W]2H[5[Z\4\?C])%A>,H>*3X&G[A0B!7.)%<=6@]N9=QPQRBJ$-%/PTAN
MJ)N&D_WAP63T(MW(QDU,2/S;S(1(;F,3["?Q&W8>">A>WVS07]41?5O7LDHP
M>A@F6K8QQ783IIDM:<GX:3=K\A<%&AD2">D/&W??X!)!DT&1EKP-!/7@.-1#
M<O)V)U.V,V-+&ZJO(C6"(Y8RGW8#Q%Q,"9/E> 8E[I"\K#S,L.)B?07/S<+B
M"9'1<IDHV0TERQVJIO:DI;Z<$1L$))+8;8P4;X0U&B2)6/!QF&C8PHC\';M&
M)D1"^L/&HS1S'TI'4M8:$/6?%@WGB:=DHF@W6XIWL[:TQ2C:+9L7KO$UPR62
M,I^&B?R&T?#EML!$MSR3@$2ZML?&>@]R>VNV0Z< ]XYC9)=HQ#[M'@QS7[?$
MEO#BGEG7ZYK^CQL"Y>+=U*-ST\\M9^>F=(',J0T^&50Q4,_3>\XG R5\O6#0
MMT&/IL$]HI.!(XA+5=0,I3OE[J-98025,I""!4? L.20?;%87RNRU&P0 G\J
M%57F"O5/@ONKB)4"2[E+9O\G6$"=NO_UI=+D&XJGU*-J'?E5R]5-Y\PADALN
MI3[]$'B2;=K6;-<7X0GFKP,*K,8\&#SA328VOV8.7^I?D$#UH:]7Q.XTXNRH
MES=$RL#<1_R2S*!L8T=MOY;2UR:$MZ&NN#CG2QWP8(XL]?(J<JDA[[?C*9:+
MAP46R2BLX;%Z5N^"-/)?R8%:B-(\'87F-[W[RU0XTR-?"JT=M?YNI05RQN<;
M.VJ[]7U8^;+LKB_5Z:EVHMMXNS;A/\)"F:E3>.DK6>>0E;?+#M5E,BOO-S,6
M@X10!UJ.JVMP!>;5 97CZBI$Y@N#=-LU"X96@HN55.V'2Z8MN:&_\DJ2:W9/
M9CYS@V-'*RYIVI]*GHX"=.H^:0ODE>!+,R."B_214^7D;@+U$:_#^^EF<1TM
M.FF2#BHY.@J2F?,Z!1 79OZI\]FGTOS"[VZ6FU2-.+\)+].E0EBDZB-_MC)P
M&\%N#M\<?*G)%V1++LJ0+F'M*-3WW#>SSPT*C<BG8G-'[2_>N'@D+^K,,]=V
M U^J63:N.8)O)#M2D8[=AYJS(*[O04416_K@K_1VZ@V52FGK=&?3M$\;RG3
MR:!&"]_,OV+/3Y*&E=3-G<D+G^BOWHQ,3QZW+5V5T)M_NYIU.9L11Y\G2QN7
M;VS7Q%,84-B[9HH V.H>ZV_>\SS^#+H_8.6+U*YU,];-QS0,:* [NL[=U9O4
M,?7HHF7Z2'SJ&&BJX-E4J*,I-S,!NC"THI$2+,'N!)U#3O3N4V96<G0TS%F;
M)WMV7TQ[USV8P;_Y25Y&[+@OOV%(J&[>B;BUX];K$5^)AHVA=G+G7KE?,L]F
M-Y"J-XKJUPQ?MS: Q)VI:U+/';67NM>P$(/%BOX>)RP2PXN$3GI@?HN:W9[+
M-G72:B@#I._I7_I>$9*J#3*-W5P59ZR,OXS'XD%"ZV@=3Z0CZ"K8CPDMQ\DH
M*B>W4NF$V8\X.B5#;?C1%\X"UDJG<T&"[VK\0);3Z.N@@\39@'GK9:'+EYBR
MW;RY$ ^*K!:$/9[#CX+]=G*K%M\Q G\?Z$O!V *E53M/*>/RY]\+5N;:6[7Q
M\9EX3^3QF4/<"H;:B*U:>\5] ;;<4HNQ%EJKML(HA,C]APA>S D%4KN6DB>8
MWF6V6HBM6JL!+C/60FMW=IG06:=6GM*JG9=>B++-5!NQW:@NJ%"D/+16<NMY
MJ\)B.[E=B^FLRF ;M>UL6V&OE=JJO==@R_F",OP!,SPW%"-Z<W->L+X!;P>R
MQQTK*R-*Z.WF$+T\+::.=&NK]J6_OZ!@IHW8[FC>#\9G8>1FVUNU\8P(AH5[
MSFVK'!NQW?%I.P-9'*]57.W7E%49V4YO-X_I_RROW&0[N>U:N,)@*[7MU293
MZ_+59H'8<@WT1$I7FT5:^V/W%(+WEVU=9*6V;^]9V3K.2FUYY/*2/:<"I>6U
MD2"E@]9&_%]:>SP.[AF^_QM02P,$%     @ *EUO4V; %$.N"@  PFX  !4
M  !A:6UD+3(P,C$P.3,P7V-A;"YX;6S57=MRXS82?=^J_0>L\K S5:NK9R9C
MUS@I^3(IU3JV2O:D\C8%DY"$#04H "A;^?IMD)1$\090$DTF#QY;ZFZ>QFDT
M@ :(?/GY=>&A%1&2<G;9ZG=Z+428PUW*9I<M7[:Q="AM(:DP<[''&;ELK8EL
M_?S3/__QY5_M]N]7DSMTPQU_09A"UX)@15ST0M4<Z:]^Q5(1T6Y'TK^%S[E
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M1H8WB_&=O.((V%;J+N_;=G#&#>\-XXM6[._;2EUG/-O'UUO$_22"5:T33.4
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M2$!V2=$3\H858EP26M3"@$H#+.Z &#N/[@ZW*^A5]VL[-!!!VHU^^SL/!ET
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MXAA.G#OL"EQ\01+JG6N']HCNP0')T=-9/%[8BJ<9[!8I$ [/D;8:F#(+2;$
MX21:C&PM78J';@KSM??-O'78TK@;;D.5 Q@Q=EG?V00;?]Q5R('CG$Y2.WJ#
M_"6!GA<>N;G_Q"G5Q?H7\]!E9:8#X1[BD5OUJZYA12Y&*$M4E4.8)M)SQC1Y
M)Q1,XY7HT*%5/$(N,WL.A&O&--8*@+09AU0;XLJ+]+R@FK%KSRNQ?+]E#!<N
MSP\?"/<@JEF-,S)G9<A\UM5P1B\1< 6QVN)UWMEX/'/N5@X!:D8FIF]YPF(_
M.F2JZFHX9I'Q]-069Q4YT'02.B]7,P3H,!;IYB*?=I!74S0/;$4!V;;FYTQ9
M8U .\>#D E_WE-%\LHIMA8_,'KX&Z%%WE-_\N";93/B2YM]T5ZBH59P<SI1"
MEYS)Y.39N,5+;,'[D"1BC)3/6,XB$A(FYPG:9S%),X"VX]NYRZ^H(N"NB_PI
MB5#T\>47C/YB7Q;M+*R2)WJAI#R*:]R U=HA [O5BYT;:K,#N<%TL?#A ,RA
MN$7A=K([";:$RDG6NEX!-DUXS%Y6=[738<VD>DA#SMELT$T#5BM:8?&[Y6)A
M[?*  ]AMC)^;K G#8SHITX)=R:ZA-R.YS+MJ51)FD0&Q8RX2L^5'R2'NG2=>
MAF7T+2>SV=RYQZ1#QQ?^;HHUXQEOPU2<F.G7\(5:#G?Y68C-V@*Q\). Z*+7
MW%R[MF46Z]71\_O,J[8?"I\[VHFQ/<"2>KUQ\DQJNM"&?%BVA@_PP0_)ZDEB
MF[QU.<&\ C*WN;IK@Y39JEL!9W6<N&D([%ORX@ D7H-#A"):8O,6IN@JQI]@
M&[%ZN<:]JT@59=R3C6 #_Z 6;!Z&']RQ[AEY8_7Z7LYU:*VXL9+)AP(7U"FF
M#3&3*DK*35Z2^]EBL*D;? \VI$E6*7O7J/W$GHLL+!!>'RZR&Q1OLXC4NOF$
M,-I$:.K(A=DR%$SB\.A3DGX5'8B6MX&8)K& BD871+7RD:QA_4"8]LZB??R6
M[%FZ-Y8-$(J*'JO8XN;<E+F7^#H?>7?9[2*RM<6HOT'S0/#2\ ]SCG=!H+?W
MCVT'@5[]W/P,^KP!D?]8\1W%W9V8NC2NLVL%!"_@NU\8@__DKT$MZ?N7)(-9
M^ :!3&5#SCEMT$T#;BM:83D[BV@9^W!/]6OQZP*9\:ZA8P<RSZ(GLJ'*O(9]
M;6B1A2$5M62P:: VMII$COGOTP"Y+RQAA)"O;L.4&$%:=;Q]F/S:SN<^T>6Z
M2)ZPFX/]SQ 9!A)4RFYB"/KNR,('<DUFO,U&(R^N13P$LSIHL&&Z)$S E$$>
MQZC \YDWEW%VPB4D"X5E4Y6?GU$1)J6T5H>!GJ-8EZH3T@B72(FYB[/E>NU#
MO8^!<-7$1+423:2CER3DK#7[T:M=U/@JOB0>^&4"@R3EG &-*(ODC>)H<O33
M)(:1*U.LW#CM@NAX9%(:DDCWJD<Q??0#8-8O:P;0VS'&_>6-)@#E&RTBCGCA
M!+8GJQNT:3IY@VC1N&M85"^?4&!B":G5W:PQ)EV2+34J73:%Q^-H[D,.UF&H
MU0L/?M!/J*@2$EW-<F(:P1<::CTI6*OX ]RL3_%6@3/[.E>^OD1K$E@K8'YH
MO%4+7IMN]_8.O.THU:N?F)]1J3>@\-B'Q(5#, ^-M3:-^19K_8R]R;"ZBC\_
MAP^X0^@&SZ!7&:WEDT7D#[+5_01305[>84U8O/[N@*YU[L(;H,^*98W&^"%[
MP.C#D?=YS5HB5B)KJ20S,JJ;!05NUXNY6-RU:WIN9K<Q^PFQ/R7/;%@3%DO<
M']"U3O7[ ?HL;!HLX<QE1877(Q?:%(RRF+[4NB )-_0O:-^TFQLOA+T\PTM2
M4;S@!>.O,-T.&-B>(@LUPF"TM+778U@ ]0#TPIT>T3@"2.Z&OT\R4FN<9EM1
M3/]3AW<* VCMRAFCLX@'8!\TN A_;C"L%D\N;C>;E(;G8;H[)7>1Q7GQR H+
M:0XQFFI;/,\XK$.=HXUFJBQM83D=K7P(C1\$FKN-J]7(_I0C:+7C U<OL@KA
MQU>1BSTD3Z,K8H]U(FAM:K6_9X?VIN,0^7!*5HZ,SRIEDF"#17W@PU<\+IBK
M^\RB+&J\57I[H2[)QES?8A1C:*<Z00Q3998_'*U#Y(.]?"!LSEC.LQ,Z>=%*
M=R3FIMS4>\6V$=V#9.4BON0%/>]1TFN'KF+%24 3+4O;2.8=:+:3]"JL?DD0
MC:;.R]H-!<M?3TD*K"2T 5IG!>Z;H :<[ESAFY&K78ZO+D:,7P]MR> #&G%"
MO0'=DS#1H(6ZUA<:N2_:^4KL6IYVZRY^JZM7$W<D-ZQV_';38BO#C4WM>6$R
M+XK5W$R,JB[(9D:13GU7U#2R5O?(=&K4H]7/C9VLQ&37RE$H=I-O:;) Q Y7
MBCK(B5BBC@1:0Y/>]RSP%RY7H?-)28F,NQ+OZA? I#TZBMW>HB?;\C2&0Z]]
MI%"O@C2YIW.B;"MH2 ,V+V <VJWNI8RFVFR1&4\G3B]V>2WN/E.I-,@;<1^(
M>E7<PRSY)\5SCGN0ITG$ C59=(T?) G!,#NU]H!@NJ]!I?%GWZAM>_1^TX?1
M9OZ;-,R*>HY6\[D//O(1NL3=A]'Z"6HR?MR62894]S7\05Z<3TD9IGFY+= =
M>JX^8IB_'^,Q"W_F#_(Z*1[1F[U9@M]@B2G18K3PX>SB<7O7?]_&I\#K5TY:
M.T*S#AGH64U=->M$+V=5K<0R 4>K(/8AAC\0;I^'/Z$,%7Y<D'Z+[@EN; 'F
M!8D$FT_<1IH6MR'-.]+9@M2KL9V\Q2+T8L8<#+A/OLDI\(A_'V&98*_C+ Q)
M:6'<'TFW!7+VN"4%V682)\3V3M;+R<AE",H07I\ETU- -4CLO;T0^\"9_]C"
MHD)%^M+8!*U]\_W[H%DT![=BCV\'=K#-QH%-,+\>+29>G(U]%?@^DYLV *DR
MG;R>Q)) :?,[S<_(5E"]N*4 J@'D)IBJD&7I6<M@/G,>:S=&V6?)[!2\.5'>
M*.V>5NC73&9](8NI\T)XG>3XC@0;AG&TC+Q(?U=@XXO4/SYBIY'NQOA #/X:
MAZ]YA088\.;Z-F]'&-@I]0T<$F7FGHV#< 8](.&!L/O\G)\"WRA*-A.,#3*9
ML#WRJ>&VF2:69/-'/%V&+BL3#L$HN(BC.3%+2%B"Z_K(+(F5754/J #UB5Q
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MEI%#K4FM!@JL]QY\P<\9H!A/357R]$H:R\R*7>NR.:@G8,N8$,':VQ'M;UE
M)9@N Y?7L.EP]0>\$?5JAKK(RJK8DO,6UZA(\B@)K]DE]]=%DH7)!JK>!!-E
MN[.2>7?Z\Y%>DVW&S<+EV(<JI(=@[E/REVP#DPAL=M(@@/C[\#CS#IOPVM/D
MESQ-\V])=O\SK$@%K1?1&V:D9NOLIGD7]B<Z]3ILD.+9'#EWB0:C-5S6=HV
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M<GYWA/]#N?W@V0BKF_<QL6.'6E)O*+:GI55K=M=^08 D*-%+D;4D2RWMKS=
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MN ,S(X4!"\Y'U@FN7$-X)#@PWV;I&F7%ZRT^1A5X1B"[HS79(>,UEC5)TKF
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MH,3J'88F07+5'18G%@7)IKS$<T*<EB'RVQZS5B8&&U M18&2W&4/:X&R8/$
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MH/8-%'TCO?V$_,_#F_/_^%]02P,$%     @ *EUO4_5S7:,D#0$ ,\P-  P
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M.76X/.CP]6+7#&>(EPCNG#I@6- F$+,UIA6068(,*T(3F-E>I"= LP(:_5U
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MC>BN'F\9);%SZ^E,XFMTL3[6+IE</;$>7D'0.O#JCH+:X)-"X&8 )KX2=SL
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MDH7Y*!GE'."7O$=#HIL5!!1+0CG[YN2*FOP@?+Q[&+: <(\6YE6U*JFMNKB
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M5D6);C>SS:IL;P<F3$JY*>< R>B6,=L@&;^OEX!GN2GG ,_HOB_;X!FC09?
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M!+,P:0(%6TU:VIW0A3T32#X.DK/LGRY0+5!]%%37,VFZ+N LX'P<.&?4LUT
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MY2\ <S, (G;QZ]Q7:+HS,?#L$NFFH9ODC!GX!ZJUM+S,5][[N?*^S)47P2O
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MM9/%1(IZ_)BHF5K.8/O[+X=$\.95CD.BU/;;-O(D\XBHL7[\C-.(*+7]N>T
M% %1&5-%]6;V]CNG/8Z:U&JVBQ<81:?J]@B,>.?_$9-%C7,:L>4;%T7G /?0
MJQ?]O?=F_8?85IRPB.9+E..'1:W4UNE;7S\<%=&WOEA];5GA)BIJI98HVL02
MD2::\SJUJ'PK_$1,5*8D43MST.2T;Z,TI$;QMLWJ[>AEXQZA$._\/V**J)E[
M*-204]LV>J%=1XL7#+7S8L!:."2KW":)VJFEY#<S)?LLT0Z7S4U U$YO.;(=
M@B(D*F6:J)5:2C>>MF;HG:M2M1&_6ID; 42G>?<)CG@7P!$31>W\$T7MU#(E
M-/-7P. HM?V+[>^_$AO5+I0:O[%1:DGYC3S)O!196>]$R6EHE%JQ['8 BLBH
MC)%1(WZGY%1T-4._W&Q+-7D]P\MY9-104JNV/K( E&I-DB/TFHN\D2*?JSOW
M4M).'*46&O18Q/L8K[+(3YT<.3!JR*DMN;:]_5I8Q&^I=4-.[WQ6-$?$!MJ<
MU>E5M6\!GPB)2K1_UE!26[7$4,_LW'"]+<GJP6'0L3,9BI*_OU92,QIWAI^D
M2N"R]W%=:3,@M5S.#@:L>.TZSUX[?@OY_9DB'/><VZEMJ^V H/#=Z?KNZ)9W
MN;6ZVYWG2&T',9X:9[C.EB5YK_*8A"(Z<,F^COP$_]A@C_;\8C$1JZ2P@,X9
MF9*LM"6EO9XZ3QV<^4LCA0W,?*71DNN1UU"EL5/)O7)O_V6*RYZ0S5L,54_!
M\?H-2X,;%VG?482'0]W0V65S _]JW U1QJ$\3XW5V_E_S!6FFO\*4TUHTIGP
M__[;<DL5>E]XTJ6EVCSRTE)-N+9._N;+:TI%WN.=<UOEJ DSP8FX<7*+R<RZ
M= 6V5^P:KP(X:=>8O0&<8;!:WW,9E>8BZ7 O5LW?BU439L2BA#_2;9<D39'6
M+Q;[^T?R8]44@+_KW5<\F;+'6^?FR:H)4\8)^2%\F?!E6?NR:L+,X $0SK#Z
M:=^D(%^[?K4C>+.$53H1XJ>M"_;Q9NK1O5G"XK]]WGW-FR5_Z_R\6<(2@(3\
M$-Y,>+/,O=GAJ86X$,ZP2=V1O%G*:[-Z_MZL=OC:[%X?[N7,CGTO0.WP.&[7
MJZ_[LL0OG9LOJR6LI$C&#N'*A"O+VI75#L\MQ$1PAI[L2%G&E-=EC2-XLL/7
M92\@J\2>K'$AMX_MR0Z/X7:]^HHG4_=XZ?P\V>&[IEO8(3R9\&29>[+#\PHQ
M$9SEFJP<B[)F_JZL?OBBC'6]V,>9J<<^5% _?%FV^^77W%GRU\[-G=4/7YAM
M98AP:,*A9>W0ZH<OS6)C.,M*^F8I5F>M([BTPU=G=Y1#B3U:<X^F@&F_^^'+
MLYWO'G9H*M^M$!M)[Z=/R _ASX0_R]R?';Y BPOA#$]^UTJQ0&OG[\V27HT9
M(?X'?8_EV?$OQ6PT#B]HW/7J*Z>]JSR?]FX<'MAN88=P9<*59>W*&H?G6V(B
M.,.%63G*&=4C-!UK'+XPZ[V!#&=)/=G1ZS\:AQ<S[GCS-4?&<?E'X_"(=C,W
MA!\[!3_&^Y'\1BJG*&- G,=--=',HU!8;:9PR,0"K3T&2-LM)1^09B45.=0E
M(=^>%XOW:V?X?IX+=O6^01 V-62Y(V(CTW)AF F>8?A]!=G$8(TC)AB>)$[Q
MS?^&.]D/5"D6Z(48VC&U1\K.!\K-)X^9SQXKGSQ.[GUDBRI52;OE-*/3*!N[
MY? FFY1[YQ3+E^;6.R=D7A=#*7(*L:[?/$=7;T:P(D'?L8E?"76&Z!>8P01]
M^W8C(8S&B]\#6IVIX6+3/:2CSI$[Y*2;B:^?*^V<U_!)K_/N0NC.1+R0,!,P
MR'>Y#/P'V7PU_%I"0VESD9I/>@=S*LP(YSCD_=B06XYCP^7CF3'HY-(>&SG?
M2EC#E@HT"]NRU7=#.>1X?"]&TSQ#0GC?JE!SMO8Y;5XTTMB[R%\8T<9T8\A>
M$F$<<7NHA?._S+B5<+L_II19\4L'GOU?H6[O:R2]%S0E=JQ?=,QOD-5*F&4_
MG$4BS)KS/N%F;DKP%(%6R0*M5L)4:;HZG)UWK[4*&6JU$F9'2R..(R:S6OW\
M@ZVDM]8GD?/7V%<E/Q/7MC#[!1K"#! _T5<VZ[]=_"E4])5-BFL+BT3T-5??
MX\!31%\EB[[:V21+8^IPAA>,I'+>)']Q1 ?#J41?7(OCQ*YS;&>4N&#7?SV:
M">_@X"#<:F>43=C)D")=TMS.*".XC4DBY)IO0AP+HB+H2CWHBJY1^R"S_SBJ
M56LG//*7ML9G6%V^;WN+/45WA,(X;@IL"U]/6T]Z<BRF'ARM;%UI[=M[DWM)
M12<F#EW!'$]2Z2:."U*US]B-,C0M50"L9DUAA&,CMBEGDP(Y<OT^M3!IUN_S
M)+!LDB1'%5B[7HU3U'_A]BUM1O^FI*_75ZKP,V6-#BL&[_MI2^>/J>/JPQG(
MYZ\?E(9\Y1U?8M,)*/4M6R-V!1 R@(#\4F91/(OGU\B\Z9H[@H_DGT"DQ# F
M6-/@.Y1!,*CWKI&FU2_,-[ #W!Q-^B-[=XQWM@7>?0-,=<B-HM[=OWN5[L/M
MW4//8T+46I&NI6+07$CAXP0 6.G;!/]9P4,8Y!)AXPW/G(^Q'(H_&AE??\%H
M9%/T?.A9 [#7C/_6D)IL%V;G?+G ,!!]<#-XLH8&>Z,50#(MIK_XG?0'5)-3
MF<;\3ZV^<4X=PZ , O5%&'24F0&8$+NN>-G-@4)5PK^; $'=<2Q[YOL^;!-0
M7X<,8&VML:]H4^"^"0H.,]/.$:7EC. Q!\$7I_#0= (?#^;Y$S8$7<V#UKK^
M&,ZT_P<9@(Y8Z'D*9)5:C9&>&J_L<!Q$$>!]Z?Q_/7\Y1R^4O$YM#NK M^#5
MP-Q7T2?ZP%\_M%15OEI^A/U2N?I\%:9$KVDF[V0\H;QPD&7#3P-CZK"?%A3A
MZ^>H!_^X\:]V'N,93(Y %, ^]_BBF^AM9%$@VO3?]#0?PBZC0:6'WG1W9$U=
M-"$F-MS9.0-(3N(/03(GBI1=:]"A0 &VW]H@0.\.=M0[1_0:=H:!X,B]CX_%
MJ4C_^R5GV:8S41(]%(4^^;#VGPKPS!@7Q=!/KO5*6,@:T@EV^LH)OBNA$?Y!
M4!\B6X1?;0+<!NF\85J/0&%+A\:@S"PF@: 73 +639IF@L?HJ*#2FDYU!\)E
M,.?C@(R7LT-!T@[1K!VU$"QA1S0)_6I.L X"'\/JP'4H-W^BPP-%"!HD1*]0
MI^L&9AOH4,;,-^]SL\2"$/]%J+K9Y!7;FD-GI@=D!V"$7F$,:G'@=:8>4>P1
MA5#%3R.".GMY1!J]L!?V+*5N4R,U\78,? 0NF0'*'\H&CZL>"^$7H/3TMY:?
M)8:Y^\SUWF4Q/YNRY4T'@KZ38-K1)^@'0$/S9K,^;^8YYW/V9@3Q&N,6%8(S
M-_1]ZP=9LN^>%KX!=?B^1D ?;?K^-,9'_ZA2/KV0B<N"0*1([/?>^ P3VF+F
MWES@UP[Z2ZTNM9KUU'3S *?:;S4;RN!L5T 6,?[F&,W+LU8,,G0O\=2U@E\P
MG?!^<U@8=WCZ-\2:U)+78DPQYO**F!F1 39\S0&GX5KCJPQ6P(N]* @0+?/U
MVG<67R[\GS>\<5;D Y9$4(^=CM_ O.441.9OLN2/2\W.>J[L]+PAQPP]GNYZ
MDYMSBD,>'9/Z?MF:V/IPI%?+G.B#]8$[40II;2)Z6TYG4U9QL<6LD%=AY'5+
MG(&MLPRFD%H:LP_T(-@[1VL?=7B/]PK$[5QT)"C8%"+;9_8LX9BSQ(+23B&Q
M_6<?H-[[R19A6)%,EB+_)*2US^R]XBW!.V'I3T%B&X+7(.&6LRS_Q;8)$R6Z
M=C0?];\0;+']E"E3/RCG2B,* #[Y9>JI[[!$OV2Z1\V:U81G[VYMO["@1ZL*
MPA6#CR9M'_:BOT>=*V.'RI2+JGRARO\_>V_:U3:6M@O_%:U^3G63]<IN;.;4
M<WHM J1"50*<0%5.GR_/DJUM6Q59<FN N'[]>T][D&R# 9O!^$-W$;"E/=SS
M<-UXIK-[RE[Q&<O)K,AN;IM"\0R[VET*K]]97KM]SYZC>_/'$Q7NM[;]S?;N
M[070*W.K=[8O[FW5FD</\_/>DJ[2;56\+*@Z6F6XPJ"O[M&IN-G<NZLW=/7N
MKSK-9W4V>*?8V;HGHLG#U+(F30Y@ZO@ $NJ#)YOZN^WM-R)E[K[$>T("+>(2
M6YL/O;K)KB[OC=[;]CW1P!ZL*/357011N.:X1=S</;O7'LEQ&!ZQH /K^WO\
M_=T3_O)Q]\?AB:7(RP7@)RX\FM&N13->9L7IK$#%]CWA7F:3!L,\W!:HV/IG
M:__.0,7+/+XI,8B7N=!;P@M+7O"3";-[(KC?FV*?)G30WFW[.W>@,[R.&[L[
M++"]]YBPP+VN:6%A@=T[P@*O[&[J WQ?P^+O%@4+\P1O4UZ+=^</_.WMO17@
M_#LO:&=A+M_\%[0T5WU5[F1ASMP=@GD1;OC;X92%N6AS<<HB7.RW<S<+2U;-
M<S<OQ7V>#H"[</=Y:V+(YDMTJV:YSSN+<Y\'F;IM+"5YT ?_;*$#?;!Q?%GW
MH=^]_$-\-4YT'L1!-EY%2;8XWWDFN3X1M.>!OW707@'M<[?WO+/_*._YGA>U
M( ?Z;LSEE;F>QP4W;A?[[FW4C+8%@C&_AHNX6[8M+A@PWYTL+AZPUYI,5:VB
MZ[F[N'# ?:[HX1&!;7]K>Q5"M'??S.*" G?JF\6DYS=W;D_OKLK%+"XN,"?+
M+"(TT/)W6OMOXGH6%QJ8[WH>%QW8\G>V;JM6?8GY]>U7'2#875B X&-:9G?%
M!UIM$R X>;?.LJ^S[ \7; N+%,RDVZ?"UO?W]PY60!?=[8G6!UC<SQ.]YSTM
M+$ZP.PE(_@K=TSENYU%AG-NE_SI,,+]@6UB88+XK65R4H+TSF6U;Q2C!WL*B
M!/>YH8<'"5I^:VL5(M%W7\S"@@1WZII%Q A:_M;^*BC^N^]E83&".1EF$2&"
M[:W)NUE):;:P",%\E_.X ,'!SJLK(-AMMC=?OL<X*SZPM[#XP&7T8_9,=8T4
M@-&!]N;&\>4Z.K N'[B_+%M84& 6L3Y1[7UKU]]]([7W>X\*"MSOGM:U _>]
MG$?%!&Z5^.N0P/QB;6$A@;EN9($1 ;^U$J'-.V]H?V$A@7O<T",B KO^UN[M
M8S%7Y6(6%A*X2],L)"*P[^]LOXU[65A(8#Z&64S+?GOS=BBE5;F<A84$YKJ<
MQT4$6EO^UJNK&=A[U3&!_<7%!-0U_';NJ,"Z9F!=,_ 8N;:X\,!,NGVB  $(
MO=U5T$5WNZ#[CXL/W/.B%E<UL!*NZ1S7\[@(P>WR?QTCF%^V+2Y&,-^=/-8'
MW9M,2:]B>NU@<9&!^]S+(J(W+7]OYTTXHP>+"Q+<J6X64SBPWYX,0*_BQ2PN
M2C G\RPB3K"U\T9$V^+"!//=SB,#!?[VWFWB["76#AR\ZCC!P<+B!%A3<F>8
M@*,$WL;Y2"7K0,$Z4/ (R;:P0,%,PGVB.,'>@;^]N0JVPMV>Z,&C @7WO*B%
MP?BU)E72*W1/Y[B=1\4);I?_ZS#!_))M86&"^:YD<=[H_F0;S@H:U?N;"XL7
MW.>"'E%*T/;W=]]"I_O^YL*B!'?JFH4$"=K^P?8J:/Z[+V9A48(Y668108+V
M]B3^P$K*LX4%">:[G$?&"-K^[L%MF)$OL9B@M=ELMUZ^VS@C2K"_N3B(0@HB
MG=^&/\"E!*UU@\&ZP>!!TFQQ^(33:?5IP@([!_[F2F00[O0[]S<?AWYWGUM:
M=Q?<]VX>!QQYB[1?1P3F%VF+@R6<XT(6F)W>>QL&=&MQF(1SW\_#PP'@=.Z^
M!6"U_=;B  EOUS&+B 5L^:WM5:@6O/M6%H=&. ^S+"(0L+<2AMC=-[,X(,(Y
M;N9Q48"VO]V>C#:_[$J!5NM5!P%:"PL"G,123');'&!['0=8G3B ?N"'\Z_'
M)U\;'\ZOKLZ_ %^-?GAY&D?A<XPTW6\M+%(PFZ"?"*!PT]]<+2P"]+!?H2MW
MMT/=>I1#?8?D?*T^]<L4#POSNN>\M04ZWI/VZM+][A=YA^V%>>;WNL-'3 MH
M/\,$P9=Y=0OSWN_6SHMPX+>WUDPG-[<P#W]>IEO(*,+)*K\W>GT+"P/,>7V/
MG$>P?6LKQ\.K 99J>*X?_FK880%>XA-[@_YFZ\!O31%HJ^A0M1^8/5XGBA=[
M#0_T:]?^Z]($UP+\UV7[J?O^SC-@9+S(Z]I:@*NZ%)=TZ\#?W[XMU_*6+FD!
M3NE29MGM^]N;3S](_67>T0+<SR46E6_YN\\ V? R;VH!GN92/$I_[];)D ]/
M+K]6SVS]\/7#UP]?S,-?8G_*SFL>D+F_=<_*E-.KF_1H ,[+ER !?Q[]_5_@
MU$>?/Q]5AJ6 $KEK6N:!#,M\?14J49N.X.4O%&XV+^,"X2QZ2KV^V,G=9M ]
M(XR/)=\GBD+NKEI-RNP+G",$N9Q+6X<I[WM5<X0I%Z(>7FLH\SGDWST#E0N]
MGT7.UGR&#/(S7-?V/0.52[BNQPS:W-MY"^-.]K?O&:E<E'Y:1#2S[6^VWL(T
MU/WM>X8J%\M*"QFX,65XT$H*O7N&*A=Z4X\&U=QZ;:":^\%K1M7<W]Y;"K6<
MX,T<PF?_FF<6QSHDL0Y)/%C<+2<D<0L!/TU08GO_S00EMG<7YNG>^]K688G[
M7M;BPA)W*8EU8&)^*;B<P,2\-[2XT,3V_BK4@MYY7SO+B4S<[[X>46CE[[;?
M! 3$SG)B$W.HJ84T^OBMS3<10MI93G1B;G9:1'RBY;=N+>59G<M:3H!BWLMZ
M+)K'P<YM$"LOL61BO_.J0Q0[RZF9('KY,.^XT'6(8FD+S521I<A(U\H#ISE3
M0;Z*@8J=)08JII/QTP0J]K??3*!B9W'5$_>^MG6@XKZ7M>! Q2VJ8AVHF%\*
M+C%0,<<-+7*>Y<[;,-=WEQBJF/O&'AZJV/6W#MZ$#[R[Q%#%[8IJ$:&*/?"K
MWD3D;W>)H8IYV&DAG6'^WM:;P.7=76*H8H[+>ERH8L=O3T'7>MG5%*\$>+0Z
M^>.EK_;51 *>MECA13::[BXI2D#X1N<T\^B9D#^W]MY,G&!W@7&"^U_<.E)P
MW^M:8*3@MNMZU;&"ERDMEQ1-F/L6%QA/F **\391_?:6%'"XYZ4^IG-C?_?I
M%=W+O,LE!27FT8H+F7OJ'^RNP6KX*I<4N)B?+1<1NMC>67,F7^>20AMS7^=C
M6T5V6LL9K?K*,3M>X<-?)G\LQQ&_2HL@?A:0@_V=9_*_7^O#7R99+L?CF4*6
MR^H]][=NG8G]ANYR?SF.SGQW^0CW9LO?W7[Z,7,O\PJ7X]_<HB46XM7L^IMK
MG%2YP>6X-7<RX4*<&?]@RA"6MWF-RW%G[KK&1SHQ+;^UE-F0<!1Q/@J2__VW
MK;\]G@2NSJ\./WN'1T=??S\Y?@[;KO[## KLQ' FWA;089B6G5@MDQ!;?GMS
M&R<7>--8X^+P^/CT[!>S,E@3+N:U6L)/*$6>\@[;F_[![M;#E^;=?LTO8(>\
MMYTM?QMS>?>ETQ>P@;UM?WM[_P$\]@+6WM[W=_8>(A]>P-JW=_S]O9WZ<*)_
M%ITT'.-_ WC_OTAQH=*-DC)@S;7H]?Q9YD74&_]<D2#+>\G50'E!MYN5*O0B
M4?%>0/Z2=Q/DWO^:;7\<W)9#KAOQA_R.SU'0B>*HB%1^5&89V" /+JYH^0=3
M.J>]( EO6?1!:^JB-QNM=@/G!RQYT:U]?_=@TOSQX*#3GG>I1@497M[6IN_A
M6=)NCE57?MNBW\+?X)9&BOJ'XG&32?;)"9-9A?A"OZF39J'*&F"'=:.D_WZ3
ME"6IS8G7W$1A,8 _;?X$%Z+B>!2$(7P'SPP>RDPWU0P4:R\.<CC@P:@SR/YV
MI^GXMSMEC#7EO:N3_WO5.#T[/CF[XD.8.@*W-=<[[2W\8P0V=Z.3J>![(T!/
MZ+T7Q#?!./_'7,:O/$T-__7?@3?(D*#^ZRKM O_2^0/Q'"%5)T7^W_\,X$'X
MP=E2[$EDUO3>QM96:^X84)T=OZJ8:GN"K!A?94&2,_ODQU'>C=.\S-05//1#
MG':__\U3>3<8P9<+X&!^(;"&"@^!9_$?_[.[$^QNA7^;AX+KUM]UD$4!$':"
M,B#FW]WP7;F_HD?JWSBG%:M>\7,<):HQJ'SID2PAO^>G;/_T\[7*BJ@;Q/+6
M(AW]O #/Z+_S(DN3_K_V0.S(C]/4_7)?+H3@$25X+BE,6=2S<,"3Z>Y>&L?I
M#=:/1KD7>'$$ZAND028G-((3 K7EW0Q2;Q!<*]!'0-]%\%TE7N&<FW<3%0.O
M@ <>I4-PH\=>6&;XU&( S\W4*,VH2'5$.9KW2][8/%)D[NA'78I<=@<J+&-U
MWONJ@O@DQWK!BRP=*3HIDJ>SQ,@]A<5B&'IFT(D?W]Z=8/5.6A3I<!G&LJTL
M%#8[@Z-%>D/*<6EN?*MTD)7_M B9\(!H';]^:_,Y#XY$&'+>(!J]Y+-ZOA,Z
M!M;+HA$>TBRI_I XX70%-65?#PT=!M%-D'A'0=8!Q^,L2%+O2G4'":RD/P;I
MFH$HI9OW-JZ.SJZ6WDRQ] T?]GK@'!'G=UEW/%&"_:$%+TL_D6G*_Z&'&R5I
M[GNG2;?I;1P%8_B[=YK'X!:^\S8\^JOWV[_71/0T1/24<N3P\L05')_2&&V'
M]46_O"V!%P*Z2V\'K2&^.[#$B6]O!E%W@.:Y9M=_Y%XG#;+0&W)<!X,\9'\/
MTTR!*04\WMK\29M5URE9WA2GS!<P/'WIYQ&U/<HS>C;1Z%&FT?O\^<C;T']>
M"ZT7N*7+%-P;(<OT)H'_![K]'-P A7>5]SE*?._DCPOO'+PE-E\]$(@<B?0.
MRSYX<!X'*5NOP%0[SIJ>#*WTKIH>SJU\]1=HJB;Y^E[]?BX'(%T'H/R %&LR
M<N<GCGNRV*V(29]E[3\H3 _?/!H$40:/]KV+3.51""+)]XY.SDGT'GT\?P52
M]6A0)HU/>82TF@?1J[_8#Z0!X0*/HPP$2)J!9/FANB6)DG.0K%W1C*?#H0I1
MRGH?Z:FO?N>:&''S'\Z/I])D/DK+G"(K5T#5#;A\^/QGMT/\Q4K560M^I;<U
M0:>K2927AN!0T'C3!,V+%8V?RJCQ&<CM6_GJKV%"!+[Z'3U<NSZET')-W%=_
MY+^IL3<TOM>KW\YR'8ZGM>&B0>.3 C/U\^L752M&94:]DT_!47KE':MK%:<C
MBF&0KV#^<JFZF2J";/P*I-NOZ2#Q?BV3<8JDMP)&V8K1'L@%U8.+Z8/;?@1$
MDJMX%K5YF;H!@U2%7F?L]:(?\,,0WC*(QP@@1=\"44G5::C..FE2NB+3EIAA
M.7>[Y=WCU:]#P"KTDM'Y^ 3_UW\R/)&E;:GN:;BNR*O?G/4ZON&]8=YT$+A9
MCA<K4C^H+$''\"A=A:CA1PF3N;;Z*]W*5Y7# T$LIHEW.,JBV-N9:A].J^QV
MIQV\\KKN#V"VW'!-6%X.AZ@Y))^$QQ.!;QF 25,IV:D6A%$Y!A>%IZAKW-JP
M%&Z/?M&+,C# DRA1K(6HC!D/^PDKQ);W$EV)\C%*0)E&H"'S<H25<-5ZE.>M
M@YL;M*'2S6>+X,SF+GEOGZ.\(); 1W;FJZ7="S:#K?T[R^/J-;#(TLNH#E^F
MW+H91(6B/:GW7I+>9,%"*ENGO%"7N(=X '^[LU"+C^Q@5DW;E$HKVS*Y^Q3U
M7$=I0DM#"CE+"W5[U=L=Q[RL1>I[>&5+6S5:T07>NNG8._DQ4DG^RFAF[N:0
M-3D_&SFWGZ1*VC&05(+.^W(MB(D%3':6W4H3]69-..J?7R*=K$GXR4CX$$W[
M-=6NJ?954>VDX%W3U)JF%B )5U"!+\AS77#$=D&=H[KT>G:'5>NGISJA9WVS
M<&.O5^'&^9GN+EBJO<U[PE+1S?SV[^G0;Q=9"A02YO@0M_L;@4,?BL%PL-^:
M 0OZ[)?S%M^\?(+<N7O6Q:U$Z 2ND.X>"0&R)K\7]>;ED]\]495O)44=#Y-P
MF"L2'XRCXV]/&:[R F[F+;YY^=2X^TAAB)'[_"(88Z+'(3^$1L*U1[U(A8]%
M=GJ1%+G@FI<%V;53!MVM&6<9C-.Z+V@N7\S3F;4SA\T]^]V\Q3<OGQZW[A;D
MM]+@8JW:V;,6GOTJWN*;ET]^]YT5<ALI+L&J;?N;^]-F+CS[S;S%-R^?&J>C
M>LY/@4]@U<Y"KG]%5NV316OO:,Q_?B:Z(WOQ KAK ?F5N]ENYWY*X#B32[W"
M&WTZT[BUX[?WVG?RWM2DR5N2TVOB=HE[CDC)/ 2]8#O;WVP=X!"&-36OJ?D^
MU+RW>%&]!+-]QS_8VEV3]IJT[T/:<\RRGX><G\ ':&_YNSNO0W0_?)KL&^ T
M9R+)2V6UB24N)GUT3S7BZH0GM/?]S:VM!YG\6VM-\K;I^]:9-O/2]&)-_K:/
MP?6'F/QK:G[CU+R_:&F]!)._U?*WM]:TO:;M>UK]FXN0U$]1S3)]3ME+I.^W
M@(L@!3->1W5Q=$F0>(%&<=8 "1KE@(>R54'&FAX*T=HOO2*=TE?BVWEZ(Z8P
M_)Q^/X_84R'^[I9Q=;=F^6</RJ;7">$>)N%9FG0?F;TZF S+-%<)X^$<;CZK
M(& \ \C#>A39?<178PY<F06]ZA0,^J1(L[$W*K/N(,CADST4!#C"!5BX@+<E
M_=L8>?M^C"RO.U,/=X+W,-@T60/1G+L_?;E'^H2W=Y&E8=G%"0V-T,7SZV>*
MIQ,0L#A=)8C/,B8@\2B9?9T'FZV'3A]S  6/TKS('VXV[_E;^Y-"&=?=Q0??
M-0CUUJZ(*8-045UI4^DJ"\*%JI=6N^WO[D^61^!N GFWUJ)OD( O Y[Q.6)"
MSM%HF#X?QI%%&#78VMM]@\=U-0#&;HQ5@&">B*+LD>E,\XQC!<([9.$=U/"O
M*LS_]?QW[S#/53&7>+\U65SG)@&S3?J?<3%?\1;.>[_GBE[WX-39CK_7WI\^
M#YG>XYUWX) %1'>>/>W=9T]'P2B"1]*;G!<]8C<'FY.[:7I7CH$^#+X##6CX
M2[I9%!(H6\ETOV5O<T=&ZOND#8+,^PHO"6*)@SP\4+V'4^K7&EIK:%<]P_UH
M=D1DT]OO\^"^]TDH:$?F%1_5@R]QSV^W)B_1]?D8B=3!)O5Q-SP6ZA8;X]8(
MQ^Q]B(Y^Z'9V_=V]*1/*,S4,(A <:5GD!<@4O!8"FYVNE%]$%.&MSB9OWQ-^
MZDW.)A<4P\ PW7HJ^"JI"I+*<PMA$GKWE7'/II?G1M6MOW#A+'6>U$*A?B6"
M6L&0#;Q>="UF^6C*)4YQQYO>19GA7:$13D^V'^JD\"$SWCR*8P+X":[3##\K
M#_9&@P"XJ*M*.A;?0RQM^(&O-5,89D%8=/HU8@49AT \K2:?M?<[CDVOK<#=
M:93#*Q%9E[X-?@;^4?WHQF6.S\_!@0./O(]?,].R-<G6WW55>0MHZ10_<AV%
M&'1*L\I[$9L7#Y1?1\9H[GB*U0.&/>/W)69%QD46=<I"(61\GB:)8+_W0,S%
M$1YLT_O@'G,^"/"< V"9/U.X5$0COTDPB*[^4\*IPEMI4'R:Z%UB"#R.5;?0
M?U;D:/$L2Q"8.?$L.F/XZ='T0$TW3?7XCR;X9.2WX>%5B2WB($0(GB_'1M"+
MF_%$<U04))'HP[1@@Q>6&;G5=&.T.;PQ,&+2\,7(@Z?TK%V2STN>? D>&#PW
M!5,ER)E6X+)Q(B:<,>M7H+8I/1UT^A4@=7Q +XWC]"9_?X=%N6P[P9O'7'@#
MP,=K,.67"$)&8S'SEX(!MD"$NB6N8-5HX +T_A]!7-Z.BKPF@Y4G@P@M[*=&
M)#SYT54YV9I AVL*?,L4>(7)!*EH65/"6Z:$BPRS;> >H:N8O1C%M*BN]T6M
M9'/WGUN;_ZP.)5JVZS9S8-7SU[2^F,K5!=:GMF=6[NW.U97&4WK(RG]X,^7^
MWMW-E&_JVE>9X&:FZ^]!<&#*D4?Q8)*;DK)'&GSVXW^+;UX^R<VL>KD7R47A
M:<+>Q'D/"/#AL)&MS2GECOL'+^ JWN*;ET]^,TL8[T%^Y+L<DNOR",+;G5(=
MO[OS B[A+;YY^80WLYA[/L+3M61DWI'+Y-+7Z=G'*H5=B!GXK\WFSA:*LQ=F
MT3TW5,!S>%-KA+)7@0W2GHD-8CE5'&/RBQ?O@R&8]=TL^Q(0/]94^\14N[.U
MW6Q-6*=K4GB#I#!3@&W-+ *>6X MSL%J^WL'D[*LV=I>T_":AF^AX9GHO'/3
M\"*\M"U_:PK.1!-_MZ;>%_+FI;MN6^W'T.+#';?=]O;J@#^_NC*SEZ( WBY:
MRTQ<K=UZ+],C_:T#OWTPV8WU$M%6UO3Y<NBS?:N9O=@4V1K(;4V>]R7/6RWH
M)7E[V(%]]PB5-:FN2;5"JK<:V MWZG;]G3FF3JV)]*5Z="NUW9F=[V[ST+3?
M/%7/L^W -PS;VJH/3YH?"^.R[.3J/Z5*BA-LI,ROX!$?XK3[_6^>RKO!"#Y:
M9& IK;NI'U8YO-^\M8!VN2^WE^OQ[4Y;S+-TYBT6%]#\;WMGYGNO*CW-_:"O
M0H_"/S=!H;)!6N;JB'I4<]^["J*;(/$V_OY?^^WVYL\7WX[HI];/[["Y,4I"
M-<)&9>S'Y5[30-!J:.RN=YITF_H9'[(@Z0Y Y6'O,3;9TJMKS=(A=1R?=XL4
MP2>W!9%2O_ZP#".X0/-%O18&TJG_%>0 $%7N!?3[7&77L$?;=(RMVSFV66,/
M[+'J"MZE1L'$;D[XH4T_P+ZY*YO:1!D*LQ=E0WDV]]+RHS'.-'*[:\MLE&)S
MKO1\R\GCTEM[/^?R>7X./M*'EWWUCBX.?>_SYXNF=P@LC7(UB.-QO1]=[@X6
MQZ>:JU&0(?:G.=!\QHGB2O%[L*A,\8V$UU&.F(#FH A[+4E45S>]3EL^'45"
M';()\%,,EP^'#CM)X+:Q<]:>!!!,!CP885>S7B\_>WMS6[=87P99)TA4WCC_
M$:NQ=]@MS.U?GO_?*7=/]P-+S50^@L=Q*_AP%(.\19 L:KYG NRF<!-T/%$"
M'U%>$?S0*^*STJ2!?YB7//3JY"57\-4I!/JJP$7G$2+GB:&IW6E@"9T4R_/A
M4D,X7?@@\N$(&_\14 #.+@C3$0'&PG>X1QK/&2XQC4O"VGJ_!BI]E#[??1)S
M=(E6 Y!1Y1GRI7P\[*0QK6Q_"QN1X'/S&Q0GO1[*G&NED3XLOC%2X@>B6B!4
MQ(, ZOR41V6#FON/!E%)A/L-$5<"_$5  (4D+Y6'$E+(W^ $P#^&45$H]?,]
M(8Q>3B*"J38B%?]^Z\FR'<]P4LNV0U\".?\[2(&:2T8. O+U:]2,]%TC^3J!
MLY&UINPU92^7LI>H^0U7@#4"!FH5)]\8MF3EG8 AF8X5F*4$"',A<-G>18R(
M6_01_@LX.@*^Q'\2\[#E'8OY4]4,%VD<=<?X*=^+>L8L]@63*"\[P%ZTK!QQ
M_=$NI9!BS'83/J(#7_>NTPF@?[,!ZED=I#%8,_FSTM^:4U>:4^=C)YE'XEW9
MF03"!;[W285]M/[UOY%Y\!G'$?KO43'6_"+/IC?^C!];T_2:II^/IJ=%L&8%
M7"@0<?\HVYL*3)XGWEEZS8&6&0B,'/&*.%8SA,]=9"J/0@T(>'1R[D_#9O,Q
M^!1H9$U!8,212+G@,^(3J^B*7AA=1SF!],U(-AQLSIH8W]ILM+<DU]#"O,/_
M2)+A?VI)ABG%H<<J[V81Z?CSWI%9<#5L2^1&(<51,*8-D\6^L^EO;FYZ9W #
M0E+':1QC'&OC[.KX'4%9$, X612!(/\A>:<)!T3I#X,H-U' IO<-SX>">EN;
M$A5#2,;J80&C]%2>4YR2\ BS2(%)5$=*]KT;1G;L%G;5A4&$!++H#A*&M*3+
MH1@>XB^6V<3U. "(41(548#F5X[:(XC'?VE(2IELDBNXJ!"?D>OPK<H(Z _\
M&0D*7PW@DYVT.P89H)(H8$7DX$I*"!06"S9?&@M&II8.Q2#*]!O@5\Y+W*7V
MTFZ)D/WPZ\L___Y?[>W=G^$N$VNUC9,0EJ&:WN<@+S#D:T^L& 3.L5$\6A^<
M<URX%3RO(?R.\ Q51H%8 8\4.,LXO6F$:?4P#'0GR\DUR/4\T;;%@%QOW5,_
MOSV0Z^4/S6);0D@A*(*^2?"'43Z*@_%[8!:,VOZ-5$!4J&'[;_\ZO3KYXK6;
MWA>0.VP,_",'RS4'-D=Q2#+D$$42,"@>[$>3&8$CYM0.?>:KB"OXR+G&A\V-
MW?+DP[N6>-Q 3%>5J']H3RL'PR@.O0Z*[R"4%-2?9<)RBU0URC:;7@*A5XCA
MI=V&!,<@XD^9 HG-F-A@RJ%V4W&N;O /^.0"]1RGISB!J#4&+.(F\?!CB*&;
MT1-ACUB$%F1@7&+>$W00N?L5_..<$8Q%7A-4M(?JNE<69:9$W8)*%89:@;O4
M\^;^./GZQ^G)M]4B5+T7O"S7SZ!/AV!1,)>^IV0F"0;72#.\2W>]0N="J7V?
M<_L;2/SBMCCN$25F(S2YK]2/(#>I5RJN2TPBEABD=;"_;2U[CC*C1$"3DT)D
M%?MIPO3,+0PZ?(X2UPX<>E !1*\.W)$I7\#/ QJ.V=-9;US![V!2PGHN4;SP
M$]FBKCZ"D;SQ UZ'RQMD1%.4: L\4WVPS @X'MYR>'IV?@EG=W8$#SH\_79X
MYGWX>GAV].EU98@7R#'G(,X_E#G\G*/>9)\K7UGF^:8TT0"996G9'^!_E?(Z
M^@RTWYF_]RYJ>/]?A-"/'4*_L+C_7PR9XZ%.^8,Y7QH>QAXTD#^[V.!ILD/-
M&//'UOU=@6,WD(Z5$S64]=[[K/VA./T+A%'%+PIB$#G>QNG'L\;?_^M@>P=D
M&UAK8$]T!WS40-=JPC_-RGY%<H$%6>"1^]X?)Y^/S\\.O8T_4,+AFX_QS><9
M?.W4OO807_O.1SEJ30P4@$-\'3B#9,+@! +CE7>!I^CMF:P/_4SCZH$WUXB2
M/\$T(2O_UAWZ8CBA:.PHE8A1)/:-23NBM,S #L-Q$#AMI,"D!!A)JAAS\4>.
M$\9RG![<C4N>Z3?A9M_J"/M@B(U :A1P#$?XG%Y<JN0O^-JGTS_@NX=?+]E1
M3VGF;5<;U6#:!4G?#&3HPZL0U_4FR-A,ZP;)=RQ!@K,$B^QR$/4*GC@(.Z #
MUIXZ10&#[H \<;C$1*9-$)?TRHQ?JP]>3@/VKF^9$J?5+=-Z[W#_5XGK:G++
M83OD'E3545KF?.(>F0A ZA'^MU>2N,(S#D9C*1M##^ 2WG[E;5Q&0XJ/*?S^
M%P6$C9D"+!N+KMG<^'LP'/V,_%IH ^2*'_8.[DH%!?$F\Y9C?U0MCH!C/L5X
MA$P$?S(K')4QIO2 FT;E<,32 ']ROA"JF/(8SJZ*+ #1#$LF7X(>0I$KV/P(
MBP5#'6J"!]#!Y66G6^IM@M;@K%\0#H'JX"QI7\@;'D5,\-M$PMT8'H;O&$9H
MQWC PAS! E,%]HY1/OAOH=RU ;L%<3$8D[0(HZ"C0)[E;/;0SB19"1QO*A/1
M"^LKHOKZB!8,)9:=/Z4R3[.+A-W :U9! H(F5L1= S@6=)[@BQ@B*^UH';05
MB&U9CH"^.O_C]+C1.@ 1$_3!'L5%T@O_.#]R?]?T?DE)"*39#<;T'1X.NET5
MLRJV8;+HK\"9^()"$PC>3"IU*]6Z*AJ9^3<@)(#N2*R"P5>"J,=22IU 6"UN
MGF)8.!S]3:X11[=G<&AE)E<I ?N9AH:>JW2KW0*?8/J01XK ,)S,,7%^@M8^
MS:J4 >5%Q;K"ZCC,B AG&&3?%>D #(]&P(<I)MR3$OC+:'6>.I2&0-1PXQ)X
MP) ?;!)DM\KZ/,!)QRGT K$V-0+/0*_)A!!0404<F7:M!RN:1BG&X5"I-+UO
MR"E(PM)PH5@?QY$253P@W0Q/X&0IKETB3#D)L0@V.;8A;9XN-2B! (3MB0TK
M5T=1DM#>D1/K_D\)RA3E<8]S7*[\<;P\<H[2 /^ Z:Z1F Y=/4^+(L^.MT9V
M"9& /AR\T^@Z11&"3)R+="L+O*Z&"OL@/N )4CJ*6RST+&&2,A,B (,ZN5+?
M\=?( YHF,"K_]>RPT:&QNJQUZ$IR5[#Y))ZS$B0K6T)V$)?8"A1_"@I#B20B
MPFN,SVN=HDTCIDXF% KI=RCCT0-5%PQI+*LUYJ8XP]<@Q4@V$LWI(56<X,(=
MXOBW!H@FE=!P*M0O68%M9Y'X#Z0^P$?MTJPCH.!\$(W@<32_"+<#5 ,?>$+_
M]*WF +;7.8!GUVWWC5R AD)1PV4MW/4)GUK9Z 7%OK3E16;:$ 0'^HB.O *Q
MV,5R4JGN9\7219%+:E9$)2A >&Q&\ODXZI-S5E1.$4G0^3*H(3I\H' W98Q6
M7$YJ'X?V8;&0\QT2BJ!CRBY.01R,<WHUZK^@6]2G[X$QR%^U17:X,S!?,;.*
M*AAV9HW&L(FVCM:^).[!5D9]Z#Q)TNC6:%;) +5 Z'RHH1+DH= U6TT1%/ E
MZCK46;"$;C3BR!':I8H'((**BD(?-P6J)B+UA!Y_%Q[DHP=0(N@-M?'0*_BD
M*Q;R:6)L>5]"#5WNGYIB%0]!/UH:,.HG+_O@ 8 *1?WYCYQ.#OX-&XOR 092
MX=?&RX6[&_*P1&/=H/& :1-<!OZ^:@Y%";A=,C+QU/5RE"K$3M<F"]XO45_N
M:TUOR,HX^"%7EO4B101)+-SEF.Y*!&*!,%4B)AMF+JG]"BS</Y%>TEC9.#N3
M@\,RUHXR 4ILUC._I)18@;8LWQI.Q(SZ6.SA>YJ0.V.R?@]/O3.,.^G(5X5A
MW \8:VUL/HOQ&4L=:&DE//L635RTJ7 $)ZS()<U\"&OA/>G?2IU+K(H!2'!R
MFME3(^/2A]7T@;;P>$A4..< &V;'/LWZ00)2#ND#(:2\#7 QWTUP$.[G.E(W
M/GJ@;([)(;-]C>J2-M4QQPZ[PKJ9*&:'7P:5!F:"*?*="IWLQ3>\GAZ3OGM]
M5 "%5V*.@M8 +*A;Y^AD3H^;DIQ!R7=#C!$E^B:"N)^"MS 8\E&0B:V_AT5M
M ?&3OCYT0H+$2&'Z]#4BR31 E* S)((/5HK/!^NV2$&8Y"O!7@^U%BZ-K7W!
MMO;*&@I.CA!4F7<4C)$'3O,8U%I>30&*W+5-OM0Y_-N_=1X1OM^5KE$28*CB
MTQMQ5,1SUZ47M4I-#]PF(->,G5B,DC=E]G'@7:INF;$;9,KZ#YUIR*#.*7Q&
M_NDA.$&QU]K1_<A.UE,OUZULMDM'#:17/VUZ,+Z>V";TX(7D;_T )[W J-W_
M:F]Z0_ (610'A8Y]<8S+Y5@X:2T*DJH\93L")& T4DB'7)G&RA2XF!J#&FFO
M02*O (6-HG#CXOSHRI5P%7=:9.IP#'YAZ'JR3HQ?VP<^;*Y/U7GL;'9ARRAR
M<O6CU/8>-1*%]BD;EU?'<'*C1)7#5 ?+![#Z;MJ!X\4HPCB&?7L;@Z;\^&XU
M FS?JI5^*#?A^_&XX9 0Z!B0$A[>4$X2&%0OQS"-G@KR@=?#H<,4 RC)XZ>'
MF13CC8XC16 SYH4G2J":')N57;1)VJ8)]N4E6>&]DHQ_QVR4V!\SR1'J"K0:
MK_"EOU&'B_"EDS"G:)A)LSB/D@P/'FF4-.PY5$+ 5*C*]O$/;/J'?\)6.$$6
M]=R8<LXQW.L5CM@:V836N#MZ/70JJ&H2%%NP01XJ0SVQ2%:7@)S/=P,,S11<
MJ6$FFTO"0$HLI!$19,6QZ0;/U CC6E2XQ?%!"I*"%3\D6ZX;B4WC.V\#UT;U
M,1-.<5BS!2HX!ADC;I@.H^F2+?(7H^'4G2"EP6(/,7Y" E_/1Y\FUZ=7HSMY
MD*GG:,7B%ZK=+9/&ISS"XO0\B-!(.QH$4384TJ<2]B^PI$]EU/B,70%'(/N"
M=]ZWDC[[\9P^QH^*!HU/"B7VKT'W^SOO,WWDDV*Y?&0"L,=N[#)3*()AW=_5
MV%TP/I5.%[,YO=YJ<,!#+#6^^6I$!T[ERM&!*VNW74D N6ZGC)T4>Y#G"KE6
M*R7*KQMV 6[(D+&0NOK!*-?*1=(_5H2DH8JE5$LB.? 9C"(YCANY%8,TCL@*
MH9(*-X;$!5_5*HLL[6?!<.7<C(]1AO&<SEB2XB*EM"PBEPW-PO^O:AARRF"6
M;2CQD22] 4LP)R$FN6<D?LX<T>WB!9J45"/,0&LF<H-X43:FYV9N;"D%)47(
MB+"J6C]E5*MQJMZM/[N8KRK#FTR!$F(R%K*0:L;I)C0%Q"%U8G0][%4)L=6B
M:@Y/KK62WJ'82%JR/JFWANF\]732?!ZI\5;S*COKO,JSBS#DQV-KIAOJ;WI_
MS(JSY11HR]_I&!FH#' 02W&#U(]!0*%&E$H#-'MN,%052+\7L'9("(E4E-)3
M]$/F@<>?4$_]")]'*0F/S31VC&WN03('!E-*Y^U#53!H5=,[&6*Z'R.KG-G-
MN=P_B,>2PW>=9E-8)%\7/48;TI$+"MIARX,N)H.U9%3H24Z6]O1P_U2^@^\F
MD8ONE&!71;!)*B_P%,85@D)K"L>;MT%W_5+\<ACU>BISZB; !J4_&DL=#NL&
M%346UM&!Y2Q20" .I12[$CG%B,:P$U$\10W)-< VB(UA ,8S ARD(7@"[R1&
MD>G3D>+$VA7[?'D^7R9_)[^!OS3)G<1MFG/3%XS;HBVDN#54AIXD=FC#+)NI
MF@=S**QJG) SO.X'8C:PXN+[S^'D5<*)A!1K,K[ F>JPD^XFA!>80^A$*566
M9'*+5$P)^B6+R#<N\,.RTX80LRP?]@CJB2+P:;7(4-.%CXXW$3\3-GE%?#ST
M+G+YZ(7LZ$=]SENY_4C5=S(9R7EB>8%L(]>A:[A%LN30[.-&5JYAX\JH1CDR
MA\!^Y1@CUFA,FA,D-:AL<U0'4X3QJ%=2#@A#/N ?"M7J\HN*98%GGBET]'V]
M^H)23VS+P.5<!W1GG$(K,3D5,57A[KH8]>OR!6,')>R/O%"NS)/K)@, RR2D
M2&*(L!S=012#<9NLE'&I<S!7-@=S(3D81TJ?WY6M :&=13GW79'MWRGAL/ :
M.XBA2CW&)7&C%-=86ZJIGVRLIR'&"-W71-S%K(O_W-P'&;4@G7)T&+(L #-.
M@CPC+$-&[U\;@R*:@3MT7D,JAZ<8<'!D0@K?P3S&PDF6E;+ZF@>BL-)8*21;
M/BMG\1/)'G@X[)M61659)LE"8C"O9E[$>$W)(9.,+]:.@<=4DL0%&QZY#+B(
M\V,IG_R4%%*EK(RWD4H7'*9W5L_AQXO #,#8U'>A(F>I3TE@+&Y5>4-7>MNB
MWN%(XIKP<,JKD9@SE:E2J<A5:$CYX$J(FJ@7#E<5YB-#[SYJ7 ;3-"6&DJN/
M@Y+;CYS@E<G2'X+<[&/ 2<==3;3UV9R1Y5/ S-V[8BWQ?BU!<;8,3 ?R,I<E
M\B6C<@:AP_K$IH<T*EK  F\88(L7U9)JQ:>+2<&72(QU)A>#30N-H_2/1MLL
M[BM9(.:"JLFPB<"YZ;$CW *.FQ\%60?X^2Q(4A/Z0QUK $J/SJYL8HI7+>DT
M!RK*8O?^]F^!U:W2DEFBZ0P!IS;14)Y')[1U*07 _9?$=7P>&CZ!7&.@P9,2
MHTOV&O9<T _9UD>LML4C/<;HSV&EY-WN[>/QH3D3O1Z%]KE*NF.RB(,22P#<
MNH IC&(VAW_';W4JY40NRD5>8:+7SS;.54^D:<J<R)I*D)!8V5Q&F>4JNC]1
MHH&8%!G(=2!\0D:MGNEHZB>.O>@^*N\T@844)?8BZ$L]^_3UU!*L^>:QZH&P
M5:89[H@8UG[K^,N1DSK&QDT@?*V58<7?\7H5N2*H?<&TRXK1($V4KOK%#SEQ
M\9YTG^N.*#&$N>Z,R%ZJ9$B+LFW^ ]1"*.VF]=]ZV(FBC0"](G- 8'."58VE
M&MX)?@"./C,)#:WAZ0F5OG-&V8W'NC+$F@C6J$H[U*>"6UT]77_$%?%8X%^Q
M?+1B92B7X1!M^G&#M#+6]9/;&(R"#E;>1!(3X#0F.@-]TZ5,JM:2/1(1P[_D
M2.4QY1DI&$#TQ*=<J37B%5 YGJ8SIT1]]=3P-^4(@J!J)J%Z"!M%VE (@.@>
MBI'$#@,:)X.2>T%,J6W'!F8;GJ)'?P4F],P/T)XA>H+8QH$Q'@G F";&>"P=
M(OH]46[\F5 [+OK6T2MG'"G,9L %L]6>L-E W\'?KAZ#P7T&T9 :<(:C]$;:
M\$Q=%Q^Q#:J/:'H-910R:4Z00E40G"6WA< WN"55_'6*J'#S&@4!1/5:6Y?U
MT\<83!M?_G&A)&WZZ7)K>]/[X_#"95-!!#"(&RO$7\9_MV?B&+;$?2B>I  C
M^M@(N/E%RAV=K[EW:J(A^#MRFL"BS3$WXMY4S.G _Y11]SOJ'#($*/9(Y3ZF
MH!0C@ /J9KT2)4E]4"*:9WKP3$R'S=-FI<3)73+ZK'I_Y-1AX-"\W3*Y%OO8
MV',%SO2&3<9S,1%&0>EK:1[!.T#9]\O</L#W^FF29AGL1X0(F  IU27!Y]]1
MQ K43D%1C.KZL.P&%3;&XI)PH.*0S1$N9,6PZA#16YV 5V<LFR*EHWWVBM'9
M]"[T#74IF9V*\V@L 8Q!:UU/@NB68^LCU]W !25X&M_U# ?N,7?C<%%FM*I<
M[;H?:.EYJ]UUWNH)9UUL1LE<DA84CB-GCZCK0CP3#D83^F#&EJ3T;X.,Q&1-
MK!HR#4:RVMB.&<7C"D\6.ID3Q-T4?'+.X*/O6V(KJ]5Z!*^#W>^1?NIDNX>[
M(HYNA[IK)"T+3!F(H+;LWO0^C*WWGJM8(E0BROU:*XI=#SDIF)<JN&FZ8OR:
MR2K60E#=-!_GA1H2E+7NJ\:(._H\I(%J.D>;!2R01 XY*\BQI!<_*!X6FP#H
M?I%0Y+$PU*.4C1T1:5LGV0T@)ZH<Q5B29A]!$3\Z7P[],%2F=!]5)7<U8H"U
M+5EN5:#;9V34G U-CUSYKDMCJD%&JM0"^FL CP_U#>I%NH=36\(JF3U@[VUO
ML;UG0V=N6AFYDHHZ&R#&TVY$-V.+BC?@FP11E28&Q&V(J3R=UO).CWYW"V_%
M(("+_$J0<8K+4H(86U\8\R2G:"_0'Z6@=W["Z]C>_ FD1$ 1%,P@P'IU%@,N
M!F\1+:$RL_U5"MN72/-?RQ[H+QGZ3"DZ,7BWR,QE1SJB,,J ;NZ0[0:T.XB,
M]?M0%E'G2FOS)U\:74#L$QBL_BS#6&%I=IGUZ>VP?TN,,F3)_)M;1**PP:%M
MJK.E2&*7. _]M' 8Y0P@)'=% @N%!D7GM'E4E5%<=\_R*]=Q=DS#1QG>I0EF
MC+600QZDKNB"OH'[E=:;UJ8US4Z+NNG#>5RY#WVW!D(PCK[C/7;AWOCX8=F#
MM*^PS*ABP[IF*WN"MO1*F\?2G3.>]B(B.3%0K4%*;R 3D4'38;VP4 DG<<8I
MP@!23J)*XTD9,3:B CQ*/W3*HM D4EEKE.21SJ29)[H'U-%XA:+ ,@7^<1>S
MQZLD1N[;P6-JWZ4ZGD/9G[$.;65K0@]S@@;0D1#=+UEKUA4<@;$@2)#US V6
M^"4#:L8\C617ZS;0)UM'.;/8'W?U([PRRKR'Y7D^V9QA3D6#0TCB26)N.9N,
M%00+DJVZ'\0V)D88% 7IP+88SV;C$EYT^1"[T"T)6BG*-M5I M55/V,\0J=V
M'OD=*SB]E3J$RXA UC%(!#]P>93!8JK"<EI4N=X\J'*"?.7D2)(@QQK?% MQ
MAR4X /BO(AV9?B,2*B!Q$7D'=>Z-C@;!"N((-&H(WX97<((],VA]*(?R)P+C
M _5*V#U</U$+;<,J.QGZ%Y4>%ENZ169ZCU9^U_FYH'D6\J^UN6F?)L71#><7
MT5!^S]RMJ[$$L [7?$V3-[DQ"C1=$&JT&J>]UX(>D%F(H,A!3TD;@(88LOU?
MF!OLLG]%W?YHIGY'+9!RVP_]B?/A"0;.,4V#IDV#@,,FT/.X^'\21W "-8D*
MW!"74.]'RLS9RL0.:&/Z&^O(UL"0V5\'(W1L+K&EQ,&G<K@H(SP>[FOBJE$'
MGG E/"SVITTUJ*$ %?>D&8"*$5T^=[B+/'<#;$IUDW#MW8*+9.FVT8ZX21B2
MP"W3<CB':33Z ;<_C4S<$D,#/]G/5#\P!*X).^U9J67G4K!!K%G?)'XDC8=?
MH\H:*^T,U4ZC1$84-S+30;T0IC%,CR=2\GR(.>0GGS8W-,[ ^9QR$DCH6%=*
M<T)"Q+G .J90HW9*@?24^0\5> :]FT"[BN0210.LQD#T%:=,UL71JS&R7HL!
M+*&>0BM:*@>DR098+H[ =:/&/7X.ST<E+T0W':7<"<H]04ZHZ959@;.SIQ5D
MF3FHI6+K<:DQ=57::N^)B)P^0*:?"M*=J 1M"FK7U7( )D++(A7KT71O4\(%
MJ^$S\KJI\33!$&66QE&/ND.O+2E6*BI "/15P9WPE,/#2-X(YP"@K #1RT&4
MS/R1,L"<P<<74I _KU"QYG */2"M^5A@@3RA&U\I?JI+/.R4%&FXQZ]A7T$#
M*XB%ZFI:@3G/42FL(]R D=:2;C[<%7PH>\JX6IA4G=:"V D&F]<8/1PLD7(4
M*8PB<PM8#*.W);.G5+G$P)5(,U1Y%?)(<I4TD$%SV@11:4Q@2FAH?#P^;)B1
MS2@$M+R837Q4HLAWZM@26)X:@MD<%":4@(!,%:%4%<@&@UFZEJ7/ .DB!=GE
M-!/HUPV#[UQ[/.2P")N,MGQ?][2A[^-+VHQ='7ULZX36TA-:>^N$UK.[NM:E
M:4R"?J^47\MVK!WRP%7>N9-VJRK-JGJL3/":<E1-QSG4G60\>I#,Q8"1R%*L
M=:$D.N)!JRC)*T*[%*AGUYHB78+52V.K5 7]Y3J-KSED6XW94%2\]3/I#O6#
M&GE\T8FY Y_N>X>GQY<^Z[P12J NF&U8]^!M?+D$WU9CI)-7B9'H1 .F<^4"
M%M:6,9Q_X=@!35<SD<(D7 '07I1]T;5S48*Y,;UPC.BG6,0)FZ_IRR:XVA05
M5S3_ ^6<#C\8""U6CA4%1'BE# \>% 6()Q]CW]:&%WO='J8= :?4$+'J.*I/
M:-F4FZ"Y<O1>LBOX>U*'IM"(!JK"\&,H]:C&P<36D8SFX"6PMS1AV 7=J86?
MH/@'F5P8#Y%("-I+8BSQD6@C2>>+HF00=:*Z*VIHUL?P/8'@V4^4>8,/%G&6
M<!?2:V?AT='90B;PW6WS)8DYY5PO*>/G,.E601Y],B84LZT80Q7#S3EK4U[/
M0PABRE,2.W7380>\HT+PL%E@W#EVH3)%893&X^X8S:4(OJ@RF748A#AAXJI!
M3!>K\CO^_9_Q>#@:P"Z]C<.KSY_?:1CJVEJI?@R;^!P*YM+("5)A,!5<79%7
M)+# "-F]HQ]8<"$YJ'#IM-1.K::X/!V2-I=)7QG&X'JJ@6-5, P4X9Q[S7T)
MO"ASAC#4XS\<0C12@WC:^%[$MJZT2R;C;74/F!!$:70&@UXJ+E>CP*BG$+(4
M;S4O*=>66?1N"C\%M-_!!.&XBW!=;"?<53LDREM6FIEBJO?C??4J3)[P@-6@
MDZ=9AT9*!EU0$]+I K*JQ%;L(0X\,JES.IIN<!T58[\Z>V (5]C-;]$!?.3U
MLQ47(#<!6A_DJLH*4 )T)3KZ:8Y$-LIBGQ(=7;HZ[>K@80H,-Q_,-2>RB6A&
M<= O%9VT5_=R8%%F"!RF2_*\5(3XV ,Z]F=3!R&@(FI$=7P*>HX4DA&JK:Q)
M*'I*8-)6^&-2FEG"$@:\MCJ8*J)</IHZRD![.("I4<[A&'!+N<JG2WWU.HJJ
MPZ>F:N>VD*G':"2X_=GB;#5$N EWVV C&6HF+J>[#<1PJ(?ZZB1"<6[7ZJR,
MK"'3@TL#NFG,35#N^)JN+KO^=/H'W[XK2T,S/+W*WL@N$@-D+C<E3XC(W%5R
MX> KZS'$)(/ M((;I4TB#H'.)A8112ZF6*6THES)IP4GWX111[0/(7^1"ZR!
M@A$/ 7"?Y>HQW8,$XA1UA>[M$(@"L810=R&%@KR*^GH\"NLQ^JTU@'S])EZA
ME).(^1HQ$+]65\$H'15<)PR:$ZS;41HI^J=*_AI3?&.*#097_O7LD"0&SUY!
M')\;MS:0^%F[#*)&V.PU1FHTJ5G(E@1&OA&CTHR8(!L5'E*B@"*^%CQ>,P*#
MT0 X$<9 I+[W*1@'.1B801: %&GZWN>"$:XU0A V/6 =&0?N*8I+#5O\/HJS
MBV625.QK$U%+=0W)'7LU (!$^)2V(@\JBM/"!+RQ/ET'VJW6')$2Q:(A@N0@
M5IHQH4F/2683=5I<?S5DUA?4@]7-6_N&<0'1'A^#KL)")80FGW&14V9_!>&?
M):9UM+ENPH!TB7='$&>\*8A[0:/=<<>Z6.P,XI9^G';87;8&,/FU!7I*,S*&
MV@A$-[BA\WR_!:@?O1S. XY42PG\"5'YQ '5MK"@M@!QPB<<(^".46J!A]KR
M.WJ+.JXLUD^D42D$@U*+,RV@!+RE9C+YANE[" NF3Y\^E>I96>;D.SSA#V[#
MXW&;NRB;80T(NY&;BA";Z<$P-669&*T5M0.N>L9ER<C>4(&BXB(@;(4$N8B2
MQSQ+LZCO>MI]0M6J)CBJT01;0D!A;+(MNB6<&7V6H(,SCJ%,I2_G89:62*K5
M![FQ=*D+"=-N+PJ=CWL ]"E#;]H4P0">"Z7L.1XW&% H=,\(*S,S#;8Y*C,P
M(6T*?@JEWC8M;X[9<=]D"DPH.^190>K'*#8='83>EB4.>KK+Z;:IMS,VTD(/
MR]&XEN0_C4>J%BPS:#YQFGX7B"(T/,%-8?N! 5SK^H%T,6@HN%!1S')6%M=<
MGK&.U"\]4K^_CM0_>Z3^2,NB*VNP_*;&.%N>Y,6IE1<K%;=WA'-*=8U:IX @
M0XVD0NE,-!AM=CB6[IEC0&"MVE1F7 V=8:2R 0%DK,U>F#*K"T-K5+(T14DY
MR5M=@4DJBV+@ 7>5DT26&)#)^E9+PF0(6L1#(=G*#2LZP20.W&Q!1[E5=@9G
M S,($8>F:J8?CH6IA@H( 9FM<VQJGJPM0<+#F/Y4$UF\F@0QO+$=A5P;:@6B
MZ6/&%.<*P\JQT_4%Y(%$H-,#9UR>8_9/L]N+FW2JVM2)D(?,6ZU47*#CBB]Q
M']ZE8=Z(R>"4)#EU+EQ2BR943EB?'>U:8R6@P4<W"./:I #S*>,&V@B7<<B%
M._@/; LQZ'WU D9Z?16/.HB&.<.;ZHEOXI9/P_/U/;269=( M[G@N]BN-HOD
MX];DO[(^DA:Y5S6Z62FYBE.>P&1M;;/ 0>X&*A#4E!-G:N1G</:GU<!*%A3H
M5E?A \%\LFD%[RLX1B/P3O20&7121J6NA3.(8P%6Y\+CVW79!.]N[1ZXF0JG
M&\[4KX)L.\(!3]XO);X_S4<\ \<,$)!$'38\:7%/TLU$MS)>I\=C$RH5G!S]
M'I+GQ!:_A'_P<U@GJ&)5L-B3!B0#%DK!&#E5SCW+? $L&\) 0UTH:0]4HJU-
M.X.\'B=$T6.&=BH;1:ZXAREJ.P)6Q*670\1ECKI9ZF0A73#E2@ ZQ"XN"LQA
MB*?AQ*$1V].XE#:'6<^:?!.AKRLHJ_&FVCW;.DR9UCKB_#E56ID>))J@W$UC
MTQ1[,U 4R7&*NFJ#R)7VF*>(?^P0PPE@RCPG*LS!\BQ5F1I1$>VK)>"FZL!+
MT8$K)>TJR1#RA5T;YY;:<VPT0+E SCUJOSNFTT]TT("6Y/ETW4&0<4O?7QR%
M"<'J4V/=J$,68HD=S-^4:_N1C8'6'-@?+"BWG+6U-S>W*,5UHPBA5$-"Z3@&
M1RFP^@"C;W!8(<D8UY;3);-LAH0\1;@;L!CM<A G0IEKT-7<](\>(GSKL=02
MI])H5 WP55-%$J1*X=O<%\)CSM]+MIO&-Y+7<WJJH2XTRI=N 2<!1//12+1@
M=L-((.,E4/85)0QA]J#6(WQB?= DOZVJ,M_'X%F_C$*T9%>BRO\T<=&M\:Q,
M-3R;YU7;$IP7$OM*>1M;[TR"D)*AICWH]^9ED\&8@!LV6N^</^O9/GJ$>O[^
M)05Q&CFP*$5R^)]H\ 9)\9[+SOEW-QRN<']%C]2_F;(*X)-^E#1BU2O>8ZWT
MSU@OU!A4'B2?R>AW]*%'QH[D]_R4[9]0^)M3GK97+EI[7S]B7M?[37RL<Y84
M=9GREFN<OP-25$X %.\B7ESIS'6_E(]!O\>TLOVMGTWG[>0"IZY+B[6O)X=7
M7T[.KKSSC][5IZ_G7SZ<'_W[ZOSBY.STT/O]\O3L%^_\Z^'GS__V#H^_G)Z=
M7EZ=?#TY]D[/X+\?3[Z>GVE#-Z#6Z2Z89RH4G#=PQICRB2DNB%^\L[3I'?@[
M[5U_]V#;^]#6#'(,AN*P RJC30B8K5W?.[])L-?ZY =UOF,GL@RA:V]N;37O
M&9Y;W,4_]IG,)N! PG&\WUK22R:?^0PG=2L%KCEC*F?L[6SZ>_N[#F=<JE'!
MK$&S%UM[:\Y8<\8;Y(S]K0-_=Z\]36>TVFO.6'/&&^&,J\/3;X=G+F^<[ART
M6[L[FBU^+<&%1@CQF2SQ)1A/,,13IQ#7*>;6P3K%_"*"8SK\R?->)6?'DRXX
MA,*LQ@DE%TE;S^65 A+*M"*ZM@XSZ7@"A8(DKR35AGDE VFB1^8=?B75->.%
MO6K40B,^)*$-]FA$ 0POYV7G3XEVF-B74QEEQUNZTX!Q?( SO0OULG_'1_7D
M@.H4".R"XC+$M,0XOEHM-#X];646=)/NO7/PBERT(AU;3%*L%JO.UEE%;'3;
MC,GC8+CD:\9(F)7:N46%]X4[9)(;5EGJ/#-V<",Z?#D-TG1BXC=/1*K#$U23
MU.=V[+<WBD:*&O>D\G>R[DY-FU_OUX;74ZOF[/'U&KOQ5OQ)WOO4V?:?G-GV
MWW >6:$06/ OSJS1(:# [8'*32VF&@=7T718J;25F0J ^W9 /JF*58YF[+3Z
MRC7.FEF"PQM,B!^3/9AN[6&O$"=2X<*"<650+B)JQXJ+5"8?H5MZJET3<9J.
M&BC+>(1$3O*?FL40)LD4->HDR]>KQN?#+Q=FBDWE]<GD6!)08DS[!IB;P<7-
M% )"T15%J\]/'X;9@SDI%V6\H?574#00\]>[_.UW>9+[,?RU,%&N,2OL'QT$
MVESUN0?V9L!C(>U3I6AE8']+B,-:]LDWN0^!L)X0E4@#\<X8V&+@?'2!D3D@
MG-9@!X5.&=J <J)ZT[51$.;@F$;HD"C/A755%M,4/_:DD!)/,L%5SOM6)E1
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M[S' 3H&0Q_#8@3S3?$J-.EH=V&I'H4_4AUM</114/+NJ2ZUP3C,!_<E: *(
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M"7>T4E<$X>:)_0TV=40UG#XXTA%!U:'-07Y#(%S-;6YDIV H@9., O26T4!
MB@* *8(.R$0:7J;5THBX?*!4T7Q6A;DV+=:F!3#2%6F37IH6H*($!E%;"ETL
M#Y[@IDF29XT45+]H3'GGV3SOG0<%T9 (8)=@G+\0<^.MEO*UUJ5\+[.4[ZSL
MQ@H,R,.N+@[Y+2I6JIRO;L6:62JF7\GK!3Q"*Q6,3MTNKO+W]7Y6OU)2EIL9
MG31<EW[%4JS6\&P,9BHMIBP"SC8.NN.F=\3U-1.=LYGB(<N.JX"5:&G&D!FR
M'8[L4ZF+[M+):8:QG=BN![BE_2CG.G4]N[/L#T9E@5"[<4SS(JG(.C#YC]HN
MM)5! CGX+GV.B+0+1T?(Z./<UV5N5 [);?[4CT.EZU$WDG$)W$IH%XV.258.
M#0I)X':4>684O9Z+Y]0*ZJ8FNPM=3H?%2%B+Y(P6[ 8H;='+Y2)&JLZD1B>9
M ($3'J7B2<.NA J!@)O>9U I6&'H%(^QW4=4-?VHL @^0IQ<.L\@%Z./DBW8
MH54H,ZZ!QR%2J=A*5/U]T*T ];Z)QS7\2Z=_M<6?'>T!85_9&L->(.DZV\=4
MNR><&LVC^7)NF,,"OSC-&MV!S)(4- .9.T8CLPH:.T;1#.R,#8,L]"Z.OL+M
MX90G27#:=BG3WXY\,3(-^=R+7ZT\T^'$0 ^5K/3YVC9?W358Z7;0,UIM[Q>)
MF *6T*.IB;B(AL5\-X*QDKA;65]^7>OVPKV)Y_?X3Y.B9.]B:N:0RAA(')CJ
MA8JL[XP]$AMD8)(8:7K_5M0<+.@$J*VT V,2]U1JGMEQ1;2[?N!^R,>8 $+E
MZ*+@!+1OB&CX'A4(Y7 _!=?R=0,0%0&A+@1Y%#-\?P8Z<J)H?QT;6,<&5IF;
M_P]V.0NM5TN1F(=Y\%>-AZ/$V]IL;&_B #"T+EEWDJ+&3"+:+*:HG0N24.MB
MEZ$UB)$-!U35CX$],(\;B*?2'7=UB_*:Y]8\]XSQN*-YC%BC]6SSCJ2=4L-"
MC"90MXF':.M.?6;-NW2[:I%[!FD<Z@R[A2A 0"3GG;I!AH=P"S@D'K.UKM?\
MM>:O%=5I%[=XE14[5;QDS:@44')[5;F1#7&=X(]#BL50^2J5J$N;72D 8^10
M4^S=P6<3B )B:;?T]D8): MI5V3_!L^9IF]*61U-M"1AP<_D28_HWNIMZ1EQ
MH&_1=:V($]Z-#B"A^L5AC!3RLEL14]Q@HNBHE(XWT<NH0==(IQI'O.ZJA'L$
M@SEX\A'\E<#,  4/IYLI[,&S^"L-CBN$"*8FEP"R=XRR&<XZ7*TYNJ?)=4"M
MA!1-E7B=[;&6(DI!4HUR9^#[' BG^3O?P HY('7]-$FS# [;!^J-@^$XE.E[
M"/(S2 GZ%-[5]"Y4#,SGJ1_!4 -YZ! B#QACQX^J2LM"ID!JZ K!\QH;EB"_
M4**T@O#&$($R:IXBSTY\=B6BDT<II>JM)>^D!GQG@OS(.6J?+2%G]#Q!AN$@
M/+B4CSC=7J-T4@J2OXH/_R?\MB?XET L9-UP&>]-$'&Z3T>DG0MC'#0;*$:P
ME*9WB;WOH>\.]QP":6 >0RGL[OL1J6+LMB$YDW"=[9"PST*_OE8.7W[BGT&6
M8^LZ%T$/<_@4HYU2USQ6+?2(>*\=5H"32!$MDA_L9"PP!EX*-+/IK,)V?726
MI P"_QE29"4545TH/-J>?IZS 3R8ZS+&'(% U#@6)89HT(&S87LZ7+HY9%\"
MXTIXC.:00SI=6 96?' \ME&.N,A4=Y +Q$VN4Q T>AC6B'W_3!B8"3%H!MB:
M;"&4A3BZ67J#F8:!S%W-94(#WG,N"A!NRA!%3FOC"/C8W+CDO<U5X]C0.!?E
M7=N,H1)2MR![&GE)@^N(IZ4?/F?'M2\"0LKY*/6.I:Z@S/%*2+0ISG8(\ _"
M1CCOA6/-"(V3+((H)V2FZ@J&""($=MBH2$%VE0G"(,$3X[$=T4I+X P.E[+@
M4U!J6MK'"GH\%)6;L+?12K0^AG= TU%0Q3J*U;UX\IR&48*E1A\VT.J$6K0*
M,FZJZQ9]; 0W:$K!L2=X5J[ZQ[#A<)3>8+6TOC;\'4V,1YP[9"1$1(I$/<9L
MMFEW34(B"(E!>LT@&1,^"DT*O^*\8T6YS 3=$M#;YFES&C*B7UE[E-N-6E G
MO0P'<T0&(L"/2%3>AA7VC"(>$=1*/R)IYF-2IE_F]@&.GIZBG-\AFTCPJ%E?
MGTT*H<$$S!/Z@CN-O\UUVP4^2[I3<>ZIK0S3;.="1><TZT@T 3D1::8F@EJ!
M[O@F.(F7E.99S8*7]KK@Y=G$WE1QT$<;Y08D4()<_IVU34I3TQUV8]%E(,]%
M=DW!"#$0M=7Q*J!F$C")BI5&#5E71;_\"*\Q;DU4R%%%3MUD-L3:(:RRK/$+
M@QHC&FQUI@ :A6;FM_0%K .NZX#K<Y+[F6.0DD!.4B\'/X6$/%!WI;YXZF@%
MJ9@Q1C#WY56F*A V]R#M._/:APID;XK]-P2Z2LXKF@!P4@75ZX "MW &NC\'
MO-/ -WD,=YUK1EHSTK,RTE<'3,*Z,17VT?'SJ2Z;]M4,NCI87!F.Q.LKXB=R
MRS@Q,.&@=*A2,U'RUEH"(*A&CTP%:KVV?\TV:[9Y!K9QW79K<0FS8-00ZUZM
M!V[&!E 7F("N53B"M(8;/7!A)^8!G#C4 1S;[^YTF W&N91B"R[-K4UEA/N*
M6R2P<1DN:R.B9K85X4_4[<CK- HMN#<\H1[AE,=CYD1GG5Y(M\YSI.$NX"IT
M$BZ0S&:9C5#*8G2@&) UDE'SKYG59'-T*Y6#J^1HW-USTJL8CV2N"X*EQJJA
M#TJZH24/YE(C-V.@JHJ[Z2!E]SW,RC[VI&L?":^ I];@Z>NG3LZ]J-P'EEDF
MH71E9RE&L0V>KPTP-+T/4I[-\]EDQ):.CM9',]GUT(@IF<B$9U@9HX*OK W+
M CF5C_-"#0E<1D<M:*@=GD,MA"L+E/ '/\(]#98P>- ,FF-G=O&\'A1ST50Q
M)X$3G>+'42<CEC)V[%>J)]*)\.(+8C2;:OS3R>](#HIG]'%$V=F^M43L<(:1
M&R75*:PJ;*Q.P/!$ GE6!9NL=DBUI:P"T]E;[V24VJH/:Y.:J\#+8YQW/$J[
MWQ4K[= -*$A:R!2-,+=H=RH36'."E*#91#PSC:8RR4>M!<HHSPBH4+$N>:Z,
MY>^!RS$V!5"D:*C"2WQ/'9VW?42%[,!E M6G/V 9\&O,":6Q[PW&888NG@>:
MKT=_(A=P2-%]-$ES00NW+YHR[$?,86=8A\SPP1$:!(VLQR$Y#.Q$(?4D5S/X
M+N&:T]Q6#0RP180*#S8Z@19%[VCR%LA_%$9X40%LB<QM[,JR 4T9&CM,*9<W
M .;$K.:AA6NV"/+$*X[RQGH_DD(A \'I:QSS& ZDM.KXP=?%$_=IH?QTN;VU
M^7Z^4;7.Z$7QK5JFQ'BUIB?\,==Q8$E#8F 5J6)4!B<4WNG1[XV@*U#Y-D7=
M]+[JG"V.?PIB2MTCJZB<QD[%$FO9^0DY;'OSIZ9W%#"$6@]'/YHQ/R"O4<@K
M*HPPQ2Y#A15C/&=!]D!_0?2U,,4^/V0>U/-EA_[$9B_RV9"3<RCI2,OI]Z&9
MDH*? $?[$T=\J"E29<YG,VKXP-1Z"?X,OAWV;W45S9%/)G+H88-G;%$I"CXF
M[S*:74&]\Y0:;-(B:(Y?-!S15+J )HN1X(&#EAD*71!+&7#QZ^+4F65;U;D6
M2%ZZG;-2K"47!%8:=F=&,A6/"X!8/(X4-=CQ'+I4JCG0^-%^CT^$R :J;C.D
M&7RZ?@>L0!P'*BW!/2P!\7!H'H]&TXM!=%]%P]U-8!W)NY1^1]4$J]'Y!=9E
M2?F$3T!DU+5XI+]Z4<; :&B'G9J,]R42AQF5?'1Q>FGF)%/Z:H"VV(\&YMOE
M-Q)K(65-)3V?TAMUS>.0Q-JVJ\62%Z#"E*SFO#3G"5QX5Z40GDM.-1U3#B8B
M4U5*1GG\'N@5;&.FV9"Z+H\&%,Y>L/D<-R"#C&%]"P20FV&%:=*CB0O8C5U]
MDL U.56C.29&M+?+C:%2]I)7ZEZH+3Q*:70KUAV1AW'!NZ$48OU-4H^7FV(\
M/F%RT[FJS*U%Y)*P2MA;,SEVL0>%S)85TY8L59SLXFV @'GG2)1!6ID3P[$!
M4O94F@!^/QD%\&];;&7/J1HIR)2LBTJ&E)0W./5GQN_WIUK05$5D0PPTA*M!
MY4I9.:R<J!J.HHS7Z8X]C+%<"*DF3;,Z'^HXA;)-QW!-M[P#?,A4NG@<=@VB
MV3>-)Q%AL7)74;=W7I0A,G=>]ONF6XC$<I=&8C IRJ"?G<V?>#1E[#Z1QWSP
M<D%"P>69(3:_PW5B.2Y"=KXR0VN6QT]&%?,<>L )P\I57 CQ'W@V)COCN: W
M<-'86/OH:<;"$2X%B(6P9(@<950JWL.$-48=X;48%@6E$K$A3,F<QH&.H^]H
M>V"IG*"W2YX(K?7.G^R!F ':1FJ"1(]"QY"0D7^ZDHK?*>=0B>.)=X1FMIF?
M>GC:H*JM6BT5A@'=.BNWM(HUEAV#JE]L#/HI6R5#36JG;*T4O8&JEV(RA&"W
M<%1:N#MOC*S[)+NM'72'.@2B-!0!E*E1''3U\!?Y#EDT1E9FJD_=_!@_!'H)
M& O_Y=1>K&9YT]:ZO.D%R,A*S!%-02QFG58BB,$OS&\@IW!G@"E3)OW+%\M\
MC@JF/J]7LQ[%YP1E+J-Y4BRFN&)7PJFZF)$;9WT]^BT$(8'+ 4[]+I6-U44X
M$;U54&6_X9A:J0;3KN<J5X6M\356(YDYI6T>K'V6.;HC(Y?4!5C;"5L@H0D-
M3UA4]19Z-Y&_3MVO4_<OIW1,2+A:+L::;Z+G@;R0V\US7P:D(%?\IS2A04[X
MH?&-J7'M&'>S-,\;5 @&?,..!/F7]2$U4;TQ<<U#:QYZ5AXZL0E"JS#8 Z<1
MR:P[C'->E!UE_3<$>AW2"'EPX#@"QY^W&D;F,"C8;UY1,W8"* 9U**S;*8NB
MYE%CC,])<)NH4(2]1+!EW7S).&O17S+@%#36-7;7K+EKS5W/R5T?].1LR3IX
M*<4";57F1[:N=#S&)-8%,%' ',*T2^-2,)RE8@I*4003+L=Y-H:N/(Q&1MI>
MFXBLK_EAS0_/R0^G/'0NUU%]PP<G'-NH4C_F ]P!]%-2<WI$#X9W;0K&,(<3
MBM=U5OR'G%26;ML73B)=@O-UHYP[W+O4;$S3 ^##@X G4>OLBUZU+0_(5%AV
M:_D%)[.<:2 ):CZ =]18\JEC70L+U=RG4/+4.\,R&UTF6>GZ=\IP*#&HQ[63
MS,NB[FJAE'RC=A*-T<.#I@1W&2V8?L:5"53'J+@2>6JITC -2VQ+=J?'\RDW
M]0\:_A;GV%!'?H]KC^G[W4$TTF#8[IOUNR1=2FE/^&@E-X"_,-X3@HS0)$VO
M+"),6KC9UUP-(T$ZP34'28FE9IQ<U E9V0%EB_G.4Z>R@VLB<V_CR\F7RW<K
MD3*;) %]89S_S5(4*!ZEAWHEU<$YXD:L<H>%& VAR8.4F2Y(B%$G1Q!3V4Y&
M!8#4H$^A8DK)5.KP^(M3&PTYSY,/,<^I$L8"2"617NB,?!""F4/U/PC*S16E
M;,_GI@;.HI[6 ]8BD^D@HERPEI&2^I08)T"JA+9O2_2H!D^%^!MX:Y)>!]I>
MBH,RZ7(=:P(W(+#D.G_L2A]>H&491L*B(D0;%LBYIL@,@N/:Q%PK$HS4YXT1
M6G11'%,)R&C4><<@'TWO@V),#O5C$""A\U<Y?(X7'9KGC#K\G0I(M,/,R*DA
MEC3E:5QJ8M".DJX!7@4.03RTBM!S;AWL@XP!Z057XB_$A-?50*5<>QX,L71A
M+/6I]"6RI(<JCJE3J9#* BI*HZ0S!8#T<0O)D#332Z&JYAB(,</\--9X6MP3
MQ*>A(A%XBF$BF6B,F1UD!UW/0]@GN!#O]%C7]1 L&T*QI3'9^EP=,BIC&F:,
MYQ& @8!FA$ V9O89N0%Q8P/'$2?,MUDAK9'T-8TRCCX_HY(;W[SLF$H+F6Z&
M":2HRW7NHSA(*C5"4JHMCS;5L/(=T^YB\-!?E_B>Q\#!O*58)TBT%U)>!GS[
M!=-ZV%)P'%US&HU2YPP8'3HX?5R=3>*+0YI"Z@8J1VK6M!WI$XP5E^=+M0X)
M*BXX@KO!^A^L$K:%]3C^N=%1%*QQK"E*NKZB"[G#RLR_GAU:3""J7>,C72D#
MDLO8(U-2I,TH'&&:HP\1Y0.97SI.X /(GW@P&Y?P_^X,!CN?$$=L2%:>=1(#
M1B%T'L(OP?? _AKB?ZC8\)^@;0A*"Y8P $^+H,+X0WG$GZ)!A[H(W;L&B8.<
M( 1/-JV,E&?L*=N79D90T !$O4*?N^;PG=SHT4^QL%>T@%PX<P)#7[;A9T?I
MV\$)>!*RG)QQ-VWWB/-0_1PL  I&JM2'B(U'N<R&T7D J>BD1U.U840_\;@:
M_")95FR;4 ^8F>?@()H$'07&&2JQX;!D@TU_'4Z)DL%/*3W?:I7,]KI*YCG=
M(FWS6A9A>:0M=V0L-DLT#WL<X-%,FNLA21Y*.ROA,B4SAP@*<1B17VL%%)5T
M8M !>WBP$T9*<BH]>Z[$LF7D8+?%B L!KS2%@I'I(=8+OR3QB,-N2("@S4A^
M#5NG!FD4J[$+[!O,P#^HC8KAPF9GRHV#:&27J261\3"NQ49%0["D#CUT*4%W
MJ!^4@JD.L<%O%(IP2&EFEFYG$)U ?^6+2>"\:<855Q/0/"VT6()^@,"CC.]W
M^/6R<93^T6A[X#N5C"8.B[-.9M#)9.&^-P*1VC/_HJ)VD"!4*B@0!..J<83B
M,TI*LG,)UK,[T8ZIZ[Q#3@\1F&?B2FU83>,NBM*799J\JI=&,<8;5$1![B)'
M7IIKJ(WQ827!$[]2)RBB+%HB?U<\:ZK;HI"C&924&\0K1N-CM41AH;RH0EV!
MCL:&$P?0]G59X3-><LSW3HEXI@.\FK0L2!C; EC@PZR/!H=+C%PWE4\W*WII
MEWN0$M="KUD4E:<)X4AMKV-W#2UY:5%$<0_M2)4"O DL&3=P$AIB^X^B[^Q^
M@A^%_55=TW7U :OO<K!TXM$@T+OP-C#*CL"A'UK-5G/OG=GZ*3BH#.Q=3/LT
M?'BWM==LO^,A9SU@CZ1K7TJ$K[W@JN'$[N(NM66A73<L"XV:JD-+>H<4%;(;
M 5/(::)D)+80I1:XG)C(U2*, E)56^V;XI9J:E^P%J4(!G%@XVB4XHAS? ;B
ME%+_[["4SC"J=>2^'#YW,K;T:[7FP A<,"QSGCFVP0'(J,OGF@0YD,C&L 2>
M#N)WU#>><]\K0JM_JT@?05EG\Y06;\XS\*X(BA7,ZY:W<35HO0.]PX**#4".
M,.0&=!U5E16Z>C\RQI V1O(%1,#1\3X\'&6G>0@%/ +I%L7.TE@A"C)%4# "
M@#\SW8G\SWFY'2=(!7O\$,"9I"3*C?J 94B(5J/LFD>(^"ISEEC@C:HL88^,
M-HD5]XC<3#]C4QY;R;"=\,_R6A@TLZIHAEV.3<'=F+27U4,K(>.J[HF-(B"^
M*\-?.3GF'I;_Q\%PR&=HU!,Q&>K&S&&B"E_GQJF+6.WH(E]4*$*.XL,0VZ*^
M*X?X^7*DB4!?/C\/^WJ$0&H?37&8-B_'[3;5=TP7+J\,^BE.%,XU0+>L#I^M
MJ8HHHI\%H3*6F?-0W&1><:XLT:Y&G-11):2UV'%64WUB324,.Z&# #7)<*.D
M1)UH[,<H3FG4"Y)*'U@-(]U ./D@&H'(QBX?[$]#6ZP<I8DN-A49#CH*[J/E
M@ ]B[\E&_FXUSMX-^P'1J:(14T*YFN0"OE'Q2L6?<!"F'N21\,X]WGD'#2!D
M>=HTQRXK@TG0S!F;&"A2*=A?;&D@OG7NF/?D1DE05#2W>;Q#T+4L$OE/1*SC
MZIO%OL @.:&XLPU>X) O:9 : =V2:NJ,*7%F*M90<F%Q#6GYPQQ!)5;A&J^"
MZ ;N[XB!-<Z")/6N;&CP*,U&4LD!ULG1V14# -!86$3I&==SN2P8FMXYG%'9
MA[=X+=]K;[9;)%,HOJ)S@X%WP4X]O*7A"J?#?J8XX4T'CZ]M>A=EEI<!]R83
M+HW^D$\?8'7F^%"TR(OSHRL=.D"[!#\H1 O7B#V<01?CYQ$W\F,S<67&#9O+
MBJM_3Q.Q6\C$.,_Z@3$944%>RJ ;_;N-T\MSMA5_2=/0^U(YIXL,?L02QXU?
M<" NSA^Q]K#O3.."]]*4%INJM$O6PP1TA?+03(,UV7(<BHSO@[5XK:WM_1TG
MLDK)),K\:G6@\T62.];0+5US/3+H>")W+W>0EQW&_>L*Q!GU3<[*_3,K:0#W
MH-+NJ!]3^;C.@J1<9V.+&$S] AKA)$K"VEM1/ T[TAAM)DI3,GE,MH9DY,XO
M#Z\D$V?_S *,GU![KQ"R%&Y@12Q%A/\B4 ESB#QQAQT\9TSP2MBFWQ2-^.X6
M-GGO3$5&0;JQ\PYQ[HFS44M@_,O!]8(O'/%)2W<:EUQIDJ0L!XWC"30*2QQS
M50)-9,<R*E/>-27)[SS?A)NX 8X<R.]1803$*O=XK9&_GZLZ\M#[Y?#2NSPY
MNSS_ZAV>'0.AG/W^\?#HZO>O)]Z7DZM/Y\?>U:>3KR?G'RDP+ @*H<R7"6#%
MY'1?'9Y^.SRCZ8F);E:G6$ Y!+?&.]W9W3G8WEX7^:Z+?%_;",4O)\>G1X>?
MO3].SJY./Q]> 9\<'5X<?OA\X@%/')X=?O[W_SL]^\4[/?MX<G1U>GY&;/0!
M6.CDZ^DA?N;B[.3W+^=G\(\_3IG?3C'!=_H1GDM?>#1C[;R@&8-O-2F[LT[*
MOC2S8MTZ_K*E-HK"XY,K$)L@5!\A!(_AY3L[:^MB;5TLATZ?V03X-<!=B9-Z
MEC;?>[]>>+M;!^W]5LO[T.:F!^VE@K_9QRP"?%7]Z,8EM73'$>BI7)J)<OM,
MPK7\-4A*C)5)* S=WF/55<196_S+_35KK5GK>57 T:?3L\.9&N#HS-O:W-[<
M;K>WM[W+!W'$T2!*@H=QQ.L>)3 K]#XE-%4OC;4#ZIRJ"(Q<SXAA49V1 UX7
MC+#V"T'X:0ZP]_&8BU,Y-,L0;)QK[ZND*W%P0BAL7C;].SZJP:NH[)^:CP1A
MG+]".(G9JB3A=9Z/M02'G"^R=(3Y 23EKT3G*Y7BNXPP$X+_-RH,)J]F^@&B
MB*=PZ8S_5^)TX #+"35NJ<@/S [WP,U+39165U5:9,[*F&;*&:L,T3B=;@<]
M)-D^#AM$L2Y )A5;D&62:=(SH1(*X^>Y!@B&#U/)7^:B 4O= WX4UF/J)VEN
MK5"WD_6@\L4XRKG+C=.-Y]?8ZP*'F^M1L^Y92=%I//;2FR3'CE80LMY&JX7I
MM+S$LC!W UA%J'\Q4MQ>1 ,.9A@9^#<1KE*#N-%^9YY '=CZ-O@1]$"=0.."
MG8R;$9/4@"Z;;Q117^ Q,=NC0IHM 'HBC:]U[;ML=*48_4CR;T>$(&V3@B>5
M!L"O+!<%UV%U>+^BWQ.B"9K.AWER.^-="NZ<GDBM**A"R($/QB7TLF H18P$
MFHR\O%(D4X'U=4ACI2CC@^JEIFM5BRP]\()%KU3\L4V@I60-]9@DY-@;EH1"
M39.TK+5B1B^B&>)]3 79_1CG_1R&F&>E^@[*LTOJ%BP;VT-YE9IG$JWI!Z.H
M'_/8('HQR<9^BA(UI:)_D-3U(:EB)[O%2Z)<0C4$*J="$]V"1?4,L/T0$8)M
M%W4>]+"*P-9GPLJHAH4:@0)J4],=@80V3KK.ZE+'^C+M\MPT!.<8#'$N%]M<
MB.#7SWT-_:EM25]OQG<SZKZLR_<(2C_HCGTJ!<U"[[M2(_IX'&!9#?Z$$X3
M]//=PPS)Y<CI[])QB+HO#V(9P!+B146=TBD&RX9!ERHVN<V :S-6@3%.$\D]
MQPB=2DR"U 9V!^]UZM;GYQ6RW2G[+5@GM62[$,:+R6)/^?;LW,1$ 'E%HL5+
M39Q-1@QX#]NC A<'PG!W6KA@F4NZ<.0GB(XT$Y>1ZG,8+@Z+89XWCO/&[N2R
M[,A@&1YY0#&>7%OU"*T 3R.=Z#204574Z=FQ&=& ZK*#?0)N6YZ(.>Z$JNM(
MKM"&>WCNV[[/E2S_.@Y#$-]<-BL=^:+*$11D^DEB$;;NZ198"]>>(-6MBYU
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M2S4J!!UA4^/I5INQ,5%>I 7S0W$#)#9NY-1FK/0Y^:)=V%VF(;!"+C0E<:3
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ME'/'-0+JG+%*2>SAM0U3P^_BGS[+%  /?NHMT<9%]WWFN _N/FVST7/ T^(
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M'UY@LO,?<6E+X1%^X$+$5W!>]T7>!S(?@_[FUE<'KQ0J_<7^\86"G7\=4NR
MH<&1[V?U\^%47%\[!?D--/:"CP!I,3A^B_Z_@]QA980:;G$@4%QX!5P@6:5&
MUU,'T^:_TVKQ!=>RD&,1-H>#0*!CIZ-:M3\LG U JN'FC&)E"B)P!=6X!5]C
M!P. //)"5]NE<S5QCC4U%]<W]J K_7+)0 BT&UQ@IO=9:9?FU[RIN(#4[BDA
MT8C2[N;RHK)A12/6&T\U84M=I>1W&[,XL]EI1T5PB/!GVLWP9VJM"XUTNT_%
M#)\0/0P-/NU8:JQ*X]A/6+2/84WGP)L4+LY9IR0P43#TOUC^@.X7P07]'#PB
MV&H-&!#.01(HQ].RU!>;\@(\KX!;;(IVW=>OYB+GD(I"@Z\!1""O!T$/J%!N
M$<&3!D'?70Y<*]+E%0?)AJ6N^:DK(V6A'BP,%B\/FB<SE]14R9JH? KUCQP6
M+J\T=@?&)Q2,7H$RVD;A"N7?LM7P53G.% P80VS+;S&7X_*.U5+Q,I49/\VE
M2?7(+?2#+L=*,T*YQOI\$8UUH=%2$K=J!ZGV,GZ_:4RQ].VUQ>$#URP- YDS
M-K51E341H<75H2X7<SZH2T;ZULT:U*FEY9C (E+VA8"^5L:B-(#HDU!5.$6B
M@O=RZ5F<1E5><RYB48E*Y3)/5:GMP B_CR]C!9.0Q^A929RT3MP#"1_14AW,
M,O<5DRP%JN58]P+,]AK]=3!,7'!4>" G*K9+"YV#Q EKV!!N9BX'(%0_3<(F
M*CC](:-C:^#8M(ZL:N\XMZ>F(-@,SS@EH+<T9=A&PGM+C'ZA7<1V[&N*I>,)
MZ&.R5BU=J^N91Y2K(\DY'-H$@>W>;_ODZ@H=K,TP<.Z\HSF^MX$2!P U^ (Z
MPI[1^/:8=NZE1[\[4T8/<(2M6FO>=4C]ZS1J-2ET9$FFCA8W?R>122% "40G
M.Y\&#>W#F D$#LD&KX/#6JLXXG1EOJ*,$(K4[B;.[JK;85&FV8"% T[JQA1=
MS-);7R2A0HIEV[F^1*Z)K;V"X;;L5)8G8RL UY#C['@[]#..=\H)6/,S%95P
MH,(8(@G^D<-&A8Q]%'$HB2)(+L"7=F@8F4HP;05"*-6><[S0B&-:E018E&6#
MNE1D7SO? A5_Q7W6;*S#);Y:VQPB33F;<JJ"NPD8&&+)E2[!P*RP0I:O&I-I
MK^X6QVI3>H>KYPQB'$KGR[LMG@Q"AK8(%)Z4P;7D)1B4"[1;LZK$.D,GYJ3A
M=P7Y(!C*-R$[A'$_N4T&4M#RMPL"4L.M;$9(2 >M<RLCYRHVL>NQ-<.XIX+3
M:D6W7P!JDV=:R=6G3YF+C$&62V8E6ASY"#%NQ&W%%W!@ZQTG7/T2&5+9K?JA
M87UH4-?'\6A,_*A+;$C3 AV$(U6*2Q'J4%D$.%JQI"EU;6#NFDR37HY>:V==
MVEDZ#.%X"GU4:.51H6T?%7I\!?4'<<,["C:\@X:DTY'D7*@F(X?<>OW<HEV3
M]X9O2*71-A-D_!@LOB:LXZZLX?3;/I!#03+U3PQ1G<L4(0\M2_CM7^-UW'7[
MG3;77^!3D A#"8+ Z:[>T&TOW;3])BSIKARPK3A@NZ4<&$>VZV\C][Z6=TQ/
M#+"+,RWX'7EWB3J_'1J+&7O# F$^2S;/L!_<X0G=D/L?3]S\Y"=.F9,TV*M&
M"(3>;NLVNHYR;?S\N/JZWJW:>'(_3I=:H6NK3BKVQ9@T.!C$^B4X_4Q7V2O$
M#?9/:!1>]=(/F<C!R&!//&>>?<G!ABE$3!W:M%]!H#^W1).E$ EZ=>'WG>W-
M<'-SDZ#N5 SZ($O@VR)XA>Y7>(WD7FSTUF_48@%&>+D;]CH]BD'/I,@WL%=\
M/TL9 [3#+RI45H%ZG>J[0UV !/=!=C('39-134+&&T*@A)$L"W+I#VH]0VMY
M"_ON6*:AJ,(!$#/541,88Z.[^2L1+B.LAQ2;%M9GH@#%**$4\1,$@C45-57P
MC8%MPQ8GN:0,#NQ2)R=5JJQ(=,PHUWX22%8H1[EJ;&?WQS0,X.3'^@H75X3Q
M5A$DA#2-]JZ64AI;S762L;<K3I6M&6HGH?G$<<78W^L9F0UA/(;YR-NR3="E
M,HWP?M_Z]']<\>F_S7''Z%_U_</>O?-A[[2W_&&_ZV%7N]/(H_Z RN)S=3'M
M>!?38T;I=,40^HA)]II#8.MT.&F3\_4TG!0?Q(Q+S&J'AT9A2%LYF.O>9LI-
M;2*+(_2=HZC@Q\O"2HSB74-,M]M9)$S&4T6P!AD>9Y7.*25?XX"1@H>*;^"/
M@SB7W #NBZ244XP,*G922DMG4RLM<$MHSAP$&(2(4Q58Q!PFA2>A[NNRQ-P;
M?@S5 *QHI%K]H-=KM=\W@KWVS3G]W9Q3PT4U):M&ZH>@<*<A%!YS7VU%RSW0
M44I'KWE4$G<;2>)K-,A'I?16,RA]I/I57N2"5&V2%+,;20NR>X+E+0.FTLHI
MO<V@D4V@]GXV(+8U&6&@:QIDST,@3703[PK=7)G;8:'N]1$MN]V-/VY-[F&<
ML#&D1]_AT6^Q#SM-V(';:E][R.(&L^?##--C&Z2#72P]W/.>'O;-+"CQ0M.&
M.G\@*@<83D='V$.$$63;FW,C6=N ".FT9GM0)G] T/''YV!54V7WI%6[1W6T
M)R!3^)9C+F<;,](M1\%$+ETYKLO(:FXK]!]*+$NX06'ETDJ&5*04Q'1@*C25
MV;C4ZT35 (BMD>4#"P.V\ NM,>,MKTX]T$G-FDQ546(>TYAAOE+5+$#Q9(%]
M5KAO:XH &7B$J"$T0TC@V1JHA7!E&F5)*F/8K8RCM*N91B]0 !N<U(\X!+H+
MMZ6<@CYHJ3*ZX)6<3,?8P0!K,>7@=1-.P*ENS\A@(4H8A7<317I+&40615SA
MQ<02,6$/GBBXO(>9''/Y-"@&%6:6))R56UX=[SAWJB.P5KD_HSS:Q !2VT,N
M0'Q_HS*\B:X4HM;56'F-+6T&['G278)45JC G9,#SB$WCZ&3V2E%R@D='.NI
ML/I#^19J;W\?/+DCW@1FM>W#=+OG'U!.*.V;"G<0\H3XT%50;CC[H&@DY&!?
M^A 5DN>.XS.%<<- '9@]6-71Y\\GP?[AY\_!_I^?+_X\.PSV3[Z<[AW_,PR.
MCO=/SDY/SO8N#@^T++YF,KJ2O_XB\QXL;H;QTNCA-_RYAB3>^I#$D\MLVE&9
M33LM;;,V,YE-T^?P'Y^./AQ=!,C,_WB$%?Y05Z6?%0A9@AOYMQ?=E70S>LYC
M7B,X?]FD_QS1N0Q^TV[,VQ?WSW9&'FN6=^_4X,,_@[/#CX=GA\?[AW7V_XG[
M8G'9S+F["QVN^EE99I/W*U@VM@M;<LZ/__SRX?!LR4KGNW&U?UW%K,QF_ 0+
M\?RV%]N%/1@Q#P[/]\^.3B^.3HZ;0,D').3"8?QX]!E.X5]'%Y^"BT]'YS#L
MV1?,2?K#$_:G"7MT_'MP %*.R7M^N.]I^I,T!>;T-/PY&L)%%/S2 "*V.X])
MQ4__/#T\@P/^1W!Q$O!1/_]Q]>6I:)=^3#^F'W,=Q[Q>P+SOB^CK*,^J=+ !
M]EV6O_L%NWT/AS7#:45=(K3_:UR6TW=OWEQ=7;4*&;5&V>6;O3P:QY>R>",'
M(Y&_0;R2-R#?VYOMK;<[7?IS9WNKM[W5:6]N;FWMM-\(&/I_Y+=NNS4N)R]^
MZ[;:K\1K=J$]C%']!(ET)E4 9]\T720/Y$==)3CGA@\I>7\0[$WS. G:VTXV
M"4?A^8N.*C()'H+\3V7,6[+)?:LB6V\Z[3>X&0U=WR[:H(U<6;>U)@N[X_ON
M*ERL-/E_53(+.F]1F+2W6W>\SH;TWT->9R*>#%#(=O1-U&G0-32W.!5;G=])
M)VUT+N=KC4AQWP?V'T_Q6EKQF*MW"#Q!HJSQF.MI*6RUUD5]N>/[SC$-"00B
MY28B D^915_=B_'I<4JC1/?NF]TW[5YOIZ'+._^PT6GHTIHO&IZ>XMMN"Z7Z
MMIOFA5E8HMTH9='LCV,Y# X)-@/3$T^P[;/,@U>G>9PBFGFR^.5K1ARB7WZ,
ML8H3<U;U+Q5V.$$L8#EMT.Z*C?86$!831_F3[8'^A#5Q!^[O\)N"&]]CZ,]V
MK[O%&KHJ/2+X>H7OH#.#>YL[9BB1]T4JBXV3;XF<Z5$ZFYN=UAIMK%?F_9C/
M=,SUU-D7/0;:,]]IK9,7X+Z7MW@A6$"YFJAM[U+_]?V6+5_I;F^N$66\2/5C
M/M,QGX:BW>LIF8. )FLD..Y[>?>)(;-&9/+RU8_Y3,=\&BIKK]<Q\K6!,3RS
MO/M&D5HC4GD9Z\=\IF,^%1VV:V1L=XT$QWTO[]YQY-:(5E[(^C&?Z9A/19'=
M,D)V:XT$QWTO;U5(DFM$,B]K_9C/=,RGHM!N&UF[O4:"X[Z7MRHLV34BF9>U
M?LQG.N9ZZK4&E_CQ9<,=W_<SF- ^;7\]Q?KNF\[.&U]@]^16MMW:W%Z3I=WQ
M?5@37,P5!<??_FN017];6AR\O#*XM[7]EBN#=[^B;K?N&C>LHG5T?/ZTM^X?
M'\X^!Z!#EQ1L.\BBBB!,"2<4T4-!AX[UMP/][2##\;C!K12Y[OAVA PM&&+]
M /8Y^!@G,NC+2%2%#.A-I1B!]IW+ )&V$1N:D+#5[^D)_9)UJ3KURK<?\YF.
MN9[*-XK=\_U/:R(>?D;L7HAO69I-9L'AMU*F!7J'SZ.QG @CA]=DD5X&^C&?
MZ9CKJWKN[WU>$_%PSS)P7R21:I8;?([3K]A*=TU6Z@6A'_.9CKF^RN#!X<<U
M$0_W+ @/Y)#ZGWLYN(;GP8_Y/,=<7X7P\]Z'-1$/]RP'/XN^3+P(7+NCX,=\
MGF.NKRIX>G:X)N+AGD7@:2X+D!3>*%[/$^''?)YCKJLR^.31R/:Q #0X%:-K
MHLIKLCHO^OR8SW3,)K8!Q4[S4O7Q#)*XP.1'E9NBVGN"-!K(;Y3!PMC@&6:_
MF":Z ^XQ/92YI$;013 5><G)Z'&!/XG346O%JW@04OU?"E4/"!'E%3;GCH&#
M!+7!%M$88]?%ZV L+C'_1Z9!1C5/ VY*[="BAD1U5,I)L+.)4(VOM@E"\(PZ
M:)/2>[[Q1RMH N7^#_(0(6H6@0C@1W#)3;@5<UKB18<\99IO9_DLF"8BQ0]%
MGB. HLV.>A!*K$4_9CV?FY6NF[ILWK$K\^ZMWFFWPG=EOO?N93_8E+F(1R]^
M.S_Z_7@/FZ.?/_%VS#4NW=J^]KVGCAS%^TJ!M9(@1K;Y+A K_@C$+?6SAV'&
M(-,'V/>"DC<'++-S"=<<O:(/$@$F@!=@&N!MV9=CD0SQ^L.!P.J1N7H _IW+
M*H4?T7BB*L=9#NK'8*UDF*,1_9S@6HDU8EH>=^[!MMH[.CXY#X.CXWUUH3Z"
M>5R3U*K/Y.:O]V$Y7F_+\6NZ#_.6[0=Y#;:57,%K5MX($NQX^2XX!B-_T@<[
M7W?PNE]N_#![MXQRW^W8>1_5JG OORG>!/OC*MWX5,2@ 5\4(E;W]2,>N:=A
M6]['F'.D#V$O1)Q/1%HK#0ZQX,WOR /MR%)$>D_]QHQYR_M^-2[CA[I3@CM=
M*LO7K*Z)3U6\\1DDTU^58]'YT_!(L0>[&^&UO3">JF^U9DYVXK1F.N7(#<_4
M^;/2#IJ]=7";OU'O')>3Y+?_#U!+ P04    "  J76]37TUGB<L'  !7*@
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M*2#"7>+?8B[G)W9(ZR![^4U58;N(UQ]#2NFD>=KSB!H]V.9*'.O84DY:(IY
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M4%9>57)Q #K)TOF*BQH><.[M<.[O'G#N!YS[$R3?8('Y8=U#).5M;&^1K+=
MS9%=#,:X> )O^/NA)\/M$GMJR?/3B5'[5P3(A=%LIJYE.\"J?4O&L+QEUCW3
MM^?>=XE;_Q$-S14YBYYBN>I8#))GM?5@BJ$'PX$V*X[=\,2,6COLR/*PK3!D
MM,<#@\#NY]&UXELI6X=KM&SG(['QP%5L#V7?S4[#_ $'/&'+G*H#%$/@SCH6
M@KJ>ST(>5S,JPT5 @0<)/?F2S.4NJX:_<W7R0?M_D%\$J'%;>&T3G^W=SA<F
M.0NA8PE\$Y25XJ^*;">)A9PTE<HDNA>!YQ#.WNR^-)&BNJ0<4((B6I;YNH'7
M(0\2/)O*-S'Y,:M P(V<7HF7"\KNZ$[147P_K$-MW@DJH-KXURT'V1=$K_SK
MX5;=+S?I+C0&N7[" GJ+AR^T&I=82QAH*G0!?)%;I]STJCN>05\(+S_G$+5\
M'RU"\&]9%8Z$#&R ;VWIPD"&FY3IZ*[D>FQ76G_09V:<33WHEG-$>><F@0'@
M/>T2HL!1*902C1@$B/4R#0@Q".!-V5>,E;A(*%30)GR[&_V,Y]26TN&[ZA 1
MB@U8H_,Q;*U&3QH<4AC.I#<@<$*!&)E!JI.93CZ2G[K60T"-PT[&>E%4J5<S
MR*!FI1ZGO01N0EY&*O]($8+PWXKKWU)3H/\,UQ5IYR$*>:XMSRPK8I$C"D]?
MU#R3JP+&HZ4BQ4(MYW3,Z%H0F4U8DHOSNE4F#LI?$-7/EBSMNXY#G$JZZ<6<
M/QMG1SL7KV]BGE,OI^0MJ@:FC8-A1E<#5C/22!JN\B,?D N= G"P2*R$A)JX
M:PEOR2QJ/E2=3+[[B"XYNK-FWJV\1]%7I/5@[42Z!II'4YG3,(=E7%:F/@([
M-1<J'6-],HH\Y_=[=50[(<,-):6G"B!-%EE5:N)"O#.Z)=0;:H<D&S;9*"J7
MP41?Y*[0XD0!Q< "81P0(\%FVX23FZ/"4UO)NV48]X]/#SU8D9YY5&'5<-4V
MU39H=(CSDV/?-MLO!&H;0]8U(A#>E]*?PN.-_[PNIIJX29N[]%HB6UL1)+-Z
M!FZXKPT\#-6^.I!T4KV2SKTP/;DMIG**FZ\3LR+\@&YOB6Y__X!N/Z#;7R+G
M96_7"[CIZK3MZD^V;*F7FM6'Q_1EEDFQRC5?AH4&00RR"F+#IMMJAJ<)<(4$
M(]&GG(/(>C:G,$J74H?)>C;7^1ZAV<H:N!9W&W)38L'G&YZ*5EFO[H1P5UT<
M!JJIS4QS)N(:/R=;\.M\G2&>Y70-^MHUSLL<<WF "7!V7G9:/6H[T^.I=E>>
M6&'DWENHQ7I#DW&XV(1FLXUCMD_T<W%.:Z%]D&I@V^2MFZXDD,,FM#%8NEAD
M:6*VK17WT=X&D5WAS5YQ" (":1C7O:]G6B4MU#1[@MCBK17-^Z?'87ZL4T3,
MTG5C>EJJ5ILW_6%5+8-M>9&-H>[E37F]\N6F_54I7U\\!/S#0=2A+M0GWIZ=
MOCX]/KH\/3^+CLY>];UT\=/[H[/CD^C\]1>.'>^,WEX31D.[HQ'LX34\Y-#R
MHZ&QT  P5EUZZ>P.0B&J3ZMV&@NU(%&7B+[:,NL2[ E' NUB%-R$O@XTK7*3
MOA6@5"R6$,2ZQ@,^&%M4.AD&+Z?8$:-?1>G5E427W#P/:C,&2H/<(9.ER@1=
MV7O#2*HA<V$W(.;*Z*H5O]64@D'0W3(Y2IA<>^GNE+^;*7A(N):[LF8>FPP=
MSD)&6976@B9B"6?AE/96),/X0-1C*A5EXJF*A3'N$55RI49A*SAW7N<F(;ZS
M_G*)NPR'Z[TV<^*PN&(+1+9RNJX=)@U+;J*,U_E)QEK/?2U"8#VY[!?&H^LZ
MTRX6UR0HX1+%JY9B4::@S*<&[U/150K' -NX*KC&B]TA^!%W<BI*V-#E#WG1
M2YB]E$-]8G2>*!-<B('U+6^/7$+%&,.EO43#U9N,Y=126B_4,G,]A4-L),@\
MK8"HQDU22VE7/*\FU0CD(KM(V@.D7"X9I*_G441V77OEA<T.4<K7O++(]Y8;
MC\'3*S>_?P-QJ*LWL'=Z9FKNWC!:9;MEHH;:VZ ,H2^:$>BH(-3AW\N@>(-X
M[_VO/4JP]Z:8M67.Q3'AC@3&OM9A$UC@Y'H7*7_5&H!?YZDE%ZAB3U."D5.9
M!-J4RM^@X="43+&^0\2KOR0N/-S,0&#$CEWI^2(KEIC!:*/V^YPJ1>DU9$Q/
M>UTQRZ0^VW&K7GL$5TQL&8R5:I8N8O9-1.B;;DI4<4M8-[[\@SXD300.1.4H
M$U?#"*$E)<F6E&KD!(;4)>J(',=$O3I <-*H=#&!^2P@Z,H2]O TF!I]/6.U
MNZ#2B5T/&(=PA-F19 ;R*>'^ PEBQW]':/PS@(^??4P.EOSA 99\@"6W102,
MQ=8QQ/HLN..C=Z>71V^BB\OSX_^^8W;1=G<I'_M(($),9)3T8+:?"!D&.D?@
M@W2J)55T6.W.[HS$*7^,FFQVM41/[!(:#52P?=G"0\B8Z06(7,$DY[IJOQWD
M$1M3!R%<HWN'D&[7)%711"55.L=29#77:R"O?JD]^>@AKNBC1_<V"&R[(LH!
ML"3J8PXBLQ7$Z!7^>ZE*&Y#@K% )SXSLS:=!_ 6G%?+,C5[1J\/07"EHH1'2
ML5/8(E:*5C+8A8'-"7:E;TM,GIY98"8P[R9#NG"!4ZM O>?"QA)1,%1=;C"V
M@1%L6.F2BRH$[>B;63J2J!=V4UC,C1P(= ^6O3&O,H?TGO&KI[ _AI!7\2K'
MFM:S(W,RN!@'WM!1K-E(.?->"1DJ76:O)W%\(2TYO=Y6U$ $"1@9Q:? 6YF>
M*G1-2#5%NLX3BVLC/%.A-LQ1.)C AU9&EMF*)AUNK$!'_:@?:&0PTN+9+8J[
M9@6:&I^S[K8EW^&D&*"Z%DF_[E[89V+D)9[6);H88QP-&G<)!Q=VH1SD;CW\
MT#=JL+MN44IZYK=O;J#Q@!9VGG$Y&1/-S(7 "=OX2$'S,G9+S,$$)C( \910
M **9^> 5<3VGU*^S:XM%,#MH>2,=M\\('>7C1)%O8WM_:E.S+5E0R0@)S$<(
ME*I&Y< .FGS,5]SFT>/]_;TGT1AT\5W,:-JJY\^ZT</;+,%C@_,W%R7Q=&0V
M0051+.[+.%]X5=)I#JQ(-\2E^  -+L#*^V71WTWXU!4A+$ W%.PG][AKS(G@
MGPS%,"*\BKADVO25OW\,5.+^AC5'^O=4*L)X]Q0/+S.VZ=T9'RSFHDQYNRAR
MG*Y+-3X"AB^Q^!G5!9-RGAR29U=\]3FRU]%3+<W5=(@J"8Y4"$ NW?37.#7W
M=A@27=WY)Q%G9(R+OM;Z>(['<?J7T@V!0D7<=4Y8.I<KC'0_VJCT%Q?1<EMB
M*FFATX9K"/:G1025"MK$O'YW[ZQ8QU(1JZ^NI'CQS4JM^Y>H$<A'1IZ?$<<2
MR50T*)M, M1+UY75V[FZHYX3FC].V8D$G*G,#8LCK=X+=I&6R*HRYASO-UTI
M:.CW$XH./$0\;AGQ^-<':/$!6KQE+,B'TX/H[>G%\<F;-T=G)^<_743OWI]_
M.+TX/3^[:[$5VV&(7)JGS91_HCIQ0PI[W9?MR\S1PE+#07;M' FZ9-Y>:A2\
M>L1^U9&V;CN'U;0OJ6])Y?9 $(FQWX(, 7($WKQ=L70CWOV,'B_Z:]V-QP/+
M.7";&E=Z-][@[GS0CI&:I(2L@0RR-PF =IHGZ0)#WNC^VV+B793Y!Q%$?T2<
MX18U\5ZG%2S\X&?_TJHO,7!"7_&-[*L +H[2& R?E?>"4K>Z0D:=5K.';5T#
M'W5=2Q>:JAL&<.1 Q'9GBX:S^->[1N[=3JVP%,Z&[Z%>M<>@KP_?Q6&OMN7&
M6P?2IEDBIB#FYO4,^/A5ZR9$%D5\?71#\"XS6^#8E5=WS19X *&$J8NY?RTT
MR0D]MZU5#?)SLDC\JZDE_=4",&K.J >F+IK0WFA4,,IB?%+XC)(EKTL@.KHB
M9HQ%I]V%.P)R.Z.<\P[0I$?WE=^X?$LF<$HWQ@"SJM8![%XRP/"T79E9GJ^T
M.59+CO="1 J,>T*DCCH7$\<M=Z$#[OE/(>;@[8 ++I$+?!![HEJVV P=60$.
M:RYT&W<&CY1P!6MM@-6ZN']G][O=Z+VKN="ILNEG8'@!C)R6RBG7C&+C**UZ
MXVHXV"4WP9GVXFWK<$-43*YF-U%4O'OVEFN[@8AB(^'P"QAO9-Z)@T\+OGM-
M,L$W]$2'N3G052N<7R58H-A=L-Z=IBAP+F_?X!IPXNS=\[:F?%\->:O3>HT_
M( M;(@M_>T 6'I"%+U I<$7IL]77BMGKP]X&EV<=NSNS+LV=6;>]0:S^+:X/
M"QTJP[E0X85B&U5 6G/;&/)H#@'):T^*Q!1H3E=W%Z5$\,AR 4^EQF(2$R[^
M1FJTM+T<&]UUXEUQTO4DB/ S@VREK)'*!X-,.(#$B#L,"6YRE:?SHJFZ_I@X
M"%5B;49B:XW7;%PDS5P$5DH7?M+?)FD0UA1<1DA8"WD'3<1YW+,F/6$SI?;C
M)VI>82^_Q)&EN^'D5ZL;\]XZ3;N%%)V74UB'7P7J/RY 77B,KZ'X>+IWB#_0
M'_</GQCT?@J&&&/^9A6JWM@M4E'@GQS3!A'V0:U!9:O(N_=\&+K$=\QU1[)/
M++_IVAW13G&,ZB._1AN;MGUKW166K!KG\IU1.G4Z;^9>/,E549O[;&SR0:!S
MT+9X9X&OOI$KEB1;U00+"KF&5&<SI#B/ZSKGP"VYN,=7R+F8>N[WYM])2A5X
M:@0465>TUW>:?HO2_)&#QXV)9$;.'E./#3(5(=N#^>Z@+W?''2#;:FNI/?,^
MR-7%O;*I&$*\3$;N6EU8"WM9X2[H*V;EUI*O01CEM@]G6';*D'L]<W*.=9*:
MY/FXQ7O7LJNXQ=2V9\E\B1J[OM.%]=./^4J/T&7<<.Z/-\!;,-!X_862N* 8
M'JBXJ2:7O:O(E%O,34"E29[ 3"C2_RC#"$1JFK0_K)95K>=(\G@_,MV'!7IX
M8;LG@M3)+"^R8KHTG.<4'1.YKF-/W(W$0VROJ+%CHG%3/R+%JR"]T:TQB;H\
M<(T#B;@1:U?X78)RQ$9>U<2AN%5=&3\8+X/,EO9A7[\AM8+<WU@$ ML)3L0M
MR9XR0NK?+/SM#V=?KRAM>6&KPWW.N+9S(HSA6]*MM!GLM2_D?. &A,=!B)C-
M1MN$OSSI$X#KXP2,2S\V)? X#L;^BN(F]L6+U5%XC/X]T:U<QK!:G^$A%$I@
M,@!%%9OIC'0<SA[N2_GE,B5H_,>NNB\6&=!9:L!)AL)(=[A9>I*P?W#$8^T(
MOVJ@:H5?]_0@.GI[<O8*_G]YUURYE[Z-9MP)&?D!Y=Y'/8[=+82.LK#B3#FG
MF&1[>XT?]UST768#BBH&V7-8( 6M"%(G>K!5]CC&D&BLI1>GDU:\%L: <EP:
MCI9$&X?FA\Y<]Q'AM:UF8\\^[9O9QM>\FF&;.SN[FGWL<+76F+:>B2=0'P"Y
M+0&Y_;T'1.X!D=M8N6I>O*-XW ^8.%7D!U1D_TCN@?XOS.+8WXN!4O>_NQMR
M 7%"PX6J U:^[LJ\&'^,3D]C:T4S-V"-:;X !F[SJT0TNC1$EHGDCR^RK+BN
M#J+G>NZN2=VC*\KM!</ F.$I+2#\=R@6%8;E9R28,.K@IF+4W=8B@K;RN;T8
MVD*K:.+Y(W,WJ4N&?><J@<X7[[!^A-@&%O1S?B83?4URFY'!2F4( ,F$TI)K
M$R1\M5C="BP)IJ4DI+QJ@D(T)(VIYAZ.TWG*K.X"6V*S%,QK*)7EHK$AL1PN
MJE\]18JFU#-4/YPT9O]?F Q8EPU#4)C] *:[#LO%40"'*<[05L\%.Y4*"UY)
M UY5[MPG!QP 3'-7$$BBL^BQGB]FJJ( <QK]O!BSP](+(B"\,\-9/-F-CH2@
M0Z,HCXZ:*=YM^I38&K0?G17P<IH7U0[^?6?OV[O!$<B4E'V0>HP&B' ZUZ9<
M@5%E@8=IL6+T<9@]NO>+?0O-[[?$4#SU</]^JX=?0D%[/BK&RQ?_#U!+ P04
M    "  J76]3#C[#V7T$  ! $P  #@   &%I;61?97@S,C$N:'1MW5AM;^(X
M$/XK<ZRZ:B4""6Q/NX$BA;<V4DMV(=5U[\O))(;X+MA9VVGA?OV-$Z"TU]YM
M7^B=MJJ0L#TSS\P\\]AM.]&+M--.*(D[;<UT2CN$+>+?Z++9<&JXV:Z7J^V?
M+*LOHGQ!N89(4J)I#+EB? Z#_JDWOB!*4VE9G7:]=#85\0J47J7TI-(+SH.Q
M"^_LXJ<%X> JM+QS_W3DPN^YTFRV:L$P&(4N.':F(60+JF!$;V L%H17.NUL
MX\J<LB;^KX/R:&EF#;T+__RK"[HPY&@HC6$++KSQJ8]1[&S9 DV7VB(IFW-W
M$[72><^G*FNUZUD'7CV*9/-$8XRVTE+P>6=P=>9W_1":C9K3KJ\7]QMZG^E%
MR 4J=_+K#<:A/_1[7N@'(_A\.9Y<>J,0PF#/R?X-B/,1+FN36J\&DT&O .,T
MC^VW1N%-P.L'G\-!_[^LQ:8"G^R?(1A">#: B3?N>J/!Q JNS@=?P>N%9J=A
MVXT]@WN;L;N-XG.(!.<TTDQPN&$Z 9U0^)(3B45*5S"FF9 :Q P\QH6J@L^C
M&N#9H9 +!&%]@9F0A5%&)1,Q4!ZC\DUHINEB2B4T[2I6KN$ 43!C*>YMPTQH
ME$NF&:(F/(;!,DH(GU/HB<6"*64@X:\Y&:.<0D(E12"'9N']NX^-AMTJX15?
MG-91%2B)$@/6',D1B%28+XVKP$H_$<E(=!MQQ[O"(S&+"MF>TE3<5(MXTQ5$
M5&*UC$F62Y43U'<M8&>"UM4S$U0U69)89,;-[O'-(4.R-;X)D5/"J;*"94I7
MX$5%F0W)JKA/"C-S;DI5L9,P!7]P<8,EG%/W+?FGR32EFTA3(;&NEC*%Y'/7
M;LT$UY9B?U*WB%Q\O2:28>8N1Y:0M%R[H49R[RP5+C<K.S!2.M.ME'%J)7>,
M;EBL$PQC'U2P+6F:D3A&$"<5NV)@R@W&M95SG"V+C7BS43KX<-"Z-DV-2+H.
MJ$76JNS6<T'DG''7-@Z<FBD#7O3Q'5]/<1%B']>C-,M3G*M(+++4<&H[#))^
MRYFDYOV@3+MO:75(C@!GS#D^C(^VY+D=G>W8K!GD?&I^:!EZ;U'CA_SG^CR,
MNVP)S@5B<IM%(K>TV-;CL9SO'?UW$,\I;.-U>L/XS#"L*#@*HB;(O7@C&IO&
M$684,9-4F1X5FD+2%- ,E8^DV$&58=-4M;":,4YX9-;18<P*UT9S\%2>EBT6
M*)EES'574?@RPE>UNT7##S. /\!U\VQ1>?;@?R<Y"^Y$(D4 _*32>)0KGC\*
M)G@)CE#W]SL$9<;']L'CQ'THASO6S1<9'[_$VFE\O_5^E*&/8^G"2%R7SQ#G
MN'R&/*%KW97[8(;=8-P?C*UN$(;!Q?:O-G"R)2B1LOA)ETN;+CIU58=>DG/K
M3#'*(52$M>NXOA^&/:&GKW#T7EY53!1U%/5BHWE=020^T.Y)SZX+HYJ]A-$9
M7G5X[6EV32&8S1@^S/8TA&];HO_;G?J2R7G3F3G+F76.3/HE_V'&Y3:EZIKS
MP^T[8LWY9Z?YMN^(XA]<G;\ 4$L#!!0    ( "I=;U/.%4W.4Q0  )Z    .
M    86EM9%]E>#DY,2YH=&WM'6ESV\;UKVR=26O/4+0HR8DMJIJA1-IA*Y$N
M27G2?NDL@:6X,0@@NP I]M?WO;>[N A*<A1?E#*Q+>'8X]WGXF2>+(+3D[G@
M_NE)(I- G'*Y\/\K;MZ\:37AYLE+<_7D+WM[W<A+%R),F*<$3X3/4BW#:];K
MONN,+KE.A-K;.SUY:0:;1OZ:Z60=B+\_F_1^G>QU+OKO!L<L$+.DS=X.!Y-C
MUMJ/$Y;(A= L%"NFH@4/GYV>Q.X]?&IOW/]/SSQJ7MM[V[GL7_S[N/IBFUUV
M1N_Z,,5^?--FB;A)]G@@K\-C):_G21L&UHF*PNO3WJ^_],_Z$_;F3;-U\M)>
M/'D9G[(_?6K:[;/3OX93';<_ZQ1N<YW^8#ANL/[@O/GE]Y;P:2#<---(^4 2
M.N8>D,GQ?GL6A<F>EO\3QS1M=:B5]),YW-K_\1GS1!#$W/?AQ;\_VW^&0RLW
M[EP@/H];K^(;NN&[&V?#4;<WVCL;3B;#RV/VPS[]QUKQ#=-1(/WVLR(4[@G/
MT=5%;\PZ@RY[/QJ>][I7(_AU^):=#3NC+O[0[8]ZYY/A:,PN>[U)?_!NS/[Z
MP^N#5JO-<@0XY'2'[R>][C;$W!?%5^^NQA-VL __'Y0I&-C5Q[\4_H7(V F:
M;C7WV?A\^+Z'\*Y#R,YP\548"*V9$H%8<I"T 5]IQD,?KERG 4]D%&H6*9;,
M!3N/%C$/UT1L/[<U.Q<JD3/I@6AFT8R]C=2"7L#GS]8T4JRBI?3A-KRO5E*+
M1NU(9Q%7/H[1E4IX2:0T6PB1 #-J]AR?.MAOFV<N[66ZV&J_8'K.@X!-!?.B
MT$\]U!(R9-SS0!CPT!-L)9,Y33I*8:NTM_<J\H2?*O@5YJR9_#*;'%^T"ZA[
MWRVC^;W3@:/\ Z#\\^'@0V\ @@6I/Y,QR #GOW3ZH\O.@(V&%SVV,TS@-G\B
M%@" %KN4H5RD"_:OE"LP,H)U1A" 9W@FVS@K$V5.C',1^(P#.PDP4UB$="B6
M0JW9[V9(-DT3MN#KXK/ $+1RI%^/:^*I5%V3_2,56$(Z08+6.T-K!MP'['S.
M)8B.$#>,_&: .HH"<5]P ^\O10BLC]P9 U^"S &67B*@UT;BU,Y19/HF^R5:
M(9*,B)I)!9BS4@@?-/@#W"W<&+!C( V0G"1U:L3()ZS/O<16\XC-.4ID3\@E
M/(5W PYT ,L)T\44WH%)EE&"PFB&M*13;VZ6 <*WS22M3@G&X4^RBE <+R+X
M.19*HS@GB4@OF77A!LEDU;3UM5TWC<AF@%/&%P!^F!_N+K0(EB@X0S<@2R*W
MP>+^S/9P]1:(.T:WAZPSU0(Y&]!12UY5ZNU;OKX?/3*)0$8)LA2(PC0D6Q>
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MZT/"K],IV*L+Y*S+^SZ#0;U8"+)U].GJ_?E%[^IGBVTU@-_O&MCZ6!6Z D)
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MGE_VKGKG9\@$?G_)_;N?KN6[O* U/.P]495YVXF;9R@H@Q_Z7]- BW?Z6TD
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M^)N_*+_)U8UPE23J;A/K'D">G?B'J%8HMNX$6<GOV%)W0%FH>" MN\H)EK9
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M4>&'.%1(5OL!CI]_!Z,@4#9TF@=;VXF$"F,/;D'=A\>@Z(?JU?CW3$@2:!I
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M&@R">XD@YP!X'OS'$!0CO6O:5R(1%O5*<$ 4B["+E:RM/U>(!2'+50 E3,/
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ML'CJE#0*VAYGE R* 7NHYX0<0[^X+"0&8/!<9)+F2TE< ^9ZN"".O""X3^,
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M[S1]S(1%1=33)OEV$]:EJ6ON#&,JO$V5MM>=UQ7\3@U890"K;429G(J2/,M
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M=+VPQ,:([[!7\::>UK<\6K4A]]6&G'/PE[;A7N/\O^\'[OSXOU!+ P04
M"  J76]3^Q9><2<:   SQ0  #@   &%I;61?97@Y.30N:'1M[5U]<]LVTO\J
M>-RY7C(C.7Z/8_L\H]BRH[O8REA.<^T_&4B$)-84J0*D9=VG?W87  E2I-^5
MJ+8ZG=;B"P "BWWY[6+W8!B/@L.#H>#>X4'LQX$XY/[(^RYN/GS86H6;!^_T
MU8/_J]>/HUXR$F',>E+P6'@L47XX8,WCT\;%&5>QD/7ZX<$[W5@W\J9,Q=-
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M:8-M>5$\D55!+IIKN4!0/PE[FF8H3S^W>3P<F$@YVD_NL#D0S+4(?2,"">Q
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M@^[E&?4A 6)C\MA[I4TOKWH"V8_=;7'6/QV>7:"C,7PIW@^&;RA[K#TMVWO
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M4$L! A0#%     @ *EUO4[FVJ*'M+@  2$@" !4              ( !(R<
M &%I;60M,C R,3 Y,S!?;&%B+GAM;%!+ 0(4 Q0    ( "I=;U-),?.R+B4
M ![S 0 5              "  4-6  !A:6UD+3(P,C$P.3,P7W!R92YX;6Q0
M2P$"% ,4    "  J76]3]7-=HR0- 0 SS T #               @ &D>P
M86EM9%\Q,'$N:'1M4$L! A0#%     @ *EUO4U]-9XG+!P  5RH   \
M         ( !\H@! &%I;61?97@S,3%A+FAT;5!+ 0(4 Q0    ( "I=;U/C
M+**>AR8  )O>   -              "  >J0 0!A:6UD7V5X,S(N:'1M4$L!
M A0#%     @ *EUO4PX^P]E]!   0!,   X              ( !G+<! &%I
M;61?97@S,C$N:'1M4$L! A0#%     @ *EUO4\X53<Y3%   GH    X
M         ( !1;P! &%I;61?97@Y.3$N:'1M4$L! A0#%     @ *EUO4_\Z
MWB[\)0  BMX   X              ( !Q- ! &%I;61?97@Y.3(N:'1M4$L!
M A0#%     @ *EUO4T"B_E8A(   IM,   X              ( ![/8! &%I
M;61?97@Y.3,N:'1M4$L! A0#%     @ *EUO4_L67G$G&@  ,\4   X
M         ( !.1<" &%I;61?97@Y.30N:'1M4$L! A0#%     @ *EUO4P4I
M_#71(@  4OH   X              ( !C#$" &%I;61?97@Y.34N:'1M4$L%
3!@     .  X 90,  (E4 @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
